var images_info;if (!images_info) images_info =[]; images_info["61"]={"61000":{"type":"graphic_picture","displayName":"Gastrointestinal stromal tumor CPC Light","title":"Gastrointestinal stromal tumor (GIST)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastrointestinal stromal tumor (GIST)</div><div class=\"cntnt\"><img style=\"width:375px; height:507px;\" src=\"images/GAST/61000_GIST_CPC_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Biopsy specimen from a GIST showing two histologic patterns. Part of the tumor (upper panel) is composed of spindle cells with elongated nuclei and eosinophilic cytoplasm. Other portions of the tumor (lower panel) consist of epithelioid cells having round central nuclei within eosinophilic or clear cytoplasm. On immunostaining, the tumor is positive for CD117 (C-kit) and CD34, and negative for the smooth muscle markers actin and desmin and the neuronal marker, S100 protein. This profile is diagnostic of a GIST. CD117 is the marker for the interstitial cells of Cajal, which may be the cell of origin of gut stromal tumors. CD34 is a less specific marker and is not positive in all GISTs.</div><div class=\"graphic_reference\">Courtesy of Heather Crowley, MD and Donald Antonioli, MD.</div><div id=\"graphicVersion\">Graphic 61000 Version 2.0</div></div></div>"},"61002":{"type":"graphic_picture","displayName":"Acute promyelocytic leukemia","title":"Acute promyelocytic leukemia - hypergranular variant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute&nbsp;promyelocytic leukemia -&nbsp;hypergranular variant</div><div class=\"cntnt\"><img style=\"width:431px; height:288px;\" src=\"images/HEME/61002_ANLL_FAB_M3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate from a patient with acute promyelocytic leukemia (APL; formerly described in the French-American-British [FAB] classification as the M3 variant of acute myeloid leukemia). The myeloblasts contain large numbers of azurophilic cytoplasmic granules, which almost obscure the nuclear outlines, when evaluated by Wright-Giemsa stain.</div><div class=\"graphic_reference\">Courtesy of David S Rosenthal, MD.</div><div id=\"graphicVersion\">Graphic 61002 Version 2.0</div></div></div>"},"61004":{"type":"graphic_diagnosticimage","displayName":"Right lung tumor PET scan","title":"Fluorodeoxyglucose positron emission tomography scan of mediastinal metastasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fluorodeoxyglucose positron emission tomography scan of mediastinal metastasis</div><div class=\"cntnt\"><img style=\"width:399px; height:219px;\" src=\"images/PULM/61004_Right_lung_tumor_FDG_scan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Primary tumor in the right lung with mediastinal metastatic focus (N2 lymph node, arrow) demonstrated with fluorodeoxyglucose positron emission tomography (FDG-PET) whole body scan in posterior, coronal, axial, and sagittal, projection.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 61004 Version 4.0</div></div></div>"},"61006":{"type":"graphic_form","displayName":"Allergen immunotherapy administration form","title":"Allergen immunotherapy administration form","html":"<div class=\"graphic\"><div style=\"width: 663px\" class=\"figure\"><div class=\"ttl\">Allergen immunotherapy administration form</div><div class=\"cntnt\"><img style=\"width:643px; height:801px;\" src=\"images/ALLRG/61006_SCIT-Admin1_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">v/v: volume/volume.<br />* <strong>Health screen</strong> refers to either a written or verbal interview of the patient prior to the administration of the allergy injection regarding the presence of increased asthma symptoms or symptoms of respiratory tract infection, beta-blocker use, change in health status (including pregnancy), or adverse reaction to previous infection. A \"yes\" answer to this health screen may require further evaluation.<br />&#182; <strong>Antihistamine use:</strong> To improve consistency in interpretation of reactions, it should be noted if the patient has taken an antihistamine on injection days. Clinician may also request that antihistamines be taken consistently on injection days (recommended? Y N ).<br />&Delta; <strong>Reaction:</strong> Refers to either immediate or delayed systemic or local reactions. Local reactions (noted as LR) can be reported in millimeters as the longest diameter of wheal and erythema. The details of the symptoms and treatment of a systemic reaction (noted as SR) would be recorded elsewhere in the medical record.</div><div class=\"graphic_reference\">Reproduced from: Cox L, Nelson H, Lockey R. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol 2011; 127(1 Supp):S1. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 61006 Version 5.0</div></div></div>"},"61007":{"type":"graphic_table","displayName":"Approximate dose equivalents stimulants for ADHD","title":"Dosing guidelines when switching from one stimulant to another in the treatment of attention deficit hyperactivity disorder in children and adolescents*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dosing guidelines when switching from one stimulant to another in the treatment of attention deficit hyperactivity disorder in children and adolescents*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Current medication and dose</td> <td class=\"subtitle1\">New medication</td> <td class=\"subtitle1\">Recommended starting dose</td> <td class=\"subtitle1\" colspan=\"2\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Switching from one form of methylphenidate to another</td> </tr> <tr> <td class=\"indent1\">Methylphenidate IR<br /> 5 mg twice daily or three times daily</td> <td>Methylphenidate osmotic release (Concerta)</td> <td>18 mg every morning</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Methylphenidate IR<br /> 10 mg twice daily or three times daily</td> <td>Methylphenidate osmotic release</td> <td>36 mg every morning</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Methylphenidate IR<br /> 15 mg twice daily or three times daily</td> <td>Methylphenidate osmotic release</td> <td>54 mg every morning</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Methylphenidate IR<br /> 20 mg twice daily or three times daily</td> <td>Methylphenidate osmotic release</td> <td>72 mg every morning</td> <td colspan=\"2\">Conversion dosage should not exceed 72 mg per day.</td> </tr> <tr> <td class=\"indent1\">Methylphenidate IR</td> <td>Dexmethylphenidate (Focalin or Focalin XR)</td> <td>One-half the current total daily dose</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Methylphenidate IR<br /> 5 mg three times per day</td> <td>Methylphenidate patch (Daytrana)</td> <td>10 mg (12.5 cm<sup>2</sup>)</td> <td colspan=\"2\">Methylphenidate patch has greater systemic bioavailability than oral preparations. Patients changing from oral methylphenidate IR doses &#8804;20 mg/day should be started on the 10 mg patch. Allow at least one week before increasing to the next higher patch strength, if needed.</td> </tr> <tr> <td class=\"indent1\">Methylphenidate IR<br /> 7.5 mg three times per day</td> <td>Methylphenidate patch</td> <td>15 mg (18.75 cm<sup>2</sup>)</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Methylphenidate IR<br /> 10 mg three times per day</td> <td>Methylphenidate patch</td> <td>20 mg (25 cm<sup>2</sup>)</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Methylphenidate IR<br /> 15 mg three times per day</td> <td>Methylphenidate patch</td> <td>30 mg (37.5 cm<sup>2</sup>)</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Methylphenidate osmotic release<br /> 18 mg</td> <td>Methylphenidate patch</td> <td>10 mg (12.5 cm<sup>2</sup>)</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Methylphenidate osmotic release<br /> 27 mg</td> <td>Methylphenidate patch</td> <td>15 mg (18.75 cm<sup>2</sup>)</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Methylphenidate osmotic release<br /> 36 mg</td> <td>Methylphenidate patch</td> <td>20 mg (25 cm<sup>2</sup>)</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Methylphenidate osmotic release<br /> 54 mg</td> <td>Methylphenidate patch</td> <td>30 mg (37.5 cm<sup>2</sup>)</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Switching to dextroamphetamine</td> </tr> <tr> <td class=\"indent1\">Any stimulant<sup>&#182;</sup></td> <td>Dextroamphetamine or dextroamphetamine spansules</td> <td>5 mg once or twice per day</td> <td colspan=\"2\">Daily dosage may be increased in increments of 5 mg at weekly intervals until optimal response is obtained (maximum daily dose 40 mg).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Any stimulant<sup>&#182;</sup></td> <td>Lisdexamfetamine (Vyvanse)</td> <td>30 mg once daily in the morning</td> <td colspan=\"2\">Daily dosage may be increased in increments of 10 or 20 mg at approximately weekly intervals until optimal response is obtained (maximum daily dose 70 mg).</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Switching to amphetamine-dextroamphetamine</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Methylphenidate<sup>&#182;</sup><sup>&#916;</sup></td> <td rowspan=\"2\">Amphetamine-dextroamphetamine IR</td> <td>6 to 12 years: 10 mg once daily in the morning</td> <td colspan=\"2\">Daily dosage may be adjusted in increments of 5 mg or 10 mg at weekly intervals until optimal response is obtained (maximum daily dose 30 mg; may be divided in two doses).</td> </tr> <tr> <td>13 to 17 years: 10 mg once daily</td> <td colspan=\"2\">Daily dosage may be adjusted in increments of 5 mg or 10 mg at weekly intervals until optimal response is obtained (maximum daily dose 40 mg; may be divided in two doses).</td> </tr> <tr> <td class=\"indent1\">Amphetamine-dextroamphetamine (Adderall) IR</td> <td>Amphetamine-dextroamphetamine XR</td> <td>Same total daily dose</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Any stimulant other than amphetamine-dextroamphetamine IR<sup>&#182;</sup><sup>&#916;</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">Amphetamine-dextroamphetamine XR</td> <td>6 to 12 years: 10 mg once daily in the morning</td> <td colspan=\"2\">Daily dosage may be adjusted in increments of 5 mg or 10 mg at weekly intervals until optimal response is obtained (maximum daily dose 30 mg/day).</td> </tr> <tr class=\"divider_bottom\"> <td>13 to 17 years: 10 mg once daily</td> <td colspan=\"2\">Daily dosage may be increased to 20 mg/day after one week if symptoms are not adequately controlled.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Switching from one form of XR amphetamine-dextroamphetamine to another<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\" rowspan=\"8\">Amphetamine-dextroamphetamine XR (Adderall XR) capsule</td> <td rowspan=\"8\"> <p>Amphetamine XR orally disintegrating tablet (Adzenys XR-ODT)</p> <p>Amphetamine ER oral suspension (1.25 mg amphetamine base per mL, Adzenys ER)</p> </td> <td rowspan=\"8\">Each 5 mg of amphetamine-dextroamphetamine salts (Adderall XR) is equivalent to approximately 3.1 mg of amphetamine XR-ODT (Adzenys XR-ODT) or amphetamine ER oral suspension (Adzenys ER)</td> <td class=\"divider_bottom\"><strong>Dose expressed as mixed salts: XR capsule (Adderall XR)</strong></td> <td class=\"divider_bottom\"> <p><strong>Dose expressed as base: <strong>ODT-XR tablet and ER oral suspension (Adzenys XR-ODT, Adzenys ER)</strong></strong></p> </td> </tr> <tr> <td class=\"sublist_other\" colspan=\"2\">Approximate equivalence (taken once daily in the morning):</td> </tr> <tr> <td class=\"sublist1\">5 mg</td> <td class=\"sublist_other\">3.1 mg</td> </tr> <tr> <td class=\"sublist1\">10 mg</td> <td class=\"sublist_other\">6.3 mg</td> </tr> <tr> <td class=\"sublist1\">15 mg</td> <td class=\"sublist_other\">9.4 mg</td> </tr> <tr> <td class=\"sublist1\">20 mg</td> <td class=\"sublist_other\">12.5 mg</td> </tr> <tr> <td class=\"sublist1\">25 mg</td> <td class=\"sublist_other\">15.7 mg</td> </tr> <tr> <td class=\"sublist1\">30 mg</td> <td class=\"sublist_other\">18.8 mg</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IR: immediate release; XR: extended release; ODT: orally-disintegrating tablet; ER: extended release.<br />* Ultimate dose must be individualized based upon patient needs and response as children may respond differently to new medication.<br />¶ There are no reliable data to provide guidelines for switching between different classes of long-acting stimulants.<br />Δ When switching from methylphenidate to amphetamine-dextroamphetamine, the ultimate dose of amphetamine-dextroamphetamine is approximately one-half the current dose of methylphenidate (eg, 30 mg of methylphenidate is approximately equal to 15 mg of amphetamine-dextroamphetamine); however, for children who are currently receiving ≥20 mg per day of methylphenidate, we suggest converting to amphetamine-dextroamphetamine at a starting dose of 10 mg once per day and titrating the dose to the child's response (as described in the table).<br /><FONT class=lozenge>◊</FONT> Amphetamine XR-ODT (Adzenys XR-ODT<FONT color=black>) and amphetamine ER (Adzenys ER) strengths reflect milligrams of amphetamine base, whereas amphetamine-</FONT>dextroamphetamine XR (Adderall XR) capsule strengths reflect milligrams of mixed salts. These cannot be substituted on a milligram-per-milligram basis. If switching from any other amphetamine product, discontinue the treatment and retitrate the new product from the appropriate initial starting dose.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>US Food and Drug Administration approved product information. Available at: <A spellcheck=true href=\"http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm\" target=_blank>www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm</A> (Accessed on September 19, 2017).</LI>&#xD;&#xA;<LI>Arnold LE, Lindsay RL, López FA, et al. Treating attention-deficit/hyperactivity disorder with a stimulant transdermal patch: the clinical art. Pediatrics 2007; 120:1100.</LI></OL></div><div id=\"graphicVersion\">Graphic 61007 Version 13.0</div></div></div>"},"61008":{"type":"graphic_picture","displayName":"Western black widow","title":"Western black widow","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Western black widow</div><div class=\"cntnt\"><img style=\"width:504px; height:341px;\" src=\"images/EM/61008_WesternblackwidowPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The western black widow is found throughout the southwestern United States, Colorado, and the dry interior region of Washington State.</div><div class=\"graphic_reference\">Courtesy of Richard Vetter, MS.</div><div id=\"graphicVersion\">Graphic 61008 Version 1.0</div></div></div>"},"61009":{"type":"graphic_figure","displayName":"Pathways of ethanol metabolism","title":"Pathways of ethanol metabolism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathways of ethanol metabolism</div><div class=\"cntnt\"><img style=\"width:433px; height:245px;\" src=\"images/GAST/61009_Pathways_of_ethanol_metabol.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 61009 Version 1.0</div></div></div>"},"61012":{"type":"graphic_table","displayName":"PD cath exit site appearance","title":"Grading of peritoneal catheter exit site based upon appearance","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Grading of peritoneal catheter exit site based upon appearance</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Perfect</td> <td class=\"subtitle1\">Good</td> <td class=\"subtitle1\">Equivocal</td> <td class=\"subtitle1\">Acute infection &#60;4 weeks</td> <td class=\"subtitle1\">Chronic infection &#62;4 weeks</td> <td class=\"subtitle1\">Cuff infection without exit infection</td> </tr> <tr> <td>Pain/tenderness</td> <td>None</td> <td>None</td> <td>None</td> <td>May be present</td> <td>Only if exacerbation</td> <td>May be present over cuff</td> </tr> <tr> <td>Color</td> <td>Natural, pale pink or dark</td> <td>Natural, pale pink, purplish or dark, bright pink &#60;13 mm</td> <td>Bright pink or red &#60;13 mm</td> <td>Bright pink or red &#62;13 mm</td> <td>Bright pink or red &#62;13 mm only if exacerbation</td> <td>Natural, pale pink, purplish or dark, bright pink</td> </tr> <tr> <td>Crust</td> <td>None or small, easily detached or specks of crust on dressing</td> <td>None or small, easily detached or specks of crust on dressing</td> <td>Present, may be large and difficult to detach</td> <td>Present</td> <td>Present, may be difficult to detach</td> <td>Typically absent</td> </tr> <tr> <td>Scab</td> <td>None</td> <td>None</td> <td>None</td> <td>May be present</td> <td>May be present</td> <td>Absent</td> </tr> <tr> <td rowspan=\"2\">Drainage</td> <td rowspan=\"2\">None</td> <td rowspan=\"2\">None</td> <td rowspan=\"2\">None even with pressure on sinus; dried exudate on dressing</td> <td rowspan=\"2\">Purulent or bloody, spontaneous or after pressure on sinus; wet exudate on dressing</td> <td rowspan=\"2\">Purulent or bloody, wet exudate on dressing</td> <td>Chronic or intermittent</td> </tr> <tr> <td>Purulent, bloody, tenacious or \"gluey\"</td> </tr> <tr> <td>Swelling</td> <td>None</td> <td>None</td> <td>None</td> <td>May be present</td> <td>Occurs only if exacerbation</td> <td>Cuff induration may be felt on palpation; negative ultrasound does not rule out the diagnosis</td> </tr> <tr> <td>Granulation tissue</td> <td>None</td> <td>None</td> <td>Plain or slightly exuberant</td> <td>Slightly exuberant or \"proud flesh\" may be present</td> <td>\"Proud flesh\" or slightly exuberant typically visible</td> <td>None</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Trauma may result in pain, bleeding, scab, and deterioration of exit apearance. Exit appearance depends on intensity of trauma and time of evaluation.</div><div class=\"graphic_reference\">Reproduced with permission from Twardowski, ZJ, Prowant, BF. Nephrol Dial Transplant 1997; 12:1284. Copyright © 1997 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 61012 Version 3.0</div></div></div>"},"61013":{"type":"graphic_table","displayName":"Diagnosis of probable MSA","title":"Criteria for the diagnosis of probable multiple system atrophy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for the diagnosis of probable multiple system atrophy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">A sporadic, progressive, adult (&#62;30 years of age)-onset disease characterized by:</td> </tr> <tr> <td class=\"indent1\">Autonomic failure involving urinary incontinence (inability to control the release of urine from the bladder, with erectile dysfunction in males) or an orthostatic decrease of blood pressure within 3 min of standing by at least 30 mmHg systolic or 15 mmHg diastolic <strong>and</strong></td> </tr> <tr> <td class=\"indent1\">Poorly levodopa-responsive parkinsonism (bradykinesia with rigidity, tremor, or postural instability) <strong>or</strong></td> </tr> <tr> <td class=\"indent1\">A cerebellar syndrome (gait ataxia with cerebellar dysarthria, limb ataxia, or cerebellar oculomotor dysfunction)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71:670.</div><div id=\"graphicVersion\">Graphic 61013 Version 3.0</div></div></div>"},"61014":{"type":"graphic_table","displayName":"Methods for assessment of macrosomia","title":"Methods for assessment of macrosomia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Methods for assessment of macrosomia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Method </td> <td class=\"subtitle1\">Sensitivity, percent </td> <td class=\"subtitle1\">Specificity, percent </td> <td class=\"subtitle1\">PPV, percent </td> <td class=\"subtitle1\">NPV, percent </td> </tr> <tr> <td>Maternal estimate: parous women estimate of&nbsp;weight&nbsp;&#62;4000 g<sup>[1]</sup></td> <td>56</td> <td>94</td> <td>77</td> <td>86</td> </tr> <tr> <td>Clinician's estimate of weight&nbsp;&#62;4000 g<sup>[2,15] </sup></td> <td>10 to 43</td> <td>99.0 to 99.8</td> <td>28 to 53</td> <td>-</td> </tr> <tr> <td>Sonographic estimates for weight &#62;4000 g unless otherwise specified<sup> [1-16]</sup></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"5\">1. AC </td> </tr> <tr> <td class=\"sublist1\">for weight &#62;4000 g </td> <td class=\"sublist_other\">77 </td> <td class=\"sublist_other\">75 </td> <td class=\"sublist_other\">91 </td> <td class=\"sublist_other\">50 </td> </tr> <tr> <td class=\"sublist1\">for weight &#62;4500 g </td> <td class=\"sublist_other\">89 </td> <td class=\"sublist_other\">94 </td> <td class=\"sublist_other\">93 </td> <td class=\"sublist_other\">89 </td> </tr> <tr> <td>2. Serial ACs</td> <td>84</td> <td>94</td> <td>93</td> <td>89</td> </tr> <tr> <td>3. FL and AC</td> <td>63</td> <td>-</td> <td>68</td> <td>-</td> </tr> <tr> <td>4. AC and BPD</td> <td>65</td> <td>90</td> <td>-</td> <td>-</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"5\">5. BPD and AC and FL </td> </tr> <tr> <td class=\"sublist1\">for weight &#62;4000 g </td> <td class=\"sublist_other\">71 </td> <td class=\"sublist_other\">92 </td> <td class=\"sublist_other\">55 </td> <td class=\"sublist_other\">96 </td> </tr> <tr> <td class=\"sublist1\">for weight &#62;4500 g </td> <td class=\"sublist_other\">22 to 44 </td> <td class=\"sublist_other\">99 </td> <td class=\"sublist_other\">30 to 44 </td> <td class=\"sublist_other\">97 to 99 </td> </tr> <tr> <td class=\"sublist1_start\">6. BPD and AC and FL adjusted by maternal characteristics </td> <td rowspan=\"2\">86 </td> <td rowspan=\"2\">95 </td> <td rowspan=\"2\">- </td> <td rowspan=\"2\">- </td> </tr> <tr> <td class=\"sublist1_start\" rowspan=\"2\">7. Abdominal wall thickness &#62;11 mm</td> </tr> <tr> <td>70</td> <td>96</td> <td>Less than 50</td> <td>-</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PPV: positive predictive value; NPV: negative predictive value; AC: abdominal circumference; FL: femur length; BPD: biparietal diameter.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Chauhan SP, Sullivan CA, Lutton TC, et al. Parous patients' estimate of birth weight in postterm pregnancy. J Perinatol 1995; 15:192.</LI>&#xD;&#xA;<LI>Chauhan SP, Hendrix NW, Magann EF, et al. Limitations of clinical and sonographic estimates of birth weight: experience with 1034 parturients. Obstet Gynecol 1998; 91:72.</LI>&#xD;&#xA;<LI>Combs CA, Rosenn B, Miodovnik M, Siddiqi TA. Sonographic EFW and macrosomia: is there an optimum formula to predict diabetic fetal macrosomia? J Matern Fetal Med 2000; 9:55.</LI>&#xD;&#xA;<LI>Gilby JR, Williams MC, Spellacy WN. Fetal abdominal circumference measurements of 35 and 38 cm as predictors of macrosomia. A risk factor for shoulder dystocia. J Reprod Med 2000; 45:936. </LI>&#xD;&#xA;<LI>Al-Inany H, Alaa N, Momtaz M, Abdel Badii M. Intrapartum prediction of macrosomia: accuracy of abdominal circumference estimation. Gynecol Obstet Invest 2001; 51:116.</LI>&#xD;&#xA;<LI>Pinette MG, Pan Y, Pinette SG, et al. Estimation of fetal weight: mean value from multiple formulas. J Ultrasound Med 1999; 18:813.</LI>&#xD;&#xA;<LI>Benacerraf BE, Gelman R, Frigoletto FD. Sonographically estimated fetal weights: accuracy and limitation. Am J Obstet Gynecol 1988; 159:1118.</LI>&#xD;&#xA;<LI>Sokol RJ, Chik L, Dombrowski MP, Zador IE. Correctly identifying the macrosomic fetus: improving ultrasonography-based prediction. Am J Obstet Gynecol 2000; 182:1489.</LI>&#xD;&#xA;<LI>Hirata GI, Medearis AL, Horenstein J, et al. Ultrasonographic estimation of fetal weight in the clinically macrosomic fetus. Am J Obstet Gynecol 1990; 162:238.</LI>&#xD;&#xA;<LI>Owen P, Ogston S. Conditional centiles for the quantification of fetal growth. Ultrasound Obstet Gynecol 1998; 11:110.</LI>&#xD;&#xA;<LI>Shields LE, Huff RW, Jackson GM, et al. Fetal growth: a comparison of growth curves with mathematical modeling. J Ultrasound Med 1993; 12:271.</LI>&#xD;&#xA;<LI>Crane JP, Kopta MM, Welt SI, Sauvage JP. Abnormal fetal growth patterns. Ultrasonic diagnosis and management. Obstet Gynecol 1977; 50:205.</LI>&#xD;&#xA;<LI>Hedriana HL, Moore TR. A comparison of single versus multiple growth ultrasonographic examinations in predicting birth weight. Am J Obstet Gynecol 1994; 170:1600.</LI>&#xD;&#xA;<LI>Petrikovsky BM, Oleschuk C, Lesser M, et al. Prediction of fetal macrosomia using sonographically measured abdominal subcutaneous tissue thickness. J Clin Ultrasound 1997; 25:378.</LI>&#xD;&#xA;<LI>Gonen R, Spiegel D, Abend M. Is macrosomia predictable, and are shoulder dystocia and birth trauma preventable? Obstet Gynecol 1996; 88:526.</LI>&#xD;&#xA;<LI>Henrichs C, Magann EF, Brantley KL, et al. Detecting fetal macrosomia with abdominal circumference alone. J Reprod Med 2003; 48:339.</LI></OL></div><div id=\"graphicVersion\">Graphic 61014 Version 5.0</div></div></div>"},"61015":{"type":"graphic_diagnosticimage","displayName":"Villous adenoma BE","title":"Villous adenoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Villous adenoma</div><div class=\"cntnt\"><img style=\"width:246px; height:288px;\" src=\"images/GAST/61015_Villous_adenoma_BE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Double contrast barium enema shows a focal region of mucosal irregularity (arrows) caused by a flat villous adenoma. These benign tumors may be pedunculated or sessile.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 61015 Version 2.0</div></div></div>"},"61016":{"type":"graphic_figure","displayName":"Insertion of donut pessary","title":"Insertion of the donut vaginal pessary","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Insertion of the donut vaginal pessary</div><div class=\"cntnt\"><img style=\"width:352px; height:328px;\" src=\"images/OBGYN/61016_Insertion_of_donut_pessary.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Milex Products, Inc., Chicago, IL.</div><div id=\"graphicVersion\">Graphic 61016 Version 2.0</div></div></div>"},"61017":{"type":"graphic_picture","displayName":"Palm crease PI","title":"Transverse palmar crease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse palmar crease</div><div class=\"cntnt\"><img style=\"width:271px; height:360px;\" src=\"images/PI/61017_Palm_crease_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Children with Down syndrome often have a crease across their palms.</div><div class=\"graphic_reference\">Reproduced with permission from: Clark DA. Atlas of Neonatology, WB Saunders, Philadelphia 2000. Copyright © 2000 Elsevier.</div><div id=\"graphicVersion\">Graphic 61017 Version 2.0</div></div></div>"},"61019":{"type":"graphic_algorithm","displayName":"Dx small intestinal villus atrophy","title":"Diagnostic algorithm for small intestinal villous atrophy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagnostic algorithm for small intestinal villous atrophy</div><div class=\"cntnt\"><img style=\"width:447px; height:478px;\" src=\"images/GAST/61019_Dx_sm_intest_villus_atrophy.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NCE: non-celiac enteropathy; tTG: tissue transglutaminase antibody; IgA: immunoglobulin A; IgG: immunoglobulin G; DGP: deamidated gliadin peptide; HLA: human leukocyte antigen; NRCD: nonresponsive celiac disease; CVID: common variable immunodeficiency; CD: celiac disease.</div><div class=\"graphic_reference\">From: Pallav K, Leffler DA, Tariq S, et al. Noncoeliac enteropathy: the differential diagnosis of villous atrophy in contemporary clinical practice. Aliment Pharmacol Ther 2012; 35:380. Copyright &#169; 2012. Reproduced with permission of John Wiley &amp; Sons, Inc.</div><div id=\"graphicVersion\">Graphic 61019 Version 1.0</div></div></div>"},"61020":{"type":"graphic_table","displayName":"Describing a fracture","title":"Describing a fracture","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Describing a fracture</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n<tbody>\n\n<tr>\n\t<td class=\"container\">\n\t<table cellspacing=\"0\">\n\n <tr>\n    <td class=\"subtitle1_single\">Clinical descriptors</td>\n  </tr>\n  <tr>\n    <td>Age</td>\n  </tr>\n  <tr>\n    <td>Gender</td>\n  </tr>\n  <tr>\n    <td>Mechanism of injury</td>\n  </tr>\n  <tr>\n    <td>Anatomic location</td>\n  </tr>\n  <tr>\n    <td>Soft tissue involvement</td>\n  </tr>\n  <tr>\n    <td>Key physical exam findings</td>\n  </tr>\n\n</table>\n</td>\n\n<td class=\"container\">\n<table cellspacing=\"0\">\n\t\n  <tr>\n    <td class=\"subtitle1_single\">Radiologic descriptors</td>\n  </tr>\n  <tr>\n    <td>Type of imaging</td>\n  </tr>\n  <tr>\n    <td>Anatomic location</td>\n  </tr>\n  <tr>\n    <td>Fracture pattern</td>\n  </tr>\n  <tr>\n    <td>Relationship of fragments</td>\n  </tr>\n  <tr>\n    <td>Physeal involvement</td>\n  </tr>\n  <tr>\n    <td>Apophyseal disruption</td>\n  </tr>\n  <tr>\n    <td>Joint involvement</td>\n  </tr>\n  <tr>\n    <td>Soft tissue involvement</td>\n  </tr>\n\n</table>\n</td>\n</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 61020 Version 1.0</div></div></div>"},"61021":{"type":"graphic_picture","displayName":"Gastric MALT lymphoma Light","title":"Gastric MALT lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric MALT lymphoma</div><div class=\"cntnt\"><img style=\"width:369px; height:562px;\" src=\"images/GAST/61021_Gastric_MALT_lymphoma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Biopsy of a gastric MALT lymphoma showing a dense cellular infiltrate showing virtually complete obliteration of the normal architecture (upper panel). At high power (lower panel) the infiltrate is composed of atypical lymphoid cells that are infiltrating and partially destroying the glands (arrows), referred to as &quot;lymphoepithelial lesions&quot;. Immunohistochemical studies demonstrated that the lymphoid cells were CD20 positive and CD5 and 10 negative. This findings supports the diagnosis of mucosa-associated lymphoma (MALT). The other major consideration in the differential diagnosis is poorly differentiated carcinoma, which would be negative with the CD makers but positive with stains for cytokeratins. Special stainings revealed the presence of Helicobacter pylori.</div><div class=\"graphic_reference\">Courtesy of Heather Crowley, MD and Donald Antonioli, MD.</div><div id=\"graphicVersion\">Graphic 61021 Version 2.0</div></div></div>"},"61027":{"type":"graphic_table","displayName":"Diff dx sudden severe headache","title":"Differential diagnosis of sudden onset severe headache","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of sudden onset severe headache</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Subarachnoid hemorrhage</td>\n</tr>\n<tr>\n<td>Expansion or thrombosis of unruptured intracranial aneurysm</td>\n</tr>\n<tr>\n<td>Intracerebral hemorrhage</td>\n</tr>\n<tr>\n<td>Acute ischemic stroke</td>\n</tr>\n<tr>\n<td>Subdural and epidural hematomas</td>\n</tr>\n<tr>\n<td>Internal carotid and vertebral artery dissection (with face or neck pain)</td>\n</tr>\n<tr>\n<td>Cerebral venous thrombosis</td>\n</tr>\n<tr>\n<td>Pituitary apoplexy</td>\n</tr>\n<tr>\n<td>Colloid cyst of the third ventricle</td>\n</tr>\n<tr>\n<td>Acute expansion of mass lesion in the posterior fossa</td>\n</tr>\n<tr>\n<td>Hypertensive encephalopathy</td>\n</tr>\n<tr>\n<td>Spontaneous intracranial hypotension</td>\n</tr>\n<tr>\n<td>Coital headache</td>\n</tr>\n<tr>\n<td>Acute narrow angle glaucoma</td>\n</tr>\n<tr>\n<td>Exertional headache</td>\n</tr>\n<tr>\n<td>Acute sinusitis (with barotrauma)</td>\n</tr>\n<tr>\n<td>Benign thunderclap headaches</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 61027 Version 1.0</div></div></div>"},"61028":{"type":"graphic_figure","displayName":"Upper airway size analysis","title":"Upper airway size analysis in obstructive sleep apnea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Upper airway size analysis in obstructive sleep apnea</div><div class=\"cntnt\"><img style=\"width:335px; height:722px;\" src=\"images/PEDS/61028_Segment_analysis_percent_ai.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Segmental analysis-percent airway centerline length versus (A) mean airway cross-sectional area, (B) minimal cross-sectional area, and (C) volume. Data points represent mean values ±SD along 10 percent segments. Dotted lines represent estimated measurements between data points. Solid blue circles = subjects with obstructive sleep apnea; open red circles = control subjects. Regions of the adenoid and tonsils adjacent to the airway are shown by horizontal bars. Note the overlap regions for tonsils and adenoid.</div><div class=\"graphic_footnotes\">OSA: obstructive sleep apnea <BR>* p &lt;0.05<BR>** p &lt;0.005<BR>*** p &lt;0.0005</div><div class=\"graphic_reference\">Reproduced with permission from Arens R, McDonough JM, Corbin AM, et al. Upper airway size analysis of children with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2003; 167:65. Official Journal of the American Thoracic Society. Copyright © 2003 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 61028 Version 2.0</div></div></div>"},"61029":{"type":"graphic_figure","displayName":"C1 and C2 bone anatomy","title":"C1 and C2 bone anatomy","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">C1 and C2 bone anatomy</div><div class=\"cntnt\"><img style=\"width:614px; height:622px;\" src=\"images/EM/61029_C1C2boneanatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Observe the occipital condyles that articulate with the superior articular surfaces (facets) of the atlas (vertebra C1).<br> (B) The atlas, on which the cranium rests, has neither a spinous process nor a body. It consists of two lateral masses connected by anterior and posterior arches.<br> (C, D) The tooth-like dens characterizes the axis (vertebra C2) and provides a pivot around which the atlas turns and carries the cranium. It articulates anteriorly with the anterior arch of the atlas (&quot;Facet for dens&quot; in part B) and posteriorly with the transverse ligament of the atlas (see part B).</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 61029 Version 9.0</div></div></div>"},"61030":{"type":"graphic_diagnosticimage","displayName":"Thyroid nodule with spongiform appearance on ultrasound","title":"Thyroid nodule with spongiform appearance on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thyroid nodule with spongiform appearance on ultrasound</div><div class=\"cntnt\"><img style=\"width:283px; height:532px;\" src=\"images/ENDO/61030_Thyroid_nod_appear2_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These are two ultrasound images of thyroid nodules. Panel A shows a layered appearance like Napoleon pastry and panel B a spongiform appearance. Both patterns correlate highly with benign disease.</div><div class=\"graphic_reference\">Courtesy of John Bonavita, MD, Department of Radiology, NYU Langone Medical Center.</div><div id=\"graphicVersion\">Graphic 61030 Version 5.0</div></div></div>"},"61031":{"type":"graphic_figure","displayName":"Fracture geometry","title":"Fracture geometry","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fracture geometry</div><div class=\"cntnt\"><img style=\"width:442px; height:334px;\" src=\"images/SURG/61031_Fracture_geometry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fracture geometry refers to the orientation of the fracture to the long axis of the bone.<br> Fractures are classified as: <ul> <li>Transverse - perpendicular to long axis of bone </li> <li>Oblique - tangential to long axis of bone </li> <li>Spiral - tangential and spiraling around the shaft </li> <li>Longitudinal - parallel to long axis of bone </li> <li>A combination of two or more of the above </li> </ul></div><div id=\"graphicVersion\">Graphic 61031 Version 2.0</div></div></div>"},"61032":{"type":"graphic_figure","displayName":"Tolerance to ISDN","title":"Tolerance to sustained isosorbide dinitrate","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Tolerance to sustained isosorbide dinitrate</div><div class=\"cntnt\"><img style=\"width:506px; height:277px;\" src=\"images/CARD/61032_Tolerance_to_ISDN.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Duration of action of single oral doses of ISDN or placebo during acute and sustained therapy in 12 patients with stable angina. Compared to placebo, ISDN was associated with an increase in exercise time to angina that persisted for eight hours during acute therapy but was attenuated in degree and lasted for only two hours during sustained therapy. The improvement was dose-dependent up to the 30 mg dose; there was no further improvement with the 60 mg (not shown) and 120 mg doses.</div><div class=\"graphic_reference\">Data from Thadani U, Fung H, Darke AC, Parker JO. Am J Cardiol 1982; 49:411.</div><div id=\"graphicVersion\">Graphic 61032 Version 2.0</div></div></div>"},"61033":{"type":"graphic_picture","displayName":"Elastosis 1","title":"Photoaged skin: Solar elastosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Photoaged skin: Solar elastosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/61033_Elastosis_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yellowish discoloration and pebbled appearance of photodamaged, elastotic skin. Note the lighter color and even appearance of the adjacent, sun-protected skin at the bottom of the photograph.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 61033 Version 5.0</div></div></div>"},"61034":{"type":"graphic_table","displayName":"Alfredson's rehabilitation of Achilles tendinopathy","title":"Alfredson's intensive rehabilitation of Achilles tendinopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Alfredson's intensive rehabilitation of Achilles tendinopathy</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   1. Eccentric heel drop description\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   a. Stand with the heel of the affected foot beyond the edge of the step or platform with the foot plantar flexed. Slowly lower the heel, bringing the foot into dorsiflexion.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   b. Perform the exercise both with the knee straight (gastrocnemius) and with the knee bent 45 degrees (soleus).\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   c. Avoid concentric exercise by raising the foot back to the plantar flexed starting position using the unaffected foot, and hands if a railing is available.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   2. Number of exercises\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   a. Perform 3 sets of 15 repetitions with straight knees, then 3 sets of 15 repetitions with bent knees.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   b. Perform this cycle twice daily (180 drops/day).\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   c. Continue the program 7 days per week for 12 to 24 weeks.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   3. Exercise progression\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   a. The exercises must be uncomfortable; when heel drops are no longer painful add weight by using a backpack, dumbbells, or a weight machine.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">3.00000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=10171&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Achilles_tndnpthy_rehab.htm</title></head></div><div class=\"graphic_reference\">Alfredson H, et al. Heavy-load eccentric calf muscle training for the treatment of chronic Achilles tendinosis. Am J Sports Med 1998; 26:360.</div><div id=\"graphicVersion\">Graphic 61034 Version 3.0</div></div></div>"},"61035":{"type":"graphic_figure","displayName":"Breast exam","title":"Breast exam","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Breast exam</div><div class=\"cntnt\"><img style=\"width:534px; height:692px;\" src=\"images/PC/61035_Breast_exam.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A. The breast exam is started with the patient in a seated position with her arms relaxed. Breast inspection is aided by patient positioning. The patient is asked to raise her arms over her head so the lower part of the breasts can be inspected for asymmetry, skin changes, and nipple inversion or retraction. The patient then puts her hands on her hips and presses in to contract the pectoral muscles so that any other areas of retraction can be visualized. <br>B. The regional lymph node exam is completed while the patient is still in the sitting position and includes the cervical, supraclavicular, infraclavicular, and axillary nodal basins.<br>C. A bimanual examination of the breasts can be performed while the patient is still in the sitting position. This is especially useful for women with large pendulous breasts. <br>D. The breast exam is completed with the patient in a supine position with the ipsilateral arm raised above her head. The area examined should extend from the clavicle superiorly to the rib cage inferiorly and from the sternum medially to the mid-axillary line laterally. A systematic approach ensures that the entire breast is examined. This can be accomplished with either concentric circles, a radial approach, or vertical strips, referred to as the &quot;lawnmower&quot; method.</div><div id=\"graphicVersion\">Graphic 61035 Version 2.0</div></div></div>"},"61036":{"type":"graphic_picture","displayName":"Full-thickness burn","title":"Full-thickness burn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Full-thickness burn</div><div class=\"cntnt\"><img style=\"width:342px; height:303px;\" src=\"images/EM/61036_Full_thickness_burn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Burn areas that are waxy white or leathery gray and insensate characterize full-thickness burns.</div><div class=\"graphic_reference\">Courtesy of Eric D Morgan, MD and William F Miser, MD.</div><div id=\"graphicVersion\">Graphic 61036 Version 3.0</div></div></div>"},"61037":{"type":"graphic_table","displayName":"Papules","title":"Differential diagnosis of papules","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of papules</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Isolated papules</td></tr>\n\t\t\t\t\t\t<tr><td>Acrochordon</td></tr>\n\t\t\t\t\t\t<tr><td>Actinic keratosis</td></tr>\n\t\t\t\t\t\t<tr><td>Angiofibroma</td></tr>\n\t\t\t\t\t\t<tr><td>Appendageal tumors (benign or malignant)</td></tr>\n\t\t\t\t\t\t<tr><td>Bacillary angiomatosis</td></tr>\n\t\t\t\t\t\t<tr><td>Basal cell carcinoma</td></tr>\n\t\t\t\t\t\t<tr><td>Chondrodermatitis nodularis helicis</td></tr>\n\t\t\t\t\t\t<tr><td>Dermatofibroma</td></tr>\n\t\t\t\t\t\t<tr><td>Fungal infections (early)</td></tr>\n\t\t\t\t\t\t<tr><td>Hemangioma</td></tr>\n\t\t\t\t\t\t<tr><td>Keratoacanthoma</td></tr>\n\t\t\t\t\t\t<tr><td>Melanoma</td></tr>\n\t\t\t\t\t\t<tr><td>Milia</td></tr>\n\t\t\t\t\t\t<tr><td>Molluscum contagiosum</td></tr>\n\t\t\t\t\t\t<tr><td>Neurofibroma</td></tr>\n\t\t\t\t\t\t<tr><td>Nevus</td></tr>\n\t\t\t\t\t\t<tr><td>Pyogenic granuloma</td></tr>\n\t\t\t\t\t\t<tr><td>Sebaceous hyperplasia</td></tr>\n\t\t\t\t\t\t<tr><td>Seborrheic keratosis</td></tr>\n\t\t\t\t\t\t<tr><td>Squamous cell carcinoma</td></tr>\n\t\t\t\t\t\t<tr><td>Venous lake</td></tr>\n\t\t\t\t\t\t<tr><td>Wart</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Papular eruptions</td></tr>\n\t\t\t\t\t\t<tr><td>Acne rosacea</td></tr>\n\t\t\t\t\t\t<tr><td>Acne vulgaris</td></tr>\n\t\t\t\t\t\t<tr><td>Appendageal tumors (usually benign)</td></tr>\n\t\t\t\t\t\t<tr><td>Arthropod bite</td></tr>\n\t\t\t\t\t\t<tr><td>Bacillary angiomatosis</td></tr>\n\t\t\t\t\t\t<tr><td>Dermatomyositis</td></tr>\n\t\t\t\t\t\t<tr><td>Drug eruption</td></tr>\n\t\t\t\t\t\t<tr><td>Eczematous dermatitis</td></tr>\n\t\t\t\t\t\t<tr><td>Flat warts</td></tr>\n\t\t\t\t\t\t<tr><td>Folliculitis</td></tr>\n\t\t\t\t\t\t<tr><td>Granuloma annulare</td></tr>\n\t\t\t\t\t\t<tr><td>Keratosis pilaris</td></tr>\n\t\t\t\t\t\t<tr><td>Lichen nitidus</td></tr>\n\t\t\t\t\t\t<tr><td>Lichen planus</td></tr>\n\t\t\t\t\t\t<tr><td>Lichen sclerosus</td></tr>\n\t\t\t\t\t\t<tr><td>Lupus erythematosus</td></tr>\n\t\t\t\t\t\t<tr><td>Lymphoma</td></tr>\n\t\t\t\t\t\t<tr><td>Miliaria</td></tr>\n\t\t\t\t\t\t<tr><td>Molluscum contagiosum</td></tr>\n\t\t\t\t\t\t<tr><td>Neurofibromatosis</td></tr>\n\t\t\t\t\t\t<tr><td>Pediculosis corporis</td></tr>\n\t\t\t\t\t\t<tr><td>Perioral dermatitis</td></tr>\n\t\t\t\t\t\t<tr><td>Pityriasis rosea</td></tr>\n\t\t\t\t\t\t<tr><td>Polymorphous light eruption</td></tr>\n\t\t\t\t\t\t<tr><td>Psoriasis</td></tr>\n\t\t\t\t\t\t<tr><td>Sarcoidosis</td></tr>\n\t\t\t\t\t\t<tr><td>Sarcoma</td></tr>\n\t\t\t\t\t\t<tr><td>Scabies</td></tr>\n\t\t\t\t\t\t<tr><td>Syphilis</td></tr>\n\t\t\t\t\t\t<tr><td>Urticaria</td></tr>\n\t\t\t\t\t\t<tr><td>Vasculitis</td></tr>\n\t\t\t\t\t\t<tr><td>Viral exanthem</td></tr>\n\t\t\t\t\t\t<tr><td>Xanthoma</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 61037 Version 1.0</div></div></div>"},"61038":{"type":"graphic_figure","displayName":"Pressures mitral stenosis II","title":"Pressure tracings in mitral stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pressure tracings in mitral stenosis</div><div class=\"cntnt\"><img style=\"width:394px; height:198px;\" src=\"images/CARD/61038_Pressuresmitralstenosis1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intracardiac pressures, measured simultaneosuly from the left atrium (LA) via a transseptal catheter and left ventricle (LV) in a patient with mitral stenosis, demonstrate a persistent diastolic pressure gradient (shaded area) between the LA and LV. The time for diastole (sec per beat), known as the diastolic filling period (DFP), and the mean gradient are used to compute the valve area from the Gorlin formula (mitral valve area = cardiac output ÷ [37.7 x DFP x heart rate x sq rt mean gradient]).</div><div class=\"graphic_reference\">Redrawn from Kern MJ (Ed). Cardiac Catheterization Handbook, 2nd ed. Mosby-Year Book, St. Louis, 1995.</div><div id=\"graphicVersion\">Graphic 61038 Version 3.0</div></div></div>"},"61039":{"type":"graphic_picture","displayName":"Localized granuloma annulare on hand","title":"Granuloma annulare, localized","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Granuloma annulare, localized</div><div class=\"cntnt\"><img style=\"width:432px; height:340px;\" src=\"images/DERM/61039_Localized_granuloma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 27-year-old presented with a nine month history of a solitary, slowly enlarging, annular patch of granuloma annulare 10 cm in diameter on the right hand. It has 1 to 1.5 mm skin-colored papules at the periphery and complete clearing in the center of the lesion.</div><div id=\"graphicVersion\">Graphic 61039 Version 2.0</div></div></div>"},"61040":{"type":"graphic_picture","displayName":"Oral candidiasis - palate","title":"Oral candidiasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oral candidiasis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/61040_Oral_candidiasis_palate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">White papules and plaques are present on the palate and tongue.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 61040 Version 3.0</div></div></div>"},"61044":{"type":"graphic_picture","displayName":"Short protrusion of the tongue","title":"Short protrusion of the tongue","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Short protrusion of the tongue</div><div class=\"cntnt\"><img style=\"width:371px; height:356px;\" src=\"images/PEDS/61044_Short_protrusion_tongue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inability to protrude the tongue more than 1 to 2 mm past the lower central incisors.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 61044 Version 3.0</div></div></div>"},"61045":{"type":"graphic_table","displayName":"Syndromic microcephaly","title":"Selected syndromes with microcephaly as a characteristic feature","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected syndromes with microcephaly as a characteristic feature</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td> <p>Down syndrome</p> <p><a href=\"http://omim.org/entry/190685\" target=\"_blank\">MIM #190685</a></p> </td> <td>Brachycephaly, upslanting palpebral fissures, epicanthal folds, short neck, transverse palmar crease, space between first and second toes, hypotonia</td> </tr> <tr class=\"divider_top\"> <td>Trisomy 18</td> <td>Prominent occiput, narrow bifrontal diameter, hypoplastic supraorbital ridge, short palpebral fissures, micrognathia, structural cardiac lesions (ventricular septal defect, atrial septal defect, patent ductus arteriosus)</td> </tr> <tr class=\"divider_top\"> <td>Trisomy 13</td> <td>Holoprosencephaly, wide sagittal suture, cleft lip, cleft palate, loose skin, transverse palmar crease, polydactyly, posterior prominence of heel; structural cardiac lesions (ventricular septal defect, patent ductus arteriosus, atrial septal defect, dextrocardia)</td> </tr> <tr class=\"divider_top\"> <td>Fetal alcohol syndrome</td> <td>Pre- and postnatal growth retardation, short palpebral fissures, flat philtrum, thin upper lip</td> </tr> <tr class=\"divider_top\"> <td> <p>Seckel syndrome</p> <p><a href=\"http://omim.org/entry/210600\" target=\"_blank\">MIM #210600</a></p> </td> <td>Pre- and postnatal growth retardation, average birth weight approximately 1540 g, proportionate short stature; micrognathia, facial asymmetry, downslanting palpebral fissures, prominent beaked nose; limb hypoplasia; gap between first and second toes</td> </tr> <tr class=\"divider_top\"> <td> <p>Smith-Lemli-Opitz</p> <p><a href=\"http://omim.org/entry/270400\" target=\"_blank\">MIM #270400</a></p> </td> <td>Ptosis, broad nasal tip, anteverted nostrils, cleft palate, micrognathia, congenital heart defects, syndactyly of second and third toes, postaxial polydactyly, hypospadias or cryptorchidism (in boys)</td> </tr> <tr class=\"divider_top\"> <td> <p>Williams-Beuren (7q11.23 deletion)</p> <p><a href=\"http://omim.org/entry/194050\" target=\"_blank\">MIM #194050</a></p> </td> <td>Cardiovascular disease (supravalvular aortic stenosis), idiopathic hypercalcemia, periorbital fullness, short upturned nose, long philtrum, wide mouth, full lips</td> </tr> <tr class=\"divider_top\"> <td> <p>Cornelia de Lange</p> <p><a href=\"http://omim.org/entry/122470\" target=\"_blank\">MIM 122470</a>, <a href=\"http://omim.org/entry/300590\" target=\"_blank\">300590</a>, <a href=\"http://omim.org/entry/610759\" target=\"_blank\">610759</a></p> </td> <td>Pre- and postnatal growth retardation, generalized hirsutism, fusion of eyebrows (synophrys), arched brows, long eyelashes, small upturned nose, thin lips, midline beaking of the upper lip; limb reduction defects, missing fingers, syndactyly of second and third toes</td> </tr> <tr class=\"divider_top\"> <td> <p>Miller-Dieker lissencephaly (17p13.3 deletion)</p> <p><a href=\"http://omim.org/entry/247200\" target=\"_blank\">MIM #247200</a></p> </td> <td>Bitemporal narrowing, upturned nose, small jaw, vertical furrowing of forehead, micrognathia, genitourinary anomalies</td> </tr> <tr class=\"divider_top\"> <td> <p>Wolf-Hirschhorn (4p deletion)</p> <p><a href=\"http://omim.org/entry/194190\" target=\"_blank\">MIM #194190</a></p> </td> <td>Congenital heart disease, hearing loss, prominent glabella, hypertelorism, wide nasal bridge, beaked nose, short philtrum, down-turned upper lip</td> </tr> <tr class=\"divider_top\"> <td> <p>Cri-du-chat (5p15.2 deletion)</p> <p><a href=\"http://omim.org/entry/123450\" target=\"_blank\">MIM #123450</a></p> </td> <td>Round face, hypertelorism, micrognathia, epicanthal folds, hypotonia, high-pitched cry</td> </tr> <tr class=\"divider_top\"> <td> <p>Monosomy 1p36 deletion</p> <p><a href=\"http://omim.org/entry/607872\" target=\"_blank\">MIM #607872</a></p> </td> <td>Brachycephaly, large fontanelle, pointed chin, hearing loss, flat nasal bridge, flat nose, cleft lip, cleft palate, short fifth finger</td> </tr> <tr class=\"divider_top\"> <td> <p>Mowat-Wilson</p> <p><a href=\"http://omim.org/entry/235730\" target=\"_blank\">MIM #235730</a></p> </td> <td>Pre- or postnatal microcephaly, short stature, hypertelorism, iris coloboma, deep-set eyes, downslanting palpebral fissures, cupped ears, pointed chin, seizures, hypospadias (in boys), Hirschsprung's disease, congenital heart disease</td> </tr> <tr class=\"divider_top\"> <td> <p>Rubinstein-Taybi</p> <p><a href=\"http://omim.org/entry/180849\" target=\"_blank\">MIM #180849</a></p> </td> <td>Postnatal short stature, low anterior hairline, hypoplastic maxilla, micrognathia, heavy eyebrows, long eyelashes, broad thumbs and big toes</td> </tr> <tr class=\"divider_top\"> <td> <p>Aicardi-Gouti&#232;res syndrome</p> <p><a href=\"http://omim.org/entry/225750\" target=\"_blank\">MIM #225750</a></p> </td> <td>Congenital microcephaly, abnormal eye movements, hepatosplenomegaly, cerebral calcification, thrombocytopenia, spasticity, seizures</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:<br> <ol> <li>Abuelo D. Microcephaly syndromes. Semin Pediatr Neurol 2007; 14:118. </li> <li>Firth HV, Hurst JA, Hall JG. Microcephaly. In: Oxford Desk Reference: Clinical Genetics, 1st ed. Oxford University Press, Oxford 2005. p.172. </li> </ol></div><div id=\"graphicVersion\">Graphic 61045 Version 8.0</div></div></div>"},"61046":{"type":"graphic_table","displayName":"Drugs causing lymphadenopathy","title":"Drugs that cause lymphadenopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs that cause lymphadenopathy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Allopurinol</td>\n\n</tr>\n<tr>\n<td>Atenolol</td>\n\n</tr>\n<tr>\n<td>Captopril</td>\n\n</tr>\n<tr>\n<td>Carbamazepine</td>\n\n</tr>\n<tr>\n<td>Cephalosporins</td>\n\n</tr>\n<tr>\n<td>Gold</td>\n\n</tr>\n<tr>\n<td>Hydralazine</td>\n\n</tr><tr><td>Penicillin</td></tr><tr><td>Phenytoin</td></tr><tr><td>Primidone</td></tr><tr><td>Pyrimethamine</td></tr><tr><td>Quinidine</td></tr><tr><td>Sulfonamides</td></tr><tr><td>Sulindac</td></tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Data&nbsp;from Pangalis GA, Vassilakopoulos TP, Boussiotis VA, Fessas P. Clinical approach to lymphadenopathy. Semin Oncol 1993; 20:570.</div><div id=\"graphicVersion\">Graphic 61046 Version 3.0</div></div></div>"},"61047":{"type":"graphic_picture","displayName":"Back leg raise exercise","title":"Strength exercise: Back leg raise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Strength exercise: Back leg raise</div><div class=\"cntnt\"><img style=\"width:369px; height:297px;\" src=\"images/PC/61047_Back_leg_raise_exercise_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This exercise strengthens your buttocks and lower back. For an added challenge, you can modify the exercise to improve your balance.   <OL>  <LI>Stand behind a sturdy chair, holding on for balance. Breathe in slowly. </LI>  <LI>Breathe out and slowly lift one leg straight back without bending your knee or pointing your toes. Try not to lean forward. The leg you are standing on should be slightly bent. </LI>  <LI>Hold position for one second. </LI>  <LI>Breathe in as you slowly lower your leg. </LI>  <LI>Repeat 10 to 15 times. </LI>  <LI>Repeat 10 to 15 times with other leg. </LI>  <LI>Repeat 10 to 15 more times with each leg. </LI></OL>As you progress, you may want to add ankle weights.</div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 61047 Version 3.0</div></div></div>"},"61048":{"type":"graphic_table","displayName":"Age related shoulder pain","title":"Age-related causes and clinical characteristics of intrinsic shoulder pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Age-related causes and clinical characteristics of intrinsic shoulder pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Clinical characteristics</td> </tr> <tr> <td rowspan=\"3\">Adolescents and young adults</td> <td>Overuse injuries</td> <td>Pain and loss of function associated with a particular athletic activity</td> </tr> <tr> <td>Acromioclavicular sprain</td> <td>Focal pain over acromioclavicular joint; history of trauma</td> </tr> <tr> <td>Shoulder instability</td> <td>Minor trauma, high risk of recurrence</td> </tr> <tr> <td rowspan=\"7\">Middle-aged and older individuals</td> <td>Rotator cuff tendinopathy or impingement syndrome</td> <td>Pain, difficulty with active abduction and external rotation, pain at night, crepitus may be felt with lifting arm beyond 60&#176; in impingement syndrome</td> </tr> <tr> <td>Rotator cuff tears</td> <td>Pain and inability to actively abduct the arm, passive abduction is preserved</td> </tr> <tr> <td>Subacromial bursitis or inflammatory synovitis</td> <td>Features resemble rotator cuff tendinopathy, may be seen with rheumatoid arthritis, polymyalgia rheumatica, or crystal-induced arthritis</td> </tr> <tr> <td>Adhesive capsulitis (frozen shoulder)</td> <td>Pain, stiffness, and marked loss of shoulder motion; risk factors include diabetes mellitus and prolonged immobilization</td> </tr> <tr> <td>Bicipital tendinitis</td> <td>Pain and tenderness anteriorly within the bicipital groove</td> </tr> <tr> <td>Osteoarthritis</td> <td>Associated with damage to the rotator cuff, rheumatoid arthritis, or chondrocalcinosis</td> </tr> <tr> <td>Myofascial pain</td> <td>Diffuse soft tissue tenderness in the shoulder region and over the chest wall</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 61048 Version 2.0</div></div></div>"},"61049":{"type":"graphic_picture","displayName":"Severe eczema hyper IgE","title":"Severe eczema in an infant with hyperimmunoglobulin E syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe eczema in an infant with hyperimmunoglobulin E syndrome</div><div class=\"cntnt\"><img style=\"width:390px; height:583px;\" src=\"images/ALLRG/61049_Severe_eczema_hyper_IgE_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 61049 Version 7.0</div></div></div>"},"61050":{"type":"graphic_table","displayName":"ACC AHA Treatment critical limb ischemia","title":"ACC/AHA guideline summary: Treatment of critical limb ischemia ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA guideline summary: Treatment of critical limb ischemia </div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Class I - There is evidence and/or general\nagreement for the following approach to the management of critical limb\nischemia</td>\n</tr>\n<tr>\n<td>&#8226;&nbsp; Rapid evaluation and treatment of factors known to increase the risk of primary amputation. These include significant necrosis of weight-bearing parts of the foot in ambulatory patients, an uncorrectable flexion contracture, paresis of the extremity, ischemic rest pain, sepsis, or limited life expectancy due to comorbid disease</td>\n</tr>\n\n\n\n<tr>\n<td>&#8226;&nbsp; The development of acute limb symptoms in patients at risk for CLI (those with diabetes, neuropathy, chronic renal failure, or infection) is a potential vascular emergency that should be assessed immediately and treated by a specialist in vascular disease.</td>\n</tr>\n\n\n<tr>\n<td>&#8226;&nbsp; Prompt initiation of systemic antibiotics in patients with skin ulceration and evidence of limb infection.</td>\n</tr>\n\n<tr>\n<td>&#8226;&nbsp; Evaluation for aneurysmal disease (eg, in the abdominal aorta or popliteal or common femoral artery) in patients with evidence of atheroembolization, such as blue toe syndrome or livedo reticularis.</td>\n</tr>\n\n\n<tr>\n<td>&#8226;&nbsp; Catheter-based thrombolysis for acute limb ischemia (Rutherford category I or IIa) of less than 14 days duration.</td>\n</tr>\n\n<tr>\n<td>&#8226;&nbsp; Preoperative estimation of cardiovascular risk if open surgical repair is anticipated.</td>\n</tr>\n<tr>\n<td>&#8226;&nbsp; When endovascular treatment or surgery is performed for combined inflow and outflow disease, the inflow lesions should be addressed first. If symptoms or infection persist after inflow revascularization, an outflow revascularization should be performed.</td>\n</tr>\n\n\n<tr>\n<td>&#8226;&nbsp; If it is uncertain if there is hemodynamically significant inflow disease, intraarterial pressure should be measured before and after administration of a vasodilator.</td>\n</tr>\n\n<tr>\n<td>&#8226;&nbsp; Patients with skin breakdown should be referred to a healthcare provider with expertise in wound care.</td>\n</tr>\n\n<tr>\n<td>&#8226;&nbsp; Patients who have been successfully treated for CLI are at relatively high risk for recurrence. They should be evaluated at least twice yearly by a vascular specialist and be given verbal and written instructions for self-surveillance for recurrence.</td>\n</tr>\n\n\n<tr>\n<td class=\"subtitle1_single\">Class IIa - The weight of evidence or\nopinion is in favor of benefit for the following modality in the\nmanagement of critical limb ischemia</td>\n</tr>\n<tr>\n<td>&#8226;&nbsp; Mechanical thrombectomy as adjunctive therapy for acute limb ischemia due to peripheral artery occlusion.</td>\n</tr>\n\n<tr>\n<td class=\"subtitle1_single\">Class IIb - The evidence or opinion is\nless well established for the following modalities in the management of\ncritical limb ischemia</td>\n</tr>\n<tr>\n<td>&#8226;&nbsp; Angiogenic growth factors.</td>\n</tr>\n<tr>\n<td>&#8226;&nbsp; Catheter-based thrombolysis or thrombectomy for acute limb ischemia (Rutherford category IIb) of more than 14 days duration.</td>\n</tr>\n\n<tr>\n<td class=\"subtitle1_single\">Class III - There is evidence and/or\ngeneral agreement that the following modalities are not useful in the\nmanagement of critical limb ischemia</td>\n</tr>\n<tr>\n<td>&#8226;&nbsp; Parenteral pentoxifylline.</td>\n</tr>\n<tr>\n<td>&#8226;&nbsp; Oral iloprost.</td>\n</tr>\n<tr>\n<td>&#8226;&nbsp; Surgery or endovascular treatment for severe hypoperfusion (eg, ABI less than 0.4) in the absence of symptoms.</td>\n</tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Hirsch, AT, Haskal, ZJ, Hertzer, NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.</div><div id=\"graphicVersion\">Graphic 61050 Version 2.0</div></div></div>"},"61051":{"type":"graphic_picture","displayName":"Emerson iron lung","title":"Emerson iron lung","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Emerson iron lung</div><div class=\"cntnt\"><img style=\"width:360px; height:242px;\" src=\"images/PULM/61051_Emerson_iron_lung.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Emerson iron lung exemplifying design dating back to the 1930s. Patient's head protrudes through neck collar on left, and electric motor beneath the tank generates negative pressure via the leather bellows on the right. The device weighs 300 kg.</div><div id=\"graphicVersion\">Graphic 61051 Version 2.0</div></div></div>"},"61052":{"type":"graphic_table","displayName":"Treatment of Pneumocystis infection","title":"Drugs used in the treatment of <EM>Pneumocystis </EM>pneumonia (PCP) in adults and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs used in the treatment of <EM>Pneumocystis </EM>pneumonia (PCP) in adults and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dosage</td> <td class=\"subtitle1\">Major adverse reactions</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Preferred regimen</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">TMP-SMX</td> <td>TMP-SMX (15 to 20 mg/kg/day of the trimethoprim component) orally or IV given in three or four divided doses*<sup>&#182;</sup></td> <td>Rash (rarely SJS/TEN), fever, neutropenia, hyperkalemia, transaminase elevations, photosensitivity, increased serum creatinine</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Alternative regimens</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">TMP <strong>plus</strong> dapsone<sup>&#916;</sup></td> <td>TMP: 5 mg/kg orally three times daily<sup>&#182;</sup></td> <td>Trimethoprim: Rash, gastrointestinal distress, transaminase elevation, neutropenia, hyperkalemia</td> </tr> <tr> <td>Dapsone: 100 mg orally once per day</td> <td>Dapsone: Rash, fever, lymphadenopathy, transaminase elevations (sulfone hypersensitivity syndrome), gastrointestinal upset, methemoglobinemia, hemolytic anemia</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Primaquine<sup>&#916;</sup> <strong>plus</strong> clindamycin*</td> <td>Primaquine: 30 mg (base) orally once per day</td> <td>Primaquine: Rash, fever, gastrointestinal distress, methemoglobinemia, hemolytic anemia, leukopenia, neutropenia</td> </tr> <tr> <td>Clindamycin: 900 mg IV every&nbsp;eight hours <strong>OR</strong> 600 mg IV every&nbsp;six hours <strong>OR</strong> 600 mg orally three times daily <strong>OR</strong> 450 mg orally four times daily</td> <td>Clindamycin: Rash, diarrhea, <em>Clostridium difficile </em>colitis, abdominal pain</td> </tr> <tr> <td class=\"indent1\">Atovaquone suspension</td> <td>750 mg orally twice daily (must be taken with food)</td> <td>Gastrointestinal distress, fever, transaminase elevation, rash (less frequently than with other regimens)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pentamidine<sup>&#9674;</sup></td> <td>4 mg/kg IV once daily<sup>&#182;</sup></td> <td> <p>Nephrotoxicity, infusion reactions, hyperkalemia, hyperglycemia, pancreatitis, cardiac arrhythmias (including TdP), transaminase elevations, hypotension, hypoglycemia, hypokalemia, hypocalcemia</p> <p>Certain adverse effects can be life threatening (eg, hypoglycemia and hypotension)<sup>&#167;</sup></p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Adjunctive glucocorticoids<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Prednisone</td> <td> <p>40 mg orally twice daily for&nbsp;five days, followed by</p> <p>40 mg orally once daily for&nbsp;five days, followed by</p> 20 mg orally once daily for 11 days</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Patients should receive 21 days of therapy.</div><div class=\"graphic_footnotes\">IV: intravenously; G6PD: glucose-6-phosphate dehydrogenase; SJS/TEN: Stevens-Johnson syndrome and toxic epidermal necrolysis; TdP: torsades de pointes; TMP-SMX: trimethoprim-sulfamethoxazole (cotrimoxazole).<br />* IV preferred in patients with PaO2 &lt;60 mmHg, respiratory rate &gt;25 or respiratory fatigue, unable to take oral medications.<br />¶ Dose shown in table is for patients with normal renal function. Dose modification for renal impairment may be needed.<br />Δ Check for G6PD deficiency.<br />◊ Pentamidine should only be used for patients with severe disease. Individuals requiring pentamidine should be admitted to the hospital and closely monitored with bedside telemetry and frequent measurement of blood pressure. Pentamidine dose may be reduced to 3 mg/kg IV daily due to toxicity. Refer to accompanying text.<br />§&nbsp;Adjunctive glucocorticoids should be given to patients with a room air PaO2 &lt;70 mmHg, an alveolar-arterial (A-a) oxygen gradient ≥35 mmHg, and/or evidence of hypoxemia (eg,&nbsp;room air O2 saturation &lt;92 percent). IV methylprednisolone can be administered as 75 percent&nbsp;of prednisone dose.</div><div class=\"graphic_reference\">Prepared with data from: DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. (Updated April 22, 2015.)</div><div id=\"graphicVersion\">Graphic 61052 Version 11.0</div></div></div>"},"61054":{"type":"graphic_table","displayName":"Summary of meta analyses of heart failure management programs","title":"Summary results from meta analyses of heart failure disease management programs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary results from meta analyses of heart failure disease management programs</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Outcome</td> <td class=\"subtitle1\"> <p>All types of chronic disease management</p> <p>RR (95% CI)</p> </td> <td class=\"subtitle1\">N</td> <td class=\"subtitle1\"> <p>Specialized follow-up by multidisciplinary team</p> <p>RR (95% CI)</p> </td> <td class=\"subtitle1\">N</td> <td class=\"subtitle1\"> <p>Telephone contact and improved coordination of primary care services</p> <p>RR (95% CI)</p> </td> <td class=\"subtitle1\">N</td> <td class=\"subtitle1\"> <p>Enhanced self-care or patient education</p> <p>RR (95% CI)</p> </td> <td class=\"subtitle1\">N</td> <td class=\"subtitle1\">&nbsp;Home-visiting program (95% CI)</td> <td class=\"subtitle1\">&nbsp;N</td> </tr> <tr> <td rowspan=\"3\"><strong>Mortality (most studies three to six months)</strong></td> <td>0.94 (0.75-1.19)<sup>[1]</sup></td> <td>2067</td> <td>0.75 (0.59-0.96)<sup>[3]</sup></td> <td>946</td> <td>0.91 (0.67-1.29)<sup>[3]</sup></td> <td>1193</td> <td>1.14 (0.67-1.94)<sup>[3]</sup></td> <td>459</td> <td>0.77 (0.60-0.997)<sup>[10]</sup></td> <td>&nbsp;1693</td> </tr> <tr> <td>0.80 (0.69, 0.93)<sup>[2]</sup></td> <td>5308</td> <td>0.98 (0.72-1.34)<sup>[4]</sup></td> <td>1039</td> <td>0.85 (0.72-1.01)<sup>[5]</sup></td> <td>3542</td> <td>0.87 (0.72-1.06)<sup>[7]</sup></td> <td>3238</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"2\">&nbsp;</td> <td rowspan=\"2\">&nbsp;</td> <td>&nbsp;0.56 (0.34-0.92)<sup>[10]</sup></td> <td>&nbsp;536</td> <td>0.88 (0.76-1.01)<sup>[6]</sup></td> <td>5563</td> <td>0.93 (0.57-1.51)<sup>[8]</sup></td> <td>385</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;0.74 (0.56-0.97)<sup>[10]</sup></td> <td>2011</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\"><strong>All-cause hospitalization (most studies three to six months)</strong></td> <td>0.88 (0.79-0.97)<sup>[9]</sup></td> <td>4440</td> <td>0.77 (0.68-0.86)<sup>[1]</sup></td> <td>1366</td> <td>1.15 (0.96-1.37)<sup>[1]</sup></td> <td>646</td> <td>0.73 (0.57-0.93)<sup>[3]</sup></td> <td>459</td> <td>0.75 (0.68-0.86)<sup>[10]</sup></td> <td>&nbsp;1563</td> </tr> <tr> <td>0.87 (0.79-0.96)<sup>[1]</sup></td> <td>2067</td> <td>0.81 (0.71-0.92)<sup>[3]</sup></td> <td>1145</td> <td>0.98 (0.80-1.20)<sup>[3]</sup></td> <td>1581</td> <td>0.80 (0.71-0.89)<sup>[7]</sup></td> <td>1519</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>0.80 (0.68-0.94)<sup>[2]</sup></td> <td>4603</td> <td>0.79 (0.68-0.91)<sup>[4]</sup></td> <td>1246</td> <td>0.94 (0.87-1.02)<sup>[5]</sup></td> <td>3200</td> <td>0.59 (0.44-0.80)<sup>[8]</sup></td> <td>787</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"3\">&nbsp;</td> <td rowspan=\"3\">&nbsp;</td> <td rowspan=\"3\">&nbsp;0.70 (0.55-0.89)<sup>[10]</sup></td> <td rowspan=\"3\">&nbsp;336</td> <td>0.86 (0.73-1.02)<sup>[7]</sup></td> <td>3349</td> <td rowspan=\"2\">&nbsp;</td> <td rowspan=\"2\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>0.92 (0.95-0.99)<sup>[6]</sup></td> <td>4295</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;0.92 (0.77-1.10)<sup>[10]</sup></td> <td>&nbsp;2166</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>Heart failure hospitalization (most studies three to six months)</strong></td> <td>0.70 (0.62-0.79)<sup>[9]</sup></td> <td>3160</td> <td>0.74 (0.63-0.87)<sup>[3]</sup></td> <td>657</td> <td>0.75 (0.57-0.99)<sup>[3]</sup></td> <td>1024</td> <td>0.66 (0.52-0.83)<sup>[3]</sup></td> <td>568</td> <td>&nbsp;0.51 (0.31-0.82)<sup>[10]</sup></td> <td>&nbsp;282</td> </tr> <tr> <td rowspan=\"3\">&nbsp;</td> <td rowspan=\"3\">&nbsp;</td> <td rowspan=\"3\">&nbsp;0.70 (0.29-1.70)<sup>[10]</sup></td> <td rowspan=\"3\">&nbsp;106</td> <td>0.78 (0.68-0.89)<sup>[5]</sup></td> <td>3268</td> <td>0.44 (0.27-0.71)<sup>[8]</sup></td> <td>381</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>0.77 (0.68-0.87)<sup>[6]</sup></td> <td>4269</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;0.74 (0.61-0.90)<sup>[10]</sup></td> <td>&nbsp;1790</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td><strong>Combined mortality and hospitalization (most studies three to six months)</strong></td> <td>0.82 (0.72-0.94)<sup>[9]</sup></td> <td>2985</td> <td>&nbsp;0.80 (0.43-1.01)</td> <td>306&nbsp;</td> <td>&nbsp;0.81 (0.58-1.12)<sup>[10]</sup></td> <td>&nbsp;977</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;0.78 (0.65-0.94)<sup>[10]</sup></td> <td>&nbsp;824</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>McAlister FA, Lawson FM, Teo KK, Armstrong PW. A systematic review of randomized trials of disease management programs in heart failure. Am J Med 2001; 110:378. </LI>&#xD;&#xA;<LI>Roccaforte R, Demers C, Baldassarre F, et al. Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta-analysis. Eur J Heart Fail 2005; 7:1133. </LI>&#xD;&#xA;<LI>McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 2004; 44:810. </LI>&#xD;&#xA;<LI>Gwadry-Sridhar FH, Flintoft V, Lee DS, et al. A systematic review and meta-analysis of studies comparing readmission rates and mortality rates in patients with heart failure. Arch Intern Med 2004; 164:2315. </LI>&#xD;&#xA;<LI>Clark RA, Inglis SC, McAlister FA, et al. Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis. BMJ 2007; 334:942. </LI>&#xD;&#xA;<LI>Inglis SC, Clark RA, McAlister FA, et al. Structured telephone support or telemonitoring programmes for patients with chronic heart failure. Cochrane Database Syst Rev 2010; 8:CD007228. </LI>&#xD;&#xA;<LI>Holland R, Battersby J, Harvey I, et al. Systematic review of multidisciplinary interventions in heart failure. Heart 2005; 91:899. </LI>&#xD;&#xA;<LI>Jovicic A, Holroyd-Leduc JM, Straus SE. Effects of self-management intervention on health outcomes of patients with heart failure: a systematic review of randomized controlled trials. BMC Cardiovasc Disord 2006; 6:43. </LI>&#xD;&#xA;<LI>Gonseth J, Guallar-Castillon P, Banegas JR, Rodriguez-Artalejo F. The effectiveness of disease management programmes in reducing hospital re-admission in older patients with heart failure: a systematic review and meta-analysis of published reports. Eur Heart J 2004; 25:1570. </LI>&#xD;&#xA;<LI>Feltner C, Jones CD, Cene CW, et al. Transitional care interventions to prevent readmissions for persons with heart failure: A systematic review and meta-analysis. Ann Intern Med 2014; 160:774.</LI></OL></div><div id=\"graphicVersion\">Graphic 61054 Version 5.0</div></div></div>"},"61055":{"type":"graphic_picture","displayName":"Acute graft-versus-host disease histopathology","title":"Histologic grade 2 acute graft-versus-host disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histologic grade 2 acute graft-versus-host disease</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/61055_Acute_GVHD_histopath.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apoptotic keratinocytes in the epidermis, vacuolization of the basal layer, and lymphocyte exocytosis are present in this specimen of histologic grade 2 acute graft-versus-host disease. A lymphocytic infiltrate at the dermal-epidermal junction and surrounding blood vessels is also present.</div><div id=\"graphicVersion\">Graphic 61055 Version 5.0</div></div></div>"},"61056":{"type":"graphic_table","displayName":"Choosing between mastectomy and lumpectomy PI","title":"Choosing between mastectomy and lumpectomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Choosing between mastectomy and lumpectomy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Mastectomy</td> <td class=\"subtitle1\">Lumpectomy</td> </tr> <tr> <td>How will I look?</td> <td>If you decide not to have your breast reconstructed, you will have a scar where your breast used to be. If you do have your breast reconstructed, you will have a new breast made of an implant or out of skin, muscle, and fat taken from other parts of your body. Reconstructed breasts do not have as much sensation as breasts that have had a lumpectomy.</td> <td>Your breast will have a scar and might have a dent or dimple where the tissue was removed. The treated breast might be a little smaller than the other breast. Still, it will feel more like a real breast than a reconstructed breast and have more sensation.</td> </tr> <tr> <td>What will my recovery from surgery be like?</td> <td> <p>You will stay in the hospital for 1 to 2 days (or a little longer if you have reconstruction done, too). You will go home with drains that must be emptied twice a day and that stay in for about 2 weeks.</p> <p>Your recovery will take 4 to 6 weeks. During that time you will need to rest and avoid sports, swimming, and heavy lifting. You might need physical therapy.</p> </td> <td>You will go home from the hospital the same day as your surgery, and your recovery will take 1 to 2 weeks. During that time, you will need to rest and avoid sports, swimming, and heavy lifting. You might need physical therapy.</td> </tr> <tr> <td>What are the risks or side effects of this surgery?</td> <td>Mastectomy is usually safe, but it can sometimes lead to bleeding, infection, or fluid build-up. Plus, the surgery can sometimes damage the skin on the chest. (This is more common in women who smoke.)</td> <td>Lumpectomy is usually safe, but it can sometimes lead to bleeding, infection, or fluid build-up where the cancer was removed.</td> </tr> <tr> <td>Will I need more than 1 surgery?</td> <td>Possibly, if you decide to have your breast reconstructed later.</td> <td>Possibly, if the cancer comes up to the margins and the surgeon has to take more tissue.</td> </tr> <tr> <td>Will I need radiation therapy?</td> <td>Probably not. But some women who have mastectomy do need radiation.</td> <td>Yes. After lumpectomy, most women must have radiation therapy 5 days a week for 3 to 6 weeks.</td> </tr> <tr> <td>What are the chances that cancer will come back in the same area?</td> <td>Cancer can still recur after mastectomy because all the breast tissue cannot be totally removed. About 5 out of 100 women who have a mastectomy will have cancer come back on the chest wall after mastectomy.</td> <td>Fewer than 10 out of 100 women who have a lumpectomy will have cancer recur.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 61056 Version 2.0</div></div></div>"},"61057":{"type":"graphic_table","displayName":"Medication interactions travel and transplant ","title":"Interactions between common travel and transplant medications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interactions between common travel and transplant medications</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Calcineurin inhibitors (CNI)</td> <td class=\"subtitle1\">Trimethoprim/sulfamethoxazole</td> </tr> <tr> <td>Acetazolamide (Diamox)</td> <td>May increase levels</td> <td>&nbsp;</td> </tr> <tr> <td>Artemether/lumefantrine (Coartem)</td> <td>May enhance the QT-prolonging effect </td> <td>&nbsp;</td> </tr> <tr> <td>Atovaquone/proguanil (Malarone)</td> <td>&nbsp;</td> <td>May increase risk of bone marrow toxicity</td> </tr> <tr> <td>Azithromycin (Zithromax)</td> <td>May increase levels</td> <td>&nbsp;</td> </tr> <tr> <td>Chloroquine (Aralen)</td> <td>May increase levels; may enhance the QT-prolonging effect </td> <td>&nbsp;</td> </tr> <tr> <td>Doxycycline</td> <td>May increase levels</td> <td>&nbsp;</td> </tr> <tr> <td>Mefloquine (Lariam)</td> <td>May increase levels; may enhance the QT-prolonging effect </td> <td>&nbsp;</td> </tr> <tr> <td>Primaquine</td> <td>May increase levels</td> <td>&nbsp;</td> </tr> <tr> <td>Sulfadoxine/pyrimethamine (Fansidar) </td> <td>May decrease levels</td> <td>May increase risk of bone marrow toxicity</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Significant interactions of azathioprine, mycophenolate mofetil, and corticosteroids with travel medicines and have not been reported.</div><div class=\"graphic_reference\">Data from: MicroMedex DrugReax Interactive Drug Interactions and Lexicomp Online Interaction Analysis.</div><div id=\"graphicVersion\">Graphic 61057 Version 3.0</div></div></div>"},"61058":{"type":"graphic_movie","displayName":"Generation of the myocardial action potential","title":"Generation of the fast action potential in myocardial cells","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Generation of the fast action potential in myocardial cells</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/61058_genmyoapconv.mp4\" style=\"width:448px;height:348px\"></div><img style=\"width:455px; height:342px;\" src=\"images/CARD/61058_genmyoap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the ionic events during the different phases of the fast action potential. The resting membrane potential (phase 4) is maintained by an energy-dependent ATPase sodium-potassium mechanism which pumps potassium (green spheres) into the cell in exchange for sodium (magenta spheres) which is extruded. Rapid depolarization during phase 0 is characterized by opening of voltage-dependent sodium channels and rapid entry of sodium ions into the cell. This is followed by delayed opening of slow calcium channels and influx of calcium ions (blue spheres). The calcium channels remain open during phase 2 (early repolarization) and there is also opening of potassium channels and efflux of potassium ions which results in late repolarization (phase 3) and a return to resting membrane potential (phase 4).</div><div class=\"graphic_reference\">Courtesy of Entropy, Inc.</div><div id=\"graphicVersion\">Graphic 61058 Version 2.0</div></div></div>"},"61059":{"type":"graphic_figure","displayName":"Natural history of membranous nephropathy","title":"High incidence of remission in untreated membranous nephropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">High incidence of remission in untreated membranous nephropathy</div><div class=\"cntnt\"><img style=\"width:428px; height:219px;\" src=\"images/NEPH/61059_Natural_history_of_MN.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Course of 100 consecutive untreated patients with idiopathic membranous nephropathy. Over a&nbsp;five-year period, there was a progressive increase in the incidence of partial or complete remission, while the incidence of the nephrotic syndrome fell.</div><div class=\"graphic_reference\">Data from: Schieppati A, Mosconi L, Perna A, et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993; 329:85.</div><div id=\"graphicVersion\">Graphic 61059 Version 2.0</div></div></div>"},"61061":{"type":"graphic_table","displayName":"Bacteria sepsis term infant","title":"Common bacterial agents causing neonatal sepsis in term infants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common bacterial agents causing neonatal sepsis in term infants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Bacterial species</td> <td class=\"subtitle1\" colspan=\"2\">Frequency of isolation</td> </tr> <tr> <td class=\"subtitle2\">Early-onset</td> <td class=\"subtitle2\">Late-onset</td> </tr> <tr> <td>Group B <em>Streptococcus</em></td> <td class=\"centered\">+++</td> <td class=\"centered\">+++</td> </tr> <tr> <td><em>Escherichia coli</em></td> <td class=\"centered\">+++</td> <td class=\"centered\">++</td> </tr> <tr> <td><em>Klebsiella</em> spp.</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td><em>Enterobacter</em> spp.</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td><em>Listeria monocytogenes</em></td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td>Other enteric gram-negatives</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td>Non-enteric gram-negatives*</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td>Viridans streptococci</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td><em>Staphylococcus aureus</em></td> <td class=\"centered\">+</td> <td class=\"centered\">+++</td> </tr> <tr> <td><em>Citrobacter</em> spp.</td> <td class=\"centered\">0</td> <td class=\"centered\">+</td> </tr> <tr> <td><em>Salmonella</em> spp.</td> <td class=\"centered\">0</td> <td class=\"centered\">+</td> </tr> <tr> <td>Coagulase-negative staphylococci</td> <td class=\"centered\">0</td> <td class=\"centered\">+</td> </tr> <tr> <td><em>Enterococcus</em> spp.</td> <td class=\"centered\">0</td> <td class=\"centered\">+</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">+++: commonly associated; ++: frequently associated; +: occasionally associated; 0: rarely associated.</div><div class=\"graphic_footnotes\">* Includes nontypable <em>Hemophilus influenzae</em> and <em>Neisseria meningitidis</em>.</div><div class=\"graphic_reference\">Adapted from: Edwards MS, Baker CJ. Bacterial infections in the neonate. In: Principles and Practice of Pediatric Infectious Disease, 4th ed, Long SS, Pickering LK, Prober CG. Elsevier Saunders, Philadelphia 2012.</div><div id=\"graphicVersion\">Graphic 61061 Version 6.0</div></div></div>"},"61062":{"type":"graphic_picture","displayName":"Gingivitis mouth breather","title":"Gingivitis associated with mouth breathing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gingivitis associated with mouth breathing</div><div class=\"cntnt\"><img style=\"width:260px; height:152px;\" src=\"images/PEDS/61062_Gingivitis_mouth_breath_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Ann Griffen, DDS, MS.</div><div id=\"graphicVersion\">Graphic 61062 Version 3.0</div></div></div>"},"61064":{"type":"graphic_table","displayName":"IUD mechanism of action","title":"Possible mechanisms of action of intrauterine devices","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Possible mechanisms of action of intrauterine devices</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Changes in cervical mucus that inhibit sperm transport (eg,\nincreased copper concentration, thickening, glandular atrophy or\ndecidualization)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Chronic inflammatory changes of the endometrium and fallopian\ntubes, which have spermicidal effects and inhibit fertilization and\nimplantation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Thinning and glandular atrophy of the endometrium, which inhibits implantation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Direct ovicidal effects</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=22901&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>IUD_mechanism_of_action.htm</title></head></div><div class=\"graphic_reference\">Data&nbsp;from: Stanford JB, Mikolajczyk RT. Am J Obstet Gynecol 2002; 187:1699.</div><div id=\"graphicVersion\">Graphic 61064 Version 2.0</div></div></div>"},"61066":{"type":"graphic_table","displayName":"Macules","title":"Differential diagnosis of macules","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of macules</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Erythematous macules</td> </tr> <tr> <td>Drug eruption</td> </tr> <tr> <td>Viral exanthem</td> </tr> <tr> <td>Secondary syphilis</td> </tr> <tr> <td>Rheumatic fever</td> </tr> <tr> <td class=\"subtitle1_single\">Photodistributed macules</td> </tr> <tr> <td>Drugs</td> </tr> <tr> <td>Dermatomyositis</td> </tr> <tr> <td>Lupus erythematosus</td> </tr> <tr> <td>Porphyria cutanea tarda</td> </tr> <tr> <td>Polymorphous light eruption</td> </tr> <tr> <td class=\"subtitle1_single\">Hypopigmented macules</td> </tr> <tr> <td>Postinflammatory</td> </tr> <tr> <td>Tinea versicolor</td> </tr> <tr> <td>Vitiligo</td> </tr> <tr> <td>Halo nevus</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td>Tuberous sclerosis</td> </tr> <tr> <td>Cutaneous T cell lymphoma</td> </tr> <tr> <td>Leprosy</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Hyperpigmented macules</td> </tr> <tr> <td>Nevi</td> </tr> <tr> <td>Fixed drug eruption</td> </tr> <tr> <td>Postinflammatory</td> </tr> <tr> <td>Ephelis (freckle)</td> </tr> <tr> <td>Lentigo</td> </tr> <tr> <td>Schamberg's purpura</td> </tr> <tr> <td>Nevus</td> </tr> <tr> <td>Mongolian spot</td> </tr> <tr> <td>Purpura</td> </tr> <tr> <td>Stasis dermatitis</td> </tr> <tr> <td>Melasma</td> </tr> <tr> <td>Melanoma</td> </tr> <tr> <td>Ochronosis</td> </tr> <tr> <td>Mastocytosis</td> </tr> <tr> <td>Caf&#233;-au-lait spot</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 61066 Version 2.0</div></div></div>"},"61067":{"type":"graphic_picture","displayName":"Gross and light microscopic features of plaque rupture","title":"Gross and light microscopic features of plaque rupture","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">Gross and light microscopic features of plaque rupture</div><div class=\"cntnt\"><img style=\"width:568px; height:588px;\" src=\"images/CARD/61067_Gross_light_plaque_rupture2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross and light microscopic features of plaque rupture.<br> (A) Gross photograph of a coronary artery in cross-section showing site of plaque rupture (arrow) with an underlying necrotic core (NC) and luminal thrombus (Th).<br> (B) Histologic section of the artery in A shows the rupture site (arrows), necrotic core (NC), and luminal thrombus (Th) (Movat pentachrome, x20).<br> (C) Higher-power view of the fibrous cap shows disruption (arrow), where there is communication of the luminal thrombus (Th) with the underlying necrotic core (NC) (x200).<br> (D) Higher-power view of the thin fibrous cap shows a paucity of smooth muscle cells (α-actin, brown reaction product, x200).<br> (E, F) The fibrous cap is heavily infiltrated by macrophages and T-lymphocytes (CD68 and CD45Ro, respectively) (x200).<br> (G) The strong expression of HLA-DR (an antigen expressed in activated cells), particularly in macrophages and T-cells of the fibrous cap.</div><div class=\"graphic_reference\">Reproduced with permission from: Farb A, Burke AP, Tang AL, et al. Coronary Plaque Erosion Without Rupture Into a Lipid Core: A Frequent Cause of Coronary Thrombosis in Sudden Coronary Death. Circulation 1996; 93:1354. Copyright © 1996 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 61067 Version 8.0</div></div></div>"},"61068":{"type":"graphic_table","displayName":"Potential artery & nerve injuries associated w common fractures","title":"Potential artery and nerve injuries associated with some common fractures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential artery and nerve injuries associated with some common fractures</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Fracture</td> <td class=\"subtitle1\">Artery</td> <td class=\"subtitle1\">Nerves</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Torso</strong></td> <td>Vertebral</td> <td>&nbsp;</td> <td>Spinal cord or nerve root</td> </tr> <tr class=\"divider_bottom\"> <td>Clavicle</td> <td>Subclavian</td> <td>Brachial plexus</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Upper extremity</strong></td> <td>Proximal humerus</td> <td> <p>Axillary</p> Brachial</td> <td> <p>Axillary</p> Suprascapular</td> </tr> <tr> <td>Humerus shaft</td> <td>Brachial</td> <td> <p>Radial</p> <p>Median</p> Ulnar</td> </tr> <tr> <td>Supracondylar (humerus)</td> <td>Brachial</td> <td> <p>Median</p> <p>Anterior interosseous</p> <p>Radial</p> Ulnar</td> </tr> <tr> <td>Radius/ulna</td> <td> <p>Brachial</p> <p>Axillary</p> Ulnar</td> <td> <p>Median</p> Ulnar</td> </tr> <tr class=\"divider_bottom\"> <td>Scaphoid</td> <td>&nbsp;</td> <td>Median (acute carpal tunnel)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Pelvis</strong></td> <td>Sacroiliac</td> <td>Sacral plexus*</td> <td>Lumbosacral plexus</td> </tr> <tr class=\"divider_bottom\"> <td>Acetabulum</td> <td>&nbsp;</td> <td>Sciatic</td> </tr> <tr> <td rowspan=\"3\"><strong>Lower extremity</strong></td> <td>Femur</td> <td>Femoral</td> <td>Femoral</td> </tr> <tr> <td>Tibia</td> <td> <p>Popliteal</p> <p>Anterior tibial</p> Posterior tibial</td> <td> <p>Tibial</p> <p>Superficial peroneal</p> Deep peroneal</td> </tr> <tr> <td>Fibular head and neck</td> <td>&nbsp;</td> <td>Peroneal</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Bleeding&nbsp;may be&nbsp;venous and can be life-threatening.</div><div class=\"graphic_reference\">Data from: Schlickewei W, Kuner EH, Mullaji AB, et al. Upper and lower limb fractures with concomitant arterial injury. J Bone Joint Surg Br 1992; 74:181.</div><div id=\"graphicVersion\">Graphic 61068 Version 9.0</div></div></div>"},"61069":{"type":"graphic_figure","displayName":"Circadian rhythm in serum cortisol","title":"Circadian rhythm in serum cortisol","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Circadian rhythm in serum cortisol</div><div class=\"cntnt\"><img style=\"width:364px; height:427px;\" src=\"images/ENDO/61069_Circadian_rhythm_cortisol.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Circadian rhythm in serum cortisol concentrations in two normal subjects. Blood samples were drawn every 20 to 30 minutes. The shaded areas indicate the hours of the day during which the lights were turned out. To convert serum cortisol values to nmol/L, multiply by 27.6.</div><div class=\"graphic_reference\">Data from: Weitzman ED, Fukushima DK, Nogeire C, et al. Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects.&nbsp;J Clin Endocrinol Metab. 1971; 33:14.</div><div id=\"graphicVersion\">Graphic 61069 Version 3.0</div></div></div>"},"61070":{"type":"graphic_picture","displayName":"PAS positive macrophage","title":"PAS positive macrophages on microscopy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">PAS positive macrophages on microscopy</div><div class=\"cntnt\"><img style=\"width:504px; height:336px;\" src=\"images/GAST/61070_PAS_positive_macrophage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PAS-positive macrophages in the small intestine of an untreated patient with Whipple's disease.</div><div class=\"graphic_reference\">Reproduced with permission from: Schneider T, Zeitz M. [Illness and immune manifestations in Whipple disease. Differential rheumatic diseases diagnosis] Internist (Berl) 2003; 44:184. Copyright © 2003 Springer-Verlag.</div><div id=\"graphicVersion\">Graphic 61070 Version 2.0</div></div></div>"},"61072":{"type":"graphic_table","displayName":"Dx osteo diabetic foot","title":"Summary statistics of imaging modalities for diagnosis of osteomyelitis associated with diabetic foot ulcer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary statistics of imaging modalities for diagnosis of osteomyelitis associated with diabetic foot ulcer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Diagnostic modality </td> <td class=\"subtitle1\">Total patients </td> <td class=\"subtitle1\"> <p>Sensitivity </p> <p>(95% confidence interval)</p> </td> <td class=\"subtitle1\">P value </td> <td class=\"subtitle1\"> <p>Specificity </p> <p>(95% confidence interval)</p> </td> <td class=\"subtitle1\">P value </td> </tr> <tr> <td>Probe-to-bone test or exposed bone</td> <td>288</td> <td>0.60 (0.46-0.73)</td> <td>&#60;0.001</td> <td>0.91 (0.86-0.94)</td> <td>0.11</td> </tr> <tr> <td>Radiography</td> <td>177</td> <td>0.54 (0.44-0.63)</td> <td>0.006</td> <td>0.68 (0.53-0.80)</td> <td>0.01</td> </tr> <tr> <td>Magnetic resonance imaging</td> <td>135</td> <td>0.90 (0.82-0.95)</td> <td>&#60;0.001</td> <td>0.79 (0.62-0.91)</td> <td>0.41</td> </tr> <tr> <td>Bone scan</td> <td>185</td> <td>0.81 (0.73-0.87)</td> <td>&#60;0.001</td> <td>0.28 (0.17-0.42)</td> <td>0.01</td> </tr> <tr> <td>Leukocyte scan</td> <td>269</td> <td>0.74 (0.67-0.80)</td> <td>&#60;0.001</td> <td>0.68 (0.57-0.78)</td> <td>0.61</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Dinh MT, Abad CL, Safdar N. Diagnostic accuracy of the physical examination and imaging tests for osteomyelitis underlying diabetic foot ulcers: Meta-analysis. Clin Infect Dis 2008; 47:519-527. Copyright ©2008 University of Chicago Press.</div><div class=\"contractual\"><br/><a href=\"http://www.journals.uchicago.edu/\">http://www.journals.uchicago.edu/</a></div><div id=\"graphicVersion\">Graphic 61072 Version 2.0</div></div></div>"},"61073":{"type":"graphic_picture","displayName":"F solani microscopy","title":"<EM>Fusarium solani</EM> microscopy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\"><EM>Fusarium solani</EM> microscopy</div><div class=\"cntnt\"><img style=\"width:504px; height:340px;\" src=\"images/ID/61073_F_solani_microscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Fusarium solani</EM> observed on microscopy. The patient had <EM innerHtml>Fusarium </EM>keratitis.</div><div class=\"graphic_reference\">Courtesy of www.doctorfungus.org ©2006. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 61073 Version 5.0</div></div></div>"},"61074":{"type":"graphic_movie","displayName":"Astigmatism","title":"Astigmatism","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Astigmatism</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/61074_astigmatconv.mp4\" style=\"width:336px;height:226px\"></div><img style=\"width:334px; height:208px;\" src=\"images/CARD/61074_astigmat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Astigmatism is due to abnormal curvature of the cornea which results in multiple focus points in front of or behind the retina. This results in blurry distance and near vision.</div><div class=\"graphic_reference\">Reproduced with permission from: The University of Michigan Kellogg Eye Center, www.kellogg.umich.edu.</div><div id=\"graphicVersion\">Graphic 61074 Version 3.0</div></div></div>"},"61076":{"type":"graphic_diagnosticimage","displayName":"MRI Dementia with Lewy bodies versus Alzheimer disease","title":"MRI appearance of dementia with Lewy bodies compared to Alzheimer disease","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">MRI appearance of dementia with Lewy bodies compared to Alzheimer disease</div><div class=\"cntnt\"><img style=\"width:463px; height:242px;\" src=\"images/NEURO/61076_MRI_in_DLB_vs_AD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thin section coronal T1 weighted images from a 61-year-old male with pathologically proven Dementia with Lewy bodies (A) and a 69-year-old male with Alzheimer disease (B). There is relative preservation of the medial temporal lobes and hippocampal structures in the DLB patient as compared with the AD patient.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; DLB: dementia with Lewy bodies; AD: Alzheimer disease.</div><div id=\"graphicVersion\">Graphic 61076 Version 6.0</div></div></div>"},"61077":{"type":"graphic_figure","displayName":"Port placement left adrenalectomy","title":"Port placement left adrenalectomy*","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Port placement left adrenalectomy*</div><div class=\"cntnt\"><img style=\"width:457px; height:587px;\" src=\"images/SURG/61077_Ports_lap_left_adrenalectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The peritoneal cavity is accessed with a Veres technique through a midclavicular, subcostal site. Three additional 5 mm ports are placed that include a flank port in the mid-axillary line between the subcostal margin and the iliac crest, an epigastric port and a medial subcostal port. Once the adrenal gland is resected, it is captured in a laparoscopic bag that is placed through the 12 mm subcostal port site and removed by extending this incision, as needed.</div><div class=\"graphic_footnotes\">* Port placement and technique may vary amongst laparoscopic surgeons.</div><div id=\"graphicVersion\">Graphic 61077 Version 5.0</div></div></div>"},"61079":{"type":"graphic_figure","displayName":"Ankle and foot ligaments medial view","title":"Ankle and foot ligaments medial view","html":"<div class=\"graphic\"><div style=\"width: 647px\" class=\"figure\"><div class=\"ttl\">Ankle and foot ligaments medial view</div><div class=\"cntnt\"><img style=\"width:627px; height:439px;\" src=\"images/EM/61079_Ft_antmy_mdl_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 61079 Version 5.0</div></div></div>"},"61080":{"type":"graphic_diagnosticimage","displayName":"Radial head fracture complex","title":"Displaced and comminuted fracture of the radial head","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Displaced and comminuted fracture of the radial head</div><div class=\"cntnt\"><img style=\"width:224px; height:402px;\" src=\"images/EM/61080_Radial_head_fx_complex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These radiographs show a significantly displaced and comminuted fracture of the radial head (Mason Type III).</div><div class=\"graphic_reference\">Courtesy of Mark Slabaugh, MD.</div><div id=\"graphicVersion\">Graphic 61080 Version 2.0</div></div></div>"},"61082":{"type":"graphic_picture","displayName":"Hemoglobin C disease","title":"Hemoglobin C disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemoglobin C disease</div><div class=\"cntnt\"><img style=\"width:399px; height:254px;\" src=\"images/HEME/61082_Hemoglobin_C_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral smear from a patient with homozygous hemoglobin C disease, showing the presence of hemoglobin crystals (blue arrows) within erythrocytes. This phenomenon is most commonly seen when a wet preparation of red cells is allowed to partially dehydrate. Target cells (black arrow) are also present.</div><div class=\"graphic_reference\">Courtesy of Stephen A. Landaw, MD.</div><div id=\"graphicVersion\">Graphic 61082 Version 1.0</div></div></div>"},"61083":{"type":"graphic_picture","displayName":"Histol melan in situ sup spread","title":"Malignant melanoma in situ, superficial spreading type","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malignant melanoma in situ, superficial spreading type</div><div class=\"cntnt\"><img style=\"width:360px; height:283px;\" src=\"images/ONC/61083_Histol_melan_in_situ_sup_sp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power light micrograph of a superficial spreading malignant melanoma in situ, showing epidermal hyperplasia with associated proliferation of large malignant epithelioid melanocytes at all levels of the epidermis (the so-called pagetoid spread).</div><div class=\"graphic_reference\">Courtesy of Roy King, MD.</div><div id=\"graphicVersion\">Graphic 61083 Version 1.0</div></div></div>"},"61084":{"type":"graphic_diagnosticimage","displayName":"Proton plan lumbar vert EFT","title":"Proton radiation therapy treatment plan for a patient with a lumbar vertebral Ewing's sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proton radiation therapy treatment plan for a patient with a lumbar vertebral Ewing's sarcoma</div><div class=\"cntnt\"><img style=\"width:432px; height:435px;\" src=\"images/ONC/61084_Proton_plan_lumbar_vert_EFT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note significant sparing of normal tissue anterior and lateral to the vertebrae with protons.</div><div class=\"graphic_reference\">Courtesy of John A Jackson, Medical Dosimetrist, Massachusetts General Hospital.</div><div id=\"graphicVersion\">Graphic 61084 Version 2.0</div></div></div>"},"61085":{"type":"graphic_figure","displayName":"Ear temperature PI","title":"Measuring ear temperature","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Measuring ear temperature</div><div class=\"cntnt\"><img style=\"width:405px; height:416px;\" src=\"images/PI/61085_Ear_temperature_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To take an ear temperature,&nbsp;make sure you are using a thermometer meant for this. Pull your child's ear back before inserting the thermometer. Then hold the tip in your child's ear for about 2 seconds.</div><div id=\"graphicVersion\">Graphic 61085 Version 6.0</div></div></div>"},"61087":{"type":"graphic_table","displayName":"Tetanus prophylaxis","title":"Wound management and tetanus prophylaxis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Wound management and tetanus prophylaxis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Previous doses of tetanus toxoid*</td> <td class=\"subtitle1\" colspan=\"2\">Clean and minor wound</td> <td class=\"subtitle1\" colspan=\"2\">All other wounds<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2\">Tetanus toxoid-containing vaccine<sup>&#916;</sup></td> <td class=\"subtitle2\">Human tetanus immune globulin</td> <td class=\"subtitle2\">Tetanus toxoid-containing vaccine<sup>&#916;</sup></td> <td class=\"subtitle2\">Human tetanus immune globulin<sup>&#9674;</sup></td> </tr> <tr> <td>&#60;3 doses or unknown</td> <td>Yes<sup>&#167;</sup></td> <td>No</td> <td>Yes<sup>&#167;</sup></td> <td>Yes</td> </tr> <tr> <td>&#8805;3 doses</td> <td>Only if last dose given &#8805;10 years ago</td> <td>No</td> <td>Only if last dose given &#8805;5 years ago<sup>&#165;</sup></td> <td>No</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Appropriate tetanus prophylaxis should be administered as soon as possible following a wound but should be given even to patients who present late for medical attention. This is because the incubation period is quite variable; most cases occur within&nbsp;8 days, but the incubation period can be as short as&nbsp;3 days or as long as 21 days. For patients who have been vaccinated against tetanus previously but who are not up to date, there is likely to be little benefit in administering human tetanus immune globulin more than one week or so after the injury. However, for patients thought to be completely unvaccinated, human tetanus immune globulin should be given up to 21 days following the injury; Td or Tdap should be given concurrently to such patients.</div><div class=\"graphic_footnotes\">* Tetanus toxoid may have been administered as diphtheria-tetanus toxoids adsorbed (DT), diphtheria-tetanus-whole cell pertussis (DTP, DTwP; no longer available in the United States), diphtheria-tetanus-acellular pertussis (DTaP), tetanus-diphtheria toxoids adsorbed (Td), booster tetanus toxoid-reduced diphtheria toxoid-acellular pertussis (Tdap), or tetanus toxoid (TT).<br />¶&nbsp;Such as, but not limited to, wounds contaminated with dirt, feces, soil, or saliva; puncture wounds; avulsions; wounds resulting from missiles, crushing, burns, or frostbite.<br />Δ&nbsp;The preferred vaccine preparation depends upon the age and vaccination history of the patient: &#xD;&#xA;<UL>&#xD;&#xA;<LI>&lt;7 years: DTaP</LI>&#xD;&#xA;<LI>Underimmunized children ≥7 and &lt;11 years who have not received Tdap previously: Tdap. Children who receive Tdap between age 7 and 11 years do not require revaccination at age 11 years.</LI>&#xD;&#xA;<LI>≥11 years: A single dose of Tdap is preferred to Td for all individuals in this age group who have not previously received Tdap. Pregnant women should receive Tdap during each pregnancy. </LI>&#xD;&#xA;<LI>Td is preferred to TT for those who received Tdap previously and when Tdap is not available.</LI></UL>◊ 250 units intramuscularly at a different site than tetanus toxoid; intravenous immune globulin should be administered if human tetanus immune globulin is not available.<br />§&nbsp;The vaccine series should be continued through completion as necessary.<br />¥&nbsp;Booster doses given more frequently than every five years are not needed and can increase adverse effects.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2012. Ann Intern Med 2012; 156:211.</LI>&#xD;&#xA;<LI>Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:13. </LI>&#xD;&#xA;<LI>Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older — Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2012; 61:468.</LI>&#xD;&#xA;<LI>Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2013; 62:131.</LI>&#xD;&#xA;<LI>Immunization Action Coalition. Ask the experts: Diseases &amp; vaccines - Diphtheria, tetanus, pertussis. http://www.immunize.org/askexperts/experts_per.asp#wound (Accessed September 6, 2017.)</LI></OL>Adapted from: American Academy of Pediatrics. Tetanus (lockjaw). In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th Edition, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015.</div><div id=\"graphicVersion\">Graphic 61087 Version 27.0</div></div></div>"},"61088":{"type":"graphic_table","displayName":"Treatment options for refractory angina","title":"Summary of treatment options in refractory angina pectoris","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of treatment options in refractory angina pectoris</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Therapy</td>\n\n      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">Documented\neffect</td>\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Strength of evidence</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td class=\"subtitle2\">Symptoms</td>\n\n      <td class=\"subtitle2\">Ischemia</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>TENS</td>\n\n      <td>+</td>\n\n      <td>+</td>\n\n      <td>B</td>\n\n    </tr>\n\n    <tr>\n\n      <td>SCS</td>\n\n      <td>+</td>\n\n      <td>+</td>\n\n      <td>A</td>\n\n    </tr>\n\n    <tr>\n\n      <td>TMR</td>\n\n      <td>+</td>\n\n      <td>?</td>\n\n      <td>A</td>\n\n    </tr>\n\n    <tr>\n\n      <td>PLR </td>\n\n      <td>+</td>\n\n      <td>?</td>\n\n      <td>B</td>\n\n    </tr>\n\n    <tr>\n\n      <td>LSGB</td>\n\n      <td>+</td>\n\n      <td>?</td>\n\n      <td>C</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">TENS: transcutaneous electrical nerve stimulation; SCS: spinal cord stimulation; TMR: transmyocardial laser revascularization; PLR: percutaneous laser revascularization; LSGB: left stellate ganglion blockade.<br> Strength of evidence is based upon amount of scientific documentation: A: Well-designed, well-conducted, controlled trials (randomized and non-randomized) with statistically significant results that consistently support the recommendations. B: Observational studies or controlled trials with less consistent results to support the guideline recommendations. C: Expert opinion that supports the guideline recommendation because the available scientific evidence did not present consistent results, or controlled trials were lacking.</div><div class=\"graphic_reference\">Data from Mannheimer C, Camicci P, Chester MR, et al. Eur Heart J 2002; 23:355.</div><div id=\"graphicVersion\">Graphic 61088 Version 3.0</div></div></div>"},"61091":{"type":"graphic_table","displayName":"Prolif rate recept breast tiss","title":"Distribution of Ki67, ER-α, and PgR-positive cells in the lobular structures of the human breast","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distribution of Ki67, ER-&alpha;, and PgR-positive cells in the lobular structures of the human breast</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Lobule type</td> <td class=\"subtitle1\">No. cells</td> <td class=\"subtitle1\">Ki67</td> <td class=\"subtitle1\">ER</td> <td class=\"subtitle1\">PgR</td> <td class=\"subtitle1\">Ki67 + ER**</td> <td class=\"subtitle1\">Ki67 + PgR<sup>&#134;</sup></td> </tr> <tr> <td>Lob 1</td> <td>19,339*</td> <td>4.72 &#177; 1.00<sup>&#9674;</sup><sup>&#167;</sup></td> <td>7.46 &#177; 2.88<sup>&#182;&#182;</sup></td> <td>5.70 &#177; 1.36<sup>&#167;&#167;</sup></td> <td>0.48 &#177; 0.28</td> <td>0.09 &#177; 0.01</td> </tr> <tr> <td>Lob 2</td> <td>8490<sup>&#182;</sup></td> <td>1.58 &#177; 0.45<sup>&#165;</sup></td> <td>3.83 &#177; 2.44<sup>&#916;&#916;</sup></td> <td>0.73 &#177; 0.57<sup>&#165;&#165;</sup></td> <td>0.31 &#177; 0.21</td> <td>0.28 &#177; 0.27</td> </tr> <tr> <td>Lob 3</td> <td>17,750<sup>&#916;</sup></td> <td>0.40 &#177; 0.18<sup>&#135;</sup></td> <td>0.76 &#177; 0.04<sup>&#9674;&#9674;</sup></td> <td>0.09 &#177; 0.04<sup>&#135;&#135;</sup></td> <td>0.01 &#177; 0.01</td> <td>0.01 &#177; 0.01</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Total number of cells in lobule 1 (Lob 1) in breast tissue samples of 12 donors.<br />¶ Total number of cells counted in Lob 2 in breast tissue samples of 5 donors.<br />Δ Total number of cells counted in Lob 3 in breast tissue samples of 3 donors.<br /><FONT class=lozenge>◊</FONT> Proliferative activity determined by the percentage of cells Ki67 positive, expressed as the mean ± standard deviation. Differences were significant in<br />§ Lob 1 versus<br />¥ Lob 2 (t = 1.98; P&lt;0.05), ¥Lob 2 versus<br />‡ Lob 3 (t = 2.27; P&lt;0.04), and §Lob 1 versus ‡Lob 3 (t = 2.56; P&lt;0.01). Estrogen receptor (ER)-positive cells were significantly different in<br />† Percentage of cells positive for both Ki67 and PgR, expressed as the mean ± standard deviation.<br />** Percentage of cells positive for both Ki67 and ER, expressed as the mean ± SD.<br />¶¶ Lob 1 versus<br />ΔΔ Lob 2 and<br />§§ Lob 3 (t = 2.04; P&lt;0.05). Progesterone receptor (PgR)-positive cells were significantly different in §§Lob 1 versus<br />¥¥ Lob 2 (I = 2.27; P&lt;0.05) and in §§Lob 1 versus ‡‡Lob 3 (t = 2.60; P&lt;0.03).</div><div class=\"graphic_reference\">Russo J, et al. Breast Cancer Res Treatment 1999; 53:217. Reprinted with permission by Kluwer Academic Publishers.</div><div id=\"graphicVersion\">Graphic 61091 Version 3.0</div></div></div>"},"61093":{"type":"graphic_table","displayName":"IBD nutr monitor","title":"Monitoring of nutritional status in children with inflammatory bowel disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Monitoring of nutritional status in children with inflammatory bowel disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"55%\"></colgroup><colgroup span=\"3\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Measurement</td> <td class=\"subtitle1\">At diagnosis</td> <td class=\"subtitle1\">Every 4 to 6 months</td> <td class=\"subtitle1\">Growth failure</td> </tr> <tr> <td>Weight (plot on growth chart to track percentile)</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td>Height (plot on growth chart to track percentile and/or calculate height velocity)</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td>BMI (calculate from weight and height, and plot on growth chart to track percentile)*</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td>Pubertal status<sup>&#182;</sup></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td>Biological parents' height</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>24-hour diet recall, or 3 to 5 day diet record</td> <td class=\"centered\">If concerns</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td>Nutritional supplement intake<sup>&#916;</sup></td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td>Anticipatory guidance for diet and feeding behavior</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td>Laboratory testing for micronutrient deficiencies</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td>Bone age<sup>&#9674;</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td>Bone densitometry (DXA)<sup>&#167;</sup></td> <td class=\"centered\">If practical</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This chart depicts the authors' approach to monitoring nutritional issues in children with inflammatory bowel disease, and is consistent with expert panels.<sup>[1]</sup> We generally define growth failure as a persistent decline in height percentiles or height velocity less than 10th percentile for age.</div><div class=\"graphic_footnotes\">BMI: body mass index; DXA: dual energy x-ray absorptiometry.<br />* In children 2 to 18 years.<br />&#182; Pubertal staging is suggested at least annually in girls starting at age 9 years, and boys starting at age 10 years.<br />&Delta; A review of vitamins, minerals, oral or enteral formulas, herbal/botanical or other complimentary and alternative medicine produces.<br /><span class=\"lozenge\">&loz;</span> Determination of bone age requires expert interpretation by a radiologist or endocrinologist with experience in the technique.<br />&sect; Bone densitometry is strongly recommended in patients with growth failure, secondary or primary amenorrhea, pubertal delay, severe course of inflammatory bowel disease, or prolonged use of glucocorticoids. If the bone mineral density (BMD) z-score is more than 1 standard deviation (SD) below the mean, the scan should be repeated every 1 to 2 years.<sup>[2]</sup> Bone densitometry is also suggested for older children and adolescents at the time of diagnosis with inflammatory bowel disease, if this test is practical and available. The optimal age for starting monitoring is not defined.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Rufo PA, Denson LA, Sylvester FA, et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr 2012; 55:93.</li>&#xD;&#xA;    <li>​Pappa H, Thayu M, Sylvester F, et al. Skeletal health of children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011; 53:11.</li>&#xD;&#xA;</ol>&#xD;&#xA;Courtesy of Drs. Jonathan Teitelbaum and Paul Rufo.</div><div id=\"graphicVersion\">Graphic 61093 Version 6.0</div></div></div>"},"61095":{"type":"graphic_figure","displayName":"Thyroid function sick patients","title":"Thyroid function tests in nonthyroidal illness","html":"<div class=\"graphic\"><div style=\"width: 648px\" class=\"figure\"><div class=\"ttl\">Thyroid function tests in nonthyroidal illness</div><div class=\"cntnt\"><img style=\"width:628px; height:356px;\" src=\"images/ENDO/61095_Thyroid_function_sick_patie.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the changes in thyroid function tests in patients with nonthyroidal illness of increasing severity.</div><div class=\"graphic_footnotes\">rT3: reverse triiodothyronine; T4: thyroxine; TSH: thyroid-stimulating hormone; T3: triiodothyronine.</div><div id=\"graphicVersion\">Graphic 61095 Version 3.0</div></div></div>"},"61097":{"type":"graphic_table","displayName":"Comparison conization technique","title":"Comparison of different techniques for cervical (uterine cervix) conization","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of different techniques for cervical (uterine cervix) conization</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Advantages\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Disadvantages\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">\r\n  \r\n   Cold knife conization\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Technical simplicity</td>\r\n  \r\n   <td>General or regional anesthetic required</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Excellent specimen quality</td>\r\n  \r\n   <td>Distortion after healing</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   <td>Complication rate higher</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">\r\n  \r\n   Laser conization\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Good specimen quality</td>\r\n  \r\n   <td>Technically difficult</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Good hemostasis</td>\r\n  \r\n   <td>Expense and upkeep of equipment</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Healing with minimal distortion</td>\r\n  \r\n   <td>Some thermal damage</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Low complication rate</td>\r\n  \r\n   <td>A narrow deep cone is difficult</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Can be done in an office setting</td>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"2\">\r\n  \r\n   &nbsp;\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Flexible treatment of endocervix</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"2\" rowspan=\"1\" class=\"subtitle2\">\r\n  \r\n   Large loop excision of the transformation zone\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Easily done in the office setting</td>\r\n  \r\n   <td>Some thermal damage</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Rapid performance</td>\r\n  \r\n   <td>A large or deep cone may be difficult to perform in the office and result in more thermal damage if a second loop excision is required</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Technically easy</td>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"5\">\r\n  \r\n   &nbsp;\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Equipment inexpensive</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Low complication rate</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Good specimen quality</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Healing with minimal distortion</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 61097 Version 2.0</div></div></div>"},"61098":{"type":"graphic_figure","displayName":"OSullivan OConnor retractor","title":"O'Sullivan-O'Connor retractor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">O'Sullivan-O'Connor retractor</div><div class=\"cntnt\"><img style=\"width:381px; height:503px;\" src=\"images/OBGYN/61098_OSullivanOConnorretractor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This retractor has an adjustable bladder blade and an adjustable upper abdominal blade.</div><div id=\"graphicVersion\">Graphic 61098 Version 1.0</div></div></div>"},"61100":{"type":"graphic_diagnosticimage","displayName":"Rounded atelectasis RLL CT","title":"Rounded atelectasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rounded atelectasis</div><div class=\"cntnt\"><img style=\"width:371px; height:258px;\" src=\"images/PULM/61100_Rounded_atelectasis_RLL_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rounded atelectasis in the right lower lobe. The lesion has a curvilinear connection to the right hilum, a so-called comet tail. Adjacent pleural thickening is present, which is characteristic of rounded atelectasis.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 61100 Version 3.0</div></div></div>"},"61103":{"type":"graphic_picture","displayName":"BAL in differentiation syndrome","title":"Bronchoalveolar lavage of alveolar hemorrhage in the differentiation syndrome","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Bronchoalveolar lavage of alveolar hemorrhage in the differentiation syndrome</div><div class=\"cntnt\"><img style=\"width:514px; height:341px;\" src=\"images/PULM/61103_BAL_diff_synd_new.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchoalveolar lavage from a patient with differentiation syndrome and alveolar hemorrhage. Image A shows an alveolar macrophage ringed by acute promyelocytic leukemia (APL) cells on a background of erythrocytes. Image B shows two alveolar macrophages ingesting erythrocytes on a background of erythrocytes and scattered APL cells. The presence of erythrocytes within the alveolar macrophages suggests alveolar hemorrhage rather than acute trauma at the time of bronchoscopy. The APL cells are present in the BAL due to the degree of hemorrhage.</div><div class=\"graphic_reference\">Courtesy of German Pihan, MD, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.</div><div id=\"graphicVersion\">Graphic 61103 Version 2.0</div></div></div>"},"61104":{"type":"graphic_picture","displayName":"Immunostaining for EBV LMP","title":"Immunostaining for Epstein-Barr virus (EBV) latent membrane protein (LMP) in a case of EBV-associated Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Immunostaining for Epstein-Barr virus (EBV) latent membrane protein (LMP) in a case of EBV-associated Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:505px; height:756px;\" src=\"images/HEME/61104_ImmunostainingEBVLMP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunostaining for EBV LMP demonstrates strong cytoplasmic staining, with paranuclear accentuation in the Hodgkin cells. EBV-positive small lymphocytes do not stain for LMP in Hodgkin lymphoma.</div><div class=\"graphic_reference\">Reproduced with permission from: Weiss LM, Warnke RA, Hansmann ML, et al. Pathology of Hodgkin Lymphoma. In: Hodgkin Lymphoma, 2nd ed, Hoppe RT, Mauch PT, Armitage JO, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 61104 Version 7.0</div></div></div>"},"61105":{"type":"graphic_figure","displayName":"Chest wall impact VF","title":"Chest wall trauma causes ventricular fibrillation","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Chest wall trauma causes ventricular fibrillation</div><div class=\"cntnt\"><img style=\"width:502px; height:225px;\" src=\"images/CARD/61105_Chest_wall_impact_VF_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Differences in the frequency with which ventricular fibrillation resulted from chest-wall impact at 30 miles per hour during the period of cardiac cycle vulnerable to induction of ventricular fibrillation, ie, from 30 to 15 msec before T-wave peak.</div><div class=\"graphic_footnotes\">* p&lt;0.03 for the differences between regulation baseball and very soft baseball.<br> <span class=bullet>&#8226;</span> p&lt;0.01 for the differences between wooden object and each type of baseball.</div><div class=\"graphic_reference\">Data from: Link MS, Wang PJ, Pandian NG, et al. N Engl J Med 1998; 338:1805.</div><div id=\"graphicVersion\">Graphic 61105 Version 4.0</div></div></div>"},"61107":{"type":"graphic_picture","displayName":"HSV primary","title":"Primary genital herpes simplex infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary genital herpes simplex infection</div><div class=\"cntnt\"><img style=\"width:432px; height:312px;\" src=\"images/OBGYN/61107_HSV_primary.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 61107 Version 1.0</div></div></div>"},"61109":{"type":"graphic_figure","displayName":"Painful and thermal pathways","title":"Some pathways concerned with transmission of impulses activated by peripheral painful and thermal stimuli","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Some pathways concerned with transmission of impulses activated by peripheral painful and thermal stimuli</div><div class=\"cntnt\"><img style=\"width:549px; height:448px;\" src=\"images/PC/61109_Painful_and_thermal_pathway.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Entering peripheral nerve fibers ascend and descend several segments and then cross over to ascend to the thalamus on the opposite side of entry (L: lower extremity; U: upper extremity; F: face). (B) Many fibers terminate in the mesencephalon. Layering of fibers in the lateral spinothalamic tract is shown in (C) and details of synapses in (D). Pain and temperature fibers from the face descend from the midpontine level to the upper cervical levels before postsynaptic fibers synapse and cross to the opposite side.</div><div class=\"graphic_reference\">Reproduced with permission from Wilderholt, WC, Neurology for Non-neurologists, 4th ed, WB Saunders, Philadelphia 2000. Copyright &#169; 2000 Elsevier.</div><div id=\"graphicVersion\">Graphic 61109 Version 1.0</div></div></div>"},"61112":{"type":"graphic_table","displayName":"Etiology and frequency of esophageal perforation","title":"Etiology and frequency of esophageal perforation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology and frequency of esophageal perforation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Etiology of esophageal perforation</td> <td class=\"subtitle1\">Frequency (percent)</td> </tr> <tr> <td>Iatrogenic</td> <td class=\"centered\">59</td> </tr> <tr> <td>Spontaneous</td> <td class=\"centered\">15</td> </tr> <tr> <td>Foreign body ingestion</td> <td class=\"centered\">12</td> </tr> <tr> <td>Trauma</td> <td class=\"centered\">9</td> </tr> <tr> <td>Operative injury</td> <td class=\"centered\">2</td> </tr> <tr> <td>Malignancy</td> <td class=\"centered\">1</td> </tr> <tr> <td>Other</td> <td class=\"centered\">2</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table depicts the causes of esophageal perforation.</div><div class=\"graphic_reference\">Data from: Brinster CJ, Singhal S, Lee L, et al. Evolving options in the management of esophageal perforation. Ann Thorac Surg 2004; 77:1475.</div><div id=\"graphicVersion\">Graphic 61112 Version 1.0</div></div></div>"},"61113":{"type":"graphic_picture","displayName":"Psoriasis palmar 2","title":"Hand psoriasis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Hand psoriasis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/61113_Psoriasis_palmar_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Well circumscribed, erythematous, and scaly plaques on the hand of a patient with psoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 61113 Version 5.0</div></div></div>"},"61115":{"type":"graphic_picture","displayName":"Glomus tumor subungual 1","title":"Subungual glomus tumor","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Subungual glomus tumor</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/61115_Glom_tum_sunbung_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left: Red flush of the nail bed induced by a subungual glomus tumor.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 61115 Version 3.0</div></div></div>"},"61116":{"type":"graphic_figure","displayName":"Follicle devel follicular phase","title":"Human follicle development","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Human follicle development</div><div class=\"cntnt\"><img style=\"width:447px; height:323px;\" src=\"images/ENDO/61116_Follicle_devel_follicular_p.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of human follicle development during the follicular phase of the menstrual cycle. There are two major events in this process: increased sensitivity of a maturing follicle and selection of a single dominant follicle. In spontaneous cycles, this is achieved at the beginning of the cycle by a transient increase in serum FSH concentrations above some threshold value; the concentrations then decrease, preventing more than one follicle from undergoing preovulatory development.</div><div class=\"graphic_footnotes\">E2: estradiol; FSH: follicle-stimulating hormone.</div><div class=\"graphic_reference\">Fauser, BC, Van Hevsdeau, AM, et al. Manipulation of human ovarian function: Physiological concepts and clinical consequences. Endocr Rev 1997; 18:71.</div><div id=\"graphicVersion\">Graphic 61116 Version 2.0</div></div></div>"},"61118":{"type":"graphic_diagnosticimage","displayName":"Carmustine lung fibrosis CT","title":"Carmustine-induced pulmonary fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Carmustine-induced pulmonary fibrosis</div><div class=\"cntnt\"><img style=\"width:395px; height:290px;\" src=\"images/PULM/61118_Carmustine_lung_fibrosis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High resolution CT scan in a patient with carmustine (BCNU)-induced pulmonary fibrosis. There are coarse linear strands, many of which are subpleural in distribution.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Ronan O'Driscoll, MD.</div><div id=\"graphicVersion\">Graphic 61118 Version 3.0</div></div></div>"},"61119":{"type":"graphic_picture","displayName":"Saber sheath gross","title":"Saber sheath tracheal deformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Saber sheath tracheal deformation</div><div class=\"cntnt\"><img style=\"width:350px; height:216px;\" src=\"images/PULM/61119_Saber_sheath_gross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical specimens demonstrate a normal trachea (left) and a saber-sheath trachea (right) in cross-section.</div><div class=\"graphic_reference\">Courtesy of Luis LG Fajardo, MD.</div><div id=\"graphicVersion\">Graphic 61119 Version 2.0</div></div></div>"},"61122":{"type":"graphic_waveform","displayName":"Normal arterial Doppler waveform","title":"Normal arterial Doppler waveform","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal arterial Doppler waveform</div><div class=\"cntnt\"><img style=\"width:373px; height:266px;\" src=\"images/SURG/61122_Norm_art_Doppler_wave_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal Doppler waveform has a rapid upstroke, sharp peak, rapid downstroke, flow reversal and resumption of forward flow.</div><div class=\"graphic_reference\">Courtesy of the Division of Vascular Surgery at OHSU.</div><div id=\"graphicVersion\">Graphic 61122 Version 2.0</div></div></div>"},"61123":{"type":"graphic_picture","displayName":"Cautery of epistaxis with a silver nitrate stick","title":"Cautery of epistaxis with a silver nitrate stick","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cautery of epistaxis with a silver nitrate stick</div><div class=\"cntnt\"><img style=\"width:432px; height:354px;\" src=\"images/EM/61123_Cautery_epistaxis_silver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The silver nitrate applicator tip should be applied to a small area surrounding the bleeding site, starting proximally. The bleeding point itself cannot be cauterized until hemostasis is achieved through proximal cautery, vasoconstrictive agents, or direct pressure.</div><div class=\"graphic_reference\">Courtesy of Glenn Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 61123 Version 2.0</div></div></div>"},"61124":{"type":"graphic_picture","displayName":"Cutaneous aspergillosis","title":"Aspergillus fumigatus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aspergillus fumigatus</div><div class=\"cntnt\"><img style=\"width:393px; height:260px;\" src=\"images/GAST/61124_Cutaneous_aspergillosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cutaneous lesions due to disseminated Aspergillus infection in a patient who has undergone liver transplantation.</div><div class=\"graphic_reference\">Courtesy of Jean-Fran&#231;ois Dufour, MD.</div><div id=\"graphicVersion\">Graphic 61124 Version 2.0</div></div></div>"},"61125":{"type":"graphic_picture","displayName":"Eczema vaccinatum rash","title":"Abdomen and chest of a boy aged 28 months with a rash of umbilicated lesions caused by eczema vaccinatum - United States, 2007","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abdomen and chest of a boy aged 28 months with a rash of umbilicated lesions caused by eczema vaccinatum - United States, 2007</div><div class=\"cntnt\"><img style=\"width:432px; height:321px;\" src=\"images/ID/61125_Eczema_vaccinatum_rash.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Household Transmission of Vaccinia Virus from Contact with a Military Smallpox Vaccine - Illinois and Indiana, 2007. MMWR Morb Mortal Wkly Rep 2007; 56:478.</div><div id=\"graphicVersion\">Graphic 61125 Version 4.0</div></div></div>"},"61127":{"type":"graphic_diagnosticimage","displayName":"CT scan thickened pericardium","title":"Computed tomography (CT) showing thickened pericardium in a patient with pericardial mesothelioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography (CT) showing thickened pericardium in a patient with pericardial mesothelioma</div><div class=\"cntnt\"><img style=\"width:342px; height:291px;\" src=\"images/CARD/61127_CTscanpericardmesothelio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This axial image of a contrast-enhanced thoracic CT scan reveals a thickened pericardium (arrow). This young man was referred for pericardiectomy to treat what was initially diagnosed as tuberculous constrictive pericarditis. At the time of surgery, the pathologic diagnosis was mesothelioma.</div><div class=\"graphic_reference\">Courtesy of Ralph Shabetai, MD.</div><div id=\"graphicVersion\">Graphic 61127 Version 4.0</div></div></div>"},"61130":{"type":"graphic_diagnosticimage","displayName":"Ultrasound normal fetal brain transthalamic view","title":"Transthalamic plane","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Transthalamic plane</div><div class=\"cntnt\"><img style=\"width:480px; height:407px;\" src=\"images/OBGYN/61130_Transthalamic_plane.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 61130 Version 4.0</div></div></div>"},"61133":{"type":"graphic_table","displayName":"DDx vomiting infants","title":"Differential diagnosis of vomiting in infants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of vomiting in infants</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Gastrointestinal obstruction</td> </tr> <tr> <td>Pyloric stenosis</td> </tr> <tr> <td>Malrotation with volvulus</td> </tr> <tr> <td>Intussusception (may be intermittent)</td> </tr> <tr> <td>Intestinal duplication, stenosis, or atresia</td> </tr> <tr> <td>Hirschsprung disease</td> </tr> <tr> <td>Antral/duodenal web</td> </tr> <tr> <td>Foreign body</td> </tr> <tr> <td>Incarcerated hernia</td> </tr> <tr> <td class=\"subtitle1_single\">Other gastrointestinal causes</td> </tr> <tr> <td>Physiological gastroesophageal reflux or GERD</td> </tr> <tr> <td>Food protein-induced (eg,&nbsp;anaphylaxis,&nbsp;food protein-induced enteropathy,&nbsp;or FPIES)</td> </tr> <tr> <td>Gastroenteritis</td> </tr> <tr> <td>Peptic ulcer disease</td> </tr> <tr> <td>Eosinophilic esophagitis/gastroenteritis</td> </tr> <tr> <td>Gastroparesis</td> </tr> <tr> <td>Pancreatitis</td> </tr> <tr> <td class=\"subtitle1_single\">Neurologic</td> </tr> <tr> <td>Hydrocephalus</td> </tr> <tr> <td>Subdural hematoma</td> </tr> <tr> <td>Intracranial hemorrhage</td> </tr> <tr> <td>Mass lesion</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infectious</td> </tr> <tr> <td>Sepsis</td> </tr> <tr> <td>Meningitis</td> </tr> <tr> <td>Urinary tract infection</td> </tr> <tr> <td>Pneumonia</td> </tr> <tr> <td>Otitis media</td> </tr> <tr> <td>Hepatitis</td> </tr> <tr> <td class=\"subtitle1_single\">Metabolic/endocrine</td> </tr> <tr> <td>Galactosemia</td> </tr> <tr> <td>Hereditary fructose intolerance</td> </tr> <tr> <td>Urea cycle defects</td> </tr> <tr> <td>Amino and organic acidemias</td> </tr> <tr> <td>Fatty acid oxidation disorders</td> </tr> <tr> <td>Metabolic acidosis</td> </tr> <tr> <td>Congenital adrenal hyperplasia/adrenal crisis</td> </tr> <tr> <td class=\"subtitle1_single\">Renal</td> </tr> <tr> <td>Obstructive uropathy</td> </tr> <tr> <td>Renal insufficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Toxic</td> </tr> <tr> <td>Lead</td> </tr> <tr> <td>Iron </td> </tr> <tr> <td>Vitamin A or D </td> </tr> <tr> <td>Medications (ipecac, digoxin, theophylline, etc)</td> </tr> <tr> <td>Other toxins</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiac</td> </tr> <tr> <td>Heart failure</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GERD: gastroesophageal reflux disease; FPIES: food protein-induced enterocolitis syndrome.</div><div class=\"graphic_reference\">Modified with permission from: Rudolph CD, Mazur LJ, Liptak GS, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001; 32:S1. Copyright © 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 61133 Version 11.0</div></div></div>"},"61137":{"type":"graphic_table","displayName":"Toxicity of gold compounds","title":"Toxicity profile with gold compounds","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Toxicity profile with gold compounds</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse effects</td> <td class=\"subtitle1\">Gold sodium thiomalate</td> <td class=\"subtitle1\">Auranofin</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Postinjection reactions</td> </tr> <tr> <td class=\"indent1\">Vasomotor (nitritoid)</td> <td>Uncommon*</td> <td>Rare*</td> </tr> <tr> <td class=\"indent1\">Anaphylaxis/syncope</td> <td>Rare</td> <td>Unknown</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Myalgias/arthralgias</td> <td>Uncommon</td> <td>Unknown</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Mucocutaneous effects</td> </tr> <tr> <td class=\"indent1\">Dermatitis/stomatitis</td> <td>Common<sup>&#182;</sup></td> <td>Common</td> </tr> <tr> <td class=\"indent1\">Pruritus</td> <td>Common</td> <td>Common</td> </tr> <tr> <td class=\"indent1\">Alopecia</td> <td>Rare</td> <td>Rare</td> </tr> <tr> <td class=\"indent1\">Urticaria</td> <td>Rare</td> <td>Uncommon</td> </tr> <tr> <td class=\"indent1\">Trophic nails</td> <td>Rare</td> <td>Unknown</td> </tr> <tr> <td class=\"indent1\">Chrysiasis/pigmentation</td> <td>Uncommon</td> <td>Unknown</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Photosensitivity</td> <td>Rare</td> <td>Unknown</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Kidney</td> </tr> <tr> <td class=\"indent1\">Proteinuria</td> <td>Common<sup>&#916;</sup></td> <td>Rare</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Nephrotic syndrome</td> <td>Rare</td> <td>Rare</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Blood</td> </tr> <tr> <td class=\"indent1\">Eosinophilia</td> <td>Common</td> <td>Rare</td> </tr> <tr> <td class=\"indent1\">Thrombocytopenia</td> <td>Rare<sup>&#916;</sup></td> <td>Rare</td> </tr> <tr> <td class=\"indent1\">Granulocytopenia</td> <td>Rare</td> <td>Rare</td> </tr> <tr> <td class=\"indent1\">Lymphocytopenia</td> <td>Uncommon</td> <td>Rare</td> </tr> <tr> <td class=\"indent1\">Hypogammaglobulinemia</td> <td>Rare</td> <td>Unknown</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Aplastic anemia</td> <td>Rare</td> <td>Unknown</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Pulmonary complications</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Diffuse infiltrates</td> <td>Rare</td> <td>Rare</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Intestinal effects</td> </tr> <tr> <td class=\"indent1\">Upper GI symptoms</td> <td>Rare</td> <td>Uncommon</td> </tr> <tr> <td class=\"indent1\">Mild enterocolitis</td> <td>Rare</td> <td>Common</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Severe enterocolitis</td> <td>Rare</td> <td>Rare</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Liver</td> </tr> <tr> <td class=\"indent1\">Cholestatic jaundice</td> <td>Rare</td> <td>Unknown</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hepatocellular effects</td> <td>Rare</td> <td>Uncommon</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Pancreas</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pancreatitis</td> <td>Rare</td> <td>Rare</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Nervous system</td> </tr> <tr> <td class=\"indent1\">Peripheral/cranial neuropathies</td> <td>Rare</td> <td>Rare</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Encephalopathy</td> <td>Rare</td> <td>Rare</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Eye</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Corneal or lens chrysiasis</td> <td>Common</td> <td>Unknown</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Metallic taste</td> <td>Common</td> <td>Common</td> </tr> <tr> <td class=\"indent1\">Lymph node infarction</td> <td>Rare</td> <td>Unknown</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Reported in hypertensives on angiotensin converting enzyme inhibitors.<br />¶ Possible relationship with HLA-DR3.<br />Δ Proven relationship with HLA-DR3.</div><div id=\"graphicVersion\">Graphic 61137 Version 3.0</div></div></div>"},"61139":{"type":"graphic_algorithm","displayName":"Snake bite management algorithm","title":"Algorithm for the management of snake bites","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Algorithm for the management of snake bites</div><div class=\"cntnt\"><img style=\"width:586px; height:708px;\" src=\"images/ID/61139_Snake_bite_management_algor.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 61139 Version 1.0</div></div></div>"},"61140":{"type":"graphic_movie","displayName":"Restenosis within a saphenous vein graft","title":"Restenosis within a saphenous vein graft","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Restenosis within a saphenous vein graft</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/61140_restsaphconv.mp4\" style=\"width:160px;height:304px\"></div><img style=\"width:160px; height:289px;\" src=\"images/CARD/61140_restsaph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A saphenous vein bypass graft to the obtuse marginal branch of the circumflex artery is shown here. In the mid portion of the graft a long area of irregular narrowing is seen. This represents a restenosis from a previous intervention (stent placement) two months ago.</div><div class=\"graphic_reference\">Courtesy of John D Carroll, MD. This type of movie will be part of The Multimedia Textbook of Coronary Arteriography and Interventions, Williams &amp; Wilkins, Baltimore, Fall 1996.</div><div id=\"graphicVersion\">Graphic 61140 Version 2.0</div></div></div>"},"61144":{"type":"graphic_picture","displayName":"Fungiform papilloma Light","title":"Fungiform papilloma of the nasal septum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fungiform papilloma of the nasal septum</div><div class=\"cntnt\"><img style=\"width:382px; height:266px;\" src=\"images/ONC/61144_Fungiform_papilloma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph of a fungiform papilloma, an exophytic lesion that arises from the nasal septum.</div><div class=\"graphic_reference\">Courtesy of G Kenneth Haines, MD.</div><div id=\"graphicVersion\">Graphic 61144 Version 3.0</div></div></div>"},"61145":{"type":"graphic_picture","displayName":"Multiple myeloma marrow","title":"Multiple myeloma","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Multiple myeloma</div><div class=\"cntnt\"><img style=\"width:525px; height:310px;\" src=\"images/HEME/61145_Multiple_myeloma_marrow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate smears from two different patients with multiple myeloma, illustrating a preponderance of mostly mature-appearing plasma cells with eccentrically placed nuclei and prominent Golgi zones (arrow) (Wright Giemsa stain).</div><div class=\"graphic_reference\">From: Brunning RD, McKenna RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 61145 Version 2.0</div></div></div>"},"61146":{"type":"graphic_table","displayName":"Sonographic signs appendicitis","title":"Ultrasonographic signs of acute appendicitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ultrasonographic signs of acute appendicitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Non-compressible tubular structure in the right lower quadrant</td> </tr> <tr> <td>Wall thickness &#62;2 mm</td> </tr> <tr> <td>Overall diameter &#62;6 mm</td> </tr> <tr> <td>Free fluid in the right lower quadrant</td> </tr> <tr> <td>Thickening of the mesentery</td> </tr> <tr> <td>Localized tenderness with graded compression</td> </tr> <tr> <td>Presence of a calcified appendicolith</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 61146 Version 2.0</div></div></div>"},"61147":{"type":"graphic_figure","displayName":"Hand symptom diagram CTS","title":"Hand symptom diagram for carpal tunnel syndrome","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Hand symptom diagram for carpal tunnel syndrome</div><div class=\"cntnt\"><img style=\"width:511px; height:496px;\" src=\"images/RHEUM/61147_Hand_symptom_diagram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Diagram-rated classic CTS for both hands; nerve conduction tests confirmed bilateral CTS. <br />(B) Diagram-rated probable because of palmar symptoms; nerve conduction tests revealed right CTS. <br />(C) Diagram rated unlikely; nerve conduction tests indicated left ulnar nerve entrapment.</div><div class=\"graphic_footnotes\">CTS: carpal tunnel syndrome.</div><div class=\"graphic_reference\">Redrawn with permission from Katz JN, Stirrat CR, Larson MG, et al. A self-administered hand symptom diagram for the diagnosis and epidemiologic study of carpal tunnel syndrome.&nbsp;J Rheumatol 1990; 17:1495.</div><div id=\"graphicVersion\">Graphic 61147 Version 3.0</div></div></div>"},"61148":{"type":"graphic_diagnosticimage","displayName":"MRI vertebral body hemangioma","title":"MRI vertebral body hemangioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI vertebral body hemangioma</div><div class=\"cntnt\"><img style=\"width:421px; height:592px;\" src=\"images/ONC/61148_MRI_vertebral_hemangioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) T1 hemangioma L1: Sagittal image of a T1-weighted MRI of the lumbar spine without intravenous contrast demonstrates a round lesion with increased signal intensity in the first lumbar vertebra.<br />(B) T2 hemangioma L1: Sagittal image of a T2-weighted MRI of the lumbar spine without intravenous contrast demonstrates a round lesion with increased signal intensity in the first lumbar vertebra.<br />(C) Axial T2 hemangioma L1: Axial image of a T2-weighted MRI of the lumbar spine without intravenous contrast demonstrates a round lesion with increased signal intensity in the first lumbar vertebra.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Pierre J Sasson, MD.</div><div id=\"graphicVersion\">Graphic 61148 Version 4.0</div></div></div>"},"61150":{"type":"graphic_figure","displayName":"Bipolar radiofrequency ablation 2","title":"Bipolar radiofrequency endometrial ablation","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Bipolar radiofrequency endometrial ablation</div><div class=\"cntnt\"><img style=\"width:547px; height:221px;\" src=\"images/OBGYN/61150_NovaSure_endometrial_ablati.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Purdon, TF. NovaSure System Bipolar Radio Frequency Technology: Very short procedure time. OBG Management 2005. Copyright &#169; 2005 Dowden Health Media.</div><div id=\"graphicVersion\">Graphic 61150 Version 3.0</div></div></div>"},"61151":{"type":"graphic_picture","displayName":"APL - microgranular variant","title":"Acute promyelocytic leukemia - microgranular variant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute promyelocytic leukemia - microgranular variant</div><div class=\"cntnt\"><img style=\"width:391px; height:288px;\" src=\"images/HEME/61151_AML_FAB_M3V_Microgran.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blood smear from a patient with the microgranular variant of acute promyelocytic leukemia (APL; formerly described in the French-American-British [FAB] classification as M3V).&nbsp;The promyelocytes vary in size and degree of cytoplasmic basophilia. The cytoplasm contains abundant, fine, azurophilic granules and&nbsp;the nuclei are markedly lobulated and invaginated. (Wright-Giemsa stain)</div><div class=\"graphic_reference\">From Brunning RD, McKenna RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 61151 Version 2.0</div></div></div>"},"61153":{"type":"graphic_diagnosticimage","displayName":"Color Doppler umbilical cord gastroschisis","title":"Gastroschisis transverse section of a 14 week fetus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastroschisis transverse section of a 14 week fetus</div><div class=\"cntnt\"><img style=\"width:321px; height:258px;\" src=\"images/OBGYN/61153_Color_Doppler_cord_gastrosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Color Doppler shows umbilical vessels/cord adjacent to the abdominal wall defect with herniated abdominal organs.</div><div class=\"graphic_footnotes\">V: umbilical vein; A: umbilical artery.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 61153 Version 4.0</div></div></div>"},"61154":{"type":"graphic_diagnosticimage","displayName":"MR placenta accreta","title":"Magnetic resonance image suggestive of placenta accreta","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance image suggestive of placenta accreta</div><div class=\"cntnt\"><img style=\"width:458px; height:355px;\" src=\"images/OBGYN/61154_MR_placenta_accreta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the placental &quot;bulge&quot;, loss of the continuity of the uterine wall, and the dary, intraplacental bands.</div><div class=\"graphic_reference\">Courtesy of Robert Resnik, MD.</div><div id=\"graphicVersion\">Graphic 61154 Version 2.0</div></div></div>"},"61155":{"type":"graphic_table","displayName":"Aromatase inhibitors","title":"Aromatase inhibitors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Aromatase inhibitors</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Generation</td>\n\n      <td class=\"subtitle1\">Steroidal (type 1)</td>\n\n      <td class=\"subtitle1\">Nonsteroidal (type 2)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>First (nonselective)</td>\n\n      <td>-</td>\n\n      <td>Aminoglutethimide</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Second (selective)</td>\n\n      <td>Formestane </td>\n\n      <td>Fadrozole</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Third (superselective)</td>\n\n      <td colspan=\"1\" rowspan=\"2\">Exemestane (Aromasin)</td>\n\n      <td>Anastrozole (Arimidex)</td>\n\n    </tr>\n    <tr>\n      \n      \n      <td>Letrozole (Femara)</td>\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 61155 Version 1.0</div></div></div>"},"61158":{"type":"graphic_picture","displayName":"Superficial spreading melanoma 3","title":"Superficial spreading melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial spreading melanoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/61158_Superficial_spread_melan_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lesion is asymmetric and&nbsp;presents irregular borders and&nbsp;irregular distribution of the pigmentation.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 61158 Version 4.0</div></div></div>"},"61159":{"type":"graphic_table","displayName":"Components of early ambulatory palliative care consultation","title":"Components of early ambulatory palliative care consultation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Components of early ambulatory palliative care consultation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Illness understanding/education</td> </tr> <tr> <td>Inquire about illness and prognostic understanding</td> </tr> <tr> <td>Offer clarification of treatment goals</td> </tr> <tr> <td class=\"subtitle1_single\">Symptom management</td> </tr> <tr> <td class=\"subtitle2_single\">Inquire about uncontrolled symptoms with a focus on:</td> </tr> <tr> <td class=\"indent1\">Pain</td> </tr> <tr> <td class=\"indent1\">Pulmonary symptoms (cough, dyspnea)</td> </tr> <tr> <td class=\"indent1\">Fatigue and sleep disturbance</td> </tr> <tr> <td class=\"indent1\">Mood (depression and anxiety)</td> </tr> <tr> <td class=\"indent1\">Gastrointestinal (anorexia and weight loss, nausea and vomiting, constipation)</td> </tr> <tr> <td class=\"subtitle1_single\">Decision making</td> </tr> <tr> <td>Inquire about mode of decision making</td> </tr> <tr> <td>Assist with treatment decision-making, if necessary</td> </tr> <tr> <td class=\"subtitle1_single\">Coping with life-threatening illness</td> </tr> <tr> <td>Patient</td> </tr> <tr> <td>Family/family caregivers</td> </tr> <tr> <td class=\"subtitle1_single\">Referrals/prescriptions</td> </tr> <tr> <td>Identify care plan for future appointments</td> </tr> <tr> <td>Indicate referrals to other care providers</td> </tr> <tr> <td>Note new medications prescribed</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Jacobsen J, Jackson V, Dahlin C, et al. Components of early outpatient palliative care consultation in patients with metastatic nonsmall cell lung cancer. J Palliat Medicine 2011; 14:459. Copyright &#169; 2011 Mary Ann Liebert, Inc.</div><div id=\"graphicVersion\">Graphic 61159 Version 1.0</div></div></div>"},"61160":{"type":"graphic_figure","displayName":"Benign patterns","title":"Pattern analysis: Dermoscopic benign nevus patterns","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pattern analysis: Dermoscopic benign nevus patterns</div><div class=\"cntnt\"><img style=\"width:399px; height:691px;\" src=\"images/DERM/61160_Benign_patterns2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 61160 Version 3.0</div></div></div>"},"61161":{"type":"graphic_table","displayName":"Thrombocytopenia causes","title":"Causes of thrombocytopenia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of thrombocytopenia</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t    <td class=\"subtitle1_single\">Defective production</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_single\">Congenital/genetic</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Thrombocytopenia with absent radii (TAR) syndrome</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Amegakaryocytic thrombocytopenia</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Fanconi anemia</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Metabolic disorders</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Wiskott-Aldrich syndrome</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Bernard-Soulier syndrome</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Other rare familial syndromes (eg, MHY-9 mutations)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_single\">Acquired</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Aplastic anemia</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Drug-associated marrow suppression</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Virus-associated marrow suppression (eg, HIV)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Chemotherapy</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Radiation injury</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Nutritional deficiencies (eg, vitamin B12 and folate)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_single\">Marrow infiltration</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Neoplasia (eg, leukemia, neuroblastoma)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Histiocytosis</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Osteopetrosis</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Myelofibrosis</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Hemophagocytic syndromes</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Storage diseases</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle1_single\">Increased destruction</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Idiopathic thrombocytopenic purpura (ITP)</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Neonatal alloimmune thrombocytopenia</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Maternal autoimmune thrombocytopenia</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Drug-induced (heparin, sulfonamides, digoxin, chloroquine)</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Sepsis/DIC</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Infection: viral, bacterial, fungal, rickettsial</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Microangiopathic process (eg, TTP/HUS)</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Kasabach-Merritt syndrome</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Hypersplenism</td>\n\t  </tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Courtesy of Leslie Raffini, MD.</div><div id=\"graphicVersion\">Graphic 61161 Version 1.0</div></div></div>"},"61163":{"type":"graphic_table","displayName":"Causes of thrombocytopenia in children","title":"Major causes of thrombocytopenia in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of thrombocytopenia in children</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Destructive thrombocytopenias</td> </tr> <tr> <td class=\"subtitle2_single\">Immune-mediated</td> </tr> <tr> <td class=\"indent1\">Immune thrombocytopenia (ITP)</td> </tr> <tr> <td class=\"indent1\">Drug-induced thrombocytopenia</td> </tr> <tr> <td class=\"indent1\">Systemic lupus erythematosus</td> </tr> <tr> <td class=\"indent1\">Autoimmune lymphoproliferative syndrome</td> </tr> <tr> <td class=\"indent1\">Neonatal alloimmune thrombocytopenia</td> </tr> <tr> <td class=\"indent1\">Post-transplant thrombocytopenia</td> </tr> <tr> <td class=\"subtitle2_single\">Nonimmune</td> </tr> <tr> <td class=\"indent1\">Hemolytic-uremic syndrome</td> </tr> <tr> <td class=\"indent1\">Thrombotic thrombocytopenic purpura</td> </tr> <tr> <td class=\"indent1\">Disseminated intravascular coagulation</td> </tr> <tr> <td class=\"indent1\">Major surgery or trauma</td> </tr> <tr> <td class=\"indent1\">Kasabach-Merritt syndrome</td> </tr> <tr> <td class=\"indent1\">Extracorporeal therapies (eg, cardiopulmonary bypass)</td> </tr> <tr> <td class=\"indent1\">Hypersplenism</td> </tr> <tr> <td class=\"indent1\">Hypothermia</td> </tr> <tr> <td class=\"indent1\">Type 2B or platelet-type von Willebrand disease</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Decreased platelet production</td> </tr> <tr> <td class=\"indent1\"><strong>Infection </strong>(Epstein-Barr virus, cytomegalovirus, parvovirus, varicella, rickettsia, bacterial sepsis)</td> </tr> <tr> <td class=\"indent1\"><strong>Nutritional deficiencies</strong> (folate, B12, iron)</td> </tr> <tr> <td class=\"sublist2_start\"><strong>Acquired bone marrow failure</strong></td> </tr> <tr> <td class=\"sublist2\"> <p>Aplastic anemia</p> </td> </tr> <tr> <td class=\"sublist2\">Myelodysplastic syndromes</td> </tr> <tr> <td class=\"sublist2\">Medications (eg, chemotherapy)</td> </tr> <tr> <td class=\"sublist2\">Radiation</td> </tr> <tr> <td class=\"sublist2_start\"><strong>Infiltrative bone marrow diseases</strong></td> </tr> <tr> <td class=\"sublist2\">Leukemias</td> </tr> <tr> <td class=\"sublist2\">Lymphomas</td> </tr> <tr> <td class=\"sublist2\">Metastatic cancers</td> </tr> <tr> <td class=\"sublist2\">Infectious granulomas</td> </tr> <tr> <td class=\"sublist2\">Storage diseases</td> </tr> <tr> <td class=\"sublist2_start\"><strong>Genetic causes of impaired thrombopoiesis</strong><sup>*</sup></td> </tr> <tr> <td class=\"sublist2\">Wiskott-Aldrich syndrome/X-linked thrombocytopenia</td> </tr> <tr> <td class=\"sublist2\">Inherited bone marrow failure syndromes</td> </tr> <tr> <td class=\"sublist3\">Fanconi anemia</td> </tr> <tr> <td class=\"sublist3\">Dyskeratosis congenita</td> </tr> <tr> <td class=\"sublist3\">Shwachman-Diamond syndrome</td> </tr> <tr> <td class=\"sublist3\">Congenital amegakaryocytic thrombocytopenia</td> </tr> <tr> <td class=\"sublist2\">Thrombocytopenia with absent radii syndrome</td> </tr> <tr> <td class=\"sublist2\">Amegakaryocytic thrombocytopenia with radioulnar synostosis</td> </tr> <tr> <td class=\"sublist2\">Familial platelet disorder with predisposition to hematologic malignancy</td> </tr> <tr> <td class=\"sublist2\">Bernard-Soulier syndrome</td> </tr> <tr> <td class=\"sublist2\"><em>MYH9</em>-related disorders</td> </tr> <tr> <td class=\"sublist2\">Paris-Trousseau syndrome</td> </tr> <tr> <td class=\"sublist2\">X-linked thrombocytopenia with dyserythropoiesis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><EM>MYH9</EM>: nonmuscle myosin heavy chain gene.<br />* This is a partial list. For&nbsp;further details,&nbsp;refer to UpToDate topics on causes of thrombocytopenia in children and disorders of&nbsp;platelet function.</div><div id=\"graphicVersion\">Graphic 61163 Version 13.0</div></div></div>"},"61164":{"type":"graphic_diagnosticimage","displayName":"Osteomyelitis bone scan","title":"Osteomyelitis three-phase bone scan","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Osteomyelitis three-phase bone scan</div><div class=\"cntnt\"><img style=\"width:490px; height:289px;\" src=\"images/PEDS/61164_Osteomyelitis_bone_scan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three-phase bone scan demonstrating asymmetric increased uptake in the left proximal femur (arrows) of this four-month-old with osteomyelitis.</div><div class=\"graphic_reference\">Courtesy of Rajvee Shah, MD.</div><div id=\"graphicVersion\">Graphic 61164 Version 3.0</div></div></div>"},"61165":{"type":"graphic_diagnosticimage","displayName":"Bronchiectasis CF PA","title":"Bronchiectasis in cystic fibrosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchiectasis in cystic fibrosis</div><div class=\"cntnt\"><img style=\"width:326px; height:290px;\" src=\"images/PULM/61165_Bronchiectasis_CF_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast bronchogram in a young patient with cystic fibrosis shows fusiform and saccular bronchiectasis in the right lower lobe.</div><div class=\"graphic_reference\">Courtesy of Julie P Katkin, MD.</div><div id=\"graphicVersion\">Graphic 61165 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"61166":{"type":"graphic_table","displayName":"Ear pressurization techniques","title":"Middle ear pressure equalization maneuvers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Middle ear pressure equalization maneuvers</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Maneuver</td>\n<td class=\"subtitle1\">Description</td>\n<td class=\"subtitle1\">Comment</td>\n</tr>\n<tr>\n<td>Simple techniques</td>\n<td>Yawn, swallow, jaw thrust, head tilt</td>\n<td>Useful in patients with widely patent Eustachian tubes, but usually ineffective with marginally patent Eustachian tubes</td>\n</tr>\n<tr>\n<td>Frenzel maneuver</td>\n<td>Diver pinches the nostrils, closes the glottis, and makes a \"k\" or \"guh\" sound to compress air in the back of the throat</td>\n<td>Can be performed at any point in the respiratory cycle and can be quickly repeated.</td>\n</tr>\n<tr>\n<td>Valsalva maneuver</td>\n<td>Diver pinches the nostrils, tightens cheek muscle and exhales forcefully</td>\n<td>Prolonged efforts can reduce systemic venous return and cause hypotension</td>\n</tr>\n<tr>\n<td>Toynbee maneuver</td>\n<td>Diver pinches the nostrils while swallowing</td>\n<td>Limited effectiveness during rapid descent</td>\n</tr>\n<tr>\n<td>Beance tubaire voluntaire maneuver</td>\n<td>Diver contracts the muscles of the soft palate while using the muscles of the upper throat to open the Eustachian tubes</td>\n<td>Difficult to teach and not easily mastered</td>\n</tr>\n<tr>\n<td>Roydhouse maneuver</td>\n<td>Diver contracts the muscles of the soft palate while tensing the tongue to open the Eustachian tubes</td>\n<td>Difficult to teach and not easily mastered; concomitant jaw thrust may be helpful</td>\n</tr>\n<tr>\n<td>Edmonds technique</td>\n<td>Combination of pressurization from the Frenzel or Valsalva maneuver with a jaw thrust or head tilt</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>Lowry technique</td>\n<td>Diver pinches the nostrils, builds up pressure with a Frenzel or Valsalva maneuver, and simultaneously swallows</td>\n<td>Requires coordination and practice but is very effective</td>\n</tr>\n<tr>\n<td>Twitch maneuver</td>\n<td>Diver builds up pressure with a Frenzel or Valsalva maneuver, then suddenly twitches the head sideways</td>\n<td>Throat muscle tension increases effectiveness of the technique</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Kay, E, Undersea J 2000; 4:30.</div><div id=\"graphicVersion\">Graphic 61166 Version 1.0</div></div></div>"},"61167":{"type":"graphic_table","displayName":"Anatomic diagnosis of weakness","title":"Differential diagnosis of weakness","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of weakness</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\" rowspan=\"2\">Diagnostic category</td>\r\n                    <td class=\"subtitle1\" colspan=\"5\">Site of lesion</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2\">Upper motor neuron</td>\r\n                    <td class=\"subtitle2\">Anterior horn cell</td>\r\n                    <td class=\"subtitle2\">Peripheral nerve</td>\r\n                    <td class=\"subtitle2\">NM junction</td>\r\n                    <td class=\"subtitle2\">Muscle</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Genetic</td>\r\n                    <td>Leukodystrophies</td>\r\n                    <td>Spinal muscular atrophy</td>\r\n                    <td>Peroneal muscular atrophy</td>\r\n                    <td>Myasthenia gravis</td>\r\n                    <td>Muscular dystrophies</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Inflammatory</td>\r\n                    <td>Vasculitis</td>\r\n                    <td>Amyotrophic lateral sclerosis</td>\r\n                    <td>Guillain- Barre</td>\r\n                    <td>Myasthenia gravis</td>\r\n                    <td>Polymyositis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Infectious</td>\r\n                    <td>Brain abscess</td>\r\n                    <td>Poliomyelitis</td>\r\n                    <td>Leprosy</td>\r\n                    <td>Botulism</td>\r\n                    <td>HIV</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Neoplastic</td>\r\n                    <td>Brain tumor</td>\r\n                    <td>Paraneoplastic syndrome</td>\r\n                    <td>Myeloma/ amyloid</td>\r\n                    <td>Eaton-Lambert syndrome</td>\r\n                    <td>Malignancy- associated myositis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Toxic/drug</td>\r\n                    <td>Radiation</td>\r\n                    <td>Lead</td>\r\n                    <td>Lead</td>\r\n                    <td>Organophosphate poisoning</td>\r\n                    <td>Steroid</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Metabolic/ endocrine</td>\r\n                    <td>Vitamin B12 deficiency</td>\r\n                    <td>&nbsp;</td>\r\n                    <td>Diabetes</td>\r\n                    <td>---</td>\r\n                    <td>\r\n                    <p>Hypothyroid</p>\r\n                    <p>Hypoglycemia</p>\r\n                    </td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 61167 Version 2.0</div></div></div>"},"61168":{"type":"graphic_diagnosticimage","displayName":"Ultrasound oil cyst","title":"Ultrasound oil cyst","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Ultrasound oil cyst</div><div class=\"cntnt\"><img style=\"width:588px; height:580px;\" src=\"images/SURG/61168_Ultrasound_oil_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Oil cyst (anti-radial). B) Oil cyst (radial). C) Mammographic appearance of oil cyst.</div><div id=\"graphicVersion\">Graphic 61168 Version 2.0</div></div></div>"},"61170":{"type":"graphic_figure","displayName":"AFP levels in AF by GA","title":"The approximate relationship between alpha-fetoprotein (AFP) values in amniotic fluid and gestational age","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">The approximate relationship between alpha-fetoprotein (AFP) values in amniotic fluid and gestational age</div><div class=\"cntnt\"><img style=\"width:472px; height:352px;\" src=\"images/OBGYN/61170_AFP_levels_in_AF_by_GA.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Habib ZA. Maternal serum alpha-fetoprotein: Its value in antenatal diagnosis of genetic disease and in obstetrical-gynaecological care. Acta Obstet Gynecol Scand 1977; 61:1.</div><div id=\"graphicVersion\">Graphic 61170 Version 2.0</div></div></div>"},"61171":{"type":"graphic_table","displayName":"Drugs and toxins associated with pericardial disease","title":"Drugs and toxins associated with pericardial disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs and toxins associated with pericardial disease</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Drug-induced lupus erythematosus</td> </tr> <tr> <td class=\"indent1\">Procainamide</td> </tr> <tr> <td class=\"indent1\">Tocainide</td> </tr> <tr> <td class=\"indent1\">Hydralazine</td> </tr> <tr> <td class=\"indent1\">Methyldopa</td> </tr> <tr> <td class=\"indent1\">Mesalazine</td> </tr> <tr> <td class=\"indent1\">Reserpine</td> </tr> <tr> <td class=\"indent1\">Isoniazid</td> </tr> <tr> <td class=\"indent1\">Hydantoins</td> </tr> <tr> <td class=\"subtitle1_single\">Hypersensitivity reaction</td> </tr> <tr> <td class=\"indent1\">Penicillins</td> </tr> <tr> <td class=\"indent1\">Tryptophan</td> </tr> <tr> <td class=\"indent1\">Cromolyn sodium</td> </tr> <tr> <td class=\"subtitle1_single\">Idiosyncratic reaction or hypersensitivity</td> </tr> <tr> <td class=\"indent1\">Methysergide</td> </tr> <tr> <td class=\"indent1\">Minoxidil</td> </tr> <tr> <td class=\"indent1\">Practolol</td> </tr> <tr> <td class=\"indent1\">Bromocriptine</td> </tr> <tr> <td class=\"indent1\">Psicofuranine</td> </tr> <tr> <td class=\"indent1\">Phenylbutazone</td> </tr> <tr> <td class=\"indent1\">Cytarabine</td> </tr> <tr> <td class=\"indent1\">Amiodarone</td> </tr> <tr> <td class=\"indent1\">Streptokinase</td> </tr> <tr> <td class=\"indent1\">p-Aminosalicylic acid</td> </tr> <tr> <td class=\"indent1\">Thiazides</td> </tr> <tr> <td class=\"indent1\">Streptomycin</td> </tr> <tr> <td class=\"indent1\">Sulfa drugs</td> </tr> <tr> <td class=\"indent1\">Thiouracils</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Idiosyncratic reaction or hypersensitivity (con't)</td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide</td> </tr> <tr> <td class=\"indent1\">Cyclosporine</td> </tr> <tr> <td class=\"indent1\">Mesalazine</td> </tr> <tr> <td class=\"indent1\">5-Fluorouracil</td> </tr> <tr> <td class=\"indent1\">Vaccines (Smallpox, Yellow fever)</td> </tr> <tr> <td class=\"indent1\">GM-CSF</td> </tr> <tr> <td class=\"subtitle1_single\">Anthracycline derivatives</td> </tr> <tr> <td class=\"indent1\">Doxorubicin</td> </tr> <tr> <td class=\"indent1\">Daunorubicin</td> </tr> <tr> <td class=\"subtitle1_single\">Serum sickness</td> </tr> <tr> <td class=\"indent1\">Foreign antisera (eg, antitetanus)</td> </tr> <tr> <td class=\"indent1\">Blood products</td> </tr> <tr> <td class=\"subtitle1_single\">Venom</td> </tr> <tr> <td class=\"indent1\">Scorpion fish sting</td> </tr> <tr> <td class=\"subtitle1_single\">Foreign-substance reactions (direct pericardial application)</td> </tr> <tr> <td class=\"indent1\">Talc (Mg silicate)</td> </tr> <tr> <td class=\"indent1\">Silicones</td> </tr> <tr> <td class=\"indent1\">Tetracycline/other sclerosants</td> </tr> <tr> <td class=\"indent1\">Iron in &#946;-thalassemia</td> </tr> <tr> <td class=\"indent1\">Asbestos</td> </tr> <tr> <td class=\"subtitle1_single\">Secondary pericardial bleeding/hemopericardium</td> </tr> <tr> <td class=\"indent1\">Anticoagulants</td> </tr> <tr> <td class=\"indent1\">Thrombolytic agents</td> </tr> <tr> <td class=\"subtitle1_single\">Polymer fume fever</td> </tr> <tr> <td class=\"indent1\">Inhalation of the burning fumes of polytetrafluoroethylene (Teflon)</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Maisch B, Seferovic PM, Ristic AD, et al. Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericaridal diseases of the European society of cardiology. Eur Heart J 2004; 25:587. Copyright &copy; 2004 European Society of Cardiology.</div><div id=\"graphicVersion\">Graphic 61171 Version 4.0</div></div></div>"},"61174":{"type":"graphic_table","displayName":"Hx GERD child","title":"Key elements of history in child with suspected gastroesophageal reflux disease (GERD)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key elements of history in child with suspected gastroesophageal reflux disease (GERD)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Symptoms suggesting GERD</td> </tr> <tr> <td class=\"indent1\">Discomfort or irritability (if this is the only symptom in an infant, it is unlikely to be due to GERD)</td> </tr> <tr> <td class=\"indent1\">Heartburn, chest pain,&nbsp;or epigastric abdominal pain</td> </tr> <tr> <td class=\"indent1\">Recurrent hematemesis&nbsp;</td> </tr> <tr> <td class=\"indent1\">Acid brash, regurgitation (often triggered by recumbent position, food, activity or anxiety), or \"wet burps\"</td> </tr> <tr> <td class=\"indent1\">Nocturnal cough</td> </tr> <tr> <td class=\"indent1\">Chronic sore throat</td> </tr> <tr> <td class=\"indent1\">Rapid relief of symptoms when taking antacids or acid-suppressing medications&nbsp;</td> </tr> <tr> <td class=\"indent1\">Dystonic posturing (Sandifer's syndrome)&nbsp;</td> </tr> <tr> <td class=\"indent1\">Wheezing, stridor, or hoarseness</td> </tr> <tr> <td class=\"indent1\">Symptoms increase after large meals</td> </tr> <tr> <td class=\"indent1\">Constipation</td> </tr> <tr> <td class=\"subtitle1_single\">Signs suggesting GERD&nbsp;</td> </tr> <tr> <td class=\"indent1\">Erosion of tooth enamel, mainly on the palatal aspects of the maxillary teeth</td> </tr> <tr> <td class=\"indent1\">Unexplained iron deficiency anemia</td> </tr> <tr> <td class=\"indent1\">Esophagitis, esophageal stricture, or Barrett's esophagus</td> </tr> <tr> <td class=\"indent1\">Brief resolved unexplained events (BRUEs)&nbsp;</td> </tr> <tr> <td class=\"indent1\">Asthma&nbsp;</td> </tr> <tr> <td class=\"indent1\">Recurrent aspiration pneumonia</td> </tr> <tr> <td class=\"indent1\">Recurrent otitis media</td> </tr> <tr> <td class=\"subtitle1_single\">Symptoms less commonly attributable to GERD&nbsp;</td> </tr> <tr> <td class=\"indent1\">Dysphagia or odynophagia*</td> </tr> <tr> <td class=\"indent1\">Failure to thrive or weight loss</td> </tr> <tr> <td class=\"indent1\">Feeding refusal/aversion<sup>&#182;</sup>&nbsp;</td> </tr> <tr> <td class=\"indent1\">School absences</td> </tr> <tr> <td class=\"indent1\">Anxiety/depression</td> </tr> <tr> <td class=\"indent1\">Marijuana use (heavy, daily use may be associated with hyperemesis)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><FONT color=black>* Patients with dysphagia (difficulty swallowing) or odynophagia (pain with swallowing) usually should undergo a specific evaluation, as described in the topic text.&nbsp;In adolescents, odynophagia is often associated with pill esophagitis or a viral infection of the esophagitis.<br />¶ Food aversion may be associated with GERD in toddlers or eosinophilic esophagitis in young children.&nbsp;Psychosocial stressors should also be considered. </FONT></div><div id=\"graphicVersion\">Graphic 61174 Version 6.0</div></div></div>"},"61175":{"type":"graphic_table","displayName":"Medical treatment of chronic constipation in children","title":"Typical regimen for a child with recurrent or chronic constipation without fecal impaction or incontinence","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Typical regimen for a child with recurrent or chronic constipation without fecal impaction or incontinence</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\">Step 1</td> <td class=\"divider_bottom\">Start 2 to 4 teaspoons (3.5 teaspoons = 17 grams) of PEG 3350 (eg, MiraLax, GlycoLax) once daily, in 4 to 8 ounces (120 to 240 mL) of noncarbonated beverage (or appropriate dose of another laxative).</td> </tr> <tr> <td class=\"subtitle1_left\">Step 2</td> <td class=\"divider_bottom\">Increase or decrease PEG 3350 by 1 to 2 teaspoons every 2 to 3 days, until the desired result of daily soft stools is achieved. Maximum dose is 1 heaping tablespoon (17 grams) twice daily.</td> </tr> <tr> <td class=\"subtitle1_left\">Step 3</td> <td class=\"divider_bottom\">Follow-up by phone or a return visit within 1 month to be sure the laxative is effective.</td> </tr> <tr> <td class=\"subtitle1_left\">Step 4</td> <td class=\"divider_bottom\">Continue to work on adding dietary fiber and extra liquids to the diet each day.</td> </tr> <tr> <td class=\"subtitle1_left\">Step 5</td> <td class=\"divider_bottom\">After 6 to 8 weeks of soft daily bowel movements, begin to taper the dose of PEG 3350 by <span style=\"font-family: calibri; font-size: 16px;\">&#189;</span> to 1 teaspoon every 2 weeks, until daily movements continue without the need for a laxative.</td> </tr> <tr> <td class=\"subtitle1_left\">Step 6</td> <td class=\"divider_bottom\">If stools become hard once again, increase the dose slightly and retry weaning off the laxative in another 6 to 8 weeks.</td> </tr> <tr> <td class=\"subtitle1_left\">Step 7</td> <td class=\"divider_bottom\">This process may take from 2 to 4 weeks to six months, but the end result should be resolution of the constipation.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table describes a typical regimen for children older than three years with mild or moderate constipation <strong>without</strong> fecal impaction. Children with mild chronic constipation may be treated with dietary changes alone rather than medication, if desired. Children <strong>with</strong> fecal impaction, with or without overflow incontinence, should first be disimpacted with a regimen of oral and/or rectal medications. In most cases, these steps should be combined with family education and behavior modification (toileting) to enhance efficacy and prevent relapse. For details, refer to the text of the UpToDate topic on chronic constipation in children.</div><div class=\"graphic_footnotes\">PEG 3350: polyethylene glycol without electrolytes, also known as macrogol.</div><div id=\"graphicVersion\">Graphic 61175 Version 7.0</div></div></div>"},"61176":{"type":"graphic_figure","displayName":"Classic Z-plasty","title":"Classic Z-plasty","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Classic Z-plasty</div><div class=\"cntnt\"><img style=\"width:504px; height:418px;\" src=\"images/SURG/61176_Classic_z-plasty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The classic Z-plasty consists of three limbs of equal length. The angles between the central limb and each lateral limb are equal and measure 60°.</div><div id=\"graphicVersion\">Graphic 61176 Version 2.0</div></div></div>"},"61177":{"type":"graphic_figure","displayName":"Adrenal glands in relation to the kidneys and great vessels","title":"Adrenal glands in relation to the kidneys and great vessels","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Adrenal glands in relation to the kidneys and great vessels</div><div class=\"cntnt\"><img style=\"width:501px; height:347px;\" src=\"images/SURG/61177_Adrenal-glands-in-relation-to-the-kidneys-and-great-vessels.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The adrenal glands are retroperitoneal and are located on the superior medial aspect of the upper pole of each kidney. This illustrates the frontal or intra-abdominal view of the kidneys and adrenal glands.</div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Company. Copyright &#169; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 61177 Version 3.0</div></div></div>"},"61178":{"type":"graphic_figure","displayName":"Injectable soft tissue filler treatment sites","title":"Potential sites for treatment with injectable soft tissue fillers","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Potential sites for treatment with injectable soft tissue fillers</div><div class=\"cntnt\"><img style=\"width:523px; height:561px;\" src=\"images/DERM/61178_Soft_tissue_filler_treatment_sites.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 61178 Version 5.0</div></div></div>"},"61180":{"type":"graphic_picture","displayName":"Granuloma giant cell Crohns","title":"Gastric granuloma in Crohn's disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric granuloma in Crohn's disease</div><div class=\"cntnt\"><img style=\"width:396px; height:288px;\" src=\"images/GAST/61180_Granuloma_giant_cell_Crohns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph showing a granuloma (arrow) in a patient with Crohn's disease with gastric involvement.</div><div class=\"graphic_reference\">Courtesy of Beverly Dickson, MD.</div><div id=\"graphicVersion\">Graphic 61180 Version 1.0</div></div></div>"},"61181":{"type":"graphic_figure","displayName":"Syndesmotic sprain","title":"Syndesmotic sprain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Syndesmotic sprain</div><div class=\"cntnt\"><img style=\"width:424px; height:304px;\" src=\"images/PC/61181_Syndesmotic_sprain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A syndesmotic sprain can be caused by dorsiflexion and eversion of the ankle with internal rotation of the tibia as shown by the picture on the right. The figure on the left shows a posterior view with injury to the posterior tibiofibular ligament. The anterior tibiofibular ligament cannot be seen in this view but would also be damaged by the injury.</div><div id=\"graphicVersion\">Graphic 61181 Version 1.0</div></div></div>"},"61185":{"type":"graphic_figure","displayName":"Overdrive pacing","title":"Effect of overdrive pacing on spontaneous automaticity of Purkinje fiber","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effect of overdrive pacing on spontaneous automaticity of Purkinje fiber</div><div class=\"cntnt\"><img style=\"width:432px; height:306px;\" src=\"images/CARD/61185_Overdrive_pacing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The more rapid discharge from the sinus node produces overdrive suppression of Purkinje fiber automaticity. Microelectrode recording from a Purkinje fiber at baseline shows a maximum diastolic potential of -77 mV. During overdrive pacing, the membrane becomes hyperpolarized and maximum diastolic potential increases to -85 mV, resulting in part from the accumulation of sodium ions, activation of the sodium-potassium pump, and an increased influx of potassium as sodium is extruded. After the cessation of overdrive pacing, the onset of the next spontaneous action potential is delayed since the slow of phase 4 diastolic depolarization is reduced and the more negative diastolic potential increases in the time required to reach threshold.</div><div id=\"graphicVersion\">Graphic 61185 Version 2.0</div></div></div>"},"61186":{"type":"graphic_figure","displayName":"Phases of diastole","title":"Phases of diastole","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Phases of diastole</div><div class=\"cntnt\"><img style=\"width:432px; height:382px;\" src=\"images/CARD/61186_Phases_of_diastole.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 61186 Version 1.0</div></div></div>"},"61189":{"type":"graphic_waveform","displayName":"Sinusoidal FHR pattern","title":"Sinusoidal FHR pattern","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Sinusoidal FHR pattern</div><div class=\"cntnt\"><img style=\"width:535px; height:235px;\" src=\"images/OBGYN/61189_Sinusoidal_FHR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sinusoidal heart rate pattern in a patient presenting with spontaneous fetomaternal hemorrhage near term. The patient reported decreased fetal movement.</div><div id=\"graphicVersion\">Graphic 61189 Version 3.0</div></div></div>"},"61190":{"type":"graphic_picture","displayName":"Nodular basal cell carcinomas","title":"Nodular basal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nodular basal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:435px; height:258px;\" src=\"images/ONC/61190_Nodular_basal_cell_CA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A typical nodular basal cell carcinoma presents as a well-circumscribed nodule with a translucent or pearly appearance and telangiectasias (most evident in the left panel).</div><div class=\"graphic_reference\">Courtesy of James C Shaw, MD.</div><div id=\"graphicVersion\">Graphic 61190 Version 2.0</div></div></div>"},"61192":{"type":"graphic_figure","displayName":"Retinal hemorrhage types","title":"Types of retinal hemorrhage (RH) in children","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Types of retinal hemorrhage (RH) in children</div><div class=\"cntnt\"><img style=\"width:538px; height:664px;\" src=\"images/PEDS/61192_Retinal-hemorrhage-types-edit2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Aryan HE, Ghosheh FR, Jandial R, Levy ML. Retinal hemorrhage and pediatric brain injury: etiology and review of the literature. J Clin Neurosci 2005; 12:624.</div><div id=\"graphicVersion\">Graphic 61192 Version 6.0</div></div></div>"},"61193":{"type":"graphic_figure","displayName":"Normal esophageal shortening","title":"Esophageal shortening during swallow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal shortening during swallow</div><div class=\"cntnt\"><img style=\"width:432px; height:290px;\" src=\"images/GAST/61193_Norm_esoph_short_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Before swallow - Clip B marks the position of the squamocolumnar junction (SCJ), 35 mm distal to the anchor point on the vertebral body; clip A is affixed to the esophageal mucosa 31 mm proximally. Clip movements are referenced to point V on the vertebral column.<br />(B) At the time of maximal esophageal shortening during swallow, clip B is 20 mm distal to point V and the distance between clips A and B is reduced to 22 mm, indicative of 29 percent shortening.<br />(C) As elongation proceeds, first both clips descend, after which clip B descends, stretching the A-B segment back to its initial length.<br />(D) After swallow recovery to normal.</div><div class=\"graphic_reference\">With permission from: Kahrilas PJ, Wu S, Lin S, et al. Attenuation of esophageal shortening during peristalsis with hiatus hernia. Gastroenterology 1995; 109:1818.</div><div id=\"graphicVersion\">Graphic 61193 Version 4.0</div></div></div>"},"61194":{"type":"graphic_figure","displayName":"Alveolar edema development","title":"Development of alveolar edema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Development of alveolar edema</div><div class=\"cntnt\"><img style=\"width:360px; height:506px;\" src=\"images/PULM/61194_Alveolar_edema_development.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Breakdown of the alveolar epithelial barrier allows leakage of edema fluid into the alveolar space. Arrows represent lymphatic movement; small circles represent protein.</div><div id=\"graphicVersion\">Graphic 61194 Version 1.0</div></div></div>"},"61196":{"type":"graphic_diagnosticimage","displayName":"Short axis LV mass","title":"Short axis views for estimating left ventricular mass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Short axis views for estimating left ventricular mass</div><div class=\"cntnt\"><img style=\"width:375px; height:350px;\" src=\"images/CARD/61196_Short_axis_LV_mass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These short axis echocardiographic images&nbsp;have been hand digitized to demonstrate the method for outlining the epicardium (left) and the endocardium (right). These measurements are performed in both diastole and systole; since mass changes only 10 to 20 percent during the cardiac cycle (presumably due to myocardial blood volume) obtaining both systolic and diastolic mass estimates&nbsp;can serve as an internal check on accuracy.</div><div id=\"graphicVersion\">Graphic 61196 Version 5.0</div></div></div>"},"61198":{"type":"graphic_diagnosticimage","displayName":"Displaced Salter-Harris type II fracture of the proximal phalanx","title":"Displaced Salter-Harris type II fracture of the proximal phalanx","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Displaced Salter-Harris type II fracture of the proximal phalanx</div><div class=\"cntnt\"><img style=\"width:265px; height:393px;\" src=\"images/EM/61198_DisplacedPIPfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Displaced&nbsp;Salter-Harris II fracture of the proximal phalanx that was irreducible. The distal fragment was herniated through a rent in the periosteum and extensor mechanism that prohibited reduction.</div><div class=\"graphic_reference\">Reproduced with permission from: Kozin SH, Waters PM. Fractures and dislocations of the hand and carpus in children. In: Rockwood and Wilkins' Fractures in Children, 7th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 61198 Version 13.0</div></div></div>"},"61200":{"type":"graphic_figure","displayName":"Fibrosis duration infection","title":"Association between stage of hepatic fibrosis and age at biopsy or duration of infection by alcohol consumption in patients with hepatitis C virus infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Association between stage of hepatic fibrosis and age at biopsy or duration of infection by alcohol consumption in patients with hepatitis C virus infection</div><div class=\"cntnt\"><img style=\"width:368px; height:629px;\" src=\"images/GAST/61200_Fibrosis_duration_infection.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349:825. Copyright &#169;1997 Elsevier.</div><div id=\"graphicVersion\">Graphic 61200 Version 2.0</div></div></div>"},"61201":{"type":"graphic_picture","displayName":"Micro P marneffei yeasts","title":"Microscopic examination of <em>Penicillium marneffei</em> yeasts after incubating at 37°C on brain heart infusion agar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Microscopic examination of <em>Penicillium marneffei</em> yeasts after incubating at 37&#176;C on brain heart infusion agar</div><div class=\"cntnt\"><img style=\"width:283px; height:228px;\" src=\"images/ID/61201_Micro_P_marneffei_yeasts.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Drs. Khuanchai Supparatpinyo and Thira Sirisanthana.</div><div id=\"graphicVersion\">Graphic 61201 Version 1.0</div></div></div>"},"61202":{"type":"graphic_table","displayName":"Rx staph PVE","title":"Suggested regimens for therapy of prosthetic valve endocarditis due to <EM innerHtml>Staphylococcus </EM>species","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested regimens for therapy of prosthetic valve endocarditis due to <EM innerHtml>Staphylococcus </EM>species</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">American Heart Association (AHA)</td> <td class=\"subtitle1\">European Society of Cardiology (ESC)</td> </tr> <tr> <td class=\"subtitle2\">Adult</td> <td class=\"subtitle2\">Pediatric<sup>*</sup></td> <td class=\"subtitle2\">Adult&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\">Methicillin-susceptible strains</td> <td class=\"subtitle2_left\">Methicillin-susceptible strains</td> <td class=\"subtitle2_left\">Methicillin-susceptible strains</td> </tr> <tr> <td> <p><strong>One of the following<sup>&#182;</sup>:</strong></p> <p>Nafcillin or oxacillin 12 g per 24 hours IV in&nbsp;six divided doses for &#8805;6 weeks</p> <p><strong>or</strong></p> <p>Cefazolin<sup>&#916;</sup> 6 g per 24 hours IV in three divided doses for &#8805;6 weeks</p> <p><strong>plus</strong></p> <p>Rifampin<sup>&#9674; </sup>900 mg per 24 hours IV or&nbsp;orally&nbsp;in&nbsp;three divided doses for &#8805;6 weeks</p> <p><strong>plus</strong></p> <p>Gentamicin<sup>&#167;&#165; </sup>3 mg/kg per 24 hours IV or IM in&nbsp;two or&nbsp;three divided doses for 2 weeks</p> </td> <td> <p><strong>One of the following<strong><sup>&#182;</sup></strong>:</strong></p> <p>Nafcillin or oxacillin 200 mg/kg per 24 hours IV (maximum dose: 12 g per 24 hours) in&nbsp;four or&nbsp;six divided doses for &#8805;6 weeks</p> <p><strong>or</strong></p> <p>Cefazolin<sup>&#916;</sup> 100 mg/kg per 24 hours IV (maximum dose: 12 g per 24 hours)&nbsp;in&nbsp;three divided doses for &#8805;6 weeks</p> <p><strong>plus</strong></p> <p>Rifampin<sup>&#9674;</sup> 20 mg/kg per 24 hours IV (maximum dose:&nbsp;900 mg per 24 hours)&nbsp;in&nbsp;three divided doses for &#8805;6 weeks</p> <p><strong>plus</strong></p> <p>Gentamicin<sup>&#167;&#165;</sup> 3 to 6 mg/kg per 24 hours IV or IM in&nbsp;three divided doses for first 2 weeks</p> </td> <td> <p><strong>One of the following<strong><sup>&#182;</sup></strong>:</strong></p> <p>Oxacillin or cloxacillin or flucloxacillin 12 g per 24 hours IV in&nbsp;four&nbsp;or&nbsp;six divided doses for &#8805;6 weeks</p> <p><strong>or</strong></p> <p>Cefazolin<sup>&#916;</sup> 6 g per 24 hours IV in three divided&nbsp;doses for &#8805;6 weeks</p> <p><strong>or</strong></p> <p>Cefotaxime<sup>&#916;</sup> 6 g per 24 hours IV in three divided doses for &#8805;6 weeks</p> <p><strong>plus</strong></p> <p>Rifampin<sup>&#9674;</sup> 900 to 1200 mg per 24 hours IV or&nbsp;orally&nbsp;in&nbsp;two or three&nbsp;divided doses for &#8805;6 weeks</p> <p><strong>plus</strong></p> <p>Gentamicin<sup>&#167;</sup> 3 mg/kg per 24 hours IV or IM in&nbsp;one or two&nbsp;doses for the first 2 weeks</p> </td> </tr> <tr> <td class=\"subtitle2_left\">Methicillin-resistant strains</td> <td class=\"subtitle2_left\">Methicillin-resistant strains</td> <td class=\"subtitle2_left\">Methicillin-resistant strains</td> </tr> <tr> <td> <p>Vancomycin<sup>&#135;</sup> 30 mg/kg per 24 hours IV in&nbsp;two divided doses for &#8805;6 weeks</p> <p><strong>plus</strong></p> <p>Rifampin<sup>&#9674;</sup> 900 mg per 24 hours IV or&nbsp;orally&nbsp;in&nbsp;three divided doses for &#8805;6 weeks</p> <p><strong>plus</strong></p> <p>Gentamicin<sup>&#167;&#165;</sup> 3 mg/kg per 24 hours IV or IM in&nbsp;two or&nbsp;three divided doses for 2 weeks</p> </td> <td> <p>Vancomycin<sup>&#135;</sup> 40 mg/kg per 24 hours IV (maximum dose: 2 g per 24 hours)&nbsp;in&nbsp;two or&nbsp;three divided doses for &#8805;6 weeks</p> <p><strong>plus</strong></p> <p>Rifampin<sup>&#9674;</sup> (see dosing above) for &#8805;6 weeks</p> <p><strong>plus</strong></p> <p>Gentamicin<sup>&#167;&#165;</sup>&nbsp;(see dosing above)&nbsp;for first&nbsp;2 weeks</p> </td> <td> <p>Vancomycin<sup>&#135;</sup> 30 to 60&nbsp;mg/kg per 24 hours IV in&nbsp;two&nbsp;or three divided&nbsp;doses for &#8805;6 weeks</p> <p><strong>plus</strong></p> <p>Rifampin<sup>&#9674; </sup>900 to 1200 mg per 24 hours IV or orally in two or three divided doses for &#8805;6 weeks</p> <p><strong>plus</strong></p> <p>Gentamicin<sup>&#167; </sup>3 mg/kg per 24 hours IV or IM in&nbsp;one or two divided doses for first&nbsp;2 weeks</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses in this table are intended for patients with normal renal function. The doses of many of these agents must be adjusted in the setting of renal insufficiency; refer to the Lexicomp drug-specific monographs for renal dose adjustments.<br />​Wherever intramuscular administration is provided as an alternative, intravenous route is preferred, particularly in infants and children.</div><div class=\"graphic_footnotes\">PVE: prosthetic valve endocarditis; IV: intravenously; IM: intramuscularly.<br />*&nbsp;Consultation with a pediatric infectious disease specialist is recommended.<br />¶&nbsp;Patients with infection due to methicillin-susceptible&nbsp;Staphylococcus aureus and severe hypersensitivity to penicillins and cephalosporins may be treated with vancomycin (adults: 30 mg/kg per 24 hours IV in&nbsp;two divided doses for ≥6 weeks; children: 40 mg/kg per 24 hours IV in&nbsp;two or&nbsp;three divided doses for ≥6 weeks) as an alternative to nafcillin, oxacillin, or cefazolin. In such patients, an allergy evaluation should be conducted; if presence of immediate hypersensitivity is questionable, skin testing should be pursued. Beta-lactam desensitization may be attempted in stable patients.<br />Δ&nbsp;For use in patients with nonsevere penicillin allergy. Avoid cefazolin in complicating brain abscess; nafcillin is preferred.<br />◊&nbsp;Rifampin is believed to be&nbsp;important in PVE as it may help eradicate bacteria attached to foreign material. It should always be used in combination with another effective antistaphylococcal drug (ideally two active agents) to minimize risk of treatment-emergent resistance. Rifampin increases hepatic clearance of warfarin and other drugs. Starting rifampin three to five days after vancomycin and gentamicin has been suggested by some experts.<br />§&nbsp;Gentamicin is recommended for PVE and, in non-obese adults, is&nbsp;based on ideal body weight. Renal function and serum gentamicin concentrations should be monitored at least once per week. When given in three divided doses, pre-dose (trough) concentrations should be &lt;1 mcg/mL and post-dose (peak, 1 hour after infusion) concentrations should be between 3&nbsp;and 4 mcg/mL. When given in a single daily dose, pre-dose (trough) concentrations should be &lt;1 mcg/mL. Per ESC guidelines, post-dose (peak, one hour after injection) serum concentrations should be approximately 10 to 12 mcg/mL (per AHA guidelines, there is no role for measuring peak gentamicin concentration following single daily dosing).<br />¥&nbsp;If organism is gentamicin resistant, an alternative drug such as another aminoglycoside (eg, amikacin), a fluoroquinolone, or another antimicrobial to which the organism is susceptible may be substituted (refer to the UpToDate topic on antimicrobial therapy of prosthetic valve endocarditis).<br />‡&nbsp;Vancomycin dose should be adjusted for trough level of 10 to 20 mcg/mL; some favor trough concentrations of 15 to 20 mcg/mL. In adults, vancomycin is dosed based on actual body weight. The dose may need to be increased beyond 30 mg/kg actual body weight and frequency may need to be increased to&nbsp;three divided doses. (Refer to UpToDate topic on antimicrobial therapy of prosthetic valve endocarditis regarding the use of daptomycin when vancomycin is not tolerated or ineffective.) </div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Circulation 2015; 132:1435.</LI>&#xD;&#xA;<LI>Baltimore RS, Gewitz M, Baddour LM, et al. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. Circulation 2015; 132:1487.</LI>&#xD;&#xA;<LI>Authors/Task Force Members, Habib G, Lancellotti P, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC) Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075.</LI>&#xD;&#xA;<LI>Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Disease Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. CID 2011; 52:285.</LI></OL></div><div id=\"graphicVersion\">Graphic 61202 Version 10.0</div></div></div>"},"61207":{"type":"graphic_figure","displayName":"PEG rHuMGDF PBPC mobilization","title":"PEG-rHuMGDF enhances mobilization of PBPCs","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">PEG-rHuMGDF enhances mobilization of PBPCs</div><div class=\"cntnt\"><img style=\"width:510px; height:316px;\" src=\"images/HEME/61207_PEG_rHuMGDF_PBPC_mobilizati.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The fold increase in peripheral blood progenitor cells (PBPCs) from day 1 (baseline) to day 15 in patients treated with chemotherapy on day 1 followed by either granulocyte colony-stimulating factor (G-CSF) alone or in combination with PEG-rHuMGDF. PBPC mobilization was markedly enhanced by combination therapy with G-CSF and PEG-rHuMDGF.</div><div class=\"graphic_reference\">Data from Basser, RL, Rasko, JE, Clarke, K, et al, Blood 1997; 89:3118.</div><div id=\"graphicVersion\">Graphic 61207 Version 1.0</div></div></div>"},"61208":{"type":"graphic_table","displayName":"IADPSG and ADA criteria for a positive two-hour 75-gram oral GTT","title":"IADPSG and ADA criteria for a positive two-hour 75-gram oral glucose tolerance test for the diagnosis of gestational diabetes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">IADPSG and ADA criteria for a positive two-hour 75-gram oral glucose tolerance test for the diagnosis of gestational diabetes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Two-hour 75-gram oral glucose tolerance test&nbsp;</td> </tr> <tr> <td>Fasting</td> <td>&#8805;92 mg/dL (5.1 mmol/L)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td>One hour</td> <td>&#8805;180 mg/dL (10.0 mmol/L)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td>Two hour</td> <td>&#8805;153 mg/dL (8.5 mmol/L)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The diagnosis of gestational diabetes is made at 24 to 28 weeks of gestation&nbsp;when one or more plasma glucose values meets or exceeds the above values. </div><div class=\"graphic_footnotes\">IADPSG: International Association of the Diabetes and Pregnancy Study Groups; ADA: American Diabetes Association.</div><div id=\"graphicVersion\">Graphic 61208 Version 16.0</div></div></div>"},"61209":{"type":"graphic_picture","displayName":"Capillary loop PI","title":"Swelling of the blood vessels in the nail fold in a person with dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Swelling of the blood vessels in the nail fold in a person with dermatomyositis</div><div class=\"cntnt\"><img style=\"width:334px; height:295px;\" src=\"images/PI/61209_Capillary_loop_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of John H. Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 61209 Version 1.0</div></div></div>"},"61211":{"type":"graphic_picture","displayName":"Porokeratosis histopathology 2","title":"Histopathology of porokeratosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Histopathology of porokeratosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/61211_Porokeratosis_histopath_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A thin vertical column of parakeratotic cells within a keratin-filled epidermal invagination, known as a cornoid lamella, is present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 61211 Version 5.0</div></div></div>"},"61212":{"type":"graphic_picture","displayName":"Livedo reticularis in cold agglutinin disease","title":"Livedo reticularis in cold agglutinin disease","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Livedo reticularis in cold agglutinin disease</div><div class=\"cntnt\"><img style=\"width:468px; height:452px;\" src=\"images/HEME/61212_Livedo_reticular_cold_aggl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph demonstrates a severe degree of livedo reticularis in a patient with cold agglutinin disease following exposure to cold. The patient's skin changes disappear completely without residua within several minutes following warming.</div><div class=\"graphic_reference\">Photo courtesy of Dr. Jason Gotlib, Stanford University School of Medicine.</div><div id=\"graphicVersion\">Graphic 61212 Version 3.0</div></div></div>"},"61214":{"type":"graphic_figure","displayName":"Orbital venous drainage","title":"Venous drainage of the orbit","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Venous drainage of the orbit</div><div class=\"cntnt\"><img style=\"width:543px; height:512px;\" src=\"images/ID/61214_Orbital_venous_drainage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The diagram demonstrates the communication between ethmoidal sinuses, the orbit, and the cavernous sinus.</div><div id=\"graphicVersion\">Graphic 61214 Version 2.0</div></div></div>"},"61217":{"type":"graphic_table","displayName":"Muscular dystrophy PI","title":"Most common forms of muscular dystrophy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Most common forms of muscular dystrophy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Duchenne and Becker muscular dystrophy</td> </tr> <tr> <td class=\"indent1\">When do they start?</td> <td>Duchenne and Becker muscular dystrophy are very similar. Duchenne usually starts by age 2 or 3 years. Children with Duchenne are often in a wheelchair by age 9 or 10 years, but some may need a wheelchair much earlier or later. Becker causes similar symptoms but starts later and is usually less severe.</td> </tr> <tr> <td class=\"indent1\">Who does it affect?</td> <td>Mostly boys, but it can affect girls sometimes, too</td> </tr> <tr> <td class=\"indent1\">Which muscles are affected most by weakness?</td> <td>Weakness starts in the trunk but spreads to the arms and legs. The legs usually get weak first. This can make it hard to run, jump, or climb stairs.</td> </tr> <tr> <td class=\"indent1\">What other problems can it cause?</td> <td> <p>Heart and lung problems</p> <p>Abnormal curves in the spine</p> Mental problems in some but not all children</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Emery-Dreifuss muscular dystrophy</td> </tr> <tr> <td class=\"indent1\">When does it start?</td> <td>Early childhood to age 20 years or later</td> </tr> <tr> <td class=\"indent1\">Who does it affect?</td> <td>Boys and girls</td> </tr> <tr> <td class=\"indent1\">Which muscles are affected most?</td> <td>Weakness usually starts in the arms and later affects the legs, too. Sometimes the face weakens a little.</td> </tr> <tr> <td class=\"indent1\">What other problems can it cause?</td> <td> <p>Heart problems</p> Limited movement at certain joints caused by a tightening of the tissues around the joint (called \"contracture\")</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Myotonic dystrophy</td> </tr> <tr> <td class=\"indent1\">When does it start?</td> <td>Can start in infancy, childhood, teenage years, or adulthood</td> </tr> <tr> <td class=\"indent1\">Who does it affect?</td> <td>Boys and girls</td> </tr> <tr> <td class=\"indent1\">Which muscles are affected most?</td> <td>Face muscles, arms, and legs</td> </tr> <tr> <td class=\"indent1\">What other problems can it cause?</td> <td> <p>Muscle pain</p> <p>Problems affecting the heart, eyes, brain, and sexual organs</p> <p>Problems breathing and swallowing</p> <p>Stomach pain, diarrhea and constipation</p> <p>Being too sleepy during the day</p> Nerve damage (called neuropathy)</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Limb girdle muscular dystrophy</td> </tr> <tr> <td class=\"indent1\">When does it start?</td> <td>Early childhood or later in life</td> </tr> <tr> <td class=\"indent1\">Who does it affect?</td> <td>Boys and girls</td> </tr> <tr> <td class=\"indent1\">Which muscles are affected most?</td> <td>Shoulders and hips</td> </tr> <tr> <td class=\"indent1\">What other problems can it cause?</td> <td> <p>Heart problems</p> Limited movement at certain joints caused by a tightening of the tissues around the joint (called \"contracture\")</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Facioscapulohumeral muscular dystrophy (FSHD)</td> </tr> <tr> <td class=\"indent1\">When does it start?</td> <td>Usually affects people ages 10 to 20 years, but can happen younger</td> </tr> <tr> <td class=\"indent1\">Who does it affect?</td> <td>Boys and girls</td> </tr> <tr> <td class=\"indent1\">Which muscles are affected most?</td> <td>The face muscles get so weak that the person cannot smile, whistle, or shut his or her eyes tight. In some cases, weakness affects the legs; in other cases, the shoulders and upper arms.</td> </tr> <tr> <td class=\"indent1\">What other problems can it cause?</td> <td> <p>Pain</p> <p>Hearing problems</p> <p>Heart problems</p> Mental problems or seizures in some who get the disease very early in life</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Congenital muscular dystrophy</td> </tr> <tr> <td class=\"indent1\">When does it start?</td> <td>At birth</td> </tr> <tr> <td class=\"indent1\">Who does it affect?</td> <td>Boys and girls</td> </tr> <tr> <td class=\"indent1\">Which muscles are affected most?</td> <td>Many muscles can be weak. Sometimes this is called \"floppy baby.\"</td> </tr> <tr> <td class=\"indent1\">What other problems can it cause?</td> <td>Limited movement at certain joints caused by a tightening of the tissues around the joint (called \"contracture\")</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 61217 Version 4.0</div></div></div>"},"61221":{"type":"graphic_figure","displayName":"Numeric pain scale","title":"Numeric pain scale","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">Numeric pain scale</div><div class=\"cntnt\"><img style=\"width:591px; height:245px;\" src=\"images/SURG/61221_Numeric_pain_scale.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 61221 Version 1.0</div></div></div>"},"61222":{"type":"graphic_diagnosticimage","displayName":"Diaphragmatic injury with left hemidiaphragm discontinuity","title":"Diaphragmatic injury with left hemidiaphragm discontinuity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diaphragmatic injury with left hemidiaphragm discontinuity</div><div class=\"cntnt\"><img style=\"width:415px; height:398px;\" src=\"images/SURG/61222_Diaphragmatic_injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (axial imaging) demonstrates discontinuity of the posterior left hemidiaphragm.</div><div id=\"graphicVersion\">Graphic 61222 Version 2.0</div></div></div>"},"61224":{"type":"graphic_table","displayName":"Pyrrolizidine alkaloids","title":"Pyrrolizidine alkaloids","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pyrrolizidine alkaloids</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Scientific name</td> <td class=\"subtitle1\">Common names</td> </tr> <tr> <td><em>Astragalus</em></td> <td>Astragali, Beg Kei, Bei Qi, Buck Qi, Huang Qi, Huang qi, Hwanggi, Membranous Milk Vetch, Milk Vetch, Mongolian Milk, Ogi</td> </tr> <tr> <td><em>Azadirachza indica</em></td> <td>Bead Tree, Holy Tree, Indian Lilac, Margosa, Nim, Nimba, Persian Lilac, Pride of China</td> </tr> <tr> <td><em>Berberis vulgaris</em></td> <td>Agracejo, Berberidis cortex, Berberidis fructus, Berberidis radicis cortex, Berberidis radix, Berberitze, Berberry, Berbis, Common Barberry, Epine-Vinette, Espino Cambr&#243;n, Jaundice Berry, Mountain Grape, Oregon Grape, Pipperidge, Piprage, Sauerdorn, Sow Berry, Vinettier</td> </tr> <tr> <td><em>Blighia sapida</em></td> <td>Akee, Aki, Arbre Fricasse, Seso Vegetal</td> </tr> <tr> <td><em>Cassia angustifolia</em></td> <td>Alexandrian Senna, Alexandrinische Senna, Casse, Indian Senna, Khartoum Senna, Sena Alejandrina, S&#233;n&#233; d'Egypte, Sennae folium, Sennae fructus, Sennae fructus acutifoliae, Sennae fructus angustifolia, Tinnevelly Senna, True Senna</td> </tr> <tr> <td><em>Crotalaria </em>species </td> <td>Numerous products</td> </tr> <tr> <td><em>Cynoglossum</em></td> <td>Cynoglossi herba, Cynoglossi radix, Dog-Bur, Dog's Tongue, Dogs Tongue, Gypsy Flower, Hounds Tongue, Sheep-Lice, Woolmat</td> </tr> <tr> <td><em>Echinacea</em></td> <td>American Cone Flower, Black Sampson, Black Susans, Brauneria Angustifolia, Brauneria Pallida, Comb Flower, Coneflower, Echinaceawurzel, Hedgehog, Igelkopfwurzel, Indian Head, Kansas Snakeroot, Narrow-leaved Purple Cone Flower, Pale Coneflower, Purple Cone Flower, Purpursonnenhutkraut, Purpursonnenhutwurzel, Racine d'echininacea, Red Sunflower, Rock-Up-Hat, Roter Sonnenhut, Schmallblaettrige Kegelblumenwurzel, Schmallblaettriger Sonnenhut, Scurvy Root, Snakeroot, Sonnenhutwurzel</td> </tr> <tr> <td><em>Erythroxylon coca</em></td> <td>Bolivian Coca, Cocaine Plant, Health Inca Tea, Huanuco Coca, Inca Health Tea, Inca Tea, Java Coca, Mate-de-Coca, Mate de Coca, Peruvian Coca, Spadic, Truxillo Coca</td> </tr> <tr> <td><em>Eupatorium</em></td> <td>Alpenkraut, Chanvrin, Donnerkraut, Dostenkraut, Drachenkraut, Dutch Agrimony, Dutch Eupatoire Commune, Eupatorium, Gemeiner Wasswedost, Herbe de Sainte Cunegonde, Hirshklee, Holy Rope, Kunigundendraut, Leberkraut, Origan De Marais, St. John's Herb, Sweet Mandulin, Sweet-Smelling Trefoil, Thoroughwort, Wasshanf, Waterhemp, Water Maudlin; E. perfoliatum - Augeweed, Crosswort, Feverwort, Indian Sage, Sweating Plant, Teasel, Thoroughwort, Vegetable Antimony; E purpureum - Joe Pye, Joe-Pye Weed, Kidney Root, Kydney Root, Purple Boneset, Queen of the Meadow, Roter Wasserhanf, Trumpet Weed</td> </tr> <tr> <td><em>Hedeoma pulegoides</em></td> <td>American Pennyroyal, European Pennyroyal, Lurk-In-The-Ditch, Mosquito Plant, Penny Royal,</td> </tr> <tr> <td><em>Mentha pulegium</em></td> <td>Piliolerial, Pudding Grass, Pulegium, Run-By-The-Ground, Squaw Balm, Squawmint, Stinking Balm, Tickweed</td> </tr> <tr> <td><em>Heliotropium</em> species - valerian</td> <td>Amantilla, All-Heal, Baldrian, Baldrianwurzel, Belgium Valerian, Common Valerian, Fragrant Valerian, Garden Heliotrope, Garden Valerian, Indian Valerian, Mexican Valerian, Pacific Valerian, Valeriana, Valeriana officinalis, Valeriana rhizome, Valerianae radix, Valeriane</td> </tr> <tr> <td><em>Ilex paraguariensis</em></td> <td>Mate (paraquay) tea; Hervea, Ilex, Jesuit's Brazil Tea, Jesuit's Tea, Mat&#233; Folium, Paraguay Tea, St. Bartholemew's Tea, Yerba Mat&#233;, Yerba Mate</td> </tr> <tr> <td><em>Larrea tridentata</em></td> <td>Chaparral, creosote bush, greasewood; gumis; chaparro; Hediondilla, Larreastat</td> </tr> <tr> <td><em>Piper methysticum</em></td> <td>Ava, Ava Pepper, Ava Root, Awa, Gea, Gi, Intoxicating Long Pepper, Intoxicating Pepper, Kao, Kava Kava, Kava-Kava, Kava Pepper, Kava Root, Kavain, Kavapipar, Kawa, Kawa Kawa, Kawa-Kawa, Kawa Pepper, Kawapfeffer, Kew, Maori Kava, Malohu, Maluk, Meruk, Milik, Rauschpfeffer, Rhizome Di Kava-Kava, Sakau, Tonga, Wurzelstock, Yagona, Yangona, Yaqona, Yongona</td> </tr> <tr> <td><em>Sassafras albidum</em></td> <td>Ague Tree, Cinnamon Wood, Common Sassafras, Kuntze Saloop, Sassafrax, Saxifrax</td> </tr> <tr> <td><em>Scutellaria lateriflora</em></td> <td>Blue Pimpernel, Helmet Flower, Hoodwort, Mad Weed, Mad-Dog Herb, Mad-Dog Weed, Quaker</td> </tr> <tr> <td><em>Scutellaria baicalensis</em></td> <td>Bonnet, Scutelluria, Skullcap; Baikal Scullcap, Baikal Skullcap Root, Chinese Skullcap, Huang Qin, Huangquin, Hwanggum, Ogon, Ou-gon, Scute, Wogon</td> </tr> <tr> <td><em>Senecio</em> species </td> <td>Ragwort; golden senecio; liferoot; squaw weed</td> </tr> <tr> <td><em>Symphytum officinale</em></td> <td>Ass Ear, Black Root, Blackwort, Bruisewort, Common Comfrey, Consolidae Radix, Consound, Gum Plant, Healing Herb, Knitback, Knitbone, Salsify, Slippery Root, Symphytum Radix, Wallwort</td> </tr> <tr> <td><em>Teucrium chamaedrys</em></td> <td>Wall Germander, Wild Germander</td> </tr> <tr> <td><em>Viscum album</em></td> <td>All-Heal, Birdlime Mistletoe, Devil's Fuge, Drudenfuss, Eurixor, Helixor, Hexenbesen, Iscador, Isorel, Leimmistel, Mistlekraut, Mistletein, Mistletoe, Mystyldene, Visci, Visci albi folia, Visci albi fructus, Visci albi herba, Visci albi stipites, Vogelmistel, Vysorel</td> </tr> <tr> <td><em>Werneria</em></td> <td>Eye Balm, Eye Root, Golden Seal, Goldenroot, Goldsiegel, Ground Raspberry, Hydrastis, Hydrastis Canadensis, Indian Dye, Indian Plant, Indian Tumeric, Jaundice Root, Orange Root, Sceau D'Or, Turmeric Root, Warnera, Wild Curcuma, Yellow Indian Paint, Yellow Paint, Yellow Puccoon, Yellow Root.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 61224 Version 2.0</div></div></div>"},"61225":{"type":"graphic_picture","displayName":"Rectal biopsy in acute GVHD","title":"Acute graft-versus-host disease (GVHD) rectal biopsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute graft-versus-host disease (GVHD) rectal biopsy</div><div class=\"cntnt\"><img style=\"width:399px; height:252px;\" src=\"images/HEME/61225_Rectal_biopsy_in_acute_GVHD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rectal biopsy in a patient with acute graft-versus-host disease (GVHD) shows crypt cell necrosis with the accumulation of degenerative material in the dead crypts.</div><div id=\"graphicVersion\">Graphic 61225 Version 2.0</div></div></div>"},"61226":{"type":"graphic_form","displayName":"Stool and diet history PI","title":"Stool and diet history","html":"<div class=\"graphic\"><div style=\"width: 575px\" class=\"figure\"><div class=\"ttl\">Stool and diet history</div><div class=\"cntnt\"><img style=\"width:555px; height:615px;\" src=\"images/PI/61226_Stool_and_diet_history_PI.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 61226 Version 3.0</div></div></div>"},"61227":{"type":"graphic_figure","displayName":"Physical exam skin front","title":"Common disorders encountered during the physical examination of skin, front view","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Common disorders encountered during the physical examination of skin, front view</div><div class=\"cntnt\"><img style=\"width:520px; height:675px;\" src=\"images/PC/61227_Physical_exam_skin_front.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Fitzpatrick TB, Bernhard JD, Copley TG. In: Dermatology in General Medicine, Freedberg IN, Eisin AZ, Wolff K, et al. (Eds), 5th ed, McGraw-Hill 1999. Copyright © 1999 The McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 61227 Version 2.0</div></div></div>"},"61231":{"type":"graphic_picture","displayName":"Nailfold infarction in RV 1","title":"Isolated nailfold infarct","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Isolated nailfold infarct</div><div class=\"cntnt\"><img style=\"width:504px; height:329px;\" src=\"images/RHEUM/61231_Nailfold_infarction_in_RV_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nailfold infarctions such as this are generally asymptomatic and not necessarily associated with systemic, necrotizing forms of rheumatoid vasculitis.</div><div class=\"graphic_reference\">Courtesy of John Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 61231 Version 2.0</div></div></div>"},"61232":{"type":"graphic_table","displayName":"Anticoagulation bleeding AF","title":"Major bleeding during antithrombotic therapy in atrial fibrillation trials*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major bleeding during antithrombotic therapy in atrial fibrillation trials*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"5\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Study</td> <td class=\"subtitle1\" colspan=\"4\">Rate, percent/year</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Warfarin</td> <td class=\"subtitle2\" rowspan=\"2\">Aspirin</td> <td class=\"subtitle2\" rowspan=\"2\">Placebo</td> </tr> <tr> <td class=\"subtitle3\">All<sup>&#182;</sup></td> <td class=\"subtitle3\">Intracranial</td> </tr> <tr> <td>Atrial Fibrillation, Aspirin, and Anticoagulation (AFASAK 1)</td> <td>0.5</td> <td>0.2</td> <td>0.2</td> <td>0</td> </tr> <tr> <td>Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)</td> <td>1.6</td> <td>0.2</td> <td>-</td> <td>1.6<sup>&#916;</sup></td> </tr> <tr> <td>Stroke Prevention in Atrial Fibrillation (SPAF I)</td> <td>1.5</td> <td>0.8</td> <td>1.9</td> <td>1.8</td> </tr> <tr> <td>Canadian Atrial Fibrillation Anticoagulation</td> <td>2.1</td> <td>0.4</td> <td>-</td> <td>0.5</td> </tr> <tr> <td>Stroke Prevention in Nonrheumatic Atrial Fibrillation</td> <td>1.4</td> <td>0.2</td> <td>-</td> <td>1.1</td> </tr> <tr> <td>European Atrial Fibrillation Trial</td> <td>2.6</td> <td>0</td> <td>0.9</td> <td>-</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"5\">SPAF II</td> </tr> <tr> <td class=\"sublist1\">&#8804;75 y</td> <td class=\"sublist_other\">1.6</td> <td class=\"sublist_other\">0.5</td> <td class=\"sublist_other\">0.9</td> <td class=\"sublist_other\">-</td> </tr> <tr> <td class=\"sublist1\">&#62;75 y</td> <td class=\"sublist_other\">4.2</td> <td class=\"sublist_other\">1.8</td> <td class=\"sublist_other\">1.6</td> <td class=\"sublist_other\">-</td> </tr> <tr> <td>SPAF III</td> <td>2.1</td> <td>0.5</td> <td>2.4<sup>&#9674;</sup></td> <td>-</td> </tr> <tr> <td>AFASAK 2</td> <td>1.1</td> <td>0.6</td> <td>1.4</td> <td>-</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Major bleeding was defined as bleeding requiring transfusion of blood or leading to permanent disability or to death. The rate was calculated as number of events per year of treatment.<br />&para; Includes intracranial bleeding events.<br />&Delta; Aspirin voluntary.<br /><span class=\"lozenge\">&loz;</span> Aspirin plus warfarin international normalized ratio of the prothrombin time ratio, 1.2-1.5.</div><div class=\"graphic_reference\">Reproduced with permission from Gullov, AL, Koefoed, BG, Peterson, P, Arch Intern Med 1999; 159:1322.</div><div id=\"graphicVersion\">Graphic 61232 Version 2.0</div></div></div>"},"61233":{"type":"graphic_figure","displayName":"Estrogen and tamoxifen binding","title":"Simple model of estrogen (E) and tamoxifen (T) binding to the ligand binding domain of the estrogen receptor (ER)","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Simple model of estrogen (E) and tamoxifen (T) binding to the ligand binding domain of the estrogen receptor (ER)</div><div class=\"cntnt\"><img style=\"width:536px; height:313px;\" src=\"images/ONC/61233_Estrogen_and_tamoxifen_bind.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Basic model in which ligand (estrogen or tamoxifen) displaces heat shock protein (HSP), resulting in binding of ligand-receptor complex to estrogen receptor element (ERE) of gene promoter region. ER binding directly to the ERE is one mechanism, but ER can also instead tether DNA binding transcription factors for modulate genes without a classical ERE.</div><div class=\"graphic_footnotes\">Arrow: gene activation; circle: gene repression.</div><div class=\"graphic_reference\">Reproduced with permission from: Ellis MJ, Hayes DF, Lippman ME. Treatment of metastatic breast cancer. In: Diseases of the Breast, 2nd ed, Harris JR (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2000. Copyright © 2000 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 61233 Version 10.0</div></div></div>"},"61234":{"type":"graphic_table","displayName":"Anti seizure medications PI","title":"Anti-seizure medications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anti-seizure medications</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"35%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug name</td> <td class=\"subtitle1\">Tablet/capsule</td> <td class=\"subtitle1\">Liquid/syrup</td> <td class=\"subtitle1\">Side effects*</td> </tr> <tr> <td>Carbamazepine (Tegretol&#174;, Carbatrol&#174;, Oxtellar-XR&#174;)</td> <td class=\"centered\">X<br /> (including chewable)</td> <td class=\"centered\">X</td> <td>Diarrhea, rash, serious allergic reaction, low blood sodium levels</td> </tr> <tr> <td>Ethosuximide (Zarontin&#174;)</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td>Trouble sleeping, hyperactivity</td> </tr> <tr> <td>Ezogabine (Potiga&#174;)</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td>Urinary retention, blue skin, eye problems</td> </tr> <tr> <td>Gabapentin (Neurontin&#174;)</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td>Weight gain</td> </tr> <tr> <td>Lacosamide (Vimpate&#174;)</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td>Heart rhythm changes</td> </tr> <tr> <td>Lamotrigine (Lamictal&#174;</td> <td class=\"centered\">X<br /> (including chewable)</td> <td class=\"centered\">&nbsp;</td> <td>Rash, with risk of a serious allergic reaction</td> </tr> <tr> <td>Levtiracetam (Keppra&#174;)</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td>Aggressive behavior, irritability</td> </tr> <tr> <td>Oxcarbazepine (Trileptal&#174;)</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td>Rash, serious allergic reaction, low blood sodium levels</td> </tr> <tr> <td>Phenobarbital (Luminal&#174;)</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td>Slowed thinking, rash, hyperactivity and other behavioral changes in children</td> </tr> <tr> <td>Phenytoin (Dilantin&#174;, Phenytek&#174;)</td> <td class=\"centered\">X<br /> (including chewable)</td> <td class=\"centered\">X</td> <td>Abnormal growth of the gums, increased body hair, rash, swollen lymph nodes (glands)</td> </tr> <tr> <td>Pregabalin (Lyrica&#174;)</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td>Weight gain</td> </tr> <tr> <td>Rufinamide (Banzel&#174;)</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td>Heart rhythm changes</td> </tr> <tr> <td>Tiagabine (Gabitril&#174;)</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td>Tremor, difficulty concentrating, abdominal pain</td> </tr> <tr> <td>Topiramate (Topamax&#174;)</td> <td class=\"centered\">X<br /> (capsule may be opened and sprinkled on food)</td> <td class=\"centered\">&nbsp;</td> <td>Weight loss, numbness and tingling in the hands and feet; difficulty thinking clearly</td> </tr> <tr> <td>Valproic acid (Depakote&#174;, Depakene&#174;)</td> <td class=\"centered\">X<br /> (capsule may be opened and sprinkled on food)</td> <td class=\"centered\">X</td> <td>Weight gain, hair loss, bruising, tremor, liver toxicity</td> </tr> <tr> <td>Zonisamide (Zonegran&#174;)</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td>Weight loss, difficulty thinking clearly</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Many of these medications can also cause sedation and/or fatigue, dizziness, double vision and nausea.</div><div class=\"graphic_footnotes\">* These side effects occur in some, not most patients.</div><div id=\"graphicVersion\">Graphic 61234 Version 3.0</div></div></div>"},"61237":{"type":"graphic_waveform","displayName":"Intermediate case 1 with answer","title":"Acute inferior and right ventricular myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Acute inferior and right ventricular myocardial infarction</div><div class=\"cntnt\"><img style=\"width:478px; height:295px;\" src=\"images/CARD/61237_Intermediate_case_1_with_an.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram shows Q waves and prominent doming ST segment elevation in II, III, and aVF, findings which are characteristic of an acute inferior myocardial infarction. ST elevation in the right precordial leads - V4R, V5R, and V6R - indicates right ventricular involvement as well (arrows). The ST depressions in leads I and aVL represent reciprocal changes.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 61237 Version 2.0</div></div></div>"},"61238":{"type":"graphic_movie","displayName":"L monocytogenes tumbling motility","title":"Tumbling motility of <EM>Listeria monocytogenes</EM>","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tumbling motility of <EM>Listeria monocytogenes</EM></div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ID/61238_lmonocytconv.mp4\" style=\"width:432px;height:336px\"></div><img style=\"width:360px; height:360px;\" src=\"images/ID/61238_Lmonocytotumblmotility.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hanging drop slide of an overnight brain heart infusion broth inoculated with <EM>Listeria monocytogenes</EM>. In the video, the bacteria rotate slowly in and out of focus around a central axis; a characteristic and specific movement pattern referred to as \"tumbling motility\" (magnification 400x).</div><div class=\"graphic_reference\">Reproduced with permission from: Chau TTH, Campbell JI, Schultsz C, et al. Three Adult Cases of Listeria monocytogenes Meningitis in Vietnam. PLoS Med 2010; 7:e1000306. Copyright © 2010.</div><div id=\"graphicVersion\">Graphic 61238 Version 5.0</div></div></div>"},"61239":{"type":"graphic_diagnosticimage","displayName":"TEE right sided structures","title":"Right sided cardiac structures on transesophageal echocardiogram","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Right sided cardiac structures on transesophageal echocardiogram</div><div class=\"cntnt\"><img style=\"width:461px; height:183px;\" src=\"images/CARD/61239_TEE_right_sided_structures.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiplane (122º) imaging with anterior rotation of the probe allows for viewing of the right sided cardiac structures including the tricuspid valve (TV), right ventricle (RV), pulmonic valve (PV), and pulmonary artery (PA, panel A). The ascending aorta (Ao) is also seen. Panel B shows color Doppler flow at this orientation and confirms normal flow in the right ventricular outflow tract (RVOT).</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 61239 Version 3.0</div></div></div>"},"61240":{"type":"graphic_picture","displayName":"Group A streptococcal balanoposthitis","title":"Group A streptococcal balanoposthitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Group A streptococcal balanoposthitis</div><div class=\"cntnt\"><img style=\"width:298px; height:523px;\" src=\"images/EM/61240_Grp_A_strep_balanoposthitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Erosion and purulent exudates of the foreskin and glans penis in Case 1.<br />(B) Erosion and purulent exudates of the foreskin and glans penis in Case 2.</div><div class=\"graphic_reference\">Reproduced from: Sakuma, S, Komiya, H. Balanitis caused by Streptococcus pyogenes: a report of two cases. Int J STD AIDS. 2005 Sep; 16(9): 644-5, by permission of The Royal Society of Medicine Press, London. Copyright &copy;2005 Royal Society of Medicine Press.</div><div id=\"graphicVersion\">Graphic 61240 Version 5.0</div></div></div>"},"61242":{"type":"graphic_diagnosticimage","displayName":"Acoustic neuroma","title":"Acoustic neuroma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acoustic neuroma</div><div class=\"cntnt\"><img style=\"width:301px; height:339px;\" src=\"images/PC/61242_Acoustic_neuroma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A right-sided acoustic neuroma of the eighth cranial nerve is evident in the cerebellopontine angle (arrow).</div><div class=\"graphic_reference\">Courtesy of Peter C Weber, MD.</div><div id=\"graphicVersion\">Graphic 61242 Version 2.0</div></div></div>"},"61243":{"type":"graphic_picture","displayName":"Neck tilting exercise","title":"Neck tilting","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neck tilting</div><div class=\"cntnt\"><img style=\"width:365px; height:280px;\" src=\"images/PC/61243_Neck_tilting_exercise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tilt your head to the right, trying to touch your ear to the tip of your shoulder. Place tension on the temple with your fingertips. Hold for a few seconds and return to the center. Repeat to the left.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 61243 Version 2.0</div></div></div>"},"61244":{"type":"graphic_table","displayName":"Asthma patient teaching","title":"National Asthma Education and Prevention Program guidelines for the diagnosis and management of asthma: The content of patient teaching","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">National Asthma Education and Prevention Program guidelines for the diagnosis and management of asthma: The content of patient teaching</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Definition of asthma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Key points about signs and symptoms of asthma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Characteristic changes in the airways of asthma patients and the role of medication</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Asthma triggers and how to avoid or control them</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Treatment</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Patient fears concerning medication</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Use of written guidelines</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Use of written diaries</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Correct us of inhalers</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Criteria for premedicating to prevent onset of symptoms</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Optimal use of home peak expiratory flow rate monitoring</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Evaluation of results of treatment plan</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fears and misconceptions</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Family understanding and support</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Communication with the child's school (by parents and clinician)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Feelings about asthma</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 61244 Version 1.0</div></div></div>"},"61245":{"type":"graphic_figure","displayName":"Impact of sleep on neuromuscular or chest wall disease","title":"Impact of sleep on patients with neuromuscular or chest wall disease","html":"<div class=\"graphic\"><div style=\"width: 895px\" class=\"figure\"><div class=\"ttl\">Impact of sleep on patients with neuromuscular or chest wall disease</div><div class=\"cntnt\"><img style=\"width:875px; height:401px;\" src=\"images/SLEEP/61245_Sleep_impact_on_disease_ed1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">REM: rapid eye movement; PaCO<SUB>2</SUB>: partial pressure of carbon dioxide; PaO<SUB>2</SUB>: partial pressure of oxygen; SaO<SUB>2</SUB>: oxyhemoglobin saturation.</div><div id=\"graphicVersion\">Graphic 61245 Version 3.0</div></div></div>"},"61246":{"type":"graphic_diagnosticimage","displayName":"Reticular opacities PA I","title":"Reticular opacities","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reticular opacities</div><div class=\"cntnt\"><img style=\"width:361px; height:336px;\" src=\"images/PULM/61246_Reticular_opacities_PA_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Standard International Labor Office film for small irregular t opacities, 1.5-3 mm in diameter (reticular opacities).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 61246 Version 3.0</div></div></div>"},"61247":{"type":"graphic_table","displayName":"Infectious causes of uveitis","title":"Representative infectious causes of uveitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Representative infectious causes of uveitis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Bacterial/spirochetal</td> </tr> <tr> <td class=\"indent1\">Atypical mycobacteria</td> </tr> <tr> <td class=\"indent1\">Brucellosis</td> </tr> <tr> <td class=\"indent1\">Cat scratch disease</td> </tr> <tr> <td class=\"indent1\">Leprosy</td> </tr> <tr> <td class=\"indent1\">Leptospirosis</td> </tr> <tr> <td class=\"indent1\">Lyme disease</td> </tr> <tr> <td class=\"indent1\"><em>Cutibacterium</em> (formerly <em>Propionibacterium</em>)</td> </tr> <tr> <td class=\"indent1\">Rocky Mountain spotted fever</td> </tr> <tr> <td class=\"indent1\">Syphilis</td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> </tr> <tr> <td class=\"indent1\">Whipple's disease</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Viral</td> </tr> <tr> <td class=\"indent1\">Anellovirus</td> </tr> <tr> <td class=\"indent1\">Chikungunya</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus</td> </tr> <tr> <td class=\"indent1\">Ebola</td> </tr> <tr> <td class=\"indent1\">Epstein-Barr</td> </tr> <tr> <td class=\"indent1\">Herpes simplex</td> </tr> <tr> <td class=\"indent1\">Herpes zoster</td> </tr> <tr> <td class=\"indent1\">HIV-1</td> </tr> <tr> <td class=\"indent1\">Human T cell leukemia virus</td> </tr> <tr> <td class=\"indent1\">Mumps</td> </tr> <tr> <td class=\"indent1\">Parechovirus</td> </tr> <tr> <td class=\"indent1\">Rubella</td> </tr> <tr> <td class=\"indent1\">Rubeola</td> </tr> <tr> <td class=\"indent1\">Vaccinia</td> </tr> <tr> <td class=\"indent1\">West Nile virus</td> </tr> <tr> <td class=\"indent1\">Zika virus</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Fungal</td> </tr> <tr> <td class=\"indent1\">Aspergillosis</td> </tr> <tr> <td class=\"indent1\">Blastomycosis</td> </tr> <tr> <td class=\"indent1\">Candidiasis</td> </tr> <tr> <td class=\"indent1\">Coccidioidomycosis</td> </tr> <tr> <td class=\"indent1\">Cryptococcosis</td> </tr> <tr> <td class=\"indent1\">Histoplasmosis</td> </tr> <tr> <td class=\"indent1\"><em>Pneumocystis jirovecii </em>(PCP)</td> </tr> <tr> <td class=\"indent1\">Sporotrichosis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Parasitic (protozoan/helminthic)</td> </tr> <tr> <td class=\"indent1\">Acanthamoeba</td> </tr> <tr> <td class=\"indent1\">Cystercercosis</td> </tr> <tr> <td class=\"indent1\">Onchocerciasis</td> </tr> <tr> <td class=\"indent1\">Toxocariasis</td> </tr> <tr> <td class=\"indent1\">Toxoplasmosis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">HIV: human immunodeficiency virus.</div><div id=\"graphicVersion\">Graphic 61247 Version 11.0</div></div></div>"},"61248":{"type":"graphic_figure","displayName":"Antihypertensive dose response to thiazide therapy","title":"Antihypertensive dose response to thiazide therapy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Antihypertensive dose response to thiazide therapy</div><div class=\"cntnt\"><img style=\"width:410px; height:244px;\" src=\"images/NEPH/61248_Thiazide_dose_and_fall_in_B.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Antihypertensive response to bendrofluazide in relation to daily dose (in mg; multiply by 10 to get approximate equivalent doses of hydrochlorothiazide). The initial dose of 1.25 mg/day lowers the blood pressure in comparison&nbsp;with placebo; however, higher doses produced little further antihypertensive response. Each treatment group contained approximately 52 patients.</div><div class=\"graphic_reference\">Data from: Carlsen JE, Kober L, Torp-Pedersen C, Johannsen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990; 300:975.</div><div id=\"graphicVersion\">Graphic 61248 Version 4.0</div></div></div>"},"61249":{"type":"graphic_picture","displayName":"Intracellular HME EM","title":"Human monocytic ehrlichiosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Human monocytic ehrlichiosis</div><div class=\"cntnt\"><img style=\"width:287px; height:304px;\" src=\"images/ID/61249_Intracellular_HME_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph showing Ehrlichia chaffeensis, the organism responsible for human monocytic ehrlichiosis, in intracytoplasmic vacuoles (morulae) in the cytoplasm of an irradiated mouse embryo cell.</div><div class=\"graphic_reference\">Courtesy of Vsevolod Popov, PhD and Sheng-min Chen, MD.</div><div id=\"graphicVersion\">Graphic 61249 Version 1.0</div></div></div>"},"61250":{"type":"graphic_figure","displayName":"Relative incidence eumycetoma organisms","title":"Etiological agents of eumycetoma, worldwide*","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Etiological agents of eumycetoma, worldwide*</div><div class=\"cntnt\"><img style=\"width:536px; height:482px;\" src=\"images/ID/61250_Relincideumycetomaorg.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Reports with at least five cases confirmed by culture or by histopathology are included.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Bakshi R, Mathur DR. Incidence and changing pattern of mycetoma in western Rajasthan. Indian J Pathol Microbiol 2008; 51:154.</LI>&#xD;&#xA;<LI>Bendl BJ, Mackey D, Al-Saati F, Sheth KV, Ofole SN, Bailey TM. Mycetoma in Saudi Arabia. J Trop Med Hyg 1987; 90:51.</LI>&#xD;&#xA;<LI>Buot G, Lavalle P, Mariat F, Suchil P. Étude épidémiologique des mycétomes au Mexique. Bull Soc Pathol Exot 1987; 80:329.</LI>&#xD;&#xA;<LI>Castro LG, Belda Junior W, Salebian A, Cuce LC. Mycetoma: A retrospective study of 41 cases seen in São Paulo, Brazil, from 1978 to 1989. Mycoses 1993; 36:89.</LI>&#xD;&#xA;<LI>Castro LG, Piquero-Casals J. Clinical and mycologic findings and therapeutic outcome of 27 mycetoma patients from São Paulo, Brazil. Int J Dermatol. 2008; 47:160.</LI>&#xD;&#xA;<LI>Chávez G, Arenas R, Pérez-Polito A, Torres B, Estrada R. Eumycetic mycetoma due to Madurella mycetomatis. Report of six cases. Rev Iberoam Micol 1998; 15:90.</LI>&#xD;&#xA;<LI>Daoud M, Ezzine Sebai N, Badri T, Mokhtar I, Fazza B, Kamoun M R. Mycetoma: retrospective study of 13 cases in Tunisia. Acta Dermatoven APA, 2005; 14:153.</LI>&#xD;&#xA;<LI>Destombes P, Mariat L, Rosati G, Segretain G. Les mycétomes en Somalie - conclusions d'une enquête menée de 1959 à 1964. Acta Tropica 1977; 34:335.</LI>&#xD;&#xA;<LI>Develoux M, Audoin J, Treguer J, Vetter JM, Warter A, Cenac A. Mycetoma in the Republic of Niger: clinical features and epidemiology. Am J Trop Med Hyg. 1988; 38:386.</LI>&#xD;&#xA;<LI>Dieng MT, Sy MH, Diop BM, Niang SO, Ndiaye B. [Mycetoma: 130 cases] Ann Dermatol Venereol. 2003; 130:16.</LI>&#xD;&#xA;<LI>Green WO Jr, Adams TE. Mycetoma in the United States. A review and report of seven additional cases. Am J Clin Path 1964; 42:75.</LI>&#xD;&#xA;<LI>Gumaa SA, Mahgoub ES, el Sid MA. Mycetoma of the head and neck. Am J Trop Med Hyg. 1986; 35:594.</LI>&#xD;&#xA;<LI>Hazra B, Bandyopadhyay S, Saha SK, Banerjee DP, Dutta G. A study of mycetoma in eastern India. J Commun Dis 1998; 30:7.</LI>&#xD;&#xA;<LI>Khatri ML, Al-Halali HM, Fouad Khalid M, Saif SA, Vyas MC. Mycetoma in Yemen: clinicoepidemiologic and histopathologic study. Int J Dermatol 2002; 41:586.</LI>&#xD;&#xA;<LI>Klokke AH, Swamidasan G, Anguli R, Verghese A. The causal agents of mycetoma in South India. Trans R Soc Trop Med Hyg. 1968; 62:509.</LI>&#xD;&#xA;<LI>Lopez-Martinez R, Mendez-Tovar LJ, Lavalle P, Welsh O, Saúl A, Macotela Ruiz E. Epidemiology of mycetoma in Mexico: study of 2105 cases. Gac Med Mex 1992; 128:477.</LI>&#xD;&#xA;<LI>Maiti PK, Ray A, Bandyopadhyay S. Epidemiological aspects of Mycetoma from a retrospective study of 264 cases in West Bengal. Trop Med Int Health 2002; 7:788.</LI>&#xD;&#xA;<LI>Mariat F. On the geographic distribution and incidence of Mycetoma agents. Bull Soc Pathol Exot Filiales. 1963; 56:35.</LI>&#xD;&#xA;<LI>Novoa-Montero D, Serrano JA. Review on human mycoses in Venezuela. Rev Soc Ven Microbiol 2001; 21:46.</LI>&#xD;&#xA;<LI>Negroni R, López Daneri G, Arechavala A, Bianchi MH, Robles AM. Clinical and microbiological study of mycetomas at the Muñiz hospital of Buenos Aires between 1989 and 2004. Rev Argent Microbiol 2006; 38:13.</LI>&#xD;&#xA;<LI>Ravisse P, Huerre M, De Bièvre C, et al. Les mycétomes en Mauritanie: Étude histologique de 150 cas. J Mycol Med 1992; 2:154.</LI>&#xD;&#xA;<LI>Venugopal PV, Venugopal TV. Treatment of eumycetoma with ketoconazole. Australas J Dermatol 1993; 34:27.</LI>&#xD;&#xA;<LI>Yu Am, Zhao S, Nie LY. Mycetomas in northern Yemen: identification of causative organisms and epidemiologic considerations. Am J Trop Med Hyg 1993; 48:812.</LI>&#xD;&#xA;<LI>Hashemi SJ, Nasrollahi A, Guerami M, et al. Mycetoma in Iran: study of 62 cases. Asian J Epidemiol 2008; 1:77.</LI></OL></div><div id=\"graphicVersion\">Graphic 61250 Version 5.0</div></div></div>"},"61252":{"type":"graphic_table","displayName":"Compare venous arterial grafts","title":"Comparative anatomic and physiological properties of internal mammary artery and saphenous vein grafts","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparative anatomic and physiological properties of internal mammary artery and saphenous vein grafts</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Property</td> <td class=\"subtitle1\">Internal mammary artery</td> <td class=\"subtitle1\">Saphenous vein</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Anatomic</td> </tr> <tr> <td class=\"indent1\">Endothelial fenestrations</td> <td>Few</td> <td>Many</td> </tr> <tr> <td class=\"indent1\">Intercellular (IC) processes</td> <td>Many</td> <td>Few</td> </tr> <tr> <td class=\"indent1\">IC junction permeability</td> <td>Low</td> <td>High</td> </tr> <tr> <td class=\"indent1\">Internal elastic lamina (IEL)</td> <td>Well defined</td> <td>Poorly defined</td> </tr> <tr> <td class=\"indent1\">Heparan sulfate in IEL/media</td> <td>High</td> <td>Low</td> </tr> <tr> <td class=\"indent1\">Dependence on vasa vasorum</td> <td>Minimal</td> <td>High</td> </tr> <tr> <td class=\"indent1\">Valves </td> <td>Absent</td> <td>&nbsp;Present</td> </tr> <tr> <td class=\"indent1\">Size match with grafted native vessel</td> <td>Good</td> <td>Poor</td> </tr> <tr> <td class=\"indent1\">Resistance to trauma of harvesting</td> <td>High</td> <td>Low</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Physiologic</td> </tr> <tr> <td class=\"indent1\">Flow reserve</td> <td>High</td> <td>Low</td> </tr> <tr> <td class=\"indent1\">Shear stress</td> <td>High</td> <td>Low</td> </tr> <tr> <td class=\"indent1\">Nitric oxide/prostacyclin production</td> <td>High</td> <td>Low</td> </tr> <tr> <td class=\"indent1\">Vasomotor response to thrombin</td> <td>Relaxation</td> <td>Constriction</td> </tr> <tr> <td class=\"indent1\">Vasoconstrictor sensitivity</td> <td>Low</td> <td>High</td> </tr> <tr> <td class=\"indent1\">Vasodilator sensitivity</td> <td>High</td> <td>Low</td> </tr> <tr> <td class=\"indent1\">Basic fibroblast growth factor receptors</td> <td>Few</td> <td>Many (8xIMA)</td> </tr> <tr> <td class=\"indent1\">Lipolysis</td> <td>Rapid</td> <td>Slow</td> </tr> <tr> <td class=\"indent1\">Lipid synthesis</td> <td>Less active</td> <td>More active</td> </tr> <tr> <td class=\"indent1\">Lipid uptake</td> <td>Slow</td> <td>Rapid</td> </tr> <tr> <td class=\"indent1\">Oxidative stress</td> <td>Low</td> <td>High</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Motwani JG, Topol EJ. Circulation 1998; 97:916.</div><div id=\"graphicVersion\">Graphic 61252 Version 3.0</div></div></div>"},"61254":{"type":"graphic_picture","displayName":"Incision sites radic vulvectomy","title":"Incision marked for right groin node dissection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incision marked for right groin node dissection</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/OBGYN/61254_Incision_sites_radic_vulvec.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The groin incision is marked on the right side. Note markings for anterior superior iliac spine laterally, pubic tubercle medially, and the femoral artery caudally.</div><div class=\"graphic_reference\">Courtesy of C. William Helm, MD.</div><div id=\"graphicVersion\">Graphic 61254 Version 3.0</div></div></div>"},"61255":{"type":"graphic_picture","displayName":"Irreversible sickle cell TEM","title":"Sickled red blood cell by transmission electron micrography (TEM)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Sickled red blood cell by transmission electron micrography (TEM)</div><div class=\"cntnt\"><img style=\"width:504px; height:162px;\" src=\"images/HEME/61255_Irreversible_sickle_cell_TE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transmission electron micrograph of a red blood cell from a patient with homozygous sickle cell disease. Strands of polymerized deoxygenated hemoglobin S running lengthwise through the cell are just discernible at this magnification.</div><div class=\"graphic_reference\">Courtesy of Stanley L Schrier, MD.</div><div id=\"graphicVersion\">Graphic 61255 Version 2.0</div></div></div>"},"61257":{"type":"graphic_table","displayName":"IgE-inducing molds","title":"Immunoglobulin E (IgE)-inducing molds","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immunoglobulin E (IgE)-inducing molds</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Source taxonomical name</td> </tr> <tr> <td><em>Acremonium kiliense</em> (<em>Cephalosporium acremonium</em>)</td> </tr> <tr> <td><em>Alternaria alternata</em> (<em>Alternaria tenuis</em>) </td> </tr> <tr> <td><em>Aspergillus flavus</em></td> </tr> <tr> <td><em>Aspergillus fumigatus </em></td> </tr> <tr> <td><em>Aspergillus nidulans</em></td> </tr> <tr> <td><em>Aspergillus niger</em></td> </tr> <tr> <td><em>Aspergillus oryzae</em></td> </tr> <tr> <td><em>Aspergillus restrictus</em></td> </tr> <tr> <td><em>Aspergillus terreus</em></td> </tr> <tr> <td><em>Aspergillus versicolor</em></td> </tr> <tr> <td><em>Aureobasidium pullulans </em></td> </tr> <tr> <td><em>Bipolaris spicifera</em></td> </tr> <tr> <td><em>Botrytis cinerea </em></td> </tr> <tr> <td><em>Candida albicans </em></td> </tr> <tr> <td><em>Cladosporium cladosporioides</em></td> </tr> <tr> <td><em>Cladosporium herbarum</em> (<em>Hormodendrum</em>)</td> </tr> <tr> <td><em>Curvularia lunata </em></td> </tr> <tr> <td><em>Drechslera halodes </em>(<em>Setomelanomma rostrata</em>, <em>Helminthosporium halodes</em>)</td> </tr> <tr> <td><em>Epicoccum purpurascens</em> (<em>Epicoccum nigrum</em>)</td> </tr> <tr> <td><em>Fusarium culmorum</em></td> </tr> <tr> <td><em>Fusarium moniliforme</em> (<em>Fusarium proliferatum</em>)</td> </tr> <tr> <td><em>Malassezia furfur</em> (<em>Pityrosporum orbiculare</em>)</td> </tr> <tr> <td><em>Malassezia</em> spp (<em>Pityrosporum</em> spp)</td> </tr> <tr> <td><em>Mucor racemosus </em></td> </tr> <tr> <td><em>Penicillium brevicompactum</em></td> </tr> <tr> <td><em>Penicillium chrysogenum</em> (<em>Penicillium notatum</em>)</td> </tr> <tr> <td><em>Penicillium citrinum</em></td> </tr> <tr> <td><em>Penicillium glabrum</em> (<em>Penicillium frequentans</em>)</td> </tr> <tr> <td><em>Phoma betae</em></td> </tr> <tr> <td><em>Rhizopus nigricans </em></td> </tr> <tr> <td><em>Rhodotorula rubra</em> (<em>Rhodotorula mucilaginosa</em>)</td> </tr> <tr> <td><em>Saccharomyces cerevisiae</em></td> </tr> <tr> <td><em>Saccharopolyspora rectivirgula</em> (<em>Micropolyspora faeni</em>)</td> </tr> <tr> <td><em>Stachybotrys chartarum </em>(<em>Stachybotrys atra</em>)</td> </tr> <tr> <td><em>Stemphylium herbarum </em>(<em>Stemphylium botryosum</em>)</td> </tr> <tr> <td><em>Thermoactinomyces vulgaris</em></td> </tr> <tr> <td><em>Tilletia tritici</em> (<em>Ustilago nuda</em>, <em>Ustilago tritici</em>)</td> </tr> <tr> <td><em>Trichoderma viride </em></td> </tr> <tr> <td><em>Trichophyton mentagrophytes </em></td> </tr> <tr> <td><em>Trichophyton mentagrophytes var goetzii</em></td> </tr> <tr> <td><em>Trichophyton mentagrophytes var interdigitale</em></td> </tr> <tr> <td><em>Trichophyton rubrum</em></td> </tr> <tr> <td><em>Ulocladium chartarum</em></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 61257 Version 3.0</div></div></div>"},"61258":{"type":"graphic_picture","displayName":"Ichthyosis vulgaris 2","title":"Ichthyosis vulgaris","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ichthyosis vulgaris</div><div class=\"cntnt\"><img style=\"width:396px; height:291px;\" src=\"images/DERM/61258_Ichthyosis_vulgaris_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin with fine, white, adherent scale is present in this patient with ichthyosis vulgaris.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins</div><div id=\"graphicVersion\">Graphic 61258 Version 1.0</div></div></div>"},"61259":{"type":"graphic_picture","displayName":"Phalanx fracture reduction three-point technique","title":"Phalanx fracture reduction: Three-point technique","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Phalanx fracture reduction: Three-point technique</div><div class=\"cntnt\"><img style=\"width:468px; height:312px;\" src=\"images/EM/61259_Phalanx_fx_reductn_3_pt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reduction of a middle phalanx fracture is performed by applying longitudinal traction, and then using three-point pressure (shown above) to bring the distal fragment into alignment with the proximal fragment. Each thumb represents one point and adjacent index fingers a third point.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 61259 Version 3.0</div></div></div>"},"61260":{"type":"graphic_picture","displayName":"Palm hyperpigmentation Nelsons","title":"Palmar hyperpigmentation in Nelson's syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palmar hyperpigmentation in Nelson's syndrome</div><div class=\"cntnt\"><img style=\"width:350px; height:270px;\" src=\"images/ENDO/61260_Palm_hyperpigmentation_Nels.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left palm of a 16-year-old woman with Nelson's syndrome with hyperpigmentation in the palmar creases (areas protected from being worn down by friction).</div><div class=\"graphic_reference\">Reprinted with permission from Williams Textbook of Endocrinology, 8th ed, Foster DW, Wilson JD (Eds), WB Saunders, Philadelphia, 1996.</div><div id=\"graphicVersion\">Graphic 61260 Version 2.0</div></div></div>"},"61261":{"type":"graphic_diagnosticimage","displayName":"Fluoroscopic view of self-expanding stent CPC","title":"Self-expanding metal stent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Self-expanding metal stent</div><div class=\"cntnt\"><img style=\"width:288px; height:264px;\" src=\"images/GAST/61261_Esoph_stent_fluoro_CPC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluoroscopic view of the metal stent (arrow) in the distal esophagus extending into the stomach. The gastric bubble (arrowhead) can be easily visualized.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD and Douglas Pleskow, MD.</div><div id=\"graphicVersion\">Graphic 61261 Version 4.0</div></div></div>"},"61263":{"type":"graphic_picture","displayName":"Rubella rash","title":"Rubella rash on a child's back","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rubella rash on a child's back</div><div class=\"cntnt\"><img style=\"width:272px; height:396px;\" src=\"images/ID/61263_Rubella_rash.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The distribution is similar to that of measles (rubeola), though the lesions are less intensely red.</div><div class=\"graphic_reference\">Image from Centers for Disease Control and Prevention.</div><div id=\"graphicVersion\">Graphic 61263 Version 1.0</div></div></div>"},"61265":{"type":"graphic_figure","displayName":"Identification of the abnormal pupil","title":"Figures depicting the identification of the abnormal pupil","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Figures depicting the identification of the abnormal pupil</div><div class=\"cntnt\"><img style=\"width:516px; height:345px;\" src=\"images/NEURO/61265_ID_of_the_abnormal_pupil.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A)  Normal pupillary reactions. Both pupils are symmetric in the light and dark. B)  The small pupil is abnormal. The right pupil does not dilate well in the dark. C)  The large pupil is abnormal. The right pupil does not react well to light. D) Physiologic anisocoria. The amount of anisocoria is the same in light and dark.</div><div id=\"graphicVersion\">Graphic 61265 Version 2.0</div></div></div>"},"61266":{"type":"graphic_table","displayName":"Clinical risk factors for preeclampsia","title":"Clinical factors that have been associated with an increased risk of developing preeclampsia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical factors that have been associated with an increased risk of developing preeclampsia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Nulliparity</td> </tr> <tr> <td>Preeclampsia in a previous pregnancy</td> </tr> <tr> <td>Age &#62;40 years or &#60;18 years</td> </tr> <tr> <td>Family history of preeclampsia</td> </tr> <tr> <td>Chronic hypertension</td> </tr> <tr> <td>Chronic renal disease</td> </tr> <tr> <td>Autoimmune disease (eg, antiphospholipid syndrome, systemic lupus erythematosus)&nbsp;</td> </tr> <tr> <td>Vascular disease</td> </tr> <tr> <td>Diabetes mellitus (pregestational and gestational)</td> </tr> <tr> <td>Multifetal gestation</td> </tr> <tr> <td>Obesity</td> </tr> <tr> <td>Black race</td> </tr> <tr> <td>Hydrops fetalis</td> </tr> <tr> <td>Woman herself was small for gestational age</td> </tr> <tr> <td>Fetal growth restriction, abruptio placentae, or fetal demise in a previous pregnancy</td> </tr> <tr> <td>Prolonged interpregnancy interval if the previous pregnancy was normotensive; if the previous pregnancy was preeclamptic, a short interpregnancy interval increases the risk of recurrence</td> </tr> <tr> <td><span style=\"font-size: 10pt; font-family: verdana,sans-serif;\">Partner-related factors (new partner, <span style=\"font-size: 13px;\">limited sperm exposure [eg, </span>previous use of barrier contraception])</span></td> </tr> <tr> <td>In vitro fertilization</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">By comparison, smoking decreases the risk of preeclampsia, and Asian and Hispanic women have a lower risk of preeclampsia than white women and a much lower risk than black women.</div><div id=\"graphicVersion\">Graphic 61266 Version 7.0</div></div></div>"},"61268":{"type":"graphic_picture","displayName":"2-finger method PI","title":"Infant CPR: 2-finger method","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infant CPR: 2-finger method</div><div class=\"cntnt\"><img style=\"width:320px; height:540px;\" src=\"images/PI/61268_Two_finger_method_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pressing on the chest for CPR is called doing &quot;compressions.&quot; To do compressions on an infant using the 2-finger method, make sure the victim is on a flat, solid surface. Then place the tips of your index and middle fingers on the victim's breastbone, just below the nipples. With each compression, make sure the victim's chest drops down at least 1.5 inches (3.8 centimeters). Between compressions, lift all pressure off the victim's chest so that his or her chest goes back to where it was.</div><div id=\"graphicVersion\">Graphic 61268 Version 2.0</div></div></div>"},"61269":{"type":"graphic_diagnosticimage","displayName":"VSD closure device 2D and color still frame","title":"VSD closure device 2D and color still frame","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">VSD closure device 2D and color still frame</div><div class=\"cntnt\"><img style=\"width:545px; height:345px;\" src=\"images/CARD/61269_VSD_closure_device_2D_color.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Paired mid-esophageal apical four-chamber still frames with and without color Doppler imaging from intraoperative transesophageal echocardiogram (TEE). The images show a relatively empty heart on cardiopulmonary bypass during intraoperative placement of an Amplatzer muscular VSD device. The device has been positioned using a periventricular approach, introducing the sheath and later the device through the right ventricular wall using TEE guidance. The device (small arrows) is well seated on the septum and remains attached to the delivery cable (large arrow) at this point in the procedure. Color Doppler imaging has been utilized to show that the previously present muscular VSD is essentially occluded by the device.</div><div class=\"graphic_footnotes\">RA: right atrium; LA: left atrium; IVS: intraventricular septum; RV: right ventricle; LV: left ventricle; small arrows: Amplatzer VSD occluder device; large arrow: delivery cable.</div><div id=\"graphicVersion\">Graphic 61269 Version 5.0</div></div></div>"},"61271":{"type":"graphic_picture","displayName":"Endoscopy snare billie club","title":"Endoscopic view and snare of the Billie club","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Endoscopic view and snare of the Billie club</div><div class=\"cntnt\"><img style=\"width:515px; height:513px;\" src=\"images/GAST/61271_Endoscopy_snare_billie_club.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A polypectomy snare is deployed around the Billie club and gentle traction under direct visualization is used to guide the foreign body toward the rectum for transanal extraction.</div><div class=\"graphic_reference\">Courtesy of Justin A Maykel, MD.</div><div id=\"graphicVersion\">Graphic 61271 Version 1.0</div></div></div>"},"61272":{"type":"graphic_picture","displayName":"Disseminated neonatal HSV","title":"Disseminated neonatal HSV","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Disseminated neonatal HSV</div><div class=\"cntnt\"><img style=\"width:515px; height:401px;\" src=\"images/PEDS/61272_Disseminated_neonatal_HSV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adrenals (A) and liver (B) of a neonate who died from disseminated neonatal herpes simplex virus (HSV) disease, showing hemorrhagic lesions on the adrenals and patchy white areas on the liver capsule. Microscopic histopathologic sections of the involved organs (C and D) showed coagulative necrosis, hemorrhage, and Cowley type A and B viral inclusion bodies, characteristic of HSV infection. Viral culture of the organs grew HSV type 2.</div><div class=\"graphic_reference\">Courtesy of Edwina Popek, MD, Megan Dishop, MD, Jenny Ravenscroft, MD, and Gail Demmler-Harrison, MD, Department of Pediatric Pathology, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 61272 Version 2.0</div></div></div>"},"61275":{"type":"graphic_diagnosticimage","displayName":"Rotator cuff tear plain xray","title":"Rotator cuff tendon tear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rotator cuff tendon tear</div><div class=\"cntnt\"><img style=\"width:377px; height:335px;\" src=\"images/PC/61275_Rotator_cuff_tear_plain_xra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This radiograph is from a 74-year-old woman with a 25 year history of \"shoulder bursitis.\" She is unable to raise her arm overhead, cannot comb her hair, and cannot reach up to higher shelves to remove dishes. She uses her left arm to assist with abduction. Her external rotation strength is nonexistent and abduction strength is poor. The plain x-ray provides indirect evidence of a rotator cuff tendon tear. Cephalad migration of the humerus (high-riding humeral head) is evident; the subacromial space, which contains the 7 mm thick rotator cuff tendon and a 1 mm thick subacromial bursa, has worn away.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 61275 Version 2.0</div></div></div>"},"61276":{"type":"graphic_table","displayName":"Causes of bloody stool appearance PI","title":"List of foods and medicines that can make a child's bowel movements look bloody","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">List of foods and medicines that can make a child's bowel movements look bloody</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">These foods and medicines can make stools look red, like fresh blood</td> </tr> <tr> <td class=\"indent1\">Certain antibiotics*</td> </tr> <tr> <td class=\"indent1\">Beets</td> </tr> <tr> <td class=\"indent1\">Flavored gelatin (red colored)</td> </tr> <tr> <td class=\"indent1\">Kool-Aid or fruit punch (red colored)</td> </tr> <tr> <td class=\"indent1\">Red licorice</td> </tr> <tr> <td class=\"indent1\">Red-dyed snack foods (such as spicy \"red hot\" snacks)&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">These foods and medicines can make stools look black, like old blood</td> </tr> <tr> <td class=\"indent1\">Stomach medicines that contain bismuth (such as&nbsp;Pepto-Bismol, Maalox, or Kaopectate)</td> </tr> <tr> <td class=\"indent1\">Activated charcoal&nbsp;</td> </tr> <tr> <td class=\"indent1\">Chocolate</td> </tr> <tr> <td class=\"indent1\">Blueberries&nbsp;</td> </tr> <tr> <td class=\"indent1\">Iron supplements</td> </tr> <tr> <td class=\"indent1\">Lots of dark green foods (such as spinach or kale)</td> </tr> <tr> <td class=\"subtitle1_single\">These foods&nbsp;can&nbsp;interfere with the&nbsp;test&nbsp;for blood in stool (false-positive result)<sup>&#182;&nbsp;</sup></td> </tr> <tr> <td class=\"indent1\">Rare red meat&nbsp;</td> </tr> <tr> <td class=\"indent1\">Certain vegetables (turnips, horseradish, broccoli, cauliflower, and cantaloupe)&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In some cases antibiotics can cause real bleeding. If your child has bowel movements that look bloody after taking antibiotics, call the doctor. <br />¶ If the doctor or nurse is doing a test on your child's stool to see if it contains blood, tell&nbsp;them if your child has eaten these foods in the past few days. </div><div id=\"graphicVersion\">Graphic 61276 Version 8.0</div></div></div>"},"61277":{"type":"graphic_figure","displayName":"Subclasses of Type 0 superficial tumors","title":"Paris classification system of superficial neoplastic lesions of the gastrointestinal tract","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Paris classification system of superficial neoplastic lesions of the gastrointestinal tract</div><div class=\"cntnt\"><img style=\"width:349px; height:367px;\" src=\"images/GAST/61277_Subclasses_type_0_tumors.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Paris classification system of superficial neoplastic lesions of the esophagus, stomach, and colon. Type 0-I lesions are polypoid (protruded or pendunculated); type 0-II lesions are nonpolypoid and may be slightly elevated (IIa), flat (IIb), or slightly depressed (IIc); type 0-III lesions are excavated.</div><div class=\"graphic_reference\">Based on data from: The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach and colon: November 30 to December 1, 2002. Gastrointest Endosc 2003; 58(6 suppl):S3.</div><div id=\"graphicVersion\">Graphic 61277 Version 3.0</div></div></div>"},"61279":{"type":"graphic_figure","displayName":"HTLV-I genome organization","title":"Organization of the HTLV-I genome","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Organization of the HTLV-I genome</div><div class=\"cntnt\"><img style=\"width:486px; height:126px;\" src=\"images/ID/61279_HTLV-I_genome_organization.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 61279 Version 1.0</div></div></div>"},"61280":{"type":"graphic_table","displayName":"Localization Horners syndrome","title":"Etiology of Horner's syndrome in adults based on the location of the lesion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of Horner's syndrome in adults based on the location of the lesion</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n<tbody>\n<tr>\n\t<td class=\"container\">\n\t\t<table cellspacing=\"0\">\n\t\n\t\n<tr><td class=\"subtitle1_single\">Central (1st order)</td></tr>\n\t\n\t<tr><td class=\"subtitle2_single\">Hypothalamus</td></tr>\n\t<tr><td class=\"indent1\">Stroke</td></tr>\n\t<tr><td class=\"indent1\">Tumor</td></tr>\n\t<tr><td class=\"subtitle2_single\">Brainstem (lateral medulla)</td></tr>\n\t<tr><td class=\"indent1\">Stroke</td></tr>\n\t<tr><td class=\"indent1\">Demyelination</td></tr>\n\t<tr><td class=\"indent1\">Tumor</td></tr>\n\t\t<tr><td class=\"subtitle2_single\">Spinal cord (cervico-thoracic)</td></tr>\n\t\t<tr><td class=\"indent1\">Trauma </td></tr>\n\t\t<tr><td class=\"indent1\">Tumor (intramedullary)</td></tr>\n\t\t<tr><td class=\"indent1\">Myelitis</td></tr>\n\t\t<tr><td class=\"indent1\">Syringomyelia </td></tr>\n\t\t<tr><td class=\"indent1\">Demyelination</td></tr>\n\t\t<tr><td class=\"indent1\">Arteriovenous malformation</td></tr>\n\t\t<tr><td class=\"indent1\">Infarction</td></tr>\n\t\n\t</table>\n\t</td>\n\t\n\n\t<td class=\"container\">\n\t\t<table cellspacing=\"0\">\n\n\t\t\t<tr>\n\t\t\t<td class=\"subtitle1_single\">Preganglionic (2nd order)</td></tr>\n\n\t\t\t\n\t\t\t\t<tr><td class=\"subtitle2_single\">Pulmonary apical lesions</td></tr>\n\t\t\t\t<tr><td class=\"indent1\">Subclavian artery aneurysm</td></tr>\n\t\t\t\t<tr><td class=\"indent1\">Apical lung tumor (Pancoast tumor) </td></tr>\n\t\t\t\t<tr><td class=\"indent1\">Mediastinal tumors</td></tr>\n\t\t\t\t<tr><td class=\"indent1\">Cervical rib</td></tr>\n\t\t\t\t<tr><td class=\"indent1\">Iatrogenic (jugular cannulation, chest tube placement, thoracic surgery)   </td></tr>\n\t\t\t\t<tr><td class=\"subtitle2_single\">Thyroid malignancies</td></tr>\n\t\t\t\t\n\t\t\t</table>\n\t\t\t</td>\n\n\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t\n\t\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Postganglionic (3rd order)</td></tr>\n\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Superior cervical ganglion</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Trauma </td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Jugular venous ectasia</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Iatrogenic (surgical neck dissection)</td></tr>\n\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Internal carotid artery</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Dissection</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Aneurysm</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Trauma</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Arteritis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Thrombosis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Tumor</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Skull base lesions </td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">(nasopharyngeal carcinoma, lymphoma)</td></tr>\n\n\n\t\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Cavernous sinus lesion</td></tr>\n\t\t\t\t\t\t\t<tr><td class=\"indent1\">Tumors </td></tr>\n\t\t\t\t\t\t\t<tr><td class=\"indent1\">Invasive pituitary tumor</td></tr>\n\t\t\t\t\t\t\t<tr><td class=\"indent1\">Inflammation </td></tr>\n\t\t\t\t\t\t\t<tr><td class=\"indent1\">Thrombosis</td></tr>\n\t\t\t\t\t\t\t<tr><td class=\"indent1\">Carotid aneurysm</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Miscellaneous (cluster headache)</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t</table>\n\t\t\t\t\t\t</td>\n\t\t\t\t\t\t</tr>\n\n\n\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 61280 Version 1.0</div></div></div>"},"61282":{"type":"graphic_table","displayName":"Disease specific guidelines for hospice","title":"Medical guidelines for determining appropriateness of hospice referral: Disease specific guidelines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical guidelines for determining appropriateness of hospice referral: Disease specific guidelines</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td>A patient will be considered to have a life expectancy of six months and be eligible for hospice services if he/she meets criteria for the following disease specific baseline guidelines as well as evidence of decline as outlined in non disease-specific baseline guidelines (shown on a separate table):</td> </tr> <tr> <td class=\"subtitle1_single\">Cancer diagnoses</td> </tr> <tr> <td class=\"indent1\">Disease with metastases at presentation, <strong>OR</strong></td> </tr> <tr> <td class=\"indent1\">Progression from an earlier stage of disease to metastatic disease with either continued decline in spite of therapy or patient declines further disease-directed therapy.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">NOTE: Certain cancers with poor prognoses (eg, small cell lung cancer, brain cancer, and pancreatic cancer) may be hospice eligible without fulfilling the other criteria in this section.</td> </tr> <tr> <td class=\"subtitle1_single\">Dementia due to Alzheimer disease and related disorders</td> </tr> <tr> <td class=\"indent1\">Patients will be considered to be in the terminal stage of dementia (life expectancy of six months or less) if they meet all of the following criteria:</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Stage 7 or beyond according to the Functional Assessment Staging Scale; unable to walk, dress, and bathe without assistance; urinary and fecal incontinence (intermittent or constant); no consistently meaningful verbal communication (stereotypical phrases only or the ability to speak is limited to six or fewer intelligible words); <strong>AND</strong> </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>At least one medical complication within the past 12 months: Aspiration pneumonia; pyelonephritis; septicemia; multiple stage 3-4 decubitus ulcers; recurrent fever after antibiotics; inability to maintain sufficient fluid and calorie intake (&#8805;10 percent weight loss over previous six months or serum albumin &#60;2.5 g/dL). </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">NOTE: This section is specific for Alzheimer disease and related disorders, and is not appropriate for other types of dementia.</td> </tr> <tr> <td class=\"subtitle1_single\">Heart disease</td> </tr> <tr> <td class=\"indent1\">Patients will be considered to be in the terminal stage of heart disease (life expectancy of six months or less) if they meet the following criteria (1 and 2 should be present; factors from 3 will add supporting documentation):</td> </tr> <tr> <td class=\"indent1\"> <ol> <li>At the time of initial certification or recertification for hospice, the patient is or has been already optimally treated for heart disease, or the patient is either not a candidate for surgical procedures or they decline those procedures. (Optimally treated means that patients who are not on vasodilators have a medical reason for not being on these drugs, eg, hypotension or renal disease.) </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"2\"> <li>Patients with congestive heart failure or angina should meet the criteria for the New York Heart Association (NYHA) Class IV. (Class IV patients with heart disease have an inability to carry on any physical activity. Symptoms of heart failure or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.) Significant congestive heart failure may be documented by an ejection fraction of &#8804;20 percent, but assessment of ejection fraction is not required if not already available. </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ol start=\"3\"> <li>Documentation of the following factors supports but is not required to establish eligibility for hospice care: Treatment resistant symptomatic supraventricular or ventricular arrhythmias; history of cardiac arrest or resuscitation; history of unexplained syncope; brain embolism of cardiac origin; or concomitant HIV disease. </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">HIV disease</td> </tr> <tr> <td class=\"indent1\">Patients will be considered to be in the terminal stage of their illness (life expectancy of six months or less) if they meet the following criteria (1 and 2 should be present; factors from 3 will add supporting documentation):</td> </tr> <tr> <td class=\"indent1\"> <ol> <li>CD4 count &#60;25 cells per microliter or persistent (two or more assays at least one month apart) viral load &#62;100,000 copies/mL, plus one of the following: </li> </ol> </td> </tr> <tr> <td class=\"indent2\"> <ul class=\"decimal_heading\"> <li>Central nervous system (CNS) lymphoma, untreated, or persistent despite treatment; wasting (loss of at least 10 percent lean body mass); mycobacterium avium complex (MAC) bacteremia, untreated, unresponsive to treatment, or treatment refused; progressive multifocal leukoencephalopathy; systemic lymphoma, with advanced HIV disease and partial response to chemotherapy; visceral Kaposi sarcoma unresponsive to therapy; renal failure in the absence of dialysis; cryptosporidium infection; toxoplasmosis, unresponsive to therapy. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"2\"> <li>Decreased performance status, as measured by the Karnofsky Performance Status (KPS) scale, &#8804;50 percent. </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ol start=\"3\"> <li>Documentation of the following factors will support eligibility for hospice care: Chronic persistent diarrhea for one year; persistent serum albumin &#60;2.5 g/dL; concomitant, active substance abuse; age &#62;50 years; absence of, or resistance to effective antiretroviral, chemotherapeutic, and prophylactic drug therapy related specifically to HIV disease; advanced AIDS dementia complex; toxoplasmosis; congestive heart failure, symptomatic at rest; advanced liver disease. </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Liver disease</td> </tr> <tr> <td class=\"indent1\">Patients will be considered to be in the terminal stage of liver disease (life expectancy of six months or less) if they meet the following criteria (1 and 2 should be present; factors from 3 will lend supporting documentation):</td> </tr> <tr> <td class=\"indent1\"> <ol> <li>Both prolonged prothrombin time (more than five seconds over control, or INR &#62;1.5) <strong>AND</strong> serum albumin &#60;2.5 g/dL. </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"2\"> <li>End stage liver disease with at least one of the following: Ascites, refractory to treatment or patient non-compliant; spontaneous bacterial peritonitis; hepatorenal syndrome (elevated creatinine and BUN with oliguria [&#60;400 mL/day] and urine sodium concentration &#60;10 mEq/L); hepatic encephalopathy refractory to treatment or patient non-compliant; recurrent variceal bleeding, despite intensive therapy. </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ol start=\"3\"> <li>Documentation of the following factors will support eligibility for hospice care: Progressive malnutrition; muscle wasting with reduced strength and endurance; continued active alcoholism (&#62;80 g ethanol/day); hepatocellular carcinoma; chronic hepatitis B virus infection (HBsAg-positive); hepatitis C infection refractory to interferon treatment. </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Pulmonary disease</td> </tr> <tr> <td class=\"indent1\">Patients will be considered to be in the terminal stage of pulmonary disease (life expectancy of six months or less) if they meet the following criteria. The criteria refer to patients with various forms of advanced pulmonary disease who eventually follow a final common pathway for end stage pulmonary disease (1 and 2 should be present; documentation of 3, 4, and 5 will lend supporting documentation):</td> </tr> <tr> <td class=\"indent1\"> <ol> <li>Severe chronic lung disease as documented by both of the following: </li> </ol> </td> </tr> <tr> <td class=\"indent2\"> <ul class=\"decimal_heading\"> <li>Disabling dyspnea at rest, poorly or unresponsive to bronchodilators, resulting in decreased functional capacity, eg, bed to chair existence, fatigue, and cough (documentation of forced expiratory volume in one second [FEV1], &#60;30 percent predicted value after bronchodilator, is objective evidence for disabling dyspnea, but is not necessary to obtain). </li> <li>Progression of end stage pulmonary disease, as evidenced by increasing visits to the emergency department or hospitalizations for pulmonary infections and/or respiratory failure or increasing physician home visits prior to initial certification (documentation of serial decrease of FEV1 &#62;40 mL/year is objective evidence for disease progression, but is not necessary to obtain). </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"2\"> <li>Hypoxemia at rest on room air, as evidenced by pO2 &#8804;55 mmHg, or oxygen saturation &#8804;88 percent, determined either by arterial blood gases or oxygen saturation monitors (these values may be obtained from recent hospital records) OR hypercapnia, as evidenced by pCO2 &#8805;50 mmHg (this value may be obtained from recent [within three months] hospital records). </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"3\"> <li>Right heart failure (RHF) secondary to pulmonary disease (Cor pulmonale) (eg, not secondary to left heart disease or valvulopathy). </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"4\"> <li>Unintentional progressive weight loss &#62;10 percent of body weight over the preceding six months. </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ol start=\"5\"> <li>Resting tachycardia &#62;100/minute. </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Renal disease (acute and chronic)</td> </tr> <tr> <td class=\"indent1\">Patients will be considered to be in the terminal stage of renal disease (life expectancy of six months or less) if they meet the following criteria:</td> </tr> <tr> <td class=\"indent2\"><strong>Acute renal failure</strong> (1 and either 2, 3, or 4 should be present; factors from 5 will lend supporting documentation):</td> </tr> <tr> <td class=\"indent2\"> <ol> <li> <p>The patient is not seeking dialysis or renal transplant, or is discontinuing dialysis. As with any other condition, an individual with renal disease is eligible for the hospice benefit if that individual has a prognosis of six months or less, if the illness runs its normal course. There is no regulation precluding patients on dialysis from electing hospice care. However, the continuation of dialysis will significantly alter a patient's prognosis, and thus potentially impact that individual's eligibility.</p> When an individual elects hospice care for end stage renal disease (ESRD) or for a condition to which the need for dialysis is related, the hospice agency is financially responsible for the dialysis. In such cases, there is no additional reimbursement beyond the per diem rate. The only situation in which a beneficiary may access both the Hospice benefit and the ESRD benefit is when the need for dialysis is not related to the patient's terminal illness. </li> </ol> </td> </tr> <tr> <td class=\"indent2\"> <ol start=\"2\"> <li>Creatinine clearance &#60;10 cc/minute (&#60;15 cc/minute for diabetics); or &#60;15 cc/minute (&#60;20 cc/minute for diabetics) with comorbidity of congestive heart failure. </li> </ol> </td> </tr> <tr> <td class=\"indent2\"> <ol start=\"3\"> <li>Serum creatinine &#62;8.0 mg/dL (&#62;6.0 mg/dL for diabetics). </li> </ol> </td> </tr> <tr> <td class=\"indent2\"> <ol start=\"4\"> <li>Estimated glomerular filtration rate (GFR) &#60;10 mL/min. </li> </ol> </td> </tr> <tr> <td class=\"indent2\"> <ol start=\"5\"> <li>Comorbid conditions: Mechanical ventilation; malignancy (other organ system); chronic lung disease; advanced cardiac disease; advanced liver disease; immunosuppression/AIDS; albumin &#60;3.5 g/dL; platelet count &#60;25,000/microL; disseminated intravascular coagulation; gastrointestinal bleeding. </li> </ol> </td> </tr> <tr> <td class=\"indent2\"><strong>Chronic kidney disease</strong> (1 and either 2, 3, or 4 should be present; factors from 5 will lend supporting documentation):</td> </tr> <tr> <td class=\"indent2\"> <ol> <li> <p>The patient is not seeking dialysis or renal transplant, or is discontinuing dialysis; as with any other condition, an individual with renal disease is eligible for the hospice benefit if that individual has a prognosis of six months or less, if the illness runs its normal course. There is no regulation precluding patients on dialysis from electing hospice care. However, the continuation of dialysis will significantly alter a patient's prognosis, and thus potentially impact that individual's eligibility.</p> When an individual elects hospice care for end stage renal disease (ESRD) or for a condition to which the need for dialysis is related, the hospice agency is financially responsible for the dialysis. In such cases, there is no additional reimbursement beyond the per diem rate. The only situation in which a beneficiary may access both the hospice benefit and the ESRD benefit is when the need for dialysis is not related to the patient's terminal illness. </li> </ol> </td> </tr> <tr> <td class=\"indent2\"> <ol start=\"2\"> <li>Creatinine clearance &#60;10 cc/minute (&#60;15 cc/minute for diabetics); or &#60;15 cc/minute (&#60;20 cc/minute for diabetics) with comorbidity of congestive heart failure. </li> </ol> </td> </tr> <tr> <td class=\"indent2\"> <ol start=\"3\"> <li>Serum creatinine &#62;8.0 mg/dL (&#62;6.0 mg/dL for diabetics). </li> </ol> </td> </tr> <tr> <td class=\"indent2\"> <ol start=\"4\"> <li>Signs and symptoms of renal failure: Uremia; oliguria (&#60;400 cc/24 hours); intractable hyperkalemia (&#62;7.0 mEq/L) not responsive to treatment; uremic pericarditis; hepatorenal syndrome; intractable fluid overload, not responsive to treatment. </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ol start=\"5\"> <li>Estimated glomerular filtration rate (GFR) &#60;10 mL/minute. </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Stroke or coma</td> </tr> <tr> <td class=\"indent1\">Patients will be considered to be in the terminal stages of stroke or coma (life expectancy of six months or less) if they meet the following criteria:</td> </tr> <tr> <td class=\"indent2\">Stroke:</td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Karnofsky Performance Status or Palliative Performance Scale of 40 percent or less. </li> <li>Inability to maintain hydration and caloric intake with one of the following: Weight loss &#62;10 percent in the last six months or &#62;7.5 percent in the last three months; serum albumin &#60;2.5 g/dL; current history of pulmonary aspiration not responsive to speech language pathology intervention; sequential calorie counts documenting inadequate caloric/fluid intake; dysphagia severe enough to prevent the patient from continuing food and fluids necessary to sustain life, in a patient who does not receive artificial nutrition and hydration. </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Coma (any etiology): Comatose patients with any three of the following on day three of the coma: Abnormal brain stem response; absent verbal response; absent withdrawal response to pain; serum creatinine &#62;1.5 mg/dL.</td> </tr> <tr> <td class=\"indent2\">Documentation of the following factors will support eligibility for hospice care:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\"> <ul> <li>Documentation of medical complications, in the context of progressive clinical decline, within the previous 12 months, which support a terminal prognosis: <ul> <li>Aspiration pneumonia; upper urinary tract infection (pyelonephritis); refractory stage 3-4 decubitus ulcers; fever recurrent after antibiotics. </li> </ul> </li> <li>For stroke patients, documentation of diagnostic imaging factors that support poor prognosis after stroke include: <ul> <li>For non-traumatic hemorrhagic stroke: Large volume hemorrhage on CT (&#8805;20 mL if intratentorial, &#8805;50 mL if supratentorial); ventricular extension of hemorrhage; surface area of involvement of hemorrhage &#8805;30 percent of cerebrum; midline shift &#8805;1.5 cm; obstructive hydrocephalus in patient who declines or is not a candidate for ventriculoperitoneal shunt. For thrombotic/embolic stroke: Large anterior infarcts with both cortical/subcortical involvement; large bihemispheric infarcts; basilar artery occlusion; bilateral vertebral artery occlusion. </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Amyotrophic lateral sclerosis (ALS)</td> </tr> <tr> <td class=\"indent1\">Patients are considered eligible for hospice care if they do not elect tracheostomy and invasive ventilation and display evidence of critically impaired respiratory function (with or without use of noninvasive positive pressure ventilation [NIPPV]) and/or severe nutritional insufficiency (with or without use of a gastrostomy tube).</td> </tr> <tr> <td class=\"indent1\">Critically impaired respiratory function is as defined by:</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Forced vital capacity (FVC) &#60;40 percent predicted (seated or supine) and two or more of the following symptoms and/or signs: Dyspnea at rest; orthopnea; use of accessory respiratory musculature; paradoxical abdominal motion; respiratory rate &#62;20/minute; reduced speech/vocal volume; weakened cough; symptoms of sleep disordered breathing; frequent awakening; daytime somnolence/excessive daytime sleepiness; unexplained headaches; unexplained confusion; unexplained anxiety; unexplained nausea. </li> <li>If unable to perform the FVC test, patients meet this criterion if they manifest three or more of the above symptoms/signs. </li> <li>Severe nutritional insufficiency is defined as: Dysphagia with progressive weight loss of at least 5 percent of body weight with or without election for gastrostomy tube insertion. </li> <li>These revised criteria rely less on the measured FVC, and as such reflect the reality that not all patients with ALS can or will undertake regular pulmonary function tests. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Karnofsky = 50: Requires considerable assistance and frequent medical care.<br />Karnofsky &lt;50: Unable to care for self; requires equivalent of institutional or hospital care; disease may be progressing rapidly.</div><div class=\"graphic_footnotes\">INR: international normalized ratio; BUN: blood urea nitrogen; HBsAg: hepatitis B surface antigen positivity; FEV1: forced expiratory volume in one second; CT: computed tomography; NIPPV: noninvasive positive pressure ventilation; FVC: forced vital capacity.</div><div class=\"graphic_reference\">Sources:&#xD;&#xA;<ol>&#xD;&#xA;    <li>The NHO medical guidelines for non-cancer disease and local medical review policy: hospice access for patients with diseases other than cancer. Hosp J 1999.</li>&#xD;&#xA;    <li>Centers for Medicare &amp; Medicaid Services. <a href=\"https://www.cms.gov/medicare-coverage-database/license/cpt-license.aspx?from=~/overview-and-quick-search.aspx&amp;npage=/medicare-coverage-database/details/lcd-details.aspx&amp;LCDId=33393&amp;ContrId=272&amp;ver=2&amp;ContrVer=1&amp;CntrctrSelected=272*1&amp;Cntrctr=272&amp;name=National+Government+Services%2c+Inc.+(06004%2c+HHH+MAC)&amp;DocType=All&amp;s=56&amp;bc=AggAAAIAAAAAAA%3d%3d&amp;amp;\" target=\"_blank\">Local Coverage Determination (LCD) for Hospice Determining Terminal Status (L33393)</a>. (Accessed on January 18, 2016).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 61282 Version 15.0</div></div></div>"},"61283":{"type":"graphic_table","displayName":"Inher syndromes pancreas CA","title":"Inherited cancer syndromes associated with increased risk of pancreatic cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Inherited cancer syndromes associated with increased risk of pancreatic cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Gene(s)</td> <td class=\"subtitle1\">Lifetime risk of pancreatic cancer, percent</td> <td class=\"subtitle1\">Locus</td> </tr> <tr> <td>Hereditary breast/ovarian cancer</td> <td>BRCA2, BRCA1</td> <td>3 to 5</td> <td>13q</td> </tr> <tr> <td>&nbsp;</td> <td>PALB2</td> <td>Unknown</td> <td>16p</td> </tr> <tr> <td>Familial atypical multiple mole melanoma syndrome</td> <td>CDKN2A</td> <td>10 to 19</td> <td>9p</td> </tr> <tr> <td>Peutz-Jeghers syndrome</td> <td>STK 11</td> <td>11 to 36</td> <td>19p</td> </tr> <tr> <td>Familial adenomatous polyposis</td> <td>APC</td> <td>Unknown</td> <td>5q</td> </tr> <tr> <td>Hereditary nonpolyposis colon cancer (Lynch II)</td> <td>DNA mismatch repair genes</td> <td>4</td> <td>2p, 3p, 7p</td> </tr> <tr> <td>Hereditary pancreatitis</td> <td>PRSS1, SPINK1</td> <td>25 to 40</td> <td>7q, 5q</td> </tr> <tr> <td>Ataxia telangiectasia</td> <td>ATM</td> <td>Unknown</td> <td>11q</td> </tr> <tr> <td>Li-Fraumeni syndrome</td> <td>P53</td> <td>Unknown</td> <td>17p</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from: Brentnall TA. Management strategies for patients with hereditary pancreatic cancer. Curr Treat Options Oncol 2005; 6:437. Copyright © 2005 Current Medicine.</div><div id=\"graphicVersion\">Graphic 61283 Version 4.0</div></div></div>"},"61284":{"type":"graphic_table","displayName":"Smoking consequences among adolescents with chronic illnesses","title":"Consequences of smoking among adolescents with chronic illnesses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Consequences of smoking among adolescents with chronic illnesses</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Chronic illness</td> <td class=\"subtitle1\">Potential disease-specific health consequences</td> <td class=\"subtitle1\">References</td> </tr> <tr> <td>Asthma</td> <td>Increased frequency and severity of exacerbations, medication use, hospitalization, risk of respiratory arrest.</td> <td> <p>Larsson L. Thorax. 1994; 50:260.</p> <p>LeSon S. J Asthma. 1995; 32:379.</p> </td> </tr> <tr class=\"divider_top\"> <td>Cystic fibrosis</td> <td>Increased frequency and severity of bacterial lung infection and hospitalization; accelerated decline in lung function, worse nutritional status.</td> <td> <p>Britto MT. Pediatrics. 1998; 101:250.</p> <p>Verma A. J R Soc Med. 2001; 94 (suppl 40):29.</p> </td> </tr> <tr class=\"divider_top\"> <td>Juvenile idiopathic (rheumatoid) arthritis</td> <td>Increased disease severity; increased risks for cardiovascular disease and premature death. Exacerbation of osteopenia.</td> <td> <p>Nash AA. Arthritis Care Res. 1998; 11:391.</p> <p>Gordon MM. Ann Rheum Dis. 2003; 61:66.</p> <p>French AR. J Rheumatol. 2002; 29:1065.</p> </td> </tr> <tr class=\"divider_top\"> <td>Cancer</td> <td>Increased risks from several cancer treatments; respiratory infections when immunosuppressed; worse mucositis.</td> <td> <p>O'Driscoll BR. N Engl J Med. 1990; 323:378.</p> <p>Lipshultz SE. N Engl J Med. 1991; 324.</p> <p>Tyc VL. J Child Health Care. 2004; 8:288.</p> </td> </tr> <tr class=\"divider_top\"> <td>Sickle cell disease</td> <td>Increased risk of acute chest syndrome; possible increased risk of stroke.</td> <td> <p>Young RC Jr. J Natl Med Assoc. 1992; 84:267.</p> <p>Britto MT. Pediatrics. 1998; 101:250.</p> </td> </tr> <tr class=\"divider_top\"> <td>Diabetes mellitus</td> <td>Accelerated cardiovascular and peripheral vascular disease, including atherosclerosis, retinopathy, and nephropathy. Smoking increases the morbidity and mortality of type 1 diabetes by 50-75 percent.</td> <td> <p>Frey MA. J Adolesc Health. 1997; 20:38.</p> <p>Cundiff DK. MedGenMed. 2002; 4:2.</p> <p>Gay EC. Diabetes Care. 1992; 15:947.</p> <p>Karim R. Diabet Med 2005; 22:81.</p> <p>Hsu CC. Diabet Med 2010; 27:295.</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Tyc VL, Throckmorton-Belzer L. Pediatrics 2006; 118:e471, with additional sources as indicated in the table.</div><div id=\"graphicVersion\">Graphic 61284 Version 12.0</div></div></div>"},"61286":{"type":"graphic_figure","displayName":"Placement of cryoprobe","title":"Endometrial cryoablation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endometrial cryoablation</div><div class=\"cntnt\"><img style=\"width:373px; height:274px;\" src=\"images/OBGYN/61286_Placement_of_cryoprobe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Probe placement on the left side of uterus with ice ball formation.</div><div id=\"graphicVersion\">Graphic 61286 Version 2.0</div></div></div>"},"61287":{"type":"graphic_waveform","displayName":"Advanced case 16 with answer","title":"Inverted U waves","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inverted U waves</div><div class=\"cntnt\"><img style=\"width:379px; height:240px;\" src=\"images/CARD/61287_Advancedcase16withanswe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram showing inverted U waves superimposed on the end of the T waves (arrows) in the lateral precordial leads. This finding is most often a subtle sign of ischemia and/or hypertrophy (note the prominent&nbsp;R in V5). An unrelated complete right bundle branch block is also present (rSR' in lead V1 with prolonged QRS interval).</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 61287 Version 3.0</div></div></div>"},"61288":{"type":"graphic_table","displayName":"Supratherapeutic INR management","title":"Recommended management of a supratherapeutic INR","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended management of a supratherapeutic INR</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">INR</td> <td class=\"subtitle1\">Bleeding present</td> <td class=\"subtitle1\">Recommended action*</td> </tr> <tr> <td rowspan=\"3\">&#62;Ther to 5.0</td> <td rowspan=\"3\">No</td> <td>Lower warfarin dose, <strong>or</strong></td> </tr> <tr> <td>Omit a dose and resume warfarin at a lower dose when INR is in therapeutic range, <strong>or</strong></td> </tr> <tr> <td>No dose reduction needed if INR is minimally supratherapeutic</td> </tr> <tr> <td rowspan=\"2\">&#62;5.0 to 9.0</td> <td rowspan=\"2\">No</td> <td>Omit the next one to two doses of warfarin, monitor INR more frequently, and resume treatment at a lower dose when INR is in therapeutic range, <strong>or</strong></td> </tr> <tr> <td>Omit a dose and administer 1 to 2.5 mg oral vitamin K1<sup>&#182;</sup></td> </tr> <tr> <td>&#62;9.0</td> <td>No</td> <td>Hold warfarin and administer 2.5 to 5 mg oral vitamin K1. Monitor INR more frequently and administer more vitamin K1 as needed. Resume warfarin at a lower dose when INR is in therapeutic range.</td> </tr> <tr> <td>Any</td> <td>Serious or life-threatening</td> <td>Hold warfarin and administer 10 mg vitamin K by slow IV infusion; supplement with four-factor prothrombin complex concentrate (4-factor PCC) or fresh frozen plasma, depending on clinical urgency. Monitor and repeat as needed.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">INR: international normalized ratio; Ther: therapeutic INR range for the patient in question.<br />* Editor's note: These recommendations, which UpToDate supports, are consistent with the 2008 American College of Chest Physician Guidelines but differ from their 2012 guidelines. Refer to UpToDate text for details.<br />¶ This option is preferred in patients at increased risk for bleeding (eg, history of bleeding, stroke, renal insufficiency, anemia, hypertension).</div><div class=\"graphic_reference\">Adapted from: Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; (6 Suppl):160s.</div><div id=\"graphicVersion\">Graphic 61288 Version 8.0</div></div></div>"},"61290":{"type":"graphic_picture","displayName":"Sweet syndrome skin appearance","title":"Sweet syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sweet syndrome</div><div class=\"cntnt\"><img style=\"width:349px; height:292px;\" src=\"images/ONC/61290_Sweets_syndrome_skin_appear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A sudden, painful eruption that developed in a 50-year-old female who was febrile and had general malaise. There are multiple very edematous and erythematous papules and plaques, most of which appear vesicular or bullous on initial examination, but are firm with palpation (pseudovesiculation). However, the confluent lesions in the lower part of the picture are indeed bullous and here there is also exudation and crusting. Systems review in this patient revealed myelocytic leukemia.</div><div class=\"graphic_reference\">Reproduced with permission from: Fitzpatrick, TB, Johnson, RA, Wolff, K, Suurmond, D. Color Atlas of Clinical Dermatology: Common and Serious Diseases. McGraw Hill, New York 2001. p.494. Copyright © 2001 McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 61290 Version 2.0</div></div></div>"},"61291":{"type":"graphic_table","displayName":"Essential features of the toll-like receptors","title":"Essential features of the toll-like receptors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Essential features of the toll-like receptors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Receptor</td> <td class=\"subtitle1\">Ligands</td> <td class=\"subtitle1\">Cell expression</td> <td class=\"subtitle1\">Signaling intermediates</td> <td class=\"subtitle1\">Products</td> </tr> <tr> <td>TLR1 + TLR2</td> <td>Triacyl lipopeptide (Gram-positive bacteria, mycobacteria), <em>Neisseria porins</em>, <em>Borrelia burgdorferi</em> OspA</td> <td>M/M, MDC</td> <td>TIRAP, MyD88</td> <td>IC</td> </tr> <tr> <td>TLR2 + TLR6</td> <td>Diacyl lipopeptide</td> <td>M/M, MC</td> <td>TIRAP, MyD88</td> <td>IC</td> </tr> <tr> <td>TLR3</td> <td>dsRNA (viruses)</td> <td>B, T, NK</td> <td>TRIF</td> <td>IC, type&nbsp;1 IFN</td> </tr> <tr> <td>TLR4</td> <td>LPS (Gram-negative bacteria), RSV fusion protein, Chlamydia <span style=\"color: black;\">hsp60</span><span style=\"color: black;\">,</span> extracellular matrix</td> <td>M/M, MDC, MC</td> <td>TRAM, TRIF or TIRAP, MyD88</td> <td>IC, type&nbsp;1 IFN</td> </tr> <tr> <td>TLR5</td> <td>Flagellin (bacteria)</td> <td>M/M, MDC</td> <td>MyD88</td> <td>IC</td> </tr> <tr> <td>TLR7</td> <td>ssRNA (viruses), imidazoquinolines</td> <td>M/M, MDC, PDC, B</td> <td>MyD88</td> <td>IC, type&nbsp;1 IFN</td> </tr> <tr> <td>TLR8</td> <td>ssRNA (viruses), imidazoquinolines</td> <td>M/M, MDC, MC</td> <td>MyD88</td> <td>IC, type&nbsp;1 IFN</td> </tr> <tr> <td>TLR9</td> <td>CpG DNA (bacteria)</td> <td>M/M, PDC, B, T</td> <td>MyD88</td> <td>IC, type&nbsp;1 IFN</td> </tr> <tr> <td>TLR10</td> <td>(unknown)</td> <td>M/M, B</td> <td>MyD88</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TLR: toll-like receptor; OspA: outer surface protein A; M/M: macrophage/monocyte; MDC: myeloid dendritic cell; TIRAP: toll/interleukin-1 receptor<FONT color=black> (TIR) domain-containing adapter protein; MyD88: myeloid differentiation primary response protein 88; IC: inflammatory cytokines including tumor necrosis factor (TNF), interleukin-1-beta (IL-1-beta), interleukin-6 (IL-6), interleukin-12 (IL-12); MC: mast cell; dsRNA: double-stranded RNA; B: B cell; T: T cell; NK: natural killer cell; TRIF: TIR domain-containing adapter-inducing interferon-beta (IFN-beta); IFN: interferon; LPS:&nbsp;lipopolysaccharide; RSV: respiratory syncytial virus; hsp60: heat shock protein 60; TRAM: TRIF-related adapter molecule; ssRNA: single-stranded RNA; PDC: plasmacytoid dendritic cell; CpG DNA: cytosine guanine dinucleotide motifs (in bacterial DNA)</FONT>.</div><div id=\"graphicVersion\">Graphic 61291 Version 10.0</div></div></div>"},"61293":{"type":"graphic_picture","displayName":"Rigid bronchoscopic instruments","title":"Rigid bronchoscopic instruments used during foreign body extraction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rigid bronchoscopic instruments used during foreign body extraction</div><div class=\"cntnt\"><img style=\"width:408px; height:250px;\" src=\"images/PULM/61293_Rigid_bronchoscopic_instrum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">From top to bottom: optical forceps, rigid telescope, rigid foreign body forceps, rigid bronchoscope.</div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 61293 Version 2.0</div></div></div>"},"61295":{"type":"graphic_figure","displayName":"HBV precore-core ORF","title":"HBV precore/core open reading frame","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">HBV precore/core open reading frame</div><div class=\"cntnt\"><img style=\"width:444px; height:333px;\" src=\"images/GAST/61295_HBV_precore-core_ORF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the HBV precore/core open reading frame (ORF), RNA transcripts and translational products in wild type and precore mutant viruses. The precore region consists of 87 nucleotides coding for 29 amino acids. In the wild type virus, the precore mRNA is processed at the N and C terminal ends to HBeAg, a secretory protein (upper panel). In the mutant virus, a G-A mutation at nucleotide 1896 in the precore region results in a premature stop codon at codon 28 preventing the production of HBeAg (lower panel). The pregenomic RNA is translated to the core protein (HBcAg); it is also translated to the polymerase protein and reverse transcribed into HBV DNA.</div><div id=\"graphicVersion\">Graphic 61295 Version 1.0</div></div></div>"},"61296":{"type":"graphic_figure","displayName":"Causes of hematuria by age","title":"Major causes of hematuria by age and duration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Major causes of hematuria by age and duration</div><div class=\"cntnt\"><img style=\"width:378px; height:348px;\" src=\"images/NEPH/61296_Causes_of_hematuria_by_age.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the major causes of hematuria in relation to the age at which they usually occur (horizontal axis), transience or persistence (vertical axis), and frequency (blue implies more frequent).</div><div class=\"graphic_footnotes\">BPH: benign prostatic hyperplasia.</div><div id=\"graphicVersion\">Graphic 61296 Version 1.0</div></div></div>"},"61297":{"type":"graphic_table","displayName":"Features of juvenile Huntington disease","title":"Clinical features of juvenile Huntington disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of juvenile Huntington disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td>Rigidity</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Bradykinesia</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Myoclonus</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Spasticity</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Cerebellar abnormalities</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Minimal chorea</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Cognitive and behavioral dysfunction</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Epilepsy</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 61297 Version 2.0</div></div></div>"},"61298":{"type":"graphic_table","displayName":"Lansky performance scale","title":"Lansky performance scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lansky performance scale</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1_left\">100</td>\n\n      <td>Fully active; normal</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_left\" colspan=\"1\">90\n      </td>\n\n      <td>Minor restrictions in physically strenuous activity</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_left\" colspan=\"1\">80</td>\n\n      <td>Active, but tires more quickly</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_left\" colspan=\"1\">70</td>\n\n      <td>Both greater restriction of and less time spent in play\nactivity</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_left\" colspan=\"1\">60</td>\n\n      <td>Up and around, but minimal active play; keeps busy with\nquieter activities</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_left\" colspan=\"1\">50</td>\n\n      <td>Gets dressed but lies around much of the day; no active\nplay; able to participate in all quiet play and activities</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_left\" colspan=\"1\">40 </td>\n\n      <td>Mostly in bed; participates in quiet activities</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"subtitle1_left\">30 </td>\n      <td>In bed;\nneeds assistance even for quiet play</td>\n    </tr>\n    <tr>\n      <td class=\"subtitle1_left\">20\n      </td>\n      <td>Often sleeping; play entirely\nlimited to very passive activities </td>\n    </tr>\n    <tr>\n\n      <td class=\"subtitle1_left\">10</td>\n\n      <td>No play; does not get out of bed</td>\n\n    </tr>\n    <tr>\n      <td class=\"subtitle1_left\">0</td>\n      <td>Unresponsive</td>\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Courtesy of Shakila P Khan, MD.</div><div id=\"graphicVersion\">Graphic 61298 Version 1.0</div></div></div>"},"61299":{"type":"graphic_table","displayName":"Weaver table","title":"Head circumference data of Nellhaus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Head circumference data of Nellhaus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Age</td> <td class=\"subtitle1\" colspan=\"2\">Males</td> <td class=\"subtitle1\" colspan=\"2\">Females</td> </tr> <tr> <td class=\"subtitle2\">Mean (cm)</td> <td class=\"subtitle2\">1 SD</td> <td class=\"subtitle2\">Mean (cm)</td> <td class=\"subtitle2\">1 SD</td> </tr> <tr> <td>Birth</td> <td class=\"centered\">34.74</td> <td class=\"centered\">1.33</td> <td class=\"centered\">34.02</td> <td class=\"centered\">1.22</td> </tr> <tr> <td>1 mo</td> <td class=\"centered\">37.30</td> <td class=\"centered\">1.30</td> <td class=\"centered\">36.43</td> <td class=\"centered\">1.22</td> </tr> <tr> <td>3 mo</td> <td class=\"centered\">40.62</td> <td class=\"centered\">1.23</td> <td class=\"centered\">39.71</td> <td class=\"centered\">1.20</td> </tr> <tr> <td>6 mo</td> <td class=\"centered\">43.76</td> <td class=\"centered\">1.29</td> <td class=\"centered\">42.68</td> <td class=\"centered\">1.38</td> </tr> <tr> <td>9 mo</td> <td class=\"centered\">45.75</td> <td class=\"centered\">1.28</td> <td class=\"centered\">44.69</td> <td class=\"centered\">1.30</td> </tr> <tr> <td>12 mo</td> <td class=\"centered\">47.00</td> <td class=\"centered\">1.31</td> <td class=\"centered\">45.81</td> <td class=\"centered\">1.29</td> </tr> <tr> <td>18 mo</td> <td class=\"centered\">48.31</td> <td class=\"centered\">1.36</td> <td class=\"centered\">47.27</td> <td class=\"centered\">1.36</td> </tr> <tr> <td>2 yr</td> <td class=\"centered\">49.19</td> <td class=\"centered\">1.39</td> <td class=\"centered\">48.02</td> <td class=\"centered\">1.29</td> </tr> <tr> <td>3 yr</td> <td class=\"centered\">50.63</td> <td class=\"centered\">1.38</td> <td class=\"centered\">49.25</td> <td class=\"centered\">1.36</td> </tr> <tr> <td>4 yr</td> <td class=\"centered\">50.91</td> <td class=\"centered\">1.39</td> <td class=\"centered\">50.10</td> <td class=\"centered\">1.37</td> </tr> <tr> <td>5 yr</td> <td class=\"centered\">51.41</td> <td class=\"centered\">1.37</td> <td class=\"centered\">50.55</td> <td class=\"centered\">1.32</td> </tr> <tr> <td>6 yr</td> <td class=\"centered\">51.40</td> <td class=\"centered\">1.41</td> <td class=\"centered\">50.52</td> <td class=\"centered\">1.31</td> </tr> <tr> <td>7 yr</td> <td class=\"centered\">52.24</td> <td class=\"centered\">1.52</td> <td class=\"centered\">51.46</td> <td class=\"centered\">1.35</td> </tr> <tr> <td>8 yr</td> <td class=\"centered\">52.35</td> <td class=\"centered\">1.40</td> <td class=\"centered\">51.64</td> <td class=\"centered\">1.44</td> </tr> <tr> <td>9 yr</td> <td class=\"centered\">52.58</td> <td class=\"centered\">1.44</td> <td class=\"centered\">51.87</td> <td class=\"centered\">1.33</td> </tr> <tr> <td>10 yr</td> <td class=\"centered\">53.16</td> <td class=\"centered\">1.41</td> <td class=\"centered\">52.15</td> <td class=\"centered\">1.50</td> </tr> <tr> <td>11 yr</td> <td class=\"centered\">53.25</td> <td class=\"centered\">1.53</td> <td class=\"centered\">52.64</td> <td class=\"centered\">1.39</td> </tr> <tr> <td>12 vr</td> <td class=\"centered\">53.71</td> <td class=\"centered\">1.52</td> <td class=\"centered\">53.01</td> <td class=\"centered\">1.50</td> </tr> <tr> <td>13 yr</td> <td class=\"centered\">54.14</td> <td class=\"centered\">1.57</td> <td class=\"centered\">53.70</td> <td class=\"centered\">1.37</td> </tr> <tr> <td>14 yr</td> <td class=\"centered\">54.59</td> <td class=\"centered\">1.30</td> <td class=\"centered\">54.04</td> <td class=\"centered\">1.39</td> </tr> <tr> <td>15 yr</td> <td class=\"centered\">54.95</td> <td class=\"centered\">1.51</td> <td class=\"centered\">54.39</td> <td class=\"centered\">1.34</td> </tr> <tr> <td>16 yr</td> <td class=\"centered\">55.37</td> <td class=\"centered\">1.11</td> <td class=\"centered\">54.64</td> <td class=\"centered\">1.16</td> </tr> <tr> <td>17 yr</td> <td class=\"centered\">55.77</td> <td class=\"centered\">1.32</td> <td class=\"centered\">54.78</td> <td class=\"centered\">1.35</td> </tr> <tr> <td>18 yrs and older</td> <td class=\"centered\">55.95</td> <td class=\"centered\">1.34</td> <td class=\"centered\">54.94</td> <td class=\"centered\">1.40</td> </tr> </tbody></table></div><div class=\"graphic_reference\">This material may not be reproduced, stored in a retrieval system, or transmitted in any form or by any means without the prior written permission of the publisher. Reproduced with permission from: Weaver DD, Christian JC, J Pediatr 1980; 96:990. Copyright © 1980 Mosby, Inc.</div><div id=\"graphicVersion\">Graphic 61299 Version 6.0</div></div></div>"},"61302":{"type":"graphic_picture","displayName":"Ocular cicatricial pemphigoid pathology PAS","title":"Ocular cicatricial pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ocular cicatricial pemphigoid</div><div class=\"cntnt\"><img style=\"width:389px; height:582px;\" src=\"images/DERM/61302_Ocular_cicatricial_PAS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Periodic acid Schiff, 64x. Note the glycogen (purple staining) in the epithelium, but the absence of formed goblet cells.<br> (B) Pathology specimen from normal conjunctiva demonstrating the presence of goblet cells.</div><div id=\"graphicVersion\">Graphic 61302 Version 1.0</div></div></div>"},"61303":{"type":"graphic_picture","displayName":"Biceps tendon tests","title":"Biceps tendon tests","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Biceps tendon tests</div><div class=\"cntnt\"><img style=\"width:514px; height:575px;\" src=\"images/EM/61303_Biceps_tendon_tests.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Injury or inflammation of the long head of the biceps tendon can cause anterior shoulder pain. In addition to direct palpation, these two simple tests allow for evaluation of this tendon. Either test is considered positive for bicipital tendinopathy or injury if it elicits pain in the bicipital groove.</div><div id=\"graphicVersion\">Graphic 61303 Version 2.0</div></div></div>"},"61305":{"type":"graphic_figure","displayName":"Strict glycemic control slows progression of retinopathy","title":"Strict glycemic control slows progression of retinopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Strict glycemic control slows progression of retinopathy</div><div class=\"cntnt\"><img style=\"width:440px; height:242px;\" src=\"images/ENDO/61305_Retinopathyandcontrol.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative incidence of progressive retinopathy in patients with type 1 diabetes and very mild to moderate nonproliferative retinopathy who were treated with either conventional (dashed line) or intensive (solid line) insulin therapy for nine years. There was an increasing benefit of intensive therapy over time, although intensive therapy was associated with transient worsening in the first year (p&lt;0.001).</div><div class=\"graphic_reference\">Data from: Diabetes Control and Complications Trial Research Group.&nbsp;The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977.</div><div id=\"graphicVersion\">Graphic 61305 Version 7.0</div></div></div>"},"61306":{"type":"graphic_table","displayName":"Causes of endometritis","title":"Classification of endometritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of endometritis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Acute</td>\n</tr>\n<tr>\n<td class=\"subtitle2_single\">1. Nonobstetric causes</td>\n</tr>\n<tr>\n<td class=\"indent1\">Pelvic inflammatory disease related to sexually transmitted organisms</td>\n</tr>\n<tr>\n<td class=\"indent1\">Pelvic inflammatory disease related to gynecologic procedures</td>\n</tr>\n<tr>\n<td class=\"subtitle2_single\">2. Obstetric causes</td>\n</tr>\n<tr>\n<td class=\"indent1\">Postpartum endometritis</td>\n</tr>\n<tr>\n<td class=\"indent1\">Retained products of conception</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Chronic</td>\n</tr>\n<tr>\n<td class=\"subtitle2_single\">1. Nonobstetric causes</td>\n</tr>\n<tr>\n<td class=\"sublist2_start\"> A. Infectious</td>\n</tr>\n<tr>\n<td class=\"sublist2\">Chlamydia</td>\n</tr>\n<tr><td class=\"sublist2\"> Tuberculosis</td></tr><tr><td class=\"sublist2\"> Other organisms related to cervicitis and pelvic inflammatory disease</td></tr>\n<tr>\n<td class=\"sublist2_start\"> B. Intrauterine foreign bodies or growths</td>\n</tr>\n<tr><td class=\"sublist2\"> Intrauterine device</td></tr><tr><td class=\"sublist2\"> Submucous leiomyoma</td></tr><tr><td class=\"indent1\">C. Radiation related</td></tr><tr>\n<td class=\"indent1\">D. Unknown etiology</td>\n</tr>\n<tr>\n<td class=\"subtitle2_single\">2. Obstetric causes</td>\n</tr>\n<tr>\n<td class=\"indent1\">Retained products of conception</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 61306 Version 1.0</div></div></div>"},"61307":{"type":"graphic_table","displayName":"Pregnancy rate per cycle for treatment","title":"Estimated pregnancy rate per cycle for treatment of unexplained infertility","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated pregnancy rate per cycle for treatment of unexplained infertility</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Intervention</td> <td class=\"subtitle1\">Pregnancy rate per cycle (%)</td> </tr> <tr> <td>Expectant management</td> <td class=\"centered\">1 to 3</td> </tr> <tr> <td>IUI</td> <td class=\"centered\">4 to 6</td> </tr> <tr> <td>Clomiphene citrate</td> <td class=\"centered\">4 to 6</td> </tr> <tr> <td>Clomiphene plus IUI</td> <td class=\"centered\">7 to 9</td> </tr> <tr> <td>Gonadotropin injection</td> <td class=\"centered\">4 to 10</td> </tr> <tr> <td>Gonadotropin injection plus IUI</td> <td class=\"centered\">9 to 16</td> </tr> <tr> <td>In vitro fertilization</td> <td class=\"centered\">30 to 45</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IUI: intrauterine insemination.</div><div id=\"graphicVersion\">Graphic 61307 Version 4.0</div></div></div>"},"61308":{"type":"graphic_table","displayName":"Dx asbestos disease A","title":"Criteria for diagnosis of nonmalignant lung disease related to asbestos","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for diagnosis of nonmalignant lung disease related to asbestos</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">1986 Guidelines</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Chest film (irregular opacities)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Pathology (College of American Pathologists)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Consistent time interval</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Occupational and environmental history</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Asbestos bodies or fibers</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">2004 Guidelines</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1_start\">Evidence of structural change, as demonstrated by one or more of the following:</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Imaging methods</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Histology (College of American Pathologists)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1_start\">Evidence of plausible causation, as demonstrated by one or more of the following:</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Occupational and environmental history of exposure (with plausible latency)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Markers of exposure (eg, plaques)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Recovery of asbestos bodies in lung tissue</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Comparison and notes</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Demonstrates the existence of a structural lesion consistent with the effects of asbestos. The criteria outlined in the 1986 were most explicit for asbestosis.</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Chest film, HRCT, and possibly future methods based on imaging. The 1986 guidelines specified ILO classification 1/1.</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Criteria for identifying asbestosis on microscopic examination of tissue are unchanged.</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Evidence of plausible causation implies that the temporal relationship, including latency, is plausible.</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>The 2004 guidelines are not limited to lung tissue, consider the role of BAL to be established, and deemphasize fibers because they are difficult to detect and a systematic analysis for asbestos fibers is not generally available.</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table></div><div class=\"graphic_reference\">Am J Respir Crit Care Med vol 170 pp 692, 2004; www.atsjournals.org.</div><div id=\"graphicVersion\">Graphic 61308 Version 1.0</div></div></div>"},"61309":{"type":"graphic_picture","displayName":"Lymphomatoid granuloma High","title":"Lymphomatoid granulomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphomatoid granulomatosis</div><div class=\"cntnt\"><img style=\"width:392px; height:294px;\" src=\"images/PULM/61309_Lymphomatoid_granuloma_High.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High magnification photomicrograph (original magnification 600x) demonstrates the presence of polymorphic lymphocytic infiltrate with occasional large atypical cells (arrow).</div><div id=\"graphicVersion\">Graphic 61309 Version 1.0</div></div></div>"},"61312":{"type":"graphic_picture","displayName":"Thumb spica cast 8","title":"Thumb spica cast: Step 8","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thumb spica cast: Step 8</div><div class=\"cntnt\"><img style=\"width:432px; height:375px;\" src=\"images/EM/61312_Thumb_spica_cast_8.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Once the stockinette ends are folded back, apply a final layer of casting material. Approximately three layers of fiberglass casting material is sufficient.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 61312 Version 6.0</div></div></div>"},"61313":{"type":"graphic_picture","displayName":"Dermoscopy basal cell carcinoma","title":"Dermoscopy of basal cell carcinomas","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of basal cell carcinomas</div><div class=\"cntnt\"><img style=\"width:547px; height:463px;\" src=\"images/DERM/61313_Dermoscopy_basal_cell_carc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Arborizing vessels.<br />(B) Spoke-wheel-like structures/concentric structures (solid squares) and leaf-like structures (dashed square).<br />(C) Multiple blue-gray nonaggregated globules and dots.<br />(D) Large blue-gray ovoid nest (solid arrow).</div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 61313 Version 2.0</div></div></div>"},"61318":{"type":"graphic_table","displayName":"Return-to-play protocol","title":"Graduated return-to-play protocol","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Graduated return-to-play protocol</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup span=\"2\" width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Aim</td> <td class=\"subtitle1\">Activity</td> <td class=\"subtitle1\">Goal of each step</td> </tr> <tr> <td class=\"centered\">1</td> <td>Symptom-limited activity</td> <td>Daily activities that do not provoke symptoms.</td> <td>Gradual reintroduction of work/school activities.</td> </tr> <tr> <td class=\"centered\">2</td> <td>Light aerobic exercise</td> <td>Walking or stationary cycling at slow to medium pace. No resistance training.</td> <td>Increase heart rate.</td> </tr> <tr> <td class=\"centered\">3</td> <td>Sport-specific exercise</td> <td>Running or skating drills. No head impact activities.</td> <td>Add movement.</td> </tr> <tr> <td class=\"centered\">4</td> <td>Non-contact training drills</td> <td>Harder training drills, eg, passing drills. May start progressive resistance training.</td> <td>Exercise, coordination and increased thinking.</td> </tr> <tr> <td class=\"centered\">5</td> <td>Full contact practice</td> <td>Following medical clearance, participate in normal training activities.</td> <td>Restore confidence and assess functional skills by coaching staff.</td> </tr> <tr> <td class=\"centered\">6</td> <td>Return to sport</td> <td>Normal game play.</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: An initial period of 24 to 48 hours of both relative physical rest and cognitive rest is recommended before beginning the RTS progression. There should be at least 24 hours (or longer) for each step of the progression. If any symptoms worsen during exercise, the athlete should go back to the previous step. Resistance training should be added only in the later stages (stage 3 or 4 at the earliest). If symptoms are persistent (eg, more than 10 to 14 days in adults or more than 1 month in children), the athlete should be referred to a health care professional who is an expert in the management of concussion.</div><div class=\"graphic_footnotes\">RTS: return to sport.</div><div class=\"graphic_reference\">From: McCrory P, Meeuwisse W, Dvořák J, et al. Consensus statement on concussion in sport—the 5th international conference on concussion in sport held in Berlin, October 2016. Br J Sports Med 2017; 51:838. Reproduced with permission from BMJ Publishing Group Ltd. Copyright © 2017.</div><div id=\"graphicVersion\">Graphic 61318 Version 12.0</div></div></div>"},"61320":{"type":"graphic_figure","displayName":"Dissection bladder off uterus","title":"Sharp dissection of the bladder from the lower uterine segment during hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Sharp dissection of the bladder from the lower uterine segment during hysterectomy</div><div class=\"cntnt\"><img style=\"width:491px; height:449px;\" src=\"images/OBGYN/61320_Dissection_bladder_off_uter.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 61320 Version 2.0</div></div></div>"},"61321":{"type":"graphic_picture","displayName":"Radical vulvectomy4","title":"Radical vulvectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radical vulvectomy</div><div class=\"cntnt\"><img style=\"width:432px; height:425px;\" src=\"images/OBGYN/61321_Radical_vulvectomy4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The right crus has been clamped ready for transection and ligation with suture.</div><div class=\"graphic_reference\">Courtesy of C. William Helm, MD.</div><div id=\"graphicVersion\">Graphic 61321 Version 3.0</div></div></div>"},"61322":{"type":"graphic_diagnosticimage","displayName":"Lymphoma bone Xray","title":"Lymphoma of bone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphoma of bone</div><div class=\"cntnt\"><img style=\"width:279px; height:361px;\" src=\"images/HEME/61322_Lymphoma_bone_Xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral plain film of the knee demonstrates a &quot;moth-eaten&quot; pattern in the proximal tibia at the metadiaphyseal junction, along with bone destruction (large arrow). An associated periosteal reaction is present (small arrow).</div><div class=\"graphic_reference\">Courtesy of Heather Pacholke, MD.</div><div id=\"graphicVersion\">Graphic 61322 Version 2.0</div></div></div>"},"61324":{"type":"graphic_table","displayName":"Metabolic myopathy and rhabdo","title":"Metabolic myopathies associated with rhabdomyolysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Metabolic myopathies associated with rhabdomyolysis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Disorders of glycogenolysis</td> </tr> <tr> <td>Myophosphorylase deficiency (McArdle disease)</td> </tr> <tr> <td>Phosphorylase kinase deficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Disorders of glycolysis</td> </tr> <tr> <td>Phosphofructokinase deficiency</td> </tr> <tr> <td>Phosphoglycerate kinase deficiency</td> </tr> <tr> <td>Phosphoglycerate mutase deficiency</td> </tr> <tr> <td>Lactate dehydrogenase deficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Disorders of lipid metabolism</td> </tr> <tr> <td>Carnitine palmitoyltransferase deficiency</td> </tr> <tr> <td>Carnitine deficiency</td> </tr> <tr> <td>Short-chain acyl-CoA dehydrogenase deficiency</td> </tr> <tr> <td>Long-chain acyl-CoA dehydrogenase deficiency</td> </tr> <tr> <td>Lipin-1 deficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Disorders of purine metabolism</td> </tr> <tr> <td>Myoadenylate deaminase deficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Other defects</td> </tr> <tr> <td>Malignant hyperthermia susceptibility caused by RYR1 gene mutations</td> </tr> <tr> <td>Alpha-methylacyl-CoA racemase (AMACR) deficiency</td> </tr> <tr> <td>Brody myopathy (Calcium adenosine triphosphatase deficiency)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 61324 Version 4.0</div></div></div>"},"61325":{"type":"graphic_diagnosticimage","displayName":"Retained surgical sponge of the liver on computed tomography","title":"Retained surgical sponge of the liver on computed tomography","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Retained surgical sponge of the liver on computed tomography</div><div class=\"cntnt\"><img style=\"width:504px; height:339px;\" src=\"images/SURG/61325_Gossypiboma_liver_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Unenhanced computed tomography of the abdomen at level of liver shows a mass containing mixed areas of high and low attenuation (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Manoel de Souza Rocha. Originally published in Manzella A, Filho PB, Albuquerque E, et al. Imaging of gossypibomas: Pictorial review. AJR Am J Roentgenol 2009; 193:S94.</div><div id=\"graphicVersion\">Graphic 61325 Version 3.0</div></div></div>"},"61326":{"type":"graphic_picture","displayName":"Budding yeast","title":"Budding yeast","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Budding yeast</div><div class=\"cntnt\"><img style=\"width:576px; height:429px;\" src=\"images/OBGYN/61326_Buddingyeast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Budding yeast representing <EM>Candida glabrata</EM>.</div><div id=\"graphicVersion\">Graphic 61326 Version 3.0</div></div></div>"},"61327":{"type":"graphic_diagnosticimage","displayName":"TEE hemomediastinum","title":"Transesophageal echocardiogram of a traumatic hemomediastinum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiogram of a traumatic hemomediastinum</div><div class=\"cntnt\"><img style=\"width:393px; height:360px;\" src=\"images/CARD/61327_TEE_hemomediastinum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this patient, an increased distance between transesophageal echocardiogram probe and the anteromedial aortic wall, and the presence of ultrasound signal consistent with blood between the posterolateral wall of the aortic isthmus and left visceral pleura indicated the presence of a mild hemomediastinum (arrowheads).</div><div class=\"graphic_reference\">Courtesy of P Vignon, MD.</div><div id=\"graphicVersion\">Graphic 61327 Version 4.0</div></div></div>"},"61328":{"type":"graphic_diagnosticimage","displayName":"AP view ankle","title":"AP view of the ankle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AP view of the ankle</div><div class=\"cntnt\"><img style=\"width:288px; height:540px;\" src=\"images/EM/61328_AP_view_ankle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Taken to better assess the fracture, this radiograph clearly demonstrates the displaced position of the avulsed fragment (arrow). This fracture requires surgical referral.</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 61328 Version 4.0</div></div></div>"},"61331":{"type":"graphic_table","displayName":"Evaluation of comorbidities","title":"Evaluation of conditions that co-occur with asthma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of conditions that co-occur with asthma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Diagnosis </td> <td class=\"subtitle1\">Clinical features </td> <td class=\"subtitle1\">Testing </td> </tr> <tr> <td>Allergic bronchopulmonary aspergillosis</td> <td> <p>History of asthma or cystic fibrosis</p> <p>Cough productive of phlegm with \"bronchial casts\"</p> </td> <td> <p>Eosinophilia</p> <p>IgE: &#62;1000 IU/mL</p> <p>Skin test: positive for aspergillus</p> <p>Aspergillus IgG: 2 fold elevation</p> <p>HRCT: mucous plugging, proximal bronchiectasis</p> </td> </tr> <tr> <td>Cardiac disease</td> <td>Crackles or wheezes</td> <td> <p>B type natriuretic peptide: elevated</p> <p>Chest radiograph: increased interstitial opacities, &#177;cardiomegaly</p> <p>Echocardiogram</p> </td> </tr> <tr> <td>Chronic eosinophilic pneumonia</td> <td> <p>Asthma predates or develops in over 50 percent of patients</p> <p>Fever, weight loss, and night sweats are common</p> </td> <td> <p>Peripheral blood: &#177;eosinophilia</p> <p>Chest radiograph: bilateral peripheral opacities</p> <p>BAL: eosinophilia &#62;40 pecent</p> </td> </tr> <tr> <td>Eosinophilic granulomatosis polyangiitis (Churg Strauss)</td> <td> <p>Cutaneous, neurologic, or other evidence vasculitis</p> <p>Paranasal sinus disease</p> </td> <td> <p>ANCA: positive in 50 percent of patients</p> <p>Eosinophilia: &#62;10 percent</p> <p>Chest radiograph: patchy opacities</p> <p>Biopsy: granulomatous angiitis</p> </td> </tr> <tr> <td>COPD</td> <td>Smoking history</td> <td>PFTs: irreversible airflow obstruction and sometimes low DLCO</td> </tr> <tr> <td>GERD</td> <td>May complain of chest tightness/restriction or nocturnal choking</td> <td> <p>Response to empiric treatment with PPI</p> <p>pH probe monitoring: acid reflux</p> <p>Spirometry normal, methacholine negative*</p> </td> </tr> <tr> <td>Obstructive sleep apnea</td> <td> <p>Daytime hypersomnolence</p> <p>Nocturnal choking</p> <p>Snoring</p> </td> <td>Polysomnogram: elevated&nbsp;apnea hypopnea&nbsp;index</td> </tr> <tr> <td>Tobacco smoke exposure</td> <td>History</td> <td>&nbsp;</td> </tr> <tr> <td>Paradoxical vocal fold motion</td> <td> <p>Hoarseness/stridor (can be inspiratory and/or expiratory)</p> <p>Symptoms provoked by exercise</p> </td> <td> <p>Flow volume loop: slowing on inspiration</p> <p>Direct laryngoscopy (possibly during exercise or methacholine challenge): abnormal cord motion</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ANCA: antineutrophil cytoplasmic antibodies; BAL: bronchoalveolar lavage; CTD: connective tissue disease; DLCO: diffusing capacity; GERD: gastroesophageal reflux disease; HRCT: high resolution computed tomography; PFTs: pulmonary function testing; PPI: proton pump inhibitor.<br />* GERD can also coexist with asthma in which case methacholine challenge would be positive.</div><div id=\"graphicVersion\">Graphic 61331 Version 3.0</div></div></div>"},"61332":{"type":"graphic_diagnosticimage","displayName":"Malignant mesothelioma IV CT","title":"Malignant mesothelioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malignant mesothelioma</div><div class=\"cntnt\"><img style=\"width:324px; height:317px;\" src=\"images/PULM/61332_Malignant_mesothelioma_IV_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan with lung window settings shows fine nodularity throughout the contralateral left lung. The patient proves to be unresectable because of hematogenous dissemination of tumor.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 61332 Version 3.0</div></div></div>"},"61334":{"type":"graphic_table","displayName":"Usual interstitial pneumonitis","title":"Causes of usual interstitial pneumonitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of usual interstitial pneumonitis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Idiopathic pulmonary fibrosis (UIP pattern required to confirm the diagnosis)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Asbestosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Chronic aspiration pneumonia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Connective tissue diseases</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">UIP-like reaction (associated with other specific histologic findings)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Hypersensitivity pneumonitis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Lymphocytic interstitial pneumonia</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Chronic radiation pneumonitis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Chronic eosinophilic pneumonia</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Infections</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Hemosiderosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Hermansky-Pudlak syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Neurofibromatosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Alveolar proteinosis</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 61334 Version 1.0</div></div></div>"},"61335":{"type":"graphic_table","displayName":"Complications EVL vs ES","title":"Complications of endoscopic variceal ligation versus endoscopic sclerotherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of endoscopic variceal ligation versus endoscopic sclerotherapy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Study</td>\n\n      <td class=\"subtitle1\">EVL, percent</td>\n\n      <td class=\"subtitle1\">ES, percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Jensen 1993</td>\n\n      <td>4/39 (10)</td>\n\n      <td>8/37 (22)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Laine 1993</td>\n\n      <td>22/39 (56)</td>\n\n      <td>9/38 (24)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lo 1995</td>\n\n      <td>2/61 (4)</td>\n\n      <td>11/59 (19)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Stiegman 1992</td>\n\n      <td>1/64 (2)</td>\n\n      <td>14/65 (22)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hou 1995</td>\n\n      <td>3/67 (4)</td>\n\n      <td>15/67 (22)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Gimson 1993</td>\n\n      <td>1/54 (2)</td>\n\n      <td>5/49 (10)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lo 1997</td>\n\n      <td>2/37 (5)</td>\n\n      <td>10/34 (29)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lo 1995</td>\n\n      <td>1/30 (37)</td>\n\n      <td>6/27 (22)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Baroncini 1997</td>\n\n      <td>6/57 (11)</td>\n\n      <td>17/54 (31)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Avgerinos 1997</td>\n\n      <td>13/37 (35)</td>\n\n      <td>24/40 (60)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\">Total</td>\n\n      <td>55/487 (11)</td>\n\n      <td>119/470 (25)</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 61335 Version 1.0</div></div></div>"},"61338":{"type":"graphic_figure","displayName":"Rumack-Matthews acetaminophen nomogram","title":"Severity of acetaminophen intoxication","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severity of acetaminophen intoxication</div><div class=\"cntnt\"><img style=\"width:381px; height:276px;\" src=\"images/NEPH/61338_Acetaminophen_nomogram.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Rumack-Matthews nomogram summarizes the relationship between plasma acetaminophen concentration (in &#181;g/mL or &#181;mol/L), the time after drug ingestion, and the risk of hepatic toxicity. The thick diagonal line of possible hepatic toxicity represents a 25 percent likelihood of disease. A relatively low level (such as 10 &#181;g/mL) is safe soon after ingestion, but associated with appreciable risk at 24 hours since it reflects a high initial load which has now distributed into the tissues.</div><div class=\"graphic_reference\">Adapted from Rumack, BH, Matthews, H, Pediatrics 1975; 55:873.</div><div id=\"graphicVersion\">Graphic 61338 Version 2.0</div></div></div>"},"61345":{"type":"graphic_picture","displayName":"Congenital cutaneous mastocytosis in an infant","title":"Congenital cutaneous mastocytosis in an infant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital cutaneous mastocytosis in an infant</div><div class=\"cntnt\"><img style=\"width:396px; height:304px;\" src=\"images/ALLRG/61345_Masto_cutaneous_infant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this infant with cutaneous mastocytosis, brown-red plaques were spread over the whole body, including the face, but not&nbsp;affecting mucosal tissues.&nbsp;Episodic flushing and&nbsp;bronchoconstriction were triggered by heat and breastfeeding.</div><div class=\"graphic_reference\">Reproduced with permission from: Mann C, Sepp N, Simma B. Congenital cutaneous mastocytosis. J Pediatr 2004; 145:134. Copyright ©2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 61345 Version 4.0</div></div></div>"},"61346":{"type":"graphic_table","displayName":"Causes neonatal death","title":"Leading causes of neonatal death in the United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Leading causes of neonatal death in the United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Neonatal deaths</td> <td class=\"subtitle1\">Percentage of neonatal deaths</td> </tr> <tr> <td>Disorders related to prematurity and low birth weight</td> <td>4318</td> <td>23.0</td> </tr> <tr> <td>Congenital malformations, chromosomal abnormalities</td> <td>4144</td> <td>22.1</td> </tr> <tr> <td>Maternal complications</td> <td>1394</td> <td>7.4</td> </tr> <tr> <td>Placenta, cord, and membrane complications</td> <td>1049</td> <td>5.6</td> </tr> <tr> <td>Respiratory distress</td> <td>929</td> <td>4.9</td> </tr> <tr> <td>Bacterial sepsis</td> <td>737</td> <td>3.9</td> </tr> <tr> <td>Intrauterine hypoxia and birth asphyxia</td> <td>589</td> <td>3.1</td> </tr> <tr> <td>Neonatal hemorrhage</td> <td>563</td> <td>3.0</td> </tr> <tr> <td>Atelectasis</td> <td>483</td> <td>2.6 </td> </tr> <tr> <td>Necrotizing enterocolitis</td> <td>313</td> <td>1.7</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Neonatal deaths: death within 28 days of birth.</div><div class=\"graphic_reference\">Data adapted from: the Centers for Disease Control and Prevention, 2000.</div><div id=\"graphicVersion\">Graphic 61346 Version 3.0</div></div></div>"},"61348":{"type":"graphic_figure","displayName":"Right aortic arch LL","title":"Right aortic arch LL","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Right aortic arch LL</div><div class=\"cntnt\"><img style=\"width:561px; height:372px;\" src=\"images/PEDS/61348_Right_aortic_arch_LL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Right aortic arch with aberrant left subclavian artery and left ligamentum arteriosum. Kommerell's diverticulum is the bulbous vascular structure giving rise to the left subclavian artery and ligamentum. The proximity of Kommerell's diverticulum to the trachea and esophagus is apparent. <br />(B) A computer reconstructed image of a computed tomography angiogram viewed from posterior. The star represents the location of the trachea and esophagus (not shown in this projection). The Diverticulum of Kommerell demonstrates a change in caliber as it continues as the aberrant left subclavian artery.</div><div class=\"graphic_footnotes\">DK: Diverticulum of Kommerell; RAA: right aortic arch; DAo: descending aorta.</div><div class=\"graphic_reference\">Figure A) Reproduced with permission from: Fyler D, Nadas AS. Nadas' Pediatric Cardiology, 1st ed, Hanley and Belfus, Philadelphia 1992. Copyright ©1992 Elsevier.<br />Figure B) Courtesy of Laureen M Sena, MD.</div><div id=\"graphicVersion\">Graphic 61348 Version 3.0</div></div></div>"},"61349":{"type":"graphic_figure","displayName":"Zipper entrapment release","title":"Cloth cutting to release skin grasped by a zipper","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cloth cutting to release skin grasped by a zipper</div><div class=\"cntnt\"><img style=\"width:306px; height:529px;\" src=\"images/EM/61349_Zipperentraprelease2011.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The clinician releases the entrapped skin by cutting the cloth as indicated in the figure. Once the cloth is cut, the zipper teeth will easily disengage from the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: Fein JA, Zderic SA. Management of zipper injuries. In: Textbook of Pediatric Emergency Procedures, 2nd Edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 61349 Version 13.0</div></div></div>"},"61350":{"type":"graphic_table","displayName":"Allergenic herbal ingredients","title":"Potentially allergenic herbal ingredients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potentially allergenic herbal ingredients</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Drug</td>\n\n      <td class=\"subtitle1\">Effect</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Agnus Castus</td>\n\n      <td>Allergic effects reported</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Angelica</td>\n\n      <td>Furanocoumarins, photosensitivity, contact allergy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Aniseed</td>\n\n      <td>Furanocoumarins, photosensitivity, contact allergy</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Apricot</td>\n\n      <td>Contact allergy, kernels</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Arnica</td>\n\n      <td>Contact allergy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Artichoke</td>\n\n      <td>Sesquiterpene lactone constituents</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Asafoetida</td>\n\n      <td>Irritant gum, contact allergy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Boneset</td>\n\n      <td>Sesquiterpene lactone constituents</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cassia</td>\n\n      <td>Allergic reactions, mainly contact</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Celery</td>\n\n      <td>Furanocoumarins, photosensitivity</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Chamomile, German</td>\n\n      <td>Sesquiterpene lactone constituents</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Chamomile, Roman</td>\n\n      <td>Sesquiterpene lactone constituents</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cinnamon</td>\n\n      <td>Contact allergy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cornsilk</td>\n\n      <td>Allergic reactions</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cowslip</td>\n\n      <td>Allergic reactions</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Dandelion</td>\n\n      <td>Sesquiterpene lactone constituents</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Elecampane</td>\n\n      <td>Sesquiterpene lactone constituents</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Euphorbia</td>\n\n      <td>Histamine potentiating properties</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Feverfew</td>\n\n      <td>Sesquiterpene lactone constituents</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fucus</td>\n\n      <td>Iodine may aggravate/trigger acne</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Garlic</td>\n\n      <td>Sulphur-containing compounds, allergic reaction</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Gravel root</td>\n\n      <td>Sesquiterpene lactone constituents</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Guaicum</td>\n\n      <td>Irritant resin</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Holy Thistle</td>\n\n      <td>Sesquiterpene lactone constituents</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hops</td>\n\n      <td>Contact allergy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hydrangea</td>\n\n      <td>Contact allergy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hydrocotyle</td>\n\n      <td>Photosensitivity</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Juniper</td>\n\n      <td>Contact allergy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lady's Slipper</td>\n\n      <td>Contact allergy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Meadowsweet</td>\n\n      <td>Potentiation of histamine bronchospastic properties</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Motherwort</td>\n\n      <td>Dermatitis, photosensitization</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Parsley</td>\n\n      <td>Furanocoumarins, photosensitivity</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pilewort</td>\n\n      <td>Contact allergy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Plantain</td>\n\n      <td>Contact allergy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pleurisy root</td>\n\n      <td>Contact allergy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pulsatilla</td>\n\n      <td>Contact allergy, protoanemonin</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Rosemary</td>\n\n      <td>Dermatitis, photosensitization</td>\n\n    </tr>\n\n    <tr>\n\n      <td>St. Johns' Wort</td>\n\n      <td>Photodermatitis, hypericin</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Tansy</td>\n\n      <td>Sesquiterpene lactone constituents</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Wild carrot</td>\n\n      <td>Furanocoumarins, photosensitivity</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Yarrow</td>\n\n      <td>Sesquiterpene lactone constituents</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted with permission from Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals, The Pharmaceutical Press, London 1996, p.284.</div><div id=\"graphicVersion\">Graphic 61350 Version 4.0</div></div></div>"},"61351":{"type":"graphic_waveform","displayName":"LV pressure echo Doppler MV","title":"Doppler-derived mitral flow and left ventricular pressure","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Doppler-derived mitral flow and left ventricular pressure</div><div class=\"cntnt\"><img style=\"width:521px; height:331px;\" src=\"images/CARD/61351_LV_pressure_echo_Doppler_MV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Simultaneously recorded left ventricular pressure, with the change in pressure over time (dp/dt) and mitral valve inflow velocity derived from Doppler echocardiography. The peak early filling (PE) corresponds to the early part of diastole while peak atrial filling (PA) is the flow velocity increase due to atrial contraction.</div><div class=\"graphic_reference\">Redrawn from Kern MJ (Ed). Cardiac Catheterization Handbook, 2nd ed, Mosby-Year Book, St. Louis, 1995.</div><div id=\"graphicVersion\">Graphic 61351 Version 3.0</div></div></div>"},"61355":{"type":"graphic_figure","displayName":"C3a concentrations in pts on HD","title":"Figure showing plasma C3a concentrations in patients on hemodialysis with different dialyzers","html":"<div class=\"graphic\"><div style=\"width: 650px\" class=\"figure\"><div class=\"ttl\">Figure showing plasma C3a concentrations in patients on hemodialysis with different dialyzers</div><div class=\"cntnt\"><img style=\"width:630px; height:412px;\" src=\"images/NEPH/61355_C3a_activation_in_hemodialy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Venous plasma levels of C3a antigen during hemodialysis with four different types of dialyzers. Complement activation was greatest with cuprophan, intermediate with cellulose acetate, and minimal with cuprophan membranes reused for the third time or with polyacrylonitrile.</div><div class=\"graphic_reference\">Data from: Chenoweth DE. Complement activation during hemodialysis: Clinical observations, proposed mechanisms, and theoretical implications. Artif Organs 1984; 8:281.</div><div id=\"graphicVersion\">Graphic 61355 Version 3.0</div></div></div>"},"61356":{"type":"graphic_algorithm","displayName":"Hyperglycemic complications","title":"Mechanisms of hyperglycemia-induced vascular complications","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Mechanisms of hyperglycemia-induced vascular complications</div><div class=\"cntnt\"><img style=\"width:484px; height:301px;\" src=\"images/NEPH/61356_Hyperglycemic_complications.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flow diagram showing how too much glucose may lead to the long-term complications of diabetes.</div><div class=\"graphic_footnotes\">AGE: advanced glycosylation endproducts; DAG: diacylglycerol; PKC: protein kinase C.</div><div id=\"graphicVersion\">Graphic 61356 Version 2.0</div></div></div>"},"61357":{"type":"graphic_table","displayName":"Rapid overview adrenal crisis in children and adolescents","title":"Rapid overview: Adrenal crisis in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid overview: Adrenal crisis in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Signs and symptoms that may indicate adrenal crisis:</td> </tr> <tr> <td>&#8226; Hypotension or shock, particularly if disproportionate to apparent underlying illness</td> </tr> <tr> <td class=\"sublist1_start\">&#8226; Serum electrolyte abnormalities:</td> </tr> <tr> <td class=\"sublist2\">- Hyponatremia with or without hyperkalemia</td> </tr> <tr> <td class=\"sublist2\">- Metabolic acidosis</td> </tr> <tr> <td class=\"sublist2\">- Hypoglycemia</td> </tr> <tr> <td>&#8226; Vomiting and diarrhea, sometimes with severe abdominal pain or unexplained fever, weight loss, and anorexia</td> </tr> <tr> <td class=\"subtitle1_single\">Consider the diagnosis in:</td> </tr> <tr> <td>&#8226; <em>Any patient with known disorders of adrenal insufficiency</em> (eg, congenital adrenal hyperplasia), especially if exposed to stress (illness)</td> </tr> <tr> <td>&#8226; Other patients presenting with the above signs, especially with <em>hyperpigmentation or vitiligo</em></td> </tr> <tr> <td>&#8226; <em>Critically ill patients with septic shock</em>, who are unresponsive to fluid resuscitation and inotropic medications (in this case, adrenal crisis can be caused by bilateral adrenal hemorrhage)</td> </tr> <tr> <td>&#8226; Patients on or withdrawing from <em>chronic treatment with corticosteroids</em>, especially if exposed to stress</td> </tr> <tr> <td>&#8226; Patients with <em>other autoimmune endocrine deficiencies</em>, such as type 1 diabetes mellitus, hypothyroidism, or gonadal failure</td> </tr> <tr> <td class=\"sublist1_start\">&#8226; <em>Neonates with the above symptoms and signs</em> should prompt consideration of the diagnosis of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, or (very rarely) other causes of adrenal insufficiency</td> </tr> <tr> <td class=\"sublist2\">- In the United States, 21-hydroxylase deficiency is part of the newborn screen in all states, so most affected infants will be diagnosed prior to presentation with adrenal crisis. Adrenal crisis usually presents between the first and fourth week of life. Affected females will have ambiguous genitalia; males usually have no obvious genital abnormalities.</td> </tr> <tr> <td class=\"sublist2\">- The presentation of adrenal crisis in an infant may mimic that of pyloric stenosis. However, infants with pyloric stenosis typically have hypokalemic alkalosis rather than the hyperkalemic acidosis that is typical of adrenal crisis.</td> </tr> <tr> <td class=\"subtitle1_single\">Evaluation:</td> </tr> <tr> <td>&#8226; If adrenal crisis is suspected, then patients should be treated empirically with stress doses of glucocorticoids, as outlined below</td> </tr> <tr> <td>&#8226; Baseline blood samples should be drawn for subsequent testing for electrolytes, glucose, cortisol and other adrenal steroids, ACTH, and renin, prior to the administration of corticosteroids. Treatment should not be delayed pending results.</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment:</td> </tr> <tr> <td>&#8226; <em>Shock:</em> give a bolus of normal saline (0.9%), 20 mL/kg IV over one hour. If shock is persistent, repeat up to a total of 60 mL/kg within one hour.</td> </tr> <tr> <td>&#8226; <em>Hypoglycemia:</em> give an initial bolus of 0.5 to 1&nbsp;g/kg of dextrose IV (maximum single dose 25 g). The glucose bolus is infused slowly, at 2 to 3 mL per minute</td> </tr> <tr> <td class=\"sublist2\">-&nbsp;For all age groups, this&nbsp;can be given as 25% dextrose solution (D25W), 2 to 4 mL/kg. [D25W is 250 mg dextrose/mL]</td> </tr> <tr> <td class=\"sublist2\">-&nbsp;An alternative for infants&nbsp;and children up to 12 years of age is to use 10% dextrose solution (D10W),&nbsp;5 to 10&nbsp;mL/kg. [D10W is 100 mg dextrose/mL]</td> </tr> <tr> <td class=\"sublist1_start\">&#8226; <em>Stress glucocorticoids:</em> administer hydrocortisone (Solu-Cortef) as a bolus, using a dose of 50 to 100 mg/m<sup>2</sup> IV.*<sup>&#916;&nbsp;</sup> If body surface area is not available, age-based dosing may be used as follows:</td> </tr> <tr> <td class=\"sublist2\">- Infants and toddlers, 0 to 3 years old: 25 mg IV</td> </tr> <tr> <td class=\"sublist2\">- Children 3 to 12 years: 50 mg IV</td> </tr> <tr> <td class=\"sublist2\">- Children and adolescents 12 years and older: 100 mg IV</td> </tr> <tr> <td>&#8226; Continue glucocorticoids at the same dose given as a constant rate or as four divided doses over the following 24 hours</td> </tr> <tr> <td class=\"sublist1_start\">&#8226; <em>Electrolytes:</em> if hyperkalemia is present, perform EKG to evaluate:</td> </tr> <tr> <td class=\"sublist2\">- EKG changes consistent with hyperkalemia: initially a tall peaked T wave with shortened QT interval, followed by progressive lengthening of the PR interval and QRS duration</td> </tr> <tr> <td class=\"sublist2\">- If these changes are present, treat with insulin and glucose infusion, with or without other measures to treat hyperkalemia. (Refer to topic on the management of hyperkalemia in children).</td> </tr> <tr> <td class=\"sublist2\">- Monitor and treat other electrolyte abnormalities and fluid balance</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Dosing based on body surface area (BSA) is preferred if&nbsp;the patient's BSA is known, or if the BSA can be promptly calculated based on measured height and weight. A BSA calculator is available in the UpToDate program.<br />Δ Hydrocortisone also may be given intramuscularly (IM) if intravenous access is not readily available.</div><div id=\"graphicVersion\">Graphic 61357 Version 21.0</div></div></div>"},"61358":{"type":"graphic_table","displayName":"Tests for disorders mimicking mast cell activation","title":"Laboratory tests to differentiate mast cell disorders from other disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory tests to differentiate mast cell&nbsp;disorders&nbsp;from other disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td> <p>Plasma-free metanephrine</p> Urinary vanillylmandelic acid</td> <td>Elevated in pheochromocytoma, not systemic anaphylaxis.</td> </tr> <tr> <td> <p>Serum serotonin</p> Urinary 5-hydroxyindoleacetic acid</td> <td>Elevated in carcinoid syndrome, not systemic anaphylaxis.</td> </tr> <tr> <td>Serum vasointestinal polypeptide hormone panel: Pancreastatin, vasoactive intestinal peptide, substance P, neurokinin</td> <td>To rule out gastrointestinal tumors or medullary carcinoma of the thyroid, which can secrete these vasoactive mediators.</td> </tr> <tr> <td> <p><span style=\"color: black;\">Plasma kallikrein</span></p> <span style=\"color: black;\">High molecular weight kininogen</span></td> <td>To assess activation of the contact pathway, leading to production of bradykinin.</td> </tr> <tr> <td>Plasma C3a or C5a</td> <td>To assess activation of the complement pathway, leading to production of these anaphylatoxins.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">C3a: complement component 3a; C5a: complement component 5a.</div><div id=\"graphicVersion\">Graphic 61358 Version 5.0</div></div></div>"},"61359":{"type":"graphic_table","displayName":"WHO mineral mix","title":"Composition of mineral mix solution used in the treatment of malnutrition in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Composition of mineral mix solution used in the treatment of malnutrition in children</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Substance</td>\n\n      <td class=\"subtitle1\">Amount</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Potassium chloride </td>\n\n      <td>89.5 g</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Tripotassium citrate</td>\n\n      <td>32.4 g</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Magnesium chloride (MgCl<sub>2</sub> - 6H<sub>2</sub>O)</td>\n\n      <td>30.5 g</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Zinc acetate</td>\n\n      <td>3.3 g</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Copper sulfate</td>\n\n      <td>0.56 g</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sodium selenate*</td>\n\n      <td>10 mg</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Potassium iodide*</td>\n\n      <td>5 mg</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Water to make</td>\n\n      <td>1000 mL</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* If it is not possible to weigh very small amounts accurately, this substance may be omitted.</div><div class=\"graphic_reference\">Reproduced with permission from: Management of Severe Malnutrition: A Manual for Physicians and other Senior Health Workers. World Health Organization, Geneva, 1999. Copyright © 1999 World Health Organization.</div><div id=\"graphicVersion\">Graphic 61359 Version 2.0</div></div></div>"},"61361":{"type":"graphic_figure","displayName":"Epley maneuver","title":"Particle repositioning maneuver","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Particle repositioning maneuver</div><div class=\"cntnt\"><img style=\"width:536px; height:347px;\" src=\"images/PC/61361_Epley_maneuver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In patients with benign paroxysmal positional vertigo (BPPV)&nbsp;due to posterior canal&nbsp;canalithiasis, the particle repositioning maneuver encourages the calcium carbonate debris to migrate toward the common crus of the anterior and posterior canals and exit into the utricular cavity. Step 1 is the standard Dix-Hallpike positioning test. Note that this illustration demonstrates the maneuver for right-sided BPPV.</div><div class=\"graphic_reference\">Modified and reproduced with permission from: Foster CA, Baloh RW. Episodic vertigo. In: Rakel (Ed), Conn's Current Therapy, 47th ed, WB Saunders, Philadelphia, 1995. p.873.</div><div id=\"graphicVersion\">Graphic 61361 Version 5.0</div></div></div>"},"61363":{"type":"graphic_diagnosticimage","displayName":"Endstage scleroderma lung PA","title":"Endstage scleroderma lung","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endstage scleroderma lung</div><div class=\"cntnt\"><img style=\"width:359px; height:390px;\" src=\"images/PULM/61363_Endstage_scleroderma_lung_P.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows small lung volumes, coarse asymmetric reticulation of the lungs with particular involvement of the right upper lobe. Note the markedly dilated transverse colon with fecal impaction due to lack of bowel motility.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 61363 Version 3.0</div></div></div>"},"61364":{"type":"graphic_table","displayName":"Requirements for primary PCI","title":"ACCF/AHA/SCAI expert consensus document requirements for primary PCI","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACCF/AHA/SCAI expert consensus document requirements for primary PCI</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Avoid intervention in patients with:</td> </tr> <tr> <td> <ul> <li>&#62;50 percent diameter stenosis of left main artery proximal to infarct-related lesion, especially if the area in jeopardy is relatively small and overall LV function is not severely impaired </li> <li>Long, calcified, or severely angulated target lesions at high risk for PCI failure with TIMI flow grade 3 present during initial diagnostic angiography </li> <li>Lesions in other than the infarct artery (unless they appeared to be flow limiting in patients with hemodynamic instability or ongoing symptoms) </li> <li>Lesions with TIMI flow grade 3 that are not amenable to stenting in patients with left main or 3-vessel disease that will require coronary bypass surgery </li> <li>Culprit lesions in more distal branches jeopardizing only a modest amount of myocardium when there is more proximal disease that could be worsened by attempted intervention </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Transfer emergently for coronary bypass surgery patients with:</td> </tr> <tr> <td> <ul> <li>High-grade left main or 3-vessel coronary disease with clinical or hemodynamic instability after successful or unsuccessful PCI of an occluded vessel and preferably with IABP support </li> <li>Failed or unstable PCI result and ongoing ischemia, with IABP support during transfer </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IABP: intra-aortic balloon pump; LV: left ventricular; PCI: percutaneous coronary intervention; SCAI: Society for Cardiovascular Angiography and Interventions; TIMI: Thrombolysis In Myocardial Infarction.</div><div class=\"graphic_reference\">From: Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58:e44. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 61364 Version 1.0</div></div></div>"},"61365":{"type":"graphic_picture","displayName":"Curved gram negative bacilli","title":"Curved gram-negative bacilli","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Curved gram-negative bacilli</div><div class=\"cntnt\"><img style=\"width:382px; height:518px;\" src=\"images/ID/61365_Curved_Gram_neg_bacilli.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Gram stain of <EM>Campylobacter jejuni</EM> in stool. Note the curved and S-shaped forms.<br />(B) <EM>Helicobacter pylori</EM> organisms present in the mucous layer on the gastric mucosal surface.</div><div class=\"graphic_reference\">(A) Reproduced with permission from: McClatchey KD, MD, DDS. Clinical Laboratory Medicine, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2002. Copyright © 2002 Lippincott Williams &amp; Wilkins.<br />(B) Reproduced with permission from: Wolters Kluwer. Copyright © 2008.</div><div id=\"graphicVersion\">Graphic 61365 Version 6.0</div></div></div>"},"61366":{"type":"graphic_picture","displayName":"Inguinal syndrome in LGV","title":"Inguinal syndrome in lymphogranuloma venereum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inguinal syndrome in lymphogranuloma venereum</div><div class=\"cntnt\"><img style=\"width:360px; height:270px;\" src=\"images/ID/61366_Inguinal_syndrome_in_LGV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The characteristic &quot;groove&quot; sign is seen in this man with inflammed superficial and deep inguinal lymph nodes. These may go on to rupture.</div><div class=\"graphic_reference\">Reproduced from the Centers for Disease Control and Prevention.</div><div id=\"graphicVersion\">Graphic 61366 Version 2.0</div></div></div>"},"61367":{"type":"graphic_picture","displayName":"Legionella on BCYE","title":"<EM>Legionella</EM> on BCYE","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Legionella</EM> on BCYE</div><div class=\"cntnt\"><img style=\"width:396px; height:312px;\" src=\"images/ID/61367_Legionella_on_BCYE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Parallel cultures of <EM>Legionella </EM>on blood (left) and buffered charcoal-yeast extract (BCYE) agar medium (right). <EM>Legionella</EM> only rarely grows on blood agar; it is best isolated on BCYE.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 61367 Version 3.0</div></div></div>"},"61369":{"type":"graphic_movie","displayName":"Echocardiogram 5 chamber magnified view of AS","title":"Echocardiogram five chamber view of aortic stenosis with magnified view","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiogram five chamber view of aortic stenosis with magnified view</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/61369_5chaszooconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:314px; height:239px;\" src=\"images/CARD/61369_5chaszoo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnified image of the aortic valve from a five chamber view from a patient with aortic stenosis shows significant calcification of the aortic valve with markedly reduced leaflet mobility.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 61369 Version 8.0</div></div></div>"},"61374":{"type":"graphic_picture","displayName":"Lateral bending of the neck","title":"Lateral bending of the neck","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral bending of the neck</div><div class=\"cntnt\"><img style=\"width:441px; height:402px;\" src=\"images/PC/61374_Lateral_bending_of_the_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The paravertebral and facet joints of the vertebral bodies and the supporting muscles allow the neck to bend an average of 45 degrees laterally. The patient is asked to relax. The examiner places one hand on the shoulder and one hand on the side of the head. The neck is passively rotated to the affected side and compared to the opposite side. Loss of lateral bending typically accompanies loss of rotation and is a reflection of the degree of cervical arthritis, secondary muscle spasm, or both.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 61374 Version 3.0</div></div></div>"},"61375":{"type":"graphic_figure","displayName":"Patterns of referred abdominal pain","title":"Patterns of referred abdominal pain","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Patterns of referred abdominal pain</div><div class=\"cntnt\"><img style=\"width:543px; height:413px;\" src=\"images/PC/61375_Referred_pain_patterns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pain from abdominal viscera often (but not always)&nbsp;localizes according to the structure's embryologic origin, with foregut structures (mouth to proximal half of duodenum) presenting with upper abdominal pain, midgut structures (distal half of duodenum to middle of the transverse colon) presenting with periumbilical pain, and hind gut structures (remainder of colon and rectum, pelvic genitourinary organs) presenting with lower abdominal pain. Radiation of pain may provide insight into the diagnosis. As examples, pain from pancreatitis may radiate to the back while pain from gallbladder disease may radiate to the right shoulder or subscapular region.</div><div id=\"graphicVersion\">Graphic 61375 Version 7.0</div></div></div>"},"61378":{"type":"graphic_table","displayName":"Ddx of brain abscess","title":"Differential diagnosis of brain abscess","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of brain abscess</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Epidural and subdural empyema</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Septic dural sinus thrombosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mycotic cerebral aneurysms</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Septic cerebral emboli with associated infarction</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Acute focal necrotizing encephalitis (most commonly due to herpes simplex virus)</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Metastatic or primary brain tumors</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pyogenic meningitis</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 61378 Version 1.0</div></div></div>"},"61380":{"type":"graphic_diagnosticimage","displayName":"Pulmonary PCM images","title":"Radiological response to therapy in a patient with pulmonary paracoccidioidomycosis","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Radiological response to therapy in a patient with pulmonary paracoccidioidomycosis</div><div class=\"cntnt\"><img style=\"width:516px; height:326px;\" src=\"images/ID/61380_Pulmonary_PCM_images.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Complete radiological response in a patient with chronic paracoccidioidomycosis who was treated with voriconazole. A progressive improvement of the pulmonary radiological images is clearly observed during treatment, and a follow-up stabilization pattern is achieved.</div><div class=\"graphic_footnotes\">EOT: end of treatment.</div><div class=\"graphic_reference\">Reproduced with permission from: Queiroz-Telles, F, Goldani, LZ, Schlamm, HT, et al. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Clin Infect Dis 2007; 45:1462. Copyright ©2007 University of Chicago Press.</div><div class=\"contractual\"><br/><a href=\"http://www.journals.uchicago.edu/\">http://www.journals.uchicago.edu/</a></div><div id=\"graphicVersion\">Graphic 61380 Version 2.0</div></div></div>"},"61381":{"type":"graphic_diagnosticimage","displayName":"Percutaneous treatment of endograft limb thrombosis","title":"Percutaneous treatment of endograft limb thrombosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Percutaneous treatment of endograft limb thrombosis</div><div class=\"cntnt\"><img style=\"width:249px; height:370px;\" src=\"images/CARD/61381_Endograft_thrombosis_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The thrombosis of the left limb of the endograft (red arrow) was succesfully treated percutaneously with with thrombolysis, angioplasty, and stent placement.</div><div id=\"graphicVersion\">Graphic 61381 Version 3.0</div></div></div>"},"61382":{"type":"graphic_picture","displayName":"Keloids from acne","title":"Keloids from acne","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Keloids from acne</div><div class=\"cntnt\"><img style=\"width:396px; height:315px;\" src=\"images/DERM/61382_Keloids_from_acne.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright &#169; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 61382 Version 4.0</div></div></div>"},"61383":{"type":"graphic_diagnosticimage","displayName":"LVH M-mode echo","title":"Left ventricular hypertrophy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left ventricular hypertrophy</div><div class=\"cntnt\"><img style=\"width:314px; height:198px;\" src=\"images/CARD/61383_LVHMmodeecho.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">M-mode echocardiogram recorded within the left ventricle, just below the level of the mitral valve annulus. Concentric left ventricular hypertrophy is seen as both the left ventricular septum and posterior left ventricular wall are significantly thickened, measuring almost 3 cm.</div><div id=\"graphicVersion\">Graphic 61383 Version 3.0</div></div></div>"},"61384":{"type":"graphic_table","displayName":"Benefits and risks of genetic testing","title":"Benefits and risks of genetic testing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Benefits and risks of genetic testing</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Type\n   </td>\n   <td  class=\"subtitle1\">\n   Purpose\n   </td>\n   <td  class=\"subtitle1\">\n   When used\n   </td>\n   <td  class=\"subtitle1\">\n   Examples/benefits and harms\n   </td>\n   </tr>\n   <tr>\n   <td  colspan=\"1\" rowspan=\"2\">\n   Diagnostic testing\n   </td>\n   <td  colspan=\"1\" rowspan=\"2\">\n   To provide definite diagnosis\n   </td>\n   <td  colspan=\"1\" rowspan=\"2\">\n   In a patient with an existing condition\n   </td>\n   <td>Turner syndrome 45,X</td>\n   </tr>\n   <tr>\n   <td>Accurate diagnosis can lead to proper treatment</td>\n   </tr>\n   <tr>\n   <td  colspan=\"1\" rowspan=\"2\">\n   Predictive testing\n   </td>\n   <td  colspan=\"1\" rowspan=\"2\">\n   To provide risk assessment for presymptomatic states\n   </td>\n   <td>Prenatal for reproductive choice decision</td>\n   <td  colspan=\"1\" rowspan=\"2\">\n   Presymptomatic intervention may delay onset\n   </td>\n   </tr>\n   <tr>\n   <td>For adult risk assessment</td>\n   </tr>\n   <tr>\n   <td  colspan=\"1\" rowspan=\"2\">\n   Presymptomatic testing\n   </td>\n   <td  colspan=\"1\" rowspan=\"2\">\n   To look for the presence of a gene mutation with complete penetrance, that is, having the mutation always leads to having the disease\n   </td>\n   <td  colspan=\"1\" rowspan=\"2\">\n   In families with disease, for adults who choose to have testing after counseling\n   </td>\n   <td>Huntington disease</td>\n   </tr>\n   <tr>\n   <td>Finding of mutation may lead to prognostic information for individual affecting life planning; negative test may provide relief. Harms include worry, stigmatization, labeling; possible \"survivor guilt\" or ostracism if negative in family with others positive.</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=60895&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Risks_benefits_genetic_test.htm</title></head></div><div id=\"graphicVersion\">Graphic 61384 Version 3.0</div></div></div>"},"61385":{"type":"graphic_diagnosticimage","displayName":"Congen pulm airway malform CXR I","title":"Congenital pulmonary airways malformation (Type I) in a newborn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital pulmonary airways malformation (Type I) in a newborn</div><div class=\"cntnt\"><img style=\"width:360px; height:453px;\" src=\"images/PULM/61385_Adenomatoid_malform_CXR_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The initial chest radiograph shows complete opacification of left hemithorax with compression of the right lung, which is hypoplastic and surrounded by a small right pleural effusion.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 61385 Version 3.0</div></div></div>"},"61386":{"type":"graphic_table","displayName":"Fungi health effects","title":"Health effects of indoor fungal exposure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Health effects of indoor fungal exposure</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Infections</td> </tr> <tr> <td>Ingestional mycotoxicosis</td> </tr> <tr> <td>Asthma</td> </tr> <tr> <td>Allergic rhinitis</td> </tr> <tr> <td>Hypersensitivity pneumonitis</td> </tr> <tr> <td>Allergic bronchopulmonary aspergillosis (ABPA)</td> </tr> <tr> <td>Allergic fungal rhinosinusitis</td> </tr> <tr> <td>Fungus balls</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Robert Bush, MD.</div><div id=\"graphicVersion\">Graphic 61386 Version 2.0</div></div></div>"},"61388":{"type":"graphic_table","displayName":"Rabies preexposure guide","title":"Rabies preexposure prophylaxis guide - United States, 2008","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rabies preexposure prophylaxis guide - United States, 2008</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Risk category</td> <td class=\"subtitle1\">Nature of risk</td> <td class=\"subtitle1\">Typical populations</td> <td class=\"subtitle1\">Preexposure recommendations</td> </tr> <tr> <td>Continuous</td> <td>Virus present continuously, often in high concentrations. Specific exposures likely to go unrecognized. Bite, nonbite, or aerosol exposure.</td> <td>Rabies research laboratory workers; rabies biologics production workers.</td> <td>Primary course. Serologic testing every&nbsp;six months; booster vaccination if antibody titer is below acceptable level.*</td> </tr> <tr> <td>Frequent</td> <td>Exposure usually episodic, with source recognized, but exposure also might be unrecognized. Bite, nonbite, or aerosol exposure.</td> <td>Rabies diagnostic laboratory workers, cavers, veterinarians and staff, and animal-control and wildlife workers in areas where rabies is enzootic. All persons who frequently handle bats.</td> <td>Primary course. Serologic testing every&nbsp;two years; booster vaccination if antibody titer is below acceptable level.*</td> </tr> <tr> <td>Infrequent (greater than population at large)</td> <td>Exposure nearly always episodic with source recognized. Bite or nonbite exposure.</td> <td>Veterinarians and animal-control staff working with terrestrial animals in areas where rabies is uncommon to rare. Veterinary students. Travelers visiting areas where rabies is enzootic and immediate access to appropriate medical care including biologics is limited.</td> <td>Primary course. No serologic testing or booster vaccination.</td> </tr> <tr> <td>Rare (population at large)</td> <td>Exposure always episodic with source recognized. Bite or nonbite exposure.</td> <td>US population at large, including persons in areas where rabies is epizootic.</td> <td>No vaccination necessary.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Minimum acceptable antibody level is complete virus neutralization at a 1:5 serum dilution by the rapid fluorescent focus inhibition test. A booster dose should be administered if the titer falls below this level.</div><div class=\"graphic_reference\">Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention-United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2008; 57:1.</div><div id=\"graphicVersion\">Graphic 61388 Version 2.0</div></div></div>"},"61390":{"type":"graphic_figure","displayName":"Coronary stabilizer","title":"Coronary stabilizer and its carrying wound spreader","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coronary stabilizer and its carrying wound spreader</div><div class=\"cntnt\"><img style=\"width:433px; height:395px;\" src=\"images/CARD/61390_Coronary_stabilizer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The coronary stabilizer prevents movement of the artery during the surgery.</div><div id=\"graphicVersion\">Graphic 61390 Version 1.0</div></div></div>"},"61393":{"type":"graphic_picture","displayName":"Peritonsillar abscess needle aspiration","title":"Needle aspiration of peritonsillar abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Needle aspiration of peritonsillar abscess</div><div class=\"cntnt\"><img style=\"width:396px; height:336px;\" src=\"images/PEDS/61393_Peri_abscess_needle_asp_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 61393 Version 3.0</div></div></div>"},"61394":{"type":"graphic_diagnosticimage","displayName":"Knee dislocation with bicruciate injury","title":"Anterior knee dislocation with bicruciate injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior knee dislocation with bicruciate injury</div><div class=\"cntnt\"><img style=\"width:320px; height:432px;\" src=\"images/EM/61394_Knee_dislocatn_ant2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lateral radiograph above shows an anterior knee dislocation with bicruciate ligament injury. Note how the alignment of the patella and the femur are no longer parallel and the close proximity of the femur and tibia.</div><div class=\"graphic_reference\">Reproduced with permission from: Bucholz RW, Heckman JD. Rockwood &amp; Green's Fractures in Adults, 5th ed. Lippincott, Williams &amp; Wilkins, 2001. Copyright © Lippincott, Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 61394 Version 3.0</div></div></div>"},"61395":{"type":"graphic_figure","displayName":"Oral contraceptive in PCOS","title":"Oral contraceptive therapy lowers serum free testosterone concentrations in women with polycystic ovary syndrome (PCOS)","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Oral contraceptive therapy lowers serum free testosterone concentrations in women with polycystic ovary syndrome (PCOS)</div><div class=\"cntnt\"><img style=\"width:549px; height:400px;\" src=\"images/ENDO/61395_Oral_contraceptive_in_PCOS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normalization of the serum free testosterone concentrations in seven women with PCOS after the initiation of therapy with Loestrin&#174; (estradiol 30 mcg and norethindrone acetate 1.5 mg). To convert serum free testosterone to pmol/L, multiple by 34.7.</div><div class=\"graphic_reference\">Data from: Raj SG, Raj MH, Talbert LM, Sloan CS, Hicks B. Normalization of testosterone levels using a low estrogen-containing oral contraceptive in women with polycystic ovary syndrome. Obstet Gynecol 1982; 60:15.</div><div id=\"graphicVersion\">Graphic 61395 Version 2.0</div></div></div>"},"61397":{"type":"graphic_figure","displayName":"Stroke by age and genotype","title":"Age at first stroke and cumulative incidence of stroke in SCD according to genotype","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Age at first stroke and cumulative incidence of stroke in SCD according to genotype</div><div class=\"cntnt\"><img style=\"width:500px; height:323px;\" src=\"images/HEME/61397_CVA_in_sickle_cell_disease.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Age at first stroke (ischemic or hemorrhagic) and cumulative incidence of&nbsp;stroke in 2436 patients with sickle cell disease.&nbsp;The graph shows the percentage of individuals without a stroke. These data largely represent patients who did not receive primary prevention.&nbsp;The number of patients in each genotype is as follows: HbSS, 2346; HbS-beta<SUP>0</SUP>&nbsp;thalassemia, 188; HbS-beta<SUP>+</SUP> thalassemia, 184; HbSC, 839.</div><div class=\"graphic_footnotes\">SCD: Sickle cell disease.</div><div class=\"graphic_reference\">Adapted from Ohene-Frempong, K, Weiner, SJ, Sleeper, LA, et al, Blood 1998; 91:288.</div><div id=\"graphicVersion\">Graphic 61397 Version 3.0</div></div></div>"},"61398":{"type":"graphic_table","displayName":"Differential diagnosis of localized myalgia","title":"Differential diagnosis and distinguishing features of localized myalgia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis and distinguishing features of localized myalgia</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td     class=\"subtitle1\">\n   Diagnosis\n   </td>\n   <td     class=\"subtitle1\">\n   Distinguishing features\n   </td>\n   </tr>\n   <tr>\n   <td>Unusually strenuous exercise or overuse</td>\n   <td>History</td>\n   </tr>\n   <tr>\n   <td>Trauma</td>\n   <td>History, hematoma, ecchymosis</td>\n   </tr>\n   <tr>\n   <td>Pyomyositis</td>\n   <td>Localized erythema, swelling, fever</td>\n   </tr>\n   <tr>\n   <td>Myofascial pain syndrome</td>\n   <td>Trigger points</td>\n   </tr>\n   <tr>\n   <td>Muscle infarction</td>\n   <td>Severe pain without inflammatory findings, often in a patient with diabetes</td>\n   </tr>\n   <tr>\n   <td>Compartment syndrome</td>\n   <td>Severe pain without inflammatory findings, often in a patient with recent trauma</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=58336&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Diff_diag_localized_myalgia.htm</title></head></div><div id=\"graphicVersion\">Graphic 61398 Version 3.0</div></div></div>"},"61399":{"type":"graphic_picture","displayName":"Karl Storz rigid bronchoscopes","title":"Karl Storz rigid bronchoscopes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Karl Storz rigid bronchoscopes</div><div class=\"cntnt\"><img style=\"width:432px; height:259px;\" src=\"images/PULM/61399_Karl_Storz_rigid_bronchosco.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Set of Karl Storz rigid bronchoscopes, with internal channel for rigid telescopes.</div><div class=\"graphic_reference\">Courtesy of Henri G Colt, MD.</div><div id=\"graphicVersion\">Graphic 61399 Version 2.0</div></div></div>"},"61402":{"type":"graphic_diagnosticimage","displayName":"Large distal common iliac artery aneurysm","title":"Large distal common iliac artery aneurysm","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Large distal common iliac artery aneurysm</div><div class=\"cntnt\"><img style=\"width:468px; height:468px;\" src=\"images/SURG/61402_Large_dist_comm_iliac_aneu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large distal common iliac artery aneurym extending to the bifurcation of the external and internal iliac arteries.</div><div id=\"graphicVersion\">Graphic 61402 Version 2.0</div></div></div>"},"61404":{"type":"graphic_table","displayName":"Criteria for NTM diagnosis","title":"Clinical and microbiologic criteria for diagnosing nontuberculous mycobacterial (NTM) lung disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical and microbiologic criteria for diagnosing nontuberculous mycobacterial (NTM) lung disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical (both required)</td> </tr> <tr> <td>1. Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or a high-resolution computed tomography scan that shows multifocal bronchiectasis with multiple small nodules.</td> </tr> <tr> <td><strong>and</strong></td> </tr> <tr> <td>2. Appropriate exclusion of other diagnoses.</td> </tr> <tr> <td class=\"subtitle1_single\">Microbiologic</td> </tr> <tr> <td>1. Positive culture results from at least two separate expectorated sputum samples. If the results from the initial sputum samples are nondiagnostic, consider repeat sputum acid-fast bacilli (AFB) smears and cultures.</td> </tr> <tr> <td><strong>or</strong></td> </tr> <tr> <td>2. Positive culture result from at least one bronchial wash or lavage.</td> </tr> <tr> <td><strong>or</strong></td> </tr> <tr> <td>3. Transbronchial or other lung biopsy with mycobacterial histopathologic features (granulomatous inflammation or AFB) and positive culture for NTM or biopsy showing mycobacterial histopathologic features (granulomatous inflammation or AFB) and one or more sputum or bronchial washings that are culture-positive for NTM.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_single\">Additional considerations</td> </tr> <tr> <td> <ul> <li>Expert consultation should be obtained when NTM are recovered that are either infrequently encountered or that usually represent environmental contamination. </li> <li>Patients who are suspected of having NTM lung disease but do not meet the diagnostic criteria should be followed until the diagnosis is firmly established or excluded. </li> <li>Making the diagnosis of NTM lung disease does not, per se, necessitate the institution of therapy, which is a decision based on potential risks and benefits of therapy for individual patients. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Griffith DE, Aksamit T, Brown-Elliott BA, et al. An Official ATS/IDSA Statement: Diagnosis, treatment and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367. Copyright © 2007 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 61404 Version 5.0</div></div></div>"},"61409":{"type":"graphic_figure","displayName":"Pathogenesis breast Paget","title":"Pathogenesis of Paget disease of the breast as a consequence of the motility factor heregulin-α","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of Paget disease of the breast as a consequence of the motility factor heregulin-α</div><div class=\"cntnt\"><img style=\"width:420px; height:396px;\" src=\"images/ONC/61409_Pathogenesis_breast_Paget.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Heregulin-α messenger RNA is produced by the nipple epidermal keratinocytes, which secrete heregulin-α protein. Heregulin-α then binds to a heterodimer of HER3 and HER-2/NEU or of HER4 and HER2/NEU on Paget cells. HER1 is expressed on the membranes of some normal epidermal cells and does not appear to be involved in the pathogenesis of Paget disease.</div><div class=\"graphic_reference\">Reproduced with permission from: Schelfhout VR, Coene ED, Delaey B, et al. Pathogenesis of Paget's disease: Epidermal heregulin-alpha motility factor and the HER receptor family. J Natl Cancer Inst 2000; 92:622. Copyright © 2000 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 61409 Version 2.0</div></div></div>"},"61410":{"type":"graphic_diagnosticimage","displayName":"Pediatric subdural hematoma on magnetic resonance imaging","title":"A 6-month old male imaged for macrocephaly","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">A 6-month old male imaged for macrocephaly</div><div class=\"cntnt\"><img style=\"width:411px; height:404px;\" src=\"images/EM/61410_SDH_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T1 (Panel A) and T2 (Panel B)-weighted MRI images show enlargement of the subarachnoid spaces, establishing the diagnosis of benign extra-axial fluid of infancy. Follow-up T1 (Panel C) and T2 (Panel D)-weighted images reveal chronic subdural hematoma within the enlarged spaces. The child was completely asymptomatic from this and required no treatment. The areas of hematoma resolved spontaneously.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Mark R Proctor, MD.</div><div id=\"graphicVersion\">Graphic 61410 Version 3.0</div></div></div>"},"61411":{"type":"graphic_waveform","displayName":"CCK sphincter of Oddi manometry","title":"Sphincter of oddi manometry","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Sphincter of oddi manometry</div><div class=\"cntnt\"><img style=\"width:465px; height:290px;\" src=\"images/GAST/61411_CCK_sphincter_of_Oddi_manom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Example of a paradoxical basal sphincter of Oddi (SO) pressure elevation following the intravenous administration of cholecystokinin-octapeptide (20 ng/kg). Normally, CCK reduces SO basal pressure. This finding suggests possible denervation of the sphincteric zone.</div><div class=\"graphic_reference\">Courtesy of Walter J Hogan, MD.</div><div id=\"graphicVersion\">Graphic 61411 Version 2.0</div></div></div>"},"61413":{"type":"graphic_table","displayName":"ACC AHA HRS pacing acute MI","title":"ACC/AHA/HRS guideline summary: Permanent pacing after the acute phase of myocardial infarction (MI)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA/HRS guideline summary: Permanent pacing after the acute phase of myocardial infarction (MI)</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Class I - There is evidence and/or general agreement that  permanent pacing after the acute phase of MI should be performed in the following settings:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; Persistent second-degree AV block in the His-Purkinje system with alternating bundle branch block or third-degree AV block within or below the His-Purkinje system after ST-segment elevation MI. (Level of Evidence: B)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; Transient advanced second- or third-degree infranodal AV block and associated bundle branch block. If the site of block is uncertain, an eletrophysiological study may be necessary. (Level of Evidence: B)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; Persistent and symptomatic second- or third-degree AV block. (Level of Evidence: C)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Class IIb - The evidence or opinion is less well established that permanent pacing after the acute phase of MI is beneficial in the following setting:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; Persistent second- or third-degree AV block at the AV node level, even in the absence of symptoms. (Level of Evidence: B)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Class III - There is evidence that permanent pacing after the acute phase of MI is not useful and may be harmful in the following settings:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; Transient AV block in the absence of intraventricular conduction defects. (Level of Evidence: B)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; Transient AV block in the presence of isolated left anterior fascicular block. (Level of Evidence: B)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; New bundle branch block or fascicular block in the absence of AV block. (Level of Evidence: B)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; Persistent asymptomatic first-degree AV block in the presence of bundle branch or fascicular block. (Level of Evidence: B)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">2.00000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=1920&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>ACC_AHA_HRS_pacing_acute_MI.htm</title></head></div><div class=\"graphic_footnotes\">AV: atrioventricular.</div><div class=\"graphic_reference\">Adapted from Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.</div><div id=\"graphicVersion\">Graphic 61413 Version 4.0</div></div></div>"},"61415":{"type":"graphic_figure","displayName":"Sites of acute osteomyelitis in children","title":"Sites of involvement in acute hematogenous osteomyelitis in children","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sites of involvement in acute hematogenous osteomyelitis in children</div><div class=\"cntnt\"><img style=\"width:402px; height:565px;\" src=\"images/PEDS/61415_Site_acute_osteo_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tubular bones are affected more frequently than nontubular (flat) bones or spine.</div><div class=\"graphic_footnotes\">* This does not include the osteomyelitis of the calcaneum, which accounts for 5% of cases.</div><div class=\"graphic_reference\">Data from: Dartnell J, Ramachandran M, Katchburian M. Haematogenous acute and subacute paediatric osteomyelitis: a systematic review of the literature. J Bone Joint Surg Br 2012; 94:584.</div><div id=\"graphicVersion\">Graphic 61415 Version 4.0</div></div></div>"},"61416":{"type":"graphic_figure","displayName":"Oculocephalic and caloric responses","title":"Oculocephalic and caloric response","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Oculocephalic and caloric response</div><div class=\"cntnt\"><img style=\"width:500px; height:388px;\" src=\"images/PC/61416_Oculocephaliccaloricrespo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI><STRONG>Oculocephalic (doll's eyes) response:</STRONG> This test should not be performed if a cervical spine injury is suspected. Observe the motion of the eyes while passively moving the head. In a comatose patient, conjugate movement of the eyes in the direction opposite to the head movement is expected. An absent or asymmetric response in an unconscious patient implies brainstem dysfunction.</LI>&#xD;&#xA;<LI><STRONG>Caloric response:</STRONG> After visually checking that the tympanic membrane is intact, ice cold water is used to irrigate the ear canal and should produce a slow conjugate deviation toward the irrigated side. An absent or asymmetric response indicates brainstem dysfunction. Intact eye deviation with nystagmus suggests that the patient may not be in coma.</LI></UL></div><div class=\"graphic_reference\">Adapted from: Bateman DE. Neurologic assessment of coma. J Neurol Neurosurg Psychiatry 2001; 71 Suppl 1:13.</div><div id=\"graphicVersion\">Graphic 61416 Version 6.0</div></div></div>"},"61419":{"type":"graphic_table","displayName":"Criteria for initiation of antibiotics for UTI","title":"Minimum criteria for the initiation of antibiotics for urinary tract infection in long-term care residents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Minimum criteria for the initiation of antibiotics for urinary tract infection in long-term care residents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">With indwelling catheter</td> </tr> <tr> <td class=\"subtitle2_left\">At least one of the following:</td> </tr> <tr> <td class=\"indent1\">Fever (&#62;37.9&#176;C [100&#176;F] or 1.5&#176;C [2.4&#176;F] above baseline)</td> </tr> <tr> <td class=\"indent1\">New CVA tenderness</td> </tr> <tr> <td class=\"indent1\">Rigors</td> </tr> <tr> <td class=\"indent1\">New onset delirium</td> </tr> <tr> <td class=\"subtitle1_single\">Without indwelling catheter:</td> </tr> <tr> <td>Acute dysuria <strong>OR</strong></td> </tr> <tr> <td>Fever (&#62;37.9&#176;C [100&#176;F] or 1.5&#176;C [2.4&#176;F] above baseline) <strong>AND</strong></td> </tr> <tr> <td class=\"sublist1_start\">At least one of the following:</td> </tr> <tr> <td class=\"sublist1\">New or worsening urgency</td> </tr> <tr> <td class=\"sublist1\">Frequency</td> </tr> <tr> <td class=\"sublist1\">Suprapubic pain</td> </tr> <tr> <td class=\"sublist1\">Gross hematuria</td> </tr> <tr> <td class=\"sublist1\">CVA tenderness</td> </tr> <tr> <td class=\"sublist1\">Urinary incontinence</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">16</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=86021&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">CVA: costovertebral angle.</div><div class=\"graphic_reference\">Source: Loeb M, Bentley DW, Bradley S, et al. Development of minimum criteria for the initiation of antibiotics in residents of long-term-care facilities: results of a consensus conference. Infect Control Hosp Epidemiol 2001; 22:120.</div><div id=\"graphicVersion\">Graphic 61419 Version 3.0</div></div></div>"},"61420":{"type":"graphic_picture","displayName":"Scaphoid shift test 3","title":"Scaphoid shift test: Step 3","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Scaphoid shift test: Step 3</div><div class=\"cntnt\"><img style=\"width:480px; height:361px;\" src=\"images/EM/61420_Scaphoid_shift_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Begin the test by placing the patient's hand in full ulnar deviation. Using your other thumb, keep firm pressure on the scaphoid tubercle.</div><div class=\"graphic_reference\">Courtesy of Kevin deWeber, MD, FAAFP, FACSM.</div><div id=\"graphicVersion\">Graphic 61420 Version 3.0</div></div></div>"},"61424":{"type":"graphic_picture","displayName":"Chorionic villi2","title":"Chorionic villi2","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chorionic villi2</div><div class=\"cntnt\"><img style=\"width:324px; height:309px;\" src=\"images/OBGYN/61424_Chorionic_villi2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Errol R Norwitz, MD, PhD.</div><div id=\"graphicVersion\">Graphic 61424 Version 1.0</div></div></div>"},"61425":{"type":"graphic_diagnosticimage","displayName":"Fetal scalp edema","title":"Fetal scalp edema","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Fetal scalp edema</div><div class=\"cntnt\"><img style=\"width:578px; height:403px;\" src=\"images/OBGYN/61425_Ftl_skn_edm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scalp edema. Transverse image of the fetal head at the level of the biparietal diameter. Arrows mark the excess fluid around the fetal head.</div><div class=\"graphic_reference\">Courtesy of Svena Julien, MD and Charles Lockwood, MD.</div><div id=\"graphicVersion\">Graphic 61425 Version 3.0</div></div></div>"},"61427":{"type":"graphic_figure","displayName":"Dorsal slit procedure","title":"Dorsal slit procedures for reduction of paraphimosis and balanoposthitis with urinary obstruction","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Dorsal slit procedures for reduction of paraphimosis and balanoposthitis with urinary obstruction</div><div class=\"cntnt\"><img style=\"width:523px; height:554px;\" src=\"images/EM/61427_Dorsal_slit_procedure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dorsal slit procedure is usually performed by an urologist although&nbsp;it is also appropriate for a&nbsp;knowledgeable physician if an urologist is not available and emergency reduction is necessary (eg, penile necrosis or complete urinary obstruction). Two approaches are described (Refer to UpToDate topics on treatment of paraphimosis):<br />(A)<br />1. Incision of constricting band along longitudinal axis of penis;<br />2. Reduction of paraphimosis and suture placement along transverse axis of penis;<br />3. Reduced paraphimosis with closed incision.<br />(B)<br />1. Incision of constricting band of paraphimosis (also appropriate for balanoposthitis with urinary obstruction);<br />2. Reduction of foreskin followed by suturing of incision;<br />3. Reduced paraphimosis with closed incision.</div><div id=\"graphicVersion\">Graphic 61427 Version 4.0</div></div></div>"},"61428":{"type":"graphic_picture","displayName":"Infant prepuce","title":"Infant prepuce","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infant prepuce</div><div class=\"cntnt\"><img style=\"width:413px; height:298px;\" src=\"images/EM/61428_Infantprepuce.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Balanoposthitis-cellulitis of normal foreskin with erythema, edema, and tenderness. <br />(B) Normal foreskin after treatment of balanoposthitis with antibiotics and warm soaks.</div><div class=\"graphic_reference\">Reproduced with permission from: Snyder HM. Urologic emergencies. In: Textbook of pediatric emergency medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 61428 Version 13.0</div></div></div>"},"61431":{"type":"graphic_picture","displayName":"Ferning of cervical mucus","title":"Ferning of cervical mucus","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Ferning of cervical mucus</div><div class=\"cntnt\"><img style=\"width:547px; height:413px;\" src=\"images/OBGYN/61431_Ferning_cervical_mucus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Ferning of cervical mucus.<br> (B) A ferning pattern of cervical mucus occurs with high estrogen levels.<br> (C) Incomplete ferning during secretory phase of cycle.</div><div class=\"graphic_reference\">Reproduced with permission from:<br> (A) Lexikon Medizin, 3rd Edition. Munich, Germany: Urban &amp; Schwarzenburg, 1993.<br> (B) Scott JR. Danforth's Obstetrics and Gynecology, 6th Edition. Philadelphia: J.B. Lippincott, 1990.<br> (C) Scott JR. Danforth's Obstetrics and Gynecology, 6th Edition. Philadelphia: J.B. Lippincott, 1990.</div><div id=\"graphicVersion\">Graphic 61431 Version 1.0</div></div></div>"},"61432":{"type":"graphic_diagnosticimage","displayName":"Longitudinal ultrasound scan tibiotalar effusion","title":"Longitudinal ultrasound scan showing needle puncturing tibiotalar effusion","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Longitudinal ultrasound scan showing needle puncturing tibiotalar effusion</div><div class=\"cntnt\"><img style=\"width:499px; height:362px;\" src=\"images/RHEUM/61432_Long_US_talo_crural_effus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal ultrasound scan showing needle (arrowheads) puncturing tibiotalar effusion (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Introductory Guide to Musculoskeletal Ultrasound for the Rheumatologist, Second Edition. ISBN 978-90-313-9206-3; Bohn Stafleu van Loghum, Houten 2012. Copyright &#169; 2012.</div><div id=\"graphicVersion\">Graphic 61432 Version 2.0</div></div></div>"},"61433":{"type":"graphic_diagnosticimage","displayName":"Cervical length in a curved cervix","title":"Cervical length in a curved cervix","html":"<div class=\"graphic\"><div style=\"width: 595px\" class=\"figure\"><div class=\"ttl\">Cervical length in a curved cervix</div><div class=\"cntnt\"><img style=\"width:575px; height:435px;\" src=\"images/OBGYN/61433_Cervical_length_curv_cervix.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Evaluation of cervical length in a patient with a curved cervix. If the widest distance (A, red arrow) between the dashed yellow lines is greater than 5 mm, use the sum of B and C as the best measurement of cervical length. If less than or equal to 5 mm, use D as the best measurement of cervical length.</div><div id=\"graphicVersion\">Graphic 61433 Version 3.0</div></div></div>"},"61434":{"type":"graphic_diagnosticimage","displayName":"Transthoracic v transesophageal","title":"Transthoracic versus transesophageal echocardiography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transthoracic versus transesophageal echocardiography</div><div class=\"cntnt\"><img style=\"width:414px; height:241px;\" src=\"images/CARD/61434_Transthoracic_v_transesopha.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The apical four-chamber view from a transthoracic echocardiogram demonstrates only subtle changes in the posterior leaftlet of the mitral valve (arrow). However, the transesophageal echocardiogram (panel B) shows that the posterior leaflet of the mitral valve (pML) is both flail and attached to a vegetation. The anterior leaflet, which had a bright density on transthoracic echocardiography (red arrow), is normally postitioned and of normal thickness; the bright density is seen on the transesophageal echocardiogram to be the rough edge of the valve where the chordae attach (red arrow).</div><div id=\"graphicVersion\">Graphic 61434 Version 2.0</div></div></div>"},"61435":{"type":"graphic_figure","displayName":"Subarachnoid hemorrhage PI","title":"Subarachnoid hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Subarachnoid hemorrhage</div><div class=\"cntnt\"><img style=\"width:485px; height:567px;\" src=\"images/PI/61435_Subarachnoid-hemorrhage-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A subarachnoid hemorrhage is a type of stroke. It causes bleeding around the brain. The bleeding happens between the brain and the thin layer of tissue that covers it.</div><div id=\"graphicVersion\">Graphic 61435 Version 2.0</div></div></div>"},"61436":{"type":"graphic_table","displayName":"HNPP and hereditary brachial plexopathy","title":"Hereditary neuropathy with pressure palsy and hereditary brachial plexopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hereditary neuropathy with pressure palsy and hereditary brachial plexopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Inheritance</td> <td class=\"subtitle1\">Chromosome (gene)</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr class=\"divider_bottom\"> <td>Hereditary neuropathy with pressure palsy</td> <td>AD</td> <td>17p11.2-12 (PMP22)</td> <td> <p>Usual onset in second decade</p> <p>Isolated nerve palsies after trivial trauma</p> <p>Palsies resolve in days to months</p> <p>Cranial nerve involvement</p> <p>Nerve deafness</p> <p>Scoliosis</p> </td> </tr> <tr> <td>Hereditary brachial plexopathy</td> <td>AD</td> <td>17q25 (SEPT9)</td> <td> <p>Onset in childhood</p> <p>Pain followed by paresis of brachial plexus muscles</p> <p>Resolves spontaneously and recurs at irregular intervals</p> <p>Winging of the scapula</p> <p>Facial weakness</p> <p>Autonomic nervous system dysfunction</p> <p>Short stature</p> <p>Hypertelorism</p> <p>Small palpebral fissures</p> <p>Small face</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AD: autosomal dominant.</div><div id=\"graphicVersion\">Graphic 61436 Version 3.0</div></div></div>"},"61437":{"type":"graphic_table","displayName":"Empiric rx serious SA child","title":"Parenteral antimicrobial agents for empiric treatment of bacteremia and other serious suspected <em>Staphylococcus aureus</em> infections in infants and children older than 30 days","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parenteral antimicrobial agents for empiric treatment of bacteremia and other serious suspected <em>Staphylococcus aureus</em> infections in infants and children older than 30 days</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Antimicrobial agents</td> <td class=\"subtitle1\">Dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Life-threatening infections*</td> </tr> <tr> <td class=\"indent1\">Regimen of choice</td> <td> <p>Vancomycin +</p> <p>Nafcillin or oxacillin &#177;</p> <p>Gentamicin<sup>&#182;</sup> &#177;</p> Rifampin<sup>&#182;</sup></td> <td> <p>Vancomycin: 60 mg/kg per day in 4 doses; maximum daily dose 4 g</p> <p>Nafcillin: 150 to 200 mg/kg per day in 4 to 6 doses; maximum daily dose 12 g</p> <p>Oxacillin: 150 to 200 mg/kg per day in 4 to 6 doses; maximum daily dose&nbsp;12 g</p> <p>Gentamicin: 3 mg/kg per day in 3 doses</p> Rifampin: 20 mg/kg per day in 2 doses; maximum daily dose 600 mg</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Alternate regimen<sup>&#916;</sup></td> <td> <p>Linezolid &#177;</p> Gentamicin<sup>&#182;</sup></td> <td> <p>Linezolid: &#60;12 years: 30 mg/kg per day in 3 doses; &#8805;12 years: 600 mg twice per day</p> Gentamicin: 3 mg/kg per day in 3 doses</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Nonlife-threatening infection without signs of shock<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Prevalence of MRSA infection in community &#60;5 to 10 percent<sup>&#167;</sup></td> <td>Nafcillin, <strong>or</strong></td> <td>150 to 200 mg/kg per day in 4 to 6 doses; maximum daily dose 12 g</td> </tr> <tr> <td>Oxacillin<sup>&#165;</sup></td> <td>150 to 200 mg/kg per day in 4 to 6 doses; maximum daily dose 12 g</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Prevalence of MRSA infection in community &#62;5 to 10 percent<sup>&#167;</sup> and prevalence of clindamycin resistance in community is low<sup>&#135;</sup></td> <td>Clindamycin<sup>&#134;</sup>, <strong>or</strong></td> <td>40 mg/kg per day in 3 to 4 doses; maximum daily dose 2.7 g</td> </tr> <tr> <td>Vancomycin</td> <td>60 mg/kg per day in 4 doses; maximum daily dose 4 g</td> </tr> <tr> <td class=\"indent1\">Risk factors for healthcare-associated infection**</td> <td>Vancomycin</td> <td>60 mg/kg per day in 4 doses; maximum daily dose 4 g</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MRSA: methicillin-resistant <EM>Staphylococcus aureus</EM>.<br />* Septic shock, endocarditis, central nervous system infection.<br />¶ Gentamicin may be added for suspected infectious endocarditis, although there are no data from controlled trials to indicate that combination therapy is advantageous. Rifampin may be added for central nervous system infection or infection of prosthetic material (eg, spinal instrumentation rods, prosthetic valves, ventriculo-peritoneal shunts), although there are no data from controlled trials to indicate that combination therapy is beneficial. Consultation with an expert in infectious diseases may be warranted to determine which agent to use and duration of use.<br />Δ For patients who have received several courses of vancomycin in recent past.<br /><FONT class=lozenge>◊</FONT> Skin infection, cellulitis, osteomyelitis, septic arthritis.<br />§ Others may choose to provide coverage for MRSA at different prevalence levels.<br />¥ Patients allergic to penicillins and cephalosporins should receive vancomycin as empiric therapy for serious infection.<br />‡ The threshold prevalence of clindamycin-resistant MRSA for choosing vancomycin varies from center to center, usually ranging from 10 to 25 percent, trying to balance the benefit of definitive therapy for the patient with the risk of increasing vancomycin resistance in the community. Additional considerations in the decision to choose vancomycin include the prevalence of MRSA in the community, the severity of illness, and the turn-around time for susceptibilities.<br />† If bacteremia is not likely.<br />** Risk factors for healthcare-associated infection include personal history of or frequent contact with an individual with a history of hospitalization, surgery, dialysis, or residence in a long-term care facility within the previous year, frequent contact with the healthcare environment, presence of an invasive device (eg, intravascular catheter or tracheal tube), history of MRSA infection or colonization.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Staphylococcal infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed,&nbsp;Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.715. </LI>&#xD;&#xA;<LI>American Academy of Pediatrics. Tables of antibacterial drug dosages. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed,&nbsp;Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.881. </LI>&#xD;&#xA;<LI>Liu C, Bayer A, Cosgrove SE, et, al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</LI></OL></div><div id=\"graphicVersion\">Graphic 61437 Version 12.0</div></div></div>"},"61438":{"type":"graphic_diagnosticimage","displayName":"Nasal dermoid radiograph","title":"Radiograph of a nasal dermoid (nasal pit)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiograph of a nasal dermoid (nasal pit)</div><div class=\"cntnt\"><img style=\"width:313px; height:288px;\" src=\"images/PEDS/61438_Nasal_dermoid_radiograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal magnetic resonance image (MRI) of nasal pit extending to the cribriform plate (indicated by arrow).</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 61438 Version 4.0</div></div></div>"},"61441":{"type":"graphic_figure","displayName":"Procoagulants outcome MI","title":"Elevated procoagulant levels after thrombolysis predict outcome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Elevated procoagulant levels after thrombolysis predict outcome</div><div class=\"cntnt\"><img style=\"width:320px; height:513px;\" src=\"images/CARD/61441_Procoagulants_outcome_MI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Elevated levels of hematologic markers of thrombin generation (fibrinopeptide A and prothrombin fragment 1.2) obtained 12 hours after thrombolysis predict a higher 30-day mortality and reinfarction rate.</div><div class=\"graphic_reference\">Data from Granger CB, Becker R, Tracy RP, et al, for the GUSTO-I Hemostasis Substudy Group. J Am Coll Cardiol 1998; 31:497.</div><div id=\"graphicVersion\">Graphic 61441 Version 2.0</div></div></div>"},"61444":{"type":"graphic_diagnosticimage","displayName":"Collateral flow in basilar artery occlusion","title":"Collateral blood flow in a patient with a proximal basilar artery occlusion","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Collateral blood flow in a patient with a proximal basilar artery occlusion</div><div class=\"cntnt\"><img style=\"width:504px; height:504px;\" src=\"images/NEURO/61444_Collateral_flow_BA_occlus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vertebral artery angiogram, lateral view. The proximal portion of the basilar artery is occluded. Blood flow is seen in the intracranial vertebral artery (A), which gives off the posterior inferior cerebellar artery (PICA) (B), which in turn anastamoses with the superior cerebellar artery (SCA) (C). From there, blood flows over the cerebellum to fill the rostral portion of the basilar artery (D).</div><div class=\"graphic_reference\">Reproduced with permission from: Caplan LR. Posterior circulation disease. Clinical findings, diagnosis, and management. Blackwell Science, Boston 1996. Copyright © 1996 Blackwell Science.</div><div id=\"graphicVersion\">Graphic 61444 Version 4.0</div></div></div>"},"61445":{"type":"graphic_figure","displayName":"Anchoring villi and intervillous space","title":"Diagram of anchoring villi (AV) at the maternal-fetal interface in normal and preeclamptic pregnancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagram of anchoring villi (AV) at the maternal-fetal interface in normal and preeclamptic pregnancy</div><div class=\"cntnt\"><img style=\"width:324px; height:456px;\" src=\"images/OBGYN/61445_Anchoring_villi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The floating villi (FV) are in the intervillous space in direct contact with with the maternal blood. In normal pregnancy, invasive cytotrophoblasts (CTB) form cell columns (zone II/III) and invade maternal decidua and vasculature (zone IV). During the differentiation along the invasive path, the cytotrophoblasts dramatically alter their expression of various molecules, such as integrins. In preeclampsia, the invasive cytotrophoblasts fail to differentiate along the invasive pathway and do not gain access to spiral arteries.</div><div class=\"graphic_reference\">Courtesy of Kee-Hak Lim, MD.</div><div id=\"graphicVersion\">Graphic 61445 Version 2.0</div></div></div>"},"61446":{"type":"graphic_picture","displayName":"Dental celiac PI","title":"Dental celiac","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dental celiac</div><div class=\"cntnt\"><img style=\"width:432px; height:282px;\" src=\"images/PI/61446_Dental_celiac_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Lisa Papagiannoulis, DDS, MS, School of Dental Medicine, University of Athens, Greece.</div><div id=\"graphicVersion\">Graphic 61446 Version 1.0</div></div></div>"},"61447":{"type":"graphic_picture","displayName":"Breastfeed preterm infant","title":"Breastfeeding the preterm infant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Breastfeeding the preterm infant</div><div class=\"cntnt\"><img style=\"width:363px; height:396px;\" src=\"images/PEDS/61447_Breastfeed_preterm_infant.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Wolters Kluwer. Copyright ©2009.</div><div id=\"graphicVersion\">Graphic 61447 Version 2.0</div></div></div>"},"61451":{"type":"graphic_diagnosticimage","displayName":"Stricture at the hepatic duct bifurcation","title":"Stricture at the hepatic duct bifurcation","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Stricture at the hepatic duct bifurcation</div><div class=\"cntnt\"><img style=\"width:502px; height:504px;\" src=\"images/GAST/61451_Strict_hepatic_duct_bifur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cholangiogram showing a stricture at the hepatic duct bifurcation.</div><div id=\"graphicVersion\">Graphic 61451 Version 2.0</div></div></div>"},"61452":{"type":"graphic_picture","displayName":"Solar lentigo hand 2","title":"Solar lentigines presenting as brown macules on the dorsum of the hand","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Solar lentigines presenting as brown macules on the dorsum of the hand</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/61452_Solar_lentigo_hand_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple brown macules are present on the dorsal hand.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 61452 Version 5.0</div></div></div>"},"61454":{"type":"graphic_table","displayName":"Ice therapy barrier effect","title":"Effects of barriers on magnitude of temperature reduction during ice therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Effects of barriers on magnitude of temperature reduction during ice therapy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n  <tr>\n    <td class=\"subtitle1\">Physical barrier</td>\n    <td class=\"subtitle1\">Skin temperature</td>\n  </tr>\n  <tr>\n    <td>Padded bandage</td>\n    <td>30.5&#176;C</td>\n  </tr>\n  <tr>\n    <td>Bandage alone</td>\n    <td>20.5&#176;C</td>\n  </tr>\n  <tr>\n    <td>Dry washcloth</td>\n    <td>17.8&#176;C</td>\n  </tr>\n  <tr>\n    <td>No barrier</td>\n    <td>10.8&#176;C</td>\n  </tr>\n  <tr>\n    <td>Damp washcloth</td>\n    <td>9.9&#176;C</td>\n  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Data from: LaVelle BE, Snyder M. Differential conduction of cold through barriers. J Adv Nurs 1985; 10:55.</div><div id=\"graphicVersion\">Graphic 61454 Version 2.0</div></div></div>"},"61455":{"type":"graphic_waveform","displayName":"Intermediate case 10","title":"Intermediate case 10","html":"<div class=\"graphic normal\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Intermediate case 10</div><div class=\"cntnt\"><img style=\"width:520px; height:99px;\" src=\"images/CARD/61455_Intermediate_case_10.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 61455 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"61456":{"type":"graphic_table","displayName":"Causes of chylothorax","title":"Etiology of chylothorax","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of chylothorax</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Etiology</td> <td class=\"subtitle1\">Number <span style=\"white-space: nowrap;\">of cases*<sup>[1]</sup></span> (percent)</td> <td class=\"subtitle1\">Number <span style=\"white-space: nowrap;\">of cases<sup>[2]</sup></span> (percent)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Total nontraumatic <em>PLUS</em> traumatic cases</strong></td> <td><strong>191 (100)</strong></td> <td><strong>203 (100)</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"><strong>Nontraumatic</strong></td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">Malignant neoplasia</td> </tr> <tr> <td class=\"indent2\"> <ul class=\"decimal_heading\"> <li>Lymphomatous </li> </ul> </td> <td class=\"indent1\"> <ul> <li>70 (37) </li> </ul> </td> <td class=\"indent1\"> <ul> <li>23 (11) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul class=\"decimal_heading\"> <li>Nonlymphomatous (primary lung, mediastinal, metastatic extrathoracic malignancies, leukemia) </li> </ul> </td> <td class=\"indent1\"> <ul> <li>17 (9) </li> </ul> </td> <td class=\"indent1\"> <ul> <li>11 (5) </li> </ul> </td> </tr> <tr class=\"highlight_gray_text\"> <td style=\"text-align: right;\">Total malignant neoplasia cases =</td> <td class=\"indent1\">87 (46)</td> <td class=\"indent1\">34 (17)</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">Nonmalignant neoplasia</td> </tr> <tr> <td class=\"indent2\"> <ul class=\"decimal_heading\"> <li>Idiopathic </li> </ul> </td> <td class=\"indent1\"> <ul> <li>26 (14) </li> </ul> </td> <td class=\"indent1\"> <ul> <li>13 (6) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul class=\"decimal_heading\"> <li>Miscellaneous (benign tumors, lymphangioleiomyomatosis, intestinal lymphangiectasis, protein-losing enteropathy, regional ileitis, reticular hyperplasia, pleuritis, cirrhosis, thoracic aortic aneurysm, lupus, tuberculosis, sarcoidosis, amyloidosis, venous thrombosis, mitral stenosis, nephrosis, thyroid goiter, tuberous sclerosis, filariasis, heart failure, Down syndrome, Noonan syndrome, other) </li> </ul> </td> <td class=\"indent1\"> <ul> <li>25 (13) </li> </ul> </td> <td class=\"indent1\"> <ul> <li>55 (27) </li> </ul> </td> </tr> <tr class=\"highlight_gray_text\"> <td style=\"text-align: right;\">Total nonmalignant neoplasia cases =</td> <td class=\"indent1\">51 (27)</td> <td class=\"indent1\">68 (33)</td> </tr> <tr class=\"divider_bottom highlight_green_text\"> <td style=\"text-align: right;\"><strong>Total nontraumatic cases =</strong></td> <td class=\"indent1\"><strong>138 (72)</strong></td> <td class=\"indent1\"><strong>102 (50)</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"><strong>Traumatic</strong></td> </tr> <tr> <td class=\"indent2\"> <ul class=\"decimal_heading\"> <li>Surgical (cardiovascular, aortic, thoracoplasty, esophagectomy, lobectomy, pneumonectomy, mediastinal mass resection, Bochdalek herniorrhaphy, transabdominal vagotomy, central venous catheterization, esophageal endoscopic sclerotherapy, neck surgery, spine surgery, embolization for pulmonary arteriovenous malformations, pacemaker insertion) </li> </ul> </td> <td class=\"indent1\"> <ul> <li>48 (25) </li> </ul> </td> <td class=\"indent1\"> <ul> <li>97 (48) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul class=\"decimal_heading\"> <li>Nonsurgical (penetrating or nonpenetrating trauma to the neck, thorax, and upper abdomen, straining, coughing, yawning, vomiting) </li> </ul> </td> <td class=\"indent1\"> <ul> <li>5 (3) </li> </ul> </td> <td class=\"indent1\"> <ul> <li>4 (2) </li> </ul> </td> </tr> <tr class=\"highlight_green_text\"> <td style=\"text-align: right;\"><strong>Total traumatic cases =</strong></td> <td class=\"indent1\"><strong>53 (28)</strong></td> <td class=\"indent1\"><strong>101 (50)</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NR: not reported as an etiologic class.<br />* 10 cases not accounted for in this reference's source table were added to the Miscellaneous category as \"other.\"</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Valentine VG, Raffin TA. The management of chylothorax. Chest 1992; 102:586.</li>&#xD;&#xA;    <li>Doerr CH, Allen MS, Nichols FC 3rd, Ryu JH. Etiology of chylothorax in 203 patients. Mayo Clin Proc 2005; 80:867.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 61456 Version 9.0</div></div></div>"},"61457":{"type":"graphic_diagnosticimage","displayName":"Normal trachea CXR","title":"Normal trachea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal trachea</div><div class=\"cntnt\"><img style=\"width:362px; height:542px;\" src=\"images/PULM/61457_Normal_trachea_CXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Frontal chest radiograph demonstrates the entire trachea and the tracheal bifurcation.</div><div id=\"graphicVersion\">Graphic 61457 Version 2.0</div></div></div>"},"61458":{"type":"graphic_diagnosticimage","displayName":"Pleural plaques CT","title":"Bilateral pleural plaques","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bilateral pleural plaques</div><div class=\"cntnt\"><img style=\"width:357px; height:339px;\" src=\"images/PULM/61458_Pleural_plaques_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan shows nodular and flat foci of pleural thickening that are present bilaterally. Flecks of calcium are noted within the plaques.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 61458 Version 3.0</div></div></div>"},"61461":{"type":"graphic_diagnosticimage","displayName":"SLS MRI 16 years","title":"Brain MRI of a 16-year-old with Sjogren-Larsson syndrome","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Brain MRI of a 16-year-old with Sjogren-Larsson syndrome</div><div class=\"cntnt\"><img style=\"width:468px; height:187px;\" src=\"images/NEURO/61461_SLS_MRI_16_years.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T2-weighted MR images (3100/98 [TR/TE]).<br />(A and B) Severe signal-intensity changes of the periventricular white matter with predominant involvement of the frontal trigones.<br />(C) Small areas of unmyelinated subcortical association fibers.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging. </div><div class=\"graphic_reference\">Reproduced with permission from: Willemsen, MA, Van Der, Graaf M, Van Der, Knaap MS, et al. MR imaging and proton MR spectroscopic studies in Sjogren-Larsson syndrome: characterization of the leukoencephalopathy. AJNR Am J Neuroradiol 2004; 25:649. Copyright &copy;2004 American Society of Neuroradiology.</div><div id=\"graphicVersion\">Graphic 61461 Version 3.0</div></div></div>"},"61463":{"type":"graphic_picture","displayName":"Neonatal gastroschisis 3","title":"Neonatal gastroschisis 3","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neonatal gastroschisis 3</div><div class=\"cntnt\"><img style=\"width:396px; height:373px;\" src=\"images/OBGYN/61463_Neonatal_gastroschisis_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Classic appearing gastroschisis with the abdominal wall defect to the right of the cord insertion (the yellow clamp is on the umbilical cord). Loops of small bowel can be noted with one area of dilation at the base of the mass. The bowel dilation was a &quot;new finding&quot; during ultrasound examination and was the indication for delivery (37 weeks).</div><div class=\"graphic_reference\">Courtesy of Courtney D Stephenson, DO and Tamara L Bradshaw, MD.</div><div id=\"graphicVersion\">Graphic 61463 Version 1.0</div></div></div>"},"61465":{"type":"graphic_table","displayName":"Causes of spontaneous pneumomediastinum in children","title":"Causes of spontaneous pneumomediastinum in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of spontaneous pneumomediastinum in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Medical conditions: </td> </tr> <tr> <td>Asthma</td> </tr> <tr> <td>Cystic fibrosis</td> </tr> <tr> <td>Upper and lower respiratory tract infections (laryngitis, bronchiolitis obliterans, measles, pertussis, Mycoplasma pneumonia and influenza)</td> </tr> <tr> <td>Gastro-esophageal reflux disease</td> </tr> <tr> <td>Seizure</td> </tr> <tr> <td>Rheumatologic diseases</td> </tr> <tr> <td class=\"subtitle1_single\">Respiratory maneuvers: </td> </tr> <tr> <td>Valsalva maneuver (eg, lifting heavy objects, blowing balloons, labor)</td> </tr> <tr> <td>Vomiting (especially with malnutrition)</td> </tr> <tr> <td>Coughing, crying and screaming</td> </tr> <tr> <td>Strenuous exercise</td> </tr> <tr> <td>Pulmonary function testing&nbsp;&nbsp;</td> </tr> <tr> <td><span style=\"color: black;\">SCUBA diving</span></td> </tr> <tr> <td>Centrifuge training</td> </tr> <tr> <td>Hyperpnea (eg, in the setting of ketoacidosis)</td> </tr> <tr> <td>Inhalation of helium</td> </tr> <tr> <td>Inhalation of illicit drugs</td> </tr> <tr> <td>Irritant gases</td> </tr> <tr> <td class=\"subtitle1_single\">Surgical conditions: </td> </tr> <tr> <td>Foreign body aspiration</td> </tr> <tr> <td>Spontaneous rupture of esophagus (Boerhaave's syndrome)</td> </tr> <tr> <td>Gastric perforation</td> </tr> <tr> <td>Rupture of rectum</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Chalumeau M, Le Clainche L, Sayeg N et al. Spontaneous pneumomediastinum in children. Pediatr Pulmonol 2001; 31:67. </LI>&#xD;&#xA;<LI>Vázquez JL, Vázquez I, González ML et al. Pneumomediastinum and pneumothorax as presenting signs in severe Mycoplasma pneumoniae pneumonia.&nbsp;Pediatr Radiol 2007; 37:1286. </LI>&#xD;&#xA;<LI>Yoshida K, Kurosaka D, Kingetsu I&nbsp;et al. Pneumomediastinum in dermatomyositis itself is not a poor prognostic factor: report of a case and review of the literature. Rheumatol Int 2008; 28:913. </LI>&#xD;&#xA;<LI>Muñiz AE. False-negative capnographic reading caused by a malfunctioning bag-valve-mask device resulting in a pneumomediastinum. Resuscitation. 2008; 78:378. </LI>&#xD;&#xA;<LI>Le Loch JB, Freymond N, Khettab F et al. [Pneumomediastinum, giant subcutaneous emphysema and pneumoperitoneum revealed by jaw pain. Uncommon physiopathology of pneumomediastinum]. Rev Pneumol Clin 2008; 64:30. </LI>&#xD;&#xA;<LI>HuangHR, Wong KS, Lien R and Chiu CY. Spontaneous pneumomediastinum due to gastroesophageal reflux disease in an adolescent boy. Respirology 2008; 13:744. </LI>&#xD;&#xA;<LI>Hahn CD, Choi YU, Lee D and Frizzi JD. Pneumoperitoneum due to gastric perforation after cardiopulmonary resuscitation: case report.Am J Crit Care 2008; 17:388.</LI></OL></div><div id=\"graphicVersion\">Graphic 61465 Version 4.0</div></div></div>"},"61466":{"type":"graphic_picture","displayName":"Pelvic sling SAM","title":"SAM pelvic sling","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">SAM pelvic sling</div><div class=\"cntnt\"><img style=\"width:432px; height:282px;\" src=\"images/EM/61466_Pelvic_sling_SAM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This pelvic sling includes a buckle that limits the amount of force applied to the pelvis.</div><div class=\"graphic_reference\">Reproduced with permission from: SAM Medical Products. www.sammedical.com/sam_sling.html (Accessed October 16, 2008). Copyright &#169;2008 SAM Medical Products.</div><div id=\"graphicVersion\">Graphic 61466 Version 2.0</div></div></div>"},"61467":{"type":"graphic_table","displayName":"Causes secondary hypogonadism","title":"Causes of hypogonadotropic (secondary) hypogonadism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hypogonadotropic (secondary) hypogonadism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Acquired</td> </tr> <tr> <td class=\"sublist1_start\">Tumors</td> </tr> <tr> <td class=\"sublist1\">Benign tumors and cysts</td> </tr> <tr> <td class=\"sublist1\">Craniopharyngiomas</td> </tr> <tr> <td class=\"sublist1\">Germinomas, meningiomas, gliomas, astrocytomas</td> </tr> <tr> <td class=\"sublist1\">Metastatic tumors (breast, lung, prostate)</td> </tr> <tr> <td class=\"sublist1_start\">\"Functional\" gonadotropin deficiency</td> </tr> <tr> <td class=\"sublist1\">Chronic systemic disease</td> </tr> <tr> <td class=\"sublist1\">Acute illness</td> </tr> <tr> <td class=\"sublist1\">Malnutrition</td> </tr> <tr> <td class=\"sublist1\">Hypothyroidism, hyperprolactinemia, diabetes mellitus, Cushing's disease</td> </tr> <tr> <td class=\"sublist1\">Anorexia nervosa, bulimia</td> </tr> <tr> <td class=\"sublist1\">Post-androgen abuse</td> </tr> <tr> <td class=\"sublist1_start\">Infiltrative diseases</td> </tr> <tr> <td class=\"sublist1\">Hemochromatosis</td> </tr> <tr> <td class=\"sublist1\">Granulomatous diseases</td> </tr> <tr> <td class=\"sublist1\">Histiocytosis</td> </tr> <tr> <td>Head trauma</td> </tr> <tr> <td>Pituitary apoplexy</td> </tr> <tr> <td>Drugs - marijuana, opioids, anabolic steroids</td> </tr> <tr> <td class=\"subtitle1_single\">Congenital</td> </tr> <tr> <td class=\"sublist1_start\">Isolated GnRH deficiency</td> </tr> <tr> <td class=\"sublist1\">Without anosmia</td> </tr> <tr> <td class=\"sublist1\">Kallmann syndrome</td> </tr> <tr> <td class=\"sublist1\">Associated with adrenal hypoplasia congenita</td> </tr> <tr> <td class=\"sublist1_start\">GnRH deficiency associated with mental retardation/obesity</td> </tr> <tr> <td class=\"sublist1\">Laurence-Moon-Biedl syndrome</td> </tr> <tr> <td class=\"sublist1\">Prader-Willi syndrome</td> </tr> <tr> <td>Idiopathic forms of multiple anterior pituitary hormone deficiencies</td> </tr> <tr> <td>Congenital malformations often associated with craniofacial anomalies</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GnRH: gonadotropin-releasing hormone.</div><div id=\"graphicVersion\">Graphic 61467 Version 4.0</div></div></div>"},"61473":{"type":"graphic_figure","displayName":"Pancreas anatomy PI","title":"Pancreas ","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Pancreas </div><div class=\"cntnt\"><img style=\"width:546px; height:571px;\" src=\"images/PI/61473_Pancreas_anatomy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pancreas is an organ that is found behind the stomach. It makes hormones and juices that help the body break down food. </div><div id=\"graphicVersion\">Graphic 61473 Version 5.0</div></div></div>"},"61475":{"type":"graphic_table","displayName":"Paclitaxel-cisplatin-paclitaxel for epithelial ovarian cancer","title":"Chemotherapy regimens for epithelial ovarian cancer: Intravenous (IV) paclitaxel followed by intraperitoneal (IP) cisplatin and IP paclitaxel<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chemotherapy regimens for epithelial ovarian cancer: Intravenous (IV) paclitaxel followed by intraperitoneal (IP) cisplatin and IP paclitaxel<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days.<br /> <strong>Total cycles:</strong> 6 cycles. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Paclitaxel</td> <td>135 mg/m<sup>2</sup> IV</td> <td>Dilute in 500 mL normal saline (NS) or 5% dextrose in water (D5W) and administer over 24 hours.*</td> <td>Day 1</td> </tr> <tr> <td>Cisplatin</td> <td>100 mg/m<sup>2</sup> IP<sup>&#182;</sup></td> <td>Dilute in one liter of NS and infuse through the implantable peritoneal catheter via gravity drip as rapidly as possible. A second liter of saline is then administered IP as tolerated.</td> <td>Day 2</td> </tr> <tr class=\"divider_bottom\"> <td>Paclitaxel</td> <td>60 mg/m<sup>2</sup> IP<sup>&#182;</sup></td> <td>Dilute in one liter of NS and infuse IP via gravity drip as rapidly as possible. A second liter of saline is then administered IP as tolerated.</td> <td>Day 8</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>The addition of two liters of IP NS does not replace the need for adequate IV hydration before and after cisplatin, and the maintenance of excellent urine output. On day 2, IV pre hydration with at least one liter of NS and a urine output of at least 100 mL/hour should be achieved before the administration of IP cisplatin to reduce the potential risk for nephrotoxicity.<sup>[2]</sup> Following the drug infusion, a second liter of IV NS should be given, and two hours of urine output of at least 100 mL/hour should be observed before sending the patient home. Some clinicians would add 12.5 g/L of mannitol in the pre and post hydration to enhance urinary output. Supplementation with magnesium and potassium may be required depending upon the serum electrolytes. A dose of furosemide may be required if urine output is insufficient. </li> <li>Refer to UpToDate topic on \"Intraperitoneal chemotherapy for treatment of ovarian cancer\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH (&#62;90% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Paclitaxel may cause severe hypersensitivity reactions. Premedication regimen should include dexamethasone (either 20 mg orally 12 and 6 hours before, or 20 mg IV 30 minutes before drug administration) plus both an H1 (diphenhydramine 25 to 50 mg IV) and an H2 receptor antagonist (ranitidine 50 mg or famotidine 20 mg IV) 30 to 60 minutes prior to paclitaxel administration. Severe infusion reactions (eg, skin rash, flushing, dyspnea, urticaria, back pain, hypotension, chest pain, tachycardia) occur primarily during the first and second infusions, typically within the first hour after the start of the infusion. Routine prophylaxis is generally not indicated prior to cisplatin treatment.<sup>[3]</sup> Management of infusion reactions and issues related to rechallenge are discussed separately. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>IV paclitaxel can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Patients with abnormal renal function were excluded from the phase III clinical trial demonstrating the efficacy of this regimen.<sup>[1]</sup> Dose modifications are not required for paclitaxel in renal insufficiency, but the dose should be adjusted for preexisting hepatic impairment.<sup>[3]</sup> </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Dosing of anticancer agents in adults\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes, renal, and liver function each cycle during treatment. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Each cycle should not begin until the WBC count is &#62;1500 cells/microL, platelets are &#62;100,000/microL, and creatinine clearance is &#62;50 mL/min.<sup>[1]</sup> In the original trial, treatment modifications for hematologic toxic effects included cycle delay, dose reduction, and use of granulocyte colony-stimulating factor (in that sequence). Dose modification was not performed if the WBC nadir was not accompanied by fever. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Both paclitaxel and cisplatin can cause neurotoxicity. In the original study, treatment was delayed in the case of grade 3 or 4 peripheral neuropathy until grade 1.<sup>[1]</sup> For severe neuropathy (grade 3 or 4) that persists for a week or longer, reduce the dose of paclitaxel by 20% for subsequent courses and substitute intravenous carboplatin for cisplatin.<sup>[3]</sup> Patients with mild neuropathy can continue to receive full cisplatin doses. If the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Renal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Avoidance of cisplatin-related nephrotoxicity requires close attention to volume status and adequate antiemetic control. If renal insufficiency develops, treatment should be withheld until renal function improves. In the original trial, treatment was postponed for a creatinine level &#62;2.0 mg per deciliter or a creatinine clearance of &#60;50 mL per minute.<sup>[1]</sup> Subsequent treatment was resumed only when it rose above 50 mL/min. Tolerability of the regimen may be improved by reducing the IP cisplatin dose to 75 mg/m<sup>2</sup>.</li> <li>Refer to UpToDate topic on \"Intraperitoneal chemotherapy for treatment of ovarian cancer\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Abdominal pain</strong></td> <td colspan=\"3\"> <ul> <li>Abdominal pain, which may be worse with IP paclitaxel than after cisplatin, is frequent. Peritonitis or gastrointestinal (GI) tract injury should be considered if there is guarding, rebound, nausea, vomiting, diarrhea, fever, or unexplained leucocytosis. If pain is encountered and there are no signs or symptoms to suggest peritonitis or GI tract injury, the second liter of NS can be reduced in volume or rate of flow, or withheld. In the original trial, the dose of IP chemotherapy was reduced for CTC grade 3 abdominal pain, recurrent CTC grade 2 abdominal pain, or complications involving the intraperitoneal catheter.<sup>[1]</sup> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">CBC: complete blood count; WBC: white blood cell; CTC: Common Toxicity Criteria.<br />* Paclitaxel can be administered in NS, D5W, or NS/D5W at varying concentrations between 0.3 to 1.2 mg/mL. Use glass or polypropylene bottles or polypropylene or polyolefin plastic bags, and administer through polyethylene-lined administration sets with a microporous membrane 0.22 microns or less (both IV and IP administration).<br />¶ Patients administered either paclitaxel or cisplatin by the IP route should receive the same supportive care drugs as are indicated with IV administration of these agents.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Armstrong DK, et al. N Engl J Med 2006; 354:34.</LI>&#xD;&#xA;<LI>Cisplatin injection, powder, lyophilized, for solution. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 8, 2011).</LI>&#xD;&#xA;<LI>Paclitaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online atdailymed.nlm.nih.gov, accessed on December 8, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 61475 Version 23.0</div></div></div>"},"61477":{"type":"graphic_table","displayName":"Chemo escalate for desensitiz","title":"Desensitization protocols","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Desensitization protocols</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Platinum administration\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Mix calculated total dose in 100 cc D5W.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Administer 0.1 cc of this solution in 100 cc D5W over 1 h (1:1000 dilution).</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>If tolerated, administer 1 cc of the solution in 100 cc D5W over 1 h (1:100 dilution).</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>If tolerated, administer 10 cc of the solution in 100 cc D5W over 1 h (1:10 dilution).</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>If tolerated, administer the remaining solution over 1 h (1:1 dilution)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   OR: Administer at 25 percent of usual rate for 1 h.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   If tolerated, administer at 50 percent of the usual rate for 1 h.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   If tolerated, administer at 75 percent of the usual rate for 1 h.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   If tolerated, administer the remaining at usual rate.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Reproduced with permission from: Robinson, JB, Singh, D, Bodurka-Bevers, DC, et al. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecologic Oncol 2001; 82:555. Copyright &#169;2001 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 61477 Version 1.0</div></div></div>"},"61480":{"type":"graphic_figure","displayName":"CNS tumor type child rates","title":"Age-adjusted incidence rates of pediatric brain and CNS tumors by selected histologies and age groups","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Age-adjusted incidence rates of pediatric brain and CNS tumors by selected histologies and age groups</div><div class=\"cntnt\"><img style=\"width:586px; height:382px;\" src=\"images/PEDS/61480_CNS_tumr_typ_chld_rate_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Age-adjusted incidence rates in children and adolescents of brain and CNS tumors by selected histologies and age groups (age 0-19 years), CBTRUS Statistical Report: NPCR and SEER, 2008-2012.</div><div class=\"graphic_footnotes\">CNS: central nervous system; PA: pilocytic astrocytoma; PNET: primitive neuroectodermal tumor; CBTRUS: Central Brain Tumor Registry of the United States; NPCR: National Program of Cancer Registries; SEER: Surveillance, Epidemiology, and End Results Program.<br />* All or some of this histology are included in the CBTRUS definition of gliomas, including ICD-O-3 histology codes 9380-9384, 9391-9460.<br />¶ ICD-O-3 histology codes: 9380-9384, 9391-9420, 9422-9460, 9480.<br />Δ ICD-O-3 histology codes: 9470/3, 9471/3, 9472/3, 9474/3.<br /><FONT class=lozenge>◊ </FONT>ICD-O-3 histology code: 9473/3.</div><div class=\"graphic_reference\">Reproduced with permission from: Quinn T. Ostrom, Haley Gittleman, Jordonna Fulop, Max Liu, Rachel Blanda, Courtney Kromer, Yingli Wolinsky, Carol Kruchko, and Jill S. Barnholtz-Sloan, CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008–2012, Neuro Oncol (2015) 17 (suppl 4): iv1-iv62 doi: 10.1093/neuonc/nov189.</div><div id=\"graphicVersion\">Graphic 61480 Version 5.0</div></div></div>"},"61481":{"type":"graphic_picture","displayName":"Benign microfollicular adenoma","title":"Benign microfollicular adenoma: Findings on surgical histology","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Benign microfollicular adenoma: Findings on surgical histology</div><div class=\"cntnt\"><img style=\"width:360px; height:242px;\" src=\"images/ENDO/61481_Microfollicular_adenoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical specimen of well-developed microfollicular adenoma. These lesions are benign if there is no evidence of either vascular or capsular invasion; the pathologic diagnosis is follicular cancer if invasion is seen.</div><div id=\"graphicVersion\">Graphic 61481 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Sporadic macrofollicular goiter with normal macrofollicles: Findings on surgical histology</div><div class=\"cntnt\"><img style=\"width:360px; height:236px;\" src=\"images/ENDO/71842_Thyroid_goiter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical specimen of a sporadic macrofollicular goiter with normal large thyroid follicules filled with colloid. These follicles are disrupted by needle biopsy so that the colloid will smear across the slide or occassionally aggregate into droplets.</div><div id=\"graphicVersion\">Graphic 71842 Version 3.0</div></div></div>"},"61482":{"type":"graphic_diagnosticimage","displayName":"Scan metastatic thyroid cancer","title":"131-I diagnostic scan in metastatic thyroid cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">131-I diagnostic scan in metastatic thyroid cancer</div><div class=\"cntnt\"><img style=\"width:292px; height:398px;\" src=\"images/ENDO/61482_Scan_metastatic_thyroid_can.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Whole-body scan of a 45-year-old woman with metastatic follicular thyroid carcinoma. A = physiologic nasopharygneal 131-I excretion; E = 131-I in gastrointestinal tract; and G = 131-I in the bladder. Metastatic foci are present in the right shoulder (B), left humerus (C), right lung and ribs (D), and T12 vertebra (F). The patient was subsequently treated with 200 mCi (7400 MBq) of 131-I.</div><div class=\"graphic_footnotes\">131-I: radioiodine.</div><div id=\"graphicVersion\">Graphic 61482 Version 3.0</div></div></div>"},"61483":{"type":"graphic_picture","displayName":"Angiodysplasia colon gross","title":"Angiodysplasia of the colon","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Angiodysplasia of the colon</div><div class=\"cntnt\"><img style=\"width:472px; height:288px;\" src=\"images/GAST/61483_Angiodysplasia_colon_Gross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross specimen of the colon with angiodysplasia shows a focal mucosal hemorrhagic area.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 61483 Version 2.0</div></div></div>"},"61484":{"type":"graphic_picture","displayName":"Staple line dehiscence","title":"Staple line dehiscence following gastric bypass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Staple line dehiscence following gastric bypass</div><div class=\"cntnt\"><img style=\"width:400px; height:416px;\" src=\"images/GAST/61484_Staple_line_dehiscence.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic appearance of a large staple line dehiscence, with easy access to the bypassed stomach (arrow).</div><div class=\"graphic_reference\">Courtesy of Christopher S Huang, MD.</div><div id=\"graphicVersion\">Graphic 61484 Version 3.0</div></div></div>"},"61485":{"type":"graphic_figure","displayName":"Indications for lung transplant","title":"Indications for adult lung transplants by year","html":"<div class=\"graphic\"><div style=\"width: 738px\" class=\"figure\"><div class=\"ttl\">Indications for adult lung transplants by year</div><div class=\"cntnt\"><img style=\"width:718px; height:440px;\" src=\"images/PULM/61485_Indicationsforlungtransp.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ILD: interstitial lung disease; IIP: idiopathic interstitial pneumonia; CF: cystic fibrosis; A1ATD: alpha-1 antitrypsin deficiency emphysema; COPD: chronic obstructive pulmonary disease.</div><div class=\"graphic_reference\">Reproduced from: The Registry of the International Society for Heart and Lung Transplantation: Thirty-Second Annual Report. J Heart Lung Transplant 2017; 36:1037. Illustration used with the permission of Elsevier, Inc. All rights reserved. For additional and updated information, please see the International Society for Heart and Lung Transplantation slide set \"Adult Lung Transplantation Statistics,\" at: <a href=\"https://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry\"  target=\"_blank\">https://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry</a>.</div><div id=\"graphicVersion\">Graphic 61485 Version 3.0</div></div></div>"},"61487":{"type":"graphic_picture","displayName":"Juvenile contractures","title":"Contractures in localized scleroderma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Contractures in localized scleroderma</div><div class=\"cntnt\"><img style=\"width:396px; height:287px;\" src=\"images/RHEUM/61487_Juvenile_contractures.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contractures of the hand in a child with localized scleroderma.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 61487 Version 2.0</div></div></div>"},"61488":{"type":"graphic_picture","displayName":"Atypical nevus","title":"Atypical nevus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atypical nevus</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/61488_Atypical_nevus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clinically atypical nevus with irregular borders and irregular pigmentation.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 61488 Version 3.0</div></div></div>"},"61489":{"type":"graphic_picture","displayName":"Skin ulcer caused by Fusarium spp","title":"Skin ulcer caused by <EM>Fusarium</EM> spp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin ulcer caused by <EM>Fusarium</EM> spp</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ID/61489_Skin_ulcer_Fusarium_spp.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. Marcio Nucci.</div><div id=\"graphicVersion\">Graphic 61489 Version 5.0</div></div></div>"},"61491":{"type":"graphic_figure","displayName":"Time course cerebral hemorrhage","title":"Time course of neurologic changes in intracerebral hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Time course of neurologic changes in intracerebral hemorrhage</div><div class=\"cntnt\"><img style=\"width:355px; height:324px;\" src=\"images/NEURO/61491_Time_course_cerebral_hemorr.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of rapid downhill course in terms of unusual behavior (green), hemimotor function (blue), and consciousness (red) in a patient with intracerebral (intraparenchymal) hemorrhage.</div><div id=\"graphicVersion\">Graphic 61491 Version 2.0</div></div></div>"},"61493":{"type":"graphic_table","displayName":"NCI CTCAE v5 pneumonitis","title":"NCI CTCAE v5.0 pneumonitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 pneumonitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Pneumonitis</td> <td>Asymptomatic; clinical or diagnostic observations only; intervention not indicated</td> <td>Symptomatic; medical intervention indicated; limiting instrumental ADL*</td> <td>Severe symptoms; limiting self-care ADL*; oxygen indicated</td> <td>Life-threatening respiratory compromise; urgent intervention indicated (eg, tracheostomy or intubation)</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Pneumonitis is characterized by inflammation focally or diffusely affecting the lung parenchyma.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; ADL: activities of daily living.<br />* Instrumental ADLs include preparing meals, shopping, using the telephone, managing money. Self-care ADLs include bathing, dressing, using the toilet, taking medications.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 61493 Version 9.0</div></div></div>"},"61495":{"type":"graphic_figure","displayName":"Chiari type II malformation and associated lesions","title":"Chiari type II malformation and associated lesions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chiari type II malformation and associated lesions</div><div class=\"cntnt\"><img style=\"width:400px; height:533px;\" src=\"images/NEURO/61495_Chari_II_assc_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Rubin, R, Strayer, DS. Rubin's Pathology: Clinicopathologic Foundations of Medicine, Fifth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2008. Copyright &#169; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 61495 Version 2.0</div></div></div>"},"61496":{"type":"graphic_diagnosticimage","displayName":"MRI brain Chiari II malformation","title":"Intracranial MRI findings of a child with a Chiari II malformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intracranial MRI findings of a child with a Chiari II malformation</div><div class=\"cntnt\"><img style=\"width:432px; height:431px;\" src=\"images/NEURO/61496_Chiari_II_intracranial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A sagittal T1-weighted MRI in a pediatric patient shows several characteristic intracranial findings of the Chiari II malformation, including downward displacement of cerebellar tissue through the foramen magnum (arrow), a small fourth ventricle (arrowhead), and tectal beaking (dashed arrow).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Eric D Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 61496 Version 5.0</div></div></div>"},"61498":{"type":"graphic_picture","displayName":"Lipomas multiple","title":"Multiple lipomas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple lipomas</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/61498_Lipomasmultiple.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodules are present on the arm of this patient with multiple lipomas.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 61498 Version 6.0</div></div></div>"},"61500":{"type":"graphic_picture","displayName":"Peritoneal endometriosis","title":"Peritoneal endometriosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peritoneal endometriosis</div><div class=\"cntnt\"><img style=\"width:425px; height:252px;\" src=\"images/ENDO/61500_Peritoneal_endometriosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The peritoneum in this woman with endometriosis is studded with reddish, irregularly shaped implants.</div><div class=\"graphic_reference\">Reprinted with permission. Copyright 1990 Syntex Laboratories, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 61500 Version 1.0</div></div></div>"},"61501":{"type":"graphic_table","displayName":"Breast cancer surveillance guidelines","title":"Summary of 2012 ASCO guideline recommendations for surveillance after breast cancer treatment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of 2012 ASCO guideline recommendations for surveillance after breast cancer treatment</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Mode of surveillance</td> <td class=\"subtitle1\">Recommendation*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Recommended</td> </tr> <tr> <td class=\"indent1\">History/physical examination</td> <td> <p>All women should have a careful history and physical examination every three to six months for the first three years after primary therapy, then every 6 to 12 months for the next two years, and then annually.</p> The history and physical examination should be performed by a physician<sup>&#182;</sup> experienced in the surveillance of patients with cancer and in breast examination.</td> </tr> <tr> <td class=\"indent1\">Patient education regarding symptoms of recurrence</td> <td> <p>Physicians should counsel patients about the symptoms of recurrence including new lumps, bone pain, chest pain, dyspnea, abdominal pain, or persistent headaches.</p> Helpful web sites for patient education include <a href=\"http://www.cancer.net/\" target=\"_blank\">www.cancer.net</a> and <a href=\"http://www.cancer.org/\" spellcheck=\"true\" target=\"_blank\">www.cancer.org</a>.<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Referral for genetic counseling</td> <td>Women at high risk for familial breast cancer syndromes should be referred for genetic counseling in accordance with clinical guidelines recommended by the US Preventive Services Task Force. Criteria to recommend referral include the following: Ashkenazi Jewish heritage; history of ovarian cancer at any age in the patient or any first- or second-degree relatives; any first-degree relative with a history of breast cancer diagnosed before the age of 50 years; two or more first- or second-degree relatives diagnosed with breast cancer at any age; patient or relative with diagnosis of bilateral breast cancer; and history of breast cancer in a male relative<sup>&#9674;</sup>.</td> </tr> <tr> <td class=\"indent1\">Breast self-examination</td> <td>All women should be counseled to perform monthly breast self-examination.</td> </tr> <tr> <td class=\"indent1\">Mammography</td> <td>Women treated with breast-conserving therapy should have their first posttreatment mammogram no earlier than six months after definitive radiation therapy. Subsequent mammograms should be obtained every 6 to 12 months for surveillance of abnormalities. Mammography should be performed yearly if stability of mammographic findings is achieved after completion of locoregional therapy.</td> </tr> <tr> <td class=\"indent1\">Pelvic examination</td> <td>Regular gynecologic follow-up is recommended for all women. Patients who receive tamoxifen therapy are at increased risk for developing endometrial cancer and should be advised to report any vaginal bleeding to their physicians. Longer follow-up intervals may be appropriate for women who have had a total hysterectomy and oophorectomy.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Coordination of care</td> <td> <p>The risk of breast cancer recurrence continues through 15 years after primary treatment and beyond. Continuity of care for patients with breast cancer is recommended and should be performed by a physician experienced in the surveillance of patients with cancer and in breast examination, including the examination of irradiated breasts. Follow-up by a PCP seems to lead to the same health outcomes as specialist follow-up with good patient satisfaction.</p> If a patient with early-stage breast cancer (tumor &#60;5 cm and &#60;4 positive nodes) desires follow-up exclusively by a PCP, care may be transferred to the PCP approximately one year after diagnosis. If care is transferred to a PCP, both the PCP and the patient should be informed of the appropriate follow-up and management strategy. Re-referral for further oncology assessment may be considered, as needed, especially for patients who are receiving adjuvant endocrine therapy.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Not recommended</td> </tr> <tr> <td class=\"indent1\">Routine blood tests</td> <td> <p>CBC testing is not recommended for routine breast cancer surveillance.</p> Automated chemistry studies are not recommended for routine breast cancer surveillance.</td> </tr> <tr> <td class=\"indent1\">Imaging studies</td> <td> <p>Chest x-rays are not recommended for routine breast cancer surveillance.</p> <p>Bone scans are not recommended for routine breast cancer surveillance.</p> <p>Ultrasound of the liver is not recommended for routine breast cancer surveillance.</p> <p>CT scanning is not recommended for routine breast cancer surveillance.</p> <p>FDG-PET scanning is not recommended for routine breast cancer surveillance.</p> Breast MRI is not recommended for routine breast cancer surveillance.</td> </tr> <tr> <td class=\"indent1\">Breast cancer tumor marker testing</td> <td> <p>The use of CA 15-3 or CA 27.29 is not recommended for routine surveillance of patients with breast cancer after primary therapy.</p> CEA testing is not recommended for routine surveillance of patients with breast cancer after primary therapy.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CBC: complete blood count; CEA: carcinoembryonic antigen; FDG-PET: [<SUP>18</SUP>F] fluorodeoxyglucose-positron emission tomography; MRI: magnetic resonance imaging; PCP: primary care physician.<br />* All recommendations remain the same as those published in 2006 <EM>[Khatcheressian JL, Wolff AC, Smith TJ, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 2006; 24:5091]</EM>. The Panel concluded that there was no new evidence that warranted changing any of the recommendations. The 2006 guideline provides a detailed discussion and rationale for the recommendations.<br />¶ Although the evidence is lacking, it seems likely that history as well as physical and breast exams may also be conducted by experienced non-physician providers (eg, nurse practitioners, physician assistants) under the supervision of an experienced physician.<br />Δ UpToDate also offers free patient information content: <A href=\"http://www.uptodate.com/patients\" target=_blank>www.uptodate.com/patients</A>.<br /><FONT class=lozenge>◊</FONT> Expert consensus-based recommendations are available with criteria specific to patients with cancer (eg, from the National Comprehensive Cancer Network [<A href=\"http://www.nccn.org/\" target=_blank>www.nccn.org</A>]). These recommendations include similar criteria as those from the US Preventive Services Task Force as well as other criteria such as diagnosis of triple negative breast cancer, or a combination of breast cancer and other specific cancers.</div><div class=\"graphic_reference\">Khatcheressian JL, Hurley P, Bantug E, et al. Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2013; 31:961. Reprinted with permission. Copyright &copy; 2012 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 61501 Version 9.0</div></div></div>"},"61502":{"type":"graphic_figure","displayName":"Local control and survival pulmonary metastectomy","title":"Effect of local control on survival following repeat metastasectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effect of local control on survival following repeat metastasectomy</div><div class=\"cntnt\"><img style=\"width:402px; height:342px;\" src=\"images/SURG/61502_Loc_control_survival.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Preservation of local control in the chest is associated with long-term survival following repeat metastasectomy.</div><div id=\"graphicVersion\">Graphic 61502 Version 4.0</div></div></div>"},"61503":{"type":"graphic_table","displayName":"Staging system retroperit sarc","title":"The Dutch/Memorial Sloan-Kettering cancer center classification system for retroperitoneal soft tissue sarcomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The Dutch/Memorial Sloan-Kettering cancer center classification system for retroperitoneal soft tissue sarcomas</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Classification</td>\n\n      <td class=\"subtitle1\">Definition</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Stage I</td>\n\n      <td>Low-grade, complete resection, no metastases</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Stage II</td>\n\n      <td>High-grade, complete resection, no metastases</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Stage III</td>\n\n      <td>Any grade, incomplete resection, no metastases</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Stage IV</td>\n\n      <td>Any grade, any resection, distant metastases</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=48158&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Staging_system_retroperit_s.htm</title></head></div><div class=\"graphic_reference\">Modified from: van Dalen T, Hennipman A,&nbsp;Van Coevorden F, et al. Evaluation of a clinically applicable post-surgical classification system for primary retroperitoneal soft-tissue sarcoma. Ann Surg Oncol 2004; 11:483.</div><div id=\"graphicVersion\">Graphic 61503 Version 3.0</div></div></div>"},"61504":{"type":"graphic_figure","displayName":"Stool diary blank PI","title":"Stool diary","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">Stool diary</div><div class=\"cntnt\"><img style=\"width:553px; height:611px;\" src=\"images/PI/61504_Stool_diary_blank_PI.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 61504 Version 1.0</div></div></div>"},"61505":{"type":"graphic_table","displayName":"Classification of tics","title":"Classification of tics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of tics</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Physiologic tics</td> </tr> <tr> <td>Mannerisms</td> </tr> <tr> <td class=\"subtitle1_single\">Pathologic tics</td> </tr> <tr> <td class=\"subtitle2_single\">Primary</td> </tr> <tr> <td class=\"sublist2_start\">Sporadic </td> </tr> <tr> <td class=\"sublist2\">Transient motor or phonic tics (&#60;1 year) </td> </tr> <tr> <td class=\"sublist2\">Chronic motor or phonic tics (&#62;1 year)</td> </tr> <tr> <td class=\"sublist2\">Adult-onset (recurrent) tics</td> </tr> <tr> <td class=\"sublist2\">Tourette syndrome</td> </tr> <tr> <td class=\"subtitle2_single\"><span class=\"subtitle2_single\">Secondary</span> (\"Tourettism\")</td> </tr> <tr> <td class=\"sublist2_start\">Inherited</td> </tr> <tr> <td class=\"sublist2\">Huntington disease </td> </tr> <tr> <td class=\"sublist2\">Primary dystonia</td> </tr> <tr> <td class=\"sublist2\">Neuroacanthocytosis</td> </tr> <tr> <td class=\"sublist2\">Neurodegeneration with brain iron accumulation</td> </tr> <tr> <td class=\"sublist2\">Tuberous sclerosis&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Wilson disease</td> </tr> <tr> <td class=\"indent1\">Infections: Encephalitis, Creutzfeldt-Jakob disease, Sydenham chorea</td> </tr> <tr> <td class=\"indent1\">Drugs: Stimulants, levodopa, carbamazepine, phenytoin, phenobarbital, antipsychotics (tardive tics)</td> </tr> <tr> <td class=\"indent1\">Toxins: Carbon monoxide</td> </tr> <tr> <td class=\"indent1\">Developmental: Static encephalopathy, mental retardation syndromes, chromosomal abnormalities</td> </tr> <tr> <td class=\"indent1\">Other: Head trauma, stroke, neurocutaneous syndromes, schizophrenia, neurodegenerative disorders</td> </tr> <tr> <td class=\"subtitle1_single\">Related disorders</td> </tr> <tr> <td>Stereotypies</td> </tr> <tr> <td>Self-injurious behaviors</td> </tr> <tr> <td>Hyperactivity syndrome</td> </tr> <tr> <td>Compulsions</td> </tr> <tr> <td>Excessive startle</td> </tr> <tr> <td>Jumping Frenchman, Latah, Myriachit</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from:<br />Jankovic J. Differential diagnosis and etiology of tics. Adv Neurol 2001; 85:15.<br />Jankovic J, Kurlan R. Tourette syndrome: evolving concepts. Mov Disord 2011; 26:1149.</div><div id=\"graphicVersion\">Graphic 61505 Version 3.0</div></div></div>"},"61507":{"type":"graphic_table","displayName":"Treatment of myxedema coma","title":"Treatment of myxedema coma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of myxedema coma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Draw serum for T4, TSH, and cortisol.</td> </tr> <tr> <td>Administer levothyroxine 200 to 400 mcg&nbsp;intravenously, followed by daily doses of&nbsp;50 to 100 mcg, and triiodothyronine 5 to 20 mcg intravenously, followed by 2.5 to 10 mcg every eight hours.*</td> </tr> <tr> <td>Change to an appropriate oral dose of&nbsp;levothyroxine when the patient can tolerate oral medications. (Oral dose&nbsp;is approximately the&nbsp;intravenous dose divided by&nbsp;0.75).</td> </tr> <tr> <td>&nbsp;Hydrocortisone 100 mg intravenously every eight hours until exclusion of possible adrenal insufficiency.</td> </tr> <tr> <td class=\"sublist1_start\">Supportive measures:</td> </tr> <tr> <td class=\"sublist1\">Mechanical ventilation</td> </tr> <tr> <td class=\"sublist1\">Fluids and vasopressor drugs to correct hypotension</td> </tr> <tr> <td class=\"sublist1\">Passive rewarming</td> </tr> <tr> <td class=\"sublist1\">Intravenous dextrose</td> </tr> <tr> <td class=\"sublist1\">Consider empirical antibiotic treatment</td> </tr> <tr> <td class=\"sublist1\">Monitor for arrhythmias and treat when indicated</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">T4: thyroxine; TSH: thyroid-stimulating hormone.<br />* The lower end of the dose ranges is preferred in lower weight and older patients and those at risk for cardiac complications. Refer to accompany UpToDate topic on myxedema coma.</div><div id=\"graphicVersion\">Graphic 61507 Version 3.0</div></div></div>"},"61510":{"type":"graphic_diagnosticimage","displayName":"Liver abscess CT","title":"Liver abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Liver abscess</div><div class=\"cntnt\"><img style=\"width:332px; height:288px;\" src=\"images/GAST/61510_Liver_abscess_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A contrast-enhanced CT scan of the upper abdomen demonstrates a large gas-containing abscess in the right lobe of the liver. This location is easily amenable to percutaneous CT-guided drainage.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 61510 Version 3.0</div></div></div>"},"61511":{"type":"graphic_picture","displayName":"Serous cystadenoma Gross","title":"Gross appearance of pancreatic serous cystadenoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Gross appearance of pancreatic serous cystadenoma</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/GAST/61511_Serous_cystadenoma_Gross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross appearance of pancreatic serous cystadenoma. Note central stellate scar.</div><div class=\"graphic_reference\">Courtesy of Michael L Steer, MD.</div><div id=\"graphicVersion\">Graphic 61511 Version 3.0</div></div></div>"},"61513":{"type":"graphic_picture","displayName":"Microhematocrit determination","title":"Microhematocrit determination","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Microhematocrit determination</div><div class=\"cntnt\"><img style=\"width:504px; height:189px;\" src=\"images/ID/61513_Microhct_determination.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The capillary tube is plugged at one end and centrifuged (left). The proportion of blood volume occupied by red cells can be readily determined by eye in a microhematocrit reader (right).</div><div class=\"graphic_reference\">Courtesy of Nathaniel Duke.</div><div id=\"graphicVersion\">Graphic 61513 Version 3.0</div></div></div>"},"61514":{"type":"graphic_table","displayName":"A guide to common nutrient claims and what they mean PI","title":"A guide to common nutrient claims and what they mean","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">A guide to common nutrient claims and what they mean</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">Salt/sodium free</td> <td>Less than 5 mg of sodium per&nbsp;serving</td> </tr> <tr> <td class=\"subtitle2_left\">Very low sodium</td> <td>35 mg or less of sodium per serving</td> </tr> <tr> <td class=\"subtitle2_left\">Low sodium</td> <td>140 mg or less&nbsp;of sodium per&nbsp;serving</td> </tr> <tr> <td class=\"subtitle2_left\">Reduced sodium</td> <td>At least 25% less sodium than the regular product</td> </tr> <tr> <td class=\"subtitle2_left\">Light or lite in sodium</td> <td>At least&nbsp;50% less sodium than the regular product</td> </tr> <tr> <td class=\"subtitle2_left\">&nbsp;<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">No salt added or unsalted</span></td> <td>&nbsp;<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">No salt is added during processing, but these products may not be salt/sodium free unless stated</span></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">mg: milligram; %: percent.</div><div class=\"graphic_reference\">Data from: Understanding Food Terms. American Cancer Society. Available at: <A spellcheck=true href=\"https://www.cancer.org/healthy/eat-healthy-get-active/take-control-your-weight/understanding-food-labels.html\" target=_blank>https://www.cancer.org/healthy/eat-healthy-get-active/take-control-your-weight/understanding-food-labels.html</A> (Accessed on January 8, 2018.)</div><div id=\"graphicVersion\">Graphic 61514 Version 5.0</div></div></div>"},"61517":{"type":"graphic_figure","displayName":"Number 10 cleft","title":"Number 10 cleft","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Number 10 cleft</div><div class=\"cntnt\"><img style=\"width:315px; height:325px;\" src=\"images/PEDS/61517_Number_10_cleft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Middle one-third eyebrow and lid. Fronto-orbital encephalocele. Inferior lateral displaced orbit.</div><div class=\"graphic_reference\">Kawamoto, HK Jr. Cranofacial anomalies. In: Grab &amp; Smith's Plastic Surgery, 4th ed, Smith, J, Aston, S (Eds), Little Brown, New York 1991. p.158.</div><div id=\"graphicVersion\">Graphic 61517 Version 2.0</div></div></div>"},"61518":{"type":"graphic_figure","displayName":"Flail chest injury","title":"Flail chest injury","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Flail chest injury</div><div class=\"cntnt\"><img style=\"width:452px; height:491px;\" src=\"images/EM/61518_Flail_chest_injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A flail chest occurs when three or more adjacent ribs are each fractured in two places, creating one floating segment comprised of several rib sections and the soft tissues between them.</div><div id=\"graphicVersion\">Graphic 61518 Version 3.0</div></div></div>"},"61519":{"type":"graphic_picture","displayName":"Black esophagus Endosc","title":"Acute esophageal necrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute esophageal necrosis</div><div class=\"cntnt\"><img style=\"width:313px; height:327px;\" src=\"images/GAST/61519_Black_esophagus_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Black discloration of the distal esophagus is visible on this endoscopic image of a patient with acute esophageal necrosis.</div><div class=\"graphic_reference\">Courtesy of Daniel Gelrud, MD.</div><div id=\"graphicVersion\">Graphic 61519 Version 1.0</div></div></div>"},"61520":{"type":"graphic_diagnosticimage","displayName":"IDUS showing CBD PD","title":"Intraductal ultrasound demonstrating a normal common bile duct and pancreatic duct","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraductal ultrasound demonstrating a normal common bile duct and pancreatic duct</div><div class=\"cntnt\"><img style=\"width:408px; height:288px;\" src=\"images/GAST/61520_IDUS_shw_CBD_PD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal intraductal ultrasound examination demonstrating the common bile duct (CBD) and pancreatic duct (PD).</div><div class=\"graphic_reference\">Courtesy of Drs. Michael J Levy, Enrique Vazquez-Sequeiros, and Maurits J Wiersema.</div><div id=\"graphicVersion\">Graphic 61520 Version 4.0</div></div></div>"},"61523":{"type":"graphic_picture","displayName":"Wickhams striae on plaque","title":"Lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen planus</div><div class=\"cntnt\"><img style=\"width:394px; height:259px;\" src=\"images/PC/61523_Wickhams_striae_on_plaque.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the thick, violaceous, hyperkeratotic plaque with a white, lacelike pattern on the surface (Wickham striae).</div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 61523 Version 2.0</div></div></div>"},"61524":{"type":"graphic_table","displayName":"FEV1 and survival in COPD","title":"Survival rates in COPD according to percent predicted postbronchodilator FEV<sub>1</sub> (PB FEV<sub>1</sub>) ≤65 years of age in patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Survival rates in COPD according to percent predicted postbronchodilator FEV<sub>1</sub> (PB FEV<sub>1</sub>) ≤65 years of age in patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"5\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Initial PB FEV<sub>1</sub><br /> (percent predicted)</td> <td class=\"subtitle1\" rowspan=\"2\">Number</td> <td class=\"subtitle1\" colspan=\"4\">Culmulative survival rate<br /> (percent)</td> </tr> <tr> <td class=\"subtitle2\">At 2 years</td> <td class=\"subtitle2\">At 5 years</td> <td class=\"subtitle2\">At 10 years</td> <td class=\"subtitle2\">At 15 years</td> </tr> <tr> <td>&#60;20</td> <td>9</td> <td>44</td> <td>11</td> <td>11</td> <td>0</td> </tr> <tr> <td>20 to 29</td> <td>40</td> <td>65</td> <td>30</td> <td>10</td> <td>3</td> </tr> <tr> <td>30 to 39</td> <td>43</td> <td>83</td> <td>47</td> <td>21</td> <td>7</td> </tr> <tr> <td>40 to 49</td> <td>26</td> <td>92</td> <td>89</td> <td>39</td> <td>30</td> </tr> <tr> <td>50 to 59</td> <td>21</td> <td>95</td> <td>95</td> <td>57</td> <td>32</td> </tr> <tr> <td>60+</td> <td>9</td> <td>100</td> <td>89</td> <td>89</td> <td>67</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FEV<sub>1</sub>: forced expiratory volume in one second; PB: postbronchodilator.</div><div class=\"graphic_reference\">Reference: Traver GA, Cline MG, Burrows B. Predictors of mortality in chronic obstructive pulmonary disease. A 15-year follow-up study. Am Rev Respir Dis 1979; 119:895.</div><div id=\"graphicVersion\">Graphic 61524 Version 3.0</div></div></div>"},"61525":{"type":"graphic_picture","displayName":"Wrist hypermobility","title":"Joint laxity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Joint laxity</div><div class=\"cntnt\"><img style=\"width:207px; height:351px;\" src=\"images/RHEUM/61525_Wrist_hypermobility.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Laxity of the wrist allows approximation of the thumb to the patient's ipsilateral forearm. Joint laxity is a crucial feature of the hypermobility syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from Sheon RP, Moskowitz RW, Goldberg VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.</div><div id=\"graphicVersion\">Graphic 61525 Version 2.0</div></div></div>"},"61526":{"type":"graphic_picture","displayName":"Hypertrophic osteoarthropathy 2","title":"Hypertrophic osteoarthropathy - digital clubbing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypertrophic osteoarthropathy - digital clubbing</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/61526_Hypertrophic_osteoarthr_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bulbous swelling of the distal phalanges of the fingers with increased nail curvature is present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 61526 Version 4.0</div></div></div>"},"61531":{"type":"graphic_figure","displayName":"Change in Down syndrome markers across the first trimester","title":"Change in Down syndrome markers across the first trimester","html":"<div class=\"graphic\"><div style=\"width: 715px\" class=\"figure\"><div class=\"ttl\">Change in Down syndrome markers across the first trimester</div><div class=\"cntnt\"><img style=\"width:695px; height:672px;\" src=\"images/OBGYN/61531_ChngDownsynmrkrs1sttri.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NT: nuchal translucency; PAPP-A: pregnancy-associate plasma protein A; IU: international units; hCG: human chorionic gonadotropin.</div><div class=\"graphic_reference\">Courtesy of Glenn E Palomaki, PhD.</div><div id=\"graphicVersion\">Graphic 61531 Version 5.0</div></div></div>"},"61532":{"type":"graphic_picture","displayName":"Female ectopic ureter","title":"Ectopic ureter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ectopic ureter</div><div class=\"cntnt\"><img style=\"width:320px; height:382px;\" src=\"images/PEDS/61532_Female_ectopic_ureter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ectopic ureter in a female patient. Probe indicates the location of an ectopic ureter in the vaginal vestibule between the urethra and vaginal opening.</div><div class=\"graphic_reference\">Courtesy of: Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 61532 Version 2.0</div></div></div>"},"61533":{"type":"graphic_figure","displayName":"Head-tilt/chin-lift","title":"Head-tilt/chin-lift maneuver","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Head-tilt/chin-lift maneuver</div><div class=\"cntnt\"><img style=\"width:345px; height:368px;\" src=\"images/EM/61533_Head_tilt_chin_lift.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">One of the rescuer's hands is used to tilt the head, extending the neck. The index finger of the rescuer's other hand lifts the mandible outward, raising the chin. Head tilt should not be performed if cervical spine injury is suspected.</div><div id=\"graphicVersion\">Graphic 61533 Version 2.0</div></div></div>"},"61534":{"type":"graphic_picture","displayName":"Infantile myofibroma back","title":"Infantile myofibromatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infantile myofibromatosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/61534_Infantile_myofibroma_back.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, firm nodules are present on the trunk and arm.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 61534 Version 4.0</div></div></div>"},"61535":{"type":"graphic_diagnosticimage","displayName":"Frykman I radius fracture AP view","title":"Frykman I radius fracture AP view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Frykman I radius fracture AP view</div><div class=\"cntnt\"><img style=\"width:288px; height:432px;\" src=\"images/EM/61535_Frykman_I_AP_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This radiograph, taken of a 23-year-old snowboarder after she fell back onto her outstretched left hand, shows a Frykman I distal radius fracture. The radiograph shows several abnormalities including a significant loss of radial height, decreased radial inclination, and positive ulnar variance. Also, several fracture lines are present (arrows), indicating comminution.</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Courtesy of Erik L Schroeder, MD.</div><div id=\"graphicVersion\">Graphic 61535 Version 4.0</div></div></div>"},"61536":{"type":"graphic_figure","displayName":"Androgen receptor domains","title":"Normal human androgen receptor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal human androgen receptor</div><div class=\"cntnt\"><img style=\"width:367px; height:119px;\" src=\"images/ENDO/61536_Androgen_receptor_domains.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic diagram of the normal human androgen receptor structure as deduced from cDNA. The protein contains 917 amino acids, and the positions of the homopolymeric glutamine (Gln), proline (Pro), and glycine (Gly) repeat sequences and of the DNA- and hormone-binding domains are indicated using the numbering coordinates of Tilley WD, Marcelli M, Wilson JD, McPhaul MJ. Proc Natl Acad Sci U S A 1989; 86:327.</div><div id=\"graphicVersion\">Graphic 61536 Version 2.0</div></div></div>"},"61537":{"type":"graphic_picture","displayName":"Barretts esophagus with high grade dysplasia CPC Endosc","title":"Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:252px; height:222px;\" src=\"images/GAST/61537_Barretts_high_grade_CPC_End.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of the distal esophagus shows a single, 3 cm long linear area of salmon-colored mucosa above the esophagogastric junction suggestive of Barrett's esophagus.</div><div class=\"graphic_reference\">Courtesy of Myron Falchuk, MD, and Andres Gelrud, MD.</div><div id=\"graphicVersion\">Graphic 61537 Version 2.0</div></div></div>"},"61539":{"type":"graphic_figure","displayName":"Meiosis","title":"Meiosis","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Meiosis</div><div class=\"cntnt\"><img style=\"width:524px; height:482px;\" src=\"images/PC/61539_Meiosis.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 61539 Version 2.0</div></div></div>"},"61540":{"type":"graphic_table","displayName":"Classification of burns by depth of injury","title":"Classification of burns by depth of injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of burns by depth of injury</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Depth </td> <td class=\"subtitle1\">Appearance </td> <td class=\"subtitle1\">Sensation </td> <td class=\"subtitle1\">Healing time </td> </tr> <tr> <td>Superficial (epidermal)</td> <td> <p>Dry, red</p> <p>Blanches with pressure</p> </td> <td>Painful</td> <td>3 to 6 days</td> </tr> <tr> <td>Superficial partial-thickness</td> <td> <p>Blisters</p> <p>Moist, red, weeping</p> <p>Blanches with pressure</p> </td> <td>Painful to temperature and air</td> <td>7 to 21 days</td> </tr> <tr> <td>Deep partial-thickness</td> <td> <p>Blisters (easily unroofed)</p> <p>Wet or waxy dry</p> <p>Variable color (patchy to cheesy white to red)</p> <p>Does not blanch with pressure</p> </td> <td>Perceptive of pressure only</td> <td>&#62;21 days, usually requires surgical treatment</td> </tr> <tr> <td>Full-thickness</td> <td> <p>Waxy white to leathery gray to charred and black</p> <p>Dry and inelastic</p> <p>No blanching with pressure</p> </td> <td>Deep pressure only</td> <td>Rare, unless surgically treated</td> </tr> <tr> <td>Deeper injury (ie, fourth degree)&nbsp;</td> <td>Extends into fascia and/or muscle</td> <td>Deep pressure</td> <td>Never, unless surgically treated</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from:<br /><OL>&#xD;&#xA;<LI>Mertens DM, Jenkins ME, Warden GD. Outpatient burn management. Nurs Clin North Am 1997; 32:343.</LI>&#xD;&#xA;<LI>Peate WF. Outpatient management of burns. Am Fam Physician 1992; 45:1321.</LI>&#xD;&#xA;<LI>Clayton MC, Solem LD. No ice, no butter. Advice on management of burns for primary care physicians. Postgrad Med 1995; 97:151.</LI></OL></div><div id=\"graphicVersion\">Graphic 61540 Version 5.0</div></div></div>"},"61544":{"type":"graphic_picture","displayName":"Positioning for puncture of olecranon fossa","title":"Positioning for ultrasound-guided puncture of olecranon fossa","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Positioning for ultrasound-guided puncture of olecranon fossa</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/RHEUM/61544_Pos_punc_olecranon_fossa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient and needle positioning for puncture of olecranon fossa.</div><div class=\"graphic_reference\">Reproduced with permission from: Introductory Guide to Musculoskeletal Ultrasound for the Rheumatologist, Second Edition. ISBN 978-90-313-9206-3; Bohn Stafleu van Loghum, Houten 2012. Copyright &#169; 2012.</div><div id=\"graphicVersion\">Graphic 61544 Version 2.0</div></div></div>"},"61547":{"type":"graphic_picture","displayName":"Fibrillary glomerulonephritis IF","title":"Fibrillary glomerulonephritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fibrillary glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:378px; height:280px;\" src=\"images/NEPH/61547_Fibrillary_GN_IF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunofluorescence microscopy in fibrillary glomerulonephritis shows coarse linear pattern of IgG deposition (best seen at arrows). The coarseness and the lack of circulating anti-GBM antibodies distinguish this disorder from anti-GBM antibody disease.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 61547 Version 2.0</div></div></div>"},"61548":{"type":"graphic_picture","displayName":"Listeria placentitis","title":"<EM>Listeria </EM>placentitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Listeria </EM>placentitis</div><div class=\"cntnt\"><img style=\"width:400px; height:255px;\" src=\"images/OBGYN/61548_Listeria_placentitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 61548 Version 3.0</div></div></div>"},"61549":{"type":"graphic_table","displayName":"Abbreviated screening for depression in cancer pts","title":"Abbreviated screening methods for the assessment of depression in cancer patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Abbreviated screening methods for the assessment of depression in cancer patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Single-item interview assessing depressed mood (adapted from SADS)<sup>[1]</sup></td> </tr> <tr> <td>Two-item interview assessing depressed mood and loss of interest in activities (eg, as adapted from SADS<sup>[1]</sup> or the PHQ-2<sup>[2]</sup>)</td> </tr> <tr> <td>Visual analog scale for depressed mood (adapted from Memorial Pain Assessment Card)<sup>[3]</sup></td> </tr> <tr> <td>13-item Beck Depression Inventory (adapted from 21-item Beck Depression Inventory)<sup>[4]</sup></td> </tr> <tr> <td>Brief Case-Find for Depression (BCD)<sup>[5]</sup></td> </tr> <tr> <td>Four-question algorithm for screening depression (energy level, anhedonia, depressive feelings, psychomotor agitation/retardation)<sup>[6]</sup></td> </tr> <tr> <td>Single-item interview assessing psychological distress in the MOS SF36 (36-item short-form) health survey<sup>[7]</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SADS: Schedule for Affective Disorders and Schizophrenia; PHQ-2: Patient Health Questionnaire-2.</div><div class=\"graphic_reference\">1. Chochinov HM, Wilson KG, Enns M, Lander S. \"Are you depressed?\" Screening for depression in the terminally ill. Am J Psych 1997; 154:674.<br />2. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care 2003; 41:1284.<br />3. Fishman B, Pasternak S, Wallenstein SL, et al. The Memorial Pain Assessment Card. A valid instrument for the evaluation of cancer pain. Cancer 1987; 60:1151.<br />4. Beck AT, Beck RW. Screening depressed patients in family practice. A rapid technic. Postgrad Med 1972; 52:81.<br />5. Jefford M, Mileshkin L, Richards K,&nbsp;et al. Rapid screening for depression—validation of the Brief Case-Find for Depression (BCD) in medical oncology and palliative care patients.&nbsp;Br J Cancer 2004; 91:900.<br />6. Robinson J, Crawford GB. Identifying palliative care patients with symptoms of depression: An algorithm.&nbsp;Palliat Med 2005; 19:278.<br />7. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.&nbsp;Med Care 1992; 30:473.<br /></div><div id=\"graphicVersion\">Graphic 61549 Version 4.0</div></div></div>"},"61550":{"type":"graphic_picture","displayName":"Dermatographism 2","title":"Dermatographism (\"skin writing\")","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermatographism (\"skin writing\")</div><div class=\"cntnt\"><img style=\"width:360px; height:254px;\" src=\"images/ALLRG/61550_Dermatographism_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These lesions occurred&nbsp;three minutes after stroking with the wooden tip of a cotton swab.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 61550 Version 3.0</div></div></div>"},"61552":{"type":"graphic_figure","displayName":"Reticulocyte shift","title":"Prolongation of reticulocyte maturation time in anemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prolongation of reticulocyte maturation time in anemia</div><div class=\"cntnt\"><img style=\"width:414px; height:176px;\" src=\"images/HEME/61552_Reticulocyte_shift.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With worsening anemia and increasing erythropoietin stimulation, bone marrow reticulocytes (left) leave the marrow at an earlier stage in their maturation. This prolongs the maturation time in the circulation from one day to as long as 2.5 days (right).</div><div class=\"graphic_reference\">Adapted from: Normal erythropoiesis. In: Hematology in Clinical Practice, Hillman RS, Ault KA (Eds),&nbsp;McGraw-Hill, New York. p.29.</div><div id=\"graphicVersion\">Graphic 61552 Version 3.0</div></div></div>"},"61553":{"type":"graphic_table","displayName":"Diet for pediatric hypertriglyceridemia","title":"Diet for pediatric hypertriglyceridemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diet for pediatric hypertriglyceridemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Refer to a registered dietitian for family medical nutrition therapy</td> </tr> <tr> <td class=\"sublist1_start\">Dietary components include:</td> </tr> <tr> <td> <ul> <li>25 to 30 percent of calories from fat, &#8804;7 percent from saturated fat, ~10 percent from monounsaturated fat; &#60;200 mg/d of cholesterol; avoid trans fats as much as possible. </li> <li>Decrease sugar intake, replace simple with complex carbohydrates, and no sugar sweetened beverages. </li> <li>Increase dietary fish to increase omega-3 fatty acid.&nbsp;&nbsp;Environmental Protection Agency is advising women of childbearing age who may become pregnant, pregnant women,&nbsp;nursing mothers, and young children to avoid some types of fish and shellfish and eat fish and shellfish that are low in mercury. For more information, call the United States Food and Drug Administration's FDA) food information line toll free at 1-888-SAFEFOOD or visit http://www.cfsan.fda.gov/~dms/admehg3. </li> <li>If child is obese, nutrition therapy should include calorie restriction and increased activity. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Daniels SR, Benuck I, Christakis DA, et al. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Full report, 2011. National Heart Lung and Blood Institute. Available at: <a href=\"http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>.</div><div id=\"graphicVersion\">Graphic 61553 Version 2.0</div></div></div>"},"61555":{"type":"graphic_diagnosticimage","displayName":"Nondisplaced transverse fracture of little toe: Oblique view","title":"Nondisplaced transverse fracture of little toe: Oblique view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nondisplaced transverse fracture of little toe: Oblique view</div><div class=\"cntnt\"><img style=\"width:366px; height:412px;\" src=\"images/EM/61555_Trans_fx_5th_toe_oblique.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 61555 Version 4.0</div></div></div>"},"61556":{"type":"graphic_picture","displayName":"Serum sickness of the hands and feet","title":"Serum sickness of the hands and feet","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Serum sickness of the hands and feet</div><div class=\"cntnt\"><img style=\"width:432px; height:259px;\" src=\"images/ALLRG/61556_Serum_sickness_hands_feet.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Bielory L, Gascon P, Lawley TJ, et al. Human serum sickness:&nbsp;A prospective analysis of 35 patients treated with equine anti-thymocyte globulin for bone marrow failure. Medicine 1988; 67:40. Copyright © 1988 Lippincott Williams and Wilkins.</div><div id=\"graphicVersion\">Graphic 61556 Version 12.0</div></div></div>"},"61557":{"type":"graphic_figure","displayName":"Focal RFA Barretts","title":"Schematic illustration of primary circumferential and secondary focal radiofrequency ablation (RFA) of Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">Schematic illustration of primary circumferential and secondary focal radiofrequency ablation (RFA) of Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:556px; height:580px;\" src=\"images/GAST/61557_Focal_RFA_Barretts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><STRONG>(A)</STRONG> Pre-treatment image of a Barrett's segment.<BR><STRONG>(B, C)</STRONG> The esophageal diameter is measured at 1-cm intervals with a sizing balloon placed over a guidewire.<BR><STRONG>(D)</STRONG> Introduction of the RFA balloon catheter over the guidewire.<BR><STRONG>(E)</STRONG> The inflated RFA balloon positioned 1 cm above the top of the Barrett's segment.<BR><STRONG>(F)</STRONG> The RFA balloon repositioned for ablation of the second zone after ablation of the first zone with an overlap of 1 cm with the first ablation zone.<BR><STRONG>(G)</STRONG> Image of the treated Barrett's segment immediately after the RFA ablation with visible necrosis of the superficial mucosa.<BR><STRONG>(H)</STRONG> Image of the healed distal esophagus three months after RFA treatment with regeneration with neosquamous mucosa and three small islands of residual Barrett's mucosa.<BR><STRONG>(I)</STRONG> Introduction of the endoscope with the Barrx90 cap for focal ablation.<BR><STRONG>(J)</STRONG> Ablation of the third island of Barrett's mucosa. The necrosis caused by ablation of the first two islands is visible proximally.<BR><STRONG>(K)</STRONG> Image of the distal esophagus immediately after ablation of the three residual islands of Barrett's mucosa.<BR><STRONG>(L)</STRONG> Image of the healed distal esophagus, showing complete regeneration with neosquamous mucosa.</div><div class=\"graphic_reference\">Reproduced with permission of www.endosurgery.eu. Copyright © 2010 Esophageal Research Foundation Amsterdam.</div><div id=\"graphicVersion\">Graphic 61557 Version 2.0</div></div></div>"},"61558":{"type":"graphic_figure","displayName":"Laparoscopic cystectomy a","title":"Laparoscopic ovarian cystectomy","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Laparoscopic ovarian cystectomy</div><div class=\"cntnt\"><img style=\"width:463px; height:259px;\" src=\"images/OBGYN/61558_Laparoscopic_cystectomy_a.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ovarian cortex is incised in the direction of the ovarian axis.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 61558 Version 3.0</div></div></div>"},"61559":{"type":"graphic_diagnosticimage","displayName":"PCP in AIDS PA","title":"Pneumocystis jirovecii pneumonia in patient with AIDS","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pneumocystis jirovecii pneumonia in patient with AIDS</div><div class=\"cntnt\"><img style=\"width:336px; height:260px;\" src=\"images/PULM/61559_PCP_in_AIDS_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows diffuse ground glass opacification without air bronchograms and without obliteration of the pulmonary vessels.</div><div class=\"graphic_footnotes\">AIDS: acquired immune deficiency syndrome.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 61559 Version 6.0</div></div></div>"},"61561":{"type":"graphic_picture","displayName":"AIDS-related Kaposis sarcoma - gingiva","title":"AIDS-related Kaposi's sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AIDS-related Kaposi's sarcoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/61561_Kaposis_sarcoma_gingiva.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodules of Kaposi's sarcoma are present on the gingiva.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 61561 Version 3.0</div></div></div>"},"61563":{"type":"graphic_figure","displayName":"Anatomy of the thoracic esophagus anterior","title":"Anatomy of the thoracic esophagus - anterior view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of the thoracic esophagus - anterior view</div><div class=\"cntnt\"><img style=\"width:422px; height:691px;\" src=\"images/SURG/61563_Anatomy-of-the-thoracic-esophagus-anterior.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A thorough understanding of the anterior and posterior anatomy of the mediastinum is critical to the surgical approach to control and manage the perforated thoracic esophagus.</div><div id=\"graphicVersion\">Graphic 61563 Version 2.0</div></div></div>"},"61564":{"type":"graphic_figure","displayName":"Mastectomy incisions for upper outer quadrant tumors","title":"Mastectomy incisions for tumors of the upper outer quadrant of the breast","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Mastectomy incisions for tumors of the upper outer quadrant of the breast</div><div class=\"cntnt\"><img style=\"width:504px; height:599px;\" src=\"images/SURG/61564_Mastincisupperouterquad.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Design of the classic Orr oblique incision for carcinoma of the upper outer quadrants of the breast. The skin incision is placed 1 to 2 cm from the margin of the tumor in an oblique plane that is directed cephalad toward the ipsilateral axilla. This incision is a variant of the original Greenough, Kocher, and Rodman techniques for ﬂap development.</div><div class=\"graphic_reference\">Reproduced with permission from: Bland KI. Modified radical mastectomy and total (simple) mastectomy. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 61564 Version 7.0</div></div></div>"},"61566":{"type":"graphic_picture","displayName":"Fingertip bruises 2","title":"Fingertip bruises","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fingertip bruises</div><div class=\"cntnt\"><img style=\"width:216px; height:144px;\" src=\"images/EM/61566_Fingertipbruises2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the oval shaped bruises on the child's upper arm and forearm.</div><div class=\"graphic_reference\">Courtesy of Joan E Shook, MD.</div><div id=\"graphicVersion\">Graphic 61566 Version 2.0</div></div></div>"},"61567":{"type":"graphic_picture","displayName":"Bicipital tendinitis block","title":"Bicipital tendinitis confirmed by local anesthetic block","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Bicipital tendinitis confirmed by local anesthetic block</div><div class=\"cntnt\"><img style=\"width:471px; height:343px;\" src=\"images/EM/61567_Bicipital_tendinitis_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The point of needle entry is between the lesser and greater tubercles of the humerus, 1 inch (2.5 cm)&nbsp;below the anterior corner of the acromion. A 1.5 inch (4 cm)&nbsp;22-gauge needle is inserted perpendicular to the skin to a depth of 1 to 1.5 inches (2.5 to 4 cm), and&nbsp;1 mL of lidocaine is injected into the deltoid and 1 mL into the bicipital groove.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 61567 Version 3.0</div></div></div>"},"61568":{"type":"graphic_picture","displayName":"Manual vertical traction","title":"Manual cervical traction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Manual cervical traction</div><div class=\"cntnt\"><img style=\"width:343px; height:297px;\" src=\"images/EM/61568_Manual_vertical_traction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The head is grasped at the mid jaw and at the occiput. The patient is asked to relax the neck muscles. Gentle vertical traction is performed to assess the effect on the patient's neck pain, stiffness, and, when present, radicular pain. Relief of pain with this maneuver provides additional support for the diagnosis of radiculopathy and suggests that the patient may respond to therapeutic home traction.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 61568 Version 3.0</div></div></div>"},"61570":{"type":"graphic_figure","displayName":"Improper coaxial movement","title":"Inappropriate coaxial movement","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Inappropriate coaxial movement</div><div class=\"cntnt\"><img style=\"width:496px; height:124px;\" src=\"images/PULM/61570_Improper_coaxial_movement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inappropriate coaxial movement between the bronchoscope and the forceps can push the foreign body out of the forceps cups or jaws, leading to loss of the object.</div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 61570 Version 1.0</div></div></div>"},"61574":{"type":"graphic_table","displayName":"Propose ICD10 crit CA fatigue","title":"Proposed (1998 draft) ICD-10 criteria for cancer-related fatigue","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proposed (1998 draft) ICD-10 criteria for cancer-related fatigue</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  rowspan=\"1\" colspan=\"2\">\r\n  \r\n   Six (or more) of the following symptoms have been present every day or nearly every day during the same two-week period in the past month, and at least one of the symptoms is (A1) significant fatigue.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A1.</td>\r\n  \r\n   <td  colspan=\"1\">\r\n  \r\n   Significant fatigue, diminished energy, or increased need to rest, disproportionate to any recent change in activity level\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A2.</td>\r\n  \r\n   <td>Complaints of generalized weakness or limb heaviness</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A3.</td>\r\n  \r\n   <td>Diminished concentration or attention</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A4.</td>\r\n  \r\n   <td>Decreased motivation or interest to engage in usual activities</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A5.</td>\r\n  \r\n   <td>Insomnia or hypersomnia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A6.</td>\r\n  \r\n   <td>Experience of sleep as unrefreshing or nonrestorative</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A7.</td>\r\n  \r\n   <td>Perceived need to struggle to overcome inactivity</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A8.</td>\r\n  \r\n   <td  colspan=\"1\">\r\n  \r\n   Marked emotional reactivity (eg, sadness, frustration, or irritability) to feeling fatigued\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A9.</td>\r\n  \r\n   <td>Difficulty completing daily tasks attributed to feeling fatigued</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A10.</td>\r\n  \r\n   <td>Perceived problems with short-term memory</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A11.</td>\r\n  \r\n   <td>Postexertional malaise lasting several hours</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>B.</td>\r\n  \r\n   <td>The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>C.</td>\r\n  \r\n   <td  colspan=\"1\">\r\n  \r\n   There is evidence from the history, physical examination, or laboratory findings that the symptoms are a consequence of cancer or cancer therapy\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>D.</td>\r\n  \r\n   <td  colspan=\"1\">\r\n  \r\n   The symptoms are not primarily a consequence of comorbid psychiatric disorders such as major depression, somatization disorder, somatoform disorder, or delirium\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Reproduced with permission from: World Health Organization. The ICD-10 classification of mental and behavioral disorders: Diagnostic criteria for research. Copyright &#169; World Health Organization.</div><div id=\"graphicVersion\">Graphic 61574 Version 2.0</div></div></div>"},"61575":{"type":"graphic_picture","displayName":"Metered dose inhaler PI","title":"Metered dose inhaler","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Metered dose inhaler</div><div class=\"cntnt\"><img style=\"width:490px; height:259px;\" src=\"images/PI/61575_Metered_dose_inhaler_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medicine is stored in the canister. When a person presses down on the top of the canister, the medicine travels through the dosing chamber and sprays out of the mouthpiece.</div><div id=\"graphicVersion\">Graphic 61575 Version 5.0</div></div></div>"},"61577":{"type":"graphic_picture","displayName":"Blood smear too thick","title":"Blood smear too thick","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Blood smear too thick</div><div class=\"cntnt\"><img style=\"width:410px; height:270px;\" src=\"images/HEME/61577_Blood_smear_too_thick.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Suboptimally prepared peripheral blood smear which is too thick. All that is seen on this low power view are dense collections of darkened red cells. No morphologic characteristics of the red cells can be discerned.</div><div class=\"graphic_reference\">Courtesy of Jackie Mitus, MD.</div><div id=\"graphicVersion\">Graphic 61577 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"61578":{"type":"graphic_figure","displayName":"Role of band 3 protein","title":"Model for role of cytoplasmic domain of band 3 protein in regulation of membrane extensional rigidity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Model for role of cytoplasmic domain of band 3 protein in regulation of membrane extensional rigidity</div><div class=\"cntnt\"><img style=\"width:313px; height:499px;\" src=\"images/HEME/61578_Roleofband3protein.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Conformation of the cytoplasmic domain of normal band 3 (panel A) offers little resistance to the extension of spectrin tetramers during membrane deformation. By contrast, the conformationally altered cytoplasmic domain of mutated band 3 (panel B), by getting entangled in the spectrin network, sterically hinders the extension of spectrin tetramers. For reasons of clarity, not all of the individual components of the skeletal network have been delineated.</div><div class=\"graphic_reference\">Republished with permission of the University of Michigan Press, from Mohandas, N, Winardi, R, Knowles, D, et al. J Clin Invest 1992; 89:686; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 61578 Version 3.0</div></div></div>"},"61579":{"type":"graphic_picture","displayName":"Irritant contact dermatitis acute","title":"Acute irritant contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Acute irritant contact dermatitis</div><div class=\"cntnt\"><img style=\"width:507px; height:419px;\" src=\"images/DERM/61579_Irrit_dermatitis_Acute_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Paederus dermatitis. Acute contact dermatitis may occur after accidental exposure to an insect belonging to the genus Paederus, common in the tropical regions. The insect does not sting or bite, but accidental crushing may release its hemolymph that contains paederin, a potent vesicant.<BR>(A) Well-defined erythematous patches with central hyperpigmentation and vesicles in a kissing lesion fashion. (Courtesy of Kulthanan K Siriraj Hospital, Mahidol University, Bangkok, Thailand.)<BR>(B) Well-defined linear erythematous patch with central vesicles and pustules. (Courtesy of Wanitphakdeedecha R Siriraj Hospital, Mahidol University, Bangkok, Thailand.)</div><div id=\"graphicVersion\">Graphic 61579 Version 2.0</div></div></div>"},"61580":{"type":"graphic_table","displayName":"Reasons for lack of response to epinephrine in anaphylaxis","title":"Potential reasons for lack of response to epinephrine in anaphylaxis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential reasons for lack of response to epinephrine in anaphylaxis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Relevant studies</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Patient/caregiver/clinician</td> </tr> <tr> <td class=\"indent1\">Rapid anaphylaxis progression</td> <td>Case reports, autopsy reports</td> <td>In 10% of anaphylaxis episodes, epinephrine does not work, even if given promptly</td> </tr> <tr> <td class=\"indent1\">Epinephrine given too late</td> <td>Case reports, autopsy reports</td> <td>Cause-and-effect hard to prove</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Individuals do not know how to use epinephrine autoinjectors</td> <td>Cross-sectional surveys, demonstrations</td> <td>Frequently reported</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Epinephrine-related</td> </tr> <tr> <td class=\"indent1\">Dose too low</td> <td>Few dose response studies</td> <td>Optimal dose unknown; based on tradition, 0.3 mg is used for adults in many countries, 0.5 mg in some countries</td> </tr> <tr> <td class=\"indent1\">Lack of availability of fixed doses 0.05, 0.1, 0.2, 0.25 mg in autoinjectors</td> <td>&nbsp;</td> <td>Impossible to give an appropriate dose to infants and to some young children</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Route/site not optimal</td> <td>Intramuscular versus subcutaneous*</td> <td>Intramuscular, thigh preferred to subcutaneous, arm</td> </tr> <tr> <td>Ampule and syringe*</td> <td>Nonmedical personnel lack speed and accuracy</td> </tr> <tr> <td>Pressurized metered-dose inhaler (MDI)<sup>&#182;</sup></td> <td>For systemic effects, adults need 20 to 30 puffs (children 10 to 20; has been phased out in most countries)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Past expiration date</td> <td>Bioavailability measured in animal models; content measured in vitro<sup>&#916;</sup></td> <td>Epinephrine content inversely related to number of months past expiration date</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Other</td> </tr> <tr> <td class=\"indent1\">Individual not supine</td> <td>Autopsy reports</td> <td>If the individual is standing, venous return is decreased, the ventricles are empty, and death may occur despite timely epinephrine-induced reversal of vasodilation and shock</td> </tr> <tr> <td class=\"indent1\">Individual taking medications (beta-blocker or alpha-blocker, angiotensin-converting enzyme inhibitor) that prevent optimal epinephrine effect</td> <td>Case reports</td> <td>There is more information about lack of effect in asthma than in anaphylaxis</td> </tr> <tr> <td class=\"indent1\">Adverse effects of sodium metabisulfite (antioxidant in epinephrine)</td> <td>Case reports</td> <td>Additional studies needed, because sulfite-sensitive asthmatics tolerate epinephrine</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In obese individuals, intramuscular injections of epinephrine may inadvertently end up being subcutaneous injections unless a needle at least 2.5 cm (1 in) is used to penetrate the aft pad over the vastus lateralis muscle.<br />¶ It is difficult to inhale the large number of epinephrine puffs required because of vasoconstriction of the oropharyngeal mucosa, causing tingling and burning sensations.<br />Δ Compendial limits for epinephrine content of formulations are 90 to 115% of labeled strength (United States Pharmacopeia), but in some countries, the stated content of epinephrine in autoinjectors may range from 0.23 mg to 0.37 mg. Epinephrine should be stored at room temperature (15 to 30°C) to prevent oxidation and inactivation. In an EpiPen autoinjector, it is supplied in light-resistant packaging, and each 0.3 mL dose contains 0.3 mg epinephrine, 1.8 mg sodium chloride, 0.5 mg sodium metabisulfite, and hydrochloric acid to adjust the pH from 2.2 to 5.0. An EpiPen Jr contains epinephrine 0.15 mg and the same nonmedicinal ingredients in the same amounts as in the EpiPen.</div><div class=\"graphic_reference\">Reproduced with permission from: Simons FER. First-aid treatment of anaphylaxis to food: Focus on epinephrine. J Allergy Clin Immunol 2004; 113:837. Copyright &copy;2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 61580 Version 5.0</div></div></div>"},"61581":{"type":"graphic_table","displayName":"Theophylline poisoning - Rapid overview","title":"Theophylline poisoning: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Theophylline poisoning: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">Clinical features</td> </tr> <tr> <td class=\"indent1\">Ingestion of sustained release oral preparations is most common</td> </tr> <tr> <td class=\"indent1\">Physical findings: vomiting, hypokalemia, hyperglycemia, metabolic acidosis, seizures, sinus tachycardia and other tachyarrhythmias (SVT, VT), hypotension</td> </tr> <tr> <td class=\"indent1\">Acutely poisoned patients are at high risk for seizures and arrhythmias if theophylline level &#8805;80 to 100 micrograms/mL (448 to 560 micromol/L)</td> </tr> <tr> <td class=\"indent1\">Chronically poisoned patients may be relatively asymptomatic at presentation and are at high risk for seizures and arrhythmias if age &#8804;6 months or over 65 years of age and theophylline level &#8805;30 to 40 micrograms/mL (168 to 224 micromol/L)</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic evaluation</td> </tr> <tr> <td class=\"subtitle2_single\">All symptomatic patients:</td> </tr> <tr> <td class=\"indent1\">Emergent serum theophylline level (in patients with an acute overdose, repeat every two hours until peak level occurs)</td> </tr> <tr> <td class=\"indent1\">Serum electrolytes, calcium, and glucose</td> </tr> <tr> <td class=\"indent1\">Electrocardiogram</td> </tr> <tr> <td class=\"indent1\">Chest radiograph</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td class=\"subtitle2_single\">Supportive care</td> </tr> <tr> <td class=\"sublist2_start\">Vomiting:</td> </tr> <tr> <td class=\"sublist2\">High dose ondansetron (0.15 mg/kg, maximum dose 8 to 12 mg)</td> </tr> <tr> <td class=\"sublist2_start\">Seizures:</td> </tr> <tr> <td class=\"sublist2\">First line: benzodiazepines (eg, lorazepam 0.05 to 0.1 mg/kg maximum 4 mg per dose) repeat once</td> </tr> <tr> <td class=\"sublist2\">Second line: phenobarbital (20 mg/kg loading dose maximum 1000 mg load), midazolam infusion, or propofol infusion depending on individual patient status. Avoid fosphenytoin or phenytoin.</td> </tr> <tr> <td class=\"sublist2_start\">Arrhythmias:</td> </tr> <tr> <td class=\"sublist2\">Treat according to ACLS or PALS guidelines</td> </tr> <tr> <td class=\"sublist2_start\">Hypotension:</td> </tr> <tr> <td class=\"sublist2\">First line: IV isotonic saline or Ringer's lactate (20 mL/kg, maximum 1 L), up to 60 mL/kg (3 L) and treatment of arrhythmias</td> </tr> <tr> <td class=\"sublist2\">Second line: phenylephrine (IV bolus dose 5 to 20 mcg/kg per dose, maximum initial dose: 0.5 mg) or, in patients without asthma or COPD, propranolol (IV dose 0.01 to 0.1 mg/kg per dose, maximum initial dose 1 mg to 3 mg)*</td> </tr> <tr> <td class=\"indent1\">Administer activated charcoal 1 g/kg up to 50 grams followed by repeated doses (0.5 to 1 g/kg every 2 to 4 hours with cathartic [eg, sorbitol] no more than every third dose) for any significant ingestion</td> </tr> <tr> <td class=\"indent1\">Perform high-efficiency hemodialysis in patients with high risk for life-threatening toxicity<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACLS: advanced cardiac life support; COPD: chronic obstructive pulmonary disease; IV: intravenous; PALS: pediatric advanced life support; SVT: supraventricular tachycardia; VT: ventricular tachycardia.<br />* Administer propranolol slowly and initiated at the lower end of the dosing range in infants and the elderly.<br />¶ See the discussion of extracorporeal removal in the topic on Theophylline poisoning.</div><div id=\"graphicVersion\">Graphic 61581 Version 12.0</div></div></div>"},"61582":{"type":"graphic_figure","displayName":"Genetic loci T2 DM","title":"Genetic loci associated with type 2 diabetes","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Genetic loci associated with type 2 diabetes</div><div class=\"cntnt\"><img style=\"width:594px; height:383px;\" src=\"images/ENDO/61582_Genetic_loci_T2_DM.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chronological accounting of the discovery of type 2 diabetes-associated genes, plotted by year of definitive publication and approximate effect size. Within each group, <em>darker colors</em> indicate biological candidate genes <em>(PPARG, KCNJ11, HNF1B, WFS1, HNF4A, HNF1A, and ENPP1)</em>, and <em>lighter colors</em> denote loci identified via agnostic genome-wide approaches. In <em>gray</em> are genes implicated in type 2 diabetes by considerable functional and genetic evidence but for which genome-wide statistical evidence of association has not been reached.</div><div class=\"graphic_reference\">Reproduced with permission from: Florez JC. The genetics of type 2 diabetes: A realistic appraisal in 2008. J Clin Endocrine Metab 2008; 93:4633. http://jcem.endojournals.org/. Copyright &#169; 2008 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 61582 Version 6.0</div></div></div>"},"61584":{"type":"graphic_figure","displayName":"ANC hospitalization infection","title":"Neutropenia and hospitalization for infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neutropenia and hospitalization for infection</div><div class=\"cntnt\"><img style=\"width:423px; height:341px;\" src=\"images/HEME/61584_ANC_hospitalization_infecti.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The incidence rate (per 10,000 days at risk) and 95 percent confidence intervals (vertical bars) for bacterial infection requiring hospitalization among 2047 HIV-infected patients for each absolute neutrophil count (ANC). The rate increased progressively at ANCs below 750/&#181;L.</div><div class=\"graphic_reference\">Data from Jacobson, MA, Liu, RC, Davies, D, Cohen, PT, Arch Intern Med 1997; 157:1825.</div><div id=\"graphicVersion\">Graphic 61584 Version 1.0</div></div></div>"},"61586":{"type":"graphic_picture","displayName":"Merkel cell carcinoma - polyomavirus","title":"Merkel cell carcinoma – polyomavirus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Merkel cell carcinoma – polyomavirus</div><div class=\"cntnt\"><img style=\"width:432px; height:433px;\" src=\"images/DERM/61586_Merkel_cell_carcinoma_poly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Merkel cell carcinoma&nbsp;– Immunohistochemical stain for Merkel cell polyomavirus. A CM2B4 immunohistochemical stain reveals strong immunoreactivity of Merkel tumor cells for an antibody targeting the Merkel cell polyomavirus.</div><div class=\"graphic_reference\">Courtesy of Liron Pantanowitz, MD.</div><div id=\"graphicVersion\">Graphic 61586 Version 4.0</div></div></div>"},"61587":{"type":"graphic_diagnosticimage","displayName":"Thoracolumbar fracture-dislocation radiograph","title":"Thoracolumbar fracture-dislocation radiograph","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Thoracolumbar fracture-dislocation radiograph</div><div class=\"cntnt\"><img style=\"width:512px; height:387px;\" src=\"images/EM/61587_Thoracolumbarfractdisloc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anteroposterior (A) and lateral (B) radiographs of a T12-L1 fracture-dislocation.</div><div class=\"graphic_reference\">Reproduced with permission from: Whang PW, Vaccaro AR. Fractures and dislocations of the thoracolumbar spine. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RB, (ed), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 61587 Version 8.0</div></div></div>"},"61588":{"type":"graphic_picture","displayName":"Chronic GVHD tongue erosions","title":"Oral chronic graft-versus-host disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oral chronic graft-versus-host disease</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/61588_Chron_GVHD_tongue_erosions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erosions are present on the tongue.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 61588 Version 3.0</div></div></div>"},"61589":{"type":"graphic_table","displayName":"Avoiding lead in soil PI","title":"Ways to prevent exposure to lead in soil","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ways to prevent exposure to lead in soil</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Cover bare soil with grass, plants, gravel, or wood chips</td> </tr> <tr> <td>Do not let children play near walls of house or garage on bare soil</td> </tr> <tr> <td>Have children play in grassy area or sandbox that can be covered</td> </tr> <tr> <td>Wash children's hands after they play outside or play with pets</td> </tr> <tr> <td>Use a doormat to reduce track-in of outdoor dust and soil</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Environmental Protection Agency. Additional information available at: <a href=\"http://www.epa.gov/lead/\" target=\"_blank\">http://www.epa.gov/lead/</a>.</div><div id=\"graphicVersion\">Graphic 61589 Version 3.0</div></div></div>"},"61590":{"type":"graphic_figure","displayName":"Debridement and primary repair of esophageal perforation","title":"Debridement and primary repair of esophageal perforation","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Debridement and primary repair of esophageal perforation</div><div class=\"cntnt\"><img style=\"width:528px; height:336px;\" src=\"images/SURG/61590_Debridement-and-repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Figure A depicts the exposed mucosa and muscular layer of the perforated esophagus. Devitalized tissue is sharply debrided.<br> Figure B depicts the longitudinal extension of the muscular defect to completely expose the mucosal defect. The extension of the muscularis can be performed superior and inferior to the perforation.<br> Figure C depicts the primary repair of the debrided esophageal perforation. The closure is performed in two layers.</div><div id=\"graphicVersion\">Graphic 61590 Version 3.0</div></div></div>"},"61591":{"type":"graphic_table","displayName":"Skeletal maturity timeframe","title":"Time of appearance and approximate time of fusion of secondary ossification centers, by sex and age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Time of appearance and approximate time of fusion of secondary ossification centers, by sex and age</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Secondary ossification center</td> <td class=\"subtitle1\">Girls</td> <td class=\"subtitle1\">Boys</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Age (range) of appearance</td> </tr> <tr> <td>Capitellum</td> <td>5 (1 to 11) months</td> <td>7 (1&nbsp;to 26 ) months</td> </tr> <tr> <td>Radial head</td> <td>4 (3&nbsp;to 6) years</td> <td>5 (3&nbsp;to 6) years</td> </tr> <tr> <td>Inner (medial epicondyle)</td> <td>5 (5&nbsp;to 8) years</td> <td>7 (7&nbsp;to 9) years</td> </tr> <tr> <td>Trochlea</td> <td>8 (7&nbsp;to 11) years</td> <td>9 (8&nbsp;to 13) years</td> </tr> <tr> <td>Olecranon</td> <td>9 (8&nbsp;to 10) years</td> <td>10 (8&nbsp;to 11) years</td> </tr> <tr> <td>External (lateral epicondyle)</td> <td>11 (8&nbsp;to 11) years</td> <td>12 (9&nbsp;to 13) years</td> </tr> <tr> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\" colspan=\"2\">Approximate age of fusion</td> </tr> <tr> <td>Trochlea</td> <td>10 years</td> <td>12 years</td> </tr> <tr> <td>External (lateral epicondyle)</td> <td>11 years</td> <td>13 years</td> </tr> <tr> <td>Capitellum</td> <td>12 years</td> <td>14 years</td> </tr> <tr> <td>Olecranon</td> <td>13 years </td> <td>15 years</td> </tr> <tr> <td>Radial head</td> <td>14 years </td> <td>16 years</td> </tr> <tr> <td>Inner (medial epicondyle)</td> <td>15 years</td> <td>17 years</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 61591 Version 2.0</div></div></div>"},"61592":{"type":"graphic_picture","displayName":"Supine dumbell flies","title":"Safe and unsafe range of motion for supine dumbell flies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Safe and unsafe range of motion for supine dumbell flies</div><div class=\"cntnt\"><img style=\"width:432px; height:360px;\" src=\"images/PEDS/61592_Supine_dumbell_flies.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Figure A depicts the appropriate and safe range of motion for a supine dumbell fly, with the upper arm parallel to the ground. Figure B depicts a supine dumbell fly with an increased range of motion, increasing the risk of soft tissue injury.</div><div class=\"graphic_reference\">Courtesy of Pat Vehrs, PhD, FACSM.</div><div id=\"graphicVersion\">Graphic 61592 Version 1.0</div></div></div>"},"61593":{"type":"graphic_table","displayName":"Breast ca screening over 50","title":"Breast cancer screening in women >50 years, according to life expectancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Breast cancer screening in women &gt;50 years, according to life expectancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age (years)</td> <td class=\"subtitle1\">Life expectancy (years)*</td> <td class=\"subtitle1\">Risk of dying from breast cancer (%)<sup>&#182;</sup></td> <td class=\"subtitle1\">Number needed to screen over remaining lifetime</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">50</td> <td>40</td> <td>4.4</td> <td>95</td> </tr> <tr> <td>33</td> <td>3.1</td> <td>133</td> </tr> <tr class=\"divider_bottom\"> <td>24.5</td> <td>2</td> <td>226</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">70</td> <td>21.3</td> <td>3.3</td> <td>142</td> </tr> <tr> <td>15.7</td> <td>2.2</td> <td>242</td> </tr> <tr class=\"divider_bottom\"> <td>9.5</td> <td>1.2</td> <td>642</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">75</td> <td>17</td> <td>2.8</td> <td>176</td> </tr> <tr> <td>11.9</td> <td>1.8</td> <td>330</td> </tr> <tr class=\"divider_bottom\"> <td>6.8</td> <td>0.9</td> <td>1361</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">80</td> <td>13</td> <td>2.4</td> <td>240</td> </tr> <tr> <td>8.6</td> <td>1.5</td> <td>533</td> </tr> <tr class=\"divider_bottom\"> <td>4.6</td> <td>0.7</td> <td>-</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">85</td> <td>9.6</td> <td>1.9</td> <td>417</td> </tr> <tr> <td>5.9</td> <td>1.2</td> <td>2131</td> </tr> <tr class=\"divider_bottom\"> <td>2.9</td> <td>0.6</td> <td>-</td> </tr> <tr> <td rowspan=\"3\">90</td> <td>6.8</td> <td>1.4</td> <td>1066</td> </tr> <tr> <td>3.9</td> <td>0.8</td> <td>-</td> </tr> <tr> <td>1.8</td> <td>0.4</td> <td>-</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Life expectancy is depicted as the upper, middle, and lower quartiles of life expectancy for the United States population; placing an individual into the appropriate quartile depends upon a number of factors, including the number and severity of comorbid conditions and functional impairments.<br />¶ Risk of dying refers to the risk of dying of breast cancer during the remaining lifetime.</div><div class=\"graphic_reference\">Data from: Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001; 285:2750.</div><div id=\"graphicVersion\">Graphic 61593 Version 6.0</div></div></div>"},"61594":{"type":"graphic_waveform","displayName":"ECG Left bundle branch block 2","title":"12-lead electrocardiogram (ECG) showing typical left bundle branch block","html":"<div class=\"graphic normal\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) showing typical left bundle branch block</div><div class=\"cntnt\"><img style=\"width:462px; height:309px;\" src=\"images/CARD/61594_Left_bundle_branch_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram in typical complete left bundle branch block. The asynchronous activation of the two ventricles increases the QRS duration (0.16 second in this example). The abnormal initial vector results in loss of \"normal\" septal forces as manifested by absence of q waves in leads I, aVL, and V6. The late activation of the left ventricle prolongs the dominant leftward progression of the middle and terminal forces, leading to a positive and widened R wave in the lateral leads. Both the ST segment and T wave vectors are opposite in direction from the QRS, a \"secondary\" repolarization abnormality.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 61594 Version 8.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"61596":{"type":"graphic_figure","displayName":"Passy Muir speaking valves","title":"Passy-Muir tracheostomy speaking valves","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Passy-Muir tracheostomy speaking valves</div><div class=\"cntnt\"><img style=\"width:441px; height:336px;\" src=\"images/PULM/61596_Passy_Muir_speaking_valves.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The mode of connection of Passy-Muir tracheostomy speaking valves in patients undergoing mechanical ventilation. The valve functions in a unidirectional manner such that inspiration is allowed to occur through the valve but expiration is not permitted. Consequently expiration occurs around the deflated or partially deflated tracheostomy tube cuff, permitting the patient to speak.</div><div class=\"graphic_reference\">Redrawn from Manzano, JL, Lubillos, S, Henriquez, D, et al, Crit Care Med 1993; 21:512.</div><div id=\"graphicVersion\">Graphic 61596 Version 1.0</div></div></div>"},"61598":{"type":"graphic_diagnosticimage","displayName":"Hepatosplenic candidiasis CT","title":"Hepatosplenic candidiasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hepatosplenic candidiasis</div><div class=\"cntnt\"><img style=\"width:360px; height:239px;\" src=\"images/ID/61598_Hepatosplenic_candidiasis_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) scan shows typical lucencies in the liver of a patient with acute myeloid leukemia who developed chronic disseminated candidiasis following recovery from prolonged neutropenia.</div><div class=\"graphic_reference\">Courtesy of Carol A Kauffman, MD.</div><div id=\"graphicVersion\">Graphic 61598 Version 7.0</div></div></div>"},"61601":{"type":"graphic_picture","displayName":"TSC hypomelanotic macule","title":"Tuberous sclerosis complex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tuberous sclerosis complex</div><div class=\"cntnt\"><img style=\"width:353px; height:291px;\" src=\"images/PEDS/61601_TS_hypomelanotic_macules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypomelanotic macule on the torso of a patient with tuberous sclerosis complex.</div><div id=\"graphicVersion\">Graphic 61601 Version 7.0</div></div></div>"},"61604":{"type":"graphic_picture","displayName":"Visible vessel GU Endosc","title":"Gastric ulcer with a visible vessel","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric ulcer with a visible vessel</div><div class=\"cntnt\"><img style=\"width:318px; height:322px;\" src=\"images/GAST/61604_Visible_vessel_GU_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ulcer in the gastric antrum seen on endoscopy. The visible vessel appears as a small protuberance in the one o'clock position.</div><div class=\"graphic_reference\">Courtesy of Eric D Libby, MD.</div><div id=\"graphicVersion\">Graphic 61604 Version 1.0</div></div></div>"},"61605":{"type":"graphic_figure","displayName":"Normal hymens in prepubertal girls","title":"Normal hymens in prepubertal girls","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal hymens in prepubertal girls</div><div class=\"cntnt\"><img style=\"width:449px; height:228px;\" src=\"images/PEDS/61605_Normal_hymens.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A: Fimbriated or redundant hymen; B: Posterior rim or crescentic hymen; C: Circumferential or annular hymen.</div><div class=\"graphic_reference\">Modified from Pokorny SF. Configuration of the prepubertal hymen. Am J Obstet Gynecol 1987; 157:950.</div><div id=\"graphicVersion\">Graphic 61605 Version 2.0</div></div></div>"},"61607":{"type":"graphic_diagnosticimage","displayName":"Comminuted patella fract","title":"Comminuted patellar fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Comminuted patellar fracture</div><div class=\"cntnt\"><img style=\"width:432px; height:297px;\" src=\"images/RHEUM/61607_Comminuted_patella_fract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This sunrise view of the knee demonstrates a comminuted fracture of the patella (arrow) with associated soft tissue swelling.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 61607 Version 2.0</div></div></div>"},"61608":{"type":"graphic_figure","displayName":"Rhythm versus rate control AF AFFIRM","title":"Rate control versus rhythm control in AFFIRM","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Rate control versus rhythm control in AFFIRM</div><div class=\"cntnt\"><img style=\"width:494px; height:312px;\" src=\"images/CARD/61608_Rhythm_v_rate_control_AF_AF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Results of the AFFIRM trial in which 4060 patients with atrial fibrillation (AF) that was likely to be recurrent were randomly assigned to rhythm or rate control. The primary end point was overall mortality. There was an almost significant trend toward lower mortality with rate control (21.3 versus 23.8 percent, hazard ratio 0.87, 95 percent CI 0.75 to 1.01).</div><div class=\"graphic_reference\">Data from Wyse DG, Waldo AL, DiMarco JP, et al. N Engl J Med 2002; 347:1825.</div><div id=\"graphicVersion\">Graphic 61608 Version 3.0</div></div></div>"},"61611":{"type":"graphic_picture","displayName":"Cholangiocarcinoma on cholangioscopy","title":"Cholangiocarcinoma on cholangioscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cholangiocarcinoma on cholangioscopy</div><div class=\"cntnt\"><img style=\"width:400px; height:372px;\" src=\"images/GAST/61611_Cholangiocarcin_cholang_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fiberoptic cholangioscopy showing a nodular, ulcerated stricture in the bile duct.</div><div id=\"graphicVersion\">Graphic 61611 Version 2.0</div></div></div>"},"61612":{"type":"graphic_figure","displayName":"AHT drug and stroke ALLHAT","title":"Lisinopril and increased risk of stroke","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lisinopril and increased risk of stroke</div><div class=\"cntnt\"><img style=\"width:416px; height:224px;\" src=\"images/NEPH/61612_AHT_drug_and_stroke_ALLHAT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the ALLHAT trial, cumulative event rates for the development of stroke according to primary treatment with chlorthalidone, amlodipine, or lisinopril. Compared to chlorthalidone, there was a significant increase in the six year rate of stroke with lisinopril (6.3 versus 5.6 percent, relative risk 1.15 95 percent CI 1.02 to 1.30).</div><div class=\"graphic_reference\">Data from The ALLHAT Officers, JAMA 2002; 288:2981.</div><div id=\"graphicVersion\">Graphic 61612 Version 1.0</div></div></div>"},"61615":{"type":"graphic_table","displayName":"CHADS2 score and thromboembolic risk with and without warfarin","title":"CHADS2 score, thromboembolic risk, and effect of warfarin anticoagulation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">CHADS2 score, thromboembolic risk, and effect of warfarin anticoagulation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Clinical parameter</td> <td class=\"subtitle1\">Points</td> </tr> <tr> <td colspan=\"3\"><strong>C</strong>ongestive heart failure (any history)</td> <td class=\"centered\">1</td> </tr> <tr> <td colspan=\"3\"><strong>H</strong>ypertension (prior history)</td> <td class=\"centered\">1</td> </tr> <tr> <td colspan=\"3\"><strong>A</strong>ge &#8805;75 years</td> <td class=\"centered\">1</td> </tr> <tr> <td colspan=\"3\"><strong>D</strong>iabetes mellitus</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\"><strong>S</strong>econdary prevention in patients with a prior ischemic stroke or a transient ischemic attack; most experts also include patients with a systemic embolic event</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"subtitle1\" rowspan=\"2\">CHADS2 score</td> <td class=\"subtitle1\" colspan=\"2\">Events per 100 person-years*</td> <td class=\"subtitle1\" rowspan=\"2\">NNT</td> </tr> <tr> <td class=\"subtitle2\">Warfarin</td> <td class=\"subtitle2\">No warfarin</td> </tr> <tr class=\"centered\"> <td>0</td> <td>0.25</td> <td>0.49</td> <td>417</td> </tr> <tr class=\"centered\"> <td>1</td> <td>0.72</td> <td>1.52</td> <td>125</td> </tr> <tr class=\"centered\"> <td>2</td> <td>1.27</td> <td>2.50</td> <td>81</td> </tr> <tr class=\"centered\"> <td>3</td> <td>2.20</td> <td>5.27</td> <td>33</td> </tr> <tr class=\"centered\"> <td>4</td> <td>2.35</td> <td>6.02</td> <td>27</td> </tr> <tr class=\"centered\"> <td>5 or 6</td> <td>4.60</td> <td>6.88</td> <td>44</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NNT: number needed to treat to prevent one stroke per year with warfarin.<br />* The CHADS2 score estimates the risk of stroke, which is defined as focal neurologic signs or symptoms that persist for more than 24 hours and that cannot be explained by hemorrhage, trauma, or other factors, or peripheral embolization, which is much less common. Transient ischemic attacks are not included. All differences between warfarin and no warfarin groups are statistically significant, except for a trend with a CHADS2 score of 0. Patients are considered to be at low risk with a score of 0, at intermediate risk with a score of 1 or 2, and at high risk with a score &ge;3. One exception is that most experts would consider patients with a prior ischemic stroke, transient ischemic attack, or systemic embolic event to be at high risk, even if they had no other risk factors and, therefore, a score of 2. However, the great majority of these patients have some other risk factor and a score of at least 3.</div><div class=\"graphic_reference\">Data from: Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290:2685; and CHADS2 score from Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285:2864.</div><div id=\"graphicVersion\">Graphic 61615 Version 7.0</div></div></div>"},"61616":{"type":"graphic_figure","displayName":"Effect of exercise on lipid metabolism","title":"Effect of exercise on lipid metabolism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effect of exercise on lipid metabolism</div><div class=\"cntnt\"><img style=\"width:373px; height:428px;\" src=\"images/CARD/61616_Exercise_and_lipid_metaboli.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation shows the roles of lipoprotein lipase (LPL) and hepatic triglyceride lipase (HTGL) activities in the regulation of plasma high-density lipoprotein (HDL). In the sedentary state, low LPL and high HTGL activities lead to a decrease in the production of HDL-2 particles due to reduced catabolism of triglyceride (TG)-rich lipoproteins. In contrast, in physically active individuals, LPL activity is high, contributing to the generation of HDL-2 particles; the low activity of HTGL maintains HDL-2 concentration at a higher level than in sedendary individuals.</div><div class=\"graphic_reference\">Adapted from Despres JP, Lamarche B. J Intern Med 1994; 236:7.</div><div id=\"graphicVersion\">Graphic 61616 Version 3.0</div></div></div>"},"61617":{"type":"graphic_diagnosticimage","displayName":"Decompression of the pancreatic duct","title":"Decompression of the pancreatic duct","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Decompression of the pancreatic duct</div><div class=\"cntnt\"><img style=\"width:464px; height:317px;\" src=\"images/PEDS/61617_Decompression_panc_duct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Endoscopic retrograde cholangiopancreatography (ERCP) shows a dilated pancreatic duct with a stone at the junction between the head and body of the pancreas (arrow).<br />(B) After external shock wave lithotripsy, the pancreatic stone is fractured (arrowhead).<br />(C) ERCP after the stone fragments are removed with a balloon or basket.</div><div class=\"graphic_reference\">Courtesy of Moises Guelrud, MD.</div><div id=\"graphicVersion\">Graphic 61617 Version 5.0</div></div></div>"},"61618":{"type":"graphic_picture","displayName":"Xillix image white light","title":"White light images of Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">White light images of Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:540px; height:246px;\" src=\"images/GAST/61618_Xillix_image_white_light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic images of the gastroesophageal junction obtained with the fiberoptic white light mode of the LIFE-II system (Xillix Technologies Corp., Richmond, BC, Canada) and with the high-resolution white light mode of the video-AFI system (Olympus, Tokyo, Japan) showing a clear difference in image quality between the two techniques.</div><div class=\"graphic_reference\">Reproduced with permission from: www.Barrett.nl. Copyright © Amsterdam Esophageal Research Foundation.</div><div id=\"graphicVersion\">Graphic 61618 Version 2.0</div></div></div>"},"61620":{"type":"graphic_table","displayName":"Trials of ALL in adults","title":"Treatment trials for acute lymphoblastic leukemia in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment trials for acute lymphoblastic leukemia in adults</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td   class=\"subtitle1\">Trial* (author, yr)</td>\r\n  \r\n   <td   class=\"subtitle1\">n</td>\r\n  \r\n   <td   class=\"subtitle1\">Age median (range), years</td>\r\n  \r\n   <td   class=\"subtitle1\">Induction</td>\r\n  \r\n   <td   class=\"subtitle1\">Consolidation</td>\r\n  \r\n   <td   class=\"subtitle1\">Maintenance</td>\r\n  \r\n   <td   class=\"subtitle1\">CNS-P</td>\r\n  \r\n   <td   class=\"subtitle1\">CR, percent</td>\r\n  \r\n   <td   class=\"subtitle1\">MRD, mos</td>\r\n  \r\n   <td   class=\"subtitle1\">MS, mos</td>\r\n  \r\n   <td   class=\"subtitle1\">DFS percent, yrs</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>GMALL 01 (Hoelzer 1988)</td>\r\n  \r\n   <td>368</td>\r\n  \r\n   <td>25 (15-65)</td>\r\n  \r\n   <td>V, P, D, A, C, Ara- C, MP</td>\r\n  \r\n   <td>V, Dex, Dox, C, Ara-C, TG</td>\r\n  \r\n   <td>MP, MTX</td>\r\n  \r\n   <td>IT MTX, XRT</td>\r\n  \r\n   <td>74</td>\r\n  \r\n   <td>24</td>\r\n  \r\n   <td>28</td>\r\n  \r\n   <td>35 (10)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>SWOG L10M (Hussein 1989)</td>\r\n  \r\n   <td>168</td>\r\n  \r\n   <td>28 (15-85)</td>\r\n  \r\n   <td>V, P, Dox, C</td>\r\n  \r\n   <td>Ara-C, MTX, TG, V, P, A, C</td>\r\n  \r\n   <td>V, P, Dox, MP, MTX, Dac, C, BCNU</td>\r\n  \r\n   <td>IT MTX</td>\r\n  \r\n   <td>68</td>\r\n  \r\n   <td>23</td>\r\n  \r\n   <td>18</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>MDACC (Kantarjian 1990)</td>\r\n  \r\n   <td>105</td>\r\n  \r\n   <td>30</td>\r\n  \r\n   <td>V, Dox, Dex &#177; C</td>\r\n  \r\n   <td>MTX, A, Dox, Ara-C, V, P, &#177; allo HCT</td>\r\n  \r\n   <td>MP, MTX, D, P</td>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   <td>84</td>\r\n  \r\n   <td>22</td>\r\n  \r\n   <td>19</td>\r\n  \r\n   <td>34 (5)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>UCSF (Linker 1991)</td>\r\n  \r\n   <td>109</td>\r\n  \r\n   <td>25 (16-49)</td>\r\n  \r\n   <td>V, P, D, A</td>\r\n  \r\n   <td>V, P, D, A, Ara-C, VM- 26, MTX</td>\r\n  \r\n   <td>MP, MTX</td>\r\n  \r\n   <td>IT MTX, XRT</td>\r\n  \r\n   <td>88</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>35 (5)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"2\">ECOG 3486 (Cassileth 1992)</td>\r\n  \r\n   <td>247</td>\r\n  \r\n   <td>a) 35</td>\r\n  \r\n   <td>a) V, P, D</td>\r\n  \r\n   <td>HD Ara-C;</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>a) 73</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>a) 9</td>\r\n  \r\n   <td>a) 17 (2)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   <td>b) 32</td>\r\n  \r\n   <td>b) V, P, D, Ara-C, TG</td>\r\n  \r\n   <td>MTX, A, C, Dox, V, P</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>b) 58</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>b) 11</td>\r\n  \r\n   <td>b) 35 (2)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>LALA87 (Fiere 1993)</td>\r\n  \r\n   <td>511</td>\r\n  \r\n   <td>33</td>\r\n  \r\n   <td>C, V, P, D or C, V, P, Z</td>\r\n  \r\n   <td>Ara-C, A, with D or Z, allo-HCT or auto-HCT</td>\r\n  \r\n   <td>V, P, MP, MTX, Dox, C, BCNU</td>\r\n  \r\n   <td>IT MTX</td>\r\n  \r\n   <td>76</td>\r\n  \r\n   <td>17</td>\r\n  \r\n   <td>18</td>\r\n  \r\n   <td>chemo, 32 allo-HCT, 43 auto-HCT, 39</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>CALGB 8811 (Larson 1995)</td>\r\n  \r\n   <td>197</td>\r\n  \r\n   <td>32 (16-80)</td>\r\n  \r\n   <td>V, P, D, A, C</td>\r\n  \r\n   <td>C, Ara-C, MP, V, A, Dox, Dex, TG</td>\r\n  \r\n   <td>V, P, MP, MTX</td>\r\n  \r\n   <td>IT MTX, XRT</td>\r\n  \r\n   <td>85</td>\r\n  \r\n   <td>29</td>\r\n  \r\n   <td>36</td>\r\n  \r\n   <td>46 (3)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>CALGB 9111 (Larson, 1998)</td>\r\n  \r\n   <td>198</td>\r\n  \r\n   <td>35 (16-83)</td>\r\n  \r\n   <td>V, P, D, A, C</td>\r\n  \r\n   <td>C, Ara-C, MP, V, A, Dox, Dex, TG</td>\r\n  \r\n   <td>V, P, MP, MTX</td>\r\n  \r\n   <td>IT MTX, XRT</td>\r\n  \r\n   <td>85</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>23</td>\r\n  \r\n   <td>40 (3)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>GIMEMA 0288 (Annino 2002)</td>\r\n  \r\n   <td>778</td>\r\n  \r\n   <td>28 (12-60)</td>\r\n  \r\n   <td>V, P, D, A &#177; C</td>\r\n  \r\n   <td>V, P, MIT, Dex, MTX, VM-26, Ara-C</td>\r\n  \r\n   <td>V, P, MP, MTX</td>\r\n  \r\n   <td>IT MTX</td>\r\n  \r\n   <td>82</td>\r\n  \r\n   <td>29</td>\r\n  \r\n   <td>26</td>\r\n  \r\n   <td>29 (9)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>JALSG-ALL 93 (Takeuchi, 2002)</td>\r\n  \r\n   <td>263</td>\r\n  \r\n   <td>31 (15-59)</td>\r\n  \r\n   <td>V, D, P, A, C</td>\r\n  \r\n   <td>MIT, VP-16, Ara-C, MTX, aclarubicin, allo-HCT</td>\r\n  \r\n   <td>MP, MTX</td>\r\n  \r\n   <td>IT MTX, Ara-C, P</td>\r\n  \r\n   <td>78</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>30 (5)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>LALA94 (Thomas, 2004)</td>\r\n  \r\n   <td>922</td>\r\n  \r\n   <td>33 (18-79)</td>\r\n  \r\n   <td>V, P, C, (D or I)</td>\r\n  \r\n   <td><p>MIT + Ara-C or C, Ara-C, MP</p>\r\n\t<p>In addition, high risk disease given allo-HCT or auto-HCT</p></td>\r\n  \r\n   <td>MP, MTX, C, Ara-C, V, D, Dex</td>\r\n  \r\n   <td>IT MTX, Ara-C, P &#177; XRT</td>\r\n  \r\n   <td>84</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>23</td>\r\n  \r\n   <td><p>37 (3)</p>\r\n\t<p>30 (5)</p></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>MD Anderson (Kantarjian, 2004)</td>\r\n  \r\n   <td>288</td>\r\n  \r\n   <td>40 (15-92)</td>\r\n  \r\n   <td>C, V, D, Dex, MTX, Ara-C</td>\r\n  \r\n   <td>C, V, D, Dex, MTX, Ara-C</td>\r\n  \r\n   <td>MP, MTX, V, P</td>\r\n  \r\n   <td>IT MTX</td>\r\n  \r\n   <td>92</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>32</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>International trial ALL (Rowe, 2005)</td>\r\n  \r\n   <td>1521</td>\r\n  \r\n   <td>(15-59)</td>\r\n  \r\n   <td>V, P, D, A</td>\r\n  \r\n   <td>C, Ara-C, VP-16, MP, MTX, A, V, Dex, D, TG versus allo-HCT versus auto-HCT</td>\r\n  \r\n   <td>V, P, MP, MTX</td>\r\n  \r\n   <td>IT MTX, Ara-C, XRT</td>\r\n  \r\n   <td>91</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>\t<p>NR</p>\r\n\t<p>Approx 20 mo</p></td>\r\n  \r\n   <td><p>NR</p>\r\n\t<p>OS 38 (5)</p></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>PETHEMA ALL-93 (Ribera, 2005)</td>\r\n  \r\n   <td>222</td>\r\n  \r\n   <td>27 (15-50)</td>\r\n  \r\n   <td>V, D, P, A, C</td>\r\n  \r\n   <td>V, Dex, MTX, C, Ara-C, A, MP, MIT, T, auto-HCT or allo-HCT</td>\r\n  \r\n   <td>MP, MTX</td>\r\n  \r\n   <td>IT MTX, Ara-C, HC</td>\r\n  \r\n   <td>82</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>23</td>\r\n  \r\n   <td>35 (5)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>GRAALL-2003 (Huguet, 2009)</td>\r\n  \r\n   <td>225</td>\r\n  \r\n   <td>31 (15-60)</td>\r\n  \r\n   <td>V, P, D, A, C</td>\r\n  \r\n   <td>Ara-C, Dex, A, MTX, V, MP, C, VP-16, P, D, I</td>\r\n  \r\n   <td>V, P, MP, MTX</td>\r\n  \r\n   <td>IT MTX, Ara-C, P, XRT</td>\r\n  \r\n   <td>94</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>NR</td>\r\n  \r\n   <td>59 (3.5)</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_lgnd\">This table shows results for various remission induction and postremission trials for acute lymphoblastic leukemia (ALL) in adults.</div><div class=\"graphic_footnotes\">NR: not reported; CNS-P: CNS prophylaxis; XRT: cranial irradiation; CR: complete remission; MRD: median remission duration; MS: median survival; DFS: disease-free survival; C: cyclophosphamide; P: prednisone; MP: 6 mercaptopurine; VM-26: teniposide; Z: zorubicin; D: daunorubicin; HD Ara-C: high-dose cytarabine; MTX: methotrexate; Dac: dactinomycin; V: vincristine; Dox: Doxorubin; MIT: mitoxantrone; BCNU: carmustine; A: asparaginase; Dex: dexamethasone; TG: 6 thioguanine; IT MTX: intrathecal MTX; VP-16: etoposide; I: idarubicin; HC: hydrocortisone; T: teniposide; HCT: hematopoietic cell transplantation.<br>* Trials with &gt;100 patients.</div><div id=\"graphicVersion\">Graphic 61620 Version 2.0</div></div></div>"},"61621":{"type":"graphic_figure","displayName":"Hemostatic closure device","title":"Insertion protocol for the hemostatic puncture closure device","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Insertion protocol for the hemostatic puncture closure device</div><div class=\"cntnt\"><img style=\"width:473px; height:280px;\" src=\"images/CARD/61621_Hemostatic_closure_device.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hemostatic puncture closure device consists of an absorbable plug component and delivery system. The plug has a lactide and glycolide anchor attached to a 24- to 28-mg collagen sponge by an absorbable suture. The device is contained in a carrier tube. Delivery of the device is initiated by first exchanging the existing sheath over a wire for an 8 Fr sheath. Panels A and B: The carrier tube containing the plug is inserted through the sheath deploying the anchor within the arterial lumen. Panel C: The sheath and carrier tube assembly are then retracted, maintaining tension on the assembly while pushing down the tamper tube. Panel D: Through use of a tension spring, traction is maintained along the suture line, resulting in plugging of the anterior arterial wall puncture site by the anchor and collagen plug. After 20 minutes, the tension spring is removed and the suture is cut below skin level.</div><div class=\"graphic_reference\">Reprinted from Ward SR, Lasale P, Raymond R, et al. Efficacy and safety of a hemostatic puncture closure device with early ambulation after coronary angiography. Angio-Seal Investigators. Am J Cardiol 1998; 81(5):569-72. Copyright 1998, with permission from Excerpta Medica, Inc.</div><div class=\"contractual\"><br/><a href=\"http://www.elsevier.com/locate/jacc\">http://www.elsevier.com/locate/jacc</a><br/><a href=\"http://www.sciencedirect.com/\"> http://www.sciencedirect.com</a></div><div id=\"graphicVersion\">Graphic 61621 Version 2.0</div></div></div>"},"61622":{"type":"graphic_table","displayName":"Sliding scale 2","title":"Sliding scale 2","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sliding scale 2</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Blood glucose, mg/dL</td> <td class=\"subtitle1\">Lispro insulin, units</td> </tr> <tr> <td>&#60;100</td> <td>0</td> </tr> <tr> <td>101 to 150</td> <td>2</td> </tr> <tr> <td>151 to 200</td> <td>4</td> </tr> <tr> <td>201 to 250</td> <td>5</td> </tr> <tr> <td>251 to 300</td> <td>6</td> </tr> <tr> <td>301 to 400</td> <td>8</td> </tr> <tr> <td>&#62;400</td> <td>10</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 61622 Version 2.0</div></div></div>"},"61623":{"type":"graphic_table","displayName":"Clues to severe AAT deficiency","title":"Potential clues to the diagnosis of alpha-1 antitrypsin deficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential clues to the diagnosis of alpha-1 antitrypsin deficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>Family history</strong></td> <td> <ul> <li>AAT deficiency </li> <li>Emphysema </li> <li>Bronchiectasis </li> <li>Liver disease </li> <li>Panniculitis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Lung disease</strong></td> <td> <ul> <li>Irreversible airflow limitation on spirometry </li> <li>Emphysema at a young age &#8804;45 </li> <li>Emphysema in the absence of smoking or occupational risk factor </li> <li>Emphysema characterized by predominant basilar changes on chest imaging </li> <li>Unexplained bronchiectasis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Liver disease</strong></td> <td> <ul> <li>Neonatal hepatitis </li> <li>Cirrhosis in both children and adults </li> <li>Hepatocellular carcinoma </li> <li>Hepatomegaly </li> <li>Unexplained liver disease </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Skin disease</strong></td> <td> <ul> <li>Necrotizing panniculitis (thigh, buttocks) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Other associations</strong></td> <td> <ul> <li>C-ANCA positive vasculitis </li> </ul> </td> </tr> <tr> <td><strong>Abnormal laboratory tests</strong></td> <td> <ul> <li>Persistent mild to moderate &#8593;ALT, &#8593;AST </li> <li>Low alpha<sub>1</sub>-globulin or&nbsp;presence of&nbsp;two bands in alpha<sub>1</sub> globulin region on SPEP </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AAT: alpha-1 antitrypsin; C-ANCA: Cytoplasmic antineutrophil cytoplasmic antibodies; ALT: alanine aminotransferase; AST: aspartate aminotransferase; SPEP: serum protein electrophoresis.</div><div class=\"graphic_reference\">Source: American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168:818.</div><div id=\"graphicVersion\">Graphic 61623 Version 3.0</div></div></div>"},"61626":{"type":"graphic_figure","displayName":"RANKL- and ROS-activated signals","title":"RANKL- and ROS-activated signals affecting the genesis and lifespan of osteoclasts","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">RANKL- and ROS-activated signals affecting the genesis and lifespan of osteoclasts</div><div class=\"cntnt\"><img style=\"width:522px; height:450px;\" src=\"images/ENDO/61626_RANKLROSactivatedsignals.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In osteoclast precursors, RANKL-induced activation of RANK stimulates NFATc1 activation via cFOS/AP-1 and CREB. In addition, mitochondria biogenesis coupled with activation of the transferrin receptor by the iron-transferrin complex stimulates mitochondria respiration and ROS production, which are also essential for osteoclast activation.</div><div class=\"graphic_footnotes\">RANKL: RANK ligand; ROS: reactive oxygen species; Fe: iron; Tf: transferrin; RANK: receptor activator of nuclear factor kappa-B; TfR1: transferrin receptor 1;&nbsp;CREB: cAMP response element–binding protein; NFATc1: nuclear factor of activated T cells 1; PGC-1Β: peroxisome proliferator–activated receptor-gamma coactivator 1-beta.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: Ishii KA, Fumoto T, Iwai K, et al. Coordination of PGC-1beta and iron uptake in mitochondrial biogenesis and osteoclast activation. Nat Med 2009; 15:259. Copyright © 2009.</div><div id=\"graphicVersion\">Graphic 61626 Version 3.0</div></div></div>"},"61627":{"type":"graphic_figure","displayName":"Death-censored graft survival","title":"Comparison of renal allograft survival according to months on dialysis","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Comparison of renal allograft survival according to months on dialysis</div><div class=\"cntnt\"><img style=\"width:464px; height:333px;\" src=\"images/NEPH/61627_death_censored_graft_Surviv.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes:&nbsp;A paired donor kidney analysis. Transplantation 2002; 74:1377.</div><div id=\"graphicVersion\">Graphic 61627 Version 3.0</div></div></div>"},"61630":{"type":"graphic_diagnosticimage","displayName":"Chest wall extension MRI I","title":"Lung carcinoma with chest wall invasion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lung carcinoma with chest wall invasion</div><div class=\"cntnt\"><img style=\"width:360px; height:265px;\" src=\"images/PULM/61630_Chest_wall_extension_MRI_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal T1-weighted section shows a large soft tissue mass filling the apical-posterior segment of the left upper lobe (arrow).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 61630 Version 2.0</div></div></div>"},"61632":{"type":"graphic_figure","displayName":"Vitamin K pathway","title":"Biosynthetic pathway for vitamin K-dependent production of gamma-carboxyglutamic acid","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Biosynthetic pathway for vitamin K-dependent production of gamma-carboxyglutamic acid</div><div class=\"cntnt\"><img style=\"width:562px; height:342px;\" src=\"images/HEME/61632_Vitamin_K_pathway.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">It has been hypothesized that a free cysteine residue in the carboxylase converts vitamin KH2 into a \"strong base\" of sufficient basicity to abstract a hydrogen from the gamma-carbon of glutamic acid (shown in red). However, the role of a free cysteine in the carboxylation reaction is uncertain. Subsequently, CO2 is added to the gamma-carbon of glutamic acid to form gamma-carboxyglutamic acid. The activated vitamin K species collapses into vitamin K epoxide and is recycled back to vitamin KH2, following the action of two vitamin K reductases, one of which is inhibited by warfarin.</div><div class=\"graphic_reference\">Data redrawn from Furie, B, Bouchard, BA, Furie, BC. Blood 1999;93:1798.</div><div id=\"graphicVersion\">Graphic 61632 Version 2.0</div></div></div>"},"61633":{"type":"graphic_figure","displayName":"CD40L CD40 expression","title":"Peripheral blood flow cytometry profile in HIGM","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Peripheral blood flow cytometry profile in HIGM</div><div class=\"cntnt\"><img style=\"width:522px; height:296px;\" src=\"images/ALLRG/61633_CD40L_CD40_expression.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CD40L (aka CD154) expression in unstimulated and stimulated CD4+ T cells. Normal individuals show CD40L upregulation, while patients with XL-HIGM syndrome do not. Carriers of the mutation show bimodal expression pattern.</div><div class=\"graphic_footnotes\">HIGM: hyperimmunoglobulin M syndrome; XL-HIGM: X-linked hyperimmunoglobulin&nbsp;M syndrome.</div><div id=\"graphicVersion\">Graphic 61633 Version 2.0</div></div></div>"},"61635":{"type":"graphic_waveform","displayName":"Radial pulse delay in subclavian steal syndrome","title":"Radial pulse delay in subclavian steal syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radial pulse delay in subclavian steal syndrome</div><div class=\"cntnt\"><img style=\"width:321px; height:153px;\" src=\"images/CARD/61635_Radial_pulse_subclavian_ste.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Simultaneous right and left radial pulse volumes in a patient with dizziness induced by left upper extremity exercise shows late arrival of the left subclavian artery pulsation, which can be appreciated by simultaneous palpation of the radial arteries. Note the delay in the left radial pulse at the brown bar.</div><div class=\"graphic_reference\">Courtesy of Peter Spittell, MD.</div><div id=\"graphicVersion\">Graphic 61635 Version 4.0</div></div></div>"},"61636":{"type":"graphic_figure","displayName":"WATCHMAN device","title":"WATCHMAN implant","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">WATCHMAN implant</div><div class=\"cntnt\"><img style=\"width:586px; height:375px;\" src=\"images/CARD/61636_WATCHMAN_device.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Watchman left atrial appendage (LAA) closure technology.<br />(B) Watchman LAA closure technology in anatomical position.</div><div class=\"graphic_reference\">Reproduced from: Jain AK, Gallagher S. Technology and guidelines Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism: NICE guidance. Heart 2011; 97:762, with permission from BMJ Publishing Group Ltd.</div><div id=\"graphicVersion\">Graphic 61636 Version 5.0</div></div></div>"},"61637":{"type":"graphic_table","displayName":"Causes of acute respiratory distress in children","title":"Causes of acute respiratory distress in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of acute respiratory&nbsp;distress in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Respiratory tract</td> </tr> <tr> <td class=\"sublist1_start\">Infection</td> </tr> <tr> <td class=\"sublist1\">Uvulitis</td> </tr> <tr> <td class=\"sublist1\"><span class=\"red\" style=\"color: #000000;\">Epiglottitis*</span></td> </tr> <tr> <td class=\"sublist1\">Retropharyngeal abscess</td> </tr> <tr> <td class=\"sublist1\">Peritonsillar abscess</td> </tr> <tr> <td class=\"sublist1\">Croup</td> </tr> <tr> <td class=\"sublist1\">Tracheitis</td> </tr> <tr> <td class=\"sublist1\">Bronchiolitis</td> </tr> <tr> <td class=\"sublist1\">Pneumonia</td> </tr> <tr> <td>Asthma</td> </tr> <tr> <td><span class=\"red\" style=\"color: #000000;\">Anaphylaxis*</span></td> </tr> <tr> <td>Foreign body (upper airway*, lower airway, esophagus)</td> </tr> <tr> <td>Airway anomalies (eg, laryngomalacia, laryngospasm, tracheoesophageal fistula, tracheal stenosis, tracheal ring or sling)</td> </tr> <tr> <td>Biologic or chemical weapons* (eg, anthrax, tularemia, phosgene, nitrogen mustard, nerve agents, ricin)</td> </tr> <tr> <td>Chest wall trauma or abnormalities (eg, flail chest*, open pneumothorax*, thoracic dystrophy)</td> </tr> <tr> <td>Thoracic cavity trauma or conditions (eg, pneumothorax*, hemothorax*, pleural effusion, empyema, mediastinal mass)</td> </tr> <tr> <td>Pulmonary trauma or conditions (contusion, embolism, hemorrhage)</td> </tr> <tr> <td>Smoke inhalation*</td> </tr> <tr> <td>Chemical agent exposures* (eg, phosgene, chlorine, cyanide)</td> </tr> <tr> <td>Submersion injury (near-drowning)*</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiovascular</td> </tr> <tr> <td>Congenital heart disease*</td> </tr> <tr> <td>Acute decompensated heart failure*</td> </tr> <tr> <td>Myocarditis*</td> </tr> <tr> <td>Pericarditis</td> </tr> <tr> <td>Arrhythmia*</td> </tr> <tr> <td>Shock*</td> </tr> <tr> <td>Cardiac tamponade*</td> </tr> <tr> <td>Myocardial infarction*</td> </tr> <tr> <td class=\"subtitle1_single\">Nervous system</td> </tr> <tr> <td>Depressed ventilation* (eg, ingestion, CNS trauma, seizures, or CNS infection)</td> </tr> <tr> <td>Hypotonia* (conditions causing poor airway or respiratory muscle tone and ineffective respiratory effort)</td> </tr> <tr> <td>Pulmonary aspiration due to loss of airway protective reflexes</td> </tr> <tr> <td class=\"subtitle1_single\">Gastrointestinal</td> </tr> <tr> <td>Hypoventilation due to abdominal pain or distention (eg, intraabdominal trauma, small bowel obstruction, bowel perforation)</td> </tr> <tr> <td>Gastroesophageal reflux with pulmonary aspiration</td> </tr> <tr> <td class=\"subtitle1_single\">Metabolic and endocrine diseases</td> </tr> <tr> <td>Metabolic acidosis (eg, diabetic ketoacidosis, severe dehydration, sepsis, toxic ingestions, inborn errors of metabolism)</td> </tr> <tr> <td>Hyperthyroidism</td> </tr> <tr> <td>Hypothyroidism</td> </tr> <tr> <td>Hyperammonemia</td> </tr> <tr> <td>Hypocalcemia (laryngospasm)</td> </tr> <tr> <td class=\"subtitle1_single\">Hematologic</td> </tr> <tr> <td>Decreased O<sub>2</sub> carrying capacity (eg, acute severe anemia from hemolysis, methemoglobinemia, carbon monoxide poisoning)</td> </tr> <tr> <td>Acute chest syndrome (patients with sickle cell disease)*</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">*Condition that can be&nbsp;immediately life threatening.</div><div class=\"graphic_footnotes\">CNS: central nervous system; O2: oxygen.</div><div id=\"graphicVersion\">Graphic 61637 Version 12.0</div></div></div>"},"61638":{"type":"graphic_diagnosticimage","displayName":"Echocardiogram apical 4-chamber in ARVC","title":"Echocardiogram apical 4-chamber showing right ventricular enlargement and aneurysms in arrhythmogenic right ventricular cardiomyopathy (ARVC)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiogram apical 4-chamber showing right ventricular enlargement and aneurysms in arrhythmogenic right ventricular cardiomyopathy (ARVC)</div><div class=\"cntnt\"><img style=\"width:271px; height:349px;\" src=\"images/CARD/61638_4chamberrightventdyspla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The apical four chamber view shows marked dilatation of the right ventricle; the moderator band (septal marginal trabeculation) in the apex of the RV is enlarged with complex attachments to the septum and free wall.</div><div class=\"graphic_footnotes\">LV: left ventricle; RA: right atrium.</div><div id=\"graphicVersion\">Graphic 61638 Version 4.0</div></div></div>"},"61639":{"type":"graphic_diagnosticimage","displayName":"Apical 4 chamber Ca MV annulus","title":"Mitral annular calcification","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral annular calcification</div><div class=\"cntnt\"><img style=\"width:258px; height:251px;\" src=\"images/CARD/61639_Apical_4_chamber_Ca_MV_annu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The apical four chamber view shows a marked degree of dense echoes at the mitral annulus, a result of mitral annular calcification (MAC). The mitral valve is not easily seen because it is obscured by the highly reflective MAC.</div><div class=\"graphic_footnotes\">L: left ventricle; RV: right ventricle; LA: left atrium; RA: right atrium.</div><div id=\"graphicVersion\">Graphic 61639 Version 2.0</div></div></div>"},"61640":{"type":"graphic_table","displayName":"Rx strep PVE I","title":"Suggested regimens for therapy of prosthetic valve endocarditis due to penicillin-susceptible viridans streptococci and <EM innerHtml>Streptococcus gallolyticus </EM>(<EM innerHtml>bovis</EM>) (MIC ≤0.12 mcg/mL)*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested&nbsp;regimens for therapy of prosthetic valve endocarditis due to penicillin-susceptible viridans streptococci and <EM innerHtml>Streptococcus gallolyticus </EM>(<EM innerHtml>bovis</EM>) (MIC ≤0.12 mcg/mL)*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">American Heart Association (AHA)</td> <td class=\"subtitle1\">European Society of Cardiology (ESC)</td> </tr> <tr> <td class=\"subtitle2\">Adult</td> <td class=\"subtitle2\">Pediatric (not to exceed dose of normal adult)</td> <td class=\"subtitle2\"><span class=\"sublist2_start\"></span><span class=\"subtitle2\">Adult</span>&nbsp;<span class=\"subtitle2_single\"></span></td> </tr> <tr> <td> <p><strong>Either</strong></p> <p>Aqueous penicillin G 24 million units per 24 hours IV either continuously or in&nbsp;four or&nbsp;six divided doses for&nbsp;six weeks</p> <p><strong>or</strong></p> <p>Ampicillin 2 g IV every 4 hours for six weeks</p> <p><strong>or&nbsp;</strong></p> <p>Ceftriaxone<sup>&#182;</sup> 2 g per 24 hours IV in&nbsp;one dose for&nbsp;six weeks</p> <p><strong>with or without</strong></p> <p>Gentamicin<sup>&#916;&#9674;</sup> 3 mg/kg per 24 hours IV or IM in&nbsp;one dose for first two weeks</p> <p><strong><strong>Beta-lactam-intolerant patients:</strong></strong></p> <p>Vancomycin<sup>&#167;</sup> 30 mg/kg per 24 hours IV in&nbsp;two divided doses for&nbsp;six weeks</p> </td> <td> <p><strong>Either</strong>&nbsp;</p> <p>Aqueous penicillin G 200,000 to 300,000 units/kg per 24 hours IV in&nbsp;six divided doses (maximum dose: 24 million units per&nbsp;24 hours)&nbsp;for&nbsp;six weeks</p> <p><strong>or</strong></p> <p>Ampicillin&nbsp;200 to 300&nbsp;mg/kg per 24 hours IV divided in four&nbsp;or six divided doses&nbsp;(maximum dose: 12 g per 24 hours) for&nbsp;six weeks</p> <p><strong>or</strong></p> <p>Ceftriaxone 100 mg/kg per 24 hours IV<sup>​</sup> in two divided doses or 80 mg/kg in one daily dose (maximum dose: 4 g per 24 hours; if dose is &#62;2 g per 24 hours, use divided dosing every 12 hours) for&nbsp;six weeks</p> <p><strong>plus</strong></p> <p>Gentamicin<sup><span style=\"font-size: 13px;\">&#916;&#9674;</span></sup> 3 to 6 mg/kg per 24 hours IV&nbsp;in&nbsp;three divided doses for&nbsp;first two weeks</p> <p><strong>Beta-lactam-intolerant patients:</strong></p> <p>Vancomycin<sup>&#167;</sup> 40 mg/kg per 24 hours IV in two or three divided doses (maximum dose: 2 g per 24 hours unless levels are inappropriately low) for six weeks&nbsp;<strong>plus</strong> gentamicin (dosing as above) for first two weeks</p> </td> <td> <p><strong>Either</strong></p> <p>Aqueous penicillin G 12 to 18 million units per 24 hours IV in&nbsp;four&nbsp;or six divided doses or continuously for&nbsp;six weeks</p> <p><strong>or</strong></p> <p>Amoxicillin 100 to 200 mg/kg per 24 hours IV in&nbsp;four&nbsp;or&nbsp;six divided doses for&nbsp;six weeks</p> <p><strong>or</strong></p> <p>Ampicillin 12 g per 24 hours (or 100 to 200 mg/kg per 24 hours) IV in&nbsp;four or six divided doses for&nbsp;six weeks</p> <p><strong>or</strong></p> <p>Ceftriaxone<sup>&#182;</sup> 2 g per 24 hours IV in&nbsp;one dose for&nbsp;six weeks</p> <p><strong>or</strong></p> <p>Vancomycin<sup>&#167;</sup> 30 mg/kg per 24 hours IV in&nbsp;two divided doses for&nbsp;six weeks</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses above are intended for patients with normal renal function. The doses of many of these agents must be adjusted in the setting of renal insufficiency; refer to the individual&nbsp;Lexicomp drug monographs for renal dose adjustments.<br />Wherever intramuscular administration is provided as an alternative, intravenous route is preferred, particularly in infants and children.</div><div class=\"graphic_footnotes\">MIC: minimum inhibitory concentration; IV: intravenously; IM: intramuscularly.<br />* AHA adult guidelines use MIC ≤0.12 mcg/mL; AHA pediatric guidelines use MIC ≤0.1 mcg/mL; ESC guidelines use MIC ≤0.125 mcg/mL.<br />¶&nbsp;Alternative in patients with nonsevere penicillin allergy; preferred for outpatient therapy.<br />Δ&nbsp;Gentamicin&nbsp;should be&nbsp;omitted in patients with potential for nephrotoxicity, patients with creatinine clearance &lt;30 mL/min, or patients with impaired VIII cranial nerve function or severe decreased vision. In&nbsp;adults, aminoglycosides are dosed based on ideal body weight.<br />◊&nbsp;Renal function and gentamicin serum concentrations should be monitored at least once per week. Gentamicin dosage adjusted for peak serum concentration 3 to 4 mcg/mL, trough &lt;1 mcg/mL when&nbsp;two to three&nbsp;divided doses used; when given in a single daily dose, pre-dose (trough) concentrations should be &lt;1 mcg/mL. Per AHA guidelines, there is&nbsp;no role for measuring peak gentamicin concentration following single daily dosing.<br />§&nbsp;Vancomycin therapy only recommended for patients allergic to penicillins or cephalosporins. Penicillin desensitization can be attempted in stable patients. In adults, vancomycin is dosed based on actual body weight. The dose should be adjusted for trough concentration of 10 to 15 mcg/mL.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Circulation 2015; 132:1435.</LI>&#xD;&#xA;<LI>Baltimore RS, Gewitz M, Baddour LM, et al. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. Circulation 2015; 132:1487.</LI>&#xD;&#xA;<LI>Authors/Task Force Members, Habib G, Lancellotti P, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC) Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075.</LI></OL></div><div id=\"graphicVersion\">Graphic 61640 Version 10.0</div></div></div>"},"61641":{"type":"graphic_picture","displayName":"Candida glabrata","title":"<EM>Candida glabrata</EM>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Candida glabrata</EM></div><div class=\"cntnt\"><img style=\"width:372px; height:252px;\" src=\"images/ID/61641_Torulopsisglabrata.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Candida glabrata</EM> grows as a small, elliptical, budding, unicellular yeast. Buds rarely adhere to one another in rudimentary chains, but filamentous growth does not occur.</div><div class=\"graphic_reference\">Courtesy of Wiley Schell, MS.</div><div id=\"graphicVersion\">Graphic 61641 Version 4.0</div></div></div>"},"61643":{"type":"graphic_figure","displayName":"DeLancey levels pelvic support 2","title":"DeLancey levels of vaginal support","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">DeLancey levels of vaginal support</div><div class=\"cntnt\"><img style=\"width:534px; height:393px;\" src=\"images/OBGYN/61643_Tx_post_vaginal_wall_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Level I consists of the cardinal and uterosacral ligaments, and suspends the vaginal apex. Level II consists of the endopelvic fascia connections to the arcus tendineus fascia pelvis, which attaches the vagina to the aponeurosis of the levator ani. Level III consists of the perineal body and includes interlacing muscle fibers of the bulbospongiosus, transverse perinei, and external anal sphincter.</div><div class=\"graphic_reference\">Reproduced with permission from: Walters MD, Karram MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright © 2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 61643 Version 5.0</div></div></div>"},"61644":{"type":"graphic_table","displayName":"Mastoiditis Rx regimens","title":"Suggested empiric parenteral antibiotic regimens for the treatment of acute mastoiditis in children*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested empiric parenteral antibiotic regimens for the treatment of acute mastoiditis in children*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antibiotic</td> <td class=\"subtitle1\">Dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">For patients without a history of recurrent otitis media or recent antibiotic therapy</td> </tr> <tr> <td class=\"indent1\">Vancomycin<sup>&#182;&#916;</sup></td> <td>15&nbsp;mg/kg per <strong>dose</strong> every 6 hours (maximum&nbsp;1 g per dose)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">For patients with a history of recurrent otitis media (last episode within 6 months) or recent antibiotic therapy</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">For patients without penicillin allergy (two agents)</td> </tr> <tr> <td class=\"indent2\">Ceftazidime<sup>&#182; </sup><strong>OR</strong></td> <td>50 mg/kg per <strong>dose</strong> every 8 hours (maximum&nbsp;2 g per dose)</td> </tr> <tr> <td class=\"indent2\">Cefepime<sup>&#182; </sup><strong>OR</strong> </td> <td>50 mg/kg per <strong>dose</strong> every 8 hours (maximum&nbsp;2 g per dose)</td> </tr> <tr> <td class=\"sublist3_start\">Piperacillin-tazobactam<sup>&#182;</sup></td> <td class=\"sublist_other_start\">300&nbsp;mg/kg per<strong>&nbsp;day </strong>of piperacillin component divided every 6 or 8 hours (maximum&nbsp;daily dose 16 g&nbsp;of piperacillin component)</td> </tr> <tr> <td class=\"sublist3\" colspan=\"2\"><strong>PLUS</strong></td> </tr> <tr> <td class=\"indent2\">Vancomycin<sup>&#182;&#916;</sup></td> <td>15&nbsp;mg/kg per<strong> dose</strong> every 6 hours (maximum&nbsp;1 g per dose)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">For patients with potential severe hypersensitivity (ie, anaphylaxis) to beta-lactam antibiotics (eg, penicillin, cephalosporin)<sup>&#9674;</sup> (two agents)</td> </tr> <tr> <td class=\"sublist3_start\">Aztreonam<sup>&#182; </sup></td> <td class=\"sublist_other_start\">30 mg/kg per <strong>dose</strong> every 6 hours (maximum 2g per&nbsp;dose)</td> </tr> <tr> <td class=\"sublist3\" colspan=\"2\"><strong>PLUS</strong></td> </tr> <tr> <td class=\"indent2\">Vancomycin<sup>&#182;&#916;</sup></td> <td>15&nbsp;mg/kg per<strong> dose </strong>every 6 hours (maximum&nbsp;1 g per dose)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">For patients with non-anaphylactic hypersensitivity to penicillins (two agents)</td> </tr> <tr> <td class=\"indent2\">Ceftazidime<sup>&#182; </sup><strong>OR</strong></td> <td>50 mg/kg per <strong>dose </strong>every 8 hours (maximum&nbsp;2 g per dose)</td> </tr> <tr> <td class=\"sublist3_start\">Cefepime<sup>&#182;</sup></td> <td class=\"sublist_other_start\">50 mg/kg per <strong>dose </strong>every 8 hours (maximum&nbsp;2 g per dose)</td> </tr> <tr> <td class=\"sublist3\" colspan=\"2\"><strong>PLUS</strong></td> </tr> <tr> <td class=\"indent2\">Vancomycin<sup>&#182;&#916;</sup></td> <td>15&nbsp;mg/kg per<strong> dose</strong> every 6 hours (maximum&nbsp;1 g per dose)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Table contains suggested antibiotic options for broad-spectrum initial empirical treatment. Consider local resistance data, including prevalence of extended-spectrum beta-lactamase (ESBL)-producing organisms that may require alternate empiric coverage, including a carbapenem. <STRONG>Selection and/or dosing should be modified based on the results of culture and sensitivity testing.</STRONG> Refer to UpToDate's content on treatment of &nbsp;acute mastoiditis in children for further details..<br />¶&nbsp;Dosage modification for renal insufficiency is necessary. See drug information topic.<br />Δ Monitor blood levels to insure efficacy and avoid toxicity.<br /><FONT class=lozenge>◊</FONT> Rapid desensitization and use of first-line agents may be preferred if feasible.</div><div id=\"graphicVersion\">Graphic 61644 Version 6.0</div></div></div>"},"61645":{"type":"graphic_diagnosticimage","displayName":"Clay shoveler spinous process fracture","title":"Spinous process fractures: Clay shoveler's fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spinous process fractures: Clay shoveler's fracture</div><div class=\"cntnt\"><img style=\"width:288px; height:402px;\" src=\"images/EM/61645_Clay_shoveler_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The clay shoveler's fracture is an isolated fracture of one of the spinous processes of the lower cervical vertebrae. It is a stable injury that most often occurs with direct trauma to the spinous process.</div><div class=\"graphic_reference\">Courtesy of Mary Hochman, MD</div><div id=\"graphicVersion\">Graphic 61645 Version 3.0</div></div></div>"},"61646":{"type":"graphic_picture","displayName":"Actively bleeding GU Endosc","title":"Bleeding gastric ulcer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bleeding gastric ulcer</div><div class=\"cntnt\"><img style=\"width:266px; height:252px;\" src=\"images/GAST/61646_ActivelybleedingGUEndosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy shows an actively bleeding gastric ulcer&nbsp;(Forrest classification Ia) along the lesser curvature.</div><div class=\"graphic_reference\">Courtesy of Rome Jutabha, MD and Dennis M Jensen, MD.</div><div id=\"graphicVersion\">Graphic 61646 Version 2.0</div></div></div>"},"61647":{"type":"graphic_table","displayName":"Etiology of colonic ischemia","title":"Etiology of colonic ischemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of colonic ischemia</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Mesenteric venous thrombosis</td> </tr> <tr> <td>Hypercoagulable state</td> </tr> <tr> <td>Lymphocytic phlebitis</td> </tr> <tr> <td>Portal hypertension</td> </tr> <tr> <td>Pancreatitis</td> </tr> <tr> <td class=\"subtitle1_single\">Small vessel disease</td> </tr> <tr> <td>Diabetes</td> </tr> <tr> <td class=\"sublist1_start\">Vasculitis</td> </tr> <tr> <td class=\"sublist1\">Polyarteritis nodosa</td> </tr> <tr> <td class=\"sublist1\">Lupus erythematosus</td> </tr> <tr> <td class=\"sublist1\">Takayasu arteritis</td> </tr> <tr> <td class=\"sublist1\">Granulomatosis with polyangiitis (Wegener's)</td> </tr> <tr> <td class=\"sublist1\">Anticentromere antibodies</td> </tr> <tr> <td class=\"sublist1\">Buerger's disease</td> </tr> <tr> <td>Antiphospholipid antibodies</td> </tr> <tr> <td>Amyloidosis</td> </tr> <tr> <td>Rheumatoid arthritis</td> </tr> <tr> <td>Radiation</td> </tr> <tr> <td class=\"subtitle1_single\">Shock</td> </tr> <tr> <td>Cardiac failure</td> </tr> <tr> <td>Hemodialysis</td> </tr> <tr> <td>Pancreatitis</td> </tr> <tr> <td>Anaphylaxis</td> </tr> <tr> <td class=\"subtitle1_single\">Mechanical obstruction</td> </tr> <tr> <td>Strangulated hernia</td> </tr> <tr> <td>Colon cancer</td> </tr> <tr> <td>Adhesion</td> </tr> <tr> <td>Rectal prolapse</td> </tr> <tr> <td>Fecal impaction or pseudoobstruction</td> </tr> <tr> <td class=\"subtitle1_single\">Blood dyscrasia</td> </tr> <tr> <td>Hypercoagulable state</td> </tr> <tr> <td>Sickle cell disease</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Iatrogenic</td> </tr> <tr> <td class=\"subtitle2_single\">Surgical</td> </tr> <tr> <td class=\"indent1\">Aortoiliac reconstruction</td> </tr> <tr> <td class=\"indent1\">Cardiopulmonary bypass</td> </tr> <tr> <td class=\"indent1\">Renal transplant</td> </tr> <tr> <td class=\"indent1\">Colonoscopy</td> </tr> <tr> <td class=\"indent1\">Barium enema</td> </tr> <tr> <td class=\"subtitle2_single\">Drugs<sup>[1]</sup></td> </tr> <tr> <td class=\"indent1\">Alosetron</td> </tr> <tr> <td class=\"indent1\">Digitalis</td> </tr> <tr> <td class=\"indent1\">Diuretics</td> </tr> <tr> <td class=\"indent1\">Cocaine</td> </tr> <tr> <td class=\"indent1\">Estrogens</td> </tr> <tr> <td class=\"indent1\">Danazol</td> </tr> <tr> <td class=\"indent1\">NSAIDs</td> </tr> <tr> <td class=\"indent1\">Tegaserod</td> </tr> <tr> <td class=\"indent1\">Vasoactive substances</td> </tr> <tr> <td class=\"indent1\">Paclitaxel and carboplatin</td> </tr> <tr> <td class=\"indent1\">Sumatriptan</td> </tr> <tr> <td class=\"indent1\">Antipsychotics</td> </tr> <tr> <td class=\"indent1\">Simvastatin</td> </tr> <tr> <td class=\"indent1\">Quetiapine</td> </tr> <tr> <td class=\"indent1\">Rizatriptan</td> </tr> <tr> <td class=\"subtitle2_single\">Others</td> </tr> <tr> <td class=\"indent1\">Long-distance running</td> </tr> <tr> <td class=\"indent1\">Dialysis</td> </tr> <tr> <td class=\"indent1\">Neurogenic</td> </tr> <tr> <td class=\"indent1\">Spontaneous in young adults</td> </tr> <tr> <td class=\"indent1\">Infections (CMV, <em>E. coli</em> O157:H7)</td> </tr> <tr> <td class=\"indent1\">Airplane flight</td> </tr> <tr> <td class=\"subtitle1_single\">Major vascular occlusion</td> </tr> <tr> <td>Mesenteric artery thrombosis</td> </tr> <tr> <td>Cholesterol emboli</td> </tr> <tr> <td>Colectomy with IMA ligation</td> </tr> <tr> <td>Aortic dissection</td> </tr> <tr> <td>Aortic reconstruction</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NSAIDs: nonsteroidal antiinflammatory drugs; CMV: cytomegalovirus; <em>E. coli</em>: <em>Escherichia coli</em>; IMA: inferior mesenteric artery.</div><div class=\"graphic_reference\">Reference:<br /><ol>&#xD;&#xA;    <li>Cappell MS. Colonic toxicity of administered drugs and chemicals. Am J Gastroenterol 2004; 99:1175.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 61647 Version 7.0</div></div></div>"},"61649":{"type":"graphic_table","displayName":"Hemoglobin mutation syndromes","title":"Clinically important hemoglobin mutations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinically important hemoglobin mutations</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Sickle syndromes (abnormal polymerization)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Homozygous sickle cell disease (HbSS)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Sickle-Hemoglobin C (HbSC)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Sickle-&#946; thalassemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Thalassemic disorders - reduced production of a normal\nglobin chain</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Structural mutants also resulting in a thalassemic\nphenotype (Hb Lepore, Constant Spring, Hb E)</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Decreased solubility (crystallization, Hb C disease)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Unstable hemoglobins (congenital Heinz body hemolytic\nanemia, Hb Koln)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Abnormal oxygen affinity mutations</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">High affinity\nhemoglobin (familial erythrocytosis, Hb Chesapeake)</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Low affinity\nhemoglobin (familial cyanosis, Hb Kansas)</td>\n    </tr>\n    <tr>\n\n      <td>M hemoglobins (familial cyanosis/congenital\nmethemoglobinemia)</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from multiple sources.</div><div id=\"graphicVersion\">Graphic 61649 Version 1.0</div></div></div>"},"61650":{"type":"graphic_picture","displayName":"Pautrier microabscess","title":"Mycosis fungoides","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mycosis fungoides</div><div class=\"cntnt\"><img style=\"width:334px; height:356px;\" src=\"images/HEME/61650_Pautrier_microabscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin biopsy from a patient with mycosis fungoides, showing a large cluster of atypical lymphocytes in the epidermis (Pautrier microabscess, arrow).</div><div class=\"graphic_reference\">From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 61650 Version 1.0</div></div></div>"},"61651":{"type":"graphic_picture","displayName":"Intraluminal fulgaration of the vas during vasectomy","title":"Intraluminal fulgaration of the vas during vasectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraluminal fulgaration of the vas during vasectomy</div><div class=\"cntnt\"><img style=\"width:360px; height:331px;\" src=\"images/PC/61651_Intraluminal_cautery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A disposable cautery is used to fulgarate the lumen of the vas.</div><div class=\"graphic_reference\">Reproduced with permission from: Clenney, TL, Higgins, JC. Vasectomy Techniques. American Family Physician 1999; 60:137. Copyright &#169;1999 Timothy Clenney, MD, MPH.</div><div id=\"graphicVersion\">Graphic 61651 Version 2.0</div></div></div>"},"61652":{"type":"graphic_diagnosticimage","displayName":"Normal wrist radiograph","title":"Normal wrist radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal wrist radiograph</div><div class=\"cntnt\"><img style=\"width:342px; height:297px;\" src=\"images/PC/61652_Normal_wrist_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anterior-posterior view of the wrist is normal. The width of the articular cartilage is 2 mm and is identical to the width of the intercarpal joints.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 61652 Version 3.0</div></div></div>"},"61653":{"type":"graphic_figure","displayName":"Nutrition and diaphragm function","title":"Effect of nutrition on diaphragmatic length-tension relationship","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effect of nutrition on diaphragmatic length-tension relationship</div><div class=\"cntnt\"><img style=\"width:348px; height:359px;\" src=\"images/PULM/61653_Nutrition_and_muscle_length.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Undernutrition (calorie-restricted group) decreases the tension produced at any given muscle length in response to tetanic stimulation (50 Hz). Muscle length is expressed as a percentage of the length at which tension was maximal (Lo).</div><div class=\"graphic_reference\">Redrawn from Kelsen SG, Ference M, Dapoor S, J Appl Phsiol 1985; 58:1354.</div><div id=\"graphicVersion\">Graphic 61653 Version 2.0</div></div></div>"},"61654":{"type":"graphic_picture","displayName":"Plasma cell granuloma high","title":"Inflammatory myofibroblastic tumor (plasma cell granuloma) of the lung","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inflammatory myofibroblastic tumor (plasma cell granuloma) of the lung</div><div class=\"cntnt\"><img style=\"width:320px; height:212px;\" src=\"images/PULM/61654_Plasma_cell_granuloma_High.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High magnification photomicrograph showing a combination of spindle cells and plasma cells in inflammatory myofibroblastic tumor (plasma cell granuloma). The spindle cells likely represent the most important distinguishing feature and show immunophenotypic and ultrastructural characteristics of myofibroblasts. Although plasma cells account for most of the inflammatory cells in this example, it is not uncommon to see associated histiocytes, including lipid-laden foam cells and multinucleated giant cells.</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 61654 Version 2.0</div></div></div>"},"61655":{"type":"graphic_algorithm","displayName":"Medication review","title":"Medication review","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Medication review</div><div class=\"cntnt\"><img style=\"width:468px; height:543px;\" src=\"images/PC/61655_Good_pall_geriatric_prac.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: Addressing polypharmacy. Arch Intern Med 2010; 170:1648. Copyright © 2010 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 61655 Version 12.0</div></div></div>"},"61658":{"type":"graphic_picture","displayName":"Light micrograph showing acute hypertensive nephrosclerosis II ","title":"Light micrograph showing acute hypertensive nephrosclerosis (formerly \"malignant nephrosclerosis\") II","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light micrograph showing acute hypertensive nephrosclerosis (formerly \"malignant nephrosclerosis\") II</div><div class=\"cntnt\"><img style=\"width:378px; height:248px;\" src=\"images/NEPH/61658_Malig_nephroscl_Light_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mucoid intimal thickening and luminal narrowing in a small muscular renal artery (arrow) in the early stages of healing in acute hypertensive nephrosclerosis (formerly \"malignant nephrosclerosis\"). Similar changes can be seen in other thrombotic microangiopaties, such as scleroderma and the hemolytic-uremic syndrome.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 61658 Version 3.0</div></div></div>"},"61661":{"type":"graphic_table","displayName":"Amino acids","title":"Amino acids","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Amino acids</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Nonessential</td> </tr> <tr> <td>Alanine</td> </tr> <tr> <td>Arginine</td> </tr> <tr> <td>Asparagine</td> </tr> <tr> <td>Aspartic acid</td> </tr> <tr> <td>Citrulline</td> </tr> <tr> <td>Glutamic acid (glutamate)</td> </tr> <tr> <td>Glutamine</td> </tr> <tr> <td>Glycine</td> </tr> <tr> <td>Histidine*</td> </tr> <tr> <td>Proline</td> </tr> <tr> <td>Serine</td> </tr> <tr> <td>Tyrosine</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Essential</td> </tr> <tr> <td>Isoleucine</td> </tr> <tr> <td>Leucine</td> </tr> <tr> <td>Lysine</td> </tr> <tr> <td>Methionine</td> </tr> <tr> <td>Phenylalanine</td> </tr> <tr> <td>Threonine</td> </tr> <tr> <td>Tryptophan</td> </tr> <tr> <td>Valine</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Essential for infants.</div><div id=\"graphicVersion\">Graphic 61661 Version 4.0</div></div></div>"},"61663":{"type":"graphic_picture","displayName":"Vulvar cancer 1","title":"Vulvar cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar cancer</div><div class=\"cntnt\"><img style=\"width:374px; height:461px;\" src=\"images/ONC/61663_Vulvar_cancer_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small (T1) vulvar carcinoma at the posterior fourchette.</div><div class=\"graphic_reference\">Reproduced with permission from: Berek JS, Hacker NF. Berek &amp; Hacker's Gynecologic Oncology,&nbsp;5th ed. Philadelphia: Lippincott Williams &amp; Wilkins, 2010. Copyright &#169; 2010 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 61663 Version 2.0</div></div></div>"},"61664":{"type":"graphic_figure","displayName":"Stroke and severe aortic plaque","title":"Increasing risk of stroke with aortic plaque thickness","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Increasing risk of stroke with aortic plaque thickness</div><div class=\"cntnt\"><img style=\"width:488px; height:345px;\" src=\"images/CARD/61664_Stroke_and_severe_aortic_pl.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relation between stroke and plaque thickness and location. There is a rising likelihood of stroke with increasing plaque thickness in the ascending aorta (AA) or aortic arch. Plaque in the descending aorta is generally not associated with stroke in the absence of severe aortic regurgitation .</div><div class=\"graphic_reference\">Data from Amarenco, P, Cohen, A, Tzourio, C, et al, N Engl J Med 1994; 331:1474.</div><div id=\"graphicVersion\">Graphic 61664 Version 1.0</div></div></div>"},"61665":{"type":"graphic_diagnosticimage","displayName":"U-S fetal corpus callosum cavum septum pellucidum cavum vergae","title":"Corpus callosum, cavum septum pellucidum and cavum vergae","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Corpus callosum, cavum septum pellucidum and cavum vergae</div><div class=\"cntnt\"><img style=\"width:480px; height:331px;\" src=\"images/OBGYN/61665_US-Fetal-CC-CSP-CV.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 61665 Version 2.0</div></div></div>"},"61666":{"type":"graphic_picture","displayName":"Acanthosis nigricans with acrochordae","title":"Acanthosis nigricans","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Acanthosis nigricans</div><div class=\"cntnt\"><img style=\"width:473px; height:496px;\" src=\"images/DERM/61666_Acanthosis_nigric_ST_crop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A velvety hyperpigmented plaque with associated acrochordae is present&#160;in the axilla.</div><div id=\"graphicVersion\">Graphic 61666 Version 1.0</div></div></div>"},"61667":{"type":"graphic_diagnosticimage","displayName":"Elbow lateral view","title":"Normal elbow, lateral view","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Normal elbow, lateral view</div><div class=\"cntnt\"><img style=\"width:540px; height:623px;\" src=\"images/EM/61667_Elbow_lateral_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the normal small anterior fat pad (black arrow), and the normal alignment. The radiocapitellar line (white line) extends from the midshaft of the proximal radius and bisects the capitellum. Dislocation or displaced fracture of the radial head or capitellum will disrupt this alignment. The anterior humoral line (black line) extends along the anterior of the humerus and should cross the middle of the capitellum. A supracondylar fracture can disrupt this alignment.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 61667 Version 2.0</div></div></div>"},"61668":{"type":"graphic_diagnosticimage","displayName":"Thyroid ultrasound papillary thyroid carcinoma","title":"Thyroid ultrasound of a nonpalpable recurrent papillary thyroid carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thyroid ultrasound of a nonpalpable recurrent papillary thyroid carcinoma</div><div class=\"cntnt\"><img style=\"width:263px; height:322px;\" src=\"images/ENDO/61668_Papillary_carcin_Echo_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sonogram of the right thyroid lobe in the longitudinal plane from a patient who had had a left lobectomy for papillary thyroid carcinoma. Although the physical examination was normal, the sonogram shows a 8.6 mm hypoechogenic nodule (arrow) that represented tumor.</div><div class=\"graphic_footnotes\">L: thyroid lobe.</div><div class=\"graphic_reference\">Courtesy of Manfred Blum, MD.</div><div id=\"graphicVersion\">Graphic 61668 Version 5.0</div></div></div>"},"61669":{"type":"graphic_figure","displayName":"Pancreaticojej variations AGA","title":"Variations on pancreatojejunostomies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Variations on pancreatojejunostomies</div><div class=\"cntnt\"><img style=\"width:432px; height:343px;\" src=\"images/GAST/61669_Pancreaticojej_variations_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: American Gastroenterological Association (AGA) GTP slide set (2003), Pancreatic Disease. Authors: Gorelick F, Pandol S, Topazian M. Artist: Schoendorf J. Copyright &#169; 2003 American Gastroenterological Association.</div><div id=\"graphicVersion\">Graphic 61669 Version 3.0</div></div></div>"},"61672":{"type":"graphic_picture","displayName":"Mitosis in thymic carcinoid","title":"Well-differentiated thymic carcinoid: histology showing a mitotic figure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Well-differentiated thymic carcinoid: histology showing a mitotic figure</div><div class=\"cntnt\"><img style=\"width:360px; height:232px;\" src=\"images/PULM/61672_Mitosis_in_thymic_carcinoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Carcinoid tumors in the thymus often display areas of necrosis and mitotic figures (arrow). (Hematoxylin and eosin, magnification 250x).</div><div class=\"graphic_reference\">Courtesy of William Travis, MD.</div><div id=\"graphicVersion\">Graphic 61672 Version 2.0</div></div></div>"},"61675":{"type":"graphic_figure","displayName":"Hookworm life cycle","title":"Intestinal hookworm infection life cycle","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">Intestinal hookworm infection life cycle</div><div class=\"cntnt\"><img style=\"width:601px; height:492px;\" src=\"images/ID/61675_Hookworm_LC_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eggs are passed in the stool <STRONG>(1)</STRONG>, and under favorable conditions (moisture, warmth, shade) larvae hatch in&nbsp;one to&nbsp;two days. The released rhabditiform larvae grow in the feces and/or the soil <STRONG>(2)</STRONG>, and after 5 to 10 days (and two molts) they become filariform (third-stage) larvae that are infective <STRONG>(3)</STRONG>. These infective larvae can survive&nbsp;three to&nbsp;four weeks in favorable environmental conditions. On contact with the human host, the larvae penetrate the skin and are carried through the blood vessels to the heart and then to the lungs. They penetrate into the pulmonary alveoli, ascend the bronchial tree to the pharynx, and are swallowed <STRONG>(4)</STRONG>. The larvae reach the small intestine, where they reside and mature into adults. Adult worms live in the lumen of the small intestine, where they attach to the intestinal wall with resultant blood loss by the host <STRONG>(5)</STRONG>. Most adult worms are eliminated in&nbsp;one to&nbsp;two years, but the longevity may reach several years. Some&nbsp;<EM>Ancylostoma duodenale</EM> larvae, following penetration of the host skin, can become dormant (in the intestine or muscle). In addition, infection by <EM>A. duodenale</EM> may probably also occur by the oral and transmammary route.&nbsp;<EM>Necator americanus</EM>, however, requires a transpulmonary migration phase.</div><div class=\"graphic_reference\">Centers for Disease Control and Prevention. DPDx: Hookworm. <A href=\"http://www.cdc.gov/dpdx/hookworm/index.html\">http://www.cdc.gov/dpdx/hookworm/index.html</A>.</div><div id=\"graphicVersion\">Graphic 61675 Version 5.0</div></div></div>"},"61677":{"type":"graphic_table","displayName":"Five Ps of sexual history","title":"The five Ps: Partners, prevention of pregnancy, protection from STIs, practices, and past history of STIs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The five Ps: Partners, prevention of pregnancy, protection from STIs, practices, and past history of STIs</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Partners</td> </tr> <tr> <td>Do you have sex with men, women, or both?</td> </tr> <tr> <td>In the past 2 months, how many partners have you had sex with?</td> </tr> <tr> <td>In the past 12 months, how many partners have you had sex with?</td> </tr> <tr> <td>Is it possible that any of your sex partners in the past 12 months had sex with someone else while they were still in a sexual relationship with you?</td> </tr> <tr> <td class=\"subtitle1_single\">Prevention of pregnancy</td> </tr> <tr> <td>What are you doing to prevent pregnancy?</td> </tr> <tr> <td class=\"subtitle1_single\">Protection from STIs</td> </tr> <tr> <td>What do you do to protect yourself from STIs and HIV?</td> </tr> <tr> <td class=\"subtitle1_single\">Practices</td> </tr> <tr> <td>To understand your risks for STIs, I need to understand the kind of sex you have had recently.</td> </tr> <tr> <td>Have you had vaginal sex, meaning \"penis-in-vagina\" sex?</td> </tr> <tr> <td class=\"sublist1_start\">If yes:</td> </tr> <tr> <td class=\"sublist1\">Do you use condoms: never, sometimes, or always?</td> </tr> <tr> <td>Have you had anal sex, meaning \"penis-in-rectum/anus\" sex?</td> </tr> <tr> <td class=\"sublist1_start\">If yes:</td> </tr> <tr> <td class=\"sublist1\">Do you use condoms: never, sometimes, or always?</td> </tr> <tr> <td>Have you had oral sex, meaning \"mouth-on-penis/vagina\"?</td> </tr> <tr> <td>For condom answers:</td> </tr> <tr> <td class=\"sublist1\">If never:</td> </tr> <tr> <td class=\"sublist2\">Why do you not use condoms?</td> </tr> <tr> <td class=\"sublist1\">If sometimes:</td> </tr> <tr> <td class=\"sublist2\">In what situations (or with whom) do you not use condoms?</td> </tr> <tr> <td class=\"subtitle1_single\">Past history of STIs</td> </tr> <tr> <td>Have you ever had an STI?</td> </tr> <tr> <td>Have any of your partners had an STI?</td> </tr> <tr> <td class=\"subtitle1_single\">Additional questions to identify HIV and viral hepatitis risk:</td> </tr> <tr> <td>Have you or any of your partners ever injected drugs?</td> </tr> <tr> <td>Have you or any of your partners exchanged money or drugs for sex?</td> </tr> <tr> <td>Is there anything else about your sexual practices that I need to know about?</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">STI: sexually transmitted infection; HIV: human immunodeficiency virus.</div><div class=\"graphic_reference\">Adapted from: Workowski KA, Berman SM. Sexually transmitted diseases guidelines, 2015. MMWR Recomm Rep 2015; 64:1.</div><div id=\"graphicVersion\">Graphic 61677 Version 8.0</div></div></div>"},"61682":{"type":"graphic_diagnosticimage","displayName":"Salter IV radius fracture","title":"Salter IV radius fracture","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Salter IV radius fracture</div><div class=\"cntnt\"><img style=\"width:453px; height:474px;\" src=\"images/EM/61682_SalterIVradiusfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A) A markedly displaced Salter-Harris type IV fracture of the distal radius in an 11-year-old boy who fell from a horse. Panel B) X-ray taken three weeks after closed reduction demonstrates displacement of the comminuted fragments. Panel C) Eighteen months after injury, there was 15 mm of radial shortening, and the patient had a pronounced radial deviation deformity of the wrist.</div><div class=\"graphic_reference\">Reproduced with permission from: Waters PM, Mih AD. Fractures of the distal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 61682 Version 13.0</div></div></div>"},"61684":{"type":"graphic_table","displayName":"Causes genital bleeding by age","title":"Usual causes of abnormal genital bleeding in women by age group","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Usual causes of abnormal genital bleeding in women by age group</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Neonates</td> </tr> <tr> <td class=\"indent1\">Estrogen withdrawal</td> </tr> <tr> <td class=\"subtitle1_single\">Premenarchal</td> </tr> <tr> <td class=\"indent1\">Foreign body</td> </tr> <tr> <td class=\"indent1\">Trauma, including sexual abuse</td> </tr> <tr> <td class=\"indent1\">Infection</td> </tr> <tr> <td class=\"indent1\">Urethral prolapse</td> </tr> <tr> <td class=\"indent1\">Sarcoma botryoides</td> </tr> <tr> <td class=\"indent1\">Ovarian tumor</td> </tr> <tr> <td class=\"indent1\">Precocious puberty</td> </tr> <tr> <td class=\"subtitle1_single\">Early postmenarche</td> </tr> <tr> <td class=\"indent1\">Ovulatory dysfunction (hypothalamic immaturity)</td> </tr> <tr> <td class=\"indent1\">Bleeding diathesis</td> </tr> <tr> <td class=\"indent1\">Stress (psychogenic, exercise induced)</td> </tr> <tr> <td class=\"indent1\">Pregnancy</td> </tr> <tr> <td class=\"indent1\">Infection</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Reproductive-age</td> </tr> <tr> <td class=\"indent1\">Ovulatory dysfunction</td> </tr> <tr> <td class=\"indent1\">Pregnancy</td> </tr> <tr> <td class=\"indent1\">Cancer</td> </tr> <tr> <td class=\"indent1\">Polyps, leiomyomas, adenomyosis</td> </tr> <tr> <td class=\"indent1\">Infection</td> </tr> <tr> <td class=\"indent1\">Endocrine dysfunction (polycystic ovary syndrome, thyroid, hyperprolactinemia)</td> </tr> <tr> <td class=\"indent1\">Bleeding diathesis</td> </tr> <tr> <td class=\"indent1\">Medication related (eg, hormonal contraception)</td> </tr> <tr> <td class=\"subtitle1_single\">Menopausal transition</td> </tr> <tr> <td class=\"indent1\">Anovulation</td> </tr> <tr> <td class=\"indent1\">Polyps, fibroids, adenomyosis</td> </tr> <tr> <td class=\"indent1\">Cancer</td> </tr> <tr> <td class=\"subtitle1_single\">Menopause</td> </tr> <tr> <td class=\"indent1\">Endometrial polyps</td> </tr> <tr> <td class=\"indent1\">Cancer</td> </tr> <tr> <td class=\"indent1\">Postmenopausal hormone therapy</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: APGO educational series on women's health issues. Clinical management of abnormal uterine bleeding. Association of Professors of Gynecology and Obstetrics, May 2002.</div><div id=\"graphicVersion\">Graphic 61684 Version 6.0</div></div></div>"},"61685":{"type":"graphic_algorithm","displayName":"Treatment of the manifestations of systemic sclerosis","title":"Treatment of the manifestations of systemic sclerosis","html":"<div class=\"graphic\"><div style=\"width: 636px\" class=\"figure\"><div class=\"ttl\">Treatment of the manifestations of systemic sclerosis</div><div class=\"cntnt\"><img style=\"width:616px; height:373px;\" src=\"images/ALLRG/61685_Tx_manifest_syst_sclerosis.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ACE: angiotensin-converting enzyme.</div><div id=\"graphicVersion\">Graphic 61685 Version 3.0</div></div></div>"},"61686":{"type":"graphic_picture","displayName":"Pathologic skin picking arm","title":"Psychogenic excoriation","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Psychogenic excoriation</div><div class=\"cntnt\"><img style=\"width:504px; height:251px;\" src=\"images/DERM/61686_Pathologic_skin_pick_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sharply demarcated erosions, ulcerations, and purpuric patches in a 15-year-old girl with anxiety disorder. Lesions were restricted to areas she could reach and healed completely after a week of occlusive dressing. All lesions cleared following mental health counseling.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 61686 Version 6.0</div></div></div>"},"61687":{"type":"graphic_picture","displayName":"Proximal subungual onychomycosis - toenails","title":"Proximal subungual onychomycosis","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Proximal subungual onychomycosis</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/DERM/61687_Prox_sub_onych_toenails.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Whitish discoloration originating under the surface of the proximal nail plate is present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 61687 Version 4.0</div></div></div>"},"61689":{"type":"graphic_picture","displayName":"Hailey-Hailey 1","title":"Hailey-Hailey disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hailey-Hailey disease</div><div class=\"cntnt\"><img style=\"width:365px; height:504px;\" src=\"images/DERM/61689_Hailey_Hailey_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical axillary plaque of Hailey-Hailey disease, showing superficial erosions and crusts.</div><div id=\"graphicVersion\">Graphic 61689 Version 3.0</div></div></div>"},"61690":{"type":"graphic_table","displayName":"Pustular psoriasis ddx","title":"Generalized pustular psoriasis: Differential diagnosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Generalized pustular psoriasis: Differential diagnosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n  <tr>\n    <td>Acute generalized exanthematous pustulosis</td>\n  </tr>\n  <tr>\n    <td>Bullous impetigo</td>\n  </tr>\n  <tr>\n    <td>Superficial candidiasis</td>\n  </tr>\n  <tr>\n    <td>Acrodermatitis enteropathica (zinc deficiency)</td>\n  </tr>\n  <tr>\n    <td>Linear IgA pemphigus</td>\n  </tr>\n  <tr>\n    <td>IgA pemphigus</td>\n  </tr>\n  <tr>\n    <td>Pemphigus foliaceus</td>\n  </tr>\n  <tr>\n    <td>Langerhans cell histiocytosis</td>\n  </tr>\n  <tr>\n    <td>Pityriasis lichenoides et varioliformis acuta</td>\n  </tr>\n  <tr>\n    <td>Varicella</td>\n  </tr>\n  <tr>\n    <td>Rickettsialpox</td>\n  </tr>\n  <tr>\n    <td>Drug eruption</td>\n  </tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 61690 Version 1.0</div></div></div>"},"61691":{"type":"graphic_table","displayName":"Asthma severity 0 to 4 yrs","title":"Classifying asthma severity in children 0 to 4 years of age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classifying asthma severity in children 0 to 4 years of age</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\" colspan=\"2\">Components of severity</td> <td class=\"subtitle1\" colspan=\"4\">Classification of asthma severity (children 0 to 4 years of age)</td> </tr> <tr> <td class=\"subtitle2\" rowspan=\"2\">Intermittent</td> <td class=\"subtitle2\" colspan=\"4\">Persistent</td> </tr> <tr> <td class=\"subtitle3\">Mild</td> <td class=\"subtitle3\">Moderate</td> <td class=\"subtitle3\">Severe</td> </tr> <tr> <td rowspan=\"4\">Impairment</td> <td>Symptoms</td> <td>&#8804;2 days/week</td> <td>&#62;2 days/week, but not daily</td> <td>Daily</td> <td>Throughout the day</td> </tr> <tr> <td>Nighttime awakenings</td> <td>0</td> <td>1 to 2 times/month</td> <td>3 to 4 times/month</td> <td>&#62;1 time/week</td> </tr> <tr> <td>Short-acting beta<sub>2</sub>-agonist use for symptom control (not prevention of EIB)</td> <td>&#8804;2 days/week</td> <td>&#62;2 days/week, but not daily</td> <td>Daily</td> <td>Several times per day</td> </tr> <tr> <td>Interference with normal activity</td> <td>None</td> <td>Minor limitation</td> <td>Some limitation</td> <td>Extremely limited</td> </tr> <tr> <td rowspan=\"4\">Risk</td> <td rowspan=\"4\"><strong>Exacerbations requiring oral systemic glucocorticoids</strong></td> <td><strong>0 to 1/year</strong></td> <td colspan=\"3\"><strong>&#8805;2 exacerbations in&nbsp;six months requiring oral steroids, or &#8805;4 wheezing episodes/1 year lasting &#62;1 day AND risk factors for persistent asthma</strong></td> </tr> <tr> <td colspan=\"4\"><strong>Consider severity and interval since last exacerbation</strong></td> </tr> <tr> <td colspan=\"4\"><strong>Frequency and severity may fluctuate over time</strong></td> </tr> <tr> <td colspan=\"4\"><strong>Exacerbations of any severity may occur in patients in any severity category</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>Classifying severity in children who are not currently taking long-term control medication.</STRONG> Level of severity is determined by both impairment and risk. Assess impairment domain by caregiver's recall of previous&nbsp;two to four&nbsp;weeks. Assign severity to the most severe category in which any feature occurs. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma severity. For treatment purposes, patients who had ≥2 exacerbations requiring oral&nbsp;glucocorticoids in the past&nbsp;six months, or ≥4 wheezing episodes in the past year, and who have risk factors for persistent asthma may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.</div><div class=\"graphic_footnotes\">EIB: exercise-induced bronchoconstriction</div><div class=\"graphic_reference\">Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 61691 Version 2.0</div></div></div>"},"61692":{"type":"graphic_diagnosticimage","displayName":"Carcinoid tumor CT","title":"Carcinoid tumor presenting as pulmonary nodule","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Carcinoid tumor presenting as pulmonary nodule</div><div class=\"cntnt\"><img style=\"width:255px; height:249px;\" src=\"images/PULM/61692_Carcinoid_tumor_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) scan showing smooth right lower lobe nodule, adjacent to the posterobasal segmental bronchus. This nodule was proven to represent a carcinoid tumor.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 61692 Version 3.0</div></div></div>"},"61693":{"type":"graphic_figure","displayName":"Diaphragmatic fatigue","title":"Recovery from diaphragmatic fatigue","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Recovery from diaphragmatic fatigue</div><div class=\"cntnt\"><img style=\"width:439px; height:277px;\" src=\"images/PULM/61693_Diaphragmatic_fatigue.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Induction of diaphragmatic fatigue (red bar) produced a significant fall in transdiaphragmatic twitch pressure (Pditw). Nadir of Pditw was reached 10 minutes after conclusion of fatigue protocol, and PDitw values at 8 and 24 hours remained lower than baseline (BL). Significant difference compared with BL value, p &lt; 0.01.</div><div class=\"graphic_reference\">Adapted from Laghi, F, D'Alfonso, N, Tobin, MJ, J Appl Physiol 1995; 79:539</div><div id=\"graphicVersion\">Graphic 61693 Version 1.0</div></div></div>"},"61696":{"type":"graphic_picture","displayName":"Sausage toe reactive arthritis","title":"Sausage toe in reactive arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sausage toe in reactive arthritis</div><div class=\"cntnt\"><img style=\"width:360px; height:259px;\" src=\"images/RHEUM/61696_Sausage_toe_reactive_arthri.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sausage toe (with diffuse swelling) of the second digit and mild keratoderma blenorrhagica on the dorsum of the foot in a man with reactive arthritis (formerly Reiter's syndrome).</div><div class=\"graphic_reference\">Courtesy of Craig Wiesenhutter, MD and David Yu, MD.</div><div id=\"graphicVersion\">Graphic 61696 Version 1.0</div></div></div>"},"61697":{"type":"graphic_figure","displayName":"Decerebrate and decorticate postures","title":"Decorticate/decerebrate postures","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Decorticate/decerebrate postures</div><div class=\"cntnt\"><img style=\"width:542px; height:458px;\" src=\"images/NEURO/61697_Decorticate_decerebrate_pos.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 61697 Version 3.0</div></div></div>"},"61698":{"type":"graphic_table","displayName":"NIH Stroke Scale","title":"National Institutes of Health Stroke Scale (NIHSS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">National Institutes of Health Stroke Scale (NIHSS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"45%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"3\">Administer stroke scale items in the order listed. Record performance in each category after each subscale exam. Do not go back and change scores. Follow directions provided for each exam technique. Scores should reflect what the patient does, not what the clinician thinks the patient can do. The clinician should record answers while administering the exam and work quickly. Except where indicated, the patient should not be coached (ie, repeated requests to patient to make a special effort).</td> </tr> <tr> <td class=\"subtitle1\">Instructions</td> <td class=\"subtitle1\">Scale definition</td> <td class=\"subtitle1\">Score</td> </tr> <tr class=\"divider_bottom\"> <td><strong>1a. Level of consciousness:</strong> The investigator must choose a response if a full evaluation is prevented by such obstacles as an endotracheal tube, language barrier, orotracheal trauma/bandages. A 3 is scored only if the patient makes no movement (other than reflexive posturing) in response to noxious stimulation.</td> <td> <p>0 = <strong>Alert;</strong> keenly responsive.</p> <p>1 = <strong>Not alert;</strong> but arousable by minor stimulation to obey, answer, or respond.</p> <p>2 = <strong>Not alert;</strong> requires repeated stimulation to attend, or is obtunded and requires strong or painful stimulation to make movements (not stereotyped).</p> 3 = Responds only with reflex motor or autonomic effects or totally unresponsive, flaccid, and areflexic.</td> <td style=\"vertical-align: middle;\" class=\"centered\"><strong>_____</strong></td> </tr> <tr class=\"divider_bottom\"> <td><strong>1b. LOC questions:</strong> The patient is asked the month and his/her age. The answer must be correct - there is no partial credit for being close. Aphasic and stuporous patients who do not comprehend the questions will score 2. Patients unable to speak because of endotracheal intubation, orotracheal trauma, severe dysarthria from any cause, language barrier, or any other problem not secondary to aphasia are given a 1. It is important that only the initial answer be graded and that the examiner not \"help\" the patient with verbal or non-verbal cues.</td> <td> <p>0 = <strong>Answers</strong> both questions correctly.</p> <p>1 = <strong>Answers</strong> one question correctly.</p> 2 = <strong>Answers</strong> neither question correctly.</td> <td style=\"vertical-align: middle;\" class=\"centered\"><strong>_____</strong></td> </tr> <tr class=\"divider_bottom\"> <td><strong>1c. LOC commands:</strong> The patient is asked to open and close the eyes and then to grip and release the non-paretic hand. Substitute another one step command if the hands cannot be used. Credit is given if an unequivocal attempt is made but not completed due to weakness. If the patient does not respond to command, the task should be demonstrated to him or her (pantomime), and the result scored (ie, follows none, one or two commands). Patients with trauma, amputation, or other physical impediments should be given suitable one-step commands. Only the first attempt is scored.</td> <td> <p>0 = <strong>Performs</strong> both tasks correctly.</p> <p>1 = <strong>Performs</strong> one task correctly.</p> 2 = <strong>Performs</strong> neither task correctly.</td> <td style=\"vertical-align: middle;\" class=\"centered\"><strong>_____</strong></td> </tr> <tr class=\"divider_bottom\"> <td><strong>2. Best gaze:</strong> Only horizontal eye movements will be tested. Voluntary or reflexive (oculocephalic) eye movements will be scored, but caloric testing is not done. If the patient has a conjugate deviation of the eyes that can be overcome by voluntary or reflexive activity, the score will be 1. If a patient has an isolated peripheral nerve paresis (CN III, IV or VI), score a 1. Gaze is testable in all aphasic patients. Patients with ocular trauma, bandages, pre-existing blindness, or other disorder of visual acuity or fields should be tested with reflexive movements, and a choice made by the investigator. Establishing eye contact and then moving about the patient from side to side will occasionally clarify the presence of a partial gaze palsy.</td> <td> <p>0 = <strong>Normal.</strong></p> <p>1 = <strong>Partial gaze palsy;</strong> gaze is abnormal in one or both eyes, but forced deviation or total gaze paresis is not present.</p> 2 = <strong>Forced deviation,</strong> or total gaze paresis not overcome by the oculocephalic maneuver.</td> <td style=\"vertical-align: middle;\" class=\"centered\"><strong>_____</strong></td> </tr> <tr class=\"divider_bottom\"> <td><strong>3. Visual:</strong> Visual fields (upper and lower quadrants) are tested by confrontation, using finger counting or visual threat, as appropriate. Patients may be encouraged, but if they look at the side of the moving fingers appropriately, this can be scored as normal. If there is unilateral blindness or enucleation, visual fields in the remaining eye are scored. Score 1 only if a clear-cut asymmetry, including quadrantanopia, is found. If patient is blind from any cause, score 3. Double simultaneous stimulation is performed at this point. If there is extinction, patient receives a 1, and the results are used to respond to item 11.</td> <td> <p>0 = <strong>No visual loss.</strong></p> <p>1 = <strong>Partial hemianopia.</strong></p> <p>2 = <strong>Complete hemianopia.</strong></p> 3 = <strong>Bilateral hemianopia</strong> (blind including cortical blindness).</td> <td style=\"vertical-align: middle;\" class=\"centered\"><strong>_____</strong></td> </tr> <tr class=\"divider_bottom\"> <td><strong>4. Facial palsy:</strong> Ask - or use pantomime to encourage - the patient to show teeth or raise eyebrows and close eyes. Score symmetry of grimace in response to noxious stimuli in the poorly responsive or non-comprehending patient. If facial trauma/bandages, orotracheal tube, tape or other physical barriers obscure the face, these should be removed to the extent possible.</td> <td> <p>0 = <strong>Normal</strong> symmetrical movements.</p> <p>1 = <strong>Minor paralysis</strong> (flattened nasolabial fold, asymmetry on smiling).</p> <p>2 = <strong>Partial paralysis</strong> (total or near-total paralysis of lower face).</p> 3 = <strong>Complete paralysis</strong> of one or both sides (absence of facial movement in the upper and lower face).</td> <td style=\"vertical-align: middle;\" class=\"centered\"><strong>_____</strong></td> </tr> <tr class=\"divider_bottom\"> <td><strong>5. Motor arm:</strong> The limb is placed in the appropriate position: extend the arms (palms down) 90 degrees (if sitting) or 45 degrees (if supine). Drift is scored if the arm falls before 10 seconds. The aphasic patient is encouraged using urgency in the voice and pantomime, but not noxious stimulation. Each limb is tested in turn, beginning with the non-paretic arm. Only in the case of amputation or joint fusion at the shoulder, the examiner should record the score as untestable (UN), and clearly write the explanation for this choice.</td> <td> <p>0 = <strong>No drift;</strong> limb holds 90 (or 45) degrees for full 10 seconds.</p> <p>1 = <strong>Drift;</strong> limb holds 90 (or 45) degrees, but drifts down before full 10 seconds; does not hit bed or other support.</p> <p>2 = <strong>Some effort against gravity;</strong> limb cannot get to or maintain (if cued) 90 (or 45) degrees, drifts down to bed, but has some effort against gravity.</p> <p>3 = <strong>No effort against gravity;</strong> limb falls.</p> <p>4 = <strong>No movement.</strong></p> <p>UN = <strong>Amputation</strong> or joint fusion, explain:________________</p> <p><strong>5a. Left arm</strong></p> <strong>5b. Right arm</strong></td> <td style=\"vertical-align: middle;\" class=\"centered\"><strong>_____</strong></td> </tr> <tr class=\"divider_bottom\"> <td><strong>6. Motor leg:</strong> The limb is placed in the appropriate position: hold the leg at 30 degrees (always tested supine). Drift is scored if the leg falls before 5 seconds. The aphasic patient is encouraged using urgency in the voice and pantomime, but not noxious stimulation. Each limb is tested in turn, beginning with the non-paretic leg. Only in the case of amputation or joint fusion at the hip, the examiner should record the score as untestable (UN), and clearly write the explanation for this choice.</td> <td> <p>0 = <strong>No drift;</strong> leg holds 30-degree position for full 5 seconds.</p> <p>1 = <strong>Drift;</strong> leg falls by the end of the 5-second period but does not hit bed.</p> <p>2 = <strong>Some effort against gravity;</strong> leg falls to bed by 5 seconds, but has some effort against gravity.</p> <p>3 = <strong>No effort against gravity;</strong> leg falls to bed immediately.</p> <p>4 = <strong>No movement.</strong></p> <p>UN = <strong>Amputation</strong> or joint fusion, explain:________________</p> <p><strong>6a. Left leg</strong></p> <strong>6b. Right leg</strong></td> <td style=\"vertical-align: middle;\" class=\"centered\"><strong>_____</strong></td> </tr> <tr class=\"divider_bottom\"> <td><strong>7. Limb ataxia:</strong> This item is aimed at finding evidence of a unilateral cerebellar lesion. Test with eyes open. In case of visual defect, ensure testing is done in intact visual field. The finger-nose-finger and heel-shin tests are performed on both sides, and ataxia is scored only if present out of proportion to weakness. Ataxia is absent in the patient who cannot understand or is paralyzed. Only in the case of amputation or joint fusion, the examiner should record the score as untestable (UN), and clearly write the explanation for this choice. In case of blindness, test by having the patient touch nose from extended arm position.</td> <td> <p>0 = <strong>Absent.</strong></p> <p>1 = <strong>Present in one limb.</strong></p> <p>2 = <strong>Present in two limbs.</strong></p> UN = <strong>Amputation</strong> or joint fusion, explain:________________</td> <td style=\"vertical-align: middle;\" class=\"centered\"><strong>_____</strong></td> </tr> <tr class=\"divider_bottom\"> <td><strong>8. Sensory:</strong> Sensation or grimace to pinprick when tested, or withdrawal from noxious stimulus in the obtunded or aphasic patient. Only sensory loss attributed to stroke is scored as abnormal and the examiner should test as many body areas (arms [not hands], legs, trunk, face) as needed to accurately check for hemisensory loss. A score of 2, \"severe or total sensory loss,\" should only be given when a severe or total loss of sensation can be clearly demonstrated. Stuporous and aphasic patients will, therefore, probably score 1 or 0. The patient with brainstem stroke who has bilateral loss of sensation is scored 2. If the patient does not respond and is quadriplegic, score 2. Patients in a coma (item 1a=3) are automatically given a 2 on this item.</td> <td> <p>0 = <strong>Normal;</strong> no sensory loss.</p> <p>1 = <strong>Mild-to-moderate sensory loss;</strong> patient feels pinprick is less sharp or is dull on the affected side; or there is a loss of superficial pain with pinprick, but patient is aware of being touched.</p> 2 = <strong>Severe to total sensory loss;</strong> patient is not aware of being touched in the face, arm, and leg.</td> <td style=\"vertical-align: middle;\" class=\"centered\"><strong>_____</strong></td> </tr> <tr class=\"divider_bottom\"> <td><strong>9. Best language:</strong> A great deal of information about comprehension will be obtained during the preceding sections of the examination. For this scale item, the patient is asked to describe what is happening in the attached picture, to name the items on the attached naming sheet and to read from the attached list of sentences. Comprehension is judged from responses here, as well as to all of the commands in the preceding general neurological exam. If visual loss interferes with the tests, ask the patient to identify objects placed in the hand, repeat, and produce speech. The intubated patient should be asked to write. The patient in a coma (item 1a=3) will automatically score 3 on this item. The examiner must choose a score for the patient with stupor or limited cooperation, but a score of 3 should be used only if the patient is mute and follows no one-step commands.</td> <td> <p>0 = <strong>No aphasia;</strong> normal.</p> <p>1 = <strong>Mild-to-moderate aphasia;</strong> some obvious loss of fluency or facility of comprehension, without significant limitation on ideas expressed or form of expression. Reduction of speech and/or comprehension, however, makes conversation about provided materials difficult or impossible. For example, in conversation about provided materials, examiner can identify picture or naming card content from patient's response.</p> <p>2 = <strong>Severe aphasia;</strong> all communication is through fragmentary expression; great need for inference, questioning, and guessing by the listener. Range of information that can be exchanged is limited; listener carries burden of communication. Examiner cannot identify materials provided from patient response.</p> 3 = <strong>Mute, global aphasia;</strong> no usable speech or auditory comprehension.</td> <td style=\"vertical-align: middle;\" class=\"centered\"><strong>_____</strong></td> </tr> <tr class=\"divider_bottom\"> <td><strong>10. Dysarthria:</strong> If patient is thought to be normal, an adequate sample of speech must be obtained by asking patient to read or repeat words from the attached list. If the patient has severe aphasia, the clarity of articulation of spontaneous speech can be rated. Only if the patient is intubated or has other physical barriers to producing speech, the examiner should record the score as untestable (UN), and clearly write an explanation for this choice. Do not tell the patient why he or she is being tested.</td> <td> <p>0 = <strong>Normal.</strong></p> <p>1 = <strong>Mild-to-moderate dysarthria;</strong> patient slurs at least some words and, at worst, can be understood with some difficulty.</p> <p>2 = <strong>Severe dysarthria;</strong> patient's speech is so slurred as to be unintelligible in the absence of or out of proportion to any dysphasia, or is mute/anarthric.</p> UN = <strong>Intubated</strong> or other physical barrier, explain:________________</td> <td style=\"vertical-align: middle;\" class=\"centered\"><strong>_____</strong></td> </tr> <tr class=\"divider_bottom\"> <td><strong>11. Extinction and inattention (formerly neglect):</strong> Sufficient information to identify neglect may be obtained during the prior testing. If the patient has a severe visual loss preventing visual double simultaneous stimulation, and the cutaneous stimuli are normal, the score is normal. If the patient has aphasia but does appear to attend to both sides, the score is normal. The presence of visual spatial neglect or <span style=\"line-height: 115%; font-family: calibri,sans-serif; font-size: 11pt;\">anosognosia </span>may also be taken as evidence of abnormality. Since the abnormality is scored only if present, the item is never untestable.</td> <td> <p>0 = <strong>No abnormality.</strong></p> <p>1 = <strong>Visual, tactile, auditory, spatial, or personal inattention</strong> or extinction to bilateral simultaneous stimulation in one of the sensory modalities.</p> 2 = <strong>Profound hemi-inattention or extinction to more than one modality;</strong> does not recognize own hand or orients to only one side of space.</td> <td style=\"vertical-align: middle;\" class=\"centered\"><strong>_____</strong></td> </tr> <tr> <td class=\"highlight_gray_text\">&nbsp;</td> <td class=\"highlight_gray_text\">&nbsp;</td> <td style=\"vertical-align: middle;\" class=\"centered\"><strong>_____</strong></td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Goldstein LB, Samsa GP, Stroke 1997; 28:307.</div><div id=\"graphicVersion\">Graphic 61698 Version 4.0</div></div></div>"},"61700":{"type":"graphic_diagnosticimage","displayName":"Shepherds crook deformity","title":"Fibrous dysplasia of the proximal femur with shepherd's crook deformity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fibrous dysplasia of the proximal femur with shepherd's crook deformity</div><div class=\"cntnt\"><img style=\"width:373px; height:516px;\" src=\"images/PEDS/61700_Shepherds_crook_deformity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A radiograph of the proximal femur shows a shepherd's crook deformity caused by fractures sustained over the years. Irregular, marginated, ground-glass lucencies are surrounded by reactive bone. The shaft has an appearance that has been likened to a soap bubble.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin R, Strayer DS. Rubin's Pathology: Clinicopathologic Foundations of Medicine, Fifth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2008. Copyright &#169; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 61700 Version 2.0</div></div></div>"},"61701":{"type":"graphic_picture","displayName":"Aspiration prepatellar bursa","title":"Prepatellar bursal aspiration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prepatellar bursal aspiration</div><div class=\"cntnt\"><img style=\"width:356px; height:284px;\" src=\"images/EM/61701_Prepatellar_bursal_aspirati.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient is placed in a supine position. Ethyl chloride is sprayed on the skin. A 1 1/2 inch, 16-gauge needle is inserted at the base of the bursa; the needle is passed into the center of the sac to a depth of 1/4 to 3/8 inch and fluid is aspirated.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 61701 Version 4.0</div></div></div>"},"61702":{"type":"graphic_figure","displayName":"Mechanisms Mahaim tachy","title":"Mechanisms for a Mahaim fiber tachycardia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mechanisms for a Mahaim fiber tachycardia</div><div class=\"cntnt\"><img style=\"width:437px; height:172px;\" src=\"images/CARD/61702_Mechanisms_Mahaim_tachy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The typical Mahaim fiber tachycardia circuit involves the Mahaim fiber as the antegrade limb and the atrioventricular (AV) node/His Purkinje system as the retrograde limb (panel C). Alternatively, there may be a second accessory AV pathway which serves as the retrograde limb (panel A). A wide QRS complex tachycardia, resembling a Mahaim fiber tachycardia, can occur when a Mahaim fiber acts as a bystander pathway, conducting antegradely, during an atrioventricular nodal reentrant tachycardia (panel B). The red arrows indicate the direction of impulse conduction within the circuit.</div><div id=\"graphicVersion\">Graphic 61702 Version 2.0</div></div></div>"},"61704":{"type":"graphic_figure","displayName":"Cervical fascial spaces anatomy","title":"Relationship of various cervical fascial spaces to the superficial and deep layers of the cervical fascia","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Relationship of various cervical fascial spaces to the superficial and deep layers of the cervical fascia</div><div class=\"cntnt\"><img style=\"width:539px; height:672px;\" src=\"images/ID/61704_Cervical_fascial_spaces_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Sagittal section of the neck.<br> (B) Coronal section at the level of C7.</div><div class=\"graphic_reference\">Adapted with permission from: Chow, AW. Life-threatening infections of the head, neck, and upper respiratory tract. In: Principles of Critical Care, 2nd ed. Hall, JB, Schmidt, GA, Wood, LH (Eds), McGraw-Hill, New York 1998. p.888. Copyright &#169; 1998 McGraw-Hill.</div><div id=\"graphicVersion\">Graphic 61704 Version 4.0</div></div></div>"},"61705":{"type":"graphic_movie","displayName":"TEE aortic arch","title":"Transesophageal echocardiogram (TEE) of the aortic arch","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiogram (TEE) of the aortic arch</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/61705_teeaorticarchconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:317px; height:238px;\" src=\"images/CARD/61705_teeaorticarch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the large plaque and superimposed mobile thrombus.</div><div id=\"graphicVersion\">Graphic 61705 Version 2.0</div></div></div>"},"61706":{"type":"graphic_figure","displayName":"Pitting edema PI","title":"Pitting edema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pitting edema</div><div class=\"cntnt\"><img style=\"width:437px; height:575px;\" src=\"images/PI/61706_Pitting_edema_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To check for swelling, a doctor or nurse can press on the skin and then remove his or her finger. If the indent stays there, the person has swelling. Doctors call this \"pitting edema.\"</div><div id=\"graphicVersion\">Graphic 61706 Version 10.0</div></div></div>"},"61707":{"type":"graphic_figure","displayName":"Cervical ripening balloon","title":"Cervical ripening balloon","html":"<div class=\"graphic\"><div style=\"width: 597px\" class=\"figure\"><div class=\"ttl\">Cervical ripening balloon</div><div class=\"cntnt\"><img style=\"width:577px; height:676px;\" src=\"images/OBGYN/61707_Cervical_ripening_balloon.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cook Women's Health.</div><div id=\"graphicVersion\">Graphic 61707 Version 1.0</div></div></div>"},"61709":{"type":"graphic_algorithm","displayName":"Algorithm acute porphyria","title":"Algorithm for diagnosis of acute porphyria and use of hemin in patients with symptoms suggesting an acute porphyria attack","html":"<div class=\"graphic\"><div style=\"width: 820px\" class=\"figure\"><div class=\"ttl\">Algorithm for diagnosis of acute porphyria and use of hemin in patients with symptoms suggesting an acute porphyria attack</div><div class=\"cntnt\"><img style=\"width:800px; height:623px;\" src=\"images/HEME/61709_Diagnosisacuteporphyria.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urine PGB may be tested by a screening method on-site (semiquantitative result, available in minutes) or measured in a specialized laboratory (quantitative result, available in days to weeks). If available, a rapid method is extremely helpful because treatment can be initiated based on a positive result, and a negative result makes the diagnosis of an acute porphyria very unlikely. However, all symptomatic patients with suspected acute porphyria should have quantitative PBG, porphyrins, and creatinine measured from the same sample. Because the results of quantitative testing are not known for days to weeks, we also order ALA and total porphyrins on the same urine sample. Urine creatinine is measured to allow normalization (results expressed per gram of creatinine). Refer to UpToDate topics on acute porphyrias for further details of diagnosis and treatment, and patterns of plasma and fecal porphyrin elevation.</div><div class=\"graphic_footnotes\">PBG: porphobilinogen; ALA: delta-aminolevulinic acid; AIP: acute intermittent porphyria; HCP: hereditary coproporphyria; VP: variegate porphyria; ALAD: ALA dehydratase; ADP: ALAD porphyria.<br />* We perform genetic testing for the relevant porphyria following diagnosis; this may be used for further confirmation of the diagnosis and in some cases for genetic testing and counseling of relatives and identification of new mutations.</div><div id=\"graphicVersion\">Graphic 61709 Version 8.0</div></div></div>"},"61711":{"type":"graphic_table","displayName":"Acute iron intoxication - Rapid overview","title":"Acute iron intoxication: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acute iron intoxication: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">History</td> </tr> <tr> <td class=\"sublist2_start\">What form of iron was ingested?</td> </tr> <tr> <td class=\"sublist2\">Ferrous gluconate (12 percent elemental iron)</td> </tr> <tr> <td class=\"sublist2\">Ferrous sulfate (20 percent elemental iron)</td> </tr> <tr> <td class=\"sublist2\">Ferrous fumarate (33 percent elemental iron)</td> </tr> <tr> <td class=\"indent1\">How many mg/kg of elemental iron was ingested?</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">When did the ingestion occur?</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical features: Overlapping phases of clinical manifestations</td> </tr> <tr> <td class=\"indent1\">Gastrointestinal phase: (30 minutes to 6 hours) Abdominal pain, vomiting, diarrhea, hematemesis, melena, lethargy, shock (from capillary leak and third spacing), metabolic acidosis</td> </tr> <tr> <td class=\"indent1\">Latent: (6 to 24 hours) Improvement in GI symptoms; may have poor perfusion, tachypnea, tachycardia</td> </tr> <tr> <td class=\"indent1\">Shock and metabolic acidosis: (4 hours to 4 days) Hypovolemic, distributive, or cardiogenic shock with profound metabolic acidosis, coagulopathy, renal insufficiency/failure, pulmonary dysfunction/failure, central nervous system dysfunction</td> </tr> <tr> <td class=\"indent1\">Hepatotoxicity: (within 2 days) Coma, coagulopathy, jaundice. Severity is dose dependent.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Bowel obstruction: (2 to 4 weeks) Vomiting, dehydration, abdominal pain, usually gastric outlet obstruction</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic evaluation: For all patients with systemic symptoms, those who have ingested &#62;40 mg/kg of elemental iron, and those for whom the amount of elemental iron ingested is unknown</td> </tr> <tr> <td class=\"indent1\">Serum iron concentration: Measure serum iron concentration within 4 to 6 hours after ingestion (8 hours for extended release tablets)</td> </tr> <tr> <td class=\"indent1\">Arterial or venous pH</td> </tr> <tr> <td class=\"indent1\">Abdominal radiograph looking for radiopaque pills</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other initial labs: Electrolytes, BUN, creatinine, glucose, liver enzyme tests, total bilirubin, prothrombin, partial thromboplastin time, CBC with differential, type and cross match</td> </tr> <tr> <td class=\"subtitle1_single\">Management</td> </tr> <tr> <td class=\"indent1\">Secure airway and breathing</td> </tr> <tr> <td class=\"indent1\">Treat volume depletion aggressively with isotonic infusion</td> </tr> <tr> <td class=\"indent1\">Whole bowel irrigation: For all patients with a significant number of pills in stomach and small intestine on radiograph</td> </tr> <tr> <td class=\"sublist2_start\">Deferoxamine: Continuous IV infusion (can cause hypotension). Begin at 15 mg/kg/hour. May increase to 35/mg/kg/hour during first 24 hours for severe ingestions. A toxicologist and/or regional poison control center should be consulted to determine the optimum dose of deferoxamine and duration of therapy. Treat in the following circumstances:</td> </tr> <tr> <td class=\"sublist2\">Severe symptoms: Altered mental status, hemodynamic instability, persistent vomiting, diarrhea</td> </tr> <tr> <td class=\"sublist2\">Anion gap metabolic acidosis</td> </tr> <tr> <td class=\"sublist2\">Serum iron concentration &#62;500 mcg/dL</td> </tr> <tr> <td class=\"sublist2\">Significant number of pills on x-ray</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 61711 Version 10.0</div></div></div>"},"61712":{"type":"graphic_diagnosticimage","displayName":"Thyroid cancer spine MRI","title":"Metastatic thyroid cancer: MRI of the cervical spine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metastatic thyroid cancer: MRI of the cervical spine</div><div class=\"cntnt\"><img style=\"width:288px; height:288px;\" src=\"images/ENDO/61712_Thyroid_CA_spine_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRI&nbsp;of the cervical spine in a 67-year-old woman with a two-year history of rib pain and a destructive lesion in her right seventh rib, which, on biopsy, revealed metastatic follicular thyroid cancer. MRI shows destruction of C2 (arrows). She was treated with total thyroidectomy, external beam radiation, radioiodine, and spinal stabilization. Five years later she developed more bone metastases, but there was no evidence of progression of the lesion in C2.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of James Brierley, MB, BS, MRCP, FRCR, FRCP.</div><div id=\"graphicVersion\">Graphic 61712 Version 5.0</div></div></div>"},"61715":{"type":"graphic_table","displayName":"Risk ERCP complications","title":"Risk factors for overall complications of endoscopic retrograde cholangiopancreatography (ERCP) identified by multivariate analysis in large studies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for overall complications of endoscopic retrograde cholangiopancreatography (ERCP) identified by multivariate analysis in large studies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"14%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author</td> <td class=\"subtitle1\">Study</td> <td class=\"subtitle1\">Object of the study</td> <td class=\"subtitle1\">Number</td> <td class=\"subtitle1\">Post-procedure complications</td> <td class=\"subtitle1\">Independent risk factors</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Freeman et al 1996</td> <td class=\"divider_bottom\" rowspan=\"5\">Prospective multicenter study</td> <td class=\"divider_bottom\" rowspan=\"5\">Biliary sphincterotomy</td> <td class=\"divider_bottom\" rowspan=\"5\">2347 patients</td> <td class=\"divider_bottom\" rowspan=\"5\">9.8%</td> <td>Difficulty of cannulation</td> </tr> <tr> <td>Precut sphincterotomy</td> </tr> <tr> <td>Percutaneous-endoscopic procedure</td> </tr> <tr> <td>Sphincter of Oddi dysfunction</td> </tr> <tr class=\"divider_bottom\"> <td>Cirrhosis</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Loperfido et al 1998</td> <td class=\"divider_bottom\" rowspan=\"2\">Prospective multicenter study</td> <td class=\"divider_bottom\" rowspan=\"2\">Diagnostic and therapeutic ERCP</td> <td class=\"divider_bottom\" rowspan=\"2\">2769 patients</td> <td class=\"divider_bottom\" rowspan=\"2\">4.0%</td> <td>Small center</td> </tr> <tr class=\"divider_bottom\"> <td>Precut sphincterotomy</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Masci et al 2001</td> <td class=\"divider_bottom\" rowspan=\"3\">Prospective multicenter study</td> <td class=\"divider_bottom\" rowspan=\"3\">Diagnostic and therapeutic ERCP</td> <td class=\"divider_bottom\" rowspan=\"3\">2444 procedures</td> <td class=\"divider_bottom\" rowspan=\"3\">4.9%</td> <td>Age under 60</td> </tr> <tr> <td>Precut sphincterotomy</td> </tr> <tr class=\"divider_bottom\"> <td>Failed clearing of biliary stones</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Christensen et al 2004</td> <td class=\"divider_bottom\" rowspan=\"3\">Prospective monocenter study</td> <td class=\"divider_bottom\" rowspan=\"3\">Diagnostic and therapeutic ERCP</td> <td class=\"divider_bottom\" rowspan=\"3\">1177 patients</td> <td class=\"divider_bottom\" rowspan=\"3\">15.9%</td> <td>Dilated bile duct</td> </tr> <tr> <td>Placement of stent</td> </tr> <tr class=\"divider_bottom\"> <td>&#62;40 mg of hyoscine-N-butyl bromide</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Williams et al 2008</td> <td class=\"divider_bottom\" rowspan=\"3\">Prospective multicenter study</td> <td class=\"divider_bottom\" rowspan=\"3\">Diagnostic and therapeutic ERCP</td> <td class=\"divider_bottom\" rowspan=\"3\">4561 patients</td> <td class=\"divider_bottom\" rowspan=\"3\">5%</td> <td>Difficult cannulation</td> </tr> <tr> <td>Precut sphincterotomy</td> </tr> <tr class=\"divider_bottom\"> <td>Sphincter of Oddi dysfunction</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Wang et al 2009</td> <td class=\"divider_bottom\" rowspan=\"5\">Prospective multicenter study</td> <td class=\"divider_bottom\" rowspan=\"5\">Diagnostic and therapeutic ERCP</td> <td class=\"divider_bottom\" rowspan=\"5\">2691 patients</td> <td class=\"divider_bottom\" rowspan=\"5\">7.9%</td> <td>Female sex</td> </tr> <tr> <td>Periampullary diverticulum</td> </tr> <tr> <td>Difficult cannulation</td> </tr> <tr> <td>Pancreatic cannulation</td> </tr> <tr class=\"divider_bottom\"> <td>Precut sphincterotomy</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Cotton et al 2009</td> <td class=\"divider_bottom\" rowspan=\"2\">Retrospective multicenter study</td> <td class=\"divider_bottom\" rowspan=\"2\">Diagnostic and therapeutic ERCP</td> <td class=\"divider_bottom\" rowspan=\"2\">2691 procedures</td> <td class=\"divider_bottom\" rowspan=\"2\">4.0%</td> <td>Sphincter of Oddi dysfunction</td> </tr> <tr class=\"divider_bottom\"> <td>Biliary sphincterotomy</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Glomsaker et al 2013</td> <td class=\"divider_bottom\" rowspan=\"4\">Prospective multicenter study</td> <td class=\"divider_bottom\" rowspan=\"4\">Diagnostic and therapeutic ERCP</td> <td class=\"divider_bottom\" rowspan=\"4\">2808 procedures</td> <td class=\"divider_bottom\" rowspan=\"4\">11.6%</td> <td>Increasing age</td> </tr> <tr> <td>ASA score III or IV</td> </tr> <tr> <td>&#62;150 ERCPs/year</td> </tr> <tr class=\"divider_bottom\"> <td>Precut sphincterotomy</td> </tr> <tr> <td rowspan=\"7\">Coehlo-Prabhu et al 2013</td> <td rowspan=\"7\">Retrospective single-center study</td> <td rowspan=\"7\">Diagnostic and therapeutic ERCP</td> <td rowspan=\"7\">1072 procedures</td> <td rowspan=\"7\">5.3%</td> <td>Age under 45 years</td> </tr> <tr> <td>BMI &#62;35</td> </tr> <tr> <td>Outpatient procedure</td> </tr> <tr> <td>Patient's first ERCP</td> </tr> <tr> <td>Difficult cannulation</td> </tr> <tr> <td>Pancreatic cannulation</td> </tr> <tr> <td>Intraprocedural sphincterotomy bleeding</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ERCP: endoscopic retrograde cholangiopancreatography; ASA: American Society of Anesthesiologists; BMI: body mass index.</div><div id=\"graphicVersion\">Graphic 61715 Version 5.0</div></div></div>"},"61716":{"type":"graphic_waveform","displayName":"Aorta Doppler waveform","title":"Aorta Doppler waveform","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Aorta Doppler waveform</div><div class=\"cntnt\"><img style=\"width:452px; height:386px;\" src=\"images/SURG/61716_Aorta_doppler_waveform.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Laminar, pulsatile flow in the abdominal aorta is recorded with pulsed wave Doppler imaging. The signal demonstrates a narrow envelope during systole. The maximal peak systolic velocity of the flow is approximately 100 cm/sec. Note, however, that the ultrasound beam is not parallel to the flow direction.</div><div class=\"graphic_reference\">Reproduced with permission from: Feigenbaum H, Armstrong WF, Ryan T. Echocardiography, Sixth Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright © Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 61716 Version 2.0</div></div></div>"},"61719":{"type":"graphic_picture","displayName":"Disseminated intravascular coagulation","title":"Retiform purpura in disseminated intravascular coagulation","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Retiform purpura in disseminated intravascular coagulation</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/61719_Disseminated_intravas_coag.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Widespread retiform purpura are present in this patient with disseminated intravascular coagulation.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 61719 Version 4.0</div></div></div>"},"61720":{"type":"graphic_figure","displayName":"Mobilization of the left colon","title":"Mobilization of the left colon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mobilization of the left colon</div><div class=\"cntnt\"><img style=\"width:381px; height:485px;\" src=\"images/SURG/61720_Mobilize-left-colon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the mobilization of the left colon by retracting the sigmoid and left colon medially. The line of Toldt is incised and the colon released from the peritoneal attachments.</div><div id=\"graphicVersion\">Graphic 61720 Version 1.0</div></div></div>"},"61721":{"type":"graphic_picture","displayName":"Jersey finger PI","title":"Jersey finger","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Jersey finger</div><div class=\"cntnt\"><img style=\"width:360px; height:415px;\" src=\"images/PI/61721_Jersey_finger_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A &quot;jersey finger&quot; is a finger injury that makes the finger tip stay straight.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 61721 Version 1.0</div></div></div>"},"61722":{"type":"graphic_picture","displayName":"Glucagon injection PI","title":"Glucagon shot","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Glucagon shot</div><div class=\"cntnt\"><img style=\"width:468px; height:439px;\" src=\"images/PI/61722_GlucagoninjectionPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To give a glucagon shot:<br /><OL>&#xD;&#xA;<LI>Hold the syringe at a 90 degree angle to the upper arm or thigh (as shown in the picture). </LI>&#xD;&#xA;<LI>Quickly stick the needle in the skin and push the plunger down all the way. </LI>&#xD;&#xA;<LI>Remove the needle from the skin. </LI>&#xD;&#xA;<LI>Press down lightly on the skin where the shot was given. </LI>&#xD;&#xA;<LI>Turn the person onto his or her side in case he or she vomits. </LI></OL></div><div id=\"graphicVersion\">Graphic 61722 Version 6.0</div></div></div>"},"61723":{"type":"graphic_table","displayName":"Drug and toxin induced ocular findings","title":"Drug- and toxin-induced ocular abnormalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug- and toxin-induced ocular abnormalities</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Mydriasis</td> </tr> <tr> <td class=\"sublist1_start\">Sympathomimetics</td> </tr> <tr> <td class=\"sublist1\">Cocaine</td> </tr> <tr> <td class=\"sublist1\">Caffeine</td> </tr> <tr> <td class=\"sublist1\">Ephedrine</td> </tr> <tr> <td class=\"sublist1\">Amphetamines</td> </tr> <tr> <td class=\"sublist1\">Methylphenidate</td> </tr> <tr> <td class=\"sublist1\">Cathinones</td> </tr> <tr> <td class=\"sublist1_start\">Anticholinergics</td> </tr> <tr> <td class=\"sublist1\">Atropine</td> </tr> <tr> <td class=\"sublist1\">Scopolamine</td> </tr> <tr> <td class=\"sublist1\">TCAs</td> </tr> <tr> <td class=\"sublist1\">Antihistamines</td> </tr> <tr> <td class=\"sublist1\">Antiparkinson agents</td> </tr> <tr> <td class=\"sublist1\">Muscle relaxants</td> </tr> <tr> <td class=\"sublist1\">Antispasmodics</td> </tr> <tr> <td class=\"sublist1\">Phenothiazines (some)</td> </tr> <tr> <td class=\"sublist1\">Plants (with belladonna alkaloids)</td> </tr> <tr> <td class=\"sublist1_start\">Hallucinogens</td> </tr> <tr> <td class=\"sublist1\">LSD</td> </tr> <tr> <td class=\"sublist1\">Mescaline</td> </tr> <tr> <td class=\"sublist1\">Psilocybin</td> </tr> <tr> <td class=\"sublist1\">Designer amphetamines</td> </tr> <tr> <td class=\"sublist1_start\">Miscellaneous</td> </tr> <tr> <td class=\"sublist1\">Glutethimide</td> </tr> <tr> <td class=\"sublist1\">MAOIs</td> </tr> <tr> <td class=\"sublist1\">Nicotine</td> </tr> <tr> <td class=\"sublist1\">Serotonin syndrome</td> </tr> <tr> <td>Drug withdrawal states</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Miosis</td> </tr> <tr> <td>Opioids</td> </tr> <tr> <td class=\"sublist1\">Heroin</td> </tr> <tr> <td class=\"sublist1\">Morphine</td> </tr> <tr> <td class=\"sublist1\">Hydromorphone</td> </tr> <tr> <td class=\"sublist1\">Oxycodone</td> </tr> <tr> <td class=\"sublist1\">Hydrocodone</td> </tr> <tr> <td class=\"sublist1\">Codeine</td> </tr> <tr> <td class=\"sublist1\">Propoxyphene</td> </tr> <tr> <td class=\"sublist1_start\">Sedative-hypnotics</td> </tr> <tr> <td class=\"sublist1\">Barbiturates</td> </tr> <tr> <td class=\"sublist1\">Benzodiazepines</td> </tr> <tr> <td class=\"sublist1\">Alcohols (with deep coma)</td> </tr> <tr> <td class=\"sublist1\">Zolpidem and related medications</td> </tr> <tr> <td class=\"sublist1_start\">Cholinergics</td> </tr> <tr> <td class=\"sublist1\">Nerve agents</td> </tr> <tr> <td class=\"sublist1\">Organophosphate insecticides</td> </tr> <tr> <td class=\"sublist1\">Carbamate insecticides</td> </tr> <tr> <td class=\"sublist1\">Pilocarpine</td> </tr> <tr> <td class=\"sublist1\">Edrophonium</td> </tr> <tr> <td class=\"sublist1\">Physostigmine</td> </tr> <tr> <td class=\"sublist1_start\">Sympatholytics</td> </tr> <tr> <td class=\"sublist1\">Clonidine</td> </tr> <tr> <td class=\"sublist1\">Oxymetazoline</td> </tr> <tr> <td class=\"sublist1\">Tetrahydrazoline</td> </tr> <tr> <td class=\"sublist1\">Antipsychotics</td> </tr> <tr> <td class=\"sublist1_start\">Miscellaneous</td> </tr> <tr> <td class=\"sublist1\">Phencyclidine</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Nystagmus</td> </tr> <tr> <td>Barbiturates</td> </tr> <tr> <td>Carbamazepine</td> </tr> <tr> <td>Phencyclidine</td> </tr> <tr> <td>Phenytoin</td> </tr> <tr> <td>Lithium</td> </tr> <tr> <td>Ethanol</td> </tr> <tr> <td>Toxic alcohols</td> </tr> <tr> <td>Organophosphates</td> </tr> <tr> <td>Scorpion stings&nbsp;</td> </tr> <tr> <td>Strychnine</td> </tr> <tr> <td>MAOIs</td> </tr> <tr> <td>Serotonin syndrome</td> </tr> <tr> <td>Ketamine</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 61723 Version 7.0</div></div></div>"},"61724":{"type":"graphic_diagnosticimage","displayName":"Invasive aspergillus PA","title":"Invasive aspergillosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Invasive aspergillosis</div><div class=\"cntnt\"><img style=\"width:309px; height:330px;\" src=\"images/PULM/61724_Invasive_aspergillus_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows multiple confluent nodules and masses due to invasive aspergillosis in a patient with systemic lupus erythematosus who was receiving glucocorticoids.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD</div><div id=\"graphicVersion\">Graphic 61724 Version 2.0</div></div></div>"},"61725":{"type":"graphic_figure","displayName":"Atom with electrons orbiting the nucleus","title":"Atom with electrons orbiting the nucleus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atom with electrons orbiting the nucleus</div><div class=\"cntnt\"><img style=\"width:239px; height:246px;\" src=\"images/PULM/61725_Schema_of_atom_electron_nuc.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With excitation, an electron moves from an inner shell (1) to an outer shell (2), thereby defining the atom at ground state and excited state.</div><div id=\"graphicVersion\">Graphic 61725 Version 2.0</div></div></div>"},"61728":{"type":"graphic_figure","displayName":"Echo of Ebstein","title":"Echocardiogram of Ebstein anomaly","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Echocardiogram of Ebstein anomaly</div><div class=\"cntnt\"><img style=\"width:512px; height:226px;\" src=\"images/CARD/61728_Echocardiogram_Ebstein_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two-dimensional echocardiogram in the apical four-chamber view (panel A) from a patient with Ebstein anomaly shows a displaced, long (\"sail\"-like) anterior leaflet of the tricuspid valve, which is attached to the tricuspid annulus (dashed arrow) and apical displacement of the septal leaflet (arrowhead). Note the large right atrialized (RA) portion of the right ventricle (RV). Color Doppler echocardiogram (panel B) shows severe tricuspid regurgitation originating at the level of the displaced tricuspid valve.</div><div id=\"graphicVersion\">Graphic 61728 Version 3.0</div></div></div>"},"61729":{"type":"graphic_picture","displayName":"Hepatic metastases GI neuroendocrine tumor","title":"Extensive hepatic metastases from a neuroendocrine tumor arising in the gastrointestinal tract","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extensive hepatic metastases from a neuroendocrine tumor arising in the gastrointestinal tract</div><div class=\"cntnt\"><img style=\"width:429px; height:317px;\" src=\"images/ONC/61729_Hepatic_metastases_carcinoi.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Photograph courtesy of Matthew Kulke, MD.</div><div id=\"graphicVersion\">Graphic 61729 Version 4.0</div></div></div>"},"61730":{"type":"graphic_table","displayName":"Sarcoma after breast CA RT","title":"Secondary sarcomas and angiosarcomas after breast cancer radiotherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Secondary sarcomas and angiosarcomas after breast cancer radiotherapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">First author, year</td> <td class=\"subtitle1\" rowspan=\"2\">Trial design</td> <td class=\"subtitle1\" rowspan=\"2\">Follow-up, years</td> <td class=\"subtitle1\" colspan=\"2\">Cumulative total, percent</td> </tr> <tr> <td class=\"subtitle2\">No RT</td> <td class=\"subtitle2\">RT</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Sarcoma</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Taghian A; 1991</td> <td rowspan=\"3\">Cohort*</td> <td class=\"centered\">10</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">0.2</td> </tr> <tr> <td class=\"centered\">20</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">0.4 </td> </tr> <tr> <td class=\"centered\">30</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">0.8</td> </tr> <tr> <td class=\"indent1\">Obedian E; 2000</td> <td>Nonrandomized, cohort*</td> <td class=\"centered\">15</td> <td class=\"centered\">0.2</td> <td class=\"centered\">0.4</td> </tr> <tr> <td class=\"indent1\">Galper S; 2002</td> <td>Cohort*</td> <td class=\"centered\">11</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">0.4</td> </tr> <tr> <td class=\"indent1\">Yap J; 2002</td> <td>Case-control<sup>&#182;</sup></td> <td class=\"centered\">15</td> <td class=\"centered\">0.2</td> <td class=\"centered\">0.3</td> </tr> <tr> <td class=\"indent1\">Huang J; 2001</td> <td>Cohort</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">0.07</td> <td class=\"centered\">0.13</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"3\">Kirova Y; 2005</td> <td class=\"divider_bottom\" rowspan=\"3\">Retrospective</td> <td class=\"centered\">5</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">0.07</td> </tr> <tr> <td class=\"centered\">10</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">0.27</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">15</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">0.48</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Angiosarcoma</td> </tr> <tr> <td class=\"indent1\">Marchal C; 1999</td> <td>Retrospective</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">0.05</td> </tr> <tr> <td class=\"indent1\">Strobbe L; 1998</td> <td>Retrospective</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">0.2</td> </tr> <tr> <td class=\"indent1\">Huang J; 2001</td> <td>Cohort</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">0.005</td> <td class=\"centered\">0.08</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RT: radiation therapy.<br />* Prospective cohort.<br />¶ From tumor registry.</div><div class=\"graphic_reference\">Modified with permission from: Matesich SM, Shapiro CL. Second cancers after breast cancer treatment. Semin Oncol 2003; 30:740. Copyright &copy; 2003 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 61730 Version 5.0</div></div></div>"},"61731":{"type":"graphic_diagnosticimage","displayName":"Cerebral atrophy in pediatric HIV","title":"Cerebral atrophy in pediatric HIV infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cerebral atrophy in pediatric HIV infection</div><div class=\"cntnt\"><img style=\"width:335px; height:394px;\" src=\"images/PEDS/61731_Cerebral_atrophy_in_pedi_HI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Head computed tomography (CT) scan in an HIV-infected 8-year-old boy with generalized brain atrophy. Cerebral atrophy is common among children with HIV encephalopathy but is also observed among children with normal neurologic and developmental examinations.</div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div class=\"graphic_reference\">Courtesy of Meg Ferris, MD.</div><div id=\"graphicVersion\">Graphic 61731 Version 3.0</div></div></div>"},"61732":{"type":"graphic_table","displayName":"Enuresis alarms","title":"Enuresis alarms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Enuresis alarms</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Device</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Dri-Sleeper</p> <p>Canada</p> <p>www.DRI-Sleeper.com</p> </td> <td>Detector is clipped to standard disposable panty liner; beeper unit worn on shoulder.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Enurad</p> <p>UK Electronic</p> <p>Sweden</p> <p>www.enurad.com</p> </td> <td>Wireless moisture alarm with radio transmission to an alarm clock. (Approved for use in Europe, but not in the United States.)</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Malem Medical*</p> <p>Nottingham, England</p> <p>www.malem.co.uk</p> </td> <td>Sensor pad in underwear; alarm unit on child's shoulder. Available with both auditory and vibratory alarms, or as a wireless unit.</td> </tr> <tr class=\"divider_bottom\"> <td>Nighthawk <p>Bed Wetting Global Limited</p> <p>www.nighthawkbedwetting.com</p> </td> <td>&nbsp;Vibratory alarm with buzzer that can be silenced.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Nite Train'r</p> <p>Koregon Enterprises</p> <p>Beaverton, OR</p> <p>www.nitetrain-r.com</p> </td> <td>Moisture sensor in underwear or bed pad.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Nytone Enuretic Alarm*</p> <p>Nytone Medical Products</p> <p>Bluffdale, UT</p> <p>www.nytone.com</p> </td> <td>Sensor clips on underwear; moisture alarm on wrist.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Sleep Dry</p> <p>Star Child Labs</p> <p>www.sleepdryalarm.com</p> </td> <td>Beeper unit can be clipped to child's bedclothes near the ear.</td> </tr> <tr> <td> <p>Wet-stop*</p> <p>Palco Labs</p> <p>Santa Cruz, CA</p> <p>www.wetstop.com</p> </td> <td>Sensor patch sewn into underwear (position can be adjusted for boys and girls); beeper unit attached by velcro to child's bedclothes near the ear. Available with both auditory and vibratory alarms.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Also available from The Bedwetting Store (www.bedwettingstore.com).</div><div id=\"graphicVersion\">Graphic 61732 Version 10.0</div></div></div>"},"61736":{"type":"graphic_diagnosticimage","displayName":"DAH PA I","title":"Diffuse alveolar hemorrhage in isolated capillaritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse alveolar hemorrhage in isolated capillaritis</div><div class=\"cntnt\"><img style=\"width:356px; height:347px;\" src=\"images/PULM/61736_DAH_PA_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph from a patient with diffuse alveolar hemorrhage due to isolated pulmonary capillaritis. Note the&nbsp;bilateral&nbsp;ground glass opacities&nbsp;and normal heart size.</div><div class=\"graphic_reference\">Courtesy of Marvin I Schwarz, MD.</div><div id=\"graphicVersion\">Graphic 61736 Version 3.0</div></div></div>"},"61737":{"type":"graphic_figure","displayName":"Ventilatory response in asthma","title":"Ventilatory response in asthma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ventilatory response in asthma</div><div class=\"cntnt\"><img style=\"width:414px; height:405px;\" src=\"images/PULM/61737_Ventilatory_response_in_ast.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypoxic ventilatory responses expressed in terms of the VE slope (change in VE/change in SaO<SUB>2</SUB>) and P0.1 slope (change in P0.1/change in SaO<SUB>2</SUB>) in 16 normal subjects, 11 patients with asthma but no near fatal attacks, and 11 patients with near fatal asthma. The horizontal bars indicate mean values, and the vertical lines &#177;1 SD.</div><div class=\"graphic_reference\">Redrawn from: Kikuchi Y, Okabe S, Tamura G, et al, N Engl J Med 1994; 330:1329.</div><div id=\"graphicVersion\">Graphic 61737 Version 2.0</div></div></div>"},"61738":{"type":"graphic_figure","displayName":"Female pelvic floor childbirth","title":"Pelvic floor anatomy during childbirth","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pelvic floor anatomy during childbirth</div><div class=\"cntnt\"><img style=\"width:446px; height:602px;\" src=\"images/OBGYN/61738_Fem_pel_floor_childbirth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Injury to the pelvic floor.<br> (A) The perineum, levator ani, and pelvic fascia may be injured during childbirth.<br> (B) It is the pubococcygeus, the main part of the levator ani, that is usually torn.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore, KL, Dalley, AF. Clinical Oriented Anatomy, Fourth Edition. Baltimore, Lippincott Williams &amp; Wilkins 1999. Copyright © 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 61738 Version 2.0</div></div></div>"},"61739":{"type":"graphic_figure","displayName":"Estimated average ionizing radiation by source","title":"Estimated average ionizing radiation by source at the US population level in 2006","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Estimated average ionizing radiation by source at the US population level in 2006</div><div class=\"cntnt\"><img style=\"width:515px; height:423px;\" src=\"images/PC/61739_Avg_ionizing_radiation.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Reprinted with permission of the National Council on Radiation Protection and Measurements, <a href=\"http://ncrponline.org/\" target=\"_blank\">http://NCRPonline.org</a>. Ionizing radiation exposure of the population of the United States. Bethesda, MD: National Council on Radiation Protection and Measurements; 2009: Report No 160. Copyright &#169; 2009.</div><div id=\"graphicVersion\">Graphic 61739 Version 2.0</div></div></div>"},"61740":{"type":"graphic_diagnosticimage","displayName":"Lateral arteriogram SMA syn","title":"A lateral arteriogram in a patient with SMA Syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">A lateral arteriogram in a patient with SMA Syndrome</div><div class=\"cntnt\"><img style=\"width:88px; height:288px;\" src=\"images/GAST/61740_Lateral_arteriogram_SMA_syn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The angle between the aorta (open arrowhead) and the SMA (closed arrowhead) is reduced causing compression of the third portion of the duodenum.</div><div class=\"graphic_footnotes\">SMA: superior mesenteric artery.</div><div class=\"graphic_reference\">Reprinted from Ross J Bellavia, MD and Sheila Berlin, MD from Rainbow Babies and Children's Hospital in Cleveland, OH (uhrad.com). Reprinted with permission from Sheila Berlin, MD.</div><div id=\"graphicVersion\">Graphic 61740 Version 3.0</div></div></div>"},"61742":{"type":"graphic_picture","displayName":"Essential thrombocythemia","title":"Increased platelets on peripheral smear in essential thrombocythemia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Increased platelets on peripheral smear in essential thrombocythemia</div><div class=\"cntnt\"><img style=\"width:360px; height:239px;\" src=\"images/HEME/61742_Essential_thrombocythemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral smear from a patient with essential thrombocythemia shows an increased platelet number and clumps of large, abnormal platelets.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 61742 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"61743":{"type":"graphic_diagnosticimage","displayName":"CT of mucinous adenocarcinoma in situ","title":"CT of mucinous adenocarcinoma in situ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT of mucinous adenocarcinoma in situ</div><div class=\"cntnt\"><img style=\"width:333px; height:329px;\" src=\"images/ONC/61743_CT_muc_adenocarcin_in_situ.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT of mucinous adenocarcinoma in situ; 2 cm predominantly solid nodule with air bronchogram (arrow) is noted in the left upper lobe.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011; 6:244. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 61743 Version 9.0</div></div></div>"},"61744":{"type":"graphic_figure","displayName":"Systolic murmurs and S2","title":"Diagrammatic representation of the character of the systolic murmur and of the second heart sound in several abnormalities","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Diagrammatic representation of the character of the systolic murmur and of the second heart sound in several abnormalities</div><div class=\"cntnt\"><img style=\"width:528px; height:462px;\" src=\"images/CARD/61744_Systolic_murmurs_and_S2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The effects of posture on the intensity of the murmurs are shown.</div><div class=\"graphic_footnotes\">MSC: mid-systolic click; &ndash;: no change from control.</div><div class=\"graphic_reference\">Modified with permission from: Barlow JB. Perspectives on the Mitral Valve. F.A. Davis, Philadelphia 1987.</div><div id=\"graphicVersion\">Graphic 61744 Version 4.0</div></div></div>"},"61745":{"type":"graphic_picture","displayName":"Doyen intestinal clamp","title":"Doyen intestinal clamp","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Doyen intestinal clamp</div><div class=\"cntnt\"><img style=\"width:474px; height:413px;\" src=\"images/SURG/61745_Doyen_intestinal_clamp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Doyen noncrushing intestinal clamp, used for dividing bowel in preparation for a hand-sewn anastomosis.&nbsp;A: straight with horizontal striations; B: curved&nbsp;with horizontal striations; C: curved with longitudinal striations.</div><div id=\"graphicVersion\">Graphic 61745 Version 1.0</div></div></div>"},"61746":{"type":"graphic_diagnosticimage","displayName":"Posterior shoulder dislocation and fracture","title":"Posterior shoulder dislocation and fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior shoulder dislocation and fracture</div><div class=\"cntnt\"><img style=\"width:432px; height:305px;\" src=\"images/EM/61746_Shoulder_post_DL_axil_XR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This axillary view demonstrates the dislocation more clearly, along with an avulsion of the lesser tuberosity (white arrow).</div><div id=\"graphicVersion\">Graphic 61746 Version 2.0</div></div></div>"},"61747":{"type":"graphic_algorithm","displayName":"ADA management patients DKA","title":"Protocol for the management of adult patients with DKA","html":"<div class=\"graphic\"><div style=\"width: 1184px\" class=\"figure\"><div class=\"ttl\">Protocol for the management of adult patients with DKA</div><div class=\"cntnt\"><img style=\"width:1164px; height:816px;\" src=\"images/ENDO/61747_ADA_mgmt_patients_DKA_edit1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">DKA diagnostic criteria: Serum glucose &gt;250 mg/dL, arterial pH &lt;7.3, serum bicarbonate &lt;18 mEq/L, and at least moderate ketonuria or ketonemia. Normal laboratory values vary; check local lab normal ranges for all electrolytes.</div><div class=\"graphic_footnotes\">DKA: diabetic ketoacidosis; IV: intravenous; NaCl: sodium chloride; SC: subcutaneous; Na: sodium; NaHCO<SUB>3</SUB>: sodium bicarbonate; H<SUB>2</SUB>O: water; KCl: potassium chloride; HCO<SUB>3</SUB>: bicarbonate; K: potassium; BUN: blood urea nitrogen.<br />* After history and physical exam, obtain capillary glucose and serum or urine ketones. Begin 1 L of 0.9% NaCl over one hour, and draw arterial blood gases, complete blood count with differential, urinalysis, serum glucose, BUN, electrolytes, chemistry profile, and creatinine levels STAT. Obtain electrocardiogram, chest radiograph, and specimens for bacterial cultures, as needed.<br />¶ Serum Na<SUP>+</SUP> should be corrected for hyperglycemia (for each 100 mg/dL glucose &gt;100 mg/dL, add 2.0 mEq to sodium value for corrected serum sodium value).<br />Δ 100 mmol NaHCO<SUB>3</SUB> = 100 mEq NaHCO<SUB>3</SUB>.<br /><FONT class=lozenge>◊</FONT> An alternative IV insulin regimen is to give a continuous intravenous infusion of regular insulin at 0.14 units/kg/hour; at this dose, an initial intravenous bolus is not necessary.<br />§ Please refer to the UpToDate topic on DKA for the definition of DKA resolution.</div><div class=\"graphic_reference\">Copyright © 2006 American Diabetes Association From Diabetes Care Vol 29, Issue 12, 2006. Modifications from Diabetes Care, Vol 32, Issue 7, 2009. Reprinted with permission from the American Diabetes Association.</div><div id=\"graphicVersion\">Graphic 61747 Version 7.0</div></div></div>"},"61751":{"type":"graphic_diagnosticimage","displayName":"Four chamber view fetal heart","title":"Four chamber view fetal heart","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Four chamber view fetal heart</div><div class=\"cntnt\"><img style=\"width:288px; height:288px;\" src=\"images/OBGYN/61751_Four_chamber_view_fetal_hea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial view of the fetal chest in the second trimester. The four-chamber view of the heart is demonstrated. The hyperechoic spine and ribs are shown. Anteriorly, the ventricles are seen and are of similar sizes. The atria are posterior and are similarly of comparable sizes. The atrioventricular valves are both demonstrated, with the right atrioventricular valve slightly more apically positioned.</div><div class=\"graphic_reference\">Courtesy of Joshua Copel, MD.</div><div id=\"graphicVersion\">Graphic 61751 Version 3.0</div></div></div>"},"61753":{"type":"graphic_figure","displayName":"Total gastrectomy with reconstruction","title":"Total gastrectomy with reconstruction","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Total gastrectomy with reconstruction</div><div class=\"cntnt\"><img style=\"width:512px; height:640px;\" src=\"images/ONC/61753_Total_gastrectomy_with_reconstruction.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 61753 Version 3.0</div></div></div>"},"61754":{"type":"graphic_algorithm","displayName":"Neurohumoral stimulat HF","title":"Functional and structural modifications following neurohumoral stimulation in heart failure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Functional and structural modifications following neurohumoral stimulation in heart failure</div><div class=\"cntnt\"><img style=\"width:336px; height:239px;\" src=\"images/CARD/61754_NeurohormonalstimulatHF.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 61754 Version 3.0</div></div></div>"},"61755":{"type":"graphic_table","displayName":"Phenytoin concentrations and clinical signs","title":"Phenytoin toxicity: Approximate correlation of serum concentration and clinical signs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Phenytoin toxicity: Approximate correlation of serum concentration and clinical signs</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Serum concentration</td>\r\n                    <td class=\"subtitle1\">Clinical findings </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>&#60;10 mg/L (40 &#181;mol/L)</td>\r\n                    <td>None</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>10-20 mg/L&nbsp;(40-80 &#181;mol/L)&nbsp;<strong>(therapeutic)</strong></td>\r\n                    <td>Mild nystagmus</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>20-30 mg/L (80-120 &#181;mol/L)</td>\r\n                    <td>Nystagmus</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>30-40 mg/L (120-160 &#181;mol/L)</td>\r\n                    <td>Ataxia, slurred speech, nausea, vomiting</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>40-50 mg/L (160-200 &#181;mol/L)</td>\r\n                    <td>Lethargy and confusion</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>&#62;50 mg/L (&#62;200 &#181;mol/L)</td>\r\n                    <td>Coma</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 61755 Version 2.0</div></div></div>"},"61756":{"type":"graphic_table","displayName":"Clinical clues to causes of ED","title":"Clinical clues to causes of erectile dysfunction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical clues to causes of erectile dysfunction</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Finding</td> <td class=\"subtitle1\">Cause</td> </tr> <tr> <td rowspan=\"2\">Rapid onset</td> <td>Psychogenic</td> </tr> <tr> <td>Genitourinary trauma (eg, radical prostatectomy)</td> </tr> <tr> <td rowspan=\"2\">Nonsustained erection</td> <td>Anxiety</td> </tr> <tr> <td>Venous leak</td> </tr> <tr> <td rowspan=\"2\">Depression or use of certain drugs</td> <td>Depression</td> </tr> <tr> <td>Drug induced</td> </tr> <tr> <td rowspan=\"2\">Complete loss of nocturnal erections</td> <td>Vascular disease</td> </tr> <tr> <td>Neurologic disease</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 61756 Version 5.0</div></div></div>"},"61759":{"type":"graphic_diagnosticimage","displayName":"Tooth aspiration","title":"Tooth aspiration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tooth aspiration</div><div class=\"cntnt\"><img style=\"width:388px; height:263px;\" src=\"images/PULM/61759_Tooth_aspiration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph (left) obtained following trauma in a 28-year-old man shows a radiopaque foreign body in the right lower lobe. A fractured tooth (right) was removed bronchoscopically.</div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 61759 Version 2.0</div></div></div>"},"61760":{"type":"graphic_picture","displayName":"Epithelial cornea defect","title":"Epithelial cornea defect","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epithelial cornea defect</div><div class=\"cntnt\"><img style=\"width:400px; height:265px;\" src=\"images/RHEUM/61760_Epithelial_cornea_defect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nonhealing epithelial defect in a transplanted cornea in a patient with secondary Sjögren's syndrome.</div><div class=\"graphic_reference\">Courtesy of Reza Dana, MD, MSc, MPH.</div><div id=\"graphicVersion\">Graphic 61760 Version 2.0</div></div></div>"},"61761":{"type":"graphic_picture","displayName":"Idiopathic guttate hypomelanosis - thigh","title":"Idiopathic guttate hypomelanosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Idiopathic guttate hypomelanosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/61761_Idioguttatehypomelthigh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small, hypopigmented macules are present on the thigh.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 61761 Version 3.0</div></div></div>"},"61763":{"type":"graphic_diagnosticimage","displayName":"Small pericardial effusion II","title":"Small pericardial effusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Small pericardial effusion</div><div class=\"cntnt\"><img style=\"width:223px; height:358px;\" src=\"images/CARD/61763_Small_pericardial_effusio1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The long (panel A) and short axis (panel B) two- dimensional images show a small pericardial effusion (arrows). The M-mode echocardiogram (panel C) shows the posterior wall to be separated from the pericardium (arrow).</div><div class=\"graphic_footnotes\">LV: left ventricle; IVS: interventricular septum.</div><div id=\"graphicVersion\">Graphic 61763 Version 3.0</div></div></div>"},"61765":{"type":"graphic_figure","displayName":"Packing to control posterior epistaxis","title":"Packing to control posterior epistaxis","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Packing to control posterior epistaxis</div><div class=\"cntnt\"><img style=\"width:454px; height:448px;\" src=\"images/EM/61765_Nasal_packing_posterior.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prior to the availability of balloon catheters, tamponade was achieved by means of cotton packing. This process involves: (A) feeding a small caliber rubber hose through the nose, retrieving it from the oropharynx, and attaching a cotton pack; (B) the hose is then retracted through the nose, while digitally guiding the pack posteriorly, until it lodges against the posterior choana; (C) a second cotton pack or gauze roll is secured against the nares to secure the hose. Balloon catheters are preferable. A foley catheter may be used (D).</div><div class=\"graphic_reference\">Reproduced with permission from: Smelzter, SC, Bare, BG. Textbook of Medical-Surgical Nursing, 9th Ed. Philadelphia: Lippincott Williams &amp; Wilkins, 2000. Copyright ©2000 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 61765 Version 2.0</div></div></div>"},"61766":{"type":"graphic_table","displayName":"Lispro insulin units daily","title":"Lispro insulin units daily","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lispro insulin units daily</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Time</td> <td class=\"subtitle1\">Lispro insulin, units</td> </tr> <tr> <td>7 AM</td> <td>4</td> </tr> <tr> <td>12 PM</td> <td>6</td> </tr> <tr> <td>6 PM</td> <td>8</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 61766 Version 2.0</div></div></div>"},"61767":{"type":"graphic_diagnosticimage","displayName":"Early gastric cancer UGI","title":"Early gastric cancer as seen on upper gastrointestinal (UGI) series","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Early gastric cancer as seen on upper gastrointestinal (UGI) series</div><div class=\"cntnt\"><img style=\"width:294px; height:324px;\" src=\"images/GAST/61767_Early_gastric_cancer_UGI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A double contrast upper gastrointestinal study shows a superficial ulcer in the gastric antrum (arrow) with thickened folds radiating towards the ulcer.</div><div class=\"graphic_reference\">Courtesy of Norman Joffe, MD.</div><div id=\"graphicVersion\">Graphic 61767 Version 5.0</div></div></div>"},"61768":{"type":"graphic_picture","displayName":"Schatzki ring ulcerated Endosc","title":"Schatzki ring","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schatzki ring</div><div class=\"cntnt\"><img style=\"width:252px; height:257px;\" src=\"images/GAST/61768_Schatzki_ring_ulcerated_End.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of the distal esophagus revealed three superficial ulcerations above an esophageal ring.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD and Helen M. Shields, MD.</div><div id=\"graphicVersion\">Graphic 61768 Version 2.0</div></div></div>"},"61769":{"type":"graphic_figure","displayName":"Salpingectomy","title":"Total salpingectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Total salpingectomy</div><div class=\"cntnt\"><img style=\"width:402px; height:301px;\" src=\"images/OBGYN/61769_Salpingectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Technique of total salpingectomy at laparotomy.<br />(B) Excision and suture ligation of the mesosalpinx at laparotomy.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 61769 Version 2.0</div></div></div>"},"61770":{"type":"graphic_picture","displayName":"Size classification of varices","title":"Size classification of esophageal varices","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Size classification of esophageal varices</div><div class=\"cntnt\"><img style=\"width:379px; height:128px;\" src=\"images/GAST/61770_Size_classification_of_vari.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The size of varices, as illustrated in these endoscopic pictures, can be used to estimate the risk of variceal bleeding. The first panel shows small straight varices (F1), the second panel shows enlarged tortuous varices that occupy less than one-third of the lumen (F2), and the third panel shows large coil-shaped varices that occupy more than one-third of the lumen (F3).</div><div class=\"graphic_reference\">Courtesy of Arun Sanyal, MD.</div><div id=\"graphicVersion\">Graphic 61770 Version 2.0</div></div></div>"},"61772":{"type":"graphic_picture","displayName":"Smallpox rash","title":"Characteristics of smallpox","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Characteristics of smallpox</div><div class=\"cntnt\"><img style=\"width:391px; height:433px;\" src=\"images/ID/61772_Smallpox_rash.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with smallpox can have lesions on the palms or soles (A), umbilicated lesions (B), and confluent lesions (C). Panels D through F show days three, five, and seven in a young boy.</div><div class=\"graphic_reference\">Adapted from http://www.bt.cdc.gov/agent/smallpox/diagnosis/evalposter.asp.</div><div id=\"graphicVersion\">Graphic 61772 Version 3.0</div></div></div>"},"61773":{"type":"graphic_picture","displayName":"Low-turnover osteomalacia","title":"Micrograph showing low-turnover osteomalacia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Micrograph showing low-turnover osteomalacia</div><div class=\"cntnt\"><img style=\"width:378px; height:264px;\" src=\"images/NEPH/61773_Low_turnover_osteomalacia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone biopsy showing low-turnover osteomalacia associated with aluminum accumulation in end-stage renal failure.<br />(Left panel) Goldner Masson trichrome stain shows thin mineralized bone in blue surrounded by wide unmineralized osteoid with no cellular activity in orange-brown. There are no osteoblasts or erosive surfaces present.<br />(Right panel) Villanueva stain following tetracycline labeling and viewed under fluorescent light reveals a marked increase in width of the osteoid seams (orange) with no evidence of mineralization of new bone (which would result in tetracycline deposition, as manifested by a yellow line appearing beneath the osteoid seams).</div><div class=\"graphic_reference\">Courtesy of L Darryl Quarles, MD.</div><div id=\"graphicVersion\">Graphic 61773 Version 5.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Micrograph showing normal bone histology</div><div class=\"cntnt\"><img style=\"width:382px; height:269px;\" src=\"images/NEPH/66330_Normalboneedit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histologic appearance of normal bone.<br />(Left panel) Goldner Masson trichrome stain shows mineralized lamellar bone in blue and adjacent nonmineralized osteoid in red-brown. Osteoid usually comprises less than 25% of bone surfaces. The cellular area between the osseous structures is the marrow space.<br />(Right panel) Villanueva-stained section viewed under polarized light following time-spaced tetracycline labeling. Osteoid appears orange, mineralized bone is green, and tetracycline markers appear as luminescent yellow-green bands within bone and beneath osteoid (arrow). The distinct dual bands represent active mineralized bone formation.</div><div class=\"graphic_reference\">Courtesy of L Darryl Quarles, MD.</div><div id=\"graphicVersion\">Graphic 66330 Version 6.0</div></div></div>"},"61774":{"type":"graphic_waveform","displayName":"ICP waveforms","title":"Pathologic A waves","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathologic A waves</div><div class=\"cntnt\"><img style=\"width:435px; height:153px;\" src=\"images/NEURO/61774_Pathol_A_waves.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Interpreting ICP waveforms: A waves. The most clinically significant ICP waveforms are A waves, which may reach elevations of 50 to 100 mm Hg, persist for 5 to 20 minutes, then drop sharply - signaling exhaustion of the brain's compliance mechanisms. A waves may come and go, spiking from temporary rises in thoracic pressure or from any condition that increases ICP beyond the brain's compliance limits. Activities, such as sustained coughing or straining during defecation, can cause temporary elevations in thoracic pressure.</div><div class=\"graphic_reference\">Reproduced with permission from: Nursing Procedures, 4th Ed. Lippincott Williams &amp; Wilkins, 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 61774 Version 4.0</div></div></div>"},"61775":{"type":"graphic_picture","displayName":"Pagets vulva","title":"Vulvar Paget's disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar Paget's disease</div><div class=\"cntnt\"><img style=\"width:353px; height:468px;\" src=\"images/OBGYN/61775_Pagets_vulva.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from&#160;Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 61775 Version 3.0</div></div></div>"},"61776":{"type":"graphic_figure","displayName":"Seasonal variation death HF","title":"Mortality and hospitalizations in heart failure show a seasonal variation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mortality and hospitalizations in heart failure show a seasonal variation</div><div class=\"cntnt\"><img style=\"width:420px; height:268px;\" src=\"images/CARD/61776_Seasonal_variation_death_HF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A retrospective analysis of 324,013 hospitalizations and 138,602 deaths during a four-year period in France shows that there is a seasonal variation in hospitalizations and death from heart failure, which peak during the winter months; the distribution of monthly events differed by 35 percent when January, the month with the highest number of events, was compared to August during which the event rate was the lowest (p&lt;0.001).</div><div class=\"graphic_reference\">Data from Boulay, F, Berthier, F, Sisteron, O, et al, Circulation 1999; 100:280.</div><div id=\"graphicVersion\">Graphic 61776 Version 2.0</div></div></div>"},"61777":{"type":"graphic_diagnosticimage","displayName":"Hiatal hernia after gastric bypass","title":"Hiatal hernia after gastric bypass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hiatal hernia after gastric bypass</div><div class=\"cntnt\"><img style=\"width:422px; height:420px;\" src=\"images/SURG/61777_Hiatal_hernia_gastr_bypass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arrow shows a hiatal hernia after gastric bypass.</div><div id=\"graphicVersion\">Graphic 61777 Version 5.0</div></div></div>"},"61778":{"type":"graphic_movie","displayName":"Right hemothorax","title":"Ultrasound of right hemothorax","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Ultrasound of right hemothorax</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/61778_Righthemothoraxmovie.mp4\" style=\"width:496px;height:320px\"></div><img style=\"width:504px; height:387px;\" src=\"images/EM/61778_Righthemothoraximage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound video clip reveals fluid in the pleural space and a small portion of the lung parenchyma just superior to the liver.</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Courtesy of Greg Snead, MD.</div><div id=\"graphicVersion\">Graphic 61778 Version 1.0</div></div></div>"},"61779":{"type":"graphic_figure","displayName":"Construction of an ileostomy - transection proximal limb","title":"Construction of an ileostomy - transection proximal limb","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Construction of an ileostomy - transection proximal limb</div><div class=\"cntnt\"><img style=\"width:461px; height:504px;\" src=\"images/SURG/61779_Ileostomy-transect-proximal-limb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts opening the proximal limb of the ileum in preparation for constructing an ileostomy.</div><div id=\"graphicVersion\">Graphic 61779 Version 1.0</div></div></div>"},"61780":{"type":"graphic_figure","displayName":"Feedback loop of the alternative complement pathway","title":"Feedback loop of the alternative complement pathway","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Feedback loop of the alternative complement pathway</div><div class=\"cntnt\"><img style=\"width:430px; height:163px;\" src=\"images/ALLRG/61780_Alt_complement_path_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After C3b is generated, it binds to factor B. Factor D can then cleave factor B to form the C3 convertase (C3bBb). The attachment of properdin (P) stabilizes the complex. The end result is the deposition of large amounts of C3b on the pathogen. C3b can be generated by the classical pathway, the lectin pathway, or de novo by the alternative pathway itself. </div><div class=\"graphic_footnotes\">AP: alternative pathway.</div><div class=\"graphic_reference\">Adapted from: Liszewski MK, Atkinson JP. The complement system. In: Immunology Scope Monograph, Schwartz, BD (Ed), Upjohn, Kalamazoo, 1992.</div><div id=\"graphicVersion\">Graphic 61780 Version 7.0</div></div></div>"},"61781":{"type":"graphic_table","displayName":"CAPOX regimen for colorectal cancer","title":"Capecitabine and oxaliplatin (CAPOX) for colorectal cancer<SUP>[1,2]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Capecitabine and oxaliplatin (CAPOX) for colorectal cancer<SUP>[1,2]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Oxaliplatin</td> <td>130 mg/m<sup>2</sup> IV</td> <td>Dilute in 500 mL 5% dextrose in water (D5W)* and administer over two hours.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Capecitabine<sup>&#182;</sup></td> <td>850 mg/m<sup>2</sup><sup>&#916;</sup> per dose, by mouth</td> <td>Twice daily (total dose 1700 mg/m<sup>2</sup> per day). Swallow whole with water within 30 minutes after a meal, with each dose as close to 12 hours apart as possible. Do not cut or crush tablets.<sup>&#9674;</sup></td> <td>Evening of day 1 to morning of day 15</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin: MODERATE. </li> <li>Oral capecitabine: LOW. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>There is no standard premedication regimen for oxaliplatin. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin is an irritant but can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with granulocyte colony stimulating factors not indicated (estimated risk of febrile neutropenia &#60;5%<sup>[1]</sup>). </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Lower starting doses of oxaliplatin and capecitabine may be needed for renal impairment. </li> <li>Refer to UpToDate topic on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Maneuvers to prevent neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Counsel patients to avoid exposure to cold during and for approximately 48 hours after each infusion. Prolongation of the oxaliplatin infusion time from two to six hours may mitigate acute neurotoxicity. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>Prolongation of the corrected QT (QTc) interval and ventricular arrhythmias have been reported after oxaliplatin. ECG monitoring is recommended if therapy is initiated in patients with heart failure, bradyarrhythmias, coadministration of drugs known to prolong the QT interval, and electrolyte abnormalities. Avoid oxaliplatin in patients with congenital long QT syndrome. Correct hypokalemia and hypomagnesemia prior to initiating oxaliplatin. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes (especially potassium and magnesium) and liver and renal function every three weeks prior to treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for diarrhea and palmar-plantar erythrodysesthesias during treatment. </li> <li>Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\". </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>More frequent anticoagulant response (INR or prothrombin time) monitoring is necessary for patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Capecitabine-induced cardiotoxicity may include angina, myocardial infarction/ischemia, dysrhythmias, cardiac arrest, heart failure, sudden death, electrocardiographic changes, and cardiomyopathy. These adverse reactions may be more common in patients with a prior history of coronary artery disease. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>The treatment cycle should be delayed one week if the total white blood cell count is &#60;3000/microL, absolute neutrophil count is &#60;1500/microL, or the platelet count is &#60;100,000/microL on day 1. If treatment is delayed for two weeks or delayed for one week on two separate occasions, reduce the doses of oxaliplatin and capecitabine by 10 to 20%. Subsequent treatment cycles should be delayed until neutrophils are &#8805;1500/microL and platelets are &#8805;75,000/microL. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>In the original trial, for grade 3 paresthesias and dysesthesias lasting longer than seven days, the oxaliplatin dose was decreased by 25%, and oxaliplatin was discontinued for grade 4 or persistent grade 3 paresthesia/dysesthesias.<sup>[1]</sup> The United States Prescribing Information suggests dose reduction for persistent NCI-CTC grade 2 neurosensory events (sensory alteration or paresthesias including tingling but not interfering with activities of daily living [ADLs]) and discontinuation of oxaliplatin for persistent grade 3 (objective sensory loss or paresthesias including tingling interfering with function but not ADLs) or grade 4 neurosensory events.<sup>[3]</sup> </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin has rarely been associated with pulmonary toxicity. Withhold oxaliplatin for unexplained pulmonary symptoms until interstitial lung disease or pulmonary fibrosis is excluded. </li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Gastrointestinal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Interrupt capecitabine and delay oxaliplatin for any grade 2 or worse gastrointestinal toxicity; restart treatment only after complete recovery or improvement to &#8804;grade 1.<sup>[4]</sup> After recovery, reduce the dose of oxaliplatin by 25% after the first episode of grade 3 or worse diarrhea or mucositis. Reduce the capecitabine dose by 25% in subsequent cycles at the first occurrence of grade 2 or 3 toxicity, and by 50% at the second occurrence of a given grade 2 or grade 3 toxicity or at the first occurrence of a grade 4 event. Discontinue capecitabine permanently if, despite dose reduction, a given toxicity occurs for the third time at grade 2 or grade 3, or a second time at grade 4.<sup>[4]</sup> </li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after capecitabine should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other non-hematologic toxicity (including hepatotoxicity)</strong></td> <td colspan=\"3\"> <ul> <li>Interrupt capecitabine and delay oxaliplatin for any grade 2 or worse non-neurologic toxicity (except alopecia); restart treatment only after complete recovery or improvement to &#8804;grade 1.<sup>[4,5]</sup> Reduce the dose of oxaliplatin by 25% for drug-related grade 3 toxicity.<sup>[4]</sup> Reduce the capecitabine dose by 25% in subsequent cycles at the first occurrence of a grade 2 or grade 3 toxicity, and by 50% at the second occurrence of a given grade 2 or grade 3 toxicity or at the first occurrence of a grade 4 event.<sup>[4]</sup> Discontinue capecitabine permanently if, despite dose reduction, a given toxicity occurs for the third time at grade 2 or grade 3, or a second time at grade 4. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\"><strong>Doses of capecitabine that are omitted for toxicity are not replaced.<sup>[5]</sup> The patient should resume the planned treatment cycles at the modified dose.</strong></td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; ECG: electrocardiogram; CBC: complete blood count; INR: international normalized ratio; NCI-CTC: National Cancer Institute Common Toxicity Criteria.<br />* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />¶ No capecitabine dose has been shown to be safe in patients with complete dihydropyrimidine dehydrogenase (DPD) deficiency, and data are insufficient to recommend a dose in patients with partial DPD activity.<br />Δ In the setting of metastatic disease, American patients are usually started on capecitabine 850 mg/m<SUP>2</SUP> twice daily, as per TREE-2, while Asian and European patients are more often started at capecitabine 1000 mg/m<SUP>2</SUP> twice daily, per TREE-1.<SUP>[1]</SUP> In the adjuvant setting, the N16968 trial used capecitabine 1000 mg/m<SUP>2</SUP> in conjunction with oxaliplatin.<SUP>[2]</SUP> While this dose is appropriate for robust patients, others are started at 850 mg/m<SUP>2</SUP> with dose escalation as tolerated.<br /><FONT class=lozenge>◊</FONT> Extemporaneous compounding of liquid dosage forms has been recommended, but intravenous therapies may be more appropriate for patients with significant swallowing difficulty.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Hochster HS, et al. J Clin Oncol 2008; 26:3523.</LI>&#xD;&#xA;<LI>Haller DG, et al. J Clin Oncol 2011; 29:1465.</LI>&#xD;&#xA;<LI>Oxaliplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 29, 2016).</LI>&#xD;&#xA;<LI>Nehls O, et al. Br J Cancer 2008; 98:309.</LI>&#xD;&#xA;<LI>Capecitabine. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 29, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 61781 Version 41.0</div></div></div>"},"61782":{"type":"graphic_diagnosticimage","displayName":"CT right pneumothorax","title":"Chest CT scan showing a right-sided pneumothorax","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Chest CT scan showing a right-sided pneumothorax</div><div class=\"cntnt\"><img style=\"width:552px; height:296px;\" src=\"images/PEDS/61782_CT_right_pneumothorax.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computerized tomography (CT) of the chest showing a right-sided pneumothorax.<br />Panels A and B: The first two panels demonstrates the right-sided pneumothorax; a large apical bleb (arrow) can be seen in panel A.<br />Panels C and D: A chest tube (arrowhead) is seen.</div><div id=\"graphicVersion\">Graphic 61782 Version 4.0</div></div></div>"},"61783":{"type":"graphic_diagnosticimage","displayName":"Heart failure PA I","title":"Heart failure","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Heart failure</div><div class=\"cntnt\"><img style=\"width:349px; height:306px;\" src=\"images/CARD/61783_Heart_failure_PA_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This chest radiograph of a 65-year-old male with dyspnea and orthopnea demonstrates mild pulmonary vascular congestion, septal lymphatic distention (arrow), interstitial veiling, and enlarged hilar shadows (arrowhead), indicative of left ventricular decompensation.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 61783 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"61785":{"type":"graphic_figure","displayName":"Coronary heart disease PI","title":"Coronary heart disease","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Coronary heart disease</div><div class=\"cntnt\"><img style=\"width:544px; height:452px;\" src=\"images/PI/61785_Coronary_heart_disease_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In people with coronary heart disease, the coronary arteries get clogged with fatty deposits called plaques.</div><div id=\"graphicVersion\">Graphic 61785 Version 5.0</div></div></div>"},"61786":{"type":"graphic_picture","displayName":"Toxic shock syndrome - macular erythema","title":"Toxic shock syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Toxic shock syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/61786_TSS_macular_erythema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Macular erythema is present on the arm.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 61786 Version 3.0</div></div></div>"},"61787":{"type":"graphic_table","displayName":"Risk factors surgery in cirrhosis","title":"Risk factors for morbidity and mortality in patients with cirrhosis undergoing surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for morbidity and mortality in patients with cirrhosis undergoing surgery</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Type of surgery</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Abdominal (especially cholecystectomy, gastric resection or colectomy)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardiac</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Emergency</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hepatic resection</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Patient characteristics</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Anemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ascites</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Child's class (C&#62;B)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Encephalopathy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hypoalbuminemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hypoxemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Infection</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Jaundice</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Malnutrition</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Portal hypertension</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Prolonged prothrombin time (&#62;2.5 seconds above control that does not correct with vitamin K)</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from Friedman LS. The risk of surgery in patients with liver disease. Hepatology 1999; 29:1617. Copyright &#169; 1999 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 61787 Version 2.0</div></div></div>"},"61788":{"type":"graphic_picture","displayName":"Neisseria meingitidis in CSF","title":"<EM>Neisseria meningitidis</EM> in cerebrospinal fluid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Neisseria meningitidis</EM> in cerebrospinal fluid</div><div class=\"cntnt\"><img style=\"width:371px; height:240px;\" src=\"images/ID/61788_GramstainCSF2withanswe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of cerebrospinal fluid (x1000) shows inflammatory cells and kidney-shaped, gram-negative diplococci (arrows). <em>Neisseria meningitidis</em> grew from this specimen.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 61788 Version 4.0</div></div></div>"},"61789":{"type":"graphic_table","displayName":"Symptoms of multiple sclerosis","title":"Symptoms of multiple sclerosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms&nbsp;of multiple sclerosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Symptom</td> <td class=\"subtitle1\">Total (percent)</td> </tr> <tr> <td>Sensory in limbs</td> <td class=\"centered\">31</td> </tr> <tr> <td>Visual loss</td> <td class=\"centered\">16</td> </tr> <tr> <td>Motor (subacute)</td> <td class=\"centered\">9</td> </tr> <tr> <td>Diplopia</td> <td class=\"centered\">7</td> </tr> <tr> <td>Gait disturbance</td> <td class=\"centered\">5</td> </tr> <tr> <td>Motor (acute)</td> <td class=\"centered\">4</td> </tr> <tr> <td>Balance problems</td> <td class=\"centered\">3</td> </tr> <tr> <td>Sensory in face</td> <td class=\"centered\">3</td> </tr> <tr> <td>Lhermitte sign (electric shock-like sensations that run down the back and/or limbs upon flexion of the neck)</td> <td class=\"centered\">2</td> </tr> <tr> <td>Vertigo</td> <td class=\"centered\">2</td> </tr> <tr> <td>Bladder problems</td> <td class=\"centered\">1</td> </tr> <tr> <td>Limb ataxia</td> <td class=\"centered\">1</td> </tr> <tr> <td>Acute transverse myelopathy</td> <td class=\"centered\">1</td> </tr> <tr> <td>Pain</td> <td class=\"centered\">&#60;1</td> </tr> <tr> <td>Other</td> <td class=\"centered\">3</td> </tr> <tr> <td>Polysymptomatic onset</td> <td class=\"centered\">14</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Richards RG, Sampson FC, Beard SM, Tappenden P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 2002; 6:1. Copyright © 2002 Queen's Printer and Controller of HMSO.</div><div id=\"graphicVersion\">Graphic 61789 Version 4.0</div></div></div>"},"61790":{"type":"graphic_figure","displayName":"Pelvic extraperitoneal space","title":"Pelvic extraperitoneal space","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Pelvic extraperitoneal space</div><div class=\"cntnt\"><img style=\"width:538px; height:538px;\" src=\"images/OBGYN/61790_Pelvic_extraperitoneal_spac.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 61790 Version 3.0</div></div></div>"},"61792":{"type":"graphic_picture","displayName":"Warthin tumor Light","title":"Warthin tumor","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Warthin tumor</div><div class=\"cntnt\"><img style=\"width:554px; height:259px;\" src=\"images/ONC/61792_Warthins_tumor_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel shows a low power view of this characteristically cystic lesion with central amorphous fluid surrounded by papillary formations and an intense lymphoid infiltrate. The right panel demonstrates the typical bilayered epithelium of dense eosinophilic columnar cells. The dense eosinophilia qualifies these cells as oncocytes, which are cells with cytoplasm packed with mitochondria. These tumors are commonly accompanied by squamous or mucinous metaplasia, which should not be interpreted as malignant (mucoepidermoid carcinoma).</div><div class=\"graphic_reference\">Courtesy of G Kenneth Haines, MD.</div><div id=\"graphicVersion\">Graphic 61792 Version 3.0</div></div></div>"},"61793":{"type":"graphic_figure","displayName":"Aeroneb Solo mesh nebulizer","title":"Aeroneb Solo mesh nebulizer for intermittent or continuous nebulization","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aeroneb Solo mesh nebulizer for intermittent or continuous nebulization</div><div class=\"cntnt\"><img style=\"width:337px; height:504px;\" src=\"images/PULM/61793_Aeroneb_mesh_nebulizer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nebulizers like the Aeroneb Solo mesh nebulizer can be used for intermittent or continuous nebulization. The Aeroneb Pro controller accommodates nebulization cycles of 15 to 30 minutes.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2012 Aerogen. All rights reserved.</div><div id=\"graphicVersion\">Graphic 61793 Version 4.0</div></div></div>"},"61795":{"type":"graphic_figure","displayName":"Apoptotic programs","title":"Caspase activation","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Caspase activation</div><div class=\"cntnt\"><img style=\"width:584px; height:422px;\" src=\"images/RHEUM/61795_Apoptotic_programs.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Keith Elkon, MD.</div><div id=\"graphicVersion\">Graphic 61795 Version 2.0</div></div></div>"},"61796":{"type":"graphic_table","displayName":"HCV lookback at blood centers","title":"HCV lookback experiences of Canadian and European blood centers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">HCV lookback experiences of Canadian and European blood centers</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n\n      <td class=\"subtitle1\">Time period</td>\n\n\n      <td class=\"subtitle1\">Number recipients target</td>\n\n\n      <td class=\"subtitle1\">Percent deceased</td>\n\n\n      <td class=\"subtitle1\">Percent HCV+ pre-lookback</td>\n\n\n      <td class=\"subtitle1\">Number tested</td>\n\n\n      <td class=\"subtitle1\">Percent HCV positive</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Wall, 1997, Toronto</td>\n\n\n      <td>1990-5</td>\n\n\n      <td>2418</td>\n\n\n      <td>45</td>\n\n\n      <td>2.6</td>\n\n\n      <td>184</td>\n\n\n      <td>68*</td>\n\n\n    </tr>\n\n\n    \n\n\n    <tr>\n\n\n      <td>Christensen, 1977, Denmark</td>\n\n\n      <td>1991-6</td>\n\n\n      <td>1006</td>\n\n\n      <td>73</td>\n\n\n      <td>NA</td>\n\n\n      <td>144</td>\n\n\n      <td>75</td>\n\n\n    </tr>\n\n\n    \n\n\n    <tr>\n\n\n      <td>Vrielink, 1995, Netherlands</td>\n\n\n      <td>1990-2</td>\n\n\n      <td>270</td>\n\n\n      <td>21</td>\n\n\n      <td>NA</td>\n\n\n      <td>32*</td>\n\n\n      <td>81</td>\n\n\n    </tr>\n\n\n    \n\n\n    <tr>\n\n\n      <td>Lau, 1997, Toronto</td>\n\n\n      <td>1990-5</td>\n\n\n      <td>174</td>\n\n\n      <td>26</td>\n\n\n      <td>25</td>\n\n\n      <td>26</td>\n\n\n      <td>50</td>\n\n\n    </tr>\n\n\n    \n\n\n    <tr>\n\n\n      <td>Goldman, 1998, Canada</td>\n\n\n      <td>1995-97</td>\n\n\n      <td>1779</td>\n\n\n      <td>62</td>\n\n\n      <td>NK</td>\n\n\n      <td>580</td>\n\n\n      <td>58</td>\n\n\n    </tr>\n\n\n    \n\n\n  \n  </tbody>\n</table></div><div class=\"graphic_footnotes\">NA: not available NK: not known.<br> * Without other risk factors.</div><div id=\"graphicVersion\">Graphic 61796 Version 1.0</div></div></div>"},"61800":{"type":"graphic_table","displayName":"Pulmonary allograft rejection","title":"Classification and grading of pulmonary allograft rejection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification and grading of pulmonary allograft rejection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">A: Acute rejection*: characterized by perivascular and interstitial mononuclear cell infiltrates</td> </tr> <tr> <td class=\"indent1\">Grade 0: none</td> </tr> <tr> <td class=\"indent1\">Grade 1: minimal</td> </tr> <tr> <td class=\"indent1\">Grade 2: mild</td> </tr> <tr> <td class=\"indent1\">Grade 3: moderate</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Grade 4: severe</td> </tr> <tr> <td class=\"subtitle2_left\">B: Airway inflammation (lymphocytic bronchiolitis)*: characterized by mononuclear cell infiltrates in the submucosa of bronchioles</td> </tr> <tr> <td class=\"indent1\">Grade 0: none</td> </tr> <tr> <td class=\"indent1\">Grade 1R<sup>&#182;</sup>: low grade</td> </tr> <tr> <td class=\"indent1\">Grade 2R<sup>&#182;</sup>: high grade</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Grade X: ungradeable </td> </tr> <tr> <td class=\"subtitle2_left\">C: Chronic airway rejection (obliterative bronchiolitis): manifest by fibrous scarring that is often dense and eosinophilic</td> </tr> <tr> <td class=\"indent1\">0: absent</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">1: present</td> </tr> <tr> <td class=\"subtitle2_left\">D: Chronic vascular rejection - accelerated graft vascular sclerosis: characterized by fibrointimal thickening of the pulmonary arteries and veins. These lesions are not seen on TBB as they affect larger blood vessels than those accessed with TBB.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TBB: transbronchial biopsy.<br />* Acute vascular rejection (A1 to A4) and acute airway inflammation (B1 to B2R) can be seen independently or may both be present.<br />¶ \"R\" denotes revised grade to avoid confusion with 1996 scheme.</div><div class=\"graphic_reference\">Reproduced from: Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26:1229. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 61800 Version 4.0</div></div></div>"},"61802":{"type":"graphic_figure","displayName":"Thyroid nerves variants","title":"Variations in nerve supply of the thyroid gland","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Variations in nerve supply of the thyroid gland</div><div class=\"cntnt\"><img style=\"width:542px; height:659px;\" src=\"images/SURG/61802_Thyroidnervesvariantsedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The external branch of the superior laryngeal nerve innervates the inferior constrictor and cricothyroid muscles. The external branch travels with the superior thyroid artery until approximately 1 cm before the artery enters the superior thyroid pole and then divides into branches that enter the lateral inferior pharyngeal constrictor muscle and the cricothyroid muscle. A few smaller branches may be seen entering the superior thyroid.<br />(B) The recurrent laryngeal nerve (RLN) is associated with the inferior thyroid artery at approximately the junction of the lower and middle thirds of the thyroid gland. On the left, the RLN ascends in the tracheoesophageal groove and crosses deep to the inferior thyroid artery; on the right, the RLN crosses more obliquely and is oriented more laterally than caudally.<br />While the nerve most often crosses deep to the inferior thyroid artery, documented variations include passing anterior to the artery as well as passing between branches of the inferior thyroid artery. Another variation of the nerve is the nonrecurrent laryngeal nerve, in which the laryngeal nerve branches directly from the vagus nerve. This variation occurs more commonly on the right side.</div><div class=\"graphic_reference\">(A) Adapted from: Morton RP, Whitfield Al-Ali S. Anatomical and surgical considerations of the external branch of the superior laryngeal nerve: a systematic review. Clin Otolaryngol 2006; 31:368-374.<br />(B) Adapted from: Makay O, Icoz G, Yilmaz M, Akyildiz M, Yetkin E. The recurrent laryngeal nerve and the inferior thyroid artery-anatomical variations during surgery. Langenbecks Arch Surg 2008; 393:681.</div><div id=\"graphicVersion\">Graphic 61802 Version 8.0</div></div></div>"},"61803":{"type":"graphic_picture","displayName":"Porokeratosis ptychotropica close view","title":"Porokeratosis ptychotropica","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Porokeratosis ptychotropica</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/61803_Porokerat_ptych_close_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scaly plaques are present in the gluteal fold. Cornoid lamellae are visible in some areas.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 61803 Version 3.0</div></div></div>"},"61807":{"type":"graphic_table","displayName":"Causes of acute symptomatic seizures","title":"Causes of provoked seizures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of provoked seizures</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Alcohol &#38; drug withdrawal</td> </tr> <tr> <td>Drug intoxication</td> </tr> <tr> <td>Hyponatremia, hypernatremia</td> </tr> <tr> <td>Hypomagnesium</td> </tr> <tr> <td>Hypocalcemia</td> </tr> <tr> <td>Hypoglycemia</td> </tr> <tr> <td>Nonketotic hyperglycemia</td> </tr> <tr> <td>Uremia</td> </tr> <tr> <td>Hypoxia</td> </tr> <tr> <td>Hyperthyroidism</td> </tr> <tr> <td>Dialysis disequilibrium syndrome</td> </tr> <tr> <td>Porphyria</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 61807 Version 5.0</div></div></div>"},"61809":{"type":"graphic_figure","displayName":"Survival in acute coronary syndromes","title":"Survival in acute coronary syndromes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Survival in acute coronary syndromes</div><div class=\"cntnt\"><img style=\"width:340px; height:248px;\" src=\"images/CARD/61809_Outcome_UAP_QWMI_NSTEMI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 12,142 patients entered into GUSTO IIb, the one-year survival was the same for those with an ST elevation (Q wave) or non-ST elevation (non Q-wave) myocardial infarction (NSTEMI) who did not have recurrent ischemia (90.4 versus 91.2 percent); a higher one-year survival was seen in patients presenting with unstable angina (93 percent, p &lt;0.001).</div><div class=\"graphic_reference\">Redrawn from Armstrong PW, Fu Y, Chang WC, et al, for the GUSTO-IIb Investigators. Circulation 1998; 98:1860.</div><div id=\"graphicVersion\">Graphic 61809 Version 4.0</div></div></div>"},"61810":{"type":"graphic_table","displayName":"Treatment of giardiasis","title":"Treatment of giardiasis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of giardiasis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"2\" width=\"42%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Drug</td> <td class=\"subtitle1\" colspan=\"2\">Dose</td> </tr> <tr> <td class=\"subtitle2\">Adults</td> <td class=\"subtitle2\">Children</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Drugs of choice</td> </tr> <tr> <td class=\"indent1\">Tinidazole*</td> <td>2 g orally, single dose</td> <td>Age &#8805;3 years: 50 mg/kg orally, single dose (maximum dose 2 g)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Nitazoxanide<sup>&#182;</sup></td> <td>500 mg orally two times per day for three days</td> <td> <p>Age 1 to 3 years: 100 mg orally two times per day for 3 days</p> <p>Age 4 to 11 years: 200 mg orally two times per day for 3 days</p> Age &#8805;12 years: Same as adult dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Alternative agents</td> </tr> <tr> <td class=\"indent1\">Metronidazole</td> <td>500 mg orally twice daily OR 250 mg orally three times per day; duration 5 to 7 days</td> <td>15 mg/kg orally divided three times per day for 5 to 7 days (maximum 250 mg per dose)</td> </tr> <tr> <td class=\"indent1\">Albendazole </td> <td>400 mg orally once daily for 5 days</td> <td>10 to 15 mg/kg orally once daily for 5 days (maximum 400 mg per dose)</td> </tr> <tr> <td class=\"indent1\">Mebendazole</td> <td>200 mg orally three times per day for 5 days</td> <td>200 mg orally three times per day for 5 days</td> </tr> <tr> <td class=\"indent1\">Paromomycin<sup>&#916;</sup></td> <td>10 mg/kg orally three times per day for 5 to 10 days</td> <td>10 mg/kg orally three times per day for 5 to 10 days</td> </tr> <tr> <td class=\"indent1\">Furazolidone<sup>&#9674;</sup></td> <td>100 mg orally four times per day for 7 to 10 days</td> <td>2&nbsp;mg/kg orally four times per day for 7 to 10 days (maximum 100 mg per dose)</td> </tr> <tr> <td class=\"indent1\">Quinacrine</td> <td>100 mg orally three times per day for 5 days</td> <td>2 mg/kg orally three times per day for&nbsp;5 days (maximum 100 mg per dose)<sup>&#167;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to the UpToDate&nbsp;text for additional information regarding choice of therapy, approach to recurrent or refractory infection, and drug availability.</div><div class=\"graphic_footnotes\">* Tinidazole has US Food and Drug Administration (FDA) approval for treatment of giardiasis in patients &gt;3 years of age.<br />¶ Nitazoxanide has FDA approval for treatment of giardiasis in patients &gt;1 year of age.<br />Δ Poor intestinal absorption; it may be useful for treatment of giardiasis in pregnancy.<br />◊ Potentially significant drug and food interactions with use greater than 5 days due to monoamine oxidase inhibition. Refer to drug information section for additional information.<br />§ Use of quinacrine for treatment of giardiasis in children is reserved for refractory cases.</div><div id=\"graphicVersion\">Graphic 61810 Version 9.0</div></div></div>"},"61811":{"type":"graphic_algorithm","displayName":"Traumatic neck stiffness in children","title":"Neck stiffness or torticollis following trauma in children","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Neck stiffness or torticollis following trauma in children</div><div class=\"cntnt\"><img style=\"width:540px; height:338px;\" src=\"images/EM/61811_Neck_stiff_trauma_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">C-spine: cervical spine.<br />* May coexist with a spinal fracture, subluxation or ligamentous injury.</div><div id=\"graphicVersion\">Graphic 61811 Version 4.0</div></div></div>"},"61816":{"type":"graphic_figure","displayName":"Spleen anatomy PI","title":"Organs inside the abdomen","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Organs inside the abdomen</div><div class=\"cntnt\"><img style=\"width:517px; height:576px;\" src=\"images/PI/61816_Spleen_anatomy_PI_edt.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 61816 Version 4.0</div></div></div>"},"61817":{"type":"graphic_figure","displayName":"Dobut response outcome CABG","title":"Response to dobutamine predicts regional ventricular function recovery after bypass surgery","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Response to dobutamine predicts regional ventricular function recovery after bypass surgery</div><div class=\"cntnt\"><img style=\"width:521px; height:211px;\" src=\"images/CARD/61817_DobutresponseoutcomeCABG.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left ventricular segments that show a biphasic response with a dobutamine echocardiogram (improvement with low-dose dobutamine followed by deterioration at higher doses) have the best functional improvement three months after surgery. Segments that show improvement only, worsen, or do not change have little likelihood of recovery.</div><div class=\"graphic_reference\">Data from: Cornel JH, Bax JJ, Elhendy A, et al. J Am Coll Cardiol 1998; 31:1002.</div><div id=\"graphicVersion\">Graphic 61817 Version 3.0</div></div></div>"},"61818":{"type":"graphic_diagnosticimage","displayName":"Radiograph onion skinning Ewing sarcoma","title":"Radiograph onion skinning Ewing sarcoma","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Radiograph onion skinning Ewing sarcoma</div><div class=\"cntnt\"><img style=\"width:477px; height:365px;\" src=\"images/ONC/61818_Radiograph_onion_skinning_E.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">\"Onion skin\" periosteal reaction AP (left panel) and lateral (right panel) view of the distal femur in a 15-year-old girl with Ewing sarcoma. Multiple layers of periosteal reaction simulate the appearance of the layers of an onion's skin. Note the disruption of the outermost layer and the soft tissue mass, suggestive of a malignant process.</div><div class=\"graphic_footnotes\">AP: anteroposterior.</div><div class=\"graphic_reference\">Courtesy of the Department of Diagnostic Imaging, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 61818 Version 5.0</div></div></div>"},"61820":{"type":"graphic_waveform","displayName":"Intermediate case 8","title":"Intermediate case 8","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intermediate case 8</div><div class=\"cntnt\"><img style=\"width:450px; height:98px;\" src=\"images/CARD/61820_Intermediate_case_8.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 61820 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"61821":{"type":"graphic_figure","displayName":"Attenuation of beta agonist effect in EIB","title":"Attenuation of salmeterol effect in exercise-induced bronchoconstriction","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Attenuation of salmeterol effect in exercise-induced bronchoconstriction</div><div class=\"cntnt\"><img style=\"width:551px; height:268px;\" src=\"images/PULM/61821_Attenuation_of_B_agonist_in.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Percentage fall in FEV1 induced by exercise after the first dose and after four weeks of therapy with placebo or continuous salmeterol (50 &#181;g twice daily). Salmeterol minimized the fall in FEV1 after the first dose compared to placebo but the difference was much smaller and not significant at four weeks.</div><div class=\"graphic_footnotes\">FEV1: forced expiratory volume in one second.</div><div class=\"graphic_reference\">Data from Ramage L, Lipworth BJ, Ingram CG, et al, Respir Med 1994; 88:363.</div><div id=\"graphicVersion\">Graphic 61821 Version 2.0</div></div></div>"},"61822":{"type":"graphic_picture","displayName":"Rosacea rhinophyma","title":"Rhinophyma in rosacea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rhinophyma in rosacea</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/61822_Rosacea_rhinophyma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Marked distortion of the nose is present in this patient with severe rhinophymatous rosacea.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 61822 Version 3.0</div></div></div>"},"61824":{"type":"graphic_diagnosticimage","displayName":"CT dilated small intestine","title":"Small bowel obstruction CT (coronal images)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Small bowel obstruction CT (coronal images)</div><div class=\"cntnt\"><img style=\"width:359px; height:432px;\" src=\"images/GAST/61824_CT_dilated_small_intestine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small bowel obstruction seen by CT scan (coronal images) showing dilated, fluid-filled loops of small intestine.</div><div class=\"graphic_reference\">Courtesy of Richard A Hodin, MD.</div><div id=\"graphicVersion\">Graphic 61824 Version 3.0</div></div></div>"},"61826":{"type":"graphic_picture","displayName":"Choroidal tuberculosis","title":"Choroidal tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Choroidal tuberculosis</div><div class=\"cntnt\"><img style=\"width:455px; height:216px;\" src=\"images/ID/61826_Choroidal_tuberculosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Miliary choroids (tubercles) appear as ill-defined nodules varying in size from pinpoint to several disc diameters on funduscopic examination.</div><div class=\"graphic_reference\">Reprinted with permission. Copyright © American Society of Contemporary Ophthalmology. Annals of Ophthalmology 1989.21(6);226.</div><div id=\"graphicVersion\">Graphic 61826 Version 6.0</div></div></div>"},"61827":{"type":"graphic_picture","displayName":"Uric acid crystals in the urine","title":"Uric acid crystals in the urine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uric acid crystals in the urine</div><div class=\"cntnt\"><img style=\"width:378px; height:252px;\" src=\"images/NEPH/61827_Uric_acid_crystals.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urine sediment loaded with uric acid crystals. These crystals are pleomorphic, most often appearing as rhombic plates or rosettes. They are yellow or reddish-brown and form only in an acid urine (pH 5.5 or less).</div><div class=\"graphic_reference\">Courtesy of Harvard Medical School.</div><div id=\"graphicVersion\">Graphic 61827 Version 3.0</div></div></div>"},"61829":{"type":"graphic_table","displayName":"Foster care resources","title":"Resources for clinicians and parents caring for children in foster care","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Resources for clinicians and parents caring for children in foster care</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Resource</td> <td class=\"subtitle1\">Web address/description</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">American Academy of Pediatrics:</td> </tr> <tr> <td class=\"indent1\">- Healthy Foster Care America</td> <td><a href=\"http://www.aap.org/fostercare\" target=\"_blank\">www.aap.org/fostercare</a></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">- Healthy children.org: Adoption &#38; Foster Care</td> <td><a href=\"https://www.healthychildren.org/English/family-life/family-dynamics/adoption-and-foster-care/Pages/default.aspx\" spellcheck=\"true\" target=\"_blank\">www.healthychildren.org/English/family-life/family-dynamics/adoption-and-foster-care/Pages/default.aspx</a></td> </tr> <tr class=\"divider_bottom\"> <td>American Academy of Child and Adolescent Psychiatry</td> <td> <p><a href=\"http://www.aacap.org/\" target=\"_blank\">www.aacap.org</a></p> Helpful information for children with mental health needs</td> </tr> <tr class=\"divider_bottom\"> <td>The Annie E. Casey Family Foundation</td> <td><a href=\"http://www.aecf.org/OurWork/ChildWelfarePermanence.aspx\" target=\"_blank\">www.aecf.org/OurWork/ChildWelfarePermanence.aspx</a></td> </tr> <tr class=\"divider_bottom\"> <td>California Evidence-Based Clearinghouse for Child Welfare</td> <td><a href=\"http://www.cebc4cw.org/\" target=\"_blank\">www.cebc4cw.org</a></td> </tr> <tr class=\"divider_bottom\"> <td>Chapin Hall</td> <td> <p><a href=\"http://www.chapinhall.org/research/areas/child-welfare-and-foster-care-systems\" target=\"_blank\">www.chapinhall.org/research/areas/child-welfare-and-foster-care-systems</a></p> Has information on child welfare and maltreatment prevention</td> </tr> <tr class=\"divider_bottom\"> <td>Child Welfare League of America</td> <td><a href=\"http://www.cwla.org/\" target=\"_blank\">www.cwla.org</a></td> </tr> <tr class=\"divider_bottom\"> <td>Harvard University Center for the Developing Child</td> <td> <p><a href=\"http://developingchild.harvard.edu/\" target=\"_blank\">developingchild.harvard.edu</a></p> Provides information about the effects of toxic stress</td> </tr> <tr class=\"divider_bottom\"> <td>National Center for Medical Home Implementation</td> <td><a href=\"http://www.medicalhomeinfo.org/\" target=\"_blank\">www.medicalhomeinfo.org</a></td> </tr> <tr class=\"divider_bottom\"> <td>National Child Traumatic Stress Network</td> <td><a href=\"http://www.nctsn.org/\" target=\"_blank\">www.nctsn.org</a></td> </tr> <tr> <td>Zero to Three</td> <td> <p><a href=\"http://www.zerotothree.org/about-us/areas-of-expertise/free-parent-brochures-and-guides/age-based-handouts.html\" target=\"_blank\">www.zerotothree.org/about-us/areas-of-expertise/free-parent-brochures-and-guides/age-based-handouts.html</a></p> Has information specifically for young children and a section aimed at parent education</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 61829 Version 9.0</div></div></div>"},"61830":{"type":"graphic_table","displayName":"Canaliculoocular reflexes","title":"The canaliculoocular reflexes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The canaliculoocular reflexes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Canal</td> <td class=\"subtitle1\">Preferred head motion</td> <td class=\"subtitle1\">Eye muscles excited</td> <td class=\"subtitle1\">Resulting eye motion</td> </tr> <tr> <td>Right horizontal</td> <td>Right turn</td> <td> <p>Left lateral rectus</p> <p>Right medial rectus</p> </td> <td>Leftward</td> </tr> <tr> <td>Right anterior</td> <td> <p>Neck flexion</p> <p>Right head tilt</p> </td> <td> <p>Right superior rectus</p> <p>Left inferior oblique</p> </td> <td> <p>Elevation (right gaze)</p> <p>Counterclockwise torsion (left gaze)</p> </td> </tr> <tr> <td>Right posterior</td> <td> <p>Neck extension</p> <p>Right head tilt</p> </td> <td> <p>Left inferior rectus</p> <p>Right superior oblique</p> </td> <td> <p>Depression (left gaze)</p> <p>Counterclockwise torsion (right gaze)</p> </td> </tr> <tr> <td>Left horizontal</td> <td>Left turn</td> <td> <p>Right lateral rectus</p> <p>Left medial rectus</p> </td> <td>Rightward</td> </tr> <tr> <td>Left anterior</td> <td> <p>Neck flexion</p> <p>Left head tilt</p> </td> <td> <p>Left superior rectus</p> <p>Right inferior oblique</p> </td> <td> <p>Elevation (left gaze)</p> <p>Clockwise torsion (right gaze)</p> </td> </tr> <tr> <td>Left posterior</td> <td> <p>Neck extension</p> <p>Left head tilt</p> </td> <td> <p>Right inferior rectus</p> <p>Left superior oblique</p> </td> <td> <p>Depression (right gaze)</p> <p>Clockwise torsion (left gaze)</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Head and eye rotations are described from the point of view of the patient. As examples, a right head tilt is a clockwise rotation of the head; counterclockwise torsion of the eyes means that the superior pole of the eyes are tilted to the left.</div><div class=\"graphic_footnotes\">Right gaze: maximally in right gaze; left gaze: maximally in left gaze.</div><div id=\"graphicVersion\">Graphic 61830 Version 3.0</div></div></div>"},"61831":{"type":"graphic_table","displayName":"Hormonally active herbs","title":"Hormonally active herbal ingredients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hormonally active herbal ingredients</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Drug</td>\n<td class=\"subtitle1\">Effect</td>\n</tr>\n<tr>\n<td>Agnus castus</td>\n<td>Many uses in hormonal imbalance disorders</td>\n</tr>\n<tr>\n<td>Alfalfa</td>\n<td>Estrogenic, in vivo</td>\n</tr>\n<tr>\n<td>Aniseed</td>\n<td>Estrogenic</td>\n</tr>\n<tr>\n<td>Bayberry</td>\n<td>Mineralocorticoid</td>\n</tr>\n<tr>\n<td>Cohosh, black</td>\n<td>Estrogenic</td>\n</tr>\n<tr>\n<td>Fucus</td>\n<td>Hyper-/hypothyroidism reported</td>\n</tr>\n<tr>\n<td>Ginsengs</td>\n<td>Estrogenic, human</td>\n</tr>\n<tr>\n<td>Horseradish</td>\n<td>May depress thyroid activity</td>\n</tr>\n<tr>\n<td>Liquorice</td>\n<td>Mineralocorticoid activity, human; estrogenic in vivo, in vitro</td>\n</tr>\n<tr>\n<td>Motherwort</td>\n<td>Oxytoxic</td>\n</tr>\n<tr>\n<td>Pleurisy root</td>\n<td>Estrogenic</td>\n</tr>\n<tr>\n<td>Red clover</td>\n<td>Estrogenic in vivo</td>\n</tr>\n<tr>\n<td>Saw palmetto</td>\n<td>Estrogenic and antiadrogenic in vivo; human use in prostate cancer</td>\n</tr>\n<tr>\n<td>Vervain</td>\n<td>Inhibition of gonadotrophic activity</td>\n</tr>\n<tr>\n<td>Wild carrot</td>\n<td>Estrogenic</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted with permission from Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals, The Pharmaceutical Press, London 1996, p.283.</div><div id=\"graphicVersion\">Graphic 61831 Version 2.0</div></div></div>"},"61832":{"type":"graphic_table","displayName":"Differential diagnosis for methamphetamine intoxication","title":"Basic differential diagnosis for methamphetamine intoxication","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Basic differential diagnosis for methamphetamine intoxication</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Toxicologic</td> </tr> <tr> <td>Cocaine</td> </tr> <tr> <td>PCP (phencyclidine)/ketamine</td> </tr> <tr> <td>Synthetic cathinones and other synthetic phenethylamines&nbsp;</td> </tr> <tr> <td>Anticholinergic agents</td> </tr> <tr> <td>Salicylates</td> </tr> <tr> <td>Lithium</td> </tr> <tr> <td>MAOI (monoamine oxidase inhibitors)</td> </tr> <tr> <td>Theophylline/caffeine</td> </tr> <tr> <td>LSD (lysergic acid diethylamine)</td> </tr> <tr> <td>Isoniazid/monomethylhydrazine</td> </tr> <tr> <td>Amoxapine</td> </tr> <tr> <td>Tricyclic antidepressants</td> </tr> <tr> <td>Scorpion envenomation (Centruroides sculpturatus)</td> </tr> <tr> <td>Serotonin Syndrome</td> </tr> <tr> <td>Neuroleptic malignant syndrome</td> </tr> <tr> <td>Ethanol/sedative-hypnotic withdrawal</td> </tr> <tr> <td class=\"subtitle1_single\">Nontoxicologic</td> </tr> <tr> <td>Sepsis/meningitis/encephalitis</td> </tr> <tr> <td>Intracerebral hemorrhage or infarction</td> </tr> <tr> <td>Hypoglycemia/hyperglycemia</td> </tr> <tr> <td>Hyperthermia</td> </tr> <tr> <td>Temporal lobe epilepsy</td> </tr> <tr> <td>Thyrotoxicosis</td> </tr> <tr> <td>Pheochromocytoma</td> </tr> <tr> <td>Psychosis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 61832 Version 4.0</div></div></div>"},"61833":{"type":"graphic_table","displayName":"ADA opthalmologic exam schedule","title":"Ophthalmologic examination schedule","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ophthalmologic examination schedule</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Patient group</td> <td class=\"subtitle1\">Recommended first examination</td> <td class=\"subtitle1\">Minimum routine follow-up</td> </tr> <tr> <td> <p>Type 1 diabetes</p> </td> <td> <p>Within 5 years after diagnosis of diabetes once patient is age 10 years or older*</p> </td> <td> <p>Yearly, if retinopathy present<sup>&#182;</sup></p> <p>Every two years if there is no evidence of retinopathy</p> </td> </tr> <tr> <td>Type 2 diabetes</td> <td>At time of diagnosis of diabetes</td> <td> <p>Yearly, if retinopathy present<sup>&#182;</sup></p> <p>Every two years if there is no evidence of retinopathy</p> </td> </tr> <tr> <td>Pregnancy in preexisting diabetes</td> <td>Prior to conception and during first trimester. Counsel on the risk of development and/or progression of retinopathy.</td> <td>Close follow-up throughout pregnancy and for one year postpartum</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Some evidence suggests that the prepubertal duration of diabetes may be important in the development of microvascular complications; therefore, clinical judgment should be used when applying these recommendations to individual patients.<br />¶ Abnormal findings necessitate more frequent follow-up.</div><div class=\"graphic_reference\">Copyright &copy; 2004 American Diabetes Association From Diabetes Care Vol 27, Supplement 1, 2004. Reprinted with permission from The American Diabetes Association. Updated from American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care 2014; 37 Suppl 1:S14.</div><div id=\"graphicVersion\">Graphic 61833 Version 3.0</div></div></div>"},"61834":{"type":"graphic_figure","displayName":"Sulfonamide antimicrobial","title":"Sulfonamide antimicrobial","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sulfonamide antimicrobial</div><div class=\"cntnt\"><img style=\"width:312px; height:169px;\" src=\"images/ALLRG/61834_Sulfonamide_antimicrobial.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The antimicrobial sulfonamides contain a sulfonamide moiety, an arylamine moiety, and a substituted aromatic ring (R).</div><div id=\"graphicVersion\">Graphic 61834 Version 1.0</div></div></div>"},"61836":{"type":"graphic_diagnosticimage","displayName":"Hemoperitoneum pelvis","title":"Female pelvic hemoperitoneum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Female pelvic hemoperitoneum</div><div class=\"cntnt\"><img style=\"width:364px; height:567px;\" src=\"images/OBGYN/61836_Hemoperitoneum_pelvis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Sagittal view of the cul-de-sac shows complex fluid (F) posterior to the cervix (Cx). B) This patient also had an adnexal mass (arrows) consistent with an ectopic pregnancy.</div><div class=\"graphic_footnotes\">O: ovary.</div><div class=\"graphic_reference\">Courtesy of Tejas S Mehta, MD, MPH.</div><div id=\"graphicVersion\">Graphic 61836 Version 3.0</div></div></div>"},"61837":{"type":"graphic_diagnosticimage","displayName":"Tubal preg heartbeat","title":"Tubal pregnancy with cardiac activity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tubal pregnancy with cardiac activity</div><div class=\"cntnt\"><img style=\"width:364px; height:530px;\" src=\"images/OBGYN/61837_Tubal_preg_heartbeat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal images show A) a left ovary with corpus luteum (LO) and an adjacent tubal ring (arrow) with internal contents within the sac. B) Closer inspection of the internal contents with m-mode showed cardiac activity in a live ectopic pregnancy.</div><div class=\"graphic_footnotes\">CX: cervix.</div><div class=\"graphic_reference\">Courtesy of Tejas S Mehta, MD, MPH.</div><div id=\"graphicVersion\">Graphic 61837 Version 2.0</div></div></div>"},"61838":{"type":"graphic_picture","displayName":"Asbestos body Photomicrograph","title":"Asbestos body","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Asbestos body</div><div class=\"cntnt\"><img style=\"width:432px; height:294px;\" src=\"images/PULM/61838_Asbestos_body_Photomicrogra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph shows a dumbbell-shaped asbestos body in a bronchoalveolar lavage specimen from a patient with a history of occupational asbestos exposure. Asbestos bodies differ from other nonasbestos ferruginous bodies in that the central core is thin and colorless and is covered by hemosiderin distributed in a characteristic beaded fashion.</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 61838 Version 1.0</div></div></div>"},"61839":{"type":"graphic_waveform","displayName":"Pressure tracings pericarditis","title":"Pressure tracings in constrictive pericarditis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pressure tracings in constrictive pericarditis</div><div class=\"cntnt\"><img style=\"width:443px; height:272px;\" src=\"images/PULM/61839_Pressure_tracings_pericardi.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abnormal right atrial and ventricular pressure waveforms in a patient with constrictive pericarditis. Note the elevation and equalization of end-diastolic pressures, with a characteristic &quot;dip and plateau&quot; (or &quot;square-root sign&quot;). The steep Y descent reflects rapid early ventricular filling as right atrial emptying is rapid and unimpeded. The nadir of the Y descent reflects abrupt cessation of early diastolic ventricular filling. A similar pattern may be seen in cardiac tamponade or restrictive cardiomyopathy.</div><div id=\"graphicVersion\">Graphic 61839 Version 2.0</div></div></div>"},"61840":{"type":"graphic_picture","displayName":"Thymic squamous cell carcinoma","title":"Poorly differentiated squamous cell carcinoma of the thymus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Poorly differentiated squamous cell carcinoma of the thymus</div><div class=\"cntnt\"><img style=\"width:360px; height:233px;\" src=\"images/PULM/61840_Thymic_squamous_cell_carcin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The multilobulated appearance of a thymoma is lacking. This tumor is composed of highly atypical cells with pleomorphic nuclei and a high mitotic rate. Although immature lymphocytes of T cell type are missing, a lymphoplasmacytic reaction can be prominent. (Hematoxylin and eosin, magnification 50x).</div><div class=\"graphic_reference\">Courtesy of William Travis, MD.</div><div id=\"graphicVersion\">Graphic 61840 Version 1.0</div></div></div>"},"61841":{"type":"graphic_figure","displayName":"Groin hernia anatomy","title":"Groin hernia anatomy","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Groin hernia anatomy</div><div class=\"cntnt\"><img style=\"width:501px; height:545px;\" src=\"images/SURG/61841_Groin_hernia_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Indirect inguinal hernias develop at the internal inguinal ring and are lateral to the inferior epigastric artery. Direct inguinal hernias occur through Hesselbach's triangle (outlined in blue) formed by the inguinal ligament inferiorly, the inferior epigastric vessels laterally, and the rectus muscle medially. Femoral hernias develop in the empty space at the medial aspect of the femoral canal, inferior to the inguinal ligament.</div><div id=\"graphicVersion\">Graphic 61841 Version 2.0</div></div></div>"},"61842":{"type":"graphic_picture","displayName":"Livedo reticularis - lower leg","title":"Livedo reticularis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Livedo reticularis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/61842_Livedo_reticular_lower_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A reticulated vascular network is present on the lower leg.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 61842 Version 4.0</div></div></div>"},"61843":{"type":"graphic_figure","displayName":"Lesser sac - Sagittal section","title":"Lesser sac - Sagittal section","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Lesser sac - Sagittal section</div><div class=\"cntnt\"><img style=\"width:484px; height:527px;\" src=\"images/SURG/61843_Lesser-sac---sagittal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This sagittal view&#160;figure depicts the relationship of the lesser sac with the stomach, transverse mesocolon, head of the pancreas, transverse colon, omentum, and mesentery of&#160;the small bowel.</div><div id=\"graphicVersion\">Graphic 61843 Version 1.0</div></div></div>"},"61844":{"type":"graphic_table","displayName":"Clinically important anaerobes","title":"Clinically important and most frequently isolated anaerobes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinically important and most frequently isolated anaerobes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Gram-negative bacteria</td> </tr> <tr> <td><em>Bacteroides fragilis</em> group: <em>B. fragilis</em>, <em>B. thetaiotaomicron</em>, <em>B. distasonis</em>, <em>B. ovatus</em>, <em>B. vulgatus</em></td> </tr> <tr> <td>Pigmented <em>Prevotella</em> (formerly <em>Bacteroides</em>): <em>P. intermedia</em>, <em>P. melaninogenica</em>, <em>P. corporis</em>, <em>P. denticola</em>, <em>P. loescheii</em>, <em>P. nigrescens</em></td> </tr> <tr> <td><em>Prevotella</em> (other): <em>P. bivia</em> (formerly <em>B. bivius</em>), <em>P. disiens</em> (formerly <em>B. disiens</em>), <em>P. oralis</em> (formerly <em>B. oralis</em>)</td> </tr> <tr> <td><em>Porphyromonas asaccharolytica</em> (formerly B. <em>asaccharolyticus</em>)</td> </tr> <tr> <td><em>Fusobacterium</em>: <em>F. nucleatum</em>, <em>F. necrophorum</em>, <em>F. varium</em></td> </tr> <tr> <td><em>Bilophila</em>: <em>B. wadsworthia</em></td> </tr> <tr> <td class=\"subtitle1_single\">Gram-positive cocci</td> </tr> <tr> <td><em>Peptostreptococcus</em>: <em>P. intermedius</em>, <em>P. micros</em>, <em>P. anaerobius</em>, <em>P. magnus</em>, <em>P. asaccharolyticus</em>, <em>P. prevotii</em></td> </tr> <tr> <td class=\"subtitle1_single\">Gram-positive, spore-forming bacilli</td> </tr> <tr> <td><em>Clostridium</em>: <em>C. perfringens</em>, <em>C. difficile</em>, <em>C. sporogenes</em>, <em>C. sordellii</em>, <em>C. septicum</em>, <em>C. tertium</em>,<em> C. ramosum</em>, <em>C. novyi</em>, <em>C. histolyticum</em>, <em>C. bifermentans</em>, <em>C. innocuum</em>, <em>C. tetani</em>, <em>C. botulinum</em></td> </tr> <tr> <td class=\"subtitle1_single\">Gram-positive, non-spore-forming bacilli</td> </tr> <tr> <td><em>Cutibacterium </em>(formerly <em>Propionibacterium</em>):&nbsp;<em>C. acnes</em></td> </tr> <tr> <td><em>Eubacterium</em>: <em>E. lentum</em></td> </tr> <tr> <td><em>Bifidobacterium</em>: <em>B. dentium</em></td> </tr> <tr> <td><em>Actinomyces</em>: <em>A. israelii</em>, <em>A. naeslundii</em>, <em>A. odontolyticus</em>, <em>A. viscosus</em></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 61844 Version 4.0</div></div></div>"},"61845":{"type":"graphic_table","displayName":"Rx enterococci mening","title":"Antibiotic regimens for meningitis due to susceptible <EM>Enterococcus</EM> strains* in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibiotic regimens for meningitis due to susceptible <EM>Enterococcus</EM> strains* in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Dose and route</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">One of the following:</td> </tr> <tr> <td class=\"indent1\">Ampicillin<sup>&#182;&#916;</sup></td> <td>12 to 18+ g per 24 hours in six equally divided doses</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ceftriaxone</td> <td>4 g IV per 24 hours in two equally divided doses</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">PLUS one of the following<sup>&#9674;</sup>:</td> </tr> <tr> <td class=\"indent1\">Gentamicin</td> <td>5.1 to 7 mg/kg IV&nbsp;per 24 hours (single daily dosing)</td> </tr> <tr> <td class=\"indent1\">Streptomycin</td> <td>15 mg/kg IV per 24 hours (single daily dosing)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenously.<br />* For patients failing to respond to systemic antibiotics, intraventricular vancomycin or gentamicin may be useful. Treatment of enterococcal meningitis caused by <EM>E. faecium </EM>strains resistant to penicillin, aminoglycosides, and vancomycin is a difficult challenge; intravenous linezolid or intravenous plus intraventricular quinupristin-dalfopristin or daptomycin are reasonable antibiotic choices, although experience with intraventricular administration is limited (refer to the UpToDate topic on infections of central nervous system shunts and other devices). Daptomycin plus tigecycline has been used as well as high-dose daptomycin plus linezolid or gentamicin.<br />¶ Penicillin G (18 to 30+ million units per 24 hours) may be used in place of ampicillin for susceptible isolates. Ampicillin-sulbactam may be used in place of ampicillin for treatment of beta-lactamase-producing enterococci, which are very rare. The combination of ampicillin with imipenem is a potential alternative regimen.<br />Δ Vancomycin (30 mg/kg IV per 24 hours in two equally divided doses) is an alternative for patients unable to tolerate beta-lactam agents; goal vancomycin trough is 15 to 20 mcg/mL. An initial vancomycin loading dose of 25 to 30 mg/kg may be use to reduce the time to achieve target trough concentrations for patients with serious infections such as meningitis. In addition, repeat cerebrospinal fluid (CSF) evaluation to evaluate for sterilization and vancomycin levels is advisable. Rifampin may be added to vancomycin (if susceptible).<br />◊ No data exist to indicate that single-dose aminoglycoside therapy is superior to divided-dose therapy, but higher serum peaks may result in higher CSF levels. Serum aminoglycoside levels should be monitored (gentamicin goal peak 16 to 24 mcg per mL, goal trough &lt;1 mcg/mL; streptomycin goal peak 56 to 64 mcg per mL, goal trough &lt;1 mcg/mL). If aminoglycosides are administered together with vancomycin, aminoglycoside dose reduction may be warranted to minimize toxicity.</div><div id=\"graphicVersion\">Graphic 61845 Version 8.0</div></div></div>"},"61846":{"type":"graphic_movie","displayName":"Flail mitral leaflet apical long axis color Doppler echo","title":"Flail mitral valve with mitral regurgitation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flail mitral valve with mitral regurgitation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/61846_aplacfmvconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:259px; height:438px;\" src=\"images/CARD/61846_aplacfmv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The apical long axis view from a 2-D echocardiogram with color flow Doppler shows significant mitral regurgitation due to a flail posterior leaflet of the mitral valve.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 61846 Version 2.0</div></div></div>"},"61847":{"type":"graphic_figure","displayName":"Culprit lesion wall motion","title":"Relationship of two-dimensional views and coronary artery perfusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Relationship of two-dimensional views and coronary artery perfusion</div><div class=\"cntnt\"><img style=\"width:319px; height:385px;\" src=\"images/CARD/61847_Culprit_lesion_wall_motion.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 61847 Version 1.0</div></div></div>"},"61849":{"type":"graphic_table","displayName":"Assess calcium intake","title":"Assessment of calcium intake and risks for suboptimal bone health in infants, children, and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessment of calcium intake and risks for suboptimal bone health in infants, children, and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Calcium intake questions</td> <td class=\"subtitle1\">Approximate calcium content*</td> </tr> <tr> <td rowspan=\"4\">Intake&nbsp;of&nbsp;unflavored (\"white\") or flavored milk</td> <td>1 cup whole milk: 246 mg</td> </tr> <tr> <td>1 cup 1% milk: 264 mg</td> </tr> <tr> <td>1 cup nonfat milk: 223 mg </td> </tr> <tr> <td>1 cup calcium fortified soy milk: 200 to 500 mg</td> </tr> <tr> <td rowspan=\"5\">Intake of cheese, yogurt, yogurt drinks, or other dairy products</td> <td>1 oz cheese: 202 mg</td> </tr> <tr> <td>3/4 oz processed cheese: 144 mg</td> </tr> <tr> <td>1/2 cup part skim ricotta: 337 mg </td> </tr> <tr> <td>6 oz nonfat yogurt: 258 mg</td> </tr> <tr> <td>1/2 cup frozen vanilla yogurt: 103 mg</td> </tr> <tr> <td>Intake of&nbsp;calcium-fortified juices</td> <td>1 cup: 300 mg</td> </tr> <tr> <td rowspan=\"3\">Intake&nbsp;of calcium-fortified foods such as cereals or breads</td> <td>3/4 to 1 cup breakfast cereal: 100 mg</td> </tr> <tr> <td>1/2 cup fortified instant oatmeal (made with water): 65 mg</td> </tr> <tr> <td>1 calcium enriched English muffin: 99 mg</td> </tr> <tr> <td rowspan=\"5\">Intake of&nbsp;broccoli, beans, cooked greens, or tofu</td> <td>1 cup cooked, chopped broccoli: 62 mg</td> </tr> <tr> <td>1 cup cooked white beans: 161 mg</td> </tr> <tr> <td>1 cup canned baked beans mg: 127 mg</td> </tr> <tr> <td>1 cup cooked, chopped greens: 266 mg</td> </tr> <tr> <td>1/2 cup tofu: 204 mg</td> </tr> <tr> <td>Intake of&nbsp;calcium supplements (including those containing vitamins)</td> <td>Varies depending upon the supplement</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Bone health questions</td> </tr> <tr> <td colspan=\"2\">Intake&nbsp;of&nbsp;sweetened drinks (soft drinks, fruit drinks, etc)</td> </tr> <tr> <td colspan=\"2\">Frequency of&nbsp;participation in vigorous weight-bearing physical activity</td> </tr> <tr> <td colspan=\"2\">Has the child had any bone fractures?</td> </tr> <tr> <td colspan=\"2\">Was&nbsp;the child born prematurely?</td> </tr> <tr> <td colspan=\"2\">Family history of osteoporosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Source: U.S. Department of Agriculture, Agriculture Research Service. U.S. Department of Agriculture NutrientData Laboratory.</div><div class=\"graphic_reference\">Adapted with permission from Greer, FR, Krebs, NF. Optimizing bone health and calcium intakes of infants, children, and adolescents. Pediatrics 2006; 117:578.</div><div id=\"graphicVersion\">Graphic 61849 Version 2.0</div></div></div>"},"61850":{"type":"graphic_table","displayName":"Mindfulness-based cognitive therapy handout","title":"Mindfulness-based cognitive therapy handout","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mindfulness-based cognitive therapy handout</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">What you can expect in joining this group</td> </tr> <tr> <td>(Please read this handout before we meet)</td> </tr> <tr> <td class=\"subtitle2_single\">Depression</td> </tr> <tr> <td class=\"indent1\">Depression is a common problem. Twenty percent of adults become severely depressed at some point in their lives. Depression involves both biologic changes in the way the brain works and psychological changes in the way one thinks and feels. Thus, it is often useful to treat depression by combining medical treatments (that act on the brain) with psychological approaches (that teach new ways to deal with thoughts and feelings).</td> </tr> <tr> <td class=\"subtitle2_single\">Treatment of depression</td> </tr> <tr> <td class=\"indent1\"> <p>When you have been depressed in the past, your doctor may have prescribed antidepressant medication. This works through changes in the chemical messengers in your brain. In depression, these chemical messengers have often become abnormal, lowering mood and energy levels, and disturbing sleep and appetite. Correcting these brain chemicals may have taken time, but many people improve after six to eight weeks.</p> <p>Although antidepressants generally work well in reducing depression, they are not a permanent cure; their effects continue only so long as you keep taking the pills. Your doctor can continue to prescribe antidepressants for months or years, and this is now recommended for patients if further depression is to be prevented with medication.</p> However, many people prefer to use other ways to prevent further depression. This is the purpose of the classes for learning mindfulness-based cognitive therapy.</td> </tr> <tr> <td class=\"subtitle2_single\">Delaying or preventing more depression</td> </tr> <tr> <td class=\"indent1\"> <p>Whatever caused your depression in the first place, the experience of depression has a number of after-effects. Once you have been depressed, you are likely to become depressed again. The purpose of these classes is to improve your chance of preventing further depression. In the classes, you will learn skills that will help you to handle your thoughts and feelings differently.</p> <p>Since many people have had depression and are at risk for further depression, you will learn these skills in a class with up to a dozen other people who have also been depressed and treated with antidepressants. In eight two-hour sessions, the class will meet to learn new ways of dealing with what goes on in our minds, and to share and review experiences with other class members.</p> After the eight weekly sessions are over, the class will meet again four times over the following few months for reunions and to see how things are progressing.</td> </tr> <tr> <td class=\"subtitle2_single\">Homework: The importance of practice in between classes</td> </tr> <tr> <td class=\"indent1\"> <p>We will work together to change the patterns of mind that have often been around for a long time. These patterns may have become a habit. We can only expect to succeed in making changes if we put time and effort into learning new skills.</p> This approach depends entirely on your willingness to practice your skills at home in between class meetings. This homework will take at least an hour a day, six days a week, for eight weeks, and involves tasks such as listening to CDs, performing brief exercises, and other activities. We appreciate that it is often difficult to carve out that amount of time for something new in lives that are already busy and crowded. However, the commitment to spend time on home practice is an essential part of the class; if you do not feel able to make that commitment, it would be best not to start the classes.</td> </tr> <tr> <td class=\"subtitle2_single\">Facing difficulties</td> </tr> <tr> <td class=\"indent1\"> <p>The classes and home practice assignments can teach you how to be more fully aware and present in each moment of life. The good news is that this makes life more interesting, vivid, and fulfilling. On the other hand, this means facing what is present, even when it is unpleasant and difficult. In practice, you will find that facing and acknowledging difficulties is the most effective way to reduce unhappiness in the long run. It is also central to delaying or preventing further depression. Seeing unpleasant feelings, thoughts, or experiences clearly as they arise means that you will be in better shape to \"nip them in the bud,\" before they progress to more intense or persistent depressions.</p> In the classes, you will learn gentle ways to face difficulties, and will be supported by the instructor and the other class members.</td> </tr> <tr> <td class=\"subtitle2_single\">Patience and persistence</td> </tr> <tr> <td class=\"indent1\"> <p>Because we will be working to change well-established habits of mind, it will mean putting in a lot of time and effort. The effects of this effort may only become apparent later. In many ways, this is much like gardening&#8212;we have to prepare the ground, plant the seeds, ensure that they are adequately watered and nourished, and then wait patiently for results.</p> <p>You may be familiar with this pattern from your treatment with antidepressants&#8212;often there is little benefit until you have been taking the medication for some time. Yet improvement in your depression depended on you continuing to take the antidepressant even when you felt no immediate benefit.</p> In the same way, we ask you to approach the classes and home practice with a spirit of patience and persistence, committing yourself to put time and effort into what will be asked of you, while accepting that the fruits of your efforts may take some time.</td> </tr> <tr> <td class=\"subtitle2_single\">The initial individual meeting</td> </tr> <tr> <td class=\"indent1\">Your initial individual meeting provides an opportunity to ask questions about the classes, or to discuss issues related to the points raised in this handout. You may find it useful, before you come for that interview, to make a note of the points that you wish to raise.</td> </tr> <tr> <td class=\"indent1\">Good luck!</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Segal ZV, Williams JMG, Teasdale JD. Mindfulness Based Cognitive Therapy for Depression. Guilford Press, New York, 2013. Copyright &copy; 2013 Guilford Press. Reprinted with permission of The Guilford Press.</div><div id=\"graphicVersion\">Graphic 61850 Version 10.0</div></div></div>"},"61851":{"type":"graphic_diagnosticimage","displayName":"Flame-shaped occlusion","title":"Flame-shaped occlusion of internal carotid artery from dissection","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Flame-shaped occlusion of internal carotid artery from dissection</div><div class=\"cntnt\"><img style=\"width:504px; height:508px;\" src=\"images/NEURO/61851_Flame_shaped_occlusion_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Digital subtraction angiogram (lateral projection) shows an internal carotid artery occlusion secondary to dissection, as indicated by the typical flame-shaped appearance and location of the occlusion distal to the carotid bifurcation.</div><div class=\"graphic_reference\">Reproduced with permission from: Koch S, Lorenzo D, Rabinstein AA, Lam B. Ischemic optic neuropathy and carotid dissection. Neurology 2005; 64:827. Copyright © 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 61851 Version 5.0</div></div></div>"},"61852":{"type":"graphic_algorithm","displayName":"Algorithm for emergency management of violent patient","title":"Emergency management of the severely agitated or violent patient","html":"<div class=\"graphic\"><div style=\"width: 645px\" class=\"figure\"><div class=\"ttl\">Emergency management of the severely agitated or violent patient</div><div class=\"cntnt\"><img style=\"width:625px; height:775px;\" src=\"images/EM/61852_Mngmnt_violent_pt_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; IM: intramuscular; IV: intravenous; PT: patient.<br />* The safety of atypical antipsychotics in geriatric patients remains uncertain.</div><div id=\"graphicVersion\">Graphic 61852 Version 6.0</div></div></div>"},"61853":{"type":"graphic_table","displayName":"ADA criteria for diagnosis of diabetes","title":"ADA criteria for the diagnosis of diabetes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ADA criteria for the diagnosis of diabetes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <p>1. A1C &#8805;6.5%. The test should be performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay.*</p> <p class=\"indent2\"><strong>OR</strong></p> </td> </tr> <tr> <td> <p>2. FPG &#8805;126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least eight hours.*</p> <p class=\"indent2\"><strong>OR</strong></p> </td> </tr> <tr> <td> <p>3. Two-hour plasma glucose &#8805;200 mg/dL (11.1 mmol/L) during an OGTT. The test should be performed as described by the World Health Organization, using a glucose load containing the equivalent of 75-gram anhydrous glucose dissolved in water.*</p> <p class=\"indent2\"><strong>OR</strong></p> </td> </tr> <tr> <td>4. In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose &#8805;200 mg/dL (11.1 mmol/L).</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ADA: American Diabetes Association; A1C: glycated hemoglobin; NGSP: National Glycohemoglobin Standardization Program; DCCT: Diabetes Control and Complications Trial; FPG: fasting plasma glucose; OGTT: oral glucose tolerance test.<br />* In the absence of unequivocal hyperglycemia, criteria 1 to 3 should be confirmed by repeat testing.</div><div class=\"graphic_reference\">Reprinted with permission from: American Diabetes Association. Standards of Medical Care in Diabetes 2011. Diabetes Care 2011; 34:S11. Copyright © 2011 American Diabetes Association. The content within this table is still current as of the 2018 version of the Standards of Medical Care in Diabetes.</div><div id=\"graphicVersion\">Graphic 61853 Version 13.0</div></div></div>"},"61854":{"type":"graphic_table","displayName":"Causes chylous ascites","title":"Causes of chylous ascites","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of chylous ascites</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n<tbody>\n\t<tr>\n\t\t<td class=\"container\">\n\t\t\t<table cellspacing=\"0\">\n\t\t\t\t<tbody>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"subtitle1_single\">Neoplastic (common in adults)</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Lymphoma</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Other cancers (see text)</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Lymphangiomyomatosis</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Carcinoid tumors</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Kaposi's sarcoma</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"subtitle1_single\">Cirrhosis (common in adults)</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"subtitle1_single\">Congenital (common in children)</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Primary lymphatic hypoplasia</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Yellow nail syndrome</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Klippel-Trenaunay syndrome</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"sublist1_start\">Primary lymphatic hyperplasia</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"sublist1\">Bilateral hyperplasia</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"sublist1\">Intestinal lymphangiectasia</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"subtitle1_single\">Postoperative</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Abdominal aneurysm repair</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Retroperitoneal node dissection</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Catheter placement for peritoneal dialysis</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Inferior vena cava resection</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Laparoscopic nissen fundoplication</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"subtitle1_single\">Other causes</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Right heart failure</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Dilated cardiomyopathy</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Nephrotic syndrome</td>\n\t\t\t\t\t</tr>\n\t\t\t\t</tbody>\n\t\t\t</table>\n\t\t</td>\n\t\t<td class=\"container\">\n\t\t\t<table cellspacing=\"0\">\n\t\t\t\t<tbody>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"subtitle1_single\">Infectious</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Tuberculosis</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Filariasis (Wuchereria bancrofti)</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Mycobacterium avium intracellulare</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"subtitle1_single\">Inflammatory</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Radiation</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Pancreatitis</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Constrictive pericarditits</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Retroperitoneal fibrosis</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Sarcoidosis</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Celiac sprue</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Whipple's disease</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Retractile mesenteritis</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"subtitle1_single\">Trauma</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Blunt abdominal trauma</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Battered child syndrome</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td></td>\n\t\t\t\t\t</tr>\n\t\t\t\t</tbody>\n\t\t\t</table>\n\t\t</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 61854 Version 1.0</div></div></div>"},"61855":{"type":"graphic_table","displayName":"Causes of acute persistent visual loss by anatomy","title":"Causes of acute persistent visual loss by anatomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of acute persistent visual loss by anatomy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Media problems</td> </tr> <tr> <td class=\"sublist1_start\">Keratitis</td> </tr> <tr> <td class=\"sublist1\">&#8226; Infectious or non-infectious</td> </tr> <tr> <td class=\"sublist1_start\">Corneal edema</td> </tr> <tr> <td class=\"sublist1\">&#8226; Acute glaucoma (primarily)</td> </tr> <tr> <td class=\"sublist1_start\">Hyphema</td> </tr> <tr> <td class=\"sublist1\">&#8226; Spontaneous or traumatic</td> </tr> <tr> <td class=\"sublist1_start\">Alterations in crystalline lens</td> </tr> <tr> <td class=\"sublist1\">&#8226; Thickening, clouding or dislocation</td> </tr> <tr> <td class=\"sublist1_start\">Vitreous hemorrhage</td> </tr> <tr> <td class=\"sublist1\">&#8226; Spontaneous or traumatic</td> </tr> <tr> <td>Uveitis</td> </tr> <tr> <td class=\"subtitle1_single\">Retina problems</td> </tr> <tr> <td>Retinal vascular occlusion (CRAO, CRVO)</td> </tr> <tr> <td>Retinal detachment</td> </tr> <tr> <td>Acute maculopathy</td> </tr> <tr> <td class=\"subtitle1_single\">Problems of the neural visual pathway</td> </tr> <tr> <td class=\"sublist1_start\">Optic neuropathy</td> </tr> <tr> <td class=\"sublist1\">&#8226; Ischemia, inflammatory, or infectious process</td> </tr> <tr> <td class=\"sublist1_start\">Papilledema</td> </tr> <tr> <td class=\"sublist1\">&#8226; Elevated intracranial pressure</td> </tr> <tr> <td class=\"sublist1_start\">Chiasmal disorders</td> </tr> <tr> <td class=\"sublist1\">&#8226; Pituitary apoplexy (primarily)</td> </tr> <tr> <td class=\"sublist1_start\">Retrochiasmal disorders</td> </tr> <tr> <td class=\"sublist1\">&#8226; Brain lesions in the visual pathway</td> </tr> <tr> <td class=\"subtitle1_single\">Other considerations</td> </tr> <tr> <td>Trauma as a cause of any of the above</td> </tr> <tr> <td class=\"sublist1_start\">Acute glaucoma</td> </tr> <tr> <td class=\"sublist1\">&#8226; Vision loss due to corneal edema and/or optic nerve ischemia in the setting of severely elevated intraocular pressure</td> </tr> <tr> <td>Functional visual loss</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CRAO: central retinal artery occlusion; CRVO: central retinal vein occlusion.</div><div id=\"graphicVersion\">Graphic 61855 Version 7.0</div></div></div>"},"61856":{"type":"graphic_picture","displayName":"Heel to buttock measurement","title":"Heel to buttock measurement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Heel to buttock measurement</div><div class=\"cntnt\"><img style=\"width:334px; height:304px;\" src=\"images/EM/61856_Heel_to_buttock_measurement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The heel to buttock distance is measured to assess the ability to fully flex the knee. The knee is passively flexed and the patient's tolerance to the maneuver is noted. The distance between the posterior heel and the buttocks (arrows) is measured and compared with the opposite side.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 61856 Version 2.0</div></div></div>"},"61860":{"type":"graphic_picture","displayName":"Laparoscopic reduction of the stomach from the hernia sac","title":"Laparoscopic reduction of the stomach from the hernia sac","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoscopic reduction of the stomach from the hernia sac</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/SURG/61860_Laparo_resect_stomach.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This intraoperative photograph shows the stomach being reduced (retracted) from the paraesophageal hernia sac. The arrows identify the defect in the diaphragm.</div><div class=\"graphic_reference\">Courtesy of Michael Rosen, MD.</div><div id=\"graphicVersion\">Graphic 61860 Version 2.0</div></div></div>"},"61864":{"type":"graphic_diagnosticimage","displayName":"42-year-old MS brain MRI","title":"Brain MRI of a 42-year-old woman with multiple sclerosis","html":"<div class=\"graphic\"><div style=\"width: 583px\" class=\"figure\"><div class=\"ttl\">Brain MRI of a 42-year-old woman with multiple sclerosis</div><div class=\"cntnt\"><img style=\"width:563px; height:419px;\" src=\"images/NEURO/61864_42_yo_MS_brain_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial T2-weighted (A) and axial fluid attenuated inversion recovery (FLAIR) (B) images show multiple, ovoid shaped, hyperintense foci consistent with multiple sclerosis plaques. Sagittal FLAIR (C) image also shows these lesions to be radiating out from the corpus callosum. Axial precontrast T1-weighted (D) image shows that many of these lesions are hypointense, consistent with black holes. Axial postgadolinium fat saturated T1-weighted (E) image shows that some of these plaques enhance in a ring-like fashion consistent with active plaques.</div><div id=\"graphicVersion\">Graphic 61864 Version 4.0</div></div></div>"},"61866":{"type":"graphic_table","displayName":"Axillary recur neg SLN biopsy","title":"Axillary recurrence rates in observational series of women with negative sentinel lymph node biopsy who did not undergo completion ALND","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Axillary recurrence rates in observational series of women with negative sentinel lymph node biopsy who did not undergo completion ALND</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Author; year</td>\n<td class=\"subtitle1\">n</td>\n<td class=\"subtitle1\">Median follow-up, months</td>\n<td class=\"subtitle1\">Number with axillary recurrence (percent) </td>\n\n</tr>\n\n<tr>\n<td>Giuliano, A; 2000</td>\n<td>133</td>\n<td>39</td>\n<td>0 </td>\n\n</tr>\n\n<tr>\n<td>Roumen, RM; 2001</td>\n<td>100</td>\n<td>24</td>\n<td>1</td>\n\n</tr>\n<tr>\n<td>Schrenk, P; 2001</td>\n<td>83</td>\n<td>22</td>\n<td>0</td>\n\n</tr>\n<tr>\n<td>Chung, MA; 2002</td>\n<td>206</td>\n<td>26</td>\n<td>3 (1.5)</td>\n\n</tr>\n<tr>\n<td>Badgwel, B; 2003</td>\n<td>159</td>\n<td>32</td>\n<td>0</td>\n\n</tr>\n\n<tr>\n<td>Blanchard, DK; 2003</td>\n<td>730</td>\n<td>29</td>\n<td>1</td>\n\n</tr>\n<tr>\n<td>Reitsamer, R; 2003</td>\n<td>116</td>\n<td>22</td>\n<td>0 </td>\n\n</tr>\n<tr>\n<td>Naik, AM; 2004</td>\n<td>2340</td>\n<td>31</td>\n<td>3 </td>\n\n</tr>\n<tr>\n<td>Swenson, K; 2004</td>\n<td>647</td>\n<td>33</td>\n<td>4 (0.62)</td>\n\n</tr>\n\n\n<tr>\n<td>Palesty, JA; 2006</td>\n<td>335</td>\n<td>33</td>\n<td>15 (4.5)</td>\n\n</tr>\n\n<tr>\n<td>Pejaver, S; 2006</td>\n<td>126</td>\n<td>NR</td>\n<td>1 (0.8)</td>\n</tr>\n\n<tr>\n<td>Bergkvist, L; 2008</td>\n<td>2246</td>\n<td>37</td>\n<td>27 (1.2)</td>\n</tr>\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">ALND: axillary lymph node dissection; NR: not reported.</div><div id=\"graphicVersion\">Graphic 61866 Version 1.0</div></div></div>"},"61867":{"type":"graphic_table","displayName":"Criteria for dyssynergic defecation","title":"Criteria for dyssynergic defecation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for dyssynergic defecation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>A.</strong> Patients must satisfy the diagnostic criteria for functional chronic constipation (Rome III) <strong>and</strong></td> </tr> <tr> <td><strong>B.</strong> Patients must demonstrate dyssynergia during repeated attempts to defecate</td> </tr> <tr> <td class=\"indent2\">Dyssynergic or obstructive pattern of defecation (types 1-4) is defined as:</td> </tr> <tr> <td class=\"indent3\">Paradoxical increase in anal sphincter pressure (anal contraction) <strong>or</strong></td> </tr> <tr> <td class=\"indent3\">Less than 20 percent relaxation of the resting anal sphincter pressure <strong>or</strong></td> </tr> <tr> <td class=\"indent3\">Inadequate propulsive forces observed with manometry, imaging, or EMG recordings <strong>and</strong></td> </tr> <tr> <td class=\"indent3\">One or more of the following criteria during repeated attempts to defecate: <ul> <li>Inability to expel an artificial stool (50 mL water-filled balloon) within 1 minute </li> <li>A prolonged colonic transit time (ie, greater than five markers [&#62;20 percent marker retention]) on a plain abdominal radiograph taken 120 hours after ingestion of one sitzmark capsule containing 24 radiopaque markers </li> <li>Inability to evacuate or &#8805;50 percent retention of barium during defecography </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Rao SSC. Dyssynergic defecation and biofeedback therapy. Gastroenterol Clin N Am 2008; 37:569. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 61867 Version 2.0</div></div></div>"},"61868":{"type":"graphic_picture","displayName":"Hemangioma sharp margins","title":"Sharp-bordered hemangioma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Sharp-bordered hemangioma</div><div class=\"cntnt\"><img style=\"width:504px; height:440px;\" src=\"images/DERM/61868_Hemangioma_sharp_margins.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sharp-bordered and very raised hemangiomas, as depicted here, are associated with an increased risk of scarring.</div><div class=\"graphic_reference\">Copyright © Katherine Puttgen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 61868 Version 4.0</div></div></div>"},"61870":{"type":"graphic_diagnosticimage","displayName":"131-I scan in thyroid cancer","title":"Whole-body 131-I scan in thyroid cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Whole-body 131-I scan in thyroid cancer</div><div class=\"cntnt\"><img style=\"width:340px; height:230px;\" src=\"images/ENDO/61870_131_I_scan_in_thyroid_cance.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterior view of the head, neck, and chest of a 131-I scan in a patient with differentiated thyroid cancer who underwent thyroidectomy five weeks earlier and had discontinued T3 therapy three weeks earlier. The scan was performed 24 hours after administration of 5 mCi (185 MBq) 131-I. The arrow indicates a thyroid bed remnant with a 24-hour iodine uptake of about 1.5 percent. Physiologic uptake can be seen in the nasopharynx, and physiologic blood pooling of the isotope is seen in the mid-chest. The patient was subsequently treated with 29 mCi (1073 MBq) of 131-I.</div><div class=\"graphic_footnotes\">131-I: radioiodine; T3: liothyronine.</div><div id=\"graphicVersion\">Graphic 61870 Version 3.0</div></div></div>"},"61871":{"type":"graphic_picture","displayName":"Hysterosc myomectomy loop","title":"Hysteroscopic myomectomy: Wire loop technique","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hysteroscopic myomectomy: Wire loop technique</div><div class=\"cntnt\"><img style=\"width:380px; height:285px;\" src=\"images/OBGYN/61871_Hysterosc_myomectomy_loop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During hysteroscopic myomectomy using the wire loop technique, the wire loop is placed at the most cephalad surface of the leiomyoma. The activated electrode is then passed through the tissue.</div><div class=\"graphic_reference\">Courtesy of Linda D Bradley, MD.</div><div id=\"graphicVersion\">Graphic 61871 Version 2.0</div></div></div>"},"61873":{"type":"graphic_figure","displayName":"MV repair symptom heart failure","title":"Mitral valve repair for mitral regurgitation in heart failure improves symptoms","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral valve repair for mitral regurgitation in heart failure improves symptoms</div><div class=\"cntnt\"><img style=\"width:329px; height:310px;\" src=\"images/CARD/61873_MVrepairsymptomheartfai.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In patients with mitral regurgitation due to a congestive cardiomyopathy, mitral annuloplasty resulted in a significant improvement in symptoms and functional status at 17 weeks; NYHA functional class fell significantly from an average of 3.9 to 1.7 (p &lt;0.001*).</div><div class=\"graphic_reference\">Data from Bach DS, Bolling SF. Am Heart J 1995; 129:1165.</div><div id=\"graphicVersion\">Graphic 61873 Version 2.0</div></div></div>"},"61877":{"type":"graphic_picture","displayName":"Perineal group A streptococcal disease","title":"Perineal group A streptococcal disease","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Perineal group A streptococcal disease</div><div class=\"cntnt\"><img style=\"width:514px; height:294px;\" src=\"images/EM/61877_Perineal_gr_A_strep_dis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the fiery or beefy red appearance of the infected skin which is a clinical hallmark of group A streptococcal perineal disease.<br> (A) Perivaginal infection.<br> (B) Perianal infection.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 61877 Version 3.0</div></div></div>"},"61879":{"type":"graphic_table","displayName":"Pain synd neoplastic","title":"Acute pain syndromes associated with antineoplastic treatments","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acute pain syndromes associated with antineoplastic treatments</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Acute pain syndromes associated with chemotherapy infusion techniques:\n   </td>\n   </tr>\n   <tr>\n   <td>Intravenous infusion pain (eg, oxaliplatin)</td>\n   </tr>\n   <tr>\n   <td>Venous spasm</td>\n   </tr>\n   <tr>\n   <td>Chemical phlebitis (vinorelbine, 5-fluorouracil)</td>\n   </tr>\n   <tr>\n   <td>Vesicant extravasation</td>\n   </tr>\n   <tr>\n   <td>Anthracycline-associated localized skin flare reaction at or adjacent to drug administration site</td>\n   </tr>\n   <tr>\n   <td>Hepatic artery infusion pain</td>\n   </tr>\n   <tr>\n   <td>Abdominal pain associated with intraperitoneal chemotherapy</td>\n   </tr>\n   <tr>\n   <td>Pain associated with intravesical instillation of chemotherapy</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Acute pain syndromes associated with chemotherapy toxicity:\n   </td>\n   </tr>\n   <tr>\n   <td>Oral mucositis</td>\n   </tr>\n   <tr>\n   <td>Painful peripheral neuropathy and plexopathy</td>\n   </tr>\n   <tr>\n   <td>Headaches (eg, due to intrathecal methotrexate meningitis syndrome, l-asparaginase-associated dural sinus thrombosis, all trans-retinoic acid [ATRA]-related headache)</td>\n   </tr>\n   <tr>\n   <td>Arthralgias and myalgias</td>\n   </tr>\n   <tr>\n   <td>Palmar-plantar erythrodysesthesia syndrome (hand-foot syndrome)</td>\n   </tr>\n   <tr>\n   <td>Post-chemotherapy acute limb ischemia</td>\n   </tr>\n   <tr>\n   <td>Fluoropyrimidine-induced angina</td>\n   </tr>\n   <tr>\n   <td>Post-chemotherapy gynecomastia</td>\n   </tr>\n   <tr>\n   <td>Steroid-induced perineal burning</td>\n   </tr>\n   <tr>\n   <td>ATRA-induced diffuse bone pain</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Acute pain syndromes associated with hormonal therapy:\n   </td>\n   </tr>\n   <tr>\n   <td>Tumor flare in advanced prostate cancer treated with luteinizing hormone releasing factor (LHRH) agonists</td>\n   </tr>\n   <tr>\n   <td>Pain flare in metastatic breast cancer treated with estrogen receptor (ER) agonists such as tamoxifen or high-dose estrogen</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Acute pain syndromes associated with immunotherapy:\n   </td>\n   </tr>\n   <tr>\n   <td>Interferon-associated myalgias</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Acute pain syndromes associated with growth factors:\n   </td>\n   </tr>\n   <tr>\n   <td>Bone pain induced by hematopoietic colony stimulating factors</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Acute pain syndromes associated with radiotherapy:\n   </td>\n   </tr>\n   <tr>\n   <td>Incident pain associated with positioning</td>\n   </tr>\n   <tr>\n   <td>Oropharyngeal mucositis</td>\n   </tr>\n   <tr>\n   <td>Early onset brachial plexopathy</td>\n   </tr>\n   <tr>\n   <td>Acute radiation enteritis or proctitis</td>\n   </tr>\n   <tr>\n   <td>Acute vertebral bone pain after radiation</td>\n   </tr>\n   <tr>\n   <td>Acute and subacute radiation myelopathy</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 61879 Version 1.0</div></div></div>"},"61880":{"type":"graphic_table","displayName":"Available insulins","title":"Available insulins","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Available insulins</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"3\" width=\"10%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Onset (hours)</td> <td class=\"subtitle1\">Peak (hours)</td> <td class=\"subtitle1\">Duration (hours)</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Ultra-rapid-acting</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Faster aspart*</td> <td>0.1 to 0.2</td> <td>1 to 3</td> <td>3 to 5</td> <td>Duration of action may be shorter.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Rapid-acting</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Lispro/aspart/glulisine</td> <td>0.15 to 0.35</td> <td>1 to 3</td> <td>3 to 5</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Short-acting</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Regular</td> <td>0.5 to 1</td> <td>2 to 4</td> <td>5 to 8</td> <td>Longer action if larger dose (mass action effect).</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Intermediate-acting</td> </tr> <tr> <td class=\"indent1\">Neutral protamine Hagedorn (NPH)</td> <td>2 to 4</td> <td>4 to 12</td> <td>12 to 24</td> <td>Peak and duration quite variable.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Neutral protamine lispro (NPL)</td> <td>Approximately 2</td> <td>6</td> <td>15</td> <td>Activity profile similar to NPH; can be mixed with insulin lispro. Not available in United States.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Basal long-acting</td> </tr> <tr> <td class=\"indent1\"> <p>Glargine</p> Biosimilar glargine is approved in some countries</td> <td>2 to 4</td> <td>8 to 12 (not pronounced)</td> <td>22 to 24</td> <td> <p>Half-life is shorter in some patients, requiring division of the daily dose into two injections per day.</p> Cannot be mixed with other insulins because this alters pharmacokinetics. Insulin forms crystals at in vivo pH.</td> </tr> <tr> <td class=\"indent1\">Detemir</td> <td>1 to 2</td> <td>4 to 7 (not pronounced)</td> <td>20 to 24</td> <td> <p>Duration of action is dose-dependent. At higher doses (&#8805;0.8 units/kg), mean duration of action is longer and less variable (22 to 23 hours). At lower doses, mean duration of action is shorter and twice daily injections are often needed.</p> Cannot be mixed with other insulins because this alters pharmacokinetics.</td> </tr> <tr> <td class=\"indent1\">Glargine U300</td> <td>2 to 6</td> <td>None</td> <td>30 to 36</td> <td>Cannot be mixed with other insulins because this alters pharmacokinetics.</td> </tr> <tr> <td class=\"indent1\">Degludec</td> <td>0.5 to 1.5</td> <td>None</td> <td>&#62;42</td> <td> <p>Less day-to-day variation in glucose lowering effect at steady state (after 2 to 3 days' use) relative to glargine and detemir.</p> Can be mixed with insulin aspart; coformulation with aspart available in some countries.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The numbers indicated above are approximations, and are influenced by many factors including (but not limited to) presence and type of antibodies to the specific insulin, the site of injection, and mass action effect. Mixed insulins consisting of NPH and regular (70:30 mix), or NPH and Lispro (75:25 mix), as well as other concentrations and mixes are sometimes useful. Other new insulins are presently in clinical trials. No inhaled insulin preparation is currently available but both orally absorbed and inhaled insulin preparations are being developed.</div><div class=\"graphic_footnotes\">* Not yet approved or not for pediatric indication.</div><div id=\"graphicVersion\">Graphic 61880 Version 10.0</div></div></div>"},"61881":{"type":"graphic_figure","displayName":"Figure of eight splint","title":"Figure-of-eight splint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Figure-of-eight splint</div><div class=\"cntnt\"><img style=\"width:432px; height:314px;\" src=\"images/PEDS/61881_Figure_of_eight_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For a figure-of-eight splint to be applied properly, the patient must be erect with hands on his iliac crests and shoulders in abduction.</div><div id=\"graphicVersion\">Graphic 61881 Version 1.0</div></div></div>"},"61883":{"type":"graphic_table","displayName":"Agents causing fatal poisoning in young children","title":"Agents causing fatal poisonings among children younger than six years of age*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Agents causing fatal poisonings among children younger than six years of age*</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Analgesic drugs</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fumes, gases, vapors (eg, carbon monxide)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cough and cold preparations</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Insecticides and pesticides</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Antidepressant drugs</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardiovascular drugs</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cosmetics and personal care products</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hydrocarbons</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Stimulants and illicit drugs</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Excluding bites and envenomations.</div><div class=\"graphic_reference\">Data from: Annual Reports of the American Association of Poison Control Centers Toxic Exposure Surveillance System.</div><div id=\"graphicVersion\">Graphic 61883 Version 4.0</div></div></div>"},"61886":{"type":"graphic_picture","displayName":"LCDD tubules EM","title":"Light chain deposition disease - electron micrograph ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light chain deposition disease - electron micrograph </div><div class=\"cntnt\"><img style=\"width:378px; height:257px;\" src=\"images/NEPH/61886_LCDD_tubules_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph showing granular deposits (arrow) along the tubular basement membrane in light chain deposition disease. The appearance of these deposits is different from the fibrils seen in amyloidosis even though both types of deposits are composed of light chain fragments.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 61886 Version 2.0</div></div></div>"},"61888":{"type":"graphic_table","displayName":"Neuraminidase inhibitor dosing for flu prophylaxis in children","title":"Dosing recommendations for neuraminidase inhibiting agents for prevention of influenza in children and adolescents*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dosing recommendations for neuraminidase inhibiting agents for prevention of influenza in children and adolescents*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"5\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug/formulation</td> <td class=\"subtitle1\" colspan=\"5\">Dosing recommendations for prophylaxis<sup>&#182;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"> <p><strong>Oseltamivir (Tamiflu)</strong><sup>&#916;</sup></p> <p>30 mg capsule</p> <p>45 mg capsule</p> <p>75 mg capsule</p> 6 mg/mL suspension<sup>&#9674;</sup></td> <td class=\"subtitle2_left\" colspan=\"4\">1 through 12 years</td> <td class=\"subtitle2_left\">&#8805;13 years</td> </tr> <tr> <td class=\"indent1\">&#8804;15 kg</td> <td>&#62;15 to 23 kg</td> <td>&#62;23 to 40 kg</td> <td>&#62;40 kg</td> <td class=\"divider_bottom\" rowspan=\"2\">75 mg once daily</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">30 mg once daily</td> <td>45 mg once daily</td> <td>60 mg once daily</td> <td>75 mg once daily</td> </tr> <tr> <td rowspan=\"2\"> <p><strong>Zanamivir</strong><sup>&#167;</sup> <strong>(Relenza)</strong></p> 5 mg per inhalation (Diskhaler)</td> <td class=\"subtitle2_left\" colspan=\"5\">Children &#8805;5 years and adults</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">2 inhalations (10 mg total per dose)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The choice of agent for prophylaxis depends upon the age of the patient and the susceptibility patterns of circulating strains. Refer to UpToDate topic on prevention of seasonal influenza in children for details.<br />¶ The duration of prophylaxis depends upon the clinical circumstances of the individual case. Refer to UpToDate topic on prevention of seasonal influenza in children for details.<br />Δ Dose adjustment is necessary for patients with renal insufficiency. Refer to UpToDate topic on prevention of seasonal influenza in children for oseltamivir doses for infants younger than one year of age.<br /><FONT class=lozenge>◊</FONT> When dispensing the oral suspension of oseltamivir, providers and pharmacists must take care to provide a dosing device that matches the units of measure on the prescription.<br />§ Zanamivir inhalation powder should not be reconstituted in any liquid formulation and is not recommended for use in nebulizers or mechanical ventilators.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>American Academy of Pediatrics. Non-HIV antiviral drugs. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL, 2015. p.919. </LI>&#xD;&#xA;<LI>US Food and Drug Administration. Safety Alerts for Human Medical Products. Tamiflu (oseltamivir) for Oral Suspension. Available at: <A href=\"http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183714.htm\" target=_blank>www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183714.htm</A> (Accessed on September 23, 2013). </LI>&#xD;&#xA;<LI>US Food and Drug Administration. Safety Alerts for Human Medical Products. Relenza (zanamivir) Inhalation Powder. Available at: <A href=\"http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm186081.htm\" target=_blank>www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm186081.htm</A> (Accessed on September 23, 2013).</LI></OL></div><div id=\"graphicVersion\">Graphic 61888 Version 17.0</div></div></div>"},"61890":{"type":"graphic_picture","displayName":"Pseudopapilledema","title":"Pseudopapilledema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudopapilledema</div><div class=\"cntnt\"><img style=\"width:364px; height:280px;\" src=\"images/PEDS/61890_Pseudopapilledema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A patient with hyperopia and a small congested optic disc may have the appearance of mild optic disc swelling.</div><div class=\"graphic_reference\">Courtesy of Karl C Golnik, MD.</div><div id=\"graphicVersion\">Graphic 61890 Version 1.0</div></div></div>"},"61891":{"type":"graphic_picture","displayName":"Torsion with nonviable ovary","title":"Enlarged left ovary found torsed upon laparotomy demonstrating a dark, dusky appearance secondary to venous lymphatic congestion in the setting of continued arterial perfusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Enlarged left ovary found torsed upon laparotomy demonstrating a dark, dusky appearance secondary to venous lymphatic congestion in the setting of continued arterial perfusion</div><div class=\"cntnt\"><img style=\"width:432px; height:373px;\" src=\"images/OBGYN/61891_Torsionwithnonviableovar.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric&nbsp;and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 61891 Version 15.0</div></div></div>"},"61892":{"type":"graphic_figure","displayName":"Mobilization of left colon - Medial approach","title":"Mobilization of left colon - Medial approach","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Mobilization of left colon - Medial approach</div><div class=\"cntnt\"><img style=\"width:510px; height:556px;\" src=\"images/SURG/61892_Mobilization left colon medial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts mobilization of the left colon beginning the approach medially. The peritoneum is scored and the inferior mesenteric vessles are identified and ligated prior to mobilizing the colon.</div><div id=\"graphicVersion\">Graphic 61892 Version 1.0</div></div></div>"},"61893":{"type":"graphic_picture","displayName":"Dermoid cyst forehead","title":"Dermoid cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermoid cyst</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/61893_Dermoid_cyst_forehead.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A flesh-colored nodule is present on the forehead of this patient with a dermoid cyst.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 61893 Version 4.0</div></div></div>"},"61894":{"type":"graphic_diagnosticimage","displayName":"MRI of Grade III medial collateral ligament injury","title":"MRI of Grade III medial collateral ligament injury","html":"<div class=\"graphic\"><div style=\"width: 595px\" class=\"figure\"><div class=\"ttl\">MRI of Grade&nbsp;III medial collateral ligament injury</div><div class=\"cntnt\"><img style=\"width:575px; height:284px;\" src=\"images/EM/61894_MCL_grade3_injury_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These MRI images show a complete transverse tear through the MCL. The arrow points to the area of focal interruption of the normal dark fibers, with hemorrhage and edema surrounding the MCL. Fibers at the tear site are wavy. Note that it may be difficult to distinguish high-grade Grade II and Grade&nbsp;III tears.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; MCL: medial collateral ligament.</div><div class=\"graphic_reference\">Courtesy of Mary Hochman, MD.</div><div id=\"graphicVersion\">Graphic 61894 Version 4.0</div></div></div>"},"61895":{"type":"graphic_table","displayName":"Differential diagnosis of acute weakness organized anatomically","title":"Differential diagnosis of acute weakness organized anatomically","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of acute weakness organized anatomically</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Central</td> </tr> <tr> <td rowspan=\"5\">Cerebrum</td> <td><em><strong>Stroke</strong></em></td> </tr> <tr> <td><strong>Space occupying/structural lesion</strong></td> </tr> <tr> <td><em>Postictal (Todd) paralysis</em></td> </tr> <tr> <td><em>Multiple sclerosis</em></td> </tr> <tr> <td>Other inflammatory conditions</td> </tr> <tr> <td>Subcortex/brainstem</td> <td><em><strong>Stroke</strong></em></td> </tr> <tr> <td rowspan=\"6\">Spinal cord</td> <td><strong>Acute transverse myelitis</strong></td> </tr> <tr> <td><strong>Spinal cord infarct</strong></td> </tr> <tr> <td><strong>Spinal epidural or subdural hemorrhage</strong></td> </tr> <tr> <td><strong>Central intervertebral disc herniation</strong></td> </tr> <tr> <td><strong>Tumors (metastatic or primary)</strong></td> </tr> <tr> <td>Multiple sclerosis</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Peripheral</td> </tr> <tr> <td rowspan=\"4\">Spinal nerve root</td> <td><em>Intervertebral disc herniation</em></td> </tr> <tr> <td><strong>Epidural abscess</strong></td> </tr> <tr> <td>Tumors</td> </tr> <tr> <td>Leptomeningeal metastases</td> </tr> <tr> <td rowspan=\"8\">Polyneuropathies</td> <td><strong>Guillain-Barr&#233; syndrome</strong></td> </tr> <tr> <td><em>Diabetic</em></td> </tr> <tr> <td>Ciguatoxin (ciguatera poisoning)</td> </tr> <tr> <td>Saxitoxin (paralytic shellfish poisoning)</td> </tr> <tr> <td>Tetrodotoxin poisoning (pufferfish poisoning)</td> </tr> <tr> <td>Porphyria</td> </tr> <tr> <td>Lead or other heavy metal poisoning</td> </tr> <tr> <td>Alcohol or drug induced</td> </tr> <tr> <td rowspan=\"2\">Plexopathies</td> <td>Brachial</td> </tr> <tr> <td>Lumbar</td> </tr> <tr> <td>Peripheral neuropathies</td> <td><strong>Nerve compression syndromes</strong></td> </tr> <tr> <td rowspan=\"5\">NMJ Disorder</td> <td><strong>Myasthenia Gravis</strong></td> </tr> <tr> <td><strong>Lambert-Eaton myasthenic syndrome</strong></td> </tr> <tr> <td><strong>Botulism</strong></td> </tr> <tr> <td><strong>Organophosphate poisoning</strong></td> </tr> <tr> <td><strong>Tick paralysis</strong></td> </tr> <tr> <td rowspan=\"5\">Myopathy</td> <td><strong>Electrolyte induced</strong></td> </tr> <tr> <td>Inflammatory (polymyositis)</td> </tr> <tr> <td>Alcohol or drug-induced</td> </tr> <tr> <td>Muscular dystrophy</td> </tr> <tr> <td>Endocrine related</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Nonphysiologic/noncategorical</td> </tr> <tr> <td colspan=\"2\">Conversion disorder</td> </tr> <tr> <td colspan=\"2\">Chronic fatigue syndrome <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">(CFS, also known as systemic exertion intolerance disease [SEID])</span></td> </tr> <tr> <td colspan=\"2\">Anxiety disorders</td> </tr> <tr> <td colspan=\"2\">Fibromyalgia</td> </tr> <tr> <td colspan=\"2\">Malingering</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><em>Italicized</em>: common conditions.<br><strong>Bold</strong>: serious conditions.</div><div class=\"graphic_reference\">Reprinted with permission from: Asimos, AW. Weakness: A Systematic Approach to Acute, Non-traumatic, Neurologic and Neuromuscular Causes. Emergency Medicine Practice 2002; 4:1. Copyright © 2002 EB Practice, LLC. All rights reserved. http://www.ebmedicine.net.</div><div id=\"graphicVersion\">Graphic 61895 Version 4.0</div></div></div>"},"61896":{"type":"graphic_figure","displayName":"IGF receptors in insulin resistance","title":"Possible mechanisms by which insulin resistance leads to the clinical manifestations of the polycystic ovary syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Possible mechanisms by which insulin resistance leads to the clinical manifestations of the polycystic ovary syndrome</div><div class=\"cntnt\"><img style=\"width:433px; height:278px;\" src=\"images/ENDO/61896_IGF_receptors_in_insulin_re.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Insulin resistance in muscle and adipose tissue leads to hyperglycemia and thus increased insulin secretion from the pancreatic beta cells. This insulin can cause changes in the skin, ovary, and cartilage via activation of IGF-1 receptors or hybrid receptors formed by covalent linkage of subunits of the homologous receptors for insulin (IR) and IGF-1 (IGF-R).</div><div class=\"graphic_footnotes\">IGF-1: insulin-like growth factor 1; IR: insulin receptor; IGF-R: insulin-like growth factor receptor.</div><div class=\"graphic_reference\">Adapted from: Mantzoros CS, Flier JS. Insulin resistance: the clinical spectrum.&nbsp;Adv Endocrinol Metab 1995; 6:193.</div><div id=\"graphicVersion\">Graphic 61896 Version 5.0</div></div></div>"},"61897":{"type":"graphic_diagnosticimage","displayName":"HSG arcuate ut intravasation","title":"Hysterosalpingogram showing an arcuate uterus, absent left tube, and intravasation of dye in the uterine veins on the right obscuring the status of the right tube","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Hysterosalpingogram showing an arcuate uterus, absent left tube, and intravasation of dye in the uterine veins on the right obscuring the status of the right tube</div><div class=\"cntnt\"><img style=\"width:468px; height:331px;\" src=\"images/OBGYN/61897_HSG__arcuate_ut_intravasati.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Baramki TA. Hysterosalpingography. Fertil Steril 2005; 83:1595. Copyright © 2005 Elsevier Science, Inc.</div><div id=\"graphicVersion\">Graphic 61897 Version 3.0</div></div></div>"},"61898":{"type":"graphic_figure","displayName":"M mode echo parasternal long axis","title":"M-mode echocardiographic examination of the heart in the parasternal long axis position","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">M-mode echocardiographic examination of the heart in the parasternal long axis position</div><div class=\"cntnt\"><img style=\"width:422px; height:422px;\" src=\"images/CARD/61898_M_mode_echo_examination.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A diagrammatic representation of the long axis of the heart is seen on top; the transducer (T) sits on the anterior chest wall in the precordial parasternal window and the beam is swept from apex to base. The appearance of the echogram at three beam positions on the diagram is designated by the arrows connecting the diagram to the echogram which displays the cardiac structures that are imaged by the beam (bottom panel). A pericardial effusion (PE) is seen as an echo-free space posterior to the left ventricle. This space diminishes and finally disappears as the base of the heart is approached because the pericardium reflects at mid atrium.</div><div class=\"graphic_footnotes\">Ao: aorta; Inf-Lat LVW: inferolateral LV wall; LA: left atrium; LV: left ventricle; MV: mitral valve; P: pericardium; PE: pericardial effusion; RV: right ventricle; Ant RVW: anterior RV wall.</div><div id=\"graphicVersion\">Graphic 61898 Version 4.0</div></div></div>"},"61899":{"type":"graphic_table","displayName":"Probability of HP","title":"Clinical probability of hypersensitivity pneumonitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical probability of hypersensitivity pneumonitis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t<tbody><tr><td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">Exposure to a known offending antigen</td><td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">Recurrent episodes of symptoms</td><td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">Symptoms 4-8 h after exposure</td><td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">Weight loss</td><td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">Crackles, percent</td></tr><tr><td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">(+) Serum precipitins</td><td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">(-) Serum precipitins</td></tr><tr>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t<td class=\"subtitle3\">+</td>\n\t\t\t\t<td class=\"subtitle3\">-</td>\n\t\t\t\t<td class=\"subtitle3\">+</td>\n\t\t\t\t<td class=\"subtitle3\">-</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>98</td>\n\t\t\t\t<td>92</td>\n\t\t\t\t<td>93</td>\n\t\t\t\t<td>72</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>97</td>\n\t\t\t\t<td>85</td>\n\t\t\t\t<td>87</td>\n\t\t\t\t<td>56</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>90</td>\n\t\t\t\t<td>62</td>\n\t\t\t\t<td>66</td>\n\t\t\t\t<td>27</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>81</td>\n\t\t\t\t<td>45</td>\n\t\t\t\t<td>49</td>\n\t\t\t\t<td>15</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>95</td>\n\t\t\t\t<td>78</td>\n\t\t\t\t<td>81</td>\n\t\t\t\t<td>44</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>90</td>\n\t\t\t\t<td>64</td>\n\t\t\t\t<td>68</td>\n\t\t\t\t<td>28</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>73</td>\n\t\t\t\t<td>33</td>\n\t\t\t\t<td>37</td>\n\t\t\t\t<td>10</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>57</td>\n\t\t\t\t<td>20</td>\n\t\t\t\t<td>22</td>\n\t\t\t\t<td>5</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>62</td>\n\t\t\t\t<td>23</td>\n\t\t\t\t<td>26</td>\n\t\t\t\t<td>6</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>45</td>\n\t\t\t\t<td>13</td>\n\t\t\t\t<td>15</td>\n\t\t\t\t<td>3</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>18</td>\n\t\t\t\t<td>4</td>\n\t\t\t\t<td>5</td>\n\t\t\t\t<td>1</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>10</td>\n\t\t\t\t<td>2</td>\n\t\t\t\t<td>2</td>\n\t\t\t\t<td>0</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>33</td>\n\t\t\t\t<td>8</td>\n\t\t\t\t<td>10</td>\n\t\t\t\t<td>2</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>20</td>\n\t\t\t\t<td>4</td>\n\t\t\t\t<td>5</td>\n\t\t\t\t<td>1</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>+</td>\n\t\t\t\t<td>6</td>\n\t\t\t\t<td>1</td>\n\t\t\t\t<td>1</td>\n\t\t\t\t<td>0</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>-</td>\n\t\t\t\t<td>3</td>\n\t\t\t\t<td>1</td>\n\t\t\t\t<td>1</td>\n\t\t\t\t<td>0</td>\n\t\t\t</tr>\n\t\n\t</tbody></table></div><div class=\"graphic_lgnd\">All the predictors are dichotomous variables.</div><div class=\"graphic_footnotes\">-: absent; +: present.</div><div class=\"graphic_reference\">Reproduced with permission from: Lacasse, Y, Selman, M, Costabel, U, et al. Diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med 2003; 168:952. Copyright &#169; 2003 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 61899 Version 1.0</div></div></div>"},"61900":{"type":"graphic_diagnosticimage","displayName":"Tension pneumothorax II PA","title":"Chest radiograph of a tension pneumothorax","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of a tension pneumothorax</div><div class=\"cntnt\"><img style=\"width:324px; height:319px;\" src=\"images/PULM/61900_Tension_pneumothorax_II_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tension pneumothorax due to insertion of right-sided Swan-Ganz catheter in patient with left ventricular failure and pulmonary edema. Chest radiograph shows collapse of the right lung and cardiomediastinal silhouette to the left with marked compression of the left lung, leading to respiratory failure. The right hemidiaphragm is depressed caudad, and the right-sided rib spaces are markedly widened.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 61900 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"61901":{"type":"graphic_diagnosticimage","displayName":"Short axis rheumatic MR","title":"Rheumatic mitral regurgitation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rheumatic mitral regurgitation</div><div class=\"cntnt\"><img style=\"width:259px; height:403px;\" src=\"images/CARD/61901_ShortaxisrheumaticMR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The short axis view during diastole (D) shows a mildly stenotic mitral orifice (MVO) by area (4 cm<SUP>2</SUP>), which presented no significant obstruction to mitral inflow. The valve is shown during systole in the lower panel (arrows). The medial side of the valve has failed to coapt; in rheumatic mitral regurgitation, failure of coaptation of this degree is usually associated with significant mitral regurgitation.</div><div class=\"graphic_footnotes\">LV: left ventricle; RV: right ventricle.</div><div id=\"graphicVersion\">Graphic 61901 Version 4.0</div></div></div>"},"61902":{"type":"graphic_figure","displayName":"Five finger rotation from occiput posterior","title":"Five finger manual rotation from occiput posterior","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Five finger manual rotation from occiput posterior</div><div class=\"cntnt\"><img style=\"width:500px; height:683px;\" src=\"images/OBGYN/61902_Manual_rotation_occiput_post_edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The operator places four fingers behind the posterior parietal bone with the palm up and the thumb over the anterior parietal bone. The right hand is used for left OP position and the left hand is used for right OP position. The head is grasped with the tips of the fingers and thumb.<br> (B-F) During a contraction, the patient is encouraged to push and the operator attempts to flex and rotate the fetal head to the OA postion.</div><div class=\"graphic_footnotes\">OP: occiput posterior; OA: occiput anterior.</div><div id=\"graphicVersion\">Graphic 61902 Version 5.0</div></div></div>"},"61903":{"type":"graphic_diagnosticimage","displayName":"FAST perisplenic fluid","title":"FAST: Perisplenic view with free fluid","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">FAST: Perisplenic view with free fluid</div><div class=\"cntnt\"><img style=\"width:504px; height:406px;\" src=\"images/EM/61903_FAST_splenoren_fluid_PR_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image, obtained during a FAST examination, shows free fluid surrounding the spleen and obscuring the interface between the spleen and kidney.</div><div class=\"graphic_footnotes\">FAST: Focused Assessment with Sonography for Trauma; F: fluid; K: kidney; S: spleen.</div><div class=\"graphic_reference\">Courtesy of Greg Snead, MD.</div><div id=\"graphicVersion\">Graphic 61903 Version 5.0</div></div></div>"},"61904":{"type":"graphic_movie","displayName":"Cardiac amyloidosis four chamber echocardiogram","title":"Cardiac amyloidosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cardiac amyloidosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/61904_4chamyloconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:259px; height:437px;\" src=\"images/CARD/61904_4chamylo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four chamber view from a 2-D echocardiogram shows concentric hypertrophy of the right and left ventricular myocardium which has a &quot;sparkling&quot; appearance. The mitral and tricuspid valves are thickened and the right and left atria are dilated.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 61904 Version 2.0</div></div></div>"},"61905":{"type":"graphic_table","displayName":"ECG criteria for RBBB","title":"ECG in RBBB","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ECG in RBBB</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1_left\">QRS duration</td>\n\n\n      <td>&#8805;0.12\nsec</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_left\">Intrinsicoid deflection</td>\n\n\n      <td>&#62;0.035 in V1 and V2 due to delayed R'</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_left\">Common pattern: Posterior mid-temporal forces</td>\n\n\n      <td>qRS or qrS in I, V6; rsR' or qR in V1 -\nReflects anterior initial forces, anterior and rightward terminal forces</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_left\">Atypical pattern: Anterior mid-temporal forces</td>\n\n\n      <td>qRS, qrS, or RS in I, V6; rsR' or qR in V1 -\nReflects anterior mid-temporal right ventricular enlargement and left\nanterior fascicular block</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_left\">ST-T waves</td>\n\n\n      <td>ST depression and T inversion in right precordial\nleads, upright in left precordial and limb leads - ST-T\nvectors are discordant to terminal mean QRS spatial vector</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">Major electrocardiographic characteristics of right bundle branch block.<span style=\"font-style:italic\"></div><div class=\"graphic_reference\">Data from Willems JL, Demedina EO, Bernard R, et al. J Am Coll Cardiol 1985; 5:1261.</div><div id=\"graphicVersion\">Graphic 61905 Version 2.0</div></div></div>"},"61906":{"type":"graphic_table","displayName":"Risk strat system advanced TGCTs","title":"Risk stratification system for advanced testicular germ cell tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk stratification system for advanced testicular germ cell tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Seminomas</td> </tr> <tr> <td class=\"subtitle2_single\">Good risk</td> </tr> <tr> <td class=\"indent1\"><strong>All of the following:</strong></td> </tr> <tr> <td class=\"indent1\">Any primary site</td> </tr> <tr> <td class=\"indent1\">No metastases to organs other than the lungs and/or lymph nodes</td> </tr> <tr> <td class=\"indent1\">Normal serum AFP</td> </tr> <tr> <td class=\"subtitle2_single\">Intermediate risk</td> </tr> <tr> <td class=\"indent1\"><strong>All of the following:</strong></td> </tr> <tr> <td class=\"indent1\">Any primary site</td> </tr> <tr> <td class=\"indent1\">Metastases to organs other than the lungs and/or lymph nodes</td> </tr> <tr> <td class=\"indent1\">Normal serum AFP</td> </tr> <tr> <td class=\"subtitle1_single\">Nonseminomatous germ cell tumors</td> </tr> <tr> <td class=\"subtitle2_single\">Good risk</td> </tr> <tr> <td class=\"indent1\"><strong>All of the following:</strong></td> </tr> <tr> <td class=\"indent1\">Testicular or retroperitoneal primary tumors</td> </tr> <tr> <td class=\"indent1\">No metastases to organs other than the lungs and/or lymph nodes</td> </tr> <tr> <td class=\"indent1\">Serum AFP &#60;1000 ng/mL, beta-hCG &#60;5000 milliinternational units/mL, and LDH &#60;1.5 times the upper limit of normal</td> </tr> <tr> <td class=\"subtitle2_single\">Intermediate risk</td> </tr> <tr> <td class=\"indent1\"><strong>All of the following:</strong></td> </tr> <tr> <td class=\"indent1\">Testicular or retroperitoneal primary tumors</td> </tr> <tr> <td class=\"indent1\">No metastases to organs other than the lungs and/or lymph nodes</td> </tr> <tr> <td class=\"indent1\">Serum AFP 1000 to 10,000 mg/mL <strong>OR</strong></td> </tr> <tr> <td class=\"indent1\">Serum beta-hCG 5000 to 50,000 milliinternational units/mL <strong>OR</strong></td> </tr> <tr> <td class=\"indent1\">LDH 1.5 to 10 times upper limit of normal</td> </tr> <tr> <td class=\"subtitle2_single\">Poor risk</td> </tr> <tr> <td class=\"indent1\"><strong>Any of the following:</strong></td> </tr> <tr> <td class=\"indent1\">Mediastinal primary with or without metastases, or</td> </tr> <tr> <td class=\"indent1\">Metastases to organs other than the lungs and/or lymph nodes, or</td> </tr> <tr> <td class=\"indent1\">Serum AFP &#62;10,000 ng/mL, or</td> </tr> <tr> <td class=\"indent1\">Serum beta-hCG &#62;50,000 milliinternational units/mL, or</td> </tr> <tr> <td class=\"indent1\">LDH more than 10 times upper limit of normal</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AFP: alpha-fetoprotein; beta-hCG: beta-human chorionic gonadotropin; LDH: lactic dehydrogenase.</div><div class=\"graphic_reference\">Based upon the guidelines of the International Germ Cell Cancer collaborative group.</div><div id=\"graphicVersion\">Graphic 61906 Version 8.0</div></div></div>"},"61909":{"type":"graphic_table","displayName":"HP classification system","title":"Classification systems for hypersensitivity pneumonitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification systems for hypersensitivity pneumonitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Classical classification</td> <td class=\"subtitle1\">Boyd classification</td> <td class=\"subtitle1\">Cormier classification</td> <td class=\"subtitle1\">Selman classification</td> </tr> <tr> <td>Acute</td> <td>Acute progressive</td> <td rowspan=\"2\">Active</td> <td>Active nonprogressive and intermittent</td> </tr> <tr> <td>Subacute</td> <td>Acute intermittent nonprogressive</td> <td>Acute progressive and intermittent</td> </tr> <tr> <td rowspan=\"3\">Chronic</td> <td rowspan=\"3\">Nonacute</td> <td rowspan=\"3\">Residual</td> <td class=\"sublist1_start\">Chronic</td> </tr> <tr> <td class=\"sublist1\">Nonprogressive</td> </tr> <tr> <td class=\"sublist1\">Progressive</td> </tr> <tr> <td>J Allergy Clin Immunol 1989; 84:839</td> <td>Clin Allergy 1982; 12(Suppl):53</td> <td>Clin Pulm Med 1996; 3:72</td> <td>Interstitial Lung Disease, Schwarz MI, King TE Jr, (Eds), 5th ed, Shelton, CT, People's Medical Publishing House, 2011</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 61909 Version 3.0</div></div></div>"},"61910":{"type":"graphic_diagnosticimage","displayName":"2D TTE four-chamber descending thoracic aorta ","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from a modified four-chamber view showing the descending thoracic aorta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from a modified four-chamber view showing the descending thoracic aorta</div><div class=\"cntnt\"><img style=\"width:203px; height:385px;\" src=\"images/CARD/61910_2_4_chamber_thor_aort1_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The thoracic or descending aorta (T Ao) can be imaged from the apical two- and four-chamber view. Posterior angulation (panel B) shows the T Ao in its short axis, located below the left atrium (LA). Anterior angulation in four-chamber view (panel A) shows the origin of aortic root (Ao).</div><div class=\"graphic_footnotes\">RA: right atrium; LA: left atrium.</div><div id=\"graphicVersion\">Graphic 61910 Version 7.0</div></div></div>"},"61913":{"type":"graphic_diagnosticimage","displayName":"Metastatic ca to pleura I CT","title":"Metastatic breast cancer to pleura","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metastatic breast cancer to pleura</div><div class=\"cntnt\"><img style=\"width:342px; height:338px;\" src=\"images/PULM/61913_Metastatic_ca_to_pleura_I_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Status post right mastectomy. CT scan shows small left pleural effusion and larger right pleural effusion with tumor masses, leading to cardiomediastinal shift to the left. Sclerosis of the sternum is due to osteoblastic metastatic disease.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 61913 Version 3.0</div></div></div>"},"61914":{"type":"graphic_picture","displayName":"Pulmonary hamartoma gross","title":"Pulmonary hamartoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary hamartoma</div><div class=\"cntnt\"><img style=\"width:340px; height:266px;\" src=\"images/PULM/61914_Pulmonary_hamartoma_gross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph of a pulmonary hamartoma shows a well circumscribed mass with a variegated yellow and white appearance, which corresponds to fat and cartilage respectively.</div><div class=\"graphic_reference\">From Colby, TV, Koss, MN, Travis, WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.</div><div id=\"graphicVersion\">Graphic 61914 Version 1.0</div></div></div>"},"61915":{"type":"graphic_picture","displayName":"Nail bed repair","title":"Nail bed repair","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nail bed repair</div><div class=\"cntnt\"><img style=\"width:207px; height:252px;\" src=\"images/EM/61915_Nail_bed_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The nail bed is easily torn with the suture needle. Optimal results are typically achieved if the needle is passed from the distal to the proximal aspect of the nail bed.</div><div class=\"graphic_reference\">Courtesy of Peter M. Antevy, MD.</div><div id=\"graphicVersion\">Graphic 61915 Version 1.0</div></div></div>"},"61916":{"type":"graphic_table","displayName":"Specific ways to save your energy PI","title":"Specific ways to save your energy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Specific ways to save your energy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Bathing and grooming</td> </tr> <tr> <td>Wash your hair in the shower rather than over a sink.</td> </tr> <tr> <td>Use a terry robe instead of towels to dry off.</td> </tr> <tr> <td>Use organizers to keep things within reach.</td> </tr> <tr> <td>Use a chair in the shower or tub.</td> </tr> <tr> <td>Use a long-handled sponge or brush to reach your back and feet.</td> </tr> <tr> <td>Rest your elbows on the counter or dressing table for support.</td> </tr> <tr> <td>Use long-handled brushes or combs to avoid holding your arms overhead.</td> </tr> <tr> <td>Use liquid soap or soap on a rope.</td> </tr> <tr> <td>Use a raised toilet seat.</td> </tr> <tr> <td class=\"subtitle1_single\">Dressing</td> </tr> <tr> <td>Wear loose clothes that are easier to put on and take off.</td> </tr> <tr> <td>Bring your foot to your knee to put on socks and shoes, so that you don't have to bend over.</td> </tr> <tr> <td>Wear slip-on shoes or shoes with Velcro closures.</td> </tr> <tr> <td>Use a long-handled shoe horn.</td> </tr> <tr> <td>Fasten your bra in front and then turn it around.</td> </tr> <tr> <td>Wear clothes that button in front instead of clothes that button in back or pull over your head.</td> </tr> <tr> <td>Use a reacher or dressing stick to help with zippers in back.</td> </tr> <tr> <td class=\"subtitle1_single\">Housework</td> </tr> <tr> <td>Spread tasks out over the week or month.</td> </tr> <tr> <td>Hire help.</td> </tr> <tr> <td>Use long-handled dusters, mops, or dust pans.</td> </tr> <tr> <td>Use an automatic washer and dryer, if possible.</td> </tr> <tr> <td>Use a lightweight iron.</td> </tr> <tr> <td class=\"subtitle1_single\">Shopping</td> </tr> <tr> <td>Make a list.</td> </tr> <tr> <td>Organize your shopping list by store aisle.</td> </tr> <tr> <td>Ask for help in stores.</td> </tr> <tr> <td>Have your groceries delivered, if possible.</td> </tr> <tr> <td>Use canned, frozen, or other prepared foods. You can also order food to be delivered from a restaurant.</td> </tr> <tr> <td>On days when you feel well, cook extra food and freeze it in small containers. Reheat the frozen food on days when you're tired.</td> </tr> <tr> <td>Ask your doctor, nurse, or social worker about community resources that deliver cooked meals.</td> </tr> <tr> <td>Eat small, frequent meals instead of several large meals each day.</td> </tr> <tr> <td>Have snack foods readily available.</td> </tr> <tr> <td>Put some favorite foods and beverages in a cooler with ice next to you as you rest.</td> </tr> <tr> <td>Make quick meals with a microwave or blender.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 61916 Version 2.0</div></div></div>"},"61917":{"type":"graphic_diagnosticimage","displayName":"Ultrasound femoral vessels","title":"Ultrasound of normal femoral vessels","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound of normal femoral vessels</div><div class=\"cntnt\"><img style=\"width:329px; height:463px;\" src=\"images/EM/61917_US_femoral_vessels.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse ultrasound images of the right groin demonstrate the normal vascular orientation, with the common femoral vein (blue arrow) medial to the common femoral artery (red arrow). Nearby muscles are also seen, including the sartorius (S), rectus femoris (RF), and pectineus (P).<br />(A) Image of the right groin without compression shows the patent common femoral artery and vein.<br />(B) Image of the right groin with compression shows collapse of the common femoral vein while the artery remains patent.</div><div class=\"graphic_reference\">Courtesy of Lauren W Averill, MD.</div><div id=\"graphicVersion\">Graphic 61917 Version 4.0</div></div></div>"},"61919":{"type":"graphic_diagnosticimage","displayName":"Exencephaly","title":"Exencephalic fetus at 17 postmenstrual weeks","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Exencephalic fetus at 17 postmenstrual weeks</div><div class=\"cntnt\"><img style=\"width:314px; height:265px;\" src=\"images/OBGYN/61919_Exencephaly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The facial bones can be observed. However, no distinct cranial vault is seen above the level of the forehead. The brain falls to one side and appears as a heterogeneous, solid structure (arrow).</div><div id=\"graphicVersion\">Graphic 61919 Version 4.0</div></div></div>"},"61920":{"type":"graphic_picture","displayName":"Bowens disease","title":"Bowen's disease/squamous cell carcinoma in situ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bowen's disease/squamous cell carcinoma in situ</div><div class=\"cntnt\"><img style=\"width:260px; height:177px;\" src=\"images/ONC/61920_Bowens_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A well-demarcated, erythematous, scaling plaque that can resemble eczema, psoriasis, or superficial basal cell carcinoma.</div><div class=\"graphic_reference\">Courtesy of Clara Curiel, MD.</div><div id=\"graphicVersion\">Graphic 61920 Version 1.0</div></div></div>"},"61921":{"type":"graphic_figure","displayName":"Mammary line","title":"Location of accessory nipples","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Location of accessory nipples</div><div class=\"cntnt\"><img style=\"width:370px; height:454px;\" src=\"images/PEDS/61921_Mammary_line.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Location of accessory nipples (blue line, mammary line).</div><div class=\"graphic_reference\">Reproduced with permission from: Sadler T, PhD. Langman's Medical Embryology, Ninth Edition Image Bank. Baltimore: Lippincott Williams &amp; Wilkins, 2003. Copyright &#169;2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 61921 Version 1.0</div></div></div>"},"61923":{"type":"graphic_figure","displayName":"Cobb angle measurement 2","title":"Cobb angle measurement of kyphosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cobb angle measurement of kyphosis</div><div class=\"cntnt\"><img style=\"width:386px; height:464px;\" src=\"images/PC/61923_Cobb_angle_measurement_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Kado DM, Christianson L, Palermo L, et al. Comparing a supine radiologic versus standing clinical measurement of kyphosis in older women: the Fracture Intervention Trial. Spine 2006; 31:463. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 61923 Version 9.0</div></div></div>"},"61924":{"type":"graphic_picture","displayName":"Posterior blepharitis","title":"Posterior blepharitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior blepharitis</div><div class=\"cntnt\"><img style=\"width:432px; height:283px;\" src=\"images/PC/61924_Posterior_blepharitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lower eyelid with characteristic posterior lid inflammation and oily white plugs visible at the meibomian gland openings.</div><div id=\"graphicVersion\">Graphic 61924 Version 1.0</div></div></div>"},"61925":{"type":"graphic_table","displayName":"Orbital fracture overview","title":"Rapid overview of orbital fractures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid overview of orbital fractures</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Initial assessment and stabilization:</td> </tr> <tr> <td>Identify life-threatening injuries. Provide cervical spine immobilization when indicated.</td> </tr> <tr> <td>Identify globe threatening injuries (orbital hematoma, ruptured globe, optic nerve sheath hematoma).</td> </tr> <tr> <td>Identify injuries that may threaten vision or result in a poor cosmetic outcome. Assessment of visual acuity is essential in all patients.&nbsp;Slit lamp examination should be performed, whenever possible.</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical features - The following clinical features indicate an orbital fracture with significant associated injury:</td> </tr> <tr> <td>Proptosis - orbital hematoma</td> </tr> <tr> <td>Widened intracanthal distance - disruption of medial canthal ligament</td> </tr> <tr> <td>Orbital dystopia (affected eye is lower in the horizontal plane than the other) and/or enophthalmos (eye is receded into orbit) - orbital floor fracture</td> </tr> <tr> <td>Limitation of extraocular motility - entrapped muscle</td> </tr> <tr> <td>Decreased visual acuity - intraocular injury</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic evaluation - Thin cut coronal computed tomography should be obtained for patients with any of the following findings:</td> </tr> <tr> <td>Evidence of an orbital fracture on physical examination</td> </tr> <tr> <td>Limitation of extraocular motility</td> </tr> <tr> <td>Decreased visual acuity</td> </tr> <tr> <td>Severe pain</td> </tr> <tr> <td class=\"subtitle1_single\">Management - Following resuscitation and stabilization, patients with the following injuries require immediate ophthalmologic consultation:</td> </tr> <tr> <td>Globe injuries</td> </tr> <tr> <td>Severe vagal symptoms (nausea, vomiting, and bradycardia) secondary to stimulation of the oculocardiac reflex</td> </tr> <tr> <td class=\"subtitle1_single\">Patients with the following symptoms should be evaluated by an ophthalmologist within 24 hours:</td> </tr> <tr> <td>Muscle entrapment (either inferior rectus or medial rectus)</td> </tr> <tr> <td>Enophthalmos or orbital dystopia</td> </tr> <tr> <td class=\"subtitle1_single\">We suggest that patients with an orbital fracture receive the following:</td> </tr> <tr> <td>Follow up with an ophthalmologist within one week</td> </tr> <tr> <td>Prophylactic antibiotics for fractures that involve a sinus</td> </tr> <tr> <td>Corticosteroids for patients with limitation of extraocular movement</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 61925 Version 3.0</div></div></div>"},"61927":{"type":"graphic_figure","displayName":"Streak ovaries","title":"Pelvic organs in a patient with complete failure of gonadal development","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pelvic organs in a patient with complete failure of gonadal development</div><div class=\"cntnt\"><img style=\"width:436px; height:301px;\" src=\"images/OBGYN/61927_Streak_ovaries.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The bilateral streak ovaries can be found attached to the posterior broad ligament.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 61927 Version 1.0</div></div></div>"},"61928":{"type":"graphic_figure","displayName":"SPEP in WM","title":"Serum protein electrophoresis in Waldenström macroglobulinemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Serum protein electrophoresis in Waldenstr&#246;m macroglobulinemia</div><div class=\"cntnt\"><img style=\"width:236px; height:417px;\" src=\"images/HEME/61928_SPEP_in_WM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure shows a serum protein electrophoresis (SPEP) pattern in a patient with Waldenstr&ouml;m macroglobulinemia with a monoclonal (M) protein in the gamma region (asterisk). Immunofixation (IFE) shows that the M protein is IgM kappa.</div><div id=\"graphicVersion\">Graphic 61928 Version 4.0</div></div></div>"},"61930":{"type":"graphic_figure","displayName":"Survival of CF patients","title":"Median predicted survival of patients with cystic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Median predicted survival of patients with cystic fibrosis</div><div class=\"cntnt\"><img style=\"width:500px; height:368px;\" src=\"images/PULM/61930_Survival_CF_patients_2016.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>1940 &ndash; 1978. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med 1996; 154:1229.</li>&#xD;&#xA;    <li>1990 &ndash; 2015. Cystic Fibrosis Foundation Patient Registry, 2015 Annual Data Report, Bethesda, MD. (Each point represents a rolling 5 year average).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 61930 Version 13.0</div></div></div>"},"61931":{"type":"graphic_figure","displayName":"Plantar anatomy","title":"Plantar anatomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plantar anatomy</div><div class=\"cntnt\"><img style=\"width:433px; height:598px;\" src=\"images/RHEUM/61931_Plantar_anatomy_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The regional anatomy of the plantar (sole) aspect of the foot is illustrated above. The plantar and medial views of the foot show the origin of the plantar fascia (at the calcaneus) and its insertion onto the plantar aspect of the toes. Also illustrated are the locations of adjacent innervation and the windlass mechanism, or bowstring effect, of the plantar fascia that serves to raise the arch of the foot as the toes are extended during the push-off phase of walking.</div><div class=\"graphic_reference\">Reproduced with permission from: Clay JH, Pounds DM. Basic Clinical Massage Therapy: Integrating Anatomy and Treatment, 2nd ed. Philadelphia: Lippincott Williams &amp; Wilkins, 2008. Copyright &#169; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 61931 Version 5.0</div></div></div>"},"61932":{"type":"graphic_table","displayName":"Survival after nutrition and hydration cessation","title":"Survival duration after the decision to forgo artificial nutrition and hydration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Survival duration after the decision to forgo artificial nutrition and hydration</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Duration</td> <td class=\"subtitle1\">Absolute number</td> <td class=\"subtitle1\">Percent</td> <td class=\"subtitle1\">Cumulative percent</td> </tr> <tr> <td>0 to 2 days</td> <td class=\"centered\">50</td> <td class=\"centered\">28</td> <td class=\"centered\">28</td> </tr> <tr> <td>3 to 7 days</td> <td class=\"centered\">56</td> <td class=\"centered\">31</td> <td class=\"centered\">59</td> </tr> <tr> <td>1 to 2 weeks</td> <td class=\"centered\">28</td> <td class=\"centered\">16</td> <td class=\"centered\">75</td> </tr> <tr> <td>2 to 6 weeks</td> <td class=\"centered\">17</td> <td class=\"centered\">10</td> <td class=\"centered\">85</td> </tr> <tr> <td>Greater than 6 weeks</td> <td class=\"centered\">27</td> <td class=\"centered\">15</td> <td class=\"centered\">100</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Pasman HR, Onwuteaka-Philipsen BD, Kriegsman DM, et al. Discomfort in nursing home patients with severe dementia in whom artificial nutrition and hydration is forgone. Arch Intern Med 2005; 165:1729.</div><div id=\"graphicVersion\">Graphic 61932 Version 5.0</div></div></div>"},"61933":{"type":"graphic_picture","displayName":"Amanita muscaria variant-fly agaric mushroom","title":"Amanita muscaria variant: A. guessowii (fly agaric mushroom)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amanita muscaria variant: A. guessowii (fly agaric mushroom)</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/EM/61933_Amanita_muscaria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Amanita muscaria species contain the toxins muscimol and ibotenic acid. While occasionally causing euphoria more common effects include delirium, hyperactivity and coma. This sample was growing in the backyard of one of the Specialists in Poison Information for the Ruth Lawrence Poison and Drug Information Center at the University of Rochester Medical Center. Note the large red-orange cap of these mushrooms with the typical white plaques or spots. These mushrooms are also known as \"fly agaric\" mushrooms because of their ability to attract and kill flies that land on them.</div><div class=\"graphic_reference\">Courtesy of Paul Dengler.</div><div id=\"graphicVersion\">Graphic 61933 Version 4.0</div></div></div>"},"61934":{"type":"graphic_diagnosticimage","displayName":"Child humeral fracture","title":"Child humeral fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Child humeral fracture</div><div class=\"cntnt\"><img style=\"width:299px; height:406px;\" src=\"images/EM/61934_Child_humeral_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Diaphyseal humeral shaft fracture in 12-year-old boy treated in coaptation splint.<br />(B) Union at two months with mild varus angulation.</div><div class=\"graphic_reference\">Reprinted with permission from: Beaty JH. Fractures of the proximal humerus and shaft in children, in Eilert RE (ed): Instructional Course Lectures 41. Rosemont, IL, American Academy of Orthopaedic Surgeons, 1992, pp 369-372.</div><div id=\"graphicVersion\">Graphic 61934 Version 3.0</div></div></div>"},"61935":{"type":"graphic_table","displayName":"Causes of acute pharyngitis","title":"Causes of acute pharyngitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of acute pharyngitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Estimated frequency, percent</td> <td class=\"subtitle1\">Examples</td> </tr> <tr> <td rowspan=\"3\"><strong>Common bacterial pathogens</strong></td> <td rowspan=\"3\">15</td> <td>Group A streptococci</td> </tr> <tr> <td>Group C streptococci</td> </tr> <tr> <td>Group G streptococci</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"8\"><strong>Less common bacterial pathogens</strong></td> <td rowspan=\"8\">&#60;5</td> <td><em>Chlamydophila pneumoniae </em>(TWAR)</td> </tr> <tr> <td><em>Mycoplasma pneumoniae</em></td> </tr> <tr> <td><em>Arcanobacterium haemolyticum</em></td> </tr> <tr> <td><em>Corynebactrium diphtheriae</em></td> </tr> <tr> <td><em>Fusobacterium necrophorum</em></td> </tr> <tr> <td><em>Neisseria gonorrheae</em></td> </tr> <tr> <td><em>Treponema pallidum</em></td> </tr> <tr> <td><em>Francisella tularensis</em></td> </tr> <tr class=\"divider_top\"> <td rowspan=\"13\"><strong>Viruses</strong></td> <td rowspan=\"13\">50</td> <td>Rhinovirus</td> </tr> <tr> <td>Adenovirus</td> </tr> <tr> <td>Influenza A and B</td> </tr> <tr> <td>Parainfluenza</td> </tr> <tr> <td>Coxsackievirus</td> </tr> <tr> <td>Coronavirus</td> </tr> <tr> <td>Echovirus</td> </tr> <tr> <td>Herpes simplex virus</td> </tr> <tr> <td>Epstein Barr virus</td> </tr> <tr> <td>Human immunodeficiency virus</td> </tr> <tr> <td>Cytomegalovirus</td> </tr> <tr> <td>Respiratory syncytial virus</td> </tr> <tr> <td>Metapneumovirus</td> </tr> <tr class=\"divider_top\"> <td><strong>No pathogen isolated</strong></td> <td>30</td> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 61935 Version 6.0</div></div></div>"},"61936":{"type":"graphic_table","displayName":"Mycobacteria classification","title":"Classification of mycobacterial species causing human disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of mycobacterial species causing human disease</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\"><em><em></em>Mycobacterium tuberculosis</em> complex</td> </tr> <tr> <td><em>M. tuberculosis</em></td> </tr> <tr> <td><em>M. bovis</em></td> </tr> <tr> <td><em>M. africanum</em></td> </tr> <tr> <td><em>M. microti</em></td> </tr> <tr> <td><em>M. canetti</em></td> </tr> <tr> <td class=\"subtitle1_single\"><em>M. leprae</em></td> </tr> <tr> <td class=\"subtitle1_single\">Rapidly growing nontuberculous mycobacteria</td> </tr> <tr> <td class=\"sublist1_start\"><em>M. fortuitum </em>complex</td> </tr> <tr> <td class=\"sublist1\"><em>M. fortuitum</em></td> </tr> <tr> <td class=\"sublist1\"><em>M. peregrinum</em></td> </tr> <tr> <td class=\"sublist1\"><em>M. porcinum</em></td> </tr> <tr> <td><em>M. chelonae</em></td> </tr> <tr> <td class=\"sublist1_start\"><em>M. abscessus</em></td> </tr> <tr> <td class=\"sublist1\"><em>M. abscessus </em>subspecies<em> abscessus</em></td> </tr> <tr> <td class=\"sublist1\"><em>M</em>. <em>abscessus </em>subspecies<em> </em><em>bolletii</em></td> </tr> <tr> <td class=\"sublist1\"><em>M</em>. <em>abscessus </em>subspecies<em> </em><em>massiliense</em>&nbsp;</td> </tr> <tr> <td><em>M. smegmatis</em></td> </tr> <tr> <td><em>M. mucogenicum</em></td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Slowly growing nontuberculous mycobacteria</td> </tr> <tr> <td class=\"subtitle2_single\">Photochromogens</td> </tr> <tr> <td class=\"indent1\"><em>M. kansasii</em></td> </tr> <tr> <td class=\"indent1\"><em>M. marinum</em></td> </tr> <tr> <td class=\"subtitle2_single\">Scotochromogens</td> </tr> <tr> <td class=\"indent1\"><em>M. gordonae</em></td> </tr> <tr> <td class=\"indent1\"><em>M. scrofulaceum</em></td> </tr> <tr> <td class=\"subtitle2_single\">Nonchromogens</td> </tr> <tr> <td class=\"sublist2_start\"><em>M. avium </em>complex</td> </tr> <tr> <td class=\"sublist2\"><em>M. avium</em></td> </tr> <tr> <td class=\"sublist2\"><em>M. intracellulare</em></td> </tr> <tr> <td class=\"sublist2\"><em>M. chimaera</em></td> </tr> <tr> <td class=\"indent1\"><em>M. terrae</em> complex</td> </tr> <tr> <td class=\"indent1\"><em>M. ulcerans</em></td> </tr> <tr> <td class=\"indent1\"><em>M. xenopi</em></td> </tr> <tr> <td class=\"indent1\"><em>M. simiae</em></td> </tr> <tr> <td class=\"indent1\"><em>M. malmoense</em></td> </tr> <tr> <td class=\"indent1\"><em>M. szulgai</em></td> </tr> <tr> <td class=\"indent1\"><em>M. asiaticum</em></td> </tr> <tr> <td class=\"indent1\"><em>M. haemophilum</em></td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 61936 Version 12.0</div></div></div>"},"61938":{"type":"graphic_movie","displayName":"TEE contrast atrial septal defect","title":"Transesophageal echocardiography with contrast of a large atrial septal defect","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiography with contrast of a large atrial septal defect</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/61938_teeasdwcconv.mp4\" style=\"width:383px;height:276px\"></div><img style=\"width:498px; height:242px;\" src=\"images/CARD/61938_teeasdwc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast is seen filling the right atrium (RA) in systole and an atrial septal defect (ASD) can be seen. During diastole a large amount of contrast (red arrow) passes from the RA to the left atrium through the ASD as a result of right to left shunting of blood.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 61938 Version 2.0</div></div></div>"},"61940":{"type":"graphic_diagnosticimage","displayName":"Cryptogenic organizing pneumonia CT II","title":"Cryptogenic organizing pneumonitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cryptogenic organizing pneumonitis</div><div class=\"cntnt\"><img style=\"width:303px; height:288px;\" src=\"images/PULM/61940_BOOP_CT_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sixty-two-year-old man with a one-month history of dyspnea with exertion, fatigue, and weight loss. High resolution CT scan shows patchy airspace consolidation in the right lower lobes (multiple similar opacities were seen in both lungs). Air bronchograms also are present.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King Jr, MD.</div><div id=\"graphicVersion\">Graphic 61940 Version 3.0</div></div></div>"},"61941":{"type":"graphic_figure","displayName":"Deep veins of the upper extremity","title":"Deep veins of the upper extremity","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Deep veins of the upper extremity</div><div class=\"cntnt\"><img style=\"width:467px; height:695px;\" src=\"images/SURG/61941_Upper-extremity-deep-veins.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The deep veins of the upper extremity include the paired ulnar, radial, and interosseous veins in the forearm; paired brachial veins of the upper arm; and axillary vein. The axillary vein originates at the lower border of the teres major muscle in continuity with the brachial veins. The basilic and cephalic veins, which are superficial veins, contribute to the axillary vein, though many anatomic variations occur. After passing the outer margin of the first rib, the axillary vein continues as the subclavian vein.</div><div id=\"graphicVersion\">Graphic 61941 Version 5.0</div></div></div>"},"61946":{"type":"graphic_diagnosticimage","displayName":"PDA arteriogram III","title":"Patent ductus arteriosus arteriogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patent ductus arteriosus arteriogram</div><div class=\"cntnt\"><img style=\"width:407px; height:404px;\" src=\"images/CARD/61946_PDA_arteriogram_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A lateral angiogram of the transverse aortic arch and descending aorta (Ao) demonstrating a patent ductus arteriosus (arrow) with left to right shunt of contrast into the main pulmonary artery (MPA).</div><div class=\"graphic_reference\">Courtesy of Kevin Hill, MD.</div><div id=\"graphicVersion\">Graphic 61946 Version 3.0</div></div></div>"},"61948":{"type":"graphic_figure","displayName":"Blood volume in pregnancy","title":"Total blood volume, plasma volume, and red cell volume in normal pregnancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Total blood volume, plasma volume, and red cell volume in normal pregnancy</div><div class=\"cntnt\"><img style=\"width:438px; height:425px;\" src=\"images/OBGYN/61948_Blood_volume_in_pregnancy.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Shnider SM, Levinson G. Anesthesia for Obstetrics, 3<SUP>rd</SUP> ed, Williams &amp; Wilkins, Baltimore 1993. p.8.</div><div id=\"graphicVersion\">Graphic 61948 Version 5.0</div></div></div>"},"61951":{"type":"graphic_table","displayName":"Normal ausculatory findings of prosthetic valves","title":"Normal auscultatory findings of prosthetic valves according to type and location","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal auscultatory findings of prosthetic valves according to type and location</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Valve prosthesis</td> <td class=\"subtitle1\" colspan=\"2\">Auscultatory Findings</td> </tr> <tr> <td class=\"subtitle2\">Mitral</td> <td class=\"subtitle2\">Aortic </td> </tr> <tr> <td rowspan=\"4\">Ball valves (eg, Starr-Edwards)&nbsp;&nbsp;</td> <td>A2-MO interval 0.07 to 0.11 second</td> <td>S1-AO interval 0.07 second</td> </tr> <tr> <td>MO louder than MC</td> <td>AO louder than AC</td> </tr> <tr> <td>Soft systolic murmur </td> <td>Soft, harsh systolic ejection murmur</td> </tr> <tr> <td>No diastolic murmur</td> <td>\"Seating puff\" - diastolic rumble</td> </tr> <tr> <td rowspan=\"4\">Disc valves (eg, Bjork-Shiley)</td> <td>A2-MO interval 0.05 to 0.09 second</td> <td>S1-AO interval 0.04 second</td> </tr> <tr> <td>MO is soft or may not be audible</td> <td>AC louder than AO</td> </tr> <tr> <td>Soft systolic murmur </td> <td>Soft systolic ejection murmur </td> </tr> <tr> <td>Soft and short diastolic rumble</td> <td>\"Seating puff\" - diastolic rumble</td> </tr> <tr> <td rowspan=\"5\">Tissue valves (eg, Hancock)</td> <td>A2-MO interval 0.1 second</td> <td>S1-AO interval 0.03 to 0.08 second</td> </tr> <tr> <td>MC louder than MO</td> <td>AC louder than AO</td> </tr> <tr> <td>MO is audible in approximately 50%</td> <td>AO may be absent </td> </tr> <tr> <td>Soft apical systolic murmur</td> <td>Soft systolic ejection murmur</td> </tr> <tr> <td>Soft diastolic ramble</td> <td>No diastolic rumble</td> </tr> <tr> <td rowspan=\"2\">Bileaflet valves (eg, St. Jude)</td> <td>&nbsp;</td> <td>Loud AO and AC&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>Soft systolic ejection murmur</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">A2: aortic valve closure sound; MO: mitral prosthesis opening sound; MC: mitral prosthesis closing sound; S1: first heart sound; AO: aortic prosthesis opening sound; AC: aortic prosthesis closing sound. </div><div class=\"graphic_reference\">Data from Smith ND, Ralzada V, Abrams J: Auscultation of the normally functioning prosthetic valve. Ann Intern Med 95:594, 1981.</div><div id=\"graphicVersion\">Graphic 61951 Version 3.0</div></div></div>"},"61952":{"type":"graphic_diagnosticimage","displayName":"Subperiosteal abscess CT","title":"Subperiosteal abscess by CT scan","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subperiosteal abscess by CT scan</div><div class=\"cntnt\"><img style=\"width:372px; height:463px;\" src=\"images/ID/61952_Subperiosteal_abscess_CT_ed.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This CT scan with intravenous contrast shows a medial subperiosteal abscess associated with maxillary and ethmoid sinusitis. The arrows indicate the location of the subperiosteal abscess.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Harris GJ. Trans Am Ophthalmol Soc 1993; 91:474.</div><div id=\"graphicVersion\">Graphic 61952 Version 5.0</div></div></div>"},"61955":{"type":"graphic_picture","displayName":"Tripe palm","title":"Tripe palm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tripe palm</div><div class=\"cntnt\"><img style=\"width:266px; height:387px;\" src=\"images/DERM/61955_Tripe_palm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The palmar ridges show maximal accentuation, thus resembling the mucosa of the stomach of a ruminant (tripe palm).</div><div class=\"graphic_reference\">Reproduced with permission from: Fitzpatrick TB, Johnson RA, Wolff K, Suurmond D. Color Atlas of Clinical Dermatology: Common and Serious Diseases. McGraw Hill, New York 2001. p.151. Copyright © 2001 McGraw Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 61955 Version 4.0</div></div></div>"},"61957":{"type":"graphic_picture","displayName":"Mucinous cyst PI","title":"Cyst on the finger","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cyst on the finger</div><div class=\"cntnt\"><img style=\"width:315px; height:321px;\" src=\"images/PI/61957_Mucinous_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This person has a cyst on the finger joint nearest to the fingernail.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 61957 Version 1.0</div></div></div>"},"61958":{"type":"graphic_picture","displayName":"Measles lesions on face","title":"Measles","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Measles</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/61958_Measles_lesions_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous erythematous macules are present on the face and trunk.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 61958 Version 3.0</div></div></div>"},"61961":{"type":"graphic_waveform","displayName":"Advanced case 1","title":"Advanced case 1","html":"<div class=\"graphic normal\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Advanced case 1</div><div class=\"cntnt\"><img style=\"width:540px; height:285px;\" src=\"images/CARD/61961_Advanced_case_1.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 61961 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"61962":{"type":"graphic_table","displayName":"Motor automatisms","title":"Motor automatisms in Neonatal seizures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Motor automatisms in Neonatal seizures</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Ocular signs</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Random and roving eye movements or nystagmus (distinct from tonic eye deviation)</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">May be provoked or intensified by tactile stimulation</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Presumed pathophysiology: nonepileptic</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Oral-buccal-lingual movements</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Sucking, chewing, tongue protrusions</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">May be provoked or intensified by stimulation</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Presumed pathophysiology: nonepileptic</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Progression movements</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Rowing or swimming movements</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Pedaling or bicycling movements of the legs</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">May be provoked or intensified by stimulation</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">May be suppressed by restraint or repositioning</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Presumed pathophysiology: nonepileptic</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Complex purposeless movements</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Sudden arousal with transient increased random activity of limbs</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">May be provoked or intensified by stimulation</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Presumed pathophysiology: nonepileptic</td>\n\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted with permission from: Mizrahi, EM, Kellaway, P. Diagnosis and Management of Neonatal Seizures. Lippincott-Raven, Philadelphia 1998. p.181. Copyright &#169; 1998 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 61962 Version 2.0</div></div></div>"},"61965":{"type":"graphic_figure","displayName":"Peyronie's disease plaque cross section ","title":"Dorsal Peyronie's disease plaque on penile cross-section","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Dorsal Peyronie's disease plaque on penile cross-section</div><div class=\"cntnt\"><img style=\"width:496px; height:400px;\" src=\"images/SURG/61965_Penis_crossxn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tunica albuginea is a tough layer of fibrous connective tissue surrounding the corpora cavernosa and corpus spongiosum of the penis. Plaque in Peyronie's disease can form in the dorsal (as shown above), ventral, or lateral portions of the penis.</div><div id=\"graphicVersion\">Graphic 61965 Version 4.0</div></div></div>"},"61967":{"type":"graphic_diagnosticimage","displayName":"Brain MRI of a child with adrenoleukodystrophy","title":"Brain MRI of a child with adrenoleukodystrophy","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Brain MRI of a child with adrenoleukodystrophy</div><div class=\"cntnt\"><img style=\"width:480px; height:449px;\" src=\"images/PEDS/61967_MRI_adrenoleuk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial magnetic resonance image (MRI) from an eight-year-old male with adrenoleukodystrophy, demonstrating the typical posterior pattern involving occipitoparietal periventricular white matter and posterior corpus callosum.</div><div class=\"graphic_reference\">Courtesy of Alan K Percy, MD.</div><div id=\"graphicVersion\">Graphic 61967 Version 5.0</div></div></div>"},"61971":{"type":"graphic_figure","displayName":"Progestin effect on BMD 2","title":"BMD during/after DMPA use in adult women","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">BMD during/after DMPA use in adult women</div><div class=\"cntnt\"><img style=\"width:550px; height:345px;\" src=\"images/OBGYN/61971_Progestin_effect_on_BMD_2.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Scholes, D, LaCroix, AZ, Ichikawa, LE, et al. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 2002; 13:581. Copyright &#169;2002 Lippincott Williams and Wilkins.</div><div id=\"graphicVersion\">Graphic 61971 Version 1.0</div></div></div>"},"61972":{"type":"graphic_table","displayName":"Preterm birth rates US","title":"Percentage of preterm births based on gestational age in the United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Percentage of preterm births based on gestational age in the United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Year</td> <td class=\"subtitle1\">Total preterm*</td> <td class=\"subtitle1\">Late preterm<sup>&#182;</sup></td> <td class=\"subtitle1\">32 to 33 weeks</td> <td class=\"subtitle1\">28 to 31 weeks</td> <td class=\"subtitle1\">&nbsp;&#8804; 27 weeks</td> </tr> <tr> <td class=\"centered\">2015</td> <td class=\"centered\">9.62</td> <td class=\"centered\">6.87</td> <td class=\"centered\">1.17&nbsp;</td> <td class=\"centered\">0.91</td> <td class=\"centered\">&nbsp;0.68</td> </tr> <tr> <td class=\"centered\">2010</td> <td class=\"centered\">9.98</td> <td class=\"centered\">7.15</td> <td class=\"centered\">1.18</td> <td class=\"centered\">0.94</td> <td class=\"centered\">0.71</td> </tr> <tr> <td class=\"centered\">2007</td> <td class=\"centered\">10.44</td> <td class=\"centered\">7.51</td> <td class=\"centered\">1.22</td> <td class=\"centered\">0.97</td> <td class=\"centered\">0.74&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Preterm is less than 37 completed weeks of gestation.<br />¶ Late preterm is 34 to 36 completed weeks of gestation.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Martin JA, Hamilton BE, Osterman M, et al. Births: Final data for 2015. Natl Vital Stat Rep 2017; 66:1.</LI></OL></div><div id=\"graphicVersion\">Graphic 61972 Version 13.0</div></div></div>"},"61973":{"type":"graphic_picture","displayName":"Traumatic ulcer 1","title":"Traumatic gingival ulcer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traumatic gingival ulcer</div><div class=\"cntnt\"><img style=\"width:371px; height:240px;\" src=\"images/PEDS/61973_Traumatic_ulcer_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gingival ulceration resulting from a nervous habit of gingival scratching in an eight-year-old child.</div><div class=\"graphic_reference\">Reproduced with permission from: Delaney JE, Keels MA. Pediatric oral pathology. Soft tissue and periodontal conditions. Pediatr Clin North Am 2000; 47:1125. Copyright © 2000 W.B. Saunders.</div><div id=\"graphicVersion\">Graphic 61973 Version 3.0</div></div></div>"},"61974":{"type":"graphic_table","displayName":"Types of cold agglutinins","title":"Reactions of the cold agglutinins and their occurrence in clinical settings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Reactions of the cold agglutinins and their occurrence in clinical settings</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Specificity</td> <td class=\"subtitle1\" rowspan=\"2\">Antigen</td> <td class=\"subtitle1\" colspan=\"4\">Reaction to:</td> <td class=\"subtitle1\" rowspan=\"2\">Antibody</td> <td class=\"subtitle1\" rowspan=\"2\">Clinical presentation</td> </tr> <tr> <td class=\"subtitle2\">Adult RBC</td> <td class=\"subtitle2\">Fetal RBC</td> <td class=\"subtitle2\">Pro-T RBC</td> <td class=\"subtitle2\">Sial-T RBC</td> </tr> <tr> <td rowspan=\"2\">Anti-I</td> <td rowspan=\"2\">Branched aminyllactose polymers</td> <td rowspan=\"2\">++++</td> <td rowspan=\"2\">+</td> <td rowspan=\"2\">++++</td> <td rowspan=\"2\">++++</td> <td>IgM mono</td> <td>Benign chronic cold agglutin, non-aggressive lymphoma</td> </tr> <tr> <td>IgM oligo</td> <td><em>Mycoplasma pneumoniae</em> infection, other viruses</td> </tr> <tr> <td rowspan=\"2\">Anti-i</td> <td rowspan=\"2\">Linear aminyllactose polymers</td> <td rowspan=\"2\">+</td> <td rowspan=\"2\">++++</td> <td rowspan=\"2\">++++</td> <td rowspan=\"2\">+++++</td> <td>IgM mono</td> <td>Aggressive lymphoma</td> </tr> <tr> <td>IgM oligo</td> <td>Infectious mononucleosis</td> </tr> <tr> <td>Anti-Pr</td> <td>Polysaccharides on glycoproteins</td> <td>++++</td> <td>++++</td> <td>0</td> <td>0 to ++++</td> <td>IgM mono</td> <td>Benign or malignant lymphocytic proliferation</td> </tr> <tr> <td>Various</td> <td>Polysaccharides containing sialic acid</td> <td>+++</td> <td>+++</td> <td>+++</td> <td>0</td> <td>IgM mono</td> <td>Benign or malignant lymphocytic proliferation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Pro-T: protease-treated; Sial-T: sialidase-treated; mono: monoclonal; oligo: oligoclonal.</div><div id=\"graphicVersion\">Graphic 61974 Version 2.0</div></div></div>"},"61975":{"type":"graphic_table","displayName":"JSGE criteria for EMR","title":"Japanese Society for Gastroenterological Endoscopy criteria for endoscopic mucosal resection (EMR) of early endoluminal cancers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Japanese Society for Gastroenterological Endoscopy criteria for endoscopic mucosal resection (EMR) of early endoluminal cancers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Cancer</td> <td class=\"subtitle1\">JSGE type</td> <td class=\"subtitle1\">Criteria for EMR</td> </tr> <tr> <td rowspan=\"3\">Early gastric cancer</td> <td>I</td> <td>Less than or equal to 2 cm</td> </tr> <tr> <td>IIb and IIc</td> <td>Less than or equal to 1 cm</td> </tr> <tr> <td>Intestinal type adenocarcinoma</td> <td>Limited to the mucosa</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Esophageal cancer</td> <td rowspan=\"3\">I, IIa, IIb, IIc</td> <td>Diameter of less than or equal to 2 cm </td> </tr> <tr> <td>Involvement of less than one-third of the circumference of the esophageal wall</td> </tr> <tr> <td>Limitation to the mucosa of the esophagus</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">Colon cancer</td> <td>I</td> <td>Less than 3 cm</td> </tr> <tr> <td>IIa</td> <td>Less than 3 cm</td> </tr> <tr> <td>IIb</td> <td>Less than 5 mm</td> </tr> <tr> <td>IIc + IIa</td> <td>Less than 1 cm</td> </tr> <tr> <td>IIa + IIc</td> <td>Less than 1 cm</td> </tr> <tr> <td>IV</td> <td>Less than 3 cm</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Raju GS, Waxman I. High-frequency US probe sonography-assisted endoscopic mucosal resection. Gastrointest Endosc 2000; 52:S39.</div><div id=\"graphicVersion\">Graphic 61975 Version 2.0</div></div></div>"},"61978":{"type":"graphic_movie","displayName":"Shoulder and upper arm stretch video","title":"Flexibility exercise video: Shoulder and upper arm","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Flexibility exercise video: Shoulder and upper arm</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PC/61978_Shoulderupperarmmovie.mp4\" style=\"width:480px;height:336px\"></div><img style=\"width:374px; height:306px;\" src=\"images/PC/61978_ShoulduparmstretimgPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This exercise to increase flexibility in your shoulders and upper arms will help make it easier to reach for your seatbelt. If you have shoulder problems, talk with your doctor before trying this stretch.<br> <ol> <li>Stand with feet shoulder-width apart. </li> <li>Hold one end of a towel in your right hand. </li> <li>Raise and bend your right arm to drape the towel down your back. Keep your right arm in this position and continue holding on to the towel. </li> <li>Reach behind your lower back and grasp the towel with your left hand. </li> <li>To stretch your right shoulder, pull the towel down with your left hand. Stop when you feel a stretch or slight discomfort in your right shoulder. </li> <li>Repeat at least three to five times. </li> <li>Reverse positions, and repeat at least three to five times. </li> </ol></div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 61978 Version 1.0</div></div></div>"},"61979":{"type":"graphic_diagnosticimage","displayName":"CT middle ear trauma","title":"CT scan of middle ear trauma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan of middle ear trauma</div><div class=\"cntnt\"><img style=\"width:370px; height:426px;\" src=\"images/EM/61979_CT_middle_ear_trauma_edt3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Axial cuts from a CT scan of a patient after a Q-tip injury to the right ear. The stapes footplate is displaced into the vestibule of the inner ear, and an air bubble is noted in the vestibule. Note the subtle CT finding of displacement of the stapes footplate into the vestibule. This injury resulted in immediate hearing loss with intense vertigo associated with ipsilateral nystagmus and repeated episodes of emesis.<br />(B) Coronal cuts from the CT scan of the same patient.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Adele Karen Evans, MD, FAAP and Steven D Handler MD, MBE.</div><div id=\"graphicVersion\">Graphic 61979 Version 5.0</div></div></div>"},"61980":{"type":"graphic_table","displayName":"Gyn menstrual history","title":"Menstrual history","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Menstrual history</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">All women</td> </tr> <tr> <td>Age of menarche (onset of first period)</td> </tr> <tr> <td>Prior history of menstrual irregularity</td> </tr> <tr> <td>Prior history of heavy or intermenstrual bleeding</td> </tr> <tr> <td>Prior history of dysmenorrhea</td> </tr> <tr> <td class=\"subtitle1_single\">Women of reproductive age and in the menopausal transition</td> </tr> <tr> <td>Date of last menstrual period (lmp) (first day of bleeding or spotting)</td> </tr> <tr> <td>Date of previous menstrual period</td> </tr> <tr> <td>Current cycle length (interval between lmp and previous menstrual period) and regularity (cycle pattern over past year)</td> </tr> <tr> <td>Number of days of bleeding in an average menses</td> </tr> <tr> <td>Current or recent heavy or intermenstrual bleeding</td> </tr> <tr> <td>Current or recent postcoital bleeding</td> </tr> <tr> <td>Current or recent dysmenorrhea</td> </tr> <tr> <td>Presence of moliminal or premenstrual symptoms</td> </tr> <tr> <td class=\"subtitle1_single\">Postmenopausal women</td> </tr> <tr> <td>Age at last menses</td> </tr> <tr> <td>History of hormone therapy</td> </tr> <tr> <td>History of postmenopausal bleeding</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 61980 Version 4.0</div></div></div>"},"61981":{"type":"graphic_table","displayName":"Echinacea quality criteria","title":"Examples of echinacea products meeting specified quality criteria*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of echinacea products meeting specified quality criteria*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Product name (manufacturer or distributor)</td> </tr> <tr> <td>Gaia Herbs Echinacea Supreme (Gaia Herbs)</td> </tr> <tr> <td>GNC Herbal Plus Standardized Echinacea Extract (GNC Corp.)</td> </tr> <tr> <td>Rite Aid Echinacea (Rite Aid Corp.)</td> </tr> <tr> <td>Solgar Echinacea Herb Extract (Solgar Vitamin and Herb)</td> </tr> <tr> <td>Vitamin World Echinacea (Vitamin World, Inc.)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Full report available at www.consumerlab.com.</div><div class=\"graphic_footnotes\">* To pass testing, products had to meet all of the following criteria:<br /><OL>&#xD;&#xA;<LI>Absence of <EM>E. coli</EM>, <EM>Salmonella</EM> spp, <EM>Staphylococcus aureus</EM>, and <EM>Pseudomonas aeruginosa</EM>. </LI>&#xD;&#xA;<LI>Less than 10<SUP>5</SUP> aerobic bacteria, 10<SUP>3</SUP> yeast/mold, and 10<SUP>3</SUP> other coliform bacteria per gram. </LI>&#xD;&#xA;<LI>Meets the State of California's Prop 65 limits for lead in supplements. </LI>&#xD;&#xA;<LI>Contains &lt;0.3 mcg/gram (parts per million) of cadmium for dried herb or &lt;0.1 mcg/gram for extracts. </LI>&#xD;&#xA;<LI>Contains &lt;10 mcg of arsenic per daily serving. </LI>&#xD;&#xA;<LI>Concentration of any detectable chlorinated pesticide residue(s) must be less than the individual limit(s) listed by the US Pharmacopeial Convention (USP). </LI>&#xD;&#xA;<LI>Meets recommended USP parameters for disintegration for dietary supplements. </LI>&#xD;&#xA;<LI>Meets all US Food and Drug Administration (FDA) labeling requirements. </LI></OL></div><div id=\"graphicVersion\">Graphic 61981 Version 9.0</div></div></div>"},"61982":{"type":"graphic_table","displayName":"Nonpharmacologic therapies for subacute or chronic low back pain","title":"Nonpharmacologic therapies for subacute or chronic low back pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nonpharmacologic therapies for subacute or chronic low back pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Intervention</td> <td class=\"subtitle1\">Net benefit*</td> <td class=\"subtitle1\">Graded recommendation<sup>&#182;</sup></td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Acupuncture</td> <td>Moderate</td> <td>Suggested <strong>(2B)</strong></td> <td>Efficacy of acupuncture versus sham acupuncture inconsistent</td> </tr> <tr> <td>Cognitive behavioral therapy</td> <td>Moderate</td> <td>Suggested <strong>(2B)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Exercise therapy</td> <td>Moderate</td> <td>Suggested <strong>(2B)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Functional restoration</td> <td>Moderate</td> <td>Suggested <strong>(2B)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Interdisciplinary rehabilitation</td> <td>Moderate</td> <td>Suggested <strong>(2B)</strong></td> <td>More intense interdisciplinary rehabilitation more effective than less intense interdisciplinary rehabilitation</td> </tr> <tr> <td>Interferential therapy</td> <td>Unable to estimate</td> <td>Suggest not using <strong>(2B)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Low-level laser therapy</td> <td>Unable to estimate</td> <td>Suggest not using <strong>(2B)</strong></td> <td>Trials evaluated different types and intensity of laser, with inconsistent findings</td> </tr> <tr> <td>Lumbar supports</td> <td>Unable to estimate</td> <td>Suggest not using <strong>(2C)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Massage therapy</td> <td>Unable to estimate</td> <td>Suggested not using&nbsp;<strong>(2B)</strong></td> <td>Some trials evaluated minimal or light massage techniques</td> </tr> <tr> <td>Mindfulness-based stress reduction</td> <td>Moderate</td> <td>Suggested <strong>(2B)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Percutaneous electrical nerve stimulation</td> <td>Unable to estimate</td> <td>Suggest not using <strong>(2B)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Shortwave diathermy</td> <td>Not effective</td> <td>Suggest not using <strong>(2B)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Spinal manipulation</td> <td>Moderate</td> <td>Suggested <strong>(2B)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Traction</td> <td>Not effective (for continuous traction)</td> <td>Suggest not using <strong>(2B)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Transcutaneous electrical nerve stimulation</td> <td>Unable to estimate</td> <td>Suggest not using <strong>(2B)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Ultrasound</td> <td>Unable to estimate</td> <td>Suggest not using <strong>(2B)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Yoga</td> <td>Moderate (for Viniyoga)</td> <td>Suggested <strong>(2B)</strong></td> <td>Insufficient evidence to judge non-Viniyoga techniques</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Based on evidence showing medication is more effective than placebo, and/or evidence showing medication is at least as effective as other medications or interventions thought to be effective, for one or more of the following outcomes: pain, functional status, or work status. Versus placebo, small benefit defined as 5 to 10 points on a 100-point Visual Analogue Scale (VAS) for pain (or equivalent), 1 to 2 points on the Roland Morris Disability Questionnaire (RDQ), 10 to 20 points on the Oswestry Disability Index (ODI), or a standardized mean difference (SMD) of 0.2 to 0.5. Moderate benefit defined as 10 to 20 points on a VAS for pain, 2 to 5 points on the RDQ, 10 to 20 points on the ODI, or a SMD of 0.5 to 0.8. Large benefit defined as &gt;20 points on a 100-point VAS for pain; &gt;5 points on the RDQ, &gt;20 points on the ODI, or a SMD of &gt;0.8.<br />¶&nbsp;Grading:<br /><STRONG>1A</STRONG> - Strong recommendation. High-quality evidence. Strong recommendation, can apply to most patients in most circumstances without reservation.<br /><STRONG>1B</STRONG> - Strong recommendation. Moderate-quality evidence. Strong recommendation, likely to apply to most patients.<br /><STRONG>1C</STRONG> - Strong recommendation. Low-quality evidence. Relatively strong recommendation; might change when higher quality evidence becomes available.<br /><STRONG>2A</STRONG> - Weak recommendation. High-quality evidence. Weak recommendation, best action may differ depending on circumstances or patients or societal values.<br /><STRONG>2B</STRONG> - Weak recommendation. Moderate-quality evidence. Weak recommendation, alternative approaches likely to be better for some patients under some circumstances.<br /><STRONG>2C</STRONG> - Weak recommendation. Low-quality evidence. Very weak recommendation; other alternatives may be equally reasonable.</div><div id=\"graphicVersion\">Graphic 61982 Version 3.0</div></div></div>"},"61983":{"type":"graphic_table","displayName":"Diagnosis of COPD - PFTs","title":"Diagnosis of chronic obstructive pulmonary disease: PFTs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnosis of chronic obstructive pulmonary disease: PFTs</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_single\">Spirometry</td> </tr> <tr> <td class=\"indent1\">Spirometry is the essential test to confirm the diagnosis and establish the staging of COPD. If values are abnormal, a post-bronchodilator test may be indicated. Airflow limitation that is irreversible or only partially reversible with bronchodilator is suggestive of COPD rather than asthma. A postbronchodilator ratio of FEV1/FVC &#60;0.7 or &#60;LLN of FEV1/FVC is used to establish the presence of airflow limitation.</td> </tr> <tr> <td class=\"indent1\"> <p>In the presence of a low FEV1/FVC, the percent of predicted FEV1 is used to determine the severity of airflow limitation.</p> <p>GOLD 1: Mild (FEV1 &#8805;80 percent predicted)</p> <p>GOLD 2: Moderate (50 percent predicted &#8804;FEV1 &#60;80 percent predicted)</p> <p>GOLD 3: Severe (30 percent predicted &#8804;FEV1 &#60;50 percent predicted)</p> <p>GOLD 4: Very severe (FEV1 &#60;30 percent predicted)</p> </td> </tr> <tr> <td class=\"subtitle2_single\">Lung volumes</td> </tr> <tr> <td class=\"indent1\">Body plethysmography to assess lung volumes is not necessary except in patients with a low FVC on spirometry (&#60;80 percent predicted) or when concomitant interstitial lung disease is suspected.</td> </tr> <tr> <td class=\"subtitle2_single\">Diffusing capacity for carbon monoxide</td> </tr> <tr> <td class=\"indent1\">Measurement of DLCO can help establish the presence of emphysema, but is not necessary for the routine diagnosis of COPD.</td> </tr> <tr> <td class=\"subtitle2_single\">Chest radiography</td> </tr> <tr> <td class=\"indent1\">Only diagnostic of severe emphysema, but is frequently obtained to exclude other lung diseases.</td> </tr> <tr> <td class=\"subtitle2_single\">Arterial blood gases (ABGs)</td> </tr> <tr> <td class=\"indent1\">Mild and moderate airflow obstruction - ABG usually not needed.</td> </tr> <tr> <td class=\"indent1\">Moderately severe airflow obstruction - ABG is optional, but oximetry should be done. ABGs are obtained if oxygen saturation is &#60;92 percent.</td> </tr> <tr> <td class=\"indent1\">Severe and very severe airflow obstruction - ABGs are essential to assess for hypercapnia.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PFTs: pulmonary function tests; COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; LLN: lower limit of normal; GOLD: Global Initiative for Chronic Obstructive Lung Disease; DLCO: diffusing capacity for carbon monoxide; ABG: arterial blood gas.<BR></div><div id=\"graphicVersion\">Graphic 61983 Version 2.0</div></div></div>"},"61986":{"type":"graphic_figure","displayName":"Prevalence arrhythmias pregnancy congenital heart disease","title":"Prevalence of arrhythmias during pregnancy in women with congenital heart disease","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Prevalence of arrhythmias during pregnancy in women with congenital heart disease</div><div class=\"cntnt\"><img style=\"width:491px; height:317px;\" src=\"images/CARD/61986_Arrythmias_pregnancy_CHD.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AOS: aortic stenosis; ASD: atrial septal defect; AVSD: atrioventricular septal defect; CC-TGA: congenital corrected transposition of the great arteries; CHD: congenital heart disease; PAVSD: pulmonary atresia with ventricular septal defect; TGA: transposition of the great arteries; TOF: tetralogy of Fallot.</div><div class=\"graphic_reference\">Data from: Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 2007; 49:2303.</div><div id=\"graphicVersion\">Graphic 61986 Version 4.0</div></div></div>"},"61989":{"type":"graphic_figure","displayName":"Conduction system action potentials","title":"Action potentials generated by different parts of conduction system","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Action potentials generated by different parts of conduction system</div><div class=\"cntnt\"><img style=\"width:305px; height:464px;\" src=\"images/CARD/61989_Conduction_system_action_po.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sinoatrial (SA) and atrioventricular (AV) nodes generate a slow action potential, mediated by calcium ions. In comparison, the tissues of the atria, ventricles, and the His-Purkinje system generate a fast action potential mediated by sodium ions. Sequential activation of these structures results in the characteristic waveforms visible on the surface electrocardiogram (ECG). The AV node and bundle of His are small structures; as a result, no electrical activity is recorded on the surface ECG&nbsp;during their activation.</div><div id=\"graphicVersion\">Graphic 61989 Version 3.0</div></div></div>"},"61991":{"type":"graphic_picture","displayName":"Ankle valgus","title":"Valgus foot deformity in a child with myelomeningocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Valgus foot deformity in a child with myelomeningocele</div><div class=\"cntnt\"><img style=\"width:360px; height:539px;\" src=\"images/PEDS/61991_Ankle_valgus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of: Drs. Vineeta Swaroop and Luciano Dias.</div><div id=\"graphicVersion\">Graphic 61991 Version 2.0</div></div></div>"},"61992":{"type":"graphic_table","displayName":"Genetic test panel for PWS","title":"Genetic test panel for Prader-Willi syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic test panel for Prader-Willi syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Defect causing PWS</td> <td class=\"subtitle1\">Percent of PWS cases</td> <td class=\"subtitle1\">Molecular findings</td> <td class=\"subtitle1\">Risk of recurrence in future siblings, percent</td> </tr> <tr> <td rowspan=\"2\">Deletions of PWS-critical region on paternal 15q11-q13</td> <td rowspan=\"2\">65 to 75</td> <td>Methylation studies abnormal</td> <td rowspan=\"2\">&#60;1*</td> </tr> <tr> <td>Deletion analysis abnormal (FISH or CMA)</td> </tr> <tr> <td rowspan=\"3\">Maternal uniparental disomy</td> <td rowspan=\"3\">20 to 30</td> <td>Methylation studies abnormal</td> <td rowspan=\"3\">&#60;1*</td> </tr> <tr> <td>Deletion analysis normal (FISH or CMA)</td> </tr> <tr> <td>Uniparental disomy (UPD) analysis abnormal (DNA polymorphism analysis using microsatellite probes or SNPs). This&nbsp;requires testing of parents and child</td> </tr> <tr> <td>Imprinting center defects</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist2_start\" rowspan=\"3\">Epimutations without deletion</td> <td rowspan=\"3\">2</td> <td>Methylation studies abnormal</td> <td rowspan=\"3\">&#60;1&nbsp;</td> </tr> <tr> <td>Deletion analysis normal (FISH or CMA)</td> </tr> <tr> <td>Uniparental disomy (UPD) analysis normal</td> </tr> <tr> <td class=\"sublist2_start\">Deletion</td> <td>&#60;0.5</td> <td>Above, plus DNA sequence analysis&nbsp;</td> <td>Up to 50</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Molecular defects associated with Prader-Willi syndrome and associated risk for recurrence in siblings of an affected child.</div><div class=\"graphic_footnotes\">PWS: Prader-Willi syndrome; FISH: fluorescent in-situ hybridization; CMA: chromosomal microarray; SNP: single nucleotide polymorphism.<br />* Rare defects with a substantial risk of recurrence in a sibling are chromosomal rearrangement (&lt;1 percent of PWS cases) and maternal uniparental disomy (UPD) with predisposing parental translocation or marker chromosome (&lt; 1 percent of PWS cases).</div><div class=\"graphic_reference\">Data from Driscoll DJ, Miller JL, Schwartz S, and Cassidy SB. Prader-Willi Syndrome (1998 Oct 6 [Updated 2014 Jan 23]. In: Pagon RA, Adam MP, Bird TD, et al., editors. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. Available from: <A href=\"http://www.ncbi.nlm.nih.gov/books/NBK1330/\">http://www.ncbi.nlm.nih.gov/books/NBK1330/</A></div><div id=\"graphicVersion\">Graphic 61992 Version 6.0</div></div></div>"},"61993":{"type":"graphic_figure","displayName":"Unicornuate uter and xtra hornB","title":"Unicornuate uterus with noncommunicating uterine horn (containing an endometrial cavity) not fused to unicornuate uterus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Unicornuate uterus with noncommunicating uterine horn (containing an endometrial cavity) not fused to unicornuate uterus</div><div class=\"cntnt\"><img style=\"width:379px; height:310px;\" src=\"images/OBGYN/61993_Unicornuateuterandxtra1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from:&nbsp;Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012.&nbsp;Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 61993 Version 11.0</div></div></div>"},"61994":{"type":"graphic_picture","displayName":"Endoscopic view of the duodenum","title":"Endoscopic view of the duodenum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Endoscopic view of the duodenum</div><div class=\"cntnt\"><img style=\"width:504px; height:397px;\" src=\"images/GAST/61994_Endoscop_view_duodenum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The duodenum distal to the duodenal bulb has distinctive circular rings (valvulae conniventes).</div><div id=\"graphicVersion\">Graphic 61994 Version 2.0</div></div></div>"},"61995":{"type":"graphic_figure","displayName":"Skin sparing mastectomy flap development","title":"Skin sparing mastectomy flap development","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Skin sparing mastectomy flap development</div><div class=\"cntnt\"><img style=\"width:526px; height:343px;\" src=\"images/SURG/61995_Skinsparmastflapdevelop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Development of the skin ﬂaps with a skin-sparing incision is similar to that of the larger incision, just in a smaller ﬁeld. Tension is placed on the breast tissue by pulling down on the breast tissue toward the chest wall or by pulling the breast tissue away from the skin. The skin is initially retracted away from the chest wall, with skin rakes or hooks as the plane is developed. As the dissection progresses, one can switch to hand retraction, occasional rolling the ﬂap forward or backward for access. One could also utilize a lighted retractor in the context of space restraint.</div><div class=\"graphic_reference\">Reproduced with permission from: Shaughnessy EA. Simple mastectomy. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 61995 Version 7.0</div></div></div>"},"61997":{"type":"graphic_table","displayName":"Triatoma species found in the United States","title":"<em>Triatoma</em> species found in the United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\"><em>Triatoma</em> species found in the United States</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   <em>Triatoma</em> species\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Probable range\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Allergic reactions reported?\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><em>Triatoma rubida</em>*</td>\r\n  \r\n   <td>Arizona, California, New Mexico, Texas</td>\r\n  \r\n   <td>Yes</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><em>Triatoma protracta</em>*</td>\r\n  \r\n   <td>Arizona, California, Colorado, Nevada, New Mexico, Texas, Utah</td>\r\n  \r\n   <td>Yes</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><em>Triatoma recurva</em>*</td>\r\n  \r\n   <td>Arizona</td>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><em>Triatoma gerstaeckeri</em>*</td>\r\n  \r\n   <td>New Mexico, Texas</td>\r\n  \r\n   <td>Yes</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><em>Triatoma lecticularia</em>*</td>\r\n  \r\n   <td>Arizona, California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland, Missouri, New Mexico, North Carolina, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas</td>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><em>Triatoma sanguisuga</em>*</td>\r\n  \r\n   <td>Alabama, Arizona, Arkansas, Florida, Georgia, Illinois, Indiana, Kansas, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Virginia</td>\r\n  \r\n   <td>Yes</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><em>Triatoma incrassata</em></td>\r\n  \r\n   <td>Arizona</td>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><em>Triatoma indictiva</em></td>\r\n  \r\n   <td>Arizona, New Mexico, Texas</td>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><em>Triatoma neotomae</em></td>\r\n  \r\n   <td>Arizona, California, New Mexico, Texas</td>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><em>Triatoma rubrofasciata</em></td>\r\n  \r\n   <td>Florida</td>\r\n  \r\n   <td>Yes</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">1.00000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Media_Notes msdt:dt=\"string\">3/27/2009--Requested permission (JD).\r\n4/13/2009--Permission granted; figure to Terrence (JD).</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=1452&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Triatoma_Spp_in_US.htm</title></head></div><div class=\"graphic_footnotes\">* Most common species.</div><div class=\"graphic_reference\">Reproduced with permission from: Moffitt JE, Venarske D, Goddard J, et al. Allergic reactions to Triatoma bites. Ann Allergy Asthma Immunol 2003; 91:122. Copyright ©2003 American College of Allergy, Asthma, and Immunology.</div><div id=\"graphicVersion\">Graphic 61997 Version 3.0</div></div></div>"},"61998":{"type":"graphic_diagnosticimage","displayName":"EUS FNA esophageal CA","title":"Esophageal adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Esophageal adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:511px; height:446px;\" src=\"images/GAST/61998_EUS_FNA_esophageal_CA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 47-year old man with progressive dysphagia had an exophytic mass lesion in the distal esophagus, which on biopsy was confirmed to be an adenocarcinoma. Panels A and B: Endoscopic ultrasonography (EUS) with the radial scanning probe demonstrated transmural invasion (T3), regional lymphadenopathy (LN), and a right pleural effusion. Panels C and D: The electronic linear scanning probe also demonstrated a T3N1 tumor with perigastric lymphadenopathy. EUS fine needle aspiration demonstrated metastatic adenocarcinoma. Note that the needle traverses normal gastric wall uninvolved with tumor.</div><div class=\"graphic_reference\">From: Norton ID, Wiersema MJ. Endoscopic ultrasound-guided fine needle aspiration biopsy. In: Endoscopic Ultrasonography. Gress F, Bhattacharya I (Eds). Blackwell Science, Malden, MA 2001. p.136. Reprinted with permission of Blackwell Science, Inc. <A spellcheck=true href=\"http://www.wiley.com/wiley-blackwell\" target=_blank>http://www.blackwell-science.com</A>.</div><div id=\"graphicVersion\">Graphic 61998 Version 4.0</div></div></div>"}};